[{"header": {"dataset": "BioASQ", "split": "dev"}}]
{"context": "Specific outcomes upon activation of the c-Jun N-terminal kinase (JNK) pathway critically depend on the intensity and duration of signal transmission. Dual-specificity phosphatases (DUSPs) play a very important role in these events by modulating the extent of JNK phosphorylation and activation and thus regulating cellular responses to stress. M3/6 (DUSP8) is one of the dual-specificity protein phosphatases with distinct specificity towards JNK. It has been shown that M3/6 itself is phosphorylated by JNK upon stimulation with arsenite, but the role of this phosphorylation has not been investigated. In this study, we mapped JNK-induced phosphorylation sites on M3/6 using mass spectrometry. Phosphorylated residues Ser 515, Thr 518 and Ser 520 were identified and site-directed mutagenesis was employed to investigate their role. Upon arsenite stimulation, M3/6 mutated at these sites exhibited decreased phosphorylation compared to the wild-type protein. No difference was observed in terms of the enzyme's in vitro phosphatase activity, its substrate specificity towards JNK isoforms, its interactions with JNK and the scaffold family of JNK-interacting proteins (JIPs), its stability or its subcellular localization. Interestingly, expression of M3/6 phosphorylation mutants delayed the time-course of JNK phosphorylation and activation by arsenite. We propose that phosphorylation of the M3/6 phosphatase by JNK in response to stress stimuli results in attenuation of phosphatase activity and acceleration of JNK activation.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "a351b22b820341a499b92892e91315d8", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[48, 48], [112, 112], [77, 77], [192, 192], [186, 186], [198, 198], [226, 226], [89, 89], [242, 242], [14, 14], [257, 257]], "char_spans": [[260, 262], [630, 632], [444, 446], [1115, 1117], [1079, 1081], [1146, 1148], [1311, 1313], [505, 507], [1418, 1420], [66, 68], [1519, 1521]]}]}], "context_tokens": [["Specific", 0], ["outcomes", 9], ["upon", 18], ["activation", 23], ["of", 34], ["the", 37], ["c", 41], ["-", 42], ["Jun", 43], ["N", 47], ["-", 48], ["terminal", 49], ["kinase", 58], ["(", 65], ["JNK", 66], [")", 69], ["pathway", 71], ["critically", 79], ["depend", 90], ["on", 97], ["the", 100], ["intensity", 104], ["and", 114], ["duration", 118], ["of", 127], ["signal", 130], ["transmission", 137], [".", 149], ["Dual", 151], ["-", 155], ["specificity", 156], ["phosphatases", 168], ["(", 181], ["DUSPs", 182], [")", 187], ["play", 189], ["a", 194], ["very", 196], ["important", 201], ["role", 211], ["in", 216], ["these", 219], ["events", 225], ["by", 232], ["modulating", 235], ["the", 246], ["extent", 250], ["of", 257], ["JNK", 260], ["phosphorylation", 264], ["and", 280], ["activation", 284], ["and", 295], ["thus", 299], ["regulating", 304], ["cellular", 315], ["responses", 324], ["to", 334], ["stress", 337], [".", 343], ["M3/6", 345], ["(", 350], ["DUSP8", 351], [")", 356], ["is", 358], ["one", 361], ["of", 365], ["the", 368], ["dual", 372], ["-", 376], ["specificity", 377], ["protein", 389], ["phosphatases", 397], ["with", 410], ["distinct", 415], ["specificity", 424], ["towards", 436], ["JNK", 444], [".", 447], ["It", 449], ["has", 452], ["been", 456], ["shown", 461], ["that", 467], ["M3/6", 472], ["itself", 477], ["is", 484], ["phosphorylated", 487], ["by", 502], ["JNK", 505], ["upon", 509], ["stimulation", 514], ["with", 526], ["arsenite", 531], [",", 539], ["but", 541], ["the", 545], ["role", 549], ["of", 554], ["this", 557], ["phosphorylation", 562], ["has", 578], ["not", 582], ["been", 586], ["investigated", 591], [".", 603], ["In", 605], ["this", 608], ["study", 613], [",", 618], ["we", 620], ["mapped", 623], ["JNK", 630], ["-", 633], ["induced", 634], ["phosphorylation", 642], ["sites", 658], ["on", 664], ["M3/6", 667], ["using", 672], ["mass", 678], ["spectrometry", 683], [".", 695], ["Phosphorylated", 697], ["residues", 712], ["Ser", 721], ["515", 725], [",", 728], ["Thr", 730], ["518", 734], ["and", 738], ["Ser", 742], ["520", 746], ["were", 750], ["identified", 755], ["and", 766], ["site", 770], ["-", 774], ["directed", 775], ["mutagenesis", 784], ["was", 796], ["employed", 800], ["to", 809], ["investigate", 812], ["their", 824], ["role", 830], [".", 834], ["Upon", 836], ["arsenite", 841], ["stimulation", 850], [",", 861], ["M3/6", 863], ["mutated", 868], ["at", 876], ["these", 879], ["sites", 885], ["exhibited", 891], ["decreased", 901], ["phosphorylation", 911], ["compared", 927], ["to", 936], ["the", 939], ["wild", 943], ["-", 947], ["type", 948], ["protein", 953], [".", 960], ["No", 962], ["difference", 965], ["was", 976], ["observed", 980], ["in", 989], ["terms", 992], ["of", 998], ["the", 1001], ["enzyme", 1005], ["'s", 1011], ["in", 1014], ["vitro", 1017], ["phosphatase", 1023], ["activity", 1035], [",", 1043], ["its", 1045], ["substrate", 1049], ["specificity", 1059], ["towards", 1071], ["JNK", 1079], ["isoforms", 1083], [",", 1091], ["its", 1093], ["interactions", 1097], ["with", 1110], ["JNK", 1115], ["and", 1119], ["the", 1123], ["scaffold", 1127], ["family", 1136], ["of", 1143], ["JNK", 1146], ["-", 1149], ["interacting", 1150], ["proteins", 1162], ["(", 1171], ["JIPs", 1172], [")", 1176], [",", 1177], ["its", 1179], ["stability", 1183], ["or", 1193], ["its", 1196], ["subcellular", 1200], ["localization", 1212], [".", 1224], ["Interestingly", 1226], [",", 1239], ["expression", 1241], ["of", 1252], ["M3/6", 1255], ["phosphorylation", 1260], ["mutants", 1276], ["delayed", 1284], ["the", 1292], ["time", 1296], ["-", 1300], ["course", 1301], ["of", 1308], ["JNK", 1311], ["phosphorylation", 1315], ["and", 1331], ["activation", 1335], ["by", 1346], ["arsenite", 1349], [".", 1357], ["We", 1359], ["propose", 1362], ["that", 1370], ["phosphorylation", 1375], ["of", 1391], ["the", 1394], ["M3/6", 1398], ["phosphatase", 1403], ["by", 1415], ["JNK", 1418], ["in", 1422], ["response", 1425], ["to", 1434], ["stress", 1437], ["stimuli", 1444], ["results", 1452], ["in", 1460], ["attenuation", 1463], ["of", 1475], ["phosphatase", 1478], ["activity", 1490], ["and", 1499], ["acceleration", 1503], ["of", 1516], ["JNK", 1519], ["activation", 1523], [".", 1533]]}
{"context": "Parkinson's disease (PD) is the second most common neurodegenerative disease. A key pathological feature of PD is Lewy bodies, of which the major protein component is \u03b1-synuclein (\u03b1-syn). Human genetic studies have shown that mutations (A53T, A30P, E46K) and multiplication of the \u03b1-syn gene are linked to familial PD. Mice overexpressing the human A53T mutant \u03b1-syn gene develop severe movement disorders. However, the molecular mechanisms of \u03b1-syn toxicity are not well understood. Recently, mitochondrial dysfunction has been linked with multiple neurodegenerative diseases including Parkinson's disease. Here we investigated whether mitochondrial motility, dynamics and respiratory function are affected in primary neurons from a mouse model expressing the human A53T mutation. We found that mitochondrial motility was selectively inhibited in A53T neurons while transport of other organelles was not affected. In addition, A53T expressing neurons showed impairment in mitochondrial membrane potential and mitochondrial respiratory function. Furthermore, we found that rapamycin, an autophagy inducer, rescued the decreased mitochondrial mobility. Taken together, these data demonstrate that A53T \u03b1-syn impairs mitochondrial function and dynamics and the deficit of mitochondrial transport is reversible, providing further understanding of the disease pathogenesis and a potential therapeutic strategy for PD.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "4687700336544ca7b5e25c199a0d7523", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[31, 33]], "char_spans": [[167, 177]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["the", 28], ["second", 32], ["most", 39], ["common", 44], ["neurodegenerative", 51], ["disease", 69], [".", 76], ["A", 78], ["key", 80], ["pathological", 84], ["feature", 97], ["of", 105], ["PD", 108], ["is", 111], ["Lewy", 114], ["bodies", 119], [",", 125], ["of", 127], ["which", 130], ["the", 136], ["major", 140], ["protein", 146], ["component", 154], ["is", 164], ["\u03b1", 167], ["-", 168], ["synuclein", 169], ["(", 179], ["\u03b1", 180], ["-", 181], ["syn", 182], [")", 185], [".", 186], ["Human", 188], ["genetic", 194], ["studies", 202], ["have", 210], ["shown", 215], ["that", 221], ["mutations", 226], ["(", 236], ["A53", 237], ["T", 240], [",", 241], ["A30P", 243], [",", 247], ["E46", 249], ["K", 252], [")", 253], ["and", 255], ["multiplication", 259], ["of", 274], ["the", 277], ["\u03b1", 281], ["-", 282], ["syn", 283], ["gene", 287], ["are", 292], ["linked", 296], ["to", 303], ["familial", 306], ["PD", 315], [".", 317], ["Mice", 319], ["overexpressing", 324], ["the", 339], ["human", 343], ["A53", 349], ["T", 352], ["mutant", 354], ["\u03b1", 361], ["-", 362], ["syn", 363], ["gene", 367], ["develop", 372], ["severe", 380], ["movement", 387], ["disorders", 396], [".", 405], ["However", 407], [",", 414], ["the", 416], ["molecular", 420], ["mechanisms", 430], ["of", 441], ["\u03b1", 444], ["-", 445], ["syn", 446], ["toxicity", 450], ["are", 459], ["not", 463], ["well", 467], ["understood", 472], [".", 482], ["Recently", 484], [",", 492], ["mitochondrial", 494], ["dysfunction", 508], ["has", 520], ["been", 524], ["linked", 529], ["with", 536], ["multiple", 541], ["neurodegenerative", 550], ["diseases", 568], ["including", 577], ["Parkinson", 587], ["'s", 596], ["disease", 599], [".", 606], ["Here", 608], ["we", 613], ["investigated", 616], ["whether", 629], ["mitochondrial", 637], ["motility", 651], [",", 659], ["dynamics", 661], ["and", 670], ["respiratory", 674], ["function", 686], ["are", 695], ["affected", 699], ["in", 708], ["primary", 711], ["neurons", 719], ["from", 727], ["a", 732], ["mouse", 734], ["model", 740], ["expressing", 746], ["the", 757], ["human", 761], ["A53", 767], ["T", 770], ["mutation", 772], [".", 780], ["We", 782], ["found", 785], ["that", 791], ["mitochondrial", 796], ["motility", 810], ["was", 819], ["selectively", 823], ["inhibited", 835], ["in", 845], ["A53", 848], ["T", 851], ["neurons", 853], ["while", 861], ["transport", 867], ["of", 877], ["other", 880], ["organelles", 886], ["was", 897], ["not", 901], ["affected", 905], [".", 913], ["In", 915], ["addition", 918], [",", 926], ["A53", 928], ["T", 931], ["expressing", 933], ["neurons", 944], ["showed", 952], ["impairment", 959], ["in", 970], ["mitochondrial", 973], ["membrane", 987], ["potential", 996], ["and", 1006], ["mitochondrial", 1010], ["respiratory", 1024], ["function", 1036], [".", 1044], ["Furthermore", 1046], [",", 1057], ["we", 1059], ["found", 1062], ["that", 1068], ["rapamycin", 1073], [",", 1082], ["an", 1084], ["autophagy", 1087], ["inducer", 1097], [",", 1104], ["rescued", 1106], ["the", 1114], ["decreased", 1118], ["mitochondrial", 1128], ["mobility", 1142], [".", 1150], ["Taken", 1152], ["together", 1158], [",", 1166], ["these", 1168], ["data", 1174], ["demonstrate", 1179], ["that", 1191], ["A53", 1196], ["T", 1199], ["\u03b1", 1201], ["-", 1202], ["syn", 1203], ["impairs", 1207], ["mitochondrial", 1215], ["function", 1229], ["and", 1238], ["dynamics", 1242], ["and", 1251], ["the", 1255], ["deficit", 1259], ["of", 1267], ["mitochondrial", 1270], ["transport", 1284], ["is", 1294], ["reversible", 1297], [",", 1307], ["providing", 1309], ["further", 1319], ["understanding", 1327], ["of", 1341], ["the", 1344], ["disease", 1348], ["pathogenesis", 1356], ["and", 1369], ["a", 1373], ["potential", 1375], ["therapeutic", 1385], ["strategy", 1397], ["for", 1406], ["PD", 1410], [".", 1412]]}
{"context": "Loss-of-function mutations in the gene ced-8 lead to the late appearance of cell corpses during embryonic development in C. elegans. ced-8 functions downstream of or in parallel to-the regulatory cell death gene ced-9 and may function as a cell death effector downstream of the caspase encoded by the programmed cell death killer gene ced-3. In ced-8 mutants, embryonic programmed cell death probably initiates normally but proceeds slowly. ced-8 encodes a transmembrane protein that appears to be localized to the plasma membrane. The CED-8 protein is similar to human XK, a putative membrane transport protein implicated in McLeod Syndrome, a form of hereditary neuroacanthocytosis.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "0574b68d8a1845829336d0bb8c46aef6", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[99, 99]], "char_spans": [[570, 571]]}]}], "context_tokens": [["Loss", 0], ["-", 4], ["of", 5], ["-", 7], ["function", 8], ["mutations", 17], ["in", 27], ["the", 30], ["gene", 34], ["ced-8", 39], ["lead", 45], ["to", 50], ["the", 53], ["late", 57], ["appearance", 62], ["of", 73], ["cell", 76], ["corpses", 81], ["during", 89], ["embryonic", 96], ["development", 106], ["in", 118], ["C.", 121], ["elegans", 124], [".", 131], ["ced-8", 133], ["functions", 139], ["downstream", 149], ["of", 160], ["or", 163], ["in", 166], ["parallel", 169], ["to", 178], ["-", 180], ["the", 181], ["regulatory", 185], ["cell", 196], ["death", 201], ["gene", 207], ["ced-9", 212], ["and", 218], ["may", 222], ["function", 226], ["as", 235], ["a", 238], ["cell", 240], ["death", 245], ["effector", 251], ["downstream", 260], ["of", 271], ["the", 274], ["caspase", 278], ["encoded", 286], ["by", 294], ["the", 297], ["programmed", 301], ["cell", 312], ["death", 317], ["killer", 323], ["gene", 330], ["ced-3", 335], [".", 340], ["In", 342], ["ced-8", 345], ["mutants", 351], [",", 358], ["embryonic", 360], ["programmed", 370], ["cell", 381], ["death", 386], ["probably", 392], ["initiates", 401], ["normally", 411], ["but", 420], ["proceeds", 424], ["slowly", 433], [".", 439], ["ced-8", 441], ["encodes", 447], ["a", 455], ["transmembrane", 457], ["protein", 471], ["that", 479], ["appears", 484], ["to", 492], ["be", 495], ["localized", 498], ["to", 508], ["the", 511], ["plasma", 515], ["membrane", 522], [".", 530], ["The", 532], ["CED-8", 536], ["protein", 542], ["is", 550], ["similar", 553], ["to", 561], ["human", 564], ["XK", 570], [",", 572], ["a", 574], ["putative", 576], ["membrane", 585], ["transport", 594], ["protein", 604], ["implicated", 612], ["in", 623], ["McLeod", 626], ["Syndrome", 633], [",", 641], ["a", 643], ["form", 645], ["of", 650], ["hereditary", 653], ["neuroacanthocytosis", 664], [".", 683]]}
{"context": "Alpha-synuclein forms the major component of Lewy bodies and Lewy neurites, the defining neuropathological characteristics of Parkinson's disease and dementia with Lewy bodies. Here we show that alpha-synuclein is also the major component of the filamentous inclusions of multiple system atrophy which comprises several neurodegenerative diseases with a shared filamentous pathology in nerve cells and glial cells. These findings provide an unexpected link between multiple system atrophy and Lewy body disorders and establish that alpha-synucleinopathies constitute a major class of human neurodegenerative disorder.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "a4da3f3b9ad440b69aaf79b7d6f6f893", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2], [32, 34]], "char_spans": [[0, 14], [195, 209]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["forms", 16], ["the", 22], ["major", 26], ["component", 32], ["of", 42], ["Lewy", 45], ["bodies", 50], ["and", 57], ["Lewy", 61], ["neurites", 66], [",", 74], ["the", 76], ["defining", 80], ["neuropathological", 89], ["characteristics", 107], ["of", 123], ["Parkinson", 126], ["'s", 135], ["disease", 138], ["and", 146], ["dementia", 150], ["with", 159], ["Lewy", 164], ["bodies", 169], [".", 175], ["Here", 177], ["we", 182], ["show", 185], ["that", 190], ["alpha", 195], ["-", 200], ["synuclein", 201], ["is", 211], ["also", 214], ["the", 219], ["major", 223], ["component", 229], ["of", 239], ["the", 242], ["filamentous", 246], ["inclusions", 258], ["of", 269], ["multiple", 272], ["system", 281], ["atrophy", 288], ["which", 296], ["comprises", 302], ["several", 312], ["neurodegenerative", 320], ["diseases", 338], ["with", 347], ["a", 352], ["shared", 354], ["filamentous", 361], ["pathology", 373], ["in", 383], ["nerve", 386], ["cells", 392], ["and", 398], ["glial", 402], ["cells", 408], [".", 413], ["These", 415], ["findings", 421], ["provide", 430], ["an", 438], ["unexpected", 441], ["link", 452], ["between", 457], ["multiple", 465], ["system", 474], ["atrophy", 481], ["and", 489], ["Lewy", 493], ["body", 498], ["disorders", 503], ["and", 513], ["establish", 517], ["that", 527], ["alpha", 532], ["-", 537], ["synucleinopathies", 538], ["constitute", 556], ["a", 567], ["major", 569], ["class", 575], ["of", 581], ["human", 584], ["neurodegenerative", 590], ["disorder", 608], [".", 616]]}
{"context": "Human alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A) is the lysosomal exoglycosidase responsible for the hydrolysis of terminal alpha-galactosyl residues from glycoconjugates and is the defective enzyme causing Fabry disease (McKusick 301500). An unusally elevated level of plasma alpha-Gal A activity (> 2.5 times the normal mean) was detected in two unrelated normal males and the elevated activities were inherited as X-linked traits in their families. Sequencing of the alpha-Gal A coding region, intron/exon boundaries and 5'-flanking region from the proband identified a single mutation, a G-->A transition 30 nt upstream from the initiation of translation codon in exon 1. The -30G-->A mutation occurred in a putative NF kappa B/Ets consensus binding site that was recently shown to inhibit protein binding to the 5'-untranslated region of the gene, providing a possible explanation for its high activity. To further characterize the mutation, the mRNA and protein expressed by this variant allele were studied. Purified plasma and lymphoblast alpha-Gal A activity from individuals with the -30G-->A mutation had normal physical and kinetic properties. In vitro translation of mRNAs from the cloned normal and high plasma activity alleles resulted in similar levels of alpha-Gal A protein, indicating that this mutation did not enhance translation. These findings suggest that the -30G-->A mutation in the 5'-untranslated region of the alpha-Gal A gene enhances transcription, presumably by interfering with the binding of negatively-acting transcription factors which normally decrease alpha-Gal A expression in various cells. Preliminary studies of the frequency of the -30G-->A mutation in 395 unrelated normal males of mixed ancestry revealed two additional unrelated individuals who had high plasma enzymatic activity and the mutation, confirming the effect of this mutation on enzyme expression and suggesting that about 0.5% of normal individuals have high plasma alpha-Gal A activity due to this variant allele.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "cd3dcbcaf34943d0be36358f319a997a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[1, 3]], "char_spans": [[6, 24]]}]}], "context_tokens": [["Human", 0], ["alpha", 6], ["-", 11], ["galactosidase", 12], ["A", 26], ["(", 28], ["EC", 29], ["3.2.1.22", 32], [";", 40], ["alpha", 42], ["-", 47], ["Gal", 48], ["A", 52], [")", 53], ["is", 55], ["the", 58], ["lysosomal", 62], ["exoglycosidase", 72], ["responsible", 87], ["for", 99], ["the", 103], ["hydrolysis", 107], ["of", 118], ["terminal", 121], ["alpha", 130], ["-", 135], ["galactosyl", 136], ["residues", 147], ["from", 156], ["glycoconjugates", 161], ["and", 177], ["is", 181], ["the", 184], ["defective", 188], ["enzyme", 198], ["causing", 205], ["Fabry", 213], ["disease", 219], ["(", 227], ["McKusick", 228], ["301500", 237], [")", 243], [".", 244], ["An", 246], ["unusally", 249], ["elevated", 258], ["level", 267], ["of", 273], ["plasma", 276], ["alpha", 283], ["-", 288], ["Gal", 289], ["A", 293], ["activity", 295], ["(", 304], [">", 305], ["2.5", 307], ["times", 311], ["the", 317], ["normal", 321], ["mean", 328], [")", 332], ["was", 334], ["detected", 338], ["in", 347], ["two", 350], ["unrelated", 354], ["normal", 364], ["males", 371], ["and", 377], ["the", 381], ["elevated", 385], ["activities", 394], ["were", 405], ["inherited", 410], ["as", 420], ["X", 423], ["-", 424], ["linked", 425], ["traits", 432], ["in", 439], ["their", 442], ["families", 448], [".", 456], ["Sequencing", 458], ["of", 469], ["the", 472], ["alpha", 476], ["-", 481], ["Gal", 482], ["A", 486], ["coding", 488], ["region", 495], [",", 501], ["intron", 503], ["/", 509], ["exon", 510], ["boundaries", 515], ["and", 526], ["5'-flanking", 530], ["region", 542], ["from", 549], ["the", 554], ["proband", 558], ["identified", 566], ["a", 577], ["single", 579], ["mutation", 586], [",", 594], ["a", 596], ["G-->A", 598], ["transition", 604], ["30", 615], ["nt", 618], ["upstream", 621], ["from", 630], ["the", 635], ["initiation", 639], ["of", 650], ["translation", 653], ["codon", 665], ["in", 671], ["exon", 674], ["1", 679], [".", 680], ["The", 682], ["-30G-->A", 686], ["mutation", 695], ["occurred", 704], ["in", 713], ["a", 716], ["putative", 718], ["NF", 727], ["kappa", 730], ["B", 736], ["/", 737], ["Ets", 738], ["consensus", 742], ["binding", 752], ["site", 760], ["that", 765], ["was", 770], ["recently", 774], ["shown", 783], ["to", 789], ["inhibit", 792], ["protein", 800], ["binding", 808], ["to", 816], ["the", 819], ["5'-untranslated", 823], ["region", 839], ["of", 846], ["the", 849], ["gene", 853], [",", 857], ["providing", 859], ["a", 869], ["possible", 871], ["explanation", 880], ["for", 892], ["its", 896], ["high", 900], ["activity", 905], [".", 913], ["To", 915], ["further", 918], ["characterize", 926], ["the", 939], ["mutation", 943], [",", 951], ["the", 953], ["mRNA", 957], ["and", 962], ["protein", 966], ["expressed", 974], ["by", 984], ["this", 987], ["variant", 992], ["allele", 1000], ["were", 1007], ["studied", 1012], [".", 1019], ["Purified", 1021], ["plasma", 1030], ["and", 1037], ["lymphoblast", 1041], ["alpha", 1053], ["-", 1058], ["Gal", 1059], ["A", 1063], ["activity", 1065], ["from", 1074], ["individuals", 1079], ["with", 1091], ["the", 1096], ["-30G-->A", 1100], ["mutation", 1109], ["had", 1118], ["normal", 1122], ["physical", 1129], ["and", 1138], ["kinetic", 1142], ["properties", 1150], [".", 1160], ["In", 1162], ["vitro", 1165], ["translation", 1171], ["of", 1183], ["mRNAs", 1186], ["from", 1192], ["the", 1197], ["cloned", 1201], ["normal", 1208], ["and", 1215], ["high", 1219], ["plasma", 1224], ["activity", 1231], ["alleles", 1240], ["resulted", 1248], ["in", 1257], ["similar", 1260], ["levels", 1268], ["of", 1275], ["alpha", 1278], ["-", 1283], ["Gal", 1284], ["A", 1288], ["protein", 1290], [",", 1297], ["indicating", 1299], ["that", 1310], ["this", 1315], ["mutation", 1320], ["did", 1329], ["not", 1333], ["enhance", 1337], ["translation", 1345], [".", 1356], ["These", 1358], ["findings", 1364], ["suggest", 1373], ["that", 1381], ["the", 1386], ["-30G-->A", 1390], ["mutation", 1399], ["in", 1408], ["the", 1411], ["5'-untranslated", 1415], ["region", 1431], ["of", 1438], ["the", 1441], ["alpha", 1445], ["-", 1450], ["Gal", 1451], ["A", 1455], ["gene", 1457], ["enhances", 1462], ["transcription", 1471], [",", 1484], ["presumably", 1486], ["by", 1497], ["interfering", 1500], ["with", 1512], ["the", 1517], ["binding", 1521], ["of", 1529], ["negatively", 1532], ["-", 1542], ["acting", 1543], ["transcription", 1550], ["factors", 1564], ["which", 1572], ["normally", 1578], ["decrease", 1587], ["alpha", 1596], ["-", 1601], ["Gal", 1602], ["A", 1606], ["expression", 1608], ["in", 1619], ["various", 1622], ["cells", 1630], [".", 1635], ["Preliminary", 1637], ["studies", 1649], ["of", 1657], ["the", 1660], ["frequency", 1664], ["of", 1674], ["the", 1677], ["-30G-->A", 1681], ["mutation", 1690], ["in", 1699], ["395", 1702], ["unrelated", 1706], ["normal", 1716], ["males", 1723], ["of", 1729], ["mixed", 1732], ["ancestry", 1738], ["revealed", 1747], ["two", 1756], ["additional", 1760], ["unrelated", 1771], ["individuals", 1781], ["who", 1793], ["had", 1797], ["high", 1801], ["plasma", 1806], ["enzymatic", 1813], ["activity", 1823], ["and", 1832], ["the", 1836], ["mutation", 1840], [",", 1848], ["confirming", 1850], ["the", 1861], ["effect", 1865], ["of", 1872], ["this", 1875], ["mutation", 1880], ["on", 1889], ["enzyme", 1892], ["expression", 1899], ["and", 1910], ["suggesting", 1914], ["that", 1925], ["about", 1930], ["0.5", 1936], ["%", 1939], ["of", 1941], ["normal", 1944], ["individuals", 1951], ["have", 1963], ["high", 1968], ["plasma", 1973], ["alpha", 1980], ["-", 1985], ["Gal", 1986], ["A", 1990], ["activity", 1992], ["due", 2001], ["to", 2005], ["this", 2008], ["variant", 2013], ["allele", 2021], [".", 2027]]}
{"context": "The clinical efficacy of different doses of the specific benzodiazepine antagonist flumazenil was studied in a total of 72 patients with benzodiazepine or ethanol overdose. In a randomized double-blind study, 18 patients (group 1) and eight patients (group 2) with suspected benzodiazepine overdose received 5 mg (group 1) or 1 mg (group 2) flumazenil or placebo, respectively. The stage of coma, heart rate, blood pressure and respiratory rate were monitored within the following 15 min. If no change in the stage of coma was observed, 5 mg (group 1) or 1 mg (group 2) flumazenil were given, and the stage of coma, heart rate and blood pressure were again monitored. In a similar way, the effect of 5 and 1 mg flumazenil was investigated in 13 patients (group 3) and four patients (group 4) with ethanol intoxication. In an open trial, the clinical efficacy of flumazenil for the diagnosis of benzodiazepine or ethanol overdose was studied in 29 patients (group 5). In all patients, a toxicological screening confirmed benzodiazepine or ethanol overdose. None of the patients receiving placebo showed effects on stage of coma, heart rate, blood pressure or respiratory rate. Patients with benzodiazepine overdose who received 5 mg flumazenil regained consciousness about 1-2 min after the end of injection. The effect of 1 mg flumazenil (group 2) on benzodiazepine-induced coma was less pronounced. In patients with ethanol overdose (group 3), ethanol-induced coma was reversed after 5 mg flumazenil more slowly than in patients of group 1. No effect of flumazenil on ethanol-induced coma was observed in group 4. In group 5, flumazenil proved to be useful for diagnosing benzodiazepine or ethanol intoxication. In one patient with coma due to carbamazepine overdose, flumazenil was also found to be effective. Additionally, a possible analytical interference of flumazenil and its metabolites with the identification of other benzodiazepines by a toxicological screening procedure was studied. Even after an oral dose of 200 mg flumazenil, no interference with immunological benzodiazepine assays (EMIT, TDX, and RIA) was found. A metabolite and an artifact of flumazenil could be identified in urine by gas chromatography/mass spectrometry.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "09099c4d930143fdb85f846a03675594", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[304, 304], [320, 320], [147, 147], [11, 11], [177, 177], [291, 291], [342, 342], [357, 357], [116, 116], [383, 383], [408, 408], [258, 258], [239, 239], [65, 65]], "char_spans": [[1555, 1564], [1627, 1636], [711, 720], [83, 92], [862, 871], [1490, 1499], [1769, 1778], [1864, 1873], [570, 579], [2030, 2039], [2163, 2172], [1327, 1336], [1232, 1241], [341, 350]]}]}], "context_tokens": [["The", 0], ["clinical", 4], ["efficacy", 13], ["of", 22], ["different", 25], ["doses", 35], ["of", 41], ["the", 44], ["specific", 48], ["benzodiazepine", 57], ["antagonist", 72], ["flumazenil", 83], ["was", 94], ["studied", 98], ["in", 106], ["a", 109], ["total", 111], ["of", 117], ["72", 120], ["patients", 123], ["with", 132], ["benzodiazepine", 137], ["or", 152], ["ethanol", 155], ["overdose", 163], [".", 171], ["In", 173], ["a", 176], ["randomized", 178], ["double", 189], ["-", 195], ["blind", 196], ["study", 202], [",", 207], ["18", 209], ["patients", 212], ["(", 221], ["group", 222], ["1", 228], [")", 229], ["and", 231], ["eight", 235], ["patients", 241], ["(", 250], ["group", 251], ["2", 257], [")", 258], ["with", 260], ["suspected", 265], ["benzodiazepine", 275], ["overdose", 290], ["received", 299], ["5", 308], ["mg", 310], ["(", 313], ["group", 314], ["1", 320], [")", 321], ["or", 323], ["1", 326], ["mg", 328], ["(", 331], ["group", 332], ["2", 338], [")", 339], ["flumazenil", 341], ["or", 352], ["placebo", 355], [",", 362], ["respectively", 364], [".", 376], ["The", 378], ["stage", 382], ["of", 388], ["coma", 391], [",", 395], ["heart", 397], ["rate", 403], [",", 407], ["blood", 409], ["pressure", 415], ["and", 424], ["respiratory", 428], ["rate", 440], ["were", 445], ["monitored", 450], ["within", 460], ["the", 467], ["following", 471], ["15", 481], ["min", 484], [".", 487], ["If", 489], ["no", 492], ["change", 495], ["in", 502], ["the", 505], ["stage", 509], ["of", 515], ["coma", 518], ["was", 523], ["observed", 527], [",", 535], ["5", 537], ["mg", 539], ["(", 542], ["group", 543], ["1", 549], [")", 550], ["or", 552], ["1", 555], ["mg", 557], ["(", 560], ["group", 561], ["2", 567], [")", 568], ["flumazenil", 570], ["were", 581], ["given", 586], [",", 591], ["and", 593], ["the", 597], ["stage", 601], ["of", 607], ["coma", 610], [",", 614], ["heart", 616], ["rate", 622], ["and", 627], ["blood", 631], ["pressure", 637], ["were", 646], ["again", 651], ["monitored", 657], [".", 666], ["In", 668], ["a", 671], ["similar", 673], ["way", 681], [",", 684], ["the", 686], ["effect", 690], ["of", 697], ["5", 700], ["and", 702], ["1", 706], ["mg", 708], ["flumazenil", 711], ["was", 722], ["investigated", 726], ["in", 739], ["13", 742], ["patients", 745], ["(", 754], ["group", 755], ["3", 761], [")", 762], ["and", 764], ["four", 768], ["patients", 773], ["(", 782], ["group", 783], ["4", 789], [")", 790], ["with", 792], ["ethanol", 797], ["intoxication", 805], [".", 817], ["In", 819], ["an", 822], ["open", 825], ["trial", 830], [",", 835], ["the", 837], ["clinical", 841], ["efficacy", 850], ["of", 859], ["flumazenil", 862], ["for", 873], ["the", 877], ["diagnosis", 881], ["of", 891], ["benzodiazepine", 894], ["or", 909], ["ethanol", 912], ["overdose", 920], ["was", 929], ["studied", 933], ["in", 941], ["29", 944], ["patients", 947], ["(", 956], ["group", 957], ["5", 963], [")", 964], [".", 965], ["In", 967], ["all", 970], ["patients", 974], [",", 982], ["a", 984], ["toxicological", 986], ["screening", 1000], ["confirmed", 1010], ["benzodiazepine", 1020], ["or", 1035], ["ethanol", 1038], ["overdose", 1046], [".", 1054], ["None", 1056], ["of", 1061], ["the", 1064], ["patients", 1068], ["receiving", 1077], ["placebo", 1087], ["showed", 1095], ["effects", 1102], ["on", 1110], ["stage", 1113], ["of", 1119], ["coma", 1122], [",", 1126], ["heart", 1128], ["rate", 1134], [",", 1138], ["blood", 1140], ["pressure", 1146], ["or", 1155], ["respiratory", 1158], ["rate", 1170], [".", 1174], ["Patients", 1176], ["with", 1185], ["benzodiazepine", 1190], ["overdose", 1205], ["who", 1214], ["received", 1218], ["5", 1227], ["mg", 1229], ["flumazenil", 1232], ["regained", 1243], ["consciousness", 1252], ["about", 1266], ["1", 1272], ["-", 1273], ["2", 1274], ["min", 1276], ["after", 1280], ["the", 1286], ["end", 1290], ["of", 1294], ["injection", 1297], [".", 1306], ["The", 1308], ["effect", 1312], ["of", 1319], ["1", 1322], ["mg", 1324], ["flumazenil", 1327], ["(", 1338], ["group", 1339], ["2", 1345], [")", 1346], ["on", 1348], ["benzodiazepine", 1351], ["-", 1365], ["induced", 1366], ["coma", 1374], ["was", 1379], ["less", 1383], ["pronounced", 1388], [".", 1398], ["In", 1400], ["patients", 1403], ["with", 1412], ["ethanol", 1417], ["overdose", 1425], ["(", 1434], ["group", 1435], ["3", 1441], [")", 1442], [",", 1443], ["ethanol", 1445], ["-", 1452], ["induced", 1453], ["coma", 1461], ["was", 1466], ["reversed", 1470], ["after", 1479], ["5", 1485], ["mg", 1487], ["flumazenil", 1490], ["more", 1501], ["slowly", 1506], ["than", 1513], ["in", 1518], ["patients", 1521], ["of", 1530], ["group", 1533], ["1", 1539], [".", 1540], ["No", 1542], ["effect", 1545], ["of", 1552], ["flumazenil", 1555], ["on", 1566], ["ethanol", 1569], ["-", 1576], ["induced", 1577], ["coma", 1585], ["was", 1590], ["observed", 1594], ["in", 1603], ["group", 1606], ["4", 1612], [".", 1613], ["In", 1615], ["group", 1618], ["5", 1624], [",", 1625], ["flumazenil", 1627], ["proved", 1638], ["to", 1645], ["be", 1648], ["useful", 1651], ["for", 1658], ["diagnosing", 1662], ["benzodiazepine", 1673], ["or", 1688], ["ethanol", 1691], ["intoxication", 1699], [".", 1711], ["In", 1713], ["one", 1716], ["patient", 1720], ["with", 1728], ["coma", 1733], ["due", 1738], ["to", 1742], ["carbamazepine", 1745], ["overdose", 1759], [",", 1767], ["flumazenil", 1769], ["was", 1780], ["also", 1784], ["found", 1789], ["to", 1795], ["be", 1798], ["effective", 1801], [".", 1810], ["Additionally", 1812], [",", 1824], ["a", 1826], ["possible", 1828], ["analytical", 1837], ["interference", 1848], ["of", 1861], ["flumazenil", 1864], ["and", 1875], ["its", 1879], ["metabolites", 1883], ["with", 1895], ["the", 1900], ["identification", 1904], ["of", 1919], ["other", 1922], ["benzodiazepines", 1928], ["by", 1944], ["a", 1947], ["toxicological", 1949], ["screening", 1963], ["procedure", 1973], ["was", 1983], ["studied", 1987], [".", 1994], ["Even", 1996], ["after", 2001], ["an", 2007], ["oral", 2010], ["dose", 2015], ["of", 2020], ["200", 2023], ["mg", 2027], ["flumazenil", 2030], [",", 2040], ["no", 2042], ["interference", 2045], ["with", 2058], ["immunological", 2063], ["benzodiazepine", 2077], ["assays", 2092], ["(", 2099], ["EMIT", 2100], [",", 2104], ["TDX", 2106], [",", 2109], ["and", 2111], ["RIA", 2115], [")", 2118], ["was", 2120], ["found", 2124], [".", 2129], ["A", 2131], ["metabolite", 2133], ["and", 2144], ["an", 2148], ["artifact", 2151], ["of", 2160], ["flumazenil", 2163], ["could", 2174], ["be", 2180], ["identified", 2183], ["in", 2194], ["urine", 2197], ["by", 2203], ["gas", 2206], ["chromatography", 2210], ["/", 2224], ["mass", 2225], ["spectrometry", 2230], [".", 2242]]}
{"context": "Parkinson's disease (PD) is a neurodegenerative disease with characteristics and symptoms that are well defined. Nevertheless, its aetiology remains unknown. PD is characterized by the presence of Lewy bodies inside neurons. \u03b1-Synuclein (\u03b1-syn) is a soluble protein present in the pre-synaptic terminal of neurons. Evidence suggests that \u03b1-syn has a fundamental role in PD pathogenesis, given that it is an important component of Lewy bodies localized in the dopaminergic neurons of PD patients. In the present study, we investigated the influence of wild type (WT) and A30P \u03b1-syn overexpression on neuroblastoma SH-SY5Y toxicity induced by the conditioned medium (CM) from primary cultures of glia challenged with lipopolysaccharide (LPS) from Escherichia coli. We observed that SH-SY5Y cells transduced with \u03b1-syn (WT or A30P) and treated with CM from LPS-activated glia cells show evidence of cell death, which is not reverted by NF-\u03baB inhibition by sodium salicylate or by blockage of P50 (NF-\u03baB subunit). Furthermore, the expression of A30P \u03b1-syn in neuroblastoma SH-SY5Y decreases the cell death triggered by the CM of activated glia versus WT \u03b1-syn or control group. This effect of A30P \u03b1-syn may be due to the low MAPK42/44 phosphorylation. This finding is substantiated by MEK1 inhibition by PD98059, decreasing LDH release by CM in SH-SY5Y cells. Our results suggest that SH-SY5Y cells transduced with \u03b1-syn (WT or A30P) and treated with CM from LPS-activated glia cells show cell death, which is not reverted by NF-\u03baB blockage. Additionally, the expression of A30P \u03b1-syn on neuroblastoma SH-SY5Y leads to decreased cell death triggered by the CM of activated glia, when compared to WT \u03b1-syn or control group. The mechanism underlying this process remains to be completely elucidated, but the present data suggest that MAPK42/44 phosphorylation plays an important role in this process. CRD42015020829.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "770cdf4bff11453d9e85c2d6c5857367", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[38, 40]], "char_spans": [[225, 235]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["a", 28], ["neurodegenerative", 30], ["disease", 48], ["with", 56], ["characteristics", 61], ["and", 77], ["symptoms", 81], ["that", 90], ["are", 95], ["well", 99], ["defined", 104], [".", 111], ["Nevertheless", 113], [",", 125], ["its", 127], ["aetiology", 131], ["remains", 141], ["unknown", 149], [".", 156], ["PD", 158], ["is", 161], ["characterized", 164], ["by", 178], ["the", 181], ["presence", 185], ["of", 194], ["Lewy", 197], ["bodies", 202], ["inside", 209], ["neurons", 216], [".", 223], ["\u03b1", 225], ["-", 226], ["Synuclein", 227], ["(", 237], ["\u03b1", 238], ["-", 239], ["syn", 240], [")", 243], ["is", 245], ["a", 248], ["soluble", 250], ["protein", 258], ["present", 266], ["in", 274], ["the", 277], ["pre", 281], ["-", 284], ["synaptic", 285], ["terminal", 294], ["of", 303], ["neurons", 306], [".", 313], ["Evidence", 315], ["suggests", 324], ["that", 333], ["\u03b1", 338], ["-", 339], ["syn", 340], ["has", 344], ["a", 348], ["fundamental", 350], ["role", 362], ["in", 367], ["PD", 370], ["pathogenesis", 373], [",", 385], ["given", 387], ["that", 393], ["it", 398], ["is", 401], ["an", 404], ["important", 407], ["component", 417], ["of", 427], ["Lewy", 430], ["bodies", 435], ["localized", 442], ["in", 452], ["the", 455], ["dopaminergic", 459], ["neurons", 472], ["of", 480], ["PD", 483], ["patients", 486], [".", 494], ["In", 496], ["the", 499], ["present", 503], ["study", 511], [",", 516], ["we", 518], ["investigated", 521], ["the", 534], ["influence", 538], ["of", 548], ["wild", 551], ["type", 556], ["(", 561], ["WT", 562], [")", 564], ["and", 566], ["A30P", 570], ["\u03b1", 575], ["-", 576], ["syn", 577], ["overexpression", 581], ["on", 596], ["neuroblastoma", 599], ["SH", 613], ["-", 615], ["SY5Y", 616], ["toxicity", 621], ["induced", 630], ["by", 638], ["the", 641], ["conditioned", 645], ["medium", 657], ["(", 664], ["CM", 665], [")", 667], ["from", 669], ["primary", 674], ["cultures", 682], ["of", 691], ["glia", 694], ["challenged", 699], ["with", 710], ["lipopolysaccharide", 715], ["(", 734], ["LPS", 735], [")", 738], ["from", 740], ["Escherichia", 745], ["coli", 757], [".", 761], ["We", 763], ["observed", 766], ["that", 775], ["SH", 780], ["-", 782], ["SY5Y", 783], ["cells", 788], ["transduced", 794], ["with", 805], ["\u03b1", 810], ["-", 811], ["syn", 812], ["(", 816], ["WT", 817], ["or", 820], ["A30P", 823], [")", 827], ["and", 829], ["treated", 833], ["with", 841], ["CM", 846], ["from", 849], ["LPS", 854], ["-", 857], ["activated", 858], ["glia", 868], ["cells", 873], ["show", 879], ["evidence", 884], ["of", 893], ["cell", 896], ["death", 901], [",", 906], ["which", 908], ["is", 914], ["not", 917], ["reverted", 921], ["by", 930], ["NF", 933], ["-", 935], ["\u03baB", 936], ["inhibition", 939], ["by", 950], ["sodium", 953], ["salicylate", 960], ["or", 971], ["by", 974], ["blockage", 977], ["of", 986], ["P50", 989], ["(", 993], ["NF", 994], ["-", 996], ["\u03baB", 997], ["subunit", 1000], [")", 1007], [".", 1008], ["Furthermore", 1010], [",", 1021], ["the", 1023], ["expression", 1027], ["of", 1038], ["A30P", 1041], ["\u03b1", 1046], ["-", 1047], ["syn", 1048], ["in", 1052], ["neuroblastoma", 1055], ["SH", 1069], ["-", 1071], ["SY5Y", 1072], ["decreases", 1077], ["the", 1087], ["cell", 1091], ["death", 1096], ["triggered", 1102], ["by", 1112], ["the", 1115], ["CM", 1119], ["of", 1122], ["activated", 1125], ["glia", 1135], ["versus", 1140], ["WT", 1147], ["\u03b1", 1150], ["-", 1151], ["syn", 1152], ["or", 1156], ["control", 1159], ["group", 1167], [".", 1172], ["This", 1174], ["effect", 1179], ["of", 1186], ["A30P", 1189], ["\u03b1", 1194], ["-", 1195], ["syn", 1196], ["may", 1200], ["be", 1204], ["due", 1207], ["to", 1211], ["the", 1214], ["low", 1218], ["MAPK42/44", 1222], ["phosphorylation", 1232], [".", 1247], ["This", 1249], ["finding", 1254], ["is", 1262], ["substantiated", 1265], ["by", 1279], ["MEK1", 1282], ["inhibition", 1287], ["by", 1298], ["PD98059", 1301], [",", 1308], ["decreasing", 1310], ["LDH", 1321], ["release", 1325], ["by", 1333], ["CM", 1336], ["in", 1339], ["SH", 1342], ["-", 1344], ["SY5Y", 1345], ["cells", 1350], [".", 1355], ["Our", 1357], ["results", 1361], ["suggest", 1369], ["that", 1377], ["SH", 1382], ["-", 1384], ["SY5Y", 1385], ["cells", 1390], ["transduced", 1396], ["with", 1407], ["\u03b1", 1412], ["-", 1413], ["syn", 1414], ["(", 1418], ["WT", 1419], ["or", 1422], ["A30P", 1425], [")", 1429], ["and", 1431], ["treated", 1435], ["with", 1443], ["CM", 1448], ["from", 1451], ["LPS", 1456], ["-", 1459], ["activated", 1460], ["glia", 1470], ["cells", 1475], ["show", 1481], ["cell", 1486], ["death", 1491], [",", 1496], ["which", 1498], ["is", 1504], ["not", 1507], ["reverted", 1511], ["by", 1520], ["NF", 1523], ["-", 1525], ["\u03baB", 1526], ["blockage", 1529], [".", 1537], ["Additionally", 1539], [",", 1551], ["the", 1553], ["expression", 1557], ["of", 1568], ["A30P", 1571], ["\u03b1", 1576], ["-", 1577], ["syn", 1578], ["on", 1582], ["neuroblastoma", 1585], ["SH", 1599], ["-", 1601], ["SY5Y", 1602], ["leads", 1607], ["to", 1613], ["decreased", 1616], ["cell", 1626], ["death", 1631], ["triggered", 1637], ["by", 1647], ["the", 1650], ["CM", 1654], ["of", 1657], ["activated", 1660], ["glia", 1670], [",", 1674], ["when", 1676], ["compared", 1681], ["to", 1690], ["WT", 1693], ["\u03b1", 1696], ["-", 1697], ["syn", 1698], ["or", 1702], ["control", 1705], ["group", 1713], [".", 1718], ["The", 1720], ["mechanism", 1724], ["underlying", 1734], ["this", 1745], ["process", 1750], ["remains", 1758], ["to", 1766], ["be", 1769], ["completely", 1772], ["elucidated", 1783], [",", 1793], ["but", 1795], ["the", 1799], ["present", 1803], ["data", 1811], ["suggest", 1816], ["that", 1824], ["MAPK42/44", 1829], ["phosphorylation", 1839], ["plays", 1855], ["an", 1861], ["important", 1864], ["role", 1874], ["in", 1879], ["this", 1882], ["process", 1887], [".", 1894], ["CRD42015020829", 1896], [".", 1910]]}
{"context": "Although peak finding in next-generation sequencing (NGS) datasets has been addressed extensively, there is no consensus on how to analyze and process biological replicates. Furthermore, most peak finders do not focus on accurate determination of enrichment site widths and are not widely applicable to different types of datasets. We developed JAMM (Joint Analysis of NGS replicates via Mixture Model clustering): a peak finder that can integrate information from biological replicates, determine enrichment site widths accurately and resolve neighboring narrow peaks. JAMM is a universal peak finder that is applicable to different types of datasets. We show that JAMM is among the best performing peak finders in terms of site detection accuracy and in terms of accurate determination of enrichment sites widths. In addition, JAMM's replicate integration improves peak spatial resolution, sorting and peak finding accuracy. JAMM is available for free and can run on Linux machines through the command line: http://code.google.com/p/jamm-peak-finder.", "qas": [{"question": "Which peak calling algorithm employs mixture model clustering under the hood?", "answers": ["JAMM"], "qid": "34f812a7bd0645b481c7269f56ee725d", "question_tokens": [["Which", 0], ["peak", 6], ["calling", 11], ["algorithm", 19], ["employs", 29], ["mixture", 37], ["model", 45], ["clustering", 51], ["under", 62], ["the", 68], ["hood", 72], ["?", 76]], "detected_answers": [{"text": "JAMM", "token_spans": [[139, 139], [93, 93], [154, 154], [58, 58], [111, 111]], "char_spans": [[829, 832], [570, 573], [927, 930], [345, 348], [666, 669]]}]}], "context_tokens": [["Although", 0], ["peak", 9], ["finding", 14], ["in", 22], ["next", 25], ["-", 29], ["generation", 30], ["sequencing", 41], ["(", 52], ["NGS", 53], [")", 56], ["datasets", 58], ["has", 67], ["been", 71], ["addressed", 76], ["extensively", 86], [",", 97], ["there", 99], ["is", 105], ["no", 108], ["consensus", 111], ["on", 121], ["how", 124], ["to", 128], ["analyze", 131], ["and", 139], ["process", 143], ["biological", 151], ["replicates", 162], [".", 172], ["Furthermore", 174], [",", 185], ["most", 187], ["peak", 192], ["finders", 197], ["do", 205], ["not", 208], ["focus", 212], ["on", 218], ["accurate", 221], ["determination", 230], ["of", 244], ["enrichment", 247], ["site", 258], ["widths", 263], ["and", 270], ["are", 274], ["not", 278], ["widely", 282], ["applicable", 289], ["to", 300], ["different", 303], ["types", 313], ["of", 319], ["datasets", 322], [".", 330], ["We", 332], ["developed", 335], ["JAMM", 345], ["(", 350], ["Joint", 351], ["Analysis", 357], ["of", 366], ["NGS", 369], ["replicates", 373], ["via", 384], ["Mixture", 388], ["Model", 396], ["clustering", 402], [")", 412], [":", 413], ["a", 415], ["peak", 417], ["finder", 422], ["that", 429], ["can", 434], ["integrate", 438], ["information", 448], ["from", 460], ["biological", 465], ["replicates", 476], [",", 486], ["determine", 488], ["enrichment", 498], ["site", 509], ["widths", 514], ["accurately", 521], ["and", 532], ["resolve", 536], ["neighboring", 544], ["narrow", 556], ["peaks", 563], [".", 568], ["JAMM", 570], ["is", 575], ["a", 578], ["universal", 580], ["peak", 590], ["finder", 595], ["that", 602], ["is", 607], ["applicable", 610], ["to", 621], ["different", 624], ["types", 634], ["of", 640], ["datasets", 643], [".", 651], ["We", 653], ["show", 656], ["that", 661], ["JAMM", 666], ["is", 671], ["among", 674], ["the", 680], ["best", 684], ["performing", 689], ["peak", 700], ["finders", 705], ["in", 713], ["terms", 716], ["of", 722], ["site", 725], ["detection", 730], ["accuracy", 740], ["and", 749], ["in", 753], ["terms", 756], ["of", 762], ["accurate", 765], ["determination", 774], ["of", 788], ["enrichment", 791], ["sites", 802], ["widths", 808], [".", 814], ["In", 816], ["addition", 819], [",", 827], ["JAMM", 829], ["'s", 833], ["replicate", 836], ["integration", 846], ["improves", 858], ["peak", 867], ["spatial", 872], ["resolution", 880], [",", 890], ["sorting", 892], ["and", 900], ["peak", 904], ["finding", 909], ["accuracy", 917], [".", 925], ["JAMM", 927], ["is", 932], ["available", 935], ["for", 945], ["free", 949], ["and", 954], ["can", 958], ["run", 962], ["on", 966], ["Linux", 969], ["machines", 975], ["through", 984], ["the", 992], ["command", 996], ["line", 1004], [":", 1008], ["http://code.google.com/p/jamm-peak-finder", 1010], [".", 1051]]}
{"context": "Neurological abnormalities associated with spiculated, \"acanthocytic\" red cells in blood have been described as neuroacanthocytosis. This is a heterogeneous group of conditions that can be clearly subdivided on the basis of recent genetic findings. The McLeod Syndrome, one of the core neuroacanthocytosis syndromes, is a rare X-linked disorder caused by mutations of the XK gene, an X-chromosomal gene of unknown function characterized by haemopoietic abnormalities and late-onset neurological and muscular defects. We report two Chilean brothers with the McLeod phenotype who showed important psychiatric features. The diagnosis may be elusive if the presence of acanthocytosis is not properly studied. We describe a method which allowed the diagnosis that unmasked acanthocytosis. Otherwise the condition could have remained undiagnosed as it had been for decades in this family. This syndrome must be considered when assessing a familial movement disorder, specially affecting males with relevant psychiatric features. A reliable test for acanthocytosis assessment is available.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "c79bc1f8f85548358708cf9eb729f140", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[62, 62]], "char_spans": [[372, 373]]}]}], "context_tokens": [["Neurological", 0], ["abnormalities", 13], ["associated", 27], ["with", 38], ["spiculated", 43], [",", 53], ["\"", 55], ["acanthocytic", 56], ["\"", 68], ["red", 70], ["cells", 74], ["in", 80], ["blood", 83], ["have", 89], ["been", 94], ["described", 99], ["as", 109], ["neuroacanthocytosis", 112], [".", 131], ["This", 133], ["is", 138], ["a", 141], ["heterogeneous", 143], ["group", 157], ["of", 163], ["conditions", 166], ["that", 177], ["can", 182], ["be", 186], ["clearly", 189], ["subdivided", 197], ["on", 208], ["the", 211], ["basis", 215], ["of", 221], ["recent", 224], ["genetic", 231], ["findings", 239], [".", 247], ["The", 249], ["McLeod", 253], ["Syndrome", 260], [",", 268], ["one", 270], ["of", 274], ["the", 277], ["core", 281], ["neuroacanthocytosis", 286], ["syndromes", 306], [",", 315], ["is", 317], ["a", 320], ["rare", 322], ["X", 327], ["-", 328], ["linked", 329], ["disorder", 336], ["caused", 345], ["by", 352], ["mutations", 355], ["of", 365], ["the", 368], ["XK", 372], ["gene", 375], [",", 379], ["an", 381], ["X", 384], ["-", 385], ["chromosomal", 386], ["gene", 398], ["of", 403], ["unknown", 406], ["function", 414], ["characterized", 423], ["by", 437], ["haemopoietic", 440], ["abnormalities", 453], ["and", 467], ["late", 471], ["-", 475], ["onset", 476], ["neurological", 482], ["and", 495], ["muscular", 499], ["defects", 508], [".", 515], ["We", 517], ["report", 520], ["two", 527], ["Chilean", 531], ["brothers", 539], ["with", 548], ["the", 553], ["McLeod", 557], ["phenotype", 564], ["who", 574], ["showed", 578], ["important", 585], ["psychiatric", 595], ["features", 607], [".", 615], ["The", 617], ["diagnosis", 621], ["may", 631], ["be", 635], ["elusive", 638], ["if", 646], ["the", 649], ["presence", 653], ["of", 662], ["acanthocytosis", 665], ["is", 680], ["not", 683], ["properly", 687], ["studied", 696], [".", 703], ["We", 705], ["describe", 708], ["a", 717], ["method", 719], ["which", 726], ["allowed", 732], ["the", 740], ["diagnosis", 744], ["that", 754], ["unmasked", 759], ["acanthocytosis", 768], [".", 782], ["Otherwise", 784], ["the", 794], ["condition", 798], ["could", 808], ["have", 814], ["remained", 819], ["undiagnosed", 828], ["as", 840], ["it", 843], ["had", 846], ["been", 850], ["for", 855], ["decades", 859], ["in", 867], ["this", 870], ["family", 875], [".", 881], ["This", 883], ["syndrome", 888], ["must", 897], ["be", 902], ["considered", 905], ["when", 916], ["assessing", 921], ["a", 931], ["familial", 933], ["movement", 942], ["disorder", 951], [",", 959], ["specially", 961], ["affecting", 971], ["males", 981], ["with", 987], ["relevant", 992], ["psychiatric", 1001], ["features", 1013], [".", 1021], ["A", 1023], ["reliable", 1025], ["test", 1034], ["for", 1039], ["acanthocytosis", 1043], ["assessment", 1058], ["is", 1069], ["available", 1072], [".", 1081]]}
{"context": "CLIP-Seq protocols such as PAR-CLIP, HITS-CLIP or iCLIP allow a genome-wide analysis of protein-RNA interactions. For the processing of the resulting short read data, various tools are utilized. Some of these tools were specifically developed for CLIP-Seq data, whereas others were designed for the analysis of RNA-Seq data. To this date, however, it has not been assessed which of the available tools are most appropriate for the analysis of CLIP-Seq data. This is because an experimental gold standard dataset on which methods can be accessed and compared, is still not available. To address this lack of a gold-standard dataset, we here present Cseq-Simulator, a simulator for PAR-CLIP, HITS-CLIP and iCLIP-data. This simulator can be applied to generate realistic datasets that can serve as surrogates for experimental gold standard dataset. In this work, we also show how Cseq-Simulator can be used to perform a comparison of steps of typical CLIP-Seq analysis pipelines, such as the read alignment or the peak calling. These comparisons show which tools are useful in different settings and also allow identifying pitfalls in the data analysis.", "qas": [{"question": "Which data simulator is available for CLIP-SEQ experiments?", "answers": ["Cseq-Simulator"], "qid": "eb43bbf0c4bb484dba710614100c1204", "question_tokens": [["Which", 0], ["data", 6], ["simulator", 11], ["is", 21], ["available", 24], ["for", 34], ["CLIP", 38], ["-", 42], ["SEQ", 43], ["experiments", 47], ["?", 58]], "detected_answers": [{"text": "Cseq-Simulator", "token_spans": [[132, 134], [179, 181]], "char_spans": [[648, 661], [877, 890]]}]}], "context_tokens": [["CLIP", 0], ["-", 4], ["Seq", 5], ["protocols", 9], ["such", 19], ["as", 24], ["PAR", 27], ["-", 30], ["CLIP", 31], [",", 35], ["HITS", 37], ["-", 41], ["CLIP", 42], ["or", 47], ["iCLIP", 50], ["allow", 56], ["a", 62], ["genome", 64], ["-", 70], ["wide", 71], ["analysis", 76], ["of", 85], ["protein", 88], ["-", 95], ["RNA", 96], ["interactions", 100], [".", 112], ["For", 114], ["the", 118], ["processing", 122], ["of", 133], ["the", 136], ["resulting", 140], ["short", 150], ["read", 156], ["data", 161], [",", 165], ["various", 167], ["tools", 175], ["are", 181], ["utilized", 185], [".", 193], ["Some", 195], ["of", 200], ["these", 203], ["tools", 209], ["were", 215], ["specifically", 220], ["developed", 233], ["for", 243], ["CLIP", 247], ["-", 251], ["Seq", 252], ["data", 256], [",", 260], ["whereas", 262], ["others", 270], ["were", 277], ["designed", 282], ["for", 291], ["the", 295], ["analysis", 299], ["of", 308], ["RNA", 311], ["-", 314], ["Seq", 315], ["data", 319], [".", 323], ["To", 325], ["this", 328], ["date", 333], [",", 337], ["however", 339], [",", 346], ["it", 348], ["has", 351], ["not", 355], ["been", 359], ["assessed", 364], ["which", 373], ["of", 379], ["the", 382], ["available", 386], ["tools", 396], ["are", 402], ["most", 406], ["appropriate", 411], ["for", 423], ["the", 427], ["analysis", 431], ["of", 440], ["CLIP", 443], ["-", 447], ["Seq", 448], ["data", 452], [".", 456], ["This", 458], ["is", 463], ["because", 466], ["an", 474], ["experimental", 477], ["gold", 490], ["standard", 495], ["dataset", 504], ["on", 512], ["which", 515], ["methods", 521], ["can", 529], ["be", 533], ["accessed", 536], ["and", 545], ["compared", 549], [",", 557], ["is", 559], ["still", 562], ["not", 568], ["available", 572], [".", 581], ["To", 583], ["address", 586], ["this", 594], ["lack", 599], ["of", 604], ["a", 607], ["gold", 609], ["-", 613], ["standard", 614], ["dataset", 623], [",", 630], ["we", 632], ["here", 635], ["present", 640], ["Cseq", 648], ["-", 652], ["Simulator", 653], [",", 662], ["a", 664], ["simulator", 666], ["for", 676], ["PAR", 680], ["-", 683], ["CLIP", 684], [",", 688], ["HITS", 690], ["-", 694], ["CLIP", 695], ["and", 700], ["iCLIP", 704], ["-", 709], ["data", 710], [".", 714], ["This", 716], ["simulator", 721], ["can", 731], ["be", 735], ["applied", 738], ["to", 746], ["generate", 749], ["realistic", 758], ["datasets", 768], ["that", 777], ["can", 782], ["serve", 786], ["as", 792], ["surrogates", 795], ["for", 806], ["experimental", 810], ["gold", 823], ["standard", 828], ["dataset", 837], [".", 844], ["In", 846], ["this", 849], ["work", 854], [",", 858], ["we", 860], ["also", 863], ["show", 868], ["how", 873], ["Cseq", 877], ["-", 881], ["Simulator", 882], ["can", 892], ["be", 896], ["used", 899], ["to", 904], ["perform", 907], ["a", 915], ["comparison", 917], ["of", 928], ["steps", 931], ["of", 937], ["typical", 940], ["CLIP", 948], ["-", 952], ["Seq", 953], ["analysis", 957], ["pipelines", 966], [",", 975], ["such", 977], ["as", 982], ["the", 985], ["read", 989], ["alignment", 994], ["or", 1004], ["the", 1007], ["peak", 1011], ["calling", 1016], [".", 1023], ["These", 1025], ["comparisons", 1031], ["show", 1043], ["which", 1048], ["tools", 1054], ["are", 1060], ["useful", 1064], ["in", 1071], ["different", 1074], ["settings", 1084], ["and", 1093], ["also", 1097], ["allow", 1102], ["identifying", 1108], ["pitfalls", 1120], ["in", 1129], ["the", 1132], ["data", 1136], ["analysis", 1141], [".", 1149]]}
{"context": "To investigate whether body mass index (BMI), as a proxy for body fat, influences rheumatoid arthritis (RA) disease activity in a gender-specific manner. Consecutive patients with RA were enrolled from 25 countries into the QUEST-RA program between 2005 and 2008. Clinical and demographic data were collected by treating rheumatologists and by patient self-report. Distributions of Disease Activity Scores (DAS28), BMI, age, and disease duration were assessed for each country and for the entire dataset; mean values between genders were compared using Student's t-tests. An association between BMI and DAS28 was investigated using linear regression, adjusting for age, disease duration and country. A total of 5,161 RA patients (4,082 women and 1,079 men) were included in the analyses. Overall, women were younger, had longer disease duration, and higher DAS28 scores than men, but BMI was similar between genders. The mean DAS28 scores increased with increasing BMI from normal to overweight and obese, among women, whereas the opposite trend was observed among men. Regression results showed BMI (continuous or categorical) to be associated with DAS28. Compared to the normal BMI range, being obese was associated with a larger difference in mean DAS28 (0.23, 95% CI: 0.11, 0.34) than being overweight (0.12, 95% CI: 0.03, 0.21); being underweight was not associated with disease activity. These associations were more pronounced among women, and were not explained by any single component of the DAS28. BMI appears to be associated with RA disease activity in women, but not in men.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "caa2671c22184059b24fc1b2ad609ea4", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[189, 189], [298, 298], [150, 150], [137, 137], [274, 274]], "char_spans": [[1012, 1016], [1565, 1569], [797, 801], [736, 740], [1440, 1444]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["whether", 15], ["body", 23], ["mass", 28], ["index", 33], ["(", 39], ["BMI", 40], [")", 43], [",", 44], ["as", 46], ["a", 49], ["proxy", 51], ["for", 57], ["body", 61], ["fat", 66], [",", 69], ["influences", 71], ["rheumatoid", 82], ["arthritis", 93], ["(", 103], ["RA", 104], [")", 106], ["disease", 108], ["activity", 116], ["in", 125], ["a", 128], ["gender", 130], ["-", 136], ["specific", 137], ["manner", 146], [".", 152], ["Consecutive", 154], ["patients", 166], ["with", 175], ["RA", 180], ["were", 183], ["enrolled", 188], ["from", 197], ["25", 202], ["countries", 205], ["into", 215], ["the", 220], ["QUEST", 224], ["-", 229], ["RA", 230], ["program", 233], ["between", 241], ["2005", 249], ["and", 254], ["2008", 258], [".", 262], ["Clinical", 264], ["and", 273], ["demographic", 277], ["data", 289], ["were", 294], ["collected", 299], ["by", 309], ["treating", 312], ["rheumatologists", 321], ["and", 337], ["by", 341], ["patient", 344], ["self", 352], ["-", 356], ["report", 357], [".", 363], ["Distributions", 365], ["of", 379], ["Disease", 382], ["Activity", 390], ["Scores", 399], ["(", 406], ["DAS28", 407], [")", 412], [",", 413], ["BMI", 415], [",", 418], ["age", 420], [",", 423], ["and", 425], ["disease", 429], ["duration", 437], ["were", 446], ["assessed", 451], ["for", 460], ["each", 464], ["country", 469], ["and", 477], ["for", 481], ["the", 485], ["entire", 489], ["dataset", 496], [";", 503], ["mean", 505], ["values", 510], ["between", 517], ["genders", 525], ["were", 533], ["compared", 538], ["using", 547], ["Student", 553], ["'s", 560], ["t", 563], ["-", 564], ["tests", 565], [".", 570], ["An", 572], ["association", 575], ["between", 587], ["BMI", 595], ["and", 599], ["DAS28", 603], ["was", 609], ["investigated", 613], ["using", 626], ["linear", 632], ["regression", 639], [",", 649], ["adjusting", 651], ["for", 661], ["age", 665], [",", 668], ["disease", 670], ["duration", 678], ["and", 687], ["country", 691], [".", 698], ["A", 700], ["total", 702], ["of", 708], ["5,161", 711], ["RA", 717], ["patients", 720], ["(", 729], ["4,082", 730], ["women", 736], ["and", 742], ["1,079", 746], ["men", 752], [")", 755], ["were", 757], ["included", 762], ["in", 771], ["the", 774], ["analyses", 778], [".", 786], ["Overall", 788], [",", 795], ["women", 797], ["were", 803], ["younger", 808], [",", 815], ["had", 817], ["longer", 821], ["disease", 828], ["duration", 836], [",", 844], ["and", 846], ["higher", 850], ["DAS28", 857], ["scores", 863], ["than", 870], ["men", 875], [",", 878], ["but", 880], ["BMI", 884], ["was", 888], ["similar", 892], ["between", 900], ["genders", 908], [".", 915], ["The", 917], ["mean", 921], ["DAS28", 926], ["scores", 932], ["increased", 939], ["with", 949], ["increasing", 954], ["BMI", 965], ["from", 969], ["normal", 974], ["to", 981], ["overweight", 984], ["and", 995], ["obese", 999], [",", 1004], ["among", 1006], ["women", 1012], [",", 1017], ["whereas", 1019], ["the", 1027], ["opposite", 1031], ["trend", 1040], ["was", 1046], ["observed", 1050], ["among", 1059], ["men", 1065], [".", 1068], ["Regression", 1070], ["results", 1081], ["showed", 1089], ["BMI", 1096], ["(", 1100], ["continuous", 1101], ["or", 1112], ["categorical", 1115], [")", 1126], ["to", 1128], ["be", 1131], ["associated", 1134], ["with", 1145], ["DAS28", 1150], [".", 1155], ["Compared", 1157], ["to", 1166], ["the", 1169], ["normal", 1173], ["BMI", 1180], ["range", 1184], [",", 1189], ["being", 1191], ["obese", 1197], ["was", 1203], ["associated", 1207], ["with", 1218], ["a", 1223], ["larger", 1225], ["difference", 1232], ["in", 1243], ["mean", 1246], ["DAS28", 1251], ["(", 1257], ["0.23", 1258], [",", 1262], ["95", 1264], ["%", 1266], ["CI", 1268], [":", 1270], ["0.11", 1272], [",", 1276], ["0.34", 1278], [")", 1282], ["than", 1284], ["being", 1289], ["overweight", 1295], ["(", 1306], ["0.12", 1307], [",", 1311], ["95", 1313], ["%", 1315], ["CI", 1317], [":", 1319], ["0.03", 1321], [",", 1325], ["0.21", 1327], [")", 1331], [";", 1332], ["being", 1334], ["underweight", 1340], ["was", 1352], ["not", 1356], ["associated", 1360], ["with", 1371], ["disease", 1376], ["activity", 1384], [".", 1392], ["These", 1394], ["associations", 1400], ["were", 1413], ["more", 1418], ["pronounced", 1423], ["among", 1434], ["women", 1440], [",", 1445], ["and", 1447], ["were", 1451], ["not", 1456], ["explained", 1460], ["by", 1470], ["any", 1473], ["single", 1477], ["component", 1484], ["of", 1494], ["the", 1497], ["DAS28", 1501], [".", 1506], ["BMI", 1508], ["appears", 1512], ["to", 1520], ["be", 1523], ["associated", 1526], ["with", 1537], ["RA", 1542], ["disease", 1545], ["activity", 1553], ["in", 1562], ["women", 1565], [",", 1570], ["but", 1572], ["not", 1576], ["in", 1580], ["men", 1583], [".", 1586]]}
{"context": "Imatinib mesylate (STI 571; Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) is an orally available tyrosine kinase inhibitor that targets a constitutively activated BCR-ABL tyrosine kinase with additional inhibitory effects on platelet derived growth factor (PDGF) receptors alpha and beta, and KIT. It has revolutionized the treatment of adult and pediatric patients with Philadelphia chromosome positive chronic myelogenous leukemia (CML) and is also FDA-approved for KIT-positive advanced gastrointestinal tumor (GIST) and dermatofibrosarcoma protuberans. A wide spectrum of dermatologic toxicities has been associated with this agent, among which a maculopapular rash is the most common event. In addition, a variety of pigmentary abnormalities of the skin and mucosal surfaces have been reported. Hypopigmentation is a well-recognized adverse effect. In contrast, paradoxical hyperpigmentation has only rarely been documented. In this case report we describe imatinib-induced cutaneous hyperpigmentation and graying of hair occurring in the same patient with dermatofibrosarcoma protuberans treated with imatinib.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "631900f5ead84eacaf274c45701f595a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[27, 29]], "char_spans": [[172, 178]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["(", 18], ["STI", 19], ["571", 23], [";", 26], ["Gleevec", 28], [";", 35], ["Novartis", 37], ["Pharmaceuticals", 46], [",", 61], ["Basel", 63], [",", 68], ["Switzerland", 70], [")", 81], ["is", 83], ["an", 86], ["orally", 89], ["available", 96], ["tyrosine", 106], ["kinase", 115], ["inhibitor", 122], ["that", 132], ["targets", 137], ["a", 145], ["constitutively", 147], ["activated", 162], ["BCR", 172], ["-", 175], ["ABL", 176], ["tyrosine", 180], ["kinase", 189], ["with", 196], ["additional", 201], ["inhibitory", 212], ["effects", 223], ["on", 231], ["platelet", 234], ["derived", 243], ["growth", 251], ["factor", 258], ["(", 265], ["PDGF", 266], [")", 270], ["receptors", 272], ["alpha", 282], ["and", 288], ["beta", 292], [",", 296], ["and", 298], ["KIT", 302], [".", 305], ["It", 307], ["has", 310], ["revolutionized", 314], ["the", 329], ["treatment", 333], ["of", 343], ["adult", 346], ["and", 352], ["pediatric", 356], ["patients", 366], ["with", 375], ["Philadelphia", 380], ["chromosome", 393], ["positive", 404], ["chronic", 413], ["myelogenous", 421], ["leukemia", 433], ["(", 442], ["CML", 443], [")", 446], ["and", 448], ["is", 452], ["also", 455], ["FDA", 460], ["-", 463], ["approved", 464], ["for", 473], ["KIT", 477], ["-", 480], ["positive", 481], ["advanced", 490], ["gastrointestinal", 499], ["tumor", 516], ["(", 522], ["GIST", 523], [")", 527], ["and", 529], ["dermatofibrosarcoma", 533], ["protuberans", 553], [".", 564], ["A", 566], ["wide", 568], ["spectrum", 573], ["of", 582], ["dermatologic", 585], ["toxicities", 598], ["has", 609], ["been", 613], ["associated", 618], ["with", 629], ["this", 634], ["agent", 639], [",", 644], ["among", 646], ["which", 652], ["a", 658], ["maculopapular", 660], ["rash", 674], ["is", 679], ["the", 682], ["most", 686], ["common", 691], ["event", 698], [".", 703], ["In", 705], ["addition", 708], [",", 716], ["a", 718], ["variety", 720], ["of", 728], ["pigmentary", 731], ["abnormalities", 742], ["of", 756], ["the", 759], ["skin", 763], ["and", 768], ["mucosal", 772], ["surfaces", 780], ["have", 789], ["been", 794], ["reported", 799], [".", 807], ["Hypopigmentation", 809], ["is", 826], ["a", 829], ["well", 831], ["-", 835], ["recognized", 836], ["adverse", 847], ["effect", 855], [".", 861], ["In", 863], ["contrast", 866], [",", 874], ["paradoxical", 876], ["hyperpigmentation", 888], ["has", 906], ["only", 910], ["rarely", 915], ["been", 922], ["documented", 927], [".", 937], ["In", 939], ["this", 942], ["case", 947], ["report", 952], ["we", 959], ["describe", 962], ["imatinib", 971], ["-", 979], ["induced", 980], ["cutaneous", 988], ["hyperpigmentation", 998], ["and", 1016], ["graying", 1020], ["of", 1028], ["hair", 1031], ["occurring", 1036], ["in", 1046], ["the", 1049], ["same", 1053], ["patient", 1058], ["with", 1066], ["dermatofibrosarcoma", 1071], ["protuberans", 1091], ["treated", 1103], ["with", 1111], ["imatinib", 1116], [".", 1124]]}
{"context": "Chronic myeloid leukemia (CML) is the first human malignancy for which the promise of targeted therapy has come true. CML is invariably associated with a specific genetic lesion--the t(9;22) chromosomal translocation. As a consequence of this translocation, a BCR-ABL fusion gene is formed on the 22q- derivative (traditionally known as the Philadelphia chromosome) and the deregulated tyrosine kinase activity of the protein encoded by this gene has been shown to be both necessary and sufficient for initiation and maintenance of the disease. Imatinib mesylate, an orally available tyrosine kinase inhibitor that targets Bcr-Abl, entered clinical evaluation in 1998. Its efficacy surpassed almost everyone's predictions, and the observation of high response rates and favorable toxicity profile associated with imatinib therapy led to its approval as first-line treatment for all newly diagnosed CML patients over an exceptionally short period of time. The 6-year results of the Phase III trial have recently been reported and confirm durability of responses and declining incidence of adverse events over time, although, at present, occurrence of unexpected side effects in the long term cannot be excluded. Although imatinib does not 'cure' CML and has to be administered chronically to patients, it has revolutionized both outcome and quality of life of CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "b84adc8ad62e42e3b5cd84477d1d0750", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[46, 48], [106, 108]], "char_spans": [[260, 266], [623, 629]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["the", 34], ["first", 38], ["human", 44], ["malignancy", 50], ["for", 61], ["which", 65], ["the", 71], ["promise", 75], ["of", 83], ["targeted", 86], ["therapy", 95], ["has", 103], ["come", 107], ["true", 112], [".", 116], ["CML", 118], ["is", 122], ["invariably", 125], ["associated", 136], ["with", 147], ["a", 152], ["specific", 154], ["genetic", 163], ["lesion", 171], ["--", 177], ["the", 179], ["t(9;22", 183], [")", 189], ["chromosomal", 191], ["translocation", 203], [".", 216], ["As", 218], ["a", 221], ["consequence", 223], ["of", 235], ["this", 238], ["translocation", 243], [",", 256], ["a", 258], ["BCR", 260], ["-", 263], ["ABL", 264], ["fusion", 268], ["gene", 275], ["is", 280], ["formed", 283], ["on", 290], ["the", 293], ["22q-", 297], ["derivative", 302], ["(", 313], ["traditionally", 314], ["known", 328], ["as", 334], ["the", 337], ["Philadelphia", 341], ["chromosome", 354], [")", 364], ["and", 366], ["the", 370], ["deregulated", 374], ["tyrosine", 386], ["kinase", 395], ["activity", 402], ["of", 411], ["the", 414], ["protein", 418], ["encoded", 426], ["by", 434], ["this", 437], ["gene", 442], ["has", 447], ["been", 451], ["shown", 456], ["to", 462], ["be", 465], ["both", 468], ["necessary", 473], ["and", 483], ["sufficient", 487], ["for", 498], ["initiation", 502], ["and", 513], ["maintenance", 517], ["of", 529], ["the", 532], ["disease", 536], [".", 543], ["Imatinib", 545], ["mesylate", 554], [",", 562], ["an", 564], ["orally", 567], ["available", 574], ["tyrosine", 584], ["kinase", 593], ["inhibitor", 600], ["that", 610], ["targets", 615], ["Bcr", 623], ["-", 626], ["Abl", 627], [",", 630], ["entered", 632], ["clinical", 640], ["evaluation", 649], ["in", 660], ["1998", 663], [".", 667], ["Its", 669], ["efficacy", 673], ["surpassed", 682], ["almost", 692], ["everyone", 699], ["'s", 707], ["predictions", 710], [",", 721], ["and", 723], ["the", 727], ["observation", 731], ["of", 743], ["high", 746], ["response", 751], ["rates", 760], ["and", 766], ["favorable", 770], ["toxicity", 780], ["profile", 789], ["associated", 797], ["with", 808], ["imatinib", 813], ["therapy", 822], ["led", 830], ["to", 834], ["its", 837], ["approval", 841], ["as", 850], ["first", 853], ["-", 858], ["line", 859], ["treatment", 864], ["for", 874], ["all", 878], ["newly", 882], ["diagnosed", 888], ["CML", 898], ["patients", 902], ["over", 911], ["an", 916], ["exceptionally", 919], ["short", 933], ["period", 939], ["of", 946], ["time", 949], [".", 953], ["The", 955], ["6-year", 959], ["results", 966], ["of", 974], ["the", 977], ["Phase", 981], ["III", 987], ["trial", 991], ["have", 997], ["recently", 1002], ["been", 1011], ["reported", 1016], ["and", 1025], ["confirm", 1029], ["durability", 1037], ["of", 1048], ["responses", 1051], ["and", 1061], ["declining", 1065], ["incidence", 1075], ["of", 1085], ["adverse", 1088], ["events", 1096], ["over", 1103], ["time", 1108], [",", 1112], ["although", 1114], [",", 1122], ["at", 1124], ["present", 1127], [",", 1134], ["occurrence", 1136], ["of", 1147], ["unexpected", 1150], ["side", 1161], ["effects", 1166], ["in", 1174], ["the", 1177], ["long", 1181], ["term", 1186], ["can", 1191], ["not", 1194], ["be", 1198], ["excluded", 1201], [".", 1209], ["Although", 1211], ["imatinib", 1220], ["does", 1229], ["not", 1234], ["'", 1238], ["cure", 1239], ["'", 1243], ["CML", 1245], ["and", 1249], ["has", 1253], ["to", 1257], ["be", 1260], ["administered", 1263], ["chronically", 1276], ["to", 1288], ["patients", 1291], [",", 1299], ["it", 1301], ["has", 1304], ["revolutionized", 1308], ["both", 1323], ["outcome", 1328], ["and", 1336], ["quality", 1340], ["of", 1348], ["life", 1351], ["of", 1356], ["CML", 1359], ["patients", 1363], [".", 1371]]}
{"context": "Restless legs syndrome/Willis Ekbom disease (RLS/WED) has been recognized as a significant medical disorder since the 17th century. It was studied mostly in the last 50 years in relation to increasing interest in sleep medicine and health-related quality of life. This led to recognition that the disease is not well characterized as restless feelings in the legs. These symptoms are reported in many situations, but the subjective experience of RLS/WED patients differs from that experienced by others. Thus a new name has been introduced that avoids problems of symptom definition of a disease by naming it after those who first characterized it, i.e. 'Willis Ekbom disease'. This article emphasizes the importance of RLS/WED for psychiatry. The disease carries significant increased risk for depression and anxiety disorders. Treatment requires consideration of these co-morbid disorders. RLS/WED can exacerbate or even engender psychiatric disease, so treatment of psychiatric disease should also include consideration of RLS/WED. The need for attention to RLS/WED is particularly significant for depression. Most anti-depressants exacerbate or can even engender RLS/WED. Thus this article seeks to introduce RLS/WED in relation to psychiatric practice. It presents the RLS/WED disease, its overlap with psychiatry and the current treatment options.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "289d6353e4064a62a58db9f9192b3eff", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["/", 22], ["Willis", 23], ["Ekbom", 30], ["disease", 36], ["(", 44], ["RLS", 45], ["/", 48], ["WED", 49], [")", 52], ["has", 54], ["been", 58], ["recognized", 63], ["as", 74], ["a", 77], ["significant", 79], ["medical", 91], ["disorder", 99], ["since", 108], ["the", 114], ["17th", 118], ["century", 123], [".", 130], ["It", 132], ["was", 135], ["studied", 139], ["mostly", 147], ["in", 154], ["the", 157], ["last", 161], ["50", 166], ["years", 169], ["in", 175], ["relation", 178], ["to", 187], ["increasing", 190], ["interest", 201], ["in", 210], ["sleep", 213], ["medicine", 219], ["and", 228], ["health", 232], ["-", 238], ["related", 239], ["quality", 247], ["of", 255], ["life", 258], [".", 262], ["This", 264], ["led", 269], ["to", 273], ["recognition", 276], ["that", 288], ["the", 293], ["disease", 297], ["is", 305], ["not", 308], ["well", 312], ["characterized", 317], ["as", 331], ["restless", 334], ["feelings", 343], ["in", 352], ["the", 355], ["legs", 359], [".", 363], ["These", 365], ["symptoms", 371], ["are", 380], ["reported", 384], ["in", 393], ["many", 396], ["situations", 401], [",", 411], ["but", 413], ["the", 417], ["subjective", 421], ["experience", 432], ["of", 443], ["RLS", 446], ["/", 449], ["WED", 450], ["patients", 454], ["differs", 463], ["from", 471], ["that", 476], ["experienced", 481], ["by", 493], ["others", 496], [".", 502], ["Thus", 504], ["a", 509], ["new", 511], ["name", 515], ["has", 520], ["been", 524], ["introduced", 529], ["that", 540], ["avoids", 545], ["problems", 552], ["of", 561], ["symptom", 564], ["definition", 572], ["of", 583], ["a", 586], ["disease", 588], ["by", 596], ["naming", 599], ["it", 606], ["after", 609], ["those", 615], ["who", 621], ["first", 625], ["characterized", 631], ["it", 645], [",", 647], ["i.e.", 649], ["'", 654], ["Willis", 655], ["Ekbom", 662], ["disease", 668], ["'", 675], [".", 676], ["This", 678], ["article", 683], ["emphasizes", 691], ["the", 702], ["importance", 706], ["of", 717], ["RLS", 720], ["/", 723], ["WED", 724], ["for", 728], ["psychiatry", 732], [".", 742], ["The", 744], ["disease", 748], ["carries", 756], ["significant", 764], ["increased", 776], ["risk", 786], ["for", 791], ["depression", 795], ["and", 806], ["anxiety", 810], ["disorders", 818], [".", 827], ["Treatment", 829], ["requires", 839], ["consideration", 848], ["of", 862], ["these", 865], ["co", 871], ["-", 873], ["morbid", 874], ["disorders", 881], [".", 890], ["RLS", 892], ["/", 895], ["WED", 896], ["can", 900], ["exacerbate", 904], ["or", 915], ["even", 918], ["engender", 923], ["psychiatric", 932], ["disease", 944], [",", 951], ["so", 953], ["treatment", 956], ["of", 966], ["psychiatric", 969], ["disease", 981], ["should", 989], ["also", 996], ["include", 1001], ["consideration", 1009], ["of", 1023], ["RLS", 1026], ["/", 1029], ["WED", 1030], [".", 1033], ["The", 1035], ["need", 1039], ["for", 1044], ["attention", 1048], ["to", 1058], ["RLS", 1061], ["/", 1064], ["WED", 1065], ["is", 1069], ["particularly", 1072], ["significant", 1085], ["for", 1097], ["depression", 1101], [".", 1111], ["Most", 1113], ["anti", 1118], ["-", 1122], ["depressants", 1123], ["exacerbate", 1135], ["or", 1146], ["can", 1149], ["even", 1153], ["engender", 1158], ["RLS", 1167], ["/", 1170], ["WED", 1171], [".", 1174], ["Thus", 1176], ["this", 1181], ["article", 1186], ["seeks", 1194], ["to", 1200], ["introduce", 1203], ["RLS", 1213], ["/", 1216], ["WED", 1217], ["in", 1221], ["relation", 1224], ["to", 1233], ["psychiatric", 1236], ["practice", 1248], [".", 1256], ["It", 1258], ["presents", 1261], ["the", 1270], ["RLS", 1274], ["/", 1277], ["WED", 1278], ["disease", 1282], [",", 1289], ["its", 1291], ["overlap", 1295], ["with", 1303], ["psychiatry", 1308], ["and", 1319], ["the", 1323], ["current", 1327], ["treatment", 1335], ["options", 1345], [".", 1352]]}
{"context": "Mowat-Wilson syndrome is a genetic disease caused by heterozygous mutations or deletions of the zinc finger E-box-binding homeobox 2 (ZEB2) gene. The syndrome is characterized by typical facial features, moderate-to-severe mental retardation, epilepsy and variable congenital malformations, including Hirschsprung disease, genital anomalies, congenital heart disease, agenesis of the corpus callosum, and eye defects. The prevalence of Mowat-Wilson syndrome is currently unknown, but it seems that Mowat-Wilson syndrome is underdiagnosed, particularly in patients without Hirschsprung disease. We report here the first Egyptian case of Mowat-Wilson syndrome who was conceived by intracytoplasmic sperm injection. The patient manifested bilateral sensorineural hearing loss--a new feature not previously reported in cases of Mowat-Wilson syndrome. This report describes the first Egyptian patient of Mowat-Wilson syndrome who was conceived after intracytoplasmic sperm injection, and provides a new evidence for the inclusion of deafness among the congenital defects of the syndrome.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "c3272be6bdea40c9ac22dfe5337dc311", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[26, 26]], "char_spans": [[134, 137]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["is", 22], ["a", 25], ["genetic", 27], ["disease", 35], ["caused", 43], ["by", 50], ["heterozygous", 53], ["mutations", 66], ["or", 76], ["deletions", 79], ["of", 89], ["the", 92], ["zinc", 96], ["finger", 101], ["E", 108], ["-", 109], ["box", 110], ["-", 113], ["binding", 114], ["homeobox", 122], ["2", 131], ["(", 133], ["ZEB2", 134], [")", 138], ["gene", 140], [".", 144], ["The", 146], ["syndrome", 150], ["is", 159], ["characterized", 162], ["by", 176], ["typical", 179], ["facial", 187], ["features", 194], [",", 202], ["moderate", 204], ["-", 212], ["to", 213], ["-", 215], ["severe", 216], ["mental", 223], ["retardation", 230], [",", 241], ["epilepsy", 243], ["and", 252], ["variable", 256], ["congenital", 265], ["malformations", 276], [",", 289], ["including", 291], ["Hirschsprung", 301], ["disease", 314], [",", 321], ["genital", 323], ["anomalies", 331], [",", 340], ["congenital", 342], ["heart", 353], ["disease", 359], [",", 366], ["agenesis", 368], ["of", 377], ["the", 380], ["corpus", 384], ["callosum", 391], [",", 399], ["and", 401], ["eye", 405], ["defects", 409], [".", 416], ["The", 418], ["prevalence", 422], ["of", 433], ["Mowat", 436], ["-", 441], ["Wilson", 442], ["syndrome", 449], ["is", 458], ["currently", 461], ["unknown", 471], [",", 478], ["but", 480], ["it", 484], ["seems", 487], ["that", 493], ["Mowat", 498], ["-", 503], ["Wilson", 504], ["syndrome", 511], ["is", 520], ["underdiagnosed", 523], [",", 537], ["particularly", 539], ["in", 552], ["patients", 555], ["without", 564], ["Hirschsprung", 572], ["disease", 585], [".", 592], ["We", 594], ["report", 597], ["here", 604], ["the", 609], ["first", 613], ["Egyptian", 619], ["case", 628], ["of", 633], ["Mowat", 636], ["-", 641], ["Wilson", 642], ["syndrome", 649], ["who", 658], ["was", 662], ["conceived", 666], ["by", 676], ["intracytoplasmic", 679], ["sperm", 696], ["injection", 702], [".", 711], ["The", 713], ["patient", 717], ["manifested", 725], ["bilateral", 736], ["sensorineural", 746], ["hearing", 760], ["loss", 768], ["--", 772], ["a", 774], ["new", 776], ["feature", 780], ["not", 788], ["previously", 792], ["reported", 803], ["in", 812], ["cases", 815], ["of", 821], ["Mowat", 824], ["-", 829], ["Wilson", 830], ["syndrome", 837], [".", 845], ["This", 847], ["report", 852], ["describes", 859], ["the", 869], ["first", 873], ["Egyptian", 879], ["patient", 888], ["of", 896], ["Mowat", 899], ["-", 904], ["Wilson", 905], ["syndrome", 912], ["who", 921], ["was", 925], ["conceived", 929], ["after", 939], ["intracytoplasmic", 945], ["sperm", 962], ["injection", 968], [",", 977], ["and", 979], ["provides", 983], ["a", 992], ["new", 994], ["evidence", 998], ["for", 1007], ["the", 1011], ["inclusion", 1015], ["of", 1025], ["deafness", 1028], ["among", 1037], ["the", 1043], ["congenital", 1047], ["defects", 1058], ["of", 1066], ["the", 1069], ["syndrome", 1073], [".", 1081]]}
{"context": "Tropomyosin receptor kinases (Trks) are a family of three similar tyrosine kinases activated by peptide hormones of the neurotrophin family. The nerve growth factor antibody tanezumab has provided clinical proof of concept for inhibition of the TrkA pathway in pain. As an alternative modality, small-molecule inhibitors of the Trks have been pursued in recent years to probe the role of these neurotrophin pathways in pain, cancer and other indications. This paper reviews the patent literature between mid-2009 and 2013, claiming inhibitors of Trk family members as the primary biological targets. Additional patents have been reviewed where Trk is not the main kinase of interest but in which high Trk potency is observed and the chemical matter is particularly noteworthy. Patents pre-dating this period have been reviewed previously. Scifinder and Google were used to find relevant patents and clinical information using Trk or Tropomyosin as the search term. Considerable recent progress has been made in the identification of selective pan Trk inhibitors with pharmacodynamic and pharmacokinetic properties appropriate for clinical evaluation. Inhibitors of both active and inactive conformations of the Trks as well as peripherally restricted molecules have been identified. Furthermore, TrkA-selective allosteric inhibitors have recently been disclosed, which enables the biology of this isoform to be probed. The recent identification of a TrkA gene fusion in a subset of lung cancer patients will increase further the attraction of Trk inhibition to the pharmaceutical industry.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "6f76097048934cc28e54c79c8ca57345", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[24, 26]], "char_spans": [[145, 163]]}]}], "context_tokens": [["Tropomyosin", 0], ["receptor", 12], ["kinases", 21], ["(", 29], ["Trks", 30], [")", 34], ["are", 36], ["a", 40], ["family", 42], ["of", 49], ["three", 52], ["similar", 58], ["tyrosine", 66], ["kinases", 75], ["activated", 83], ["by", 93], ["peptide", 96], ["hormones", 104], ["of", 113], ["the", 116], ["neurotrophin", 120], ["family", 133], [".", 139], ["The", 141], ["nerve", 145], ["growth", 151], ["factor", 158], ["antibody", 165], ["tanezumab", 174], ["has", 184], ["provided", 188], ["clinical", 197], ["proof", 206], ["of", 212], ["concept", 215], ["for", 223], ["inhibition", 227], ["of", 238], ["the", 241], ["TrkA", 245], ["pathway", 250], ["in", 258], ["pain", 261], [".", 265], ["As", 267], ["an", 270], ["alternative", 273], ["modality", 285], [",", 293], ["small", 295], ["-", 300], ["molecule", 301], ["inhibitors", 310], ["of", 321], ["the", 324], ["Trks", 328], ["have", 333], ["been", 338], ["pursued", 343], ["in", 351], ["recent", 354], ["years", 361], ["to", 367], ["probe", 370], ["the", 376], ["role", 380], ["of", 385], ["these", 388], ["neurotrophin", 394], ["pathways", 407], ["in", 416], ["pain", 419], [",", 423], ["cancer", 425], ["and", 432], ["other", 436], ["indications", 442], [".", 453], ["This", 455], ["paper", 460], ["reviews", 466], ["the", 474], ["patent", 478], ["literature", 485], ["between", 496], ["mid-2009", 504], ["and", 513], ["2013", 517], [",", 521], ["claiming", 523], ["inhibitors", 532], ["of", 543], ["Trk", 546], ["family", 550], ["members", 557], ["as", 565], ["the", 568], ["primary", 572], ["biological", 580], ["targets", 591], [".", 598], ["Additional", 600], ["patents", 611], ["have", 619], ["been", 624], ["reviewed", 629], ["where", 638], ["Trk", 644], ["is", 648], ["not", 651], ["the", 655], ["main", 659], ["kinase", 664], ["of", 671], ["interest", 674], ["but", 683], ["in", 687], ["which", 690], ["high", 696], ["Trk", 701], ["potency", 705], ["is", 713], ["observed", 716], ["and", 725], ["the", 729], ["chemical", 733], ["matter", 742], ["is", 749], ["particularly", 752], ["noteworthy", 765], [".", 775], ["Patents", 777], ["pre", 785], ["-", 788], ["dating", 789], ["this", 796], ["period", 801], ["have", 808], ["been", 813], ["reviewed", 818], ["previously", 827], [".", 837], ["Scifinder", 839], ["and", 849], ["Google", 853], ["were", 860], ["used", 865], ["to", 870], ["find", 873], ["relevant", 878], ["patents", 887], ["and", 895], ["clinical", 899], ["information", 908], ["using", 920], ["Trk", 926], ["or", 930], ["Tropomyosin", 933], ["as", 945], ["the", 948], ["search", 952], ["term", 959], [".", 963], ["Considerable", 965], ["recent", 978], ["progress", 985], ["has", 994], ["been", 998], ["made", 1003], ["in", 1008], ["the", 1011], ["identification", 1015], ["of", 1030], ["selective", 1033], ["pan", 1043], ["Trk", 1047], ["inhibitors", 1051], ["with", 1062], ["pharmacodynamic", 1067], ["and", 1083], ["pharmacokinetic", 1087], ["properties", 1103], ["appropriate", 1114], ["for", 1126], ["clinical", 1130], ["evaluation", 1139], [".", 1149], ["Inhibitors", 1151], ["of", 1162], ["both", 1165], ["active", 1170], ["and", 1177], ["inactive", 1181], ["conformations", 1190], ["of", 1204], ["the", 1207], ["Trks", 1211], ["as", 1216], ["well", 1219], ["as", 1224], ["peripherally", 1227], ["restricted", 1240], ["molecules", 1251], ["have", 1261], ["been", 1266], ["identified", 1271], [".", 1281], ["Furthermore", 1283], [",", 1294], ["TrkA", 1296], ["-", 1300], ["selective", 1301], ["allosteric", 1311], ["inhibitors", 1322], ["have", 1333], ["recently", 1338], ["been", 1347], ["disclosed", 1352], [",", 1361], ["which", 1363], ["enables", 1369], ["the", 1377], ["biology", 1381], ["of", 1389], ["this", 1392], ["isoform", 1397], ["to", 1405], ["be", 1408], ["probed", 1411], [".", 1417], ["The", 1419], ["recent", 1423], ["identification", 1430], ["of", 1445], ["a", 1448], ["TrkA", 1450], ["gene", 1455], ["fusion", 1460], ["in", 1467], ["a", 1470], ["subset", 1472], ["of", 1479], ["lung", 1482], ["cancer", 1487], ["patients", 1494], ["will", 1503], ["increase", 1508], ["further", 1517], ["the", 1525], ["attraction", 1529], ["of", 1540], ["Trk", 1543], ["inhibition", 1547], ["to", 1558], ["the", 1561], ["pharmaceutical", 1565], ["industry", 1580], [".", 1588]]}
{"context": "The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells. We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma. A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg. Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematologic toxic effects. The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an additional 20% and 15% of patients in the respective groups had a partial response with lymphocytosis. The response was independent of clinical and genomic risk factors present before treatment, including advanced-stage disease, the number of previous therapies, and the 17p13.1 deletion. At 26 months, the estimated progression-free survival rate was 75% and the rate of overall survival was 83%. Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01105247.).", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "d7642cf38cf1490688ccfa02b942b4ab", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[281, 281], [129, 129], [71, 71]], "char_spans": [[1510, 1518], [702, 710], [416, 424]]}]}], "context_tokens": [["The", 0], ["treatment", 4], ["of", 14], ["relapsed", 17], ["chronic", 26], ["lymphocytic", 34], ["leukemia", 46], ["(", 55], ["CLL", 56], [")", 59], ["has", 61], ["resulted", 65], ["in", 74], ["few", 77], ["durable", 81], ["remissions", 89], [".", 99], ["Bruton", 101], ["'s", 107], ["tyrosine", 110], ["kinase", 119], ["(", 126], ["BTK", 127], [")", 130], [",", 131], ["an", 133], ["essential", 136], ["component", 146], ["of", 156], ["B", 159], ["-", 160], ["cell", 161], ["-", 165], ["receptor", 166], ["signaling", 175], [",", 184], ["mediates", 186], ["interactions", 195], ["with", 208], ["the", 213], ["tumor", 217], ["microenvironment", 223], ["and", 240], ["promotes", 244], ["the", 253], ["survival", 257], ["and", 266], ["proliferation", 270], ["of", 284], ["CLL", 287], ["cells", 291], [".", 296], ["We", 298], ["conducted", 301], ["a", 311], ["phase", 313], ["1b-2", 319], ["multicenter", 324], ["study", 336], ["to", 342], ["assess", 345], ["the", 352], ["safety", 356], [",", 362], ["efficacy", 364], [",", 372], ["pharmacokinetics", 374], [",", 390], ["and", 392], ["pharmacodynamics", 396], ["of", 413], ["ibrutinib", 416], ["(", 426], ["PCI-32765", 427], [")", 436], [",", 437], ["a", 439], ["first", 441], ["-", 446], ["in", 447], ["-", 449], ["class", 450], [",", 455], ["oral", 457], ["covalent", 462], ["inhibitor", 471], ["of", 481], ["BTK", 484], ["designed", 488], ["for", 497], ["treatment", 501], ["of", 511], ["B", 514], ["-", 515], ["cell", 516], ["cancers", 521], [",", 528], ["in", 530], ["patients", 533], ["with", 542], ["relapsed", 547], ["or", 556], ["refractory", 559], ["CLL", 570], ["or", 574], ["small", 577], ["lymphocytic", 583], ["lymphoma", 595], [".", 603], ["A", 605], ["total", 607], ["of", 613], ["85", 616], ["patients", 619], [",", 627], ["the", 629], ["majority", 633], ["of", 642], ["whom", 645], ["were", 650], ["considered", 655], ["to", 666], ["have", 669], ["high", 674], ["-", 678], ["risk", 679], ["disease", 684], [",", 691], ["received", 693], ["ibrutinib", 702], ["orally", 712], ["once", 719], ["daily", 724], [";", 729], ["51", 731], ["received", 734], ["420", 743], ["mg", 747], [",", 749], ["and", 751], ["34", 755], ["received", 758], ["840", 767], ["mg", 771], [".", 773], ["Toxic", 775], ["effects", 781], ["were", 789], ["predominantly", 794], ["grade", 808], ["1", 814], ["or", 816], ["2", 819], ["and", 821], ["included", 825], ["transient", 834], ["diarrhea", 844], [",", 852], ["fatigue", 854], [",", 861], ["and", 863], ["upper", 867], ["respiratory", 873], ["tract", 885], ["infection", 891], [";", 900], ["thus", 902], [",", 906], ["patients", 908], ["could", 917], ["receive", 923], ["extended", 931], ["treatment", 940], ["with", 950], ["minimal", 955], ["hematologic", 963], ["toxic", 975], ["effects", 981], [".", 988], ["The", 990], ["overall", 994], ["response", 1002], ["rate", 1011], ["was", 1016], ["the", 1020], ["same", 1024], ["in", 1029], ["the", 1032], ["group", 1036], ["that", 1042], ["received", 1047], ["420", 1056], ["mg", 1060], ["and", 1063], ["the", 1067], ["group", 1071], ["that", 1077], ["received", 1082], ["840", 1091], ["mg", 1095], ["(", 1098], ["71", 1099], ["%", 1101], [")", 1102], [",", 1103], ["and", 1105], ["an", 1109], ["additional", 1112], ["20", 1123], ["%", 1125], ["and", 1127], ["15", 1131], ["%", 1133], ["of", 1135], ["patients", 1138], ["in", 1147], ["the", 1150], ["respective", 1154], ["groups", 1165], ["had", 1172], ["a", 1176], ["partial", 1178], ["response", 1186], ["with", 1195], ["lymphocytosis", 1200], [".", 1213], ["The", 1215], ["response", 1219], ["was", 1228], ["independent", 1232], ["of", 1244], ["clinical", 1247], ["and", 1256], ["genomic", 1260], ["risk", 1268], ["factors", 1273], ["present", 1281], ["before", 1289], ["treatment", 1296], [",", 1305], ["including", 1307], ["advanced", 1317], ["-", 1325], ["stage", 1326], ["disease", 1332], [",", 1339], ["the", 1341], ["number", 1345], ["of", 1352], ["previous", 1355], ["therapies", 1364], [",", 1373], ["and", 1375], ["the", 1379], ["17p13.1", 1383], ["deletion", 1391], [".", 1399], ["At", 1401], ["26", 1404], ["months", 1407], [",", 1413], ["the", 1415], ["estimated", 1419], ["progression", 1429], ["-", 1440], ["free", 1441], ["survival", 1446], ["rate", 1455], ["was", 1460], ["75", 1464], ["%", 1466], ["and", 1468], ["the", 1472], ["rate", 1476], ["of", 1481], ["overall", 1484], ["survival", 1492], ["was", 1501], ["83", 1505], ["%", 1507], [".", 1508], ["Ibrutinib", 1510], ["was", 1520], ["associated", 1524], ["with", 1535], ["a", 1540], ["high", 1542], ["frequency", 1547], ["of", 1557], ["durable", 1560], ["remissions", 1568], ["in", 1579], ["patients", 1582], ["with", 1591], ["relapsed", 1596], ["or", 1605], ["refractory", 1608], ["CLL", 1619], ["and", 1623], ["small", 1627], ["lymphocytic", 1633], ["lymphoma", 1645], [",", 1653], ["including", 1655], ["patients", 1665], ["with", 1674], ["high", 1679], ["-", 1683], ["risk", 1684], ["genetic", 1689], ["lesions", 1697], [".", 1704], ["(", 1706], ["Funded", 1707], ["by", 1714], ["Pharmacyclics", 1717], ["and", 1731], ["others", 1735], [";", 1741], ["ClinicalTrials.gov", 1743], ["number", 1762], [",", 1768], ["NCT01105247", 1770], [".", 1781], [")", 1782], [".", 1783]]}
{"context": "Gefitinib, the specific inhibitor of the epidermal growth factor receptor (EGFR), may cause growth delay in cancer cell lines. Thorough understanding of the downstream cellular signaling of gefitinib will facilitate the discovery of biomarkers for predicting outcomes and monitoring anti-EGFR therapies, and provide information for key targets for therapeutic intervention. In this study, we investigated the role of transducer of erbB2.1 (TOB1) in gefitinib therapy. Using the lung carcinoma cell lines A549 and NCI-H1975, the results suggested that gefitinib might mediate cell cycle arrest in lung cancer cells at least by targeting TOB1 expression. Gefitinib treatment caused cell cycle arrest predominantly at the G1 phase, which is associated with TOB1 nuclear translocation and its interaction with cyclin D1. We also showed that knockdown of TOB1 expression by RNAi rescued lung cancer cells from gefitinib-induced cell-proliferative arrest. These results suggest that TOB1 interaction with cyclin D1 and nuclear translocation is directly involved in the gefitinib-induced anti-proliferative cell cycle arrest.", "qas": [{"question": "Which is the cellular target of gefitinib?", "answers": ["Epidermal growth factor receptor (EGFR)"], "qid": "69bb73c08e1848e080576cacd9b2c307", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["target", 22], ["of", 29], ["gefitinib", 32], ["?", 41]], "detected_answers": [{"text": "Epidermal growth factor receptor (EGFR)", "token_spans": [[7, 12]], "char_spans": [[41, 78]]}]}], "context_tokens": [["Gefitinib", 0], [",", 9], ["the", 11], ["specific", 15], ["inhibitor", 24], ["of", 34], ["the", 37], ["epidermal", 41], ["growth", 51], ["factor", 58], ["receptor", 65], ["(", 74], ["EGFR", 75], [")", 79], [",", 80], ["may", 82], ["cause", 86], ["growth", 92], ["delay", 99], ["in", 105], ["cancer", 108], ["cell", 115], ["lines", 120], [".", 125], ["Thorough", 127], ["understanding", 136], ["of", 150], ["the", 153], ["downstream", 157], ["cellular", 168], ["signaling", 177], ["of", 187], ["gefitinib", 190], ["will", 200], ["facilitate", 205], ["the", 216], ["discovery", 220], ["of", 230], ["biomarkers", 233], ["for", 244], ["predicting", 248], ["outcomes", 259], ["and", 268], ["monitoring", 272], ["anti", 283], ["-", 287], ["EGFR", 288], ["therapies", 293], [",", 302], ["and", 304], ["provide", 308], ["information", 316], ["for", 328], ["key", 332], ["targets", 336], ["for", 344], ["therapeutic", 348], ["intervention", 360], [".", 372], ["In", 374], ["this", 377], ["study", 382], [",", 387], ["we", 389], ["investigated", 392], ["the", 405], ["role", 409], ["of", 414], ["transducer", 417], ["of", 428], ["erbB2.1", 431], ["(", 439], ["TOB1", 440], [")", 444], ["in", 446], ["gefitinib", 449], ["therapy", 459], [".", 466], ["Using", 468], ["the", 474], ["lung", 478], ["carcinoma", 483], ["cell", 493], ["lines", 498], ["A549", 504], ["and", 509], ["NCI", 513], ["-", 516], ["H1975", 517], [",", 522], ["the", 524], ["results", 528], ["suggested", 536], ["that", 546], ["gefitinib", 551], ["might", 561], ["mediate", 567], ["cell", 575], ["cycle", 580], ["arrest", 586], ["in", 593], ["lung", 596], ["cancer", 601], ["cells", 608], ["at", 614], ["least", 617], ["by", 623], ["targeting", 626], ["TOB1", 636], ["expression", 641], [".", 651], ["Gefitinib", 653], ["treatment", 663], ["caused", 673], ["cell", 680], ["cycle", 685], ["arrest", 691], ["predominantly", 698], ["at", 712], ["the", 715], ["G1", 719], ["phase", 722], [",", 727], ["which", 729], ["is", 735], ["associated", 738], ["with", 749], ["TOB1", 754], ["nuclear", 759], ["translocation", 767], ["and", 781], ["its", 785], ["interaction", 789], ["with", 801], ["cyclin", 806], ["D1", 813], [".", 815], ["We", 817], ["also", 820], ["showed", 825], ["that", 832], ["knockdown", 837], ["of", 847], ["TOB1", 850], ["expression", 855], ["by", 866], ["RNAi", 869], ["rescued", 874], ["lung", 882], ["cancer", 887], ["cells", 894], ["from", 900], ["gefitinib", 905], ["-", 914], ["induced", 915], ["cell", 923], ["-", 927], ["proliferative", 928], ["arrest", 942], [".", 948], ["These", 950], ["results", 956], ["suggest", 964], ["that", 972], ["TOB1", 977], ["interaction", 982], ["with", 994], ["cyclin", 999], ["D1", 1006], ["and", 1009], ["nuclear", 1013], ["translocation", 1021], ["is", 1035], ["directly", 1038], ["involved", 1047], ["in", 1056], ["the", 1059], ["gefitinib", 1063], ["-", 1072], ["induced", 1073], ["anti", 1081], ["-", 1085], ["proliferative", 1086], ["cell", 1100], ["cycle", 1105], ["arrest", 1111], [".", 1117]]}
{"context": "The susceptibility to arbekacin (ABK) of methicillin-resistant Staphylococcus aureus (MRSA) was investigated to find out how it related to aac(6')/aph(2\") gene. In 49 isolates of MRSA for which MIC of ABK ranged from 0.125 to 64 micrograms/ml, the MICs of ABK for 38 strains carrying aac(6')/aph(2\") gene were widely distributed from 0.25 to 64, whereas those for 11 strains without that gene were all < or = 0.5 microgram/ml. Residual rate of ABK activity was higher than that of gentamicin after the reaction with each crude enzyme preparation extracted from 3 isolates of MRSA, carrying aac(6')/aph(2\") and aad(4',4\") genes. Furthermore, 97 strains of MRSA isolated at Kanagawa prefecture in Japan in 1999 were all sensitive to ABK, although 28 strains of them carried aac(6')/aph(2\") gene. These results showed that ABK resistance was not necessarily related to carrying aac(6')/aph(2\") gene in clinical isolates of MRSA.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "c28f41488c09478c988e4e82f733d188", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[14, 14], [128, 128], [34, 34], [174, 174], [111, 111]], "char_spans": [[86, 89], [655, 658], [179, 182], [920, 923], [575, 578]]}]}], "context_tokens": [["The", 0], ["susceptibility", 4], ["to", 19], ["arbekacin", 22], ["(", 32], ["ABK", 33], [")", 36], ["of", 38], ["methicillin", 41], ["-", 52], ["resistant", 53], ["Staphylococcus", 63], ["aureus", 78], ["(", 85], ["MRSA", 86], [")", 90], ["was", 92], ["investigated", 96], ["to", 109], ["find", 112], ["out", 117], ["how", 121], ["it", 125], ["related", 128], ["to", 136], ["aac(6')/aph(2", 139], ["\"", 152], [")", 153], ["gene", 155], [".", 159], ["In", 161], ["49", 164], ["isolates", 167], ["of", 176], ["MRSA", 179], ["for", 184], ["which", 188], ["MIC", 194], ["of", 198], ["ABK", 201], ["ranged", 205], ["from", 212], ["0.125", 217], ["to", 223], ["64", 226], ["micrograms", 229], ["/", 239], ["ml", 240], [",", 242], ["the", 244], ["MICs", 248], ["of", 253], ["ABK", 256], ["for", 260], ["38", 264], ["strains", 267], ["carrying", 275], ["aac(6')/aph(2", 284], ["\"", 297], [")", 298], ["gene", 300], ["were", 305], ["widely", 310], ["distributed", 317], ["from", 329], ["0.25", 334], ["to", 339], ["64", 342], [",", 344], ["whereas", 346], ["those", 354], ["for", 360], ["11", 364], ["strains", 367], ["without", 375], ["that", 383], ["gene", 388], ["were", 393], ["all", 398], ["<", 402], ["or", 404], ["=", 407], ["0.5", 409], ["microgram", 413], ["/", 422], ["ml", 423], [".", 425], ["Residual", 427], ["rate", 436], ["of", 441], ["ABK", 444], ["activity", 448], ["was", 457], ["higher", 461], ["than", 468], ["that", 473], ["of", 478], ["gentamicin", 481], ["after", 492], ["the", 498], ["reaction", 502], ["with", 511], ["each", 516], ["crude", 521], ["enzyme", 527], ["preparation", 534], ["extracted", 546], ["from", 556], ["3", 561], ["isolates", 563], ["of", 572], ["MRSA", 575], [",", 579], ["carrying", 581], ["aac(6')/aph(2", 590], ["\"", 603], [")", 604], ["and", 606], ["aad(4',4", 610], ["\"", 618], [")", 619], ["genes", 621], [".", 626], ["Furthermore", 628], [",", 639], ["97", 641], ["strains", 644], ["of", 652], ["MRSA", 655], ["isolated", 660], ["at", 669], ["Kanagawa", 672], ["prefecture", 681], ["in", 692], ["Japan", 695], ["in", 701], ["1999", 704], ["were", 709], ["all", 714], ["sensitive", 718], ["to", 728], ["ABK", 731], [",", 734], ["although", 736], ["28", 745], ["strains", 748], ["of", 756], ["them", 759], ["carried", 764], ["aac(6')/aph(2", 772], ["\"", 785], [")", 786], ["gene", 788], [".", 792], ["These", 794], ["results", 800], ["showed", 808], ["that", 815], ["ABK", 820], ["resistance", 824], ["was", 835], ["not", 839], ["necessarily", 843], ["related", 855], ["to", 863], ["carrying", 866], ["aac(6')/aph(2", 875], ["\"", 888], [")", 889], ["gene", 891], ["in", 896], ["clinical", 899], ["isolates", 908], ["of", 917], ["MRSA", 920], [".", 924]]}
{"context": "Many Prader-Willi syndrome (PWS) and Angelman syndrome (AS) patients have a cytogenetic deletion of 15q11q13. While AS and PWS share a similar cytogenetic anomaly, they have very different clinical phenotypes. DNAs from 4 AS patients were examined using 5 chromosome 15q11q13-specific cloned DNA segments. With the present level of resolution, the molecular deletions between AS and those previously reported for PWS did not appear to differ. However, in contrast to the paternal inheritance of the deleted chromosome 15 observed in the majority of PWS patients, maternal inheritance of the deleted chromosome 15 was demonstrated in the AS patients by restriction fragment length polymorphisms (RFLPs).", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "0886b5bfb37f4842a63d965014d3b9fa", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[1, 4]], "char_spans": [[5, 25]]}]}], "context_tokens": [["Many", 0], ["Prader", 5], ["-", 11], ["Willi", 12], ["syndrome", 18], ["(", 27], ["PWS", 28], [")", 31], ["and", 33], ["Angelman", 37], ["syndrome", 46], ["(", 55], ["AS", 56], [")", 58], ["patients", 60], ["have", 69], ["a", 74], ["cytogenetic", 76], ["deletion", 88], ["of", 97], ["15q11q13", 100], [".", 108], ["While", 110], ["AS", 116], ["and", 119], ["PWS", 123], ["share", 127], ["a", 133], ["similar", 135], ["cytogenetic", 143], ["anomaly", 155], [",", 162], ["they", 164], ["have", 169], ["very", 174], ["different", 179], ["clinical", 189], ["phenotypes", 198], [".", 208], ["DNAs", 210], ["from", 215], ["4", 220], ["AS", 222], ["patients", 225], ["were", 234], ["examined", 239], ["using", 248], ["5", 254], ["chromosome", 256], ["15q11q13-specific", 267], ["cloned", 285], ["DNA", 292], ["segments", 296], [".", 304], ["With", 306], ["the", 311], ["present", 315], ["level", 323], ["of", 329], ["resolution", 332], [",", 342], ["the", 344], ["molecular", 348], ["deletions", 358], ["between", 368], ["AS", 376], ["and", 379], ["those", 383], ["previously", 389], ["reported", 400], ["for", 409], ["PWS", 413], ["did", 417], ["not", 421], ["appear", 425], ["to", 432], ["differ", 435], [".", 441], ["However", 443], [",", 450], ["in", 452], ["contrast", 455], ["to", 464], ["the", 467], ["paternal", 471], ["inheritance", 480], ["of", 492], ["the", 495], ["deleted", 499], ["chromosome", 507], ["15", 518], ["observed", 521], ["in", 530], ["the", 533], ["majority", 537], ["of", 546], ["PWS", 549], ["patients", 553], [",", 561], ["maternal", 563], ["inheritance", 572], ["of", 584], ["the", 587], ["deleted", 591], ["chromosome", 599], ["15", 610], ["was", 613], ["demonstrated", 617], ["in", 630], ["the", 633], ["AS", 637], ["patients", 640], ["by", 649], ["restriction", 652], ["fragment", 664], ["length", 673], ["polymorphisms", 680], ["(", 694], ["RFLPs", 695], [")", 700], [".", 701]]}
{"context": "Idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation. Safety, pharmacokinetics and pharmacodynamics of idarucizumab were investigated in dabigatran-treated, middle-aged, elderly and renally impaired volunteers with characteristics similar to patients receiving anticoagulant therapy. In this randomized, double-blind, crossover study, 46 subjects (12 middle-aged, 45-64\u00a0years; 16 elderly, 65-80\u00a0years; and 18 with mild or moderate renal impairment) received dabigatran etexilate (DE; 220 or 150\u00a0mg twice daily) for 4\u00a0days. Idarucizumab doses of 1, 2.5 and 5\u00a0g or 2\u00a0\u00d7\u00a02.5\u00a0g 1\u00a0h apart, or placebo, were administered as a rapid (5\u00a0min) infusion ~2\u00a0h after DE at steady state. Dabigatran-prolonged diluted thrombin time, ecarin clotting time and activated partial thromboplastin time were reversed to baseline immediately after idarucizumab infusion in all groups. Reversal was sustained with doses \u22652.5\u00a0g. Idarucizumab was well tolerated under all conditions. No impact of age on idarucizumab pharmacokinetics was observed; however, subjects with mild or moderate renal impairment demonstrated increased exposure (up to 84\u00a0%), decreased clearance and prolonged (by up to 49\u00a0%) initial half-life of idarucizumab compared with healthy middle-aged subjects. Impaired renal function was associated with increased exposure and decreased clearance of idarucizumab. Idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers. The results support the clinical use of a 5\u00a0g dose of idarucizumab. http://www.clinicaltrials.gov . Unique identifier: NCT01955720.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "1617e42426ba4b0483170d68366da72d", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[262, 262], [87, 87], [23, 23], [8, 8], [142, 142]], "char_spans": [[1474, 1483], [505, 514], [184, 193], [64, 73], [720, 729]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["an", 16], ["antibody", 19], ["fragment", 28], ["that", 37], ["specifically", 42], ["reverses", 55], ["dabigatran", 64], ["-", 74], ["mediated", 75], ["anticoagulation", 84], [".", 99], ["Safety", 101], [",", 107], ["pharmacokinetics", 109], ["and", 126], ["pharmacodynamics", 130], ["of", 147], ["idarucizumab", 150], ["were", 163], ["investigated", 168], ["in", 181], ["dabigatran", 184], ["-", 194], ["treated", 195], [",", 202], ["middle", 204], ["-", 210], ["aged", 211], [",", 215], ["elderly", 217], ["and", 225], ["renally", 229], ["impaired", 237], ["volunteers", 246], ["with", 257], ["characteristics", 262], ["similar", 278], ["to", 286], ["patients", 289], ["receiving", 298], ["anticoagulant", 308], ["therapy", 322], [".", 329], ["In", 331], ["this", 334], ["randomized", 339], [",", 349], ["double", 351], ["-", 357], ["blind", 358], [",", 363], ["crossover", 365], ["study", 375], [",", 380], ["46", 382], ["subjects", 385], ["(", 394], ["12", 395], ["middle", 398], ["-", 404], ["aged", 405], [",", 409], ["45", 411], ["-", 413], ["64", 414], ["years", 417], [";", 422], ["16", 424], ["elderly", 427], [",", 434], ["65", 436], ["-", 438], ["80", 439], ["years", 442], [";", 447], ["and", 449], ["18", 453], ["with", 456], ["mild", 461], ["or", 466], ["moderate", 469], ["renal", 478], ["impairment", 484], [")", 494], ["received", 496], ["dabigatran", 505], ["etexilate", 516], ["(", 526], ["DE", 527], [";", 529], ["220", 531], ["or", 535], ["150", 538], ["mg", 542], ["twice", 545], ["daily", 551], [")", 556], ["for", 558], ["4", 562], ["days", 564], [".", 568], ["Idarucizumab", 570], ["doses", 583], ["of", 589], ["1", 592], [",", 593], ["2.5", 595], ["and", 599], ["5", 603], ["g", 605], ["or", 607], ["2", 610], ["\u00d7", 612], ["2.5", 614], ["g", 618], ["1", 620], ["h", 622], ["apart", 624], [",", 629], ["or", 631], ["placebo", 634], [",", 641], ["were", 643], ["administered", 648], ["as", 661], ["a", 664], ["rapid", 666], ["(", 672], ["5", 673], ["min", 675], [")", 678], ["infusion", 680], ["~2", 689], ["h", 692], ["after", 694], ["DE", 700], ["at", 703], ["steady", 706], ["state", 713], [".", 718], ["Dabigatran", 720], ["-", 730], ["prolonged", 731], ["diluted", 741], ["thrombin", 749], ["time", 758], [",", 762], ["ecarin", 764], ["clotting", 771], ["time", 780], ["and", 785], ["activated", 789], ["partial", 799], ["thromboplastin", 807], ["time", 822], ["were", 827], ["reversed", 832], ["to", 841], ["baseline", 844], ["immediately", 853], ["after", 865], ["idarucizumab", 871], ["infusion", 884], ["in", 893], ["all", 896], ["groups", 900], [".", 906], ["Reversal", 908], ["was", 917], ["sustained", 921], ["with", 931], ["doses", 936], ["\u22652.5", 942], ["g.", 947], ["Idarucizumab", 950], ["was", 963], ["well", 967], ["tolerated", 972], ["under", 982], ["all", 988], ["conditions", 992], [".", 1002], ["No", 1004], ["impact", 1007], ["of", 1014], ["age", 1017], ["on", 1021], ["idarucizumab", 1024], ["pharmacokinetics", 1037], ["was", 1054], ["observed", 1058], [";", 1066], ["however", 1068], [",", 1075], ["subjects", 1077], ["with", 1086], ["mild", 1091], ["or", 1096], ["moderate", 1099], ["renal", 1108], ["impairment", 1114], ["demonstrated", 1125], ["increased", 1138], ["exposure", 1148], ["(", 1157], ["up", 1158], ["to", 1161], ["84", 1164], ["%", 1167], [")", 1168], [",", 1169], ["decreased", 1171], ["clearance", 1181], ["and", 1191], ["prolonged", 1195], ["(", 1205], ["by", 1206], ["up", 1209], ["to", 1212], ["49", 1215], ["%", 1218], [")", 1219], ["initial", 1221], ["half", 1229], ["-", 1233], ["life", 1234], ["of", 1239], ["idarucizumab", 1242], ["compared", 1255], ["with", 1264], ["healthy", 1269], ["middle", 1277], ["-", 1283], ["aged", 1284], ["subjects", 1289], [".", 1297], ["Impaired", 1299], ["renal", 1308], ["function", 1314], ["was", 1323], ["associated", 1327], ["with", 1338], ["increased", 1343], ["exposure", 1353], ["and", 1362], ["decreased", 1366], ["clearance", 1376], ["of", 1386], ["idarucizumab", 1389], [".", 1401], ["Idarucizumab", 1403], ["resulted", 1416], ["in", 1425], ["immediate", 1428], [",", 1437], ["complete", 1439], ["and", 1448], ["sustained", 1452], ["reversal", 1462], ["of", 1471], ["dabigatran", 1474], ["anticoagulant", 1485], ["activity", 1499], [",", 1507], ["and", 1509], ["was", 1513], ["safe", 1517], ["and", 1522], ["well", 1526], ["tolerated", 1531], ["in", 1541], ["middle", 1544], ["-", 1550], ["aged", 1551], [",", 1555], ["elderly", 1557], ["and", 1565], ["renally", 1569], ["impaired", 1577], ["volunteers", 1586], [".", 1596], ["The", 1598], ["results", 1602], ["support", 1610], ["the", 1618], ["clinical", 1622], ["use", 1631], ["of", 1635], ["a", 1638], ["5", 1640], ["g", 1642], ["dose", 1644], ["of", 1649], ["idarucizumab", 1652], [".", 1664], ["http://www.clinicaltrials.gov", 1666], [".", 1696], ["Unique", 1698], ["identifier", 1705], [":", 1715], ["NCT01955720", 1717], [".", 1728]]}
{"context": "The Ehlers-Danlos syndrome (EDS), inherited disorder of connective tissue, frequently leads to impairment of various functional areas, including employment. In 35 subjects with classic type EDS, 14 hypermobile, 3 vascular was administered 7 visual analogical scales (pain, stiffness, activities of daily living, instrumental activities of daily living, work, social relations). An impairment of particular significance in total score and in individual areas emerges is in the hypermobile group, followed by classic, less for the vasculature. Overall there is a significant alteration of the quality of life that deserves proper evaluation to facilitate the definition of fitness and the improvement of job insertion in patients with EDS.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "82da9c6e605c480c956b7f95c0e9d90b", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[12, 13]], "char_spans": [[56, 72]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndrome", 18], ["(", 27], ["EDS", 28], [")", 31], [",", 32], ["inherited", 34], ["disorder", 44], ["of", 53], ["connective", 56], ["tissue", 67], [",", 73], ["frequently", 75], ["leads", 86], ["to", 92], ["impairment", 95], ["of", 106], ["various", 109], ["functional", 117], ["areas", 128], [",", 133], ["including", 135], ["employment", 145], [".", 155], ["In", 157], ["35", 160], ["subjects", 163], ["with", 172], ["classic", 177], ["type", 185], ["EDS", 190], [",", 193], ["14", 195], ["hypermobile", 198], [",", 209], ["3", 211], ["vascular", 213], ["was", 222], ["administered", 226], ["7", 239], ["visual", 241], ["analogical", 248], ["scales", 259], ["(", 266], ["pain", 267], [",", 271], ["stiffness", 273], [",", 282], ["activities", 284], ["of", 295], ["daily", 298], ["living", 304], [",", 310], ["instrumental", 312], ["activities", 325], ["of", 336], ["daily", 339], ["living", 345], [",", 351], ["work", 353], [",", 357], ["social", 359], ["relations", 366], [")", 375], [".", 376], ["An", 378], ["impairment", 381], ["of", 392], ["particular", 395], ["significance", 406], ["in", 419], ["total", 422], ["score", 428], ["and", 434], ["in", 438], ["individual", 441], ["areas", 452], ["emerges", 458], ["is", 466], ["in", 469], ["the", 472], ["hypermobile", 476], ["group", 488], [",", 493], ["followed", 495], ["by", 504], ["classic", 507], [",", 514], ["less", 516], ["for", 521], ["the", 525], ["vasculature", 529], [".", 540], ["Overall", 542], ["there", 550], ["is", 556], ["a", 559], ["significant", 561], ["alteration", 573], ["of", 584], ["the", 587], ["quality", 591], ["of", 599], ["life", 602], ["that", 607], ["deserves", 612], ["proper", 621], ["evaluation", 628], ["to", 639], ["facilitate", 642], ["the", 653], ["definition", 657], ["of", 668], ["fitness", 671], ["and", 679], ["the", 683], ["improvement", 687], ["of", 699], ["job", 702], ["insertion", 706], ["in", 716], ["patients", 719], ["with", 728], ["EDS", 733], [".", 736]]}
{"context": "In 1957, Simpson published a seminal paper defining the risk factors for recurrence following surgical treatment of intracranial meningiomas. Given that Simpson's study was published more than 50 years ago, preceding image guidance technology and MR imaging, the authors reviewed their own experience with surgical treatment of Grade I meningiomas to determine if Simpson's grading scale is still relevant to modern neurosurgical practice. From this cohort, the authors evaluated all patients undergoing craniotomy for resection of a histologically proven WHO Grade I meningioma as their initial therapy. Clinical information was retrospectively reconstructed using patient medical records and radiological data. Recurrence analysis was performed using the Kaplan-Meier method. The 5-year recurrence/progression-free survival for all patients receiving a Simpson Grade I, II, III, or IV resection was 95, 85, 88, and 81%, respectively (p = not significant, log-rank test). Kaplan-Meier analysis revealed no significant difference in recurrence-free survival between patients receiving a Simpson Grade I, II, III, or IV resection. Analysis limited to meningiomas arising from the skull base (excluding the cavernous sinus) similarly found no significant benefit to Simpson Grade I or II resection, and the survival curves were nearly superimposed. In this study of a cohort of patients undergoing surgery for WHO Grade I meningiomas, the authors demonstrate that the benefit of more aggressive attempts to resect the tumor with dura and underlying bone was negligible compared with simply removing the entire tumor, or even leaving small amounts of tumor attached to critical structures. The authors believe that these data reflect an evolution in the nature of meningioma surgery over the past 2 decades, and bring into question the relevance of using Simpson's grading system as the sole predictor of recurrence.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "2ae2864e473745f697faa29712bfb28c", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[303, 303], [90, 90]], "char_spans": [[1761, 1770], [568, 577]]}]}], "context_tokens": [["In", 0], ["1957", 3], [",", 7], ["Simpson", 9], ["published", 17], ["a", 27], ["seminal", 29], ["paper", 37], ["defining", 43], ["the", 52], ["risk", 56], ["factors", 61], ["for", 69], ["recurrence", 73], ["following", 84], ["surgical", 94], ["treatment", 103], ["of", 113], ["intracranial", 116], ["meningiomas", 129], [".", 140], ["Given", 142], ["that", 148], ["Simpson", 153], ["'s", 160], ["study", 163], ["was", 169], ["published", 173], ["more", 183], ["than", 188], ["50", 193], ["years", 196], ["ago", 202], [",", 205], ["preceding", 207], ["image", 217], ["guidance", 223], ["technology", 232], ["and", 243], ["MR", 247], ["imaging", 250], [",", 257], ["the", 259], ["authors", 263], ["reviewed", 271], ["their", 280], ["own", 286], ["experience", 290], ["with", 301], ["surgical", 306], ["treatment", 315], ["of", 325], ["Grade", 328], ["I", 334], ["meningiomas", 336], ["to", 348], ["determine", 351], ["if", 361], ["Simpson", 364], ["'s", 371], ["grading", 374], ["scale", 382], ["is", 388], ["still", 391], ["relevant", 397], ["to", 406], ["modern", 409], ["neurosurgical", 416], ["practice", 430], [".", 438], ["From", 440], ["this", 445], ["cohort", 450], [",", 456], ["the", 458], ["authors", 462], ["evaluated", 470], ["all", 480], ["patients", 484], ["undergoing", 493], ["craniotomy", 504], ["for", 515], ["resection", 519], ["of", 529], ["a", 532], ["histologically", 534], ["proven", 549], ["WHO", 556], ["Grade", 560], ["I", 566], ["meningioma", 568], ["as", 579], ["their", 582], ["initial", 588], ["therapy", 596], [".", 603], ["Clinical", 605], ["information", 614], ["was", 626], ["retrospectively", 630], ["reconstructed", 646], ["using", 660], ["patient", 666], ["medical", 674], ["records", 682], ["and", 690], ["radiological", 694], ["data", 707], [".", 711], ["Recurrence", 713], ["analysis", 724], ["was", 733], ["performed", 737], ["using", 747], ["the", 753], ["Kaplan", 757], ["-", 763], ["Meier", 764], ["method", 770], [".", 776], ["The", 778], ["5-year", 782], ["recurrence", 789], ["/", 799], ["progression", 800], ["-", 811], ["free", 812], ["survival", 817], ["for", 826], ["all", 830], ["patients", 834], ["receiving", 843], ["a", 853], ["Simpson", 855], ["Grade", 863], ["I", 869], [",", 870], ["II", 872], [",", 874], ["III", 876], [",", 879], ["or", 881], ["IV", 884], ["resection", 887], ["was", 897], ["95", 901], [",", 903], ["85", 905], [",", 907], ["88", 909], [",", 911], ["and", 913], ["81", 917], ["%", 919], [",", 920], ["respectively", 922], ["(", 935], ["p", 936], ["=", 938], ["not", 940], ["significant", 944], [",", 955], ["log", 957], ["-", 960], ["rank", 961], ["test", 966], [")", 970], [".", 971], ["Kaplan", 973], ["-", 979], ["Meier", 980], ["analysis", 986], ["revealed", 995], ["no", 1004], ["significant", 1007], ["difference", 1019], ["in", 1030], ["recurrence", 1033], ["-", 1043], ["free", 1044], ["survival", 1049], ["between", 1058], ["patients", 1066], ["receiving", 1075], ["a", 1085], ["Simpson", 1087], ["Grade", 1095], ["I", 1101], [",", 1102], ["II", 1104], [",", 1106], ["III", 1108], [",", 1111], ["or", 1113], ["IV", 1116], ["resection", 1119], [".", 1128], ["Analysis", 1130], ["limited", 1139], ["to", 1147], ["meningiomas", 1150], ["arising", 1162], ["from", 1170], ["the", 1175], ["skull", 1179], ["base", 1185], ["(", 1190], ["excluding", 1191], ["the", 1201], ["cavernous", 1205], ["sinus", 1215], [")", 1220], ["similarly", 1222], ["found", 1232], ["no", 1238], ["significant", 1241], ["benefit", 1253], ["to", 1261], ["Simpson", 1264], ["Grade", 1272], ["I", 1278], ["or", 1280], ["II", 1283], ["resection", 1286], [",", 1295], ["and", 1297], ["the", 1301], ["survival", 1305], ["curves", 1314], ["were", 1321], ["nearly", 1326], ["superimposed", 1333], [".", 1345], ["In", 1347], ["this", 1350], ["study", 1355], ["of", 1361], ["a", 1364], ["cohort", 1366], ["of", 1373], ["patients", 1376], ["undergoing", 1385], ["surgery", 1396], ["for", 1404], ["WHO", 1408], ["Grade", 1412], ["I", 1418], ["meningiomas", 1420], [",", 1431], ["the", 1433], ["authors", 1437], ["demonstrate", 1445], ["that", 1457], ["the", 1462], ["benefit", 1466], ["of", 1474], ["more", 1477], ["aggressive", 1482], ["attempts", 1493], ["to", 1502], ["resect", 1505], ["the", 1512], ["tumor", 1516], ["with", 1522], ["dura", 1527], ["and", 1532], ["underlying", 1536], ["bone", 1547], ["was", 1552], ["negligible", 1556], ["compared", 1567], ["with", 1576], ["simply", 1581], ["removing", 1588], ["the", 1597], ["entire", 1601], ["tumor", 1608], [",", 1613], ["or", 1615], ["even", 1618], ["leaving", 1623], ["small", 1631], ["amounts", 1637], ["of", 1645], ["tumor", 1648], ["attached", 1654], ["to", 1663], ["critical", 1666], ["structures", 1675], [".", 1685], ["The", 1687], ["authors", 1691], ["believe", 1699], ["that", 1707], ["these", 1712], ["data", 1718], ["reflect", 1723], ["an", 1731], ["evolution", 1734], ["in", 1744], ["the", 1747], ["nature", 1751], ["of", 1758], ["meningioma", 1761], ["surgery", 1772], ["over", 1780], ["the", 1785], ["past", 1789], ["2", 1794], ["decades", 1796], [",", 1803], ["and", 1805], ["bring", 1809], ["into", 1815], ["question", 1820], ["the", 1829], ["relevance", 1833], ["of", 1843], ["using", 1846], ["Simpson", 1852], ["'s", 1859], ["grading", 1862], ["system", 1870], ["as", 1877], ["the", 1880], ["sole", 1884], ["predictor", 1889], ["of", 1899], ["recurrence", 1902], [".", 1912]]}
{"context": "The completeness of meningioma resection depends on the resection of dura mater invaded by the tumor. The pathological changes of the dura around the tumor can be interpreted by evaluating the dural tail sign (DTS) on MRI studies. The goal of this study was to clarify the pathological characteristics of the DTSs, propose a classification based on the histopathological and radiological correlation, and identify the invasive range of tumor cells in different types of DTS. The authors retrospectively reviewed 179 patients with convexity meningiomas who underwent Simpson Grade I resection. All patients underwent an enhanced MRI examination preoperatively. The convexity meningiomas were dichotomized into various subtypes in accordance with the 2007 WHO classification of tumors of the CNS, and the DTS was identified based on the Goldsher criteria. The range of resection of the involved dura was 3 cm from the base of the tumor, which corresponded with the length of DTS on MRI studies. Histopathological examination of dura at 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0 cm from the base of the tumor was conducted, and the findings were correlated with the preoperative MRI appearance of the DTS. A total of 154 (86%) of 179 convexity meningiomas were classified into WHO Grade I subtype, including transitional (44 [28.6%] of 154), meningothelial (36 [23.4%] of 154), fibrous (23 [14.9%] of 154), psammomatous (22 [14.3%] of 154), secretory (10 [6.5%] of 154), and angiomatous (19 [12.3%] of 154). The other 25 (14%) were non-Grade I (WHO) tumors, including atypical (12 [48%] of 25), anaplastic (5 [20%] of 25), and papillary (8 [32%] of 25). The DTS was classified into 5 types: smooth (16 [8.9%] of 179), nodular (36 [20.1%] of 179), mixed (57 [31.8%] of 179), symmetrical multipolar (15 [8.4%] of 179), and asymmetrical multipolar (55 [30.7%] of 179). There was a significant difference in distribution of DTS type between Grade I and non-Grade I tumors (p = 0.004), whereas the difference was not significant among Grade I tumors (0.841) or among non-Grade I tumors (p = 0.818). All smooth-type DTSs were encountered in Grade I tumors, and the mixed DTS (52 [33.8%] of 154) was the most common type in these tumors. Nodular-type DTS was more commonly seen in non-Grade I tumors (12 [48%] of 25). Tumor invasion was found in 88.3% (158 of 179) of convexity meningiomas, of which the range of invasion in 82.3% (130 of 158) was within 2 cm and that in 94.9% (150 of 158) was within 2.5 cm. The incidence of invasion and the range invaded by tumor cells varied in different types of DTS, and differences were statistically significant (p < 0.001). Nodular-type DTS on MRI studies might be associated with non-Grade I tumors. The range of dural resection for convexity meningiomas should be 2.5 cm from the tumor base, and if this extent of resection is not feasible, the type of DTS should be considered. However, for skull base meningiomas, in which mostly Simpson Grade II resection is achieved, the use of this classification should be further validated. The classification of DTS enables the surgeon to predict preoperatively and then to achieve the optimal range of dural resection that might significantly reduce the recurrence rate of meningiomas.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "dfc371178f7740ec80686c0baf2ecc3a", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[3, 3]], "char_spans": [[20, 29]]}]}], "context_tokens": [["The", 0], ["completeness", 4], ["of", 17], ["meningioma", 20], ["resection", 31], ["depends", 41], ["on", 49], ["the", 52], ["resection", 56], ["of", 66], ["dura", 69], ["mater", 74], ["invaded", 80], ["by", 88], ["the", 91], ["tumor", 95], [".", 100], ["The", 102], ["pathological", 106], ["changes", 119], ["of", 127], ["the", 130], ["dura", 134], ["around", 139], ["the", 146], ["tumor", 150], ["can", 156], ["be", 160], ["interpreted", 163], ["by", 175], ["evaluating", 178], ["the", 189], ["dural", 193], ["tail", 199], ["sign", 204], ["(", 209], ["DTS", 210], [")", 213], ["on", 215], ["MRI", 218], ["studies", 222], [".", 229], ["The", 231], ["goal", 235], ["of", 240], ["this", 243], ["study", 248], ["was", 254], ["to", 258], ["clarify", 261], ["the", 269], ["pathological", 273], ["characteristics", 286], ["of", 302], ["the", 305], ["DTSs", 309], [",", 313], ["propose", 315], ["a", 323], ["classification", 325], ["based", 340], ["on", 346], ["the", 349], ["histopathological", 353], ["and", 371], ["radiological", 375], ["correlation", 388], [",", 399], ["and", 401], ["identify", 405], ["the", 414], ["invasive", 418], ["range", 427], ["of", 433], ["tumor", 436], ["cells", 442], ["in", 448], ["different", 451], ["types", 461], ["of", 467], ["DTS", 470], [".", 473], ["The", 475], ["authors", 479], ["retrospectively", 487], ["reviewed", 503], ["179", 512], ["patients", 516], ["with", 525], ["convexity", 530], ["meningiomas", 540], ["who", 552], ["underwent", 556], ["Simpson", 566], ["Grade", 574], ["I", 580], ["resection", 582], [".", 591], ["All", 593], ["patients", 597], ["underwent", 606], ["an", 616], ["enhanced", 619], ["MRI", 628], ["examination", 632], ["preoperatively", 644], [".", 658], ["The", 660], ["convexity", 664], ["meningiomas", 674], ["were", 686], ["dichotomized", 691], ["into", 704], ["various", 709], ["subtypes", 717], ["in", 726], ["accordance", 729], ["with", 740], ["the", 745], ["2007", 749], ["WHO", 754], ["classification", 758], ["of", 773], ["tumors", 776], ["of", 783], ["the", 786], ["CNS", 790], [",", 793], ["and", 795], ["the", 799], ["DTS", 803], ["was", 807], ["identified", 811], ["based", 822], ["on", 828], ["the", 831], ["Goldsher", 835], ["criteria", 844], [".", 852], ["The", 854], ["range", 858], ["of", 864], ["resection", 867], ["of", 877], ["the", 880], ["involved", 884], ["dura", 893], ["was", 898], ["3", 902], ["cm", 904], ["from", 907], ["the", 912], ["base", 916], ["of", 921], ["the", 924], ["tumor", 928], [",", 933], ["which", 935], ["corresponded", 941], ["with", 954], ["the", 959], ["length", 963], ["of", 970], ["DTS", 973], ["on", 977], ["MRI", 980], ["studies", 984], [".", 991], ["Histopathological", 993], ["examination", 1011], ["of", 1023], ["dura", 1026], ["at", 1031], ["0.5", 1034], [",", 1037], ["1.0", 1039], [",", 1042], ["1.5", 1044], [",", 1047], ["2.0", 1049], [",", 1052], ["2.5", 1054], [",", 1057], ["and", 1059], ["3.0", 1063], ["cm", 1067], ["from", 1070], ["the", 1075], ["base", 1079], ["of", 1084], ["the", 1087], ["tumor", 1091], ["was", 1097], ["conducted", 1101], [",", 1110], ["and", 1112], ["the", 1116], ["findings", 1120], ["were", 1129], ["correlated", 1134], ["with", 1145], ["the", 1150], ["preoperative", 1154], ["MRI", 1167], ["appearance", 1171], ["of", 1182], ["the", 1185], ["DTS", 1189], [".", 1192], ["A", 1194], ["total", 1196], ["of", 1202], ["154", 1205], ["(", 1209], ["86", 1210], ["%", 1212], [")", 1213], ["of", 1215], ["179", 1218], ["convexity", 1222], ["meningiomas", 1232], ["were", 1244], ["classified", 1249], ["into", 1260], ["WHO", 1265], ["Grade", 1269], ["I", 1275], ["subtype", 1277], [",", 1284], ["including", 1286], ["transitional", 1296], ["(", 1309], ["44", 1310], ["[", 1313], ["28.6", 1314], ["%", 1318], ["]", 1319], ["of", 1321], ["154", 1324], [")", 1327], [",", 1328], ["meningothelial", 1330], ["(", 1345], ["36", 1346], ["[", 1349], ["23.4", 1350], ["%", 1354], ["]", 1355], ["of", 1357], ["154", 1360], [")", 1363], [",", 1364], ["fibrous", 1366], ["(", 1374], ["23", 1375], ["[", 1378], ["14.9", 1379], ["%", 1383], ["]", 1384], ["of", 1386], ["154", 1389], [")", 1392], [",", 1393], ["psammomatous", 1395], ["(", 1408], ["22", 1409], ["[", 1412], ["14.3", 1413], ["%", 1417], ["]", 1418], ["of", 1420], ["154", 1423], [")", 1426], [",", 1427], ["secretory", 1429], ["(", 1439], ["10", 1440], ["[", 1443], ["6.5", 1444], ["%", 1447], ["]", 1448], ["of", 1450], ["154", 1453], [")", 1456], [",", 1457], ["and", 1459], ["angiomatous", 1463], ["(", 1475], ["19", 1476], ["[", 1479], ["12.3", 1480], ["%", 1484], ["]", 1485], ["of", 1487], ["154", 1490], [")", 1493], [".", 1494], ["The", 1496], ["other", 1500], ["25", 1506], ["(", 1509], ["14", 1510], ["%", 1512], [")", 1513], ["were", 1515], ["non", 1520], ["-", 1523], ["Grade", 1524], ["I", 1530], ["(", 1532], ["WHO", 1533], [")", 1536], ["tumors", 1538], [",", 1544], ["including", 1546], ["atypical", 1556], ["(", 1565], ["12", 1566], ["[", 1569], ["48", 1570], ["%", 1572], ["]", 1573], ["of", 1575], ["25", 1578], [")", 1580], [",", 1581], ["anaplastic", 1583], ["(", 1594], ["5", 1595], ["[", 1597], ["20", 1598], ["%", 1600], ["]", 1601], ["of", 1603], ["25", 1606], [")", 1608], [",", 1609], ["and", 1611], ["papillary", 1615], ["(", 1625], ["8", 1626], ["[", 1628], ["32", 1629], ["%", 1631], ["]", 1632], ["of", 1634], ["25", 1637], [")", 1639], [".", 1640], ["The", 1642], ["DTS", 1646], ["was", 1650], ["classified", 1654], ["into", 1665], ["5", 1670], ["types", 1672], [":", 1677], ["smooth", 1679], ["(", 1686], ["16", 1687], ["[", 1690], ["8.9", 1691], ["%", 1694], ["]", 1695], ["of", 1697], ["179", 1700], [")", 1703], [",", 1704], ["nodular", 1706], ["(", 1714], ["36", 1715], ["[", 1718], ["20.1", 1719], ["%", 1723], ["]", 1724], ["of", 1726], ["179", 1729], [")", 1732], [",", 1733], ["mixed", 1735], ["(", 1741], ["57", 1742], ["[", 1745], ["31.8", 1746], ["%", 1750], ["]", 1751], ["of", 1753], ["179", 1756], [")", 1759], [",", 1760], ["symmetrical", 1762], ["multipolar", 1774], ["(", 1785], ["15", 1786], ["[", 1789], ["8.4", 1790], ["%", 1793], ["]", 1794], ["of", 1796], ["179", 1799], [")", 1802], [",", 1803], ["and", 1805], ["asymmetrical", 1809], ["multipolar", 1822], ["(", 1833], ["55", 1834], ["[", 1837], ["30.7", 1838], ["%", 1842], ["]", 1843], ["of", 1845], ["179", 1848], [")", 1851], [".", 1852], ["There", 1854], ["was", 1860], ["a", 1864], ["significant", 1866], ["difference", 1878], ["in", 1889], ["distribution", 1892], ["of", 1905], ["DTS", 1908], ["type", 1912], ["between", 1917], ["Grade", 1925], ["I", 1931], ["and", 1933], ["non", 1937], ["-", 1940], ["Grade", 1941], ["I", 1947], ["tumors", 1949], ["(", 1956], ["p", 1957], ["=", 1959], ["0.004", 1961], [")", 1966], [",", 1967], ["whereas", 1969], ["the", 1977], ["difference", 1981], ["was", 1992], ["not", 1996], ["significant", 2000], ["among", 2012], ["Grade", 2018], ["I", 2024], ["tumors", 2026], ["(", 2033], ["0.841", 2034], [")", 2039], ["or", 2041], ["among", 2044], ["non", 2050], ["-", 2053], ["Grade", 2054], ["I", 2060], ["tumors", 2062], ["(", 2069], ["p", 2070], ["=", 2072], ["0.818", 2074], [")", 2079], [".", 2080], ["All", 2082], ["smooth", 2086], ["-", 2092], ["type", 2093], ["DTSs", 2098], ["were", 2103], ["encountered", 2108], ["in", 2120], ["Grade", 2123], ["I", 2129], ["tumors", 2131], [",", 2137], ["and", 2139], ["the", 2143], ["mixed", 2147], ["DTS", 2153], ["(", 2157], ["52", 2158], ["[", 2161], ["33.8", 2162], ["%", 2166], ["]", 2167], ["of", 2169], ["154", 2172], [")", 2175], ["was", 2177], ["the", 2181], ["most", 2185], ["common", 2190], ["type", 2197], ["in", 2202], ["these", 2205], ["tumors", 2211], [".", 2217], ["Nodular", 2219], ["-", 2226], ["type", 2227], ["DTS", 2232], ["was", 2236], ["more", 2240], ["commonly", 2245], ["seen", 2254], ["in", 2259], ["non", 2262], ["-", 2265], ["Grade", 2266], ["I", 2272], ["tumors", 2274], ["(", 2281], ["12", 2282], ["[", 2285], ["48", 2286], ["%", 2288], ["]", 2289], ["of", 2291], ["25", 2294], [")", 2296], [".", 2297], ["Tumor", 2299], ["invasion", 2305], ["was", 2314], ["found", 2318], ["in", 2324], ["88.3", 2327], ["%", 2331], ["(", 2333], ["158", 2334], ["of", 2338], ["179", 2341], [")", 2344], ["of", 2346], ["convexity", 2349], ["meningiomas", 2359], [",", 2370], ["of", 2372], ["which", 2375], ["the", 2381], ["range", 2385], ["of", 2391], ["invasion", 2394], ["in", 2403], ["82.3", 2406], ["%", 2410], ["(", 2412], ["130", 2413], ["of", 2417], ["158", 2420], [")", 2423], ["was", 2425], ["within", 2429], ["2", 2436], ["cm", 2438], ["and", 2441], ["that", 2445], ["in", 2450], ["94.9", 2453], ["%", 2457], ["(", 2459], ["150", 2460], ["of", 2464], ["158", 2467], [")", 2470], ["was", 2472], ["within", 2476], ["2.5", 2483], ["cm", 2487], [".", 2489], ["The", 2491], ["incidence", 2495], ["of", 2505], ["invasion", 2508], ["and", 2517], ["the", 2521], ["range", 2525], ["invaded", 2531], ["by", 2539], ["tumor", 2542], ["cells", 2548], ["varied", 2554], ["in", 2561], ["different", 2564], ["types", 2574], ["of", 2580], ["DTS", 2583], [",", 2586], ["and", 2588], ["differences", 2592], ["were", 2604], ["statistically", 2609], ["significant", 2623], ["(", 2635], ["p", 2636], ["<", 2638], ["0.001", 2640], [")", 2645], [".", 2646], ["Nodular", 2648], ["-", 2655], ["type", 2656], ["DTS", 2661], ["on", 2665], ["MRI", 2668], ["studies", 2672], ["might", 2680], ["be", 2686], ["associated", 2689], ["with", 2700], ["non", 2705], ["-", 2708], ["Grade", 2709], ["I", 2715], ["tumors", 2717], [".", 2723], ["The", 2725], ["range", 2729], ["of", 2735], ["dural", 2738], ["resection", 2744], ["for", 2754], ["convexity", 2758], ["meningiomas", 2768], ["should", 2780], ["be", 2787], ["2.5", 2790], ["cm", 2794], ["from", 2797], ["the", 2802], ["tumor", 2806], ["base", 2812], [",", 2816], ["and", 2818], ["if", 2822], ["this", 2825], ["extent", 2830], ["of", 2837], ["resection", 2840], ["is", 2850], ["not", 2853], ["feasible", 2857], [",", 2865], ["the", 2867], ["type", 2871], ["of", 2876], ["DTS", 2879], ["should", 2883], ["be", 2890], ["considered", 2893], [".", 2903], ["However", 2905], [",", 2912], ["for", 2914], ["skull", 2918], ["base", 2924], ["meningiomas", 2929], [",", 2940], ["in", 2942], ["which", 2945], ["mostly", 2951], ["Simpson", 2958], ["Grade", 2966], ["II", 2972], ["resection", 2975], ["is", 2985], ["achieved", 2988], [",", 2996], ["the", 2998], ["use", 3002], ["of", 3006], ["this", 3009], ["classification", 3014], ["should", 3029], ["be", 3036], ["further", 3039], ["validated", 3047], [".", 3056], ["The", 3058], ["classification", 3062], ["of", 3077], ["DTS", 3080], ["enables", 3084], ["the", 3092], ["surgeon", 3096], ["to", 3104], ["predict", 3107], ["preoperatively", 3115], ["and", 3130], ["then", 3134], ["to", 3139], ["achieve", 3142], ["the", 3150], ["optimal", 3154], ["range", 3162], ["of", 3168], ["dural", 3171], ["resection", 3177], ["that", 3187], ["might", 3192], ["significantly", 3198], ["reduce", 3212], ["the", 3219], ["recurrence", 3223], ["rate", 3234], ["of", 3239], ["meningiomas", 3242], [".", 3253]]}
{"context": "Ehlers-Danlos syndromes (EDSs) constitute a rare group of inherited connective tissue diseases, characterized by multisystemic manifestations and general tissue fragility. Most severe complications include vascular and gastrointestinal (GI) emergencies requiring acute surgery. The purpose of this systematic review was to assess the causes of GI-related surgery and related mortality and morbidity in patients with EDSs. A systematic search was conducted in PubMed, Embase, and Scopus to identify relevant studies. Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines for systematic reviews were followed. According to eligibility criteria, data were extracted and systematically screened by 2 authors. Screening process identified 11 studies with a total of 1,567 patients. Findings indicated that patients with EDSs had a higher occurrence of surgery demanding GI manifestations, including perforation, hemorrhage, rupture of intra-abdominal organs, and rectal prolapse. Most affected was the vascular subtype, of which up to 33% underwent GI surgery and suffered from a lowered average life expectancy of 48 years (range 6-78). Secondary complications of surgery were common in all patients with EDSs. Studies suggested that patients with EDSs present an increased need for GI surgery, but also an increased risk of surgery-related complications, most predominantly seen in the vascular subtype.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "3db08ec88fe14bf684b334546499f137", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14]], "char_spans": [[68, 84]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndromes", 14], ["(", 24], ["EDSs", 25], [")", 29], ["constitute", 31], ["a", 42], ["rare", 44], ["group", 49], ["of", 55], ["inherited", 58], ["connective", 68], ["tissue", 79], ["diseases", 86], [",", 94], ["characterized", 96], ["by", 110], ["multisystemic", 113], ["manifestations", 127], ["and", 142], ["general", 146], ["tissue", 154], ["fragility", 161], [".", 170], ["Most", 172], ["severe", 177], ["complications", 184], ["include", 198], ["vascular", 206], ["and", 215], ["gastrointestinal", 219], ["(", 236], ["GI", 237], [")", 239], ["emergencies", 241], ["requiring", 253], ["acute", 263], ["surgery", 269], [".", 276], ["The", 278], ["purpose", 282], ["of", 290], ["this", 293], ["systematic", 298], ["review", 309], ["was", 316], ["to", 320], ["assess", 323], ["the", 330], ["causes", 334], ["of", 341], ["GI", 344], ["-", 346], ["related", 347], ["surgery", 355], ["and", 363], ["related", 367], ["mortality", 375], ["and", 385], ["morbidity", 389], ["in", 399], ["patients", 402], ["with", 411], ["EDSs", 416], [".", 420], ["A", 422], ["systematic", 424], ["search", 435], ["was", 442], ["conducted", 446], ["in", 456], ["PubMed", 459], [",", 465], ["Embase", 467], [",", 473], ["and", 475], ["Scopus", 479], ["to", 486], ["identify", 489], ["relevant", 498], ["studies", 507], [".", 514], ["Preferred", 516], ["Reporting", 526], ["Items", 536], ["for", 542], ["Systematic", 546], ["Reviews", 557], ["and", 565], ["Meta", 569], ["-", 573], ["Analysis", 574], ["guidelines", 583], ["for", 594], ["systematic", 598], ["reviews", 609], ["were", 617], ["followed", 622], [".", 630], ["According", 632], ["to", 642], ["eligibility", 645], ["criteria", 657], [",", 665], ["data", 667], ["were", 672], ["extracted", 677], ["and", 687], ["systematically", 691], ["screened", 706], ["by", 715], ["2", 718], ["authors", 720], [".", 727], ["Screening", 729], ["process", 739], ["identified", 747], ["11", 758], ["studies", 761], ["with", 769], ["a", 774], ["total", 776], ["of", 782], ["1,567", 785], ["patients", 791], [".", 799], ["Findings", 801], ["indicated", 810], ["that", 820], ["patients", 825], ["with", 834], ["EDSs", 839], ["had", 844], ["a", 848], ["higher", 850], ["occurrence", 857], ["of", 868], ["surgery", 871], ["demanding", 879], ["GI", 889], ["manifestations", 892], [",", 906], ["including", 908], ["perforation", 918], [",", 929], ["hemorrhage", 931], [",", 941], ["rupture", 943], ["of", 951], ["intra", 954], ["-", 959], ["abdominal", 960], ["organs", 970], [",", 976], ["and", 978], ["rectal", 982], ["prolapse", 989], [".", 997], ["Most", 999], ["affected", 1004], ["was", 1013], ["the", 1017], ["vascular", 1021], ["subtype", 1030], [",", 1037], ["of", 1039], ["which", 1042], ["up", 1048], ["to", 1051], ["33", 1054], ["%", 1056], ["underwent", 1058], ["GI", 1068], ["surgery", 1071], ["and", 1079], ["suffered", 1083], ["from", 1092], ["a", 1097], ["lowered", 1099], ["average", 1107], ["life", 1115], ["expectancy", 1120], ["of", 1131], ["48", 1134], ["years", 1137], ["(", 1143], ["range", 1144], ["6", 1150], ["-", 1151], ["78", 1152], [")", 1154], [".", 1155], ["Secondary", 1157], ["complications", 1167], ["of", 1181], ["surgery", 1184], ["were", 1192], ["common", 1197], ["in", 1204], ["all", 1207], ["patients", 1211], ["with", 1220], ["EDSs", 1225], [".", 1229], ["Studies", 1231], ["suggested", 1239], ["that", 1249], ["patients", 1254], ["with", 1263], ["EDSs", 1268], ["present", 1273], ["an", 1281], ["increased", 1284], ["need", 1294], ["for", 1299], ["GI", 1303], ["surgery", 1306], [",", 1313], ["but", 1315], ["also", 1319], ["an", 1324], ["increased", 1327], ["risk", 1337], ["of", 1342], ["surgery", 1345], ["-", 1352], ["related", 1353], ["complications", 1361], [",", 1374], ["most", 1376], ["predominantly", 1381], ["seen", 1395], ["in", 1400], ["the", 1403], ["vascular", 1407], ["subtype", 1416], [".", 1423]]}
{"context": "Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the Philadelphia chromosome (Ph), which results in the synthesis of the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) fusion oncoprotein, a constitutively active tyrosine kinase. The introduction of imatinib, a tyrosine kinase inhibitor (TKI) that is specific for BCR-ABL, was a major breakthrough in CML therapy. Although most patients respond to first-line imatinib therapy, some experience loss of response (resistance) or require treatment discontinuation because of toxicity (intolerance). For patients with CML, failure on standard-dose imatinib therapy (400 mg daily), imatinib dose escalation (600-800 mg daily) is a second-line option. However, high-dose imatinib is not an appropriate approach for patients who experience drug toxicity, and there remain questions over the durability of responses achieved with this strategy. Alternative second-line options include the TKIs dasatinib and nilotinib. A substantial amount of long-term data for these agents is available. Although both are potent and specific BCR-ABL TKIs, dasatinib and nilotinib exhibit unique pharmacologic profiles and response patterns relative to different patient characteristics, such as disease stage and BCR-ABL mutation status. To optimize therapeutic benefit, clinicians should select treatment based on each patient's historic response, adverse-event tolerance, and risk factors.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "9f71ac936fe846a99b99d2e030c881b0", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[218, 220], [77, 79], [244, 246], [48, 50]], "char_spans": [[1195, 1201], [441, 447], [1366, 1372], [286, 292]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["progressive", 36], ["and", 48], ["often", 52], ["fatal", 58], ["myeloproliferative", 64], ["neoplasm", 83], [".", 91], ["The", 93], ["hallmark", 97], ["of", 106], ["CML", 109], ["is", 113], ["an", 116], ["acquired", 119], ["chromosomal", 128], ["translocation", 140], ["known", 154], ["as", 160], ["the", 163], ["Philadelphia", 167], ["chromosome", 180], ["(", 191], ["Ph", 192], [")", 194], [",", 195], ["which", 197], ["results", 203], ["in", 211], ["the", 214], ["synthesis", 218], ["of", 228], ["the", 231], ["breakpoint", 235], ["cluster", 246], ["region", 254], ["-", 260], ["Abelson", 261], ["murine", 269], ["leukemia", 276], ["(", 285], ["BCR", 286], ["-", 289], ["ABL", 290], [")", 293], ["fusion", 295], ["oncoprotein", 302], [",", 313], ["a", 315], ["constitutively", 317], ["active", 332], ["tyrosine", 339], ["kinase", 348], [".", 354], ["The", 356], ["introduction", 360], ["of", 373], ["imatinib", 376], [",", 384], ["a", 386], ["tyrosine", 388], ["kinase", 397], ["inhibitor", 404], ["(", 414], ["TKI", 415], [")", 418], ["that", 420], ["is", 425], ["specific", 428], ["for", 437], ["BCR", 441], ["-", 444], ["ABL", 445], [",", 448], ["was", 450], ["a", 454], ["major", 456], ["breakthrough", 462], ["in", 475], ["CML", 478], ["therapy", 482], [".", 489], ["Although", 491], ["most", 500], ["patients", 505], ["respond", 514], ["to", 522], ["first", 525], ["-", 530], ["line", 531], ["imatinib", 536], ["therapy", 545], [",", 552], ["some", 554], ["experience", 559], ["loss", 570], ["of", 575], ["response", 578], ["(", 587], ["resistance", 588], [")", 598], ["or", 600], ["require", 603], ["treatment", 611], ["discontinuation", 621], ["because", 637], ["of", 645], ["toxicity", 648], ["(", 657], ["intolerance", 658], [")", 669], [".", 670], ["For", 672], ["patients", 676], ["with", 685], ["CML", 690], [",", 693], ["failure", 695], ["on", 703], ["standard", 706], ["-", 714], ["dose", 715], ["imatinib", 720], ["therapy", 729], ["(", 737], ["400", 738], ["mg", 742], ["daily", 745], [")", 750], [",", 751], ["imatinib", 753], ["dose", 762], ["escalation", 767], ["(", 778], ["600", 779], ["-", 782], ["800", 783], ["mg", 787], ["daily", 790], [")", 795], ["is", 797], ["a", 800], ["second", 802], ["-", 808], ["line", 809], ["option", 814], [".", 820], ["However", 822], [",", 829], ["high", 831], ["-", 835], ["dose", 836], ["imatinib", 841], ["is", 850], ["not", 853], ["an", 857], ["appropriate", 860], ["approach", 872], ["for", 881], ["patients", 885], ["who", 894], ["experience", 898], ["drug", 909], ["toxicity", 914], [",", 922], ["and", 924], ["there", 928], ["remain", 934], ["questions", 941], ["over", 951], ["the", 956], ["durability", 960], ["of", 971], ["responses", 974], ["achieved", 984], ["with", 993], ["this", 998], ["strategy", 1003], [".", 1011], ["Alternative", 1013], ["second", 1025], ["-", 1031], ["line", 1032], ["options", 1037], ["include", 1045], ["the", 1053], ["TKIs", 1057], ["dasatinib", 1062], ["and", 1072], ["nilotinib", 1076], [".", 1085], ["A", 1087], ["substantial", 1089], ["amount", 1101], ["of", 1108], ["long", 1111], ["-", 1115], ["term", 1116], ["data", 1121], ["for", 1126], ["these", 1130], ["agents", 1136], ["is", 1143], ["available", 1146], [".", 1155], ["Although", 1157], ["both", 1166], ["are", 1171], ["potent", 1175], ["and", 1182], ["specific", 1186], ["BCR", 1195], ["-", 1198], ["ABL", 1199], ["TKIs", 1203], [",", 1207], ["dasatinib", 1209], ["and", 1219], ["nilotinib", 1223], ["exhibit", 1233], ["unique", 1241], ["pharmacologic", 1248], ["profiles", 1262], ["and", 1271], ["response", 1275], ["patterns", 1284], ["relative", 1293], ["to", 1302], ["different", 1305], ["patient", 1315], ["characteristics", 1323], [",", 1338], ["such", 1340], ["as", 1345], ["disease", 1348], ["stage", 1356], ["and", 1362], ["BCR", 1366], ["-", 1369], ["ABL", 1370], ["mutation", 1374], ["status", 1383], [".", 1389], ["To", 1391], ["optimize", 1394], ["therapeutic", 1403], ["benefit", 1415], [",", 1422], ["clinicians", 1424], ["should", 1435], ["select", 1442], ["treatment", 1449], ["based", 1459], ["on", 1465], ["each", 1468], ["patient", 1473], ["'s", 1480], ["historic", 1483], ["response", 1492], [",", 1500], ["adverse", 1502], ["-", 1509], ["event", 1510], ["tolerance", 1516], [",", 1525], ["and", 1527], ["risk", 1531], ["factors", 1536], [".", 1543]]}
{"context": "For dozens of years, a variety of pathological findings have been revealed through previous observations on surgically resected lesions from patients with intractable epilepsy, including excessive number of neurons in the molecular layer of cortices, unexpected existence of white matter neurons, and persistent columnar structure. These findings have sometimes been referred to as microdysgenesis (MD) or mild malformation of cortical development (mMCD), which is defined as microscopic abnormalities of brain formations with no macroscopical and neuroradiological findings. Taylor et al. (1971) described surgical cases with giant neurons and bizarre, grotesque cells as \"focal dysplasia of the cerebral cortices with epilepsy.\" Since 1997, such malformations have subsequently been referred to as focal cortical dysplasia (FCD), in Greenfield's Neuropathology. Since early 2000, the definition of FCD has gradually been given a broader interpretation than the case described by Taylor et al., as shown in Palmini's classification (2004) or the newest classification (2011) proposed by the Neuropathology Task Force of the International League Against Epilepsy (ILAE). The ILAE classification describes 3 types of disease: Type I, Type II, and Type III. Type I is equivalent to some, but not all, pathological phenotypes of MD or mMCD. Type II is Taylor's FCD alone. Type III, which was not included in Palmini's classification, merges brain malformation and other pathological findings. However, the reproducibility of pathological diagnosis by using the ILAE classification was low, except for Type IIb. Hence, future studies are necessary to provide further reliable criteria for the pathological diagnosis of epilepsy patients.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "71df3d8251d84f0f8c452651b470a6ec", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[129, 131]], "char_spans": [[800, 823]]}]}], "context_tokens": [["For", 0], ["dozens", 4], ["of", 11], ["years", 14], [",", 19], ["a", 21], ["variety", 23], ["of", 31], ["pathological", 34], ["findings", 47], ["have", 56], ["been", 61], ["revealed", 66], ["through", 75], ["previous", 83], ["observations", 92], ["on", 105], ["surgically", 108], ["resected", 119], ["lesions", 128], ["from", 136], ["patients", 141], ["with", 150], ["intractable", 155], ["epilepsy", 167], [",", 175], ["including", 177], ["excessive", 187], ["number", 197], ["of", 204], ["neurons", 207], ["in", 215], ["the", 218], ["molecular", 222], ["layer", 232], ["of", 238], ["cortices", 241], [",", 249], ["unexpected", 251], ["existence", 262], ["of", 272], ["white", 275], ["matter", 281], ["neurons", 288], [",", 295], ["and", 297], ["persistent", 301], ["columnar", 312], ["structure", 321], [".", 330], ["These", 332], ["findings", 338], ["have", 347], ["sometimes", 352], ["been", 362], ["referred", 367], ["to", 376], ["as", 379], ["microdysgenesis", 382], ["(", 398], ["MD", 399], [")", 401], ["or", 403], ["mild", 406], ["malformation", 411], ["of", 424], ["cortical", 427], ["development", 436], ["(", 448], ["mMCD", 449], [")", 453], [",", 454], ["which", 456], ["is", 462], ["defined", 465], ["as", 473], ["microscopic", 476], ["abnormalities", 488], ["of", 502], ["brain", 505], ["formations", 511], ["with", 522], ["no", 527], ["macroscopical", 530], ["and", 544], ["neuroradiological", 548], ["findings", 566], [".", 574], ["Taylor", 576], ["et", 583], ["al", 586], [".", 588], ["(", 590], ["1971", 591], [")", 595], ["described", 597], ["surgical", 607], ["cases", 616], ["with", 622], ["giant", 627], ["neurons", 633], ["and", 641], ["bizarre", 645], [",", 652], ["grotesque", 654], ["cells", 664], ["as", 670], ["\"", 673], ["focal", 674], ["dysplasia", 680], ["of", 690], ["the", 693], ["cerebral", 697], ["cortices", 706], ["with", 715], ["epilepsy", 720], [".", 728], ["\"", 729], ["Since", 731], ["1997", 737], [",", 741], ["such", 743], ["malformations", 748], ["have", 762], ["subsequently", 767], ["been", 780], ["referred", 785], ["to", 794], ["as", 797], ["focal", 800], ["cortical", 806], ["dysplasia", 815], ["(", 825], ["FCD", 826], [")", 829], [",", 830], ["in", 832], ["Greenfield", 835], ["'s", 845], ["Neuropathology", 848], [".", 862], ["Since", 864], ["early", 870], ["2000", 876], [",", 880], ["the", 882], ["definition", 886], ["of", 897], ["FCD", 900], ["has", 904], ["gradually", 908], ["been", 918], ["given", 923], ["a", 929], ["broader", 931], ["interpretation", 939], ["than", 954], ["the", 959], ["case", 963], ["described", 968], ["by", 978], ["Taylor", 981], ["et", 988], ["al", 991], [".", 993], [",", 994], ["as", 996], ["shown", 999], ["in", 1005], ["Palmini", 1008], ["'s", 1015], ["classification", 1018], ["(", 1033], ["2004", 1034], [")", 1038], ["or", 1040], ["the", 1043], ["newest", 1047], ["classification", 1054], ["(", 1069], ["2011", 1070], [")", 1074], ["proposed", 1076], ["by", 1085], ["the", 1088], ["Neuropathology", 1092], ["Task", 1107], ["Force", 1112], ["of", 1118], ["the", 1121], ["International", 1125], ["League", 1139], ["Against", 1146], ["Epilepsy", 1154], ["(", 1163], ["ILAE", 1164], [")", 1168], [".", 1169], ["The", 1171], ["ILAE", 1175], ["classification", 1180], ["describes", 1195], ["3", 1205], ["types", 1207], ["of", 1213], ["disease", 1216], [":", 1223], ["Type", 1225], ["I", 1230], [",", 1231], ["Type", 1233], ["II", 1238], [",", 1240], ["and", 1242], ["Type", 1246], ["III", 1251], [".", 1254], ["Type", 1256], ["I", 1261], ["is", 1263], ["equivalent", 1266], ["to", 1277], ["some", 1280], [",", 1284], ["but", 1286], ["not", 1290], ["all", 1294], [",", 1297], ["pathological", 1299], ["phenotypes", 1312], ["of", 1323], ["MD", 1326], ["or", 1329], ["mMCD", 1332], [".", 1336], ["Type", 1338], ["II", 1343], ["is", 1346], ["Taylor", 1349], ["'s", 1355], ["FCD", 1358], ["alone", 1362], [".", 1367], ["Type", 1369], ["III", 1374], [",", 1377], ["which", 1379], ["was", 1385], ["not", 1389], ["included", 1393], ["in", 1402], ["Palmini", 1405], ["'s", 1412], ["classification", 1415], [",", 1429], ["merges", 1431], ["brain", 1438], ["malformation", 1444], ["and", 1457], ["other", 1461], ["pathological", 1467], ["findings", 1480], [".", 1488], ["However", 1490], [",", 1497], ["the", 1499], ["reproducibility", 1503], ["of", 1519], ["pathological", 1522], ["diagnosis", 1535], ["by", 1545], ["using", 1548], ["the", 1554], ["ILAE", 1558], ["classification", 1563], ["was", 1578], ["low", 1582], [",", 1585], ["except", 1587], ["for", 1594], ["Type", 1598], ["IIb", 1603], [".", 1606], ["Hence", 1608], [",", 1613], ["future", 1615], ["studies", 1622], ["are", 1630], ["necessary", 1634], ["to", 1644], ["provide", 1647], ["further", 1655], ["reliable", 1663], ["criteria", 1672], ["for", 1681], ["the", 1685], ["pathological", 1689], ["diagnosis", 1702], ["of", 1712], ["epilepsy", 1715], ["patients", 1724], [".", 1732]]}
{"context": "Diabetic nephropathy is the leading cause of end-stage renal disease in humans in the Western world. The recent development of Na+-glucose cotransporter 2 (SGLT2) inhibitors offers a new antidiabetic therapy via enhanced glucose excretion. Whether this strategy exerts beneficial effects on the development of type 2 diabetic nephropathy is still largely unclear. We investigated the effects of the specific SGLT2 inhibitor empagliflozin in BTBR.Cg-Lep<ob>/WiscJ (BTBR ob/ob) mice, which spontaneously develop type 2 diabetic nephropathy. In the first experiment, BTBR ob/ob mice received either a diet containing 300 ppm empagliflozin or equicaloric placebo chow for 12 wk. In the second experiment, BTBR ob/ob mice received 1 \u03bcg\u00b7kg body wt(-1)\u00b7day(-1) ANG II to induce arterial hypertension and were separated into the same two diet groups for 6 wk. In both experiments, empagliflozin treatment enhanced glucosuria, thereby lowering blood glucose. Independently of hypertension, empagliflozin reduced albuminuria in diabetic mice. However, empagliflozin treatment affected diabetes-related glomerular hypertrophy, markers of renal inflammation, and mesangial matrix expansion only in BTBR ob/ob mice without hypertension. In summary, empagliflozin demonstrated significant antihyperglycemic effects, differentially ameliorating early features of diabetic nephropathy in BTBR ob/ob mice with and without hypertension.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "eee52f339cdf4af89a3273019a0da1ab", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[27, 27], [66, 66]], "char_spans": [[156, 160], [408, 412]]}]}], "context_tokens": [["Diabetic", 0], ["nephropathy", 9], ["is", 21], ["the", 24], ["leading", 28], ["cause", 36], ["of", 42], ["end", 45], ["-", 48], ["stage", 49], ["renal", 55], ["disease", 61], ["in", 69], ["humans", 72], ["in", 79], ["the", 82], ["Western", 86], ["world", 94], [".", 99], ["The", 101], ["recent", 105], ["development", 112], ["of", 124], ["Na+-glucose", 127], ["cotransporter", 139], ["2", 153], ["(", 155], ["SGLT2", 156], [")", 161], ["inhibitors", 163], ["offers", 174], ["a", 181], ["new", 183], ["antidiabetic", 187], ["therapy", 200], ["via", 208], ["enhanced", 212], ["glucose", 221], ["excretion", 229], [".", 238], ["Whether", 240], ["this", 248], ["strategy", 253], ["exerts", 262], ["beneficial", 269], ["effects", 280], ["on", 288], ["the", 291], ["development", 295], ["of", 307], ["type", 310], ["2", 315], ["diabetic", 317], ["nephropathy", 326], ["is", 338], ["still", 341], ["largely", 347], ["unclear", 355], [".", 362], ["We", 364], ["investigated", 367], ["the", 380], ["effects", 384], ["of", 392], ["the", 395], ["specific", 399], ["SGLT2", 408], ["inhibitor", 414], ["empagliflozin", 424], ["in", 438], ["BTBR.Cg", 441], ["-", 448], ["Lep", 449], ["<", 452], ["ob>/WiscJ", 453], ["(", 463], ["BTBR", 464], ["ob", 469], ["/", 471], ["ob", 472], [")", 474], ["mice", 476], [",", 480], ["which", 482], ["spontaneously", 488], ["develop", 502], ["type", 510], ["2", 515], ["diabetic", 517], ["nephropathy", 526], [".", 537], ["In", 539], ["the", 542], ["first", 546], ["experiment", 552], [",", 562], ["BTBR", 564], ["ob", 569], ["/", 571], ["ob", 572], ["mice", 575], ["received", 580], ["either", 589], ["a", 596], ["diet", 598], ["containing", 603], ["300", 614], ["ppm", 618], ["empagliflozin", 622], ["or", 636], ["equicaloric", 639], ["placebo", 651], ["chow", 659], ["for", 664], ["12", 668], ["wk", 671], [".", 673], ["In", 675], ["the", 678], ["second", 682], ["experiment", 689], [",", 699], ["BTBR", 701], ["ob", 706], ["/", 708], ["ob", 709], ["mice", 712], ["received", 717], ["1", 726], ["\u03bcg\u00b7kg", 728], ["body", 734], ["wt(-1)\u00b7day(-1", 739], [")", 752], ["ANG", 754], ["II", 758], ["to", 761], ["induce", 764], ["arterial", 771], ["hypertension", 780], ["and", 793], ["were", 797], ["separated", 802], ["into", 812], ["the", 817], ["same", 821], ["two", 826], ["diet", 830], ["groups", 835], ["for", 842], ["6", 846], ["wk", 848], [".", 850], ["In", 852], ["both", 855], ["experiments", 860], [",", 871], ["empagliflozin", 873], ["treatment", 887], ["enhanced", 897], ["glucosuria", 906], [",", 916], ["thereby", 918], ["lowering", 926], ["blood", 935], ["glucose", 941], [".", 948], ["Independently", 950], ["of", 964], ["hypertension", 967], [",", 979], ["empagliflozin", 981], ["reduced", 995], ["albuminuria", 1003], ["in", 1015], ["diabetic", 1018], ["mice", 1027], [".", 1031], ["However", 1033], [",", 1040], ["empagliflozin", 1042], ["treatment", 1056], ["affected", 1066], ["diabetes", 1075], ["-", 1083], ["related", 1084], ["glomerular", 1092], ["hypertrophy", 1103], [",", 1114], ["markers", 1116], ["of", 1124], ["renal", 1127], ["inflammation", 1133], [",", 1145], ["and", 1147], ["mesangial", 1151], ["matrix", 1161], ["expansion", 1168], ["only", 1178], ["in", 1183], ["BTBR", 1186], ["ob", 1191], ["/", 1193], ["ob", 1194], ["mice", 1197], ["without", 1202], ["hypertension", 1210], [".", 1222], ["In", 1224], ["summary", 1227], [",", 1234], ["empagliflozin", 1236], ["demonstrated", 1250], ["significant", 1263], ["antihyperglycemic", 1275], ["effects", 1293], [",", 1300], ["differentially", 1302], ["ameliorating", 1317], ["early", 1330], ["features", 1336], ["of", 1345], ["diabetic", 1348], ["nephropathy", 1357], ["in", 1369], ["BTBR", 1372], ["ob", 1377], ["/", 1379], ["ob", 1380], ["mice", 1383], ["with", 1388], ["and", 1393], ["without", 1397], ["hypertension", 1405], [".", 1417]]}
{"context": "Postoperative methicillin-resistant Staphylococcus aureus (MRSA) infections are occasionally fatal. We hypothesized that nasal MRSA screening might predict the risk of postoperative MRSA infections. The aim of the current study was to elucidate the relationship between the positivity of nasal MRSA screening and postoperative MRSA infections. Six hundred and fourteen surgical patients who were admitted to the intensive care unit and underwent nasal MRSA screening between April 2006 and March 2011 were divided into MRSA-positive and -negative groups. The incidence of postoperative MRSA infections in the MRSA-positive and MRSA-negative groups were compared, and various risk factors for MRSA infections were evaluated. The incidence of postoperative MRSA infections, such as pneumonia and enteritis, in the MRSA-positive group was significantly higher than that in the MRSA-negative group (41.9 vs. 3.1 %). The significant independent risk factors for postoperative MRSA infections were a positive MRSA screening, an operation lasting more than 300 min and an emergency operation. A positive MRSA screening was the most statistically significant risk factor for postoperative MRSA pneumonia and enteritis, but was not a risk factor for MRSA surgical site infections. Nasal MRSA screening can help to identify patients who have an increased risk of developing postoperative MRSA infections, and would enable physicians to take a prompt action if these complications occur.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "a9817a6931814cc1929eed39d878021d", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[80, 80], [160, 160], [45, 45], [205, 205], [211, 211], [7, 7], [111, 111], [120, 120], [69, 69], [131, 131], [142, 142], [226, 226], [193, 193], [49, 49], [26, 26], [91, 91], [99, 99], [165, 165], [182, 182], [18, 18], [95, 95]], "char_spans": [[519, 522], [971, 974], [294, 297], [1241, 1244], [1278, 1281], [59, 62], [692, 695], [755, 758], [452, 455], [812, 815], [874, 877], [1378, 1381], [1181, 1184], [327, 330], [182, 185], [586, 589], [627, 630], [1003, 1006], [1097, 1100], [127, 130], [609, 612]]}]}], "context_tokens": [["Postoperative", 0], ["methicillin", 14], ["-", 25], ["resistant", 26], ["Staphylococcus", 36], ["aureus", 51], ["(", 58], ["MRSA", 59], [")", 63], ["infections", 65], ["are", 76], ["occasionally", 80], ["fatal", 93], [".", 98], ["We", 100], ["hypothesized", 103], ["that", 116], ["nasal", 121], ["MRSA", 127], ["screening", 132], ["might", 142], ["predict", 148], ["the", 156], ["risk", 160], ["of", 165], ["postoperative", 168], ["MRSA", 182], ["infections", 187], [".", 197], ["The", 199], ["aim", 203], ["of", 207], ["the", 210], ["current", 214], ["study", 222], ["was", 228], ["to", 232], ["elucidate", 235], ["the", 245], ["relationship", 249], ["between", 262], ["the", 270], ["positivity", 274], ["of", 285], ["nasal", 288], ["MRSA", 294], ["screening", 299], ["and", 309], ["postoperative", 313], ["MRSA", 327], ["infections", 332], [".", 342], ["Six", 344], ["hundred", 348], ["and", 356], ["fourteen", 360], ["surgical", 369], ["patients", 378], ["who", 387], ["were", 391], ["admitted", 396], ["to", 405], ["the", 408], ["intensive", 412], ["care", 422], ["unit", 427], ["and", 432], ["underwent", 436], ["nasal", 446], ["MRSA", 452], ["screening", 457], ["between", 467], ["April", 475], ["2006", 481], ["and", 486], ["March", 490], ["2011", 496], ["were", 501], ["divided", 506], ["into", 514], ["MRSA", 519], ["-", 523], ["positive", 524], ["and", 533], ["-negative", 537], ["groups", 547], [".", 553], ["The", 555], ["incidence", 559], ["of", 569], ["postoperative", 572], ["MRSA", 586], ["infections", 591], ["in", 602], ["the", 605], ["MRSA", 609], ["-", 613], ["positive", 614], ["and", 623], ["MRSA", 627], ["-", 631], ["negative", 632], ["groups", 641], ["were", 648], ["compared", 653], [",", 661], ["and", 663], ["various", 667], ["risk", 675], ["factors", 680], ["for", 688], ["MRSA", 692], ["infections", 697], ["were", 708], ["evaluated", 713], [".", 722], ["The", 724], ["incidence", 728], ["of", 738], ["postoperative", 741], ["MRSA", 755], ["infections", 760], [",", 770], ["such", 772], ["as", 777], ["pneumonia", 780], ["and", 790], ["enteritis", 794], [",", 803], ["in", 805], ["the", 808], ["MRSA", 812], ["-", 816], ["positive", 817], ["group", 826], ["was", 832], ["significantly", 836], ["higher", 850], ["than", 857], ["that", 862], ["in", 867], ["the", 870], ["MRSA", 874], ["-", 878], ["negative", 879], ["group", 888], ["(", 894], ["41.9", 895], ["vs.", 900], ["3.1", 904], ["%", 908], [")", 909], [".", 910], ["The", 912], ["significant", 916], ["independent", 928], ["risk", 940], ["factors", 945], ["for", 953], ["postoperative", 957], ["MRSA", 971], ["infections", 976], ["were", 987], ["a", 992], ["positive", 994], ["MRSA", 1003], ["screening", 1008], [",", 1017], ["an", 1019], ["operation", 1022], ["lasting", 1032], ["more", 1040], ["than", 1045], ["300", 1050], ["min", 1054], ["and", 1058], ["an", 1062], ["emergency", 1065], ["operation", 1075], [".", 1084], ["A", 1086], ["positive", 1088], ["MRSA", 1097], ["screening", 1102], ["was", 1112], ["the", 1116], ["most", 1120], ["statistically", 1125], ["significant", 1139], ["risk", 1151], ["factor", 1156], ["for", 1163], ["postoperative", 1167], ["MRSA", 1181], ["pneumonia", 1186], ["and", 1196], ["enteritis", 1200], [",", 1209], ["but", 1211], ["was", 1215], ["not", 1219], ["a", 1223], ["risk", 1225], ["factor", 1230], ["for", 1237], ["MRSA", 1241], ["surgical", 1246], ["site", 1255], ["infections", 1260], [".", 1270], ["Nasal", 1272], ["MRSA", 1278], ["screening", 1283], ["can", 1293], ["help", 1297], ["to", 1302], ["identify", 1305], ["patients", 1314], ["who", 1323], ["have", 1327], ["an", 1332], ["increased", 1335], ["risk", 1345], ["of", 1350], ["developing", 1353], ["postoperative", 1364], ["MRSA", 1378], ["infections", 1383], [",", 1393], ["and", 1395], ["would", 1399], ["enable", 1405], ["physicians", 1412], ["to", 1423], ["take", 1426], ["a", 1431], ["prompt", 1433], ["action", 1440], ["if", 1447], ["these", 1450], ["complications", 1456], ["occur", 1470], [".", 1475]]}
{"context": "Lysosomal storage diseases arise from a genetic loss-of-function defect in enzymes mediating key catabolic steps resulting in accumulation of substrate within the lysosome. Treatment of several of these disorders has been achieved by enzyme replacement therapy (ERT), in which a recombinant version of the defective enzyme is expressed in vitro and administered by infusion. However, in many cases the biodistribution of the administered protein does not match that of the accumulated substrate due to the glycosylation-mediated clearance of the enzymes from circulation, resulting in poor or absent substrate clearance from some tissues. To overcome this limitation, we have evaluated several peptide-based targeting motifs to redirect recombinant human alpha-galactosidase (rhalphaGal) to specific receptors. A reversible thiol-based PEGylation chemistry was developed to achieve multivalent peptide display with lysosomal release. In vitro, cell uptake was peptide dependent and independent of the normal mannose-6-phosphate receptor mediated pathway. Surprisingly, despite increased plasma half-life and decreased liver uptake, none of the peptide conjugates showed significantly altered biodistribution in alphaGal-knockout mice. This suggests that these peptide-based targeting motifs are unlikely to provide substantial therapeutic benefit likely due to the complexity of factors affecting PK and biodistribution.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "17805ad0408c48df91cdeb947ccf3371", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[124, 126]], "char_spans": [[755, 773]]}]}], "context_tokens": [["Lysosomal", 0], ["storage", 10], ["diseases", 18], ["arise", 27], ["from", 33], ["a", 38], ["genetic", 40], ["loss", 48], ["-", 52], ["of", 53], ["-", 55], ["function", 56], ["defect", 65], ["in", 72], ["enzymes", 75], ["mediating", 83], ["key", 93], ["catabolic", 97], ["steps", 107], ["resulting", 113], ["in", 123], ["accumulation", 126], ["of", 139], ["substrate", 142], ["within", 152], ["the", 159], ["lysosome", 163], [".", 171], ["Treatment", 173], ["of", 183], ["several", 186], ["of", 194], ["these", 197], ["disorders", 203], ["has", 213], ["been", 217], ["achieved", 222], ["by", 231], ["enzyme", 234], ["replacement", 241], ["therapy", 253], ["(", 261], ["ERT", 262], [")", 265], [",", 266], ["in", 268], ["which", 271], ["a", 277], ["recombinant", 279], ["version", 291], ["of", 299], ["the", 302], ["defective", 306], ["enzyme", 316], ["is", 323], ["expressed", 326], ["in", 336], ["vitro", 339], ["and", 345], ["administered", 349], ["by", 362], ["infusion", 365], [".", 373], ["However", 375], [",", 382], ["in", 384], ["many", 387], ["cases", 392], ["the", 398], ["biodistribution", 402], ["of", 418], ["the", 421], ["administered", 425], ["protein", 438], ["does", 446], ["not", 451], ["match", 455], ["that", 461], ["of", 466], ["the", 469], ["accumulated", 473], ["substrate", 485], ["due", 495], ["to", 499], ["the", 502], ["glycosylation", 506], ["-", 519], ["mediated", 520], ["clearance", 529], ["of", 539], ["the", 542], ["enzymes", 546], ["from", 554], ["circulation", 559], [",", 570], ["resulting", 572], ["in", 582], ["poor", 585], ["or", 590], ["absent", 593], ["substrate", 600], ["clearance", 610], ["from", 620], ["some", 625], ["tissues", 630], [".", 637], ["To", 639], ["overcome", 642], ["this", 651], ["limitation", 656], [",", 666], ["we", 668], ["have", 671], ["evaluated", 676], ["several", 686], ["peptide", 694], ["-", 701], ["based", 702], ["targeting", 708], ["motifs", 718], ["to", 725], ["redirect", 728], ["recombinant", 737], ["human", 749], ["alpha", 755], ["-", 760], ["galactosidase", 761], ["(", 775], ["rhalphaGal", 776], [")", 786], ["to", 788], ["specific", 791], ["receptors", 800], [".", 809], ["A", 811], ["reversible", 813], ["thiol", 824], ["-", 829], ["based", 830], ["PEGylation", 836], ["chemistry", 847], ["was", 857], ["developed", 861], ["to", 871], ["achieve", 874], ["multivalent", 882], ["peptide", 894], ["display", 902], ["with", 910], ["lysosomal", 915], ["release", 925], [".", 932], ["In", 934], ["vitro", 937], [",", 942], ["cell", 944], ["uptake", 949], ["was", 956], ["peptide", 960], ["dependent", 968], ["and", 978], ["independent", 982], ["of", 994], ["the", 997], ["normal", 1001], ["mannose-6-phosphate", 1008], ["receptor", 1028], ["mediated", 1037], ["pathway", 1046], [".", 1053], ["Surprisingly", 1055], [",", 1067], ["despite", 1069], ["increased", 1077], ["plasma", 1087], ["half", 1094], ["-", 1098], ["life", 1099], ["and", 1104], ["decreased", 1108], ["liver", 1118], ["uptake", 1124], [",", 1130], ["none", 1132], ["of", 1137], ["the", 1140], ["peptide", 1144], ["conjugates", 1152], ["showed", 1163], ["significantly", 1170], ["altered", 1184], ["biodistribution", 1192], ["in", 1208], ["alphaGal", 1211], ["-", 1219], ["knockout", 1220], ["mice", 1229], [".", 1233], ["This", 1235], ["suggests", 1240], ["that", 1249], ["these", 1254], ["peptide", 1260], ["-", 1267], ["based", 1268], ["targeting", 1274], ["motifs", 1284], ["are", 1291], ["unlikely", 1295], ["to", 1304], ["provide", 1307], ["substantial", 1315], ["therapeutic", 1327], ["benefit", 1339], ["likely", 1347], ["due", 1354], ["to", 1358], ["the", 1361], ["complexity", 1365], ["of", 1376], ["factors", 1379], ["affecting", 1387], ["PK", 1397], ["and", 1400], ["biodistribution", 1404], [".", 1419]]}
{"context": "Individuals with Mowat-Wilson syndrome (MWS; OMIM#235730) have characteristic facial features, a variety of congenital anomalies such as Hirschsprung disease, and intellectual disabilities caused by mutation or deletion of ZEB2 gene. This deletion or cytogenetic abnormality has been reported primarily from Europe, Australia and the United States, but not in Korea. Here we report a patient with characteristic facial features of MWS, developmental delay and spasticity. High resolution microarray analysis revealed 0.9 Mb deletion of 2q22.3 involving two genes: ZEB2 and GTDC1. This case shows the important role of high resolution microarray in patients with unexplained psychomotor retardation and/or facial dysmorphism. Knowledge about the most striking clinical signs and implementation of effective molecular tests like microarray could significantly increase the detection rate of new cases of MWS in Korea. This is the first reported case of MWS in Korea.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "65d32f6d9c06430c970f8b3020a54497", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[92, 92], [35, 35]], "char_spans": [[564, 567], [223, 226]]}]}], "context_tokens": [["Individuals", 0], ["with", 12], ["Mowat", 17], ["-", 22], ["Wilson", 23], ["syndrome", 30], ["(", 39], ["MWS", 40], [";", 43], ["OMIM#235730", 45], [")", 56], ["have", 58], ["characteristic", 63], ["facial", 78], ["features", 85], [",", 93], ["a", 95], ["variety", 97], ["of", 105], ["congenital", 108], ["anomalies", 119], ["such", 129], ["as", 134], ["Hirschsprung", 137], ["disease", 150], [",", 157], ["and", 159], ["intellectual", 163], ["disabilities", 176], ["caused", 189], ["by", 196], ["mutation", 199], ["or", 208], ["deletion", 211], ["of", 220], ["ZEB2", 223], ["gene", 228], [".", 232], ["This", 234], ["deletion", 239], ["or", 248], ["cytogenetic", 251], ["abnormality", 263], ["has", 275], ["been", 279], ["reported", 284], ["primarily", 293], ["from", 303], ["Europe", 308], [",", 314], ["Australia", 316], ["and", 326], ["the", 330], ["United", 334], ["States", 341], [",", 347], ["but", 349], ["not", 353], ["in", 357], ["Korea", 360], [".", 365], ["Here", 367], ["we", 372], ["report", 375], ["a", 382], ["patient", 384], ["with", 392], ["characteristic", 397], ["facial", 412], ["features", 419], ["of", 428], ["MWS", 431], [",", 434], ["developmental", 436], ["delay", 450], ["and", 456], ["spasticity", 460], [".", 470], ["High", 472], ["resolution", 477], ["microarray", 488], ["analysis", 499], ["revealed", 508], ["0.9", 517], ["Mb", 521], ["deletion", 524], ["of", 533], ["2q22.3", 536], ["involving", 543], ["two", 553], ["genes", 557], [":", 562], ["ZEB2", 564], ["and", 569], ["GTDC1", 573], [".", 578], ["This", 580], ["case", 585], ["shows", 590], ["the", 596], ["important", 600], ["role", 610], ["of", 615], ["high", 618], ["resolution", 623], ["microarray", 634], ["in", 645], ["patients", 648], ["with", 657], ["unexplained", 662], ["psychomotor", 674], ["retardation", 686], ["and/or", 698], ["facial", 705], ["dysmorphism", 712], [".", 723], ["Knowledge", 725], ["about", 735], ["the", 741], ["most", 745], ["striking", 750], ["clinical", 759], ["signs", 768], ["and", 774], ["implementation", 778], ["of", 793], ["effective", 796], ["molecular", 806], ["tests", 816], ["like", 822], ["microarray", 827], ["could", 838], ["significantly", 844], ["increase", 858], ["the", 867], ["detection", 871], ["rate", 881], ["of", 886], ["new", 889], ["cases", 893], ["of", 899], ["MWS", 902], ["in", 906], ["Korea", 909], [".", 914], ["This", 916], ["is", 921], ["the", 924], ["first", 928], ["reported", 934], ["case", 943], ["of", 948], ["MWS", 951], ["in", 955], ["Korea", 958], [".", 963]]}
{"context": "Biallelic mutations of the DNA annealing helicase SMARCAL1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1) cause Schimke immuno-osseous dysplasia (SIOD, MIM 242900), an incompletely penetrant autosomal recessive disorder. Using human, Drosophila and mouse models, we show that the proteins encoded by SMARCAL1 orthologs localize to transcriptionally active chromatin and modulate gene expression. We also show that, as found in SIOD patients, deficiency of the SMARCAL1 orthologs alone is insufficient to cause disease in fruit flies and mice, although such deficiency causes modest diffuse alterations in gene expression. Rather, disease manifests when SMARCAL1 deficiency interacts with genetic and environmental factors that further alter gene expression. We conclude that the SMARCAL1 annealing helicase buffers fluctuations in gene expression and that alterations in gene expression contribute to the penetrance of SIOD.", "qas": [{"question": "Mutations in which gene cause Schimke immune-osseous dysplasia?", "answers": ["HARP", "SMARCAL1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1", "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)"], "qid": "549c82a2fcb04e38a84c3f7661eeeaf0", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["cause", 24], ["Schimke", 30], ["immune", 38], ["-", 44], ["osseous", 45], ["dysplasia", 53], ["?", 62]], "detected_answers": [{"text": "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)", "token_spans": [[7, 30]], "char_spans": [[50, 153]]}]}], "context_tokens": [["Biallelic", 0], ["mutations", 10], ["of", 20], ["the", 23], ["DNA", 27], ["annealing", 31], ["helicase", 41], ["SMARCAL1", 50], ["(", 59], ["SWI", 60], ["/", 63], ["SNF", 64], ["-", 67], ["related", 68], [",", 75], ["matrix", 77], ["-", 83], ["associated", 84], [",", 94], ["actin", 96], ["-", 101], ["dependent", 102], ["regulator", 112], ["of", 122], ["chromatin", 125], [",", 134], ["subfamily", 136], ["a", 146], ["-", 147], ["like", 148], ["1", 153], [")", 154], ["cause", 156], ["Schimke", 162], ["immuno", 170], ["-", 176], ["osseous", 177], ["dysplasia", 185], ["(", 195], ["SIOD", 196], [",", 200], ["MIM", 202], ["242900", 206], [")", 212], [",", 213], ["an", 215], ["incompletely", 218], ["penetrant", 231], ["autosomal", 241], ["recessive", 251], ["disorder", 261], [".", 269], ["Using", 271], ["human", 277], [",", 282], ["Drosophila", 284], ["and", 295], ["mouse", 299], ["models", 305], [",", 311], ["we", 313], ["show", 316], ["that", 321], ["the", 326], ["proteins", 330], ["encoded", 339], ["by", 347], ["SMARCAL1", 350], ["orthologs", 359], ["localize", 369], ["to", 378], ["transcriptionally", 381], ["active", 399], ["chromatin", 406], ["and", 416], ["modulate", 420], ["gene", 429], ["expression", 434], [".", 444], ["We", 446], ["also", 449], ["show", 454], ["that", 459], [",", 463], ["as", 465], ["found", 468], ["in", 474], ["SIOD", 477], ["patients", 482], [",", 490], ["deficiency", 492], ["of", 503], ["the", 506], ["SMARCAL1", 510], ["orthologs", 519], ["alone", 529], ["is", 535], ["insufficient", 538], ["to", 551], ["cause", 554], ["disease", 560], ["in", 568], ["fruit", 571], ["flies", 577], ["and", 583], ["mice", 587], [",", 591], ["although", 593], ["such", 602], ["deficiency", 607], ["causes", 618], ["modest", 625], ["diffuse", 632], ["alterations", 640], ["in", 652], ["gene", 655], ["expression", 660], [".", 670], ["Rather", 672], [",", 678], ["disease", 680], ["manifests", 688], ["when", 698], ["SMARCAL1", 703], ["deficiency", 712], ["interacts", 723], ["with", 733], ["genetic", 738], ["and", 746], ["environmental", 750], ["factors", 764], ["that", 772], ["further", 777], ["alter", 785], ["gene", 791], ["expression", 796], [".", 806], ["We", 808], ["conclude", 811], ["that", 820], ["the", 825], ["SMARCAL1", 829], ["annealing", 838], ["helicase", 848], ["buffers", 857], ["fluctuations", 865], ["in", 878], ["gene", 881], ["expression", 886], ["and", 897], ["that", 901], ["alterations", 906], ["in", 918], ["gene", 921], ["expression", 926], ["contribute", 937], ["to", 948], ["the", 951], ["penetrance", 955], ["of", 966], ["SIOD", 969], [".", 973]]}
{"context": "Ataxin-3 is a ubiquitously expressed deubiqutinating enzyme with important functions in the proteasomal protein degradation pathway and regulation of transcription. The C-terminus of the ataxin-3 protein contains a polyglutamine (PolyQ) region that, when mutationally expanded to over 52 glutamines, causes the neurodegenerative disease spinocerebellar ataxia 3 (SCA3). In spite of extensive research, the molecular mechanisms underlying the cellular toxicity resulting from mutant ataxin-3 remain elusive and no preventive treatment is currently available. It has become clear over the last decade that the hallmark intracellular ataxin-3 aggregates are likely not the main toxic entity in SCA3. Instead, the soluble PolyQ containing fragments arising from proteolytic cleavage of ataxin-3 by caspases and calpains are now regarded to be of greater influence in pathogenesis. In addition, recent evidence suggests potential involvement of a RNA toxicity component in SCA3 and other PolyQ expansion disorders, increasing the pathogenic complexity. Herein, we review the functioning of ataxin-3 and the involvement of known protein and RNA toxicity mechanisms of mutant ataxin-3 that have been discovered, as well as future opportunities for therapeutic intervention.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "5196d6a345bb4a5db1019bc0c286be72", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[0, 0], [96, 96], [27, 27], [182, 182], [73, 73], [169, 169], [120, 120]], "char_spans": [[0, 7], [631, 638], [187, 194], [1169, 1176], [482, 489], [1085, 1092], [782, 789]]}]}], "context_tokens": [["Ataxin-3", 0], ["is", 9], ["a", 12], ["ubiquitously", 14], ["expressed", 27], ["deubiqutinating", 37], ["enzyme", 53], ["with", 60], ["important", 65], ["functions", 75], ["in", 85], ["the", 88], ["proteasomal", 92], ["protein", 104], ["degradation", 112], ["pathway", 124], ["and", 132], ["regulation", 136], ["of", 147], ["transcription", 150], [".", 163], ["The", 165], ["C", 169], ["-", 170], ["terminus", 171], ["of", 180], ["the", 183], ["ataxin-3", 187], ["protein", 196], ["contains", 204], ["a", 213], ["polyglutamine", 215], ["(", 229], ["PolyQ", 230], [")", 235], ["region", 237], ["that", 244], [",", 248], ["when", 250], ["mutationally", 255], ["expanded", 268], ["to", 277], ["over", 280], ["52", 285], ["glutamines", 288], [",", 298], ["causes", 300], ["the", 307], ["neurodegenerative", 311], ["disease", 329], ["spinocerebellar", 337], ["ataxia", 353], ["3", 360], ["(", 362], ["SCA3", 363], [")", 367], [".", 368], ["In", 370], ["spite", 373], ["of", 379], ["extensive", 382], ["research", 392], [",", 400], ["the", 402], ["molecular", 406], ["mechanisms", 416], ["underlying", 427], ["the", 438], ["cellular", 442], ["toxicity", 451], ["resulting", 460], ["from", 470], ["mutant", 475], ["ataxin-3", 482], ["remain", 491], ["elusive", 498], ["and", 506], ["no", 510], ["preventive", 513], ["treatment", 524], ["is", 534], ["currently", 537], ["available", 547], [".", 556], ["It", 558], ["has", 561], ["become", 565], ["clear", 572], ["over", 578], ["the", 583], ["last", 587], ["decade", 592], ["that", 599], ["the", 604], ["hallmark", 608], ["intracellular", 617], ["ataxin-3", 631], ["aggregates", 640], ["are", 651], ["likely", 655], ["not", 662], ["the", 666], ["main", 670], ["toxic", 675], ["entity", 681], ["in", 688], ["SCA3", 691], [".", 695], ["Instead", 697], [",", 704], ["the", 706], ["soluble", 710], ["PolyQ", 718], ["containing", 724], ["fragments", 735], ["arising", 745], ["from", 753], ["proteolytic", 758], ["cleavage", 770], ["of", 779], ["ataxin-3", 782], ["by", 791], ["caspases", 794], ["and", 803], ["calpains", 807], ["are", 816], ["now", 820], ["regarded", 824], ["to", 833], ["be", 836], ["of", 839], ["greater", 842], ["influence", 850], ["in", 860], ["pathogenesis", 863], [".", 875], ["In", 877], ["addition", 880], [",", 888], ["recent", 890], ["evidence", 897], ["suggests", 906], ["potential", 915], ["involvement", 925], ["of", 937], ["a", 940], ["RNA", 942], ["toxicity", 946], ["component", 955], ["in", 965], ["SCA3", 968], ["and", 973], ["other", 977], ["PolyQ", 983], ["expansion", 989], ["disorders", 999], [",", 1008], ["increasing", 1010], ["the", 1021], ["pathogenic", 1025], ["complexity", 1036], [".", 1046], ["Herein", 1048], [",", 1054], ["we", 1056], ["review", 1059], ["the", 1066], ["functioning", 1070], ["of", 1082], ["ataxin-3", 1085], ["and", 1094], ["the", 1098], ["involvement", 1102], ["of", 1114], ["known", 1117], ["protein", 1123], ["and", 1131], ["RNA", 1135], ["toxicity", 1139], ["mechanisms", 1148], ["of", 1159], ["mutant", 1162], ["ataxin-3", 1169], ["that", 1178], ["have", 1183], ["been", 1188], ["discovered", 1193], [",", 1203], ["as", 1205], ["well", 1208], ["as", 1213], ["future", 1216], ["opportunities", 1223], ["for", 1237], ["therapeutic", 1241], ["intervention", 1253], [".", 1265]]}
{"context": "Diamond-Blackfan anemia (DBA) is a rare inherited bone marrow failure syndrome that is characterized by pure red-cell aplasia and associated physical deformities. It has been proven that defects of ribosomal proteins can lead to this disease and that RPS19 is the most frequently mutated gene in DBA patients. Previous studies suggest that p53-dependent genes and pathways play important roles in RPS19-deficient embryos. However, whether there are other vital factors linked to DBA has not been fully clarified. In this study, we compared the whole genome RNA-Seq data of zebrafish embryos injected with RPS19 morpholino (RPS19 MO), RPS19 and p53 morpholino simultaneously (RPS19+p53 MO) and control morpholino (control). We found that genes enriched in the functions of hematological systems, nervous system development and skeletal and muscular disorders had significant differential expression in RPS19 MO embryos compared with controls. Co-inhibition of p53 partially alleviates the abnormalities for RPS19-deficient embryos. However, the hematopoietic genes, which were down-regulated significantly in RPS19 MO embryos, were not completely recovered by the co-inhibition of p53. Furthermore, we identified the genome-wide p53-dependent and -independent genes and pathways. These results indicate that not only p53 family members but also other factors have important impacts on RPS19-deficient embryos. The detection of potential pathogenic genes and pathways provides us a new paradigm for future research on DBA, which is a systematic and complex hereditary disease.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "2ff9e79323fb48ad9fe911c391aecaa8", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[81, 81], [53, 53], [255, 255], [5, 5]], "char_spans": [[479, 481], [296, 298], [1516, 1518], [25, 27]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["rare", 35], ["inherited", 40], ["bone", 50], ["marrow", 55], ["failure", 62], ["syndrome", 70], ["that", 79], ["is", 84], ["characterized", 87], ["by", 101], ["pure", 104], ["red", 109], ["-", 112], ["cell", 113], ["aplasia", 118], ["and", 126], ["associated", 130], ["physical", 141], ["deformities", 150], [".", 161], ["It", 163], ["has", 166], ["been", 170], ["proven", 175], ["that", 182], ["defects", 187], ["of", 195], ["ribosomal", 198], ["proteins", 208], ["can", 217], ["lead", 221], ["to", 226], ["this", 229], ["disease", 234], ["and", 242], ["that", 246], ["RPS19", 251], ["is", 257], ["the", 260], ["most", 264], ["frequently", 269], ["mutated", 280], ["gene", 288], ["in", 293], ["DBA", 296], ["patients", 300], [".", 308], ["Previous", 310], ["studies", 319], ["suggest", 327], ["that", 335], ["p53-dependent", 340], ["genes", 354], ["and", 360], ["pathways", 364], ["play", 373], ["important", 378], ["roles", 388], ["in", 394], ["RPS19-deficient", 397], ["embryos", 413], [".", 420], ["However", 422], [",", 429], ["whether", 431], ["there", 439], ["are", 445], ["other", 449], ["vital", 455], ["factors", 461], ["linked", 469], ["to", 476], ["DBA", 479], ["has", 483], ["not", 487], ["been", 491], ["fully", 496], ["clarified", 502], [".", 511], ["In", 513], ["this", 516], ["study", 521], [",", 526], ["we", 528], ["compared", 531], ["the", 540], ["whole", 544], ["genome", 550], ["RNA", 557], ["-", 560], ["Seq", 561], ["data", 565], ["of", 570], ["zebrafish", 573], ["embryos", 583], ["injected", 591], ["with", 600], ["RPS19", 605], ["morpholino", 611], ["(", 622], ["RPS19", 623], ["MO", 629], [")", 631], [",", 632], ["RPS19", 634], ["and", 640], ["p53", 644], ["morpholino", 648], ["simultaneously", 659], ["(", 674], ["RPS19+p53", 675], ["MO", 685], [")", 687], ["and", 689], ["control", 693], ["morpholino", 701], ["(", 712], ["control", 713], [")", 720], [".", 721], ["We", 723], ["found", 726], ["that", 732], ["genes", 737], ["enriched", 743], ["in", 752], ["the", 755], ["functions", 759], ["of", 769], ["hematological", 772], ["systems", 786], [",", 793], ["nervous", 795], ["system", 803], ["development", 810], ["and", 822], ["skeletal", 826], ["and", 835], ["muscular", 839], ["disorders", 848], ["had", 858], ["significant", 862], ["differential", 874], ["expression", 887], ["in", 898], ["RPS19", 901], ["MO", 907], ["embryos", 910], ["compared", 918], ["with", 927], ["controls", 932], [".", 940], ["Co", 942], ["-", 944], ["inhibition", 945], ["of", 956], ["p53", 959], ["partially", 963], ["alleviates", 973], ["the", 984], ["abnormalities", 988], ["for", 1002], ["RPS19-deficient", 1006], ["embryos", 1022], [".", 1029], ["However", 1031], [",", 1038], ["the", 1040], ["hematopoietic", 1044], ["genes", 1058], [",", 1063], ["which", 1065], ["were", 1071], ["down", 1076], ["-", 1080], ["regulated", 1081], ["significantly", 1091], ["in", 1105], ["RPS19", 1108], ["MO", 1114], ["embryos", 1117], [",", 1124], ["were", 1126], ["not", 1131], ["completely", 1135], ["recovered", 1146], ["by", 1156], ["the", 1159], ["co", 1163], ["-", 1165], ["inhibition", 1166], ["of", 1177], ["p53", 1180], [".", 1183], ["Furthermore", 1185], [",", 1196], ["we", 1198], ["identified", 1201], ["the", 1212], ["genome", 1216], ["-", 1222], ["wide", 1223], ["p53-dependent", 1228], ["and", 1242], ["-independent", 1246], ["genes", 1259], ["and", 1265], ["pathways", 1269], [".", 1277], ["These", 1279], ["results", 1285], ["indicate", 1293], ["that", 1302], ["not", 1307], ["only", 1311], ["p53", 1316], ["family", 1320], ["members", 1327], ["but", 1335], ["also", 1339], ["other", 1344], ["factors", 1350], ["have", 1358], ["important", 1363], ["impacts", 1373], ["on", 1381], ["RPS19-deficient", 1384], ["embryos", 1400], [".", 1407], ["The", 1409], ["detection", 1413], ["of", 1423], ["potential", 1426], ["pathogenic", 1436], ["genes", 1447], ["and", 1453], ["pathways", 1457], ["provides", 1466], ["us", 1475], ["a", 1478], ["new", 1480], ["paradigm", 1484], ["for", 1493], ["future", 1497], ["research", 1504], ["on", 1513], ["DBA", 1516], [",", 1519], ["which", 1521], ["is", 1527], ["a", 1530], ["systematic", 1532], ["and", 1543], ["complex", 1547], ["hereditary", 1555], ["disease", 1566], [".", 1573]]}
{"context": "We investigated the expression of Na(+)/Ca(2+) exchanger (NCX) and the functional role of NCX in retinal damage by using NCX1-heterozygous deficient mice (NCX1(+/-)) and SEA0400 (2-[4-[(2,5-difluorophenyl)methoxy] phenoxy]-5-ethoxyaniline), a selective NCX inhibitor in vivo. We also examined the role of NCX in oxygen-glucose deprivation (OGD) stress with a retinal ganglion cell line (RGC-5) cell culture in vitro. The expression of NCX1 was confirmed and entirely localized in retina by immunoblotting and immunohistochemistry, respectively. NCX1(+/-) mice possessed significant protection against retinal damage induced by intravitreal injection of N-methyl-D-aspartate (NMDA). SEA0400 at 3 and 10 mg/kg significantly reduced NMDA- or high intraocular pressure-induced retinal cell damage in mice. Furthermore, SEA0400 reduced the number of TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling)-positive cells and the expression of phosphorylated mitogen-activated protein kinases (ERK1/2, JNK, p38) induced by NMDA injection. In RGC-5, SEA0400 at 0.3 and 1 microM significantly inhibited OGD-induced cell damage. OGD-induced cell damage was aggravated by ouabain (a Na(+),K(+)-ATPase inhibitor) at 100 microM, and this increased damage was significantly reduced by SEA0400 at 1 microM. In conclusion, these results suggest that NCX1 may play a role in retinal cell death induced by NMDA and ischemia-reperfusion.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "251f6ff810384420b6df79a29f772ff0", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[5, 8]], "char_spans": [[34, 55]]}, {"text": "NCX", "token_spans": [[40, 40], [17, 17], [51, 51], [10, 10]], "char_spans": [[253, 255], [90, 92], [305, 307], [58, 60]]}]}], "context_tokens": [["We", 0], ["investigated", 3], ["the", 16], ["expression", 20], ["of", 31], ["Na(+)/Ca(2", 34], ["+", 44], [")", 45], ["exchanger", 47], ["(", 57], ["NCX", 58], [")", 61], ["and", 63], ["the", 67], ["functional", 71], ["role", 82], ["of", 87], ["NCX", 90], ["in", 94], ["retinal", 97], ["damage", 105], ["by", 112], ["using", 115], ["NCX1-heterozygous", 121], ["deficient", 139], ["mice", 149], ["(", 154], ["NCX1(+/-", 155], [")", 163], [")", 164], ["and", 166], ["SEA0400", 170], ["(", 178], ["2-[4-[(2,5-difluorophenyl)methoxy", 179], ["]", 212], ["phenoxy]-5-ethoxyaniline", 214], [")", 238], [",", 239], ["a", 241], ["selective", 243], ["NCX", 253], ["inhibitor", 257], ["in", 267], ["vivo", 270], [".", 274], ["We", 276], ["also", 279], ["examined", 284], ["the", 293], ["role", 297], ["of", 302], ["NCX", 305], ["in", 309], ["oxygen", 312], ["-", 318], ["glucose", 319], ["deprivation", 327], ["(", 339], ["OGD", 340], [")", 343], ["stress", 345], ["with", 352], ["a", 357], ["retinal", 359], ["ganglion", 367], ["cell", 376], ["line", 381], ["(", 386], ["RGC-5", 387], [")", 392], ["cell", 394], ["culture", 399], ["in", 407], ["vitro", 410], [".", 415], ["The", 417], ["expression", 421], ["of", 432], ["NCX1", 435], ["was", 440], ["confirmed", 444], ["and", 454], ["entirely", 458], ["localized", 467], ["in", 477], ["retina", 480], ["by", 487], ["immunoblotting", 490], ["and", 505], ["immunohistochemistry", 509], [",", 529], ["respectively", 531], [".", 543], ["NCX1(+/-", 545], [")", 553], ["mice", 555], ["possessed", 560], ["significant", 570], ["protection", 582], ["against", 593], ["retinal", 601], ["damage", 609], ["induced", 616], ["by", 624], ["intravitreal", 627], ["injection", 640], ["of", 650], ["N", 653], ["-", 654], ["methyl", 655], ["-", 661], ["D", 662], ["-", 663], ["aspartate", 664], ["(", 674], ["NMDA", 675], [")", 679], [".", 680], ["SEA0400", 682], ["at", 690], ["3", 693], ["and", 695], ["10", 699], ["mg", 702], ["/", 704], ["kg", 705], ["significantly", 708], ["reduced", 722], ["NMDA-", 730], ["or", 736], ["high", 739], ["intraocular", 744], ["pressure", 756], ["-", 764], ["induced", 765], ["retinal", 773], ["cell", 781], ["damage", 786], ["in", 793], ["mice", 796], [".", 800], ["Furthermore", 802], [",", 813], ["SEA0400", 815], ["reduced", 823], ["the", 831], ["number", 835], ["of", 842], ["TUNEL", 845], ["(", 851], ["terminal", 852], ["deoxynucleotidyl", 861], ["transferase", 878], ["dUTP", 890], ["nick", 895], ["-", 899], ["end", 900], ["labeling)-positive", 904], ["cells", 923], ["and", 929], ["the", 933], ["expression", 937], ["of", 948], ["phosphorylated", 951], ["mitogen", 966], ["-", 973], ["activated", 974], ["protein", 984], ["kinases", 992], ["(", 1000], ["ERK1/2", 1001], [",", 1007], ["JNK", 1009], [",", 1012], ["p38", 1014], [")", 1017], ["induced", 1019], ["by", 1027], ["NMDA", 1030], ["injection", 1035], [".", 1044], ["In", 1046], ["RGC-5", 1049], [",", 1054], ["SEA0400", 1056], ["at", 1064], ["0.3", 1067], ["and", 1071], ["1", 1075], ["microM", 1077], ["significantly", 1084], ["inhibited", 1098], ["OGD", 1108], ["-", 1111], ["induced", 1112], ["cell", 1120], ["damage", 1125], [".", 1131], ["OGD", 1133], ["-", 1136], ["induced", 1137], ["cell", 1145], ["damage", 1150], ["was", 1157], ["aggravated", 1161], ["by", 1172], ["ouabain", 1175], ["(", 1183], ["a", 1184], ["Na(+),K(+)-ATPase", 1186], ["inhibitor", 1204], [")", 1213], ["at", 1215], ["100", 1218], ["microM", 1222], [",", 1228], ["and", 1230], ["this", 1234], ["increased", 1239], ["damage", 1249], ["was", 1256], ["significantly", 1260], ["reduced", 1274], ["by", 1282], ["SEA0400", 1285], ["at", 1293], ["1", 1296], ["microM.", 1298], ["In", 1306], ["conclusion", 1309], [",", 1319], ["these", 1321], ["results", 1327], ["suggest", 1335], ["that", 1343], ["NCX1", 1348], ["may", 1353], ["play", 1357], ["a", 1362], ["role", 1364], ["in", 1369], ["retinal", 1372], ["cell", 1380], ["death", 1385], ["induced", 1391], ["by", 1399], ["NMDA", 1402], ["and", 1407], ["ischemia", 1411], ["-", 1419], ["reperfusion", 1420], [".", 1431]]}
{"context": "Antisense therapy with both chemistries of phosphorodiamidate morpholino oligomers (PMOs) and 2'-O-methyl phosphorothioate has demonstrated the capability to induce dystrophin expression in Duchenne muscular dystrophy (DMD) patients in phase II-III clinical trials with benefit in muscle functions. However, potential of the therapy for DMD at different stages of the disease progression is not understood. In this study, we examined the effect of peptide-conjugated PMO (PPMO)-mediated exon skipping on disease progression of utrophin-dystrophin-deficient mice (dko) of four age groups (21-29, 30-39, 40-49 and 50+ days), representing diseases from early stage to advanced stage with severe kyphosis. Biweekly intravenous (i.v.) administration of the PPMO restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. This was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. However, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started. The PPMO treatment alleviated the disease pathology and significantly prolonged the life span of the mice receiving treatment at younger age with mild phenotype. However, restoration of high levels of dystrophin expression failed to prevent disease progression to the mice receiving treatment when disease was already at advanced stage. The results could be critical for design of clinical trials with antisense therapy to DMD.", "qas": [{"question": "In what percentage of skeletal muscle fibers is dystrophin expression restored after PPMO- mediated exon skipping?", "answers": ["100%"], "qid": "d6fb14e3be8245baaf66693d4b546e8f", "question_tokens": [["In", 0], ["what", 3], ["percentage", 8], ["of", 19], ["skeletal", 22], ["muscle", 31], ["fibers", 38], ["is", 45], ["dystrophin", 48], ["expression", 59], ["restored", 70], ["after", 79], ["PPMO-", 85], ["mediated", 91], ["exon", 100], ["skipping", 105], ["?", 113]], "detected_answers": [{"text": "100%", "token_spans": [[145, 145]], "char_spans": [[802, 804]]}]}], "context_tokens": [["Antisense", 0], ["therapy", 10], ["with", 18], ["both", 23], ["chemistries", 28], ["of", 40], ["phosphorodiamidate", 43], ["morpholino", 62], ["oligomers", 73], ["(", 83], ["PMOs", 84], [")", 88], ["and", 90], ["2'-O", 94], ["-", 98], ["methyl", 99], ["phosphorothioate", 106], ["has", 123], ["demonstrated", 127], ["the", 140], ["capability", 144], ["to", 155], ["induce", 158], ["dystrophin", 165], ["expression", 176], ["in", 187], ["Duchenne", 190], ["muscular", 199], ["dystrophy", 208], ["(", 218], ["DMD", 219], [")", 222], ["patients", 224], ["in", 233], ["phase", 236], ["II", 242], ["-", 244], ["III", 245], ["clinical", 249], ["trials", 258], ["with", 265], ["benefit", 270], ["in", 278], ["muscle", 281], ["functions", 288], [".", 297], ["However", 299], [",", 306], ["potential", 308], ["of", 318], ["the", 321], ["therapy", 325], ["for", 333], ["DMD", 337], ["at", 341], ["different", 344], ["stages", 354], ["of", 361], ["the", 364], ["disease", 368], ["progression", 376], ["is", 388], ["not", 391], ["understood", 395], [".", 405], ["In", 407], ["this", 410], ["study", 415], [",", 420], ["we", 422], ["examined", 425], ["the", 434], ["effect", 438], ["of", 445], ["peptide", 448], ["-", 455], ["conjugated", 456], ["PMO", 467], ["(", 471], ["PPMO)-mediated", 472], ["exon", 487], ["skipping", 492], ["on", 501], ["disease", 504], ["progression", 512], ["of", 524], ["utrophin", 527], ["-", 535], ["dystrophin", 536], ["-", 546], ["deficient", 547], ["mice", 557], ["(", 562], ["dko", 563], [")", 566], ["of", 568], ["four", 571], ["age", 576], ["groups", 580], ["(", 587], ["21", 588], ["-", 590], ["29", 591], [",", 593], ["30", 595], ["-", 597], ["39", 598], [",", 600], ["40", 602], ["-", 604], ["49", 605], ["and", 608], ["50", 612], ["+", 614], ["days", 616], [")", 620], [",", 621], ["representing", 623], ["diseases", 636], ["from", 645], ["early", 650], ["stage", 656], ["to", 662], ["advanced", 665], ["stage", 674], ["with", 680], ["severe", 685], ["kyphosis", 692], [".", 700], ["Biweekly", 702], ["intravenous", 711], ["(", 723], ["i.v", 724], [".", 727], [")", 728], ["administration", 730], ["of", 745], ["the", 748], ["PPMO", 752], ["restored", 757], ["the", 766], ["dystrophin", 770], ["expression", 781], ["in", 792], ["nearly", 795], ["100", 802], ["%", 805], ["skeletal", 807], ["muscle", 816], ["fibers", 823], ["in", 830], ["all", 833], ["age", 837], ["groups", 841], [".", 847], ["This", 849], ["was", 854], ["associated", 858], ["with", 869], ["the", 874], ["restoration", 878], ["of", 890], ["dystrophin", 893], ["-", 903], ["associated", 904], ["proteins", 915], ["including", 924], ["functional", 934], ["glycosylated", 945], ["dystroglycan", 958], ["and", 971], ["neuronal", 975], ["nitric", 984], ["synthase", 991], [".", 999], ["However", 1001], [",", 1008], ["therapeutic", 1010], ["outcomes", 1022], ["clearly", 1031], ["depended", 1039], ["on", 1048], ["severity", 1051], ["of", 1060], ["the", 1063], ["disease", 1067], ["at", 1075], ["the", 1078], ["time", 1082], ["the", 1087], ["treatment", 1091], ["started", 1101], [".", 1108], ["The", 1110], ["PPMO", 1114], ["treatment", 1119], ["alleviated", 1129], ["the", 1140], ["disease", 1144], ["pathology", 1152], ["and", 1162], ["significantly", 1166], ["prolonged", 1180], ["the", 1190], ["life", 1194], ["span", 1199], ["of", 1204], ["the", 1207], ["mice", 1211], ["receiving", 1216], ["treatment", 1226], ["at", 1236], ["younger", 1239], ["age", 1247], ["with", 1251], ["mild", 1256], ["phenotype", 1261], [".", 1270], ["However", 1272], [",", 1279], ["restoration", 1281], ["of", 1293], ["high", 1296], ["levels", 1301], ["of", 1308], ["dystrophin", 1311], ["expression", 1322], ["failed", 1333], ["to", 1340], ["prevent", 1343], ["disease", 1351], ["progression", 1359], ["to", 1371], ["the", 1374], ["mice", 1378], ["receiving", 1383], ["treatment", 1393], ["when", 1403], ["disease", 1408], ["was", 1416], ["already", 1420], ["at", 1428], ["advanced", 1431], ["stage", 1440], [".", 1445], ["The", 1447], ["results", 1451], ["could", 1459], ["be", 1465], ["critical", 1468], ["for", 1477], ["design", 1481], ["of", 1488], ["clinical", 1491], ["trials", 1500], ["with", 1507], ["antisense", 1512], ["therapy", 1522], ["to", 1530], ["DMD", 1533], [".", 1536]]}
{"context": "The precursor of the non-Abeta component of Alzheimer's disease amyloid (NACP) (also known as alpha-synuclein) is a presynaptic terminal molecule that abnormally accumulates in the plaques of Alzheimer's disease (AD) and in the Lewy bodies (LBs) of Lewy body variant of AD, diffuse Lewy body disease, and Parkinson's disease. To better understand the distribution of NACP/alpha-synuclein and its fragments in the LB-bearing neurons and neurites, as well as to clarify the patterns of NACP/alpha-synuclein compartmentalization, we studied NACP/alpha-synuclein immunoreactivity using antibodies against the C-terminal, N-terminal, and NAC regions after Proteinase K and formic acid treatment in the cortex of patients with LBs. Furthermore, studies of the subcellular localization of NACP/alpha-synuclein within LB-bearing neurons were performed by immunogold electron microscopy. These studies showed that the N-terminal antibody immunolabeled the LBs and dystrophic neurites with great intensity and, to a lesser extent, the synapses. In contrast, the C-terminal antibody strongly labeled the synapses and, to a lesser extent, the LBs and dystrophic neurites. Whereas Proteinase K treatment enhanced NACP/alpha-synuclein immunoreactivity with the C-terminal antibody, it diminished the N-terminal NACP/alpha-synuclein immunoreactivity. Furthermore, formic acid enhanced LB and dystrophic neurite labeling with both the C- and N-terminal antibodies. In addition, whereas without pretreatment only slight anti-NAC immunoreactivity was found in the LBs, formic acid pretreatment revealed an extensive anti-NAC immunostaining of LBs, plaques, and glial cells. Ultrastructural analysis revealed that NACP/alpha-synuclein immunoreactivity was diffusely distributed within the amorphous electrodense material in the LBs and as small clusters in the filaments of LBs and neurites. These results support the view that aggregated NACP/alpha-synuclein might play an important role in the pathogenesis of disorders associated with LBs.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "d3600ecb55744469b54fde10d8d1c38e", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[247, 249], [100, 102], [20, 22], [228, 230], [109, 111], [153, 155], [351, 353], [315, 317], [75, 77]], "char_spans": [[1302, 1316], [489, 503], [94, 108], [1205, 1219], [543, 557], [787, 801], [1925, 1939], [1700, 1714], [372, 386]]}]}], "context_tokens": [["The", 0], ["precursor", 4], ["of", 14], ["the", 17], ["non", 21], ["-", 24], ["Abeta", 25], ["component", 31], ["of", 41], ["Alzheimer", 44], ["'s", 53], ["disease", 56], ["amyloid", 64], ["(", 72], ["NACP", 73], [")", 77], ["(", 79], ["also", 80], ["known", 85], ["as", 91], ["alpha", 94], ["-", 99], ["synuclein", 100], [")", 109], ["is", 111], ["a", 114], ["presynaptic", 116], ["terminal", 128], ["molecule", 137], ["that", 146], ["abnormally", 151], ["accumulates", 162], ["in", 174], ["the", 177], ["plaques", 181], ["of", 189], ["Alzheimer", 192], ["'s", 201], ["disease", 204], ["(", 212], ["AD", 213], [")", 215], ["and", 217], ["in", 221], ["the", 224], ["Lewy", 228], ["bodies", 233], ["(", 240], ["LBs", 241], [")", 244], ["of", 246], ["Lewy", 249], ["body", 254], ["variant", 259], ["of", 267], ["AD", 270], [",", 272], ["diffuse", 274], ["Lewy", 282], ["body", 287], ["disease", 292], [",", 299], ["and", 301], ["Parkinson", 305], ["'s", 314], ["disease", 317], [".", 324], ["To", 326], ["better", 329], ["understand", 336], ["the", 347], ["distribution", 351], ["of", 364], ["NACP", 367], ["/", 371], ["alpha", 372], ["-", 377], ["synuclein", 378], ["and", 388], ["its", 392], ["fragments", 396], ["in", 406], ["the", 409], ["LB", 413], ["-", 415], ["bearing", 416], ["neurons", 424], ["and", 432], ["neurites", 436], [",", 444], ["as", 446], ["well", 449], ["as", 454], ["to", 457], ["clarify", 460], ["the", 468], ["patterns", 472], ["of", 481], ["NACP", 484], ["/", 488], ["alpha", 489], ["-", 494], ["synuclein", 495], ["compartmentalization", 505], [",", 525], ["we", 527], ["studied", 530], ["NACP", 538], ["/", 542], ["alpha", 543], ["-", 548], ["synuclein", 549], ["immunoreactivity", 559], ["using", 576], ["antibodies", 582], ["against", 593], ["the", 601], ["C", 605], ["-", 606], ["terminal", 607], [",", 615], ["N", 617], ["-", 618], ["terminal", 619], [",", 627], ["and", 629], ["NAC", 633], ["regions", 637], ["after", 645], ["Proteinase", 651], ["K", 662], ["and", 664], ["formic", 668], ["acid", 675], ["treatment", 680], ["in", 690], ["the", 693], ["cortex", 697], ["of", 704], ["patients", 707], ["with", 716], ["LBs", 721], [".", 724], ["Furthermore", 726], [",", 737], ["studies", 739], ["of", 747], ["the", 750], ["subcellular", 754], ["localization", 766], ["of", 779], ["NACP", 782], ["/", 786], ["alpha", 787], ["-", 792], ["synuclein", 793], ["within", 803], ["LB", 810], ["-", 812], ["bearing", 813], ["neurons", 821], ["were", 829], ["performed", 834], ["by", 844], ["immunogold", 847], ["electron", 858], ["microscopy", 867], [".", 877], ["These", 879], ["studies", 885], ["showed", 893], ["that", 900], ["the", 905], ["N", 909], ["-", 910], ["terminal", 911], ["antibody", 920], ["immunolabeled", 929], ["the", 943], ["LBs", 947], ["and", 951], ["dystrophic", 955], ["neurites", 966], ["with", 975], ["great", 980], ["intensity", 986], ["and", 996], [",", 999], ["to", 1001], ["a", 1004], ["lesser", 1006], ["extent", 1013], [",", 1019], ["the", 1021], ["synapses", 1025], [".", 1033], ["In", 1035], ["contrast", 1038], [",", 1046], ["the", 1048], ["C", 1052], ["-", 1053], ["terminal", 1054], ["antibody", 1063], ["strongly", 1072], ["labeled", 1081], ["the", 1089], ["synapses", 1093], ["and", 1102], [",", 1105], ["to", 1107], ["a", 1110], ["lesser", 1112], ["extent", 1119], [",", 1125], ["the", 1127], ["LBs", 1131], ["and", 1135], ["dystrophic", 1139], ["neurites", 1150], [".", 1158], ["Whereas", 1160], ["Proteinase", 1168], ["K", 1179], ["treatment", 1181], ["enhanced", 1191], ["NACP", 1200], ["/", 1204], ["alpha", 1205], ["-", 1210], ["synuclein", 1211], ["immunoreactivity", 1221], ["with", 1238], ["the", 1243], ["C", 1247], ["-", 1248], ["terminal", 1249], ["antibody", 1258], [",", 1266], ["it", 1268], ["diminished", 1271], ["the", 1282], ["N", 1286], ["-", 1287], ["terminal", 1288], ["NACP", 1297], ["/", 1301], ["alpha", 1302], ["-", 1307], ["synuclein", 1308], ["immunoreactivity", 1318], [".", 1334], ["Furthermore", 1336], [",", 1347], ["formic", 1349], ["acid", 1356], ["enhanced", 1361], ["LB", 1370], ["and", 1373], ["dystrophic", 1377], ["neurite", 1388], ["labeling", 1396], ["with", 1405], ["both", 1410], ["the", 1415], ["C-", 1419], ["and", 1422], ["N", 1426], ["-", 1427], ["terminal", 1428], ["antibodies", 1437], [".", 1447], ["In", 1449], ["addition", 1452], [",", 1460], ["whereas", 1462], ["without", 1470], ["pretreatment", 1478], ["only", 1491], ["slight", 1496], ["anti", 1503], ["-", 1507], ["NAC", 1508], ["immunoreactivity", 1512], ["was", 1529], ["found", 1533], ["in", 1539], ["the", 1542], ["LBs", 1546], [",", 1549], ["formic", 1551], ["acid", 1558], ["pretreatment", 1563], ["revealed", 1576], ["an", 1585], ["extensive", 1588], ["anti", 1598], ["-", 1602], ["NAC", 1603], ["immunostaining", 1607], ["of", 1622], ["LBs", 1625], [",", 1628], ["plaques", 1630], [",", 1637], ["and", 1639], ["glial", 1643], ["cells", 1649], [".", 1654], ["Ultrastructural", 1656], ["analysis", 1672], ["revealed", 1681], ["that", 1690], ["NACP", 1695], ["/", 1699], ["alpha", 1700], ["-", 1705], ["synuclein", 1706], ["immunoreactivity", 1716], ["was", 1733], ["diffusely", 1737], ["distributed", 1747], ["within", 1759], ["the", 1766], ["amorphous", 1770], ["electrodense", 1780], ["material", 1793], ["in", 1802], ["the", 1805], ["LBs", 1809], ["and", 1813], ["as", 1817], ["small", 1820], ["clusters", 1826], ["in", 1835], ["the", 1838], ["filaments", 1842], ["of", 1852], ["LBs", 1855], ["and", 1859], ["neurites", 1863], [".", 1871], ["These", 1873], ["results", 1879], ["support", 1887], ["the", 1895], ["view", 1899], ["that", 1904], ["aggregated", 1909], ["NACP", 1920], ["/", 1924], ["alpha", 1925], ["-", 1930], ["synuclein", 1931], ["might", 1941], ["play", 1947], ["an", 1952], ["important", 1955], ["role", 1965], ["in", 1970], ["the", 1973], ["pathogenesis", 1977], ["of", 1990], ["disorders", 1993], ["associated", 2003], ["with", 2014], ["LBs", 2019], [".", 2022]]}
{"context": "Here, we report the biochemical and genetic basis of the Vel blood group antigen, which has been a vexing mystery for decades, especially as anti-Vel regularly causes severe haemolytic transfusion reactions. The protein carrying the Vel blood group antigen was biochemically purified from red blood cell membranes. Mass spectrometry-based de novo peptide sequencing identified this protein to be small integral membrane protein 1 (SMIM1), a previously uncharacterized single-pass membrane protein. Expression of SMIM1 cDNA in Vel- cultured cells generated anti-Vel cell surface reactivity, confirming that SMIM1 encoded the Vel blood group antigen. A cohort of 70 Vel- individuals was found to be uniformly homozygous for a 17 nucleotide deletion in the coding sequence of SMIM1. The genetic homogeneity of the Vel- blood type, likely having a common origin, facilitated the development of two highly specific DNA-based tests for rapid Vel genotyping, which can be easily integrated into blood group genotyping platforms. These results answer a 60-year-old riddle and provide tools of immediate assistance to all clinicians involved in the care of Vel- patients.", "qas": [{"question": "Which gene-defect causes the Vel-blood type?", "answers": ["a 17 nucleotide deletion"], "qid": "1a0f88859ac041309e802081a92d69d7", "question_tokens": [["Which", 0], ["gene", 6], ["-", 10], ["defect", 11], ["causes", 18], ["the", 25], ["Vel", 29], ["-", 32], ["blood", 33], ["type", 39], ["?", 43]], "detected_answers": [{"text": "a 17 nucleotide deletion", "token_spans": [[125, 127]], "char_spans": [[724, 745]]}]}], "context_tokens": [["Here", 0], [",", 4], ["we", 6], ["report", 9], ["the", 16], ["biochemical", 20], ["and", 32], ["genetic", 36], ["basis", 44], ["of", 50], ["the", 53], ["Vel", 57], ["blood", 61], ["group", 67], ["antigen", 73], [",", 80], ["which", 82], ["has", 88], ["been", 92], ["a", 97], ["vexing", 99], ["mystery", 106], ["for", 114], ["decades", 118], [",", 125], ["especially", 127], ["as", 138], ["anti", 141], ["-", 145], ["Vel", 146], ["regularly", 150], ["causes", 160], ["severe", 167], ["haemolytic", 174], ["transfusion", 185], ["reactions", 197], [".", 206], ["The", 208], ["protein", 212], ["carrying", 220], ["the", 229], ["Vel", 233], ["blood", 237], ["group", 243], ["antigen", 249], ["was", 257], ["biochemically", 261], ["purified", 275], ["from", 284], ["red", 289], ["blood", 293], ["cell", 299], ["membranes", 304], [".", 313], ["Mass", 315], ["spectrometry", 320], ["-", 332], ["based", 333], ["de", 339], ["novo", 342], ["peptide", 347], ["sequencing", 355], ["identified", 366], ["this", 377], ["protein", 382], ["to", 390], ["be", 393], ["small", 396], ["integral", 402], ["membrane", 411], ["protein", 420], ["1", 428], ["(", 430], ["SMIM1", 431], [")", 436], [",", 437], ["a", 439], ["previously", 441], ["uncharacterized", 452], ["single", 468], ["-", 474], ["pass", 475], ["membrane", 480], ["protein", 489], [".", 496], ["Expression", 498], ["of", 509], ["SMIM1", 512], ["cDNA", 518], ["in", 523], ["Vel-", 526], ["cultured", 531], ["cells", 540], ["generated", 546], ["anti", 556], ["-", 560], ["Vel", 561], ["cell", 565], ["surface", 570], ["reactivity", 578], [",", 588], ["confirming", 590], ["that", 601], ["SMIM1", 606], ["encoded", 612], ["the", 620], ["Vel", 624], ["blood", 628], ["group", 634], ["antigen", 640], [".", 647], ["A", 649], ["cohort", 651], ["of", 658], ["70", 661], ["Vel-", 664], ["individuals", 669], ["was", 681], ["found", 685], ["to", 691], ["be", 694], ["uniformly", 697], ["homozygous", 707], ["for", 718], ["a", 722], ["17", 724], ["nucleotide", 727], ["deletion", 738], ["in", 747], ["the", 750], ["coding", 754], ["sequence", 761], ["of", 770], ["SMIM1", 773], [".", 778], ["The", 780], ["genetic", 784], ["homogeneity", 792], ["of", 804], ["the", 807], ["Vel-", 811], ["blood", 816], ["type", 822], [",", 826], ["likely", 828], ["having", 835], ["a", 842], ["common", 844], ["origin", 851], [",", 857], ["facilitated", 859], ["the", 871], ["development", 875], ["of", 887], ["two", 890], ["highly", 894], ["specific", 901], ["DNA", 910], ["-", 913], ["based", 914], ["tests", 920], ["for", 926], ["rapid", 930], ["Vel", 936], ["genotyping", 940], [",", 950], ["which", 952], ["can", 958], ["be", 962], ["easily", 965], ["integrated", 972], ["into", 983], ["blood", 988], ["group", 994], ["genotyping", 1000], ["platforms", 1011], [".", 1020], ["These", 1022], ["results", 1028], ["answer", 1036], ["a", 1043], ["60-year", 1045], ["-", 1052], ["old", 1053], ["riddle", 1057], ["and", 1064], ["provide", 1068], ["tools", 1076], ["of", 1082], ["immediate", 1085], ["assistance", 1095], ["to", 1106], ["all", 1109], ["clinicians", 1113], ["involved", 1124], ["in", 1133], ["the", 1136], ["care", 1140], ["of", 1145], ["Vel-", 1148], ["patients", 1153], [".", 1161]]}
{"context": "Two missense mutations (Ala-30 --> Pro and Ala-53 --> Thr) in the gene encoding alpha-synuclein are associated with rare autosomal dominant forms of familial Parkinson's disease. In addition, alpha-synuclein is an abundant component of Lewy bodies in sporadic Parkinson's disease and diffuse Lewy body disease. However, the normal conformation of alpha-synuclein, its cellular localization in neurons, and the effects of the mutations remain to be determined. In the present study, we examine these questions using sensitive fluorescence resonance energy transfer techniques. Transient transfection of alpha-synuclein expression constructs into primary cortical neurons and counterstaining with the lipophilic fluorescent marker, DiI, demonstrates a close association between alpha-synuclein and cellular membranes. Both the N- and C-terminal regions of alpha-synuclein are tightly associated with membranes. A weak interaction also occurs between the N and C termini themselves. The Parkinson's disease-associated mutations have no effect on membrane interaction; however, the Ala-30 --> Pro mutation alters the three-dimensional conformation of alpha-synuclein, as measured by significantly increased fluorescence resonance energy transfer between the N and C termini.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "9cf91c000cf144009e50440635f148d1", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[129, 131], [145, 147], [196, 198], [37, 39], [105, 107], [64, 66], [18, 20]], "char_spans": [[776, 790], [854, 868], [1147, 1161], [192, 206], [602, 616], [347, 361], [80, 94]]}]}], "context_tokens": [["Two", 0], ["missense", 4], ["mutations", 13], ["(", 23], ["Ala-30", 24], ["--", 31], [">", 33], ["Pro", 35], ["and", 39], ["Ala-53", 43], ["--", 50], [">", 52], ["Thr", 54], [")", 57], ["in", 59], ["the", 62], ["gene", 66], ["encoding", 71], ["alpha", 80], ["-", 85], ["synuclein", 86], ["are", 96], ["associated", 100], ["with", 111], ["rare", 116], ["autosomal", 121], ["dominant", 131], ["forms", 140], ["of", 146], ["familial", 149], ["Parkinson", 158], ["'s", 167], ["disease", 170], [".", 177], ["In", 179], ["addition", 182], [",", 190], ["alpha", 192], ["-", 197], ["synuclein", 198], ["is", 208], ["an", 211], ["abundant", 214], ["component", 223], ["of", 233], ["Lewy", 236], ["bodies", 241], ["in", 248], ["sporadic", 251], ["Parkinson", 260], ["'s", 269], ["disease", 272], ["and", 280], ["diffuse", 284], ["Lewy", 292], ["body", 297], ["disease", 302], [".", 309], ["However", 311], [",", 318], ["the", 320], ["normal", 324], ["conformation", 331], ["of", 344], ["alpha", 347], ["-", 352], ["synuclein", 353], [",", 362], ["its", 364], ["cellular", 368], ["localization", 377], ["in", 390], ["neurons", 393], [",", 400], ["and", 402], ["the", 406], ["effects", 410], ["of", 418], ["the", 421], ["mutations", 425], ["remain", 435], ["to", 442], ["be", 445], ["determined", 448], [".", 458], ["In", 460], ["the", 463], ["present", 467], ["study", 475], [",", 480], ["we", 482], ["examine", 485], ["these", 493], ["questions", 499], ["using", 509], ["sensitive", 515], ["fluorescence", 525], ["resonance", 538], ["energy", 548], ["transfer", 555], ["techniques", 564], [".", 574], ["Transient", 576], ["transfection", 586], ["of", 599], ["alpha", 602], ["-", 607], ["synuclein", 608], ["expression", 618], ["constructs", 629], ["into", 640], ["primary", 645], ["cortical", 653], ["neurons", 662], ["and", 670], ["counterstaining", 674], ["with", 690], ["the", 695], ["lipophilic", 699], ["fluorescent", 710], ["marker", 722], [",", 728], ["DiI", 730], [",", 733], ["demonstrates", 735], ["a", 748], ["close", 750], ["association", 756], ["between", 768], ["alpha", 776], ["-", 781], ["synuclein", 782], ["and", 792], ["cellular", 796], ["membranes", 805], [".", 814], ["Both", 816], ["the", 821], ["N-", 825], ["and", 828], ["C", 832], ["-", 833], ["terminal", 834], ["regions", 843], ["of", 851], ["alpha", 854], ["-", 859], ["synuclein", 860], ["are", 870], ["tightly", 874], ["associated", 882], ["with", 893], ["membranes", 898], [".", 907], ["A", 909], ["weak", 911], ["interaction", 916], ["also", 928], ["occurs", 933], ["between", 940], ["the", 948], ["N", 952], ["and", 954], ["C", 958], ["termini", 960], ["themselves", 968], [".", 978], ["The", 980], ["Parkinson", 984], ["'s", 993], ["disease", 996], ["-", 1003], ["associated", 1004], ["mutations", 1015], ["have", 1025], ["no", 1030], ["effect", 1033], ["on", 1040], ["membrane", 1043], ["interaction", 1052], [";", 1063], ["however", 1065], [",", 1072], ["the", 1074], ["Ala-30", 1078], ["--", 1085], [">", 1087], ["Pro", 1089], ["mutation", 1093], ["alters", 1102], ["the", 1109], ["three", 1113], ["-", 1118], ["dimensional", 1119], ["conformation", 1131], ["of", 1144], ["alpha", 1147], ["-", 1152], ["synuclein", 1153], [",", 1162], ["as", 1164], ["measured", 1167], ["by", 1176], ["significantly", 1179], ["increased", 1193], ["fluorescence", 1203], ["resonance", 1216], ["energy", 1226], ["transfer", 1233], ["between", 1242], ["the", 1250], ["N", 1254], ["and", 1256], ["C", 1260], ["termini", 1262], [".", 1269]]}
{"context": "Facioscapulohumeral dystrophy (FSHD) is characterized by chromatin relaxation of the D4Z4 macrosatellite array on chromosome 4 and expression of the D4Z4-encoded DUX4 gene in skeletal muscle. The more common form, autosomal dominant FSHD1, is caused by contraction of the D4Z4 array, whereas the genetic determinants and inheritance of D4Z4 array contraction-independent FSHD2 are unclear. Here, we show that mutations in SMCHD1 (encoding structural maintenance of chromosomes flexible hinge domain containing 1) on chromosome 18 reduce SMCHD1 protein levels and segregate with genome-wide D4Z4 CpG hypomethylation in human kindreds. FSHD2 occurs in individuals who inherited both the SMCHD1 mutation and a normal-sized D4Z4 array on a chromosome 4 haplotype permissive for DUX4 expression. Reducing SMCHD1 levels in skeletal muscle results in D4Z4 contraction-independent DUX4 expression. Our study identifies SMCHD1 as an epigenetic modifier of the D4Z4 metastable epiallele and as a causal genetic determinant of FSHD2 and possibly other human diseases subject to epigenetic regulation.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "1e975a42f37e4673a2b441a56ec1c446", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "Facioscapulohumeral dystrophy", "token_spans": [[0, 1]], "char_spans": [[0, 28]]}, {"text": "FSHD", "token_spans": [[3, 3]], "char_spans": [[31, 34]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["dystrophy", 20], ["(", 30], ["FSHD", 31], [")", 35], ["is", 37], ["characterized", 40], ["by", 54], ["chromatin", 57], ["relaxation", 67], ["of", 78], ["the", 81], ["D4Z4", 85], ["macrosatellite", 90], ["array", 105], ["on", 111], ["chromosome", 114], ["4", 125], ["and", 127], ["expression", 131], ["of", 142], ["the", 145], ["D4Z4-encoded", 149], ["DUX4", 162], ["gene", 167], ["in", 172], ["skeletal", 175], ["muscle", 184], [".", 190], ["The", 192], ["more", 196], ["common", 201], ["form", 208], [",", 212], ["autosomal", 214], ["dominant", 224], ["FSHD1", 233], [",", 238], ["is", 240], ["caused", 243], ["by", 250], ["contraction", 253], ["of", 265], ["the", 268], ["D4Z4", 272], ["array", 277], [",", 282], ["whereas", 284], ["the", 292], ["genetic", 296], ["determinants", 304], ["and", 317], ["inheritance", 321], ["of", 333], ["D4Z4", 336], ["array", 341], ["contraction", 347], ["-", 358], ["independent", 359], ["FSHD2", 371], ["are", 377], ["unclear", 381], [".", 388], ["Here", 390], [",", 394], ["we", 396], ["show", 399], ["that", 404], ["mutations", 409], ["in", 419], ["SMCHD1", 422], ["(", 429], ["encoding", 430], ["structural", 439], ["maintenance", 450], ["of", 462], ["chromosomes", 465], ["flexible", 477], ["hinge", 486], ["domain", 492], ["containing", 499], ["1", 510], [")", 511], ["on", 513], ["chromosome", 516], ["18", 527], ["reduce", 530], ["SMCHD1", 537], ["protein", 544], ["levels", 552], ["and", 559], ["segregate", 563], ["with", 573], ["genome", 578], ["-", 584], ["wide", 585], ["D4Z4", 590], ["CpG", 595], ["hypomethylation", 599], ["in", 615], ["human", 618], ["kindreds", 624], [".", 632], ["FSHD2", 634], ["occurs", 640], ["in", 647], ["individuals", 650], ["who", 662], ["inherited", 666], ["both", 676], ["the", 681], ["SMCHD1", 685], ["mutation", 692], ["and", 701], ["a", 705], ["normal", 707], ["-", 713], ["sized", 714], ["D4Z4", 720], ["array", 725], ["on", 731], ["a", 734], ["chromosome", 736], ["4", 747], ["haplotype", 749], ["permissive", 759], ["for", 770], ["DUX4", 774], ["expression", 779], [".", 789], ["Reducing", 791], ["SMCHD1", 800], ["levels", 807], ["in", 814], ["skeletal", 817], ["muscle", 826], ["results", 833], ["in", 841], ["D4Z4", 844], ["contraction", 849], ["-", 860], ["independent", 861], ["DUX4", 873], ["expression", 878], [".", 888], ["Our", 890], ["study", 894], ["identifies", 900], ["SMCHD1", 911], ["as", 918], ["an", 921], ["epigenetic", 924], ["modifier", 935], ["of", 944], ["the", 947], ["D4Z4", 951], ["metastable", 956], ["epiallele", 967], ["and", 977], ["as", 981], ["a", 984], ["causal", 986], ["genetic", 993], ["determinant", 1001], ["of", 1013], ["FSHD2", 1016], ["and", 1022], ["possibly", 1026], ["other", 1035], ["human", 1041], ["diseases", 1047], ["subject", 1056], ["to", 1064], ["epigenetic", 1067], ["regulation", 1078], [".", 1088]]}
{"context": "The Malaria Policy Advisory Committee to the World Health Organization met in Geneva, Switzerland from 13 to 15 March, 2013. This article provides a summary of the discussions, conclusions and recommendations from that meeting.Meeting sessions included: a review of the efficacy of artemisinin-based combination therapy in Guyana and Suriname; the outcomes from a consultation on non-malaria febrile illness; the outcomes from the second meeting of the Evidence Review Group on malaria burden estimation; an update on the review of the WHO Guidelines for the Treatment of Malaria; an update regarding progress on the constitution of the vector control Technical Expert Group; updates on the RTS, S/AS01 vaccine and the malaria vaccine technology roadmap; financing and resource allocation for malaria control; malaria surveillance and the need for a surveillance, monitoring and evaluation Technical Expert Group; criteria and classification related to malaria elimination; the next meeting of the Evidence Review Group on Intermittent Preventive Treatment in pregnancy; an update on the soon-to-be launched Elimination Scenario Planning Tool; and an update on the process for the Global Technical Strategy for Malaria Control and Elimination (2016-2025).Policy statements, position statements, and guidelines that arise from the MPAC meeting conclusions and recommendations will be formally issued and disseminated to World Health Organization Member States by the World Health Organization Global Malaria Programme.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "08c2300228d848599dbb36a771fdc904", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[128, 128], [83, 83], [67, 67], [138, 138], [141, 141], [100, 100], [249, 249], [162, 162], [1, 1], [207, 207]], "char_spans": [[719, 725], [478, 484], [384, 390], [793, 799], [810, 816], [572, 578], [1499, 1505], [953, 959], [4, 10], [1211, 1217]]}]}], "context_tokens": [["The", 0], ["Malaria", 4], ["Policy", 12], ["Advisory", 19], ["Committee", 28], ["to", 38], ["the", 41], ["World", 45], ["Health", 51], ["Organization", 58], ["met", 71], ["in", 75], ["Geneva", 78], [",", 84], ["Switzerland", 86], ["from", 98], ["13", 103], ["to", 106], ["15", 109], ["March", 112], [",", 117], ["2013", 119], [".", 123], ["This", 125], ["article", 130], ["provides", 138], ["a", 147], ["summary", 149], ["of", 157], ["the", 160], ["discussions", 164], [",", 175], ["conclusions", 177], ["and", 189], ["recommendations", 193], ["from", 209], ["that", 214], ["meeting", 219], [".", 226], ["Meeting", 227], ["sessions", 235], ["included", 244], [":", 252], ["a", 254], ["review", 256], ["of", 263], ["the", 266], ["efficacy", 270], ["of", 279], ["artemisinin", 282], ["-", 293], ["based", 294], ["combination", 300], ["therapy", 312], ["in", 320], ["Guyana", 323], ["and", 330], ["Suriname", 334], [";", 342], ["the", 344], ["outcomes", 348], ["from", 357], ["a", 362], ["consultation", 364], ["on", 377], ["non", 380], ["-", 383], ["malaria", 384], ["febrile", 392], ["illness", 400], [";", 407], ["the", 409], ["outcomes", 413], ["from", 422], ["the", 427], ["second", 431], ["meeting", 438], ["of", 446], ["the", 449], ["Evidence", 453], ["Review", 462], ["Group", 469], ["on", 475], ["malaria", 478], ["burden", 486], ["estimation", 493], [";", 503], ["an", 505], ["update", 508], ["on", 515], ["the", 518], ["review", 522], ["of", 529], ["the", 532], ["WHO", 536], ["Guidelines", 540], ["for", 551], ["the", 555], ["Treatment", 559], ["of", 569], ["Malaria", 572], [";", 579], ["an", 581], ["update", 584], ["regarding", 591], ["progress", 601], ["on", 610], ["the", 613], ["constitution", 617], ["of", 630], ["the", 633], ["vector", 637], ["control", 644], ["Technical", 652], ["Expert", 662], ["Group", 669], [";", 674], ["updates", 676], ["on", 684], ["the", 687], ["RTS", 691], [",", 694], ["S", 696], ["/", 697], ["AS01", 698], ["vaccine", 703], ["and", 711], ["the", 715], ["malaria", 719], ["vaccine", 727], ["technology", 735], ["roadmap", 746], [";", 753], ["financing", 755], ["and", 765], ["resource", 769], ["allocation", 778], ["for", 789], ["malaria", 793], ["control", 801], [";", 808], ["malaria", 810], ["surveillance", 818], ["and", 831], ["the", 835], ["need", 839], ["for", 844], ["a", 848], ["surveillance", 850], [",", 862], ["monitoring", 864], ["and", 875], ["evaluation", 879], ["Technical", 890], ["Expert", 900], ["Group", 907], [";", 912], ["criteria", 914], ["and", 923], ["classification", 927], ["related", 942], ["to", 950], ["malaria", 953], ["elimination", 961], [";", 972], ["the", 974], ["next", 978], ["meeting", 983], ["of", 991], ["the", 994], ["Evidence", 998], ["Review", 1007], ["Group", 1014], ["on", 1020], ["Intermittent", 1023], ["Preventive", 1036], ["Treatment", 1047], ["in", 1057], ["pregnancy", 1060], [";", 1069], ["an", 1071], ["update", 1074], ["on", 1081], ["the", 1084], ["soon", 1088], ["-", 1092], ["to", 1093], ["-", 1095], ["be", 1096], ["launched", 1099], ["Elimination", 1108], ["Scenario", 1120], ["Planning", 1129], ["Tool", 1138], [";", 1142], ["and", 1144], ["an", 1148], ["update", 1151], ["on", 1158], ["the", 1161], ["process", 1165], ["for", 1173], ["the", 1177], ["Global", 1181], ["Technical", 1188], ["Strategy", 1198], ["for", 1207], ["Malaria", 1211], ["Control", 1219], ["and", 1227], ["Elimination", 1231], ["(", 1243], ["2016", 1244], ["-", 1248], ["2025).Policy", 1249], ["statements", 1262], [",", 1272], ["position", 1274], ["statements", 1283], [",", 1293], ["and", 1295], ["guidelines", 1299], ["that", 1310], ["arise", 1315], ["from", 1321], ["the", 1326], ["MPAC", 1330], ["meeting", 1335], ["conclusions", 1343], ["and", 1355], ["recommendations", 1359], ["will", 1375], ["be", 1380], ["formally", 1383], ["issued", 1392], ["and", 1399], ["disseminated", 1403], ["to", 1416], ["World", 1419], ["Health", 1425], ["Organization", 1432], ["Member", 1445], ["States", 1452], ["by", 1459], ["the", 1462], ["World", 1466], ["Health", 1472], ["Organization", 1479], ["Global", 1492], ["Malaria", 1499], ["Programme", 1507], [".", 1516]]}
{"context": "Alpha-synuclein is phosphorylated at serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies. These inclusion bodies are the characteristic pathologic lesions of Parkinson disease. Here we define the role of phosphorylation of Ser129 in alpha-synuclein toxicity and inclusion formation using a Drosophila model of Parkinson disease. Mutation of Ser129 to alanine to prevent phosphorylation completely suppresses dopaminergic neuronal loss produced by expression of human alpha-synuclein. In contrast, altering Ser129 to the negatively charged residue aspartate, to mimic phosphorylation, significantly enhances alpha-synuclein toxicity. The G protein-coupled receptor kinase 2 (Gprk2) phosphorylates Ser129 in vivo and enhances alpha-synuclein toxicity. Blocking phosphorylation at Ser129 substantially increases aggregate formation. Thus Ser129 phosphorylation status is crucial in mediating alpha-synuclein neurotoxicity and inclusion formation. Because increased number of inclusion bodies correlates with reduced toxicity, inclusion bodies may protect neurons from alpha-synuclein toxicity.", "qas": [{"question": "Which residue of alpha-synuclein was found to be phosphorylated in Lewy bodies?", "answers": ["Serine 129"], "qid": "7161d325e39f4f4884391fb5e3adb5db", "question_tokens": [["Which", 0], ["residue", 6], ["of", 14], ["alpha", 17], ["-", 22], ["synuclein", 23], ["was", 33], ["found", 37], ["to", 43], ["be", 46], ["phosphorylated", 49], ["in", 64], ["Lewy", 67], ["bodies", 72], ["?", 78]], "detected_answers": [{"text": "Serine 129", "token_spans": [[6, 7]], "char_spans": [[37, 46]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["is", 16], ["phosphorylated", 19], ["at", 34], ["serine", 37], ["129", 44], ["(", 48], ["Ser129", 49], [")", 55], ["in", 57], ["intracellular", 60], ["protein", 74], ["aggregates", 82], ["called", 93], ["Lewy", 100], ["bodies", 105], [".", 111], ["These", 113], ["inclusion", 119], ["bodies", 129], ["are", 136], ["the", 140], ["characteristic", 144], ["pathologic", 159], ["lesions", 170], ["of", 178], ["Parkinson", 181], ["disease", 191], [".", 198], ["Here", 200], ["we", 205], ["define", 208], ["the", 215], ["role", 219], ["of", 224], ["phosphorylation", 227], ["of", 243], ["Ser129", 246], ["in", 253], ["alpha", 256], ["-", 261], ["synuclein", 262], ["toxicity", 272], ["and", 281], ["inclusion", 285], ["formation", 295], ["using", 305], ["a", 311], ["Drosophila", 313], ["model", 324], ["of", 330], ["Parkinson", 333], ["disease", 343], [".", 350], ["Mutation", 352], ["of", 361], ["Ser129", 364], ["to", 371], ["alanine", 374], ["to", 382], ["prevent", 385], ["phosphorylation", 393], ["completely", 409], ["suppresses", 420], ["dopaminergic", 431], ["neuronal", 444], ["loss", 453], ["produced", 458], ["by", 467], ["expression", 470], ["of", 481], ["human", 484], ["alpha", 490], ["-", 495], ["synuclein", 496], [".", 505], ["In", 507], ["contrast", 510], [",", 518], ["altering", 520], ["Ser129", 529], ["to", 536], ["the", 539], ["negatively", 543], ["charged", 554], ["residue", 562], ["aspartate", 570], [",", 579], ["to", 581], ["mimic", 584], ["phosphorylation", 590], [",", 605], ["significantly", 607], ["enhances", 621], ["alpha", 630], ["-", 635], ["synuclein", 636], ["toxicity", 646], [".", 654], ["The", 656], ["G", 660], ["protein", 662], ["-", 669], ["coupled", 670], ["receptor", 678], ["kinase", 687], ["2", 694], ["(", 696], ["Gprk2", 697], [")", 702], ["phosphorylates", 704], ["Ser129", 719], ["in", 726], ["vivo", 729], ["and", 734], ["enhances", 738], ["alpha", 747], ["-", 752], ["synuclein", 753], ["toxicity", 763], [".", 771], ["Blocking", 773], ["phosphorylation", 782], ["at", 798], ["Ser129", 801], ["substantially", 808], ["increases", 822], ["aggregate", 832], ["formation", 842], [".", 851], ["Thus", 853], ["Ser129", 858], ["phosphorylation", 865], ["status", 881], ["is", 888], ["crucial", 891], ["in", 899], ["mediating", 902], ["alpha", 912], ["-", 917], ["synuclein", 918], ["neurotoxicity", 928], ["and", 942], ["inclusion", 946], ["formation", 956], [".", 965], ["Because", 967], ["increased", 975], ["number", 985], ["of", 992], ["inclusion", 995], ["bodies", 1005], ["correlates", 1012], ["with", 1023], ["reduced", 1028], ["toxicity", 1036], [",", 1044], ["inclusion", 1046], ["bodies", 1056], ["may", 1063], ["protect", 1067], ["neurons", 1075], ["from", 1083], ["alpha", 1088], ["-", 1093], ["synuclein", 1094], ["toxicity", 1104], [".", 1112]]}
{"context": "Dabigatran is a direct thrombin inhibitor used to reduce the risk of stroke in patients with nonvalvular atrial fibrillation. For patients who present with an acute stroke despite dabigatran therapy, clinical data on the use of intravenous tissue plasminogen activator (IV-tPA) is limited. There is an anticipated increased risk of symptomatic intracranial hemorrhage (sICH) when using IV-tPA in patients on dabigatran therapy. In 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran. Dabigatran reversal with idarucizumab before administration of IV-tPA might reduce the risk of sICH. We report a case of a 69-year-old stroke patient on dabigatran for paroxysmal atrial fibrillation who presented with an initial National Institutes of Health Stroke Scale (NIHSS) of 12. There was no early evidence of ischemic stroke or hemorrhage on head computed tomography, and coagulation studies implied therapeutic dabigatran levels. After controlling blood pressure, dabigatran was reversed with idarucizumab, and IV-tPA was administrated beginning 197\u2009minutes after he was last seen at his baseline. Subsequent brain magnetic resonance imaging showed 2 punctate infarcts in the left temporal lobe and occipital lobe with no evidence of hemorrhage. The patient was discharged with an NIHSS of 1. Telephone follow-up 2 months later indicated that he was at his prestroke baseline, except for a complaint of worsened short-term memory. Idarucizumab reversal of dabigatran may reduce the risk of sICH and should be considered for acute stroke patients arriving in the IV-tPA time window.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "f9c27593e5f743369c33b2e1ea8791ae", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[0, 0], [176, 176], [97, 97], [29, 29], [71, 71], [263, 263], [168, 168], [126, 126], [95, 95]], "char_spans": [[0, 9], [1049, 1058], [575, 584], [180, 189], [408, 417], [1541, 1550], [996, 1005], [728, 737], [563, 572]]}]}], "context_tokens": [["Dabigatran", 0], ["is", 11], ["a", 14], ["direct", 16], ["thrombin", 23], ["inhibitor", 32], ["used", 42], ["to", 47], ["reduce", 50], ["the", 57], ["risk", 61], ["of", 66], ["stroke", 69], ["in", 76], ["patients", 79], ["with", 88], ["nonvalvular", 93], ["atrial", 105], ["fibrillation", 112], [".", 124], ["For", 126], ["patients", 130], ["who", 139], ["present", 143], ["with", 151], ["an", 156], ["acute", 159], ["stroke", 165], ["despite", 172], ["dabigatran", 180], ["therapy", 191], [",", 198], ["clinical", 200], ["data", 209], ["on", 214], ["the", 217], ["use", 221], ["of", 225], ["intravenous", 228], ["tissue", 240], ["plasminogen", 247], ["activator", 259], ["(", 269], ["IV", 270], ["-", 272], ["tPA", 273], [")", 276], ["is", 278], ["limited", 281], [".", 288], ["There", 290], ["is", 296], ["an", 299], ["anticipated", 302], ["increased", 314], ["risk", 324], ["of", 329], ["symptomatic", 332], ["intracranial", 344], ["hemorrhage", 357], ["(", 368], ["sICH", 369], [")", 373], ["when", 375], ["using", 380], ["IV", 386], ["-", 388], ["tPA", 389], ["in", 393], ["patients", 396], ["on", 405], ["dabigatran", 408], ["therapy", 419], [".", 426], ["In", 428], ["2015", 431], [",", 435], ["the", 437], ["humanized", 441], ["monoclonal", 451], ["antibody", 462], ["fragment", 471], ["idarucizumab", 480], ["was", 493], ["approved", 497], ["for", 506], ["rapid", 510], ["(", 516], ["minutes", 517], [")", 524], ["reversal", 526], ["of", 535], ["anticoagulant", 538], ["effects", 552], ["of", 560], ["dabigatran", 563], [".", 573], ["Dabigatran", 575], ["reversal", 586], ["with", 595], ["idarucizumab", 600], ["before", 613], ["administration", 620], ["of", 635], ["IV", 638], ["-", 640], ["tPA", 641], ["might", 645], ["reduce", 651], ["the", 658], ["risk", 662], ["of", 667], ["sICH", 670], [".", 674], ["We", 676], ["report", 679], ["a", 686], ["case", 688], ["of", 693], ["a", 696], ["69-year", 698], ["-", 705], ["old", 706], ["stroke", 710], ["patient", 717], ["on", 725], ["dabigatran", 728], ["for", 739], ["paroxysmal", 743], ["atrial", 754], ["fibrillation", 761], ["who", 774], ["presented", 778], ["with", 788], ["an", 793], ["initial", 796], ["National", 804], ["Institutes", 813], ["of", 824], ["Health", 827], ["Stroke", 834], ["Scale", 841], ["(", 847], ["NIHSS", 848], [")", 853], ["of", 855], ["12", 858], [".", 860], ["There", 862], ["was", 868], ["no", 872], ["early", 875], ["evidence", 881], ["of", 890], ["ischemic", 893], ["stroke", 902], ["or", 909], ["hemorrhage", 912], ["on", 923], ["head", 926], ["computed", 931], ["tomography", 940], [",", 950], ["and", 952], ["coagulation", 956], ["studies", 968], ["implied", 976], ["therapeutic", 984], ["dabigatran", 996], ["levels", 1007], [".", 1013], ["After", 1015], ["controlling", 1021], ["blood", 1033], ["pressure", 1039], [",", 1047], ["dabigatran", 1049], ["was", 1060], ["reversed", 1064], ["with", 1073], ["idarucizumab", 1078], [",", 1090], ["and", 1092], ["IV", 1096], ["-", 1098], ["tPA", 1099], ["was", 1103], ["administrated", 1107], ["beginning", 1121], ["197", 1131], ["minutes", 1135], ["after", 1143], ["he", 1149], ["was", 1152], ["last", 1156], ["seen", 1161], ["at", 1166], ["his", 1169], ["baseline", 1173], [".", 1181], ["Subsequent", 1183], ["brain", 1194], ["magnetic", 1200], ["resonance", 1209], ["imaging", 1219], ["showed", 1227], ["2", 1234], ["punctate", 1236], ["infarcts", 1245], ["in", 1254], ["the", 1257], ["left", 1261], ["temporal", 1266], ["lobe", 1275], ["and", 1280], ["occipital", 1284], ["lobe", 1294], ["with", 1299], ["no", 1304], ["evidence", 1307], ["of", 1316], ["hemorrhage", 1319], [".", 1329], ["The", 1331], ["patient", 1335], ["was", 1343], ["discharged", 1347], ["with", 1358], ["an", 1363], ["NIHSS", 1366], ["of", 1372], ["1", 1375], [".", 1376], ["Telephone", 1378], ["follow", 1388], ["-", 1394], ["up", 1395], ["2", 1398], ["months", 1400], ["later", 1407], ["indicated", 1413], ["that", 1423], ["he", 1428], ["was", 1431], ["at", 1435], ["his", 1438], ["prestroke", 1442], ["baseline", 1452], [",", 1460], ["except", 1462], ["for", 1469], ["a", 1473], ["complaint", 1475], ["of", 1485], ["worsened", 1488], ["short", 1497], ["-", 1502], ["term", 1503], ["memory", 1508], [".", 1514], ["Idarucizumab", 1516], ["reversal", 1529], ["of", 1538], ["dabigatran", 1541], ["may", 1552], ["reduce", 1556], ["the", 1563], ["risk", 1567], ["of", 1572], ["sICH", 1575], ["and", 1580], ["should", 1584], ["be", 1591], ["considered", 1594], ["for", 1605], ["acute", 1609], ["stroke", 1615], ["patients", 1622], ["arriving", 1631], ["in", 1640], ["the", 1643], ["IV", 1647], ["-", 1649], ["tPA", 1650], ["time", 1654], ["window", 1659], [".", 1665]]}
{"context": "Research during the last 15 years has conclusively shown that viroids are not only fundamentally different from viruses at the molecular level, but that they are most likely not directly related to viruses in an evolutionary sense. Today, viroids are among the most thoroughly studied biological macromolecules. Their molecular structures have been elucidated to a large extent, but much needs to be learned regarding the correlation between molecular structure and biological function. The availability of the tools of recombinant DNA technology in viroid research promises rapid progress in these areas of inquiry.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "e33fefebc3a946c4b17c7aaf7f33de2e", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[41, 41], [10, 10]], "char_spans": [[239, 245], [62, 68]]}]}], "context_tokens": [["Research", 0], ["during", 9], ["the", 16], ["last", 20], ["15", 25], ["years", 28], ["has", 34], ["conclusively", 38], ["shown", 51], ["that", 57], ["viroids", 62], ["are", 70], ["not", 74], ["only", 78], ["fundamentally", 83], ["different", 97], ["from", 107], ["viruses", 112], ["at", 120], ["the", 123], ["molecular", 127], ["level", 137], [",", 142], ["but", 144], ["that", 148], ["they", 153], ["are", 158], ["most", 162], ["likely", 167], ["not", 174], ["directly", 178], ["related", 187], ["to", 195], ["viruses", 198], ["in", 206], ["an", 209], ["evolutionary", 212], ["sense", 225], [".", 230], ["Today", 232], [",", 237], ["viroids", 239], ["are", 247], ["among", 251], ["the", 257], ["most", 261], ["thoroughly", 266], ["studied", 277], ["biological", 285], ["macromolecules", 296], [".", 310], ["Their", 312], ["molecular", 318], ["structures", 328], ["have", 339], ["been", 344], ["elucidated", 349], ["to", 360], ["a", 363], ["large", 365], ["extent", 371], [",", 377], ["but", 379], ["much", 383], ["needs", 388], ["to", 394], ["be", 397], ["learned", 400], ["regarding", 408], ["the", 418], ["correlation", 422], ["between", 434], ["molecular", 442], ["structure", 452], ["and", 462], ["biological", 466], ["function", 477], [".", 485], ["The", 487], ["availability", 491], ["of", 504], ["the", 507], ["tools", 511], ["of", 517], ["recombinant", 520], ["DNA", 532], ["technology", 536], ["in", 547], ["viroid", 550], ["research", 557], ["promises", 566], ["rapid", 575], ["progress", 581], ["in", 590], ["these", 593], ["areas", 599], ["of", 605], ["inquiry", 608], [".", 615]]}
{"context": "Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are present in lung adenocarcinomas that respond to the EGFR inhibitors gefitinib and erlotinib. Two types of mutations account for approximately 90% of mutated cases: short in-frame deletions in exon 19 and a specific point mutation in exon 21 at codon 858 (L858R). Screening for these mutations has been based mainly on direct sequencing. We report here the development and validation of polymerase chain reaction-based assays for these two predominant types of EGFR mutations. The assay for exon 19 mutations is based on length analysis of fluorescently labeled polymerase chain reaction products, and the assay for the exon 21 L858R mutation is based on a new Sau96I restriction site created by this mutation. Using serial dilutions of DNAs from lung cancer cell lines harboring either exon 19 or 21 mutations, we detected these mutations in the presence of up to approximately 90% normal DNA. In a test set of 39 lung cancer samples, direct sequencing detected mutations in 25 cases whereas our assays were positive in 29 cases, including 4 cases in which mutations were not apparent by sequencing. These assays offer higher sensitivity and ease of scoring and eliminate the need for sequencing, providing a robust and accessible approach to the rapid identification of most lung cancer patients likely to respond to EGFR inhibitors.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "a19945a83e2d457caf189e2614c1ac05", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[9, 16]], "char_spans": [[55, 98]]}]}], "context_tokens": [["Somatic", 0], ["mutations", 8], ["in", 18], ["the", 21], ["tyrosine", 25], ["kinase", 34], ["domain", 41], ["of", 48], ["the", 51], ["epidermal", 55], ["growth", 65], ["factor", 72], ["receptor", 79], ["(", 88], ["EGFR", 89], [")", 93], ["gene", 95], ["are", 100], ["present", 104], ["in", 112], ["lung", 115], ["adenocarcinomas", 120], ["that", 136], ["respond", 141], ["to", 149], ["the", 152], ["EGFR", 156], ["inhibitors", 161], ["gefitinib", 172], ["and", 182], ["erlotinib", 186], [".", 195], ["Two", 197], ["types", 201], ["of", 207], ["mutations", 210], ["account", 220], ["for", 228], ["approximately", 232], ["90", 246], ["%", 248], ["of", 250], ["mutated", 253], ["cases", 261], [":", 266], ["short", 268], ["in", 274], ["-", 276], ["frame", 277], ["deletions", 283], ["in", 293], ["exon", 296], ["19", 301], ["and", 304], ["a", 308], ["specific", 310], ["point", 319], ["mutation", 325], ["in", 334], ["exon", 337], ["21", 342], ["at", 345], ["codon", 348], ["858", 354], ["(", 358], ["L858R", 359], [")", 364], [".", 365], ["Screening", 367], ["for", 377], ["these", 381], ["mutations", 387], ["has", 397], ["been", 401], ["based", 406], ["mainly", 412], ["on", 419], ["direct", 422], ["sequencing", 429], [".", 439], ["We", 441], ["report", 444], ["here", 451], ["the", 456], ["development", 460], ["and", 472], ["validation", 476], ["of", 487], ["polymerase", 490], ["chain", 501], ["reaction", 507], ["-", 515], ["based", 516], ["assays", 522], ["for", 529], ["these", 533], ["two", 539], ["predominant", 543], ["types", 555], ["of", 561], ["EGFR", 564], ["mutations", 569], [".", 578], ["The", 580], ["assay", 584], ["for", 590], ["exon", 594], ["19", 599], ["mutations", 602], ["is", 612], ["based", 615], ["on", 621], ["length", 624], ["analysis", 631], ["of", 640], ["fluorescently", 643], ["labeled", 657], ["polymerase", 665], ["chain", 676], ["reaction", 682], ["products", 691], [",", 699], ["and", 701], ["the", 705], ["assay", 709], ["for", 715], ["the", 719], ["exon", 723], ["21", 728], ["L858R", 731], ["mutation", 737], ["is", 746], ["based", 749], ["on", 755], ["a", 758], ["new", 760], ["Sau96I", 764], ["restriction", 771], ["site", 783], ["created", 788], ["by", 796], ["this", 799], ["mutation", 804], [".", 812], ["Using", 814], ["serial", 820], ["dilutions", 827], ["of", 837], ["DNAs", 840], ["from", 845], ["lung", 850], ["cancer", 855], ["cell", 862], ["lines", 867], ["harboring", 873], ["either", 883], ["exon", 890], ["19", 895], ["or", 898], ["21", 901], ["mutations", 904], [",", 913], ["we", 915], ["detected", 918], ["these", 927], ["mutations", 933], ["in", 943], ["the", 946], ["presence", 950], ["of", 959], ["up", 962], ["to", 965], ["approximately", 968], ["90", 982], ["%", 984], ["normal", 986], ["DNA", 993], [".", 996], ["In", 998], ["a", 1001], ["test", 1003], ["set", 1008], ["of", 1012], ["39", 1015], ["lung", 1018], ["cancer", 1023], ["samples", 1030], [",", 1037], ["direct", 1039], ["sequencing", 1046], ["detected", 1057], ["mutations", 1066], ["in", 1076], ["25", 1079], ["cases", 1082], ["whereas", 1088], ["our", 1096], ["assays", 1100], ["were", 1107], ["positive", 1112], ["in", 1121], ["29", 1124], ["cases", 1127], [",", 1132], ["including", 1134], ["4", 1144], ["cases", 1146], ["in", 1152], ["which", 1155], ["mutations", 1161], ["were", 1171], ["not", 1176], ["apparent", 1180], ["by", 1189], ["sequencing", 1192], [".", 1202], ["These", 1204], ["assays", 1210], ["offer", 1217], ["higher", 1223], ["sensitivity", 1230], ["and", 1242], ["ease", 1246], ["of", 1251], ["scoring", 1254], ["and", 1262], ["eliminate", 1266], ["the", 1276], ["need", 1280], ["for", 1285], ["sequencing", 1289], [",", 1299], ["providing", 1301], ["a", 1311], ["robust", 1313], ["and", 1320], ["accessible", 1324], ["approach", 1335], ["to", 1344], ["the", 1347], ["rapid", 1351], ["identification", 1357], ["of", 1372], ["most", 1375], ["lung", 1380], ["cancer", 1385], ["patients", 1392], ["likely", 1401], ["to", 1408], ["respond", 1411], ["to", 1419], ["EGFR", 1422], ["inhibitors", 1427], [".", 1437]]}
{"context": "In patients with active rheumatoid arthritis despite therapy with DMARDS, treatment with a spleen tyrosine kinase inhibitor has achieved similar response rates to those achieved in clinical trials of other drugs, including biologic agents. Where might these agents fit in the current armamentarium against this disease?", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "6cdfaee03ce4412b9875775aca7ac48e", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[14, 16]], "char_spans": [[91, 112]]}]}], "context_tokens": [["In", 0], ["patients", 3], ["with", 12], ["active", 17], ["rheumatoid", 24], ["arthritis", 35], ["despite", 45], ["therapy", 53], ["with", 61], ["DMARDS", 66], [",", 72], ["treatment", 74], ["with", 84], ["a", 89], ["spleen", 91], ["tyrosine", 98], ["kinase", 107], ["inhibitor", 114], ["has", 124], ["achieved", 128], ["similar", 137], ["response", 145], ["rates", 154], ["to", 160], ["those", 163], ["achieved", 169], ["in", 178], ["clinical", 181], ["trials", 190], ["of", 197], ["other", 200], ["drugs", 206], [",", 211], ["including", 213], ["biologic", 223], ["agents", 232], [".", 238], ["Where", 240], ["might", 246], ["these", 252], ["agents", 258], ["fit", 265], ["in", 269], ["the", 272], ["current", 276], ["armamentarium", 284], ["against", 298], ["this", 306], ["disease", 311], ["?", 318]]}
{"context": "Mutations and deletions of the NSD1 gene, located on chromosome 5q35, are responsible for over 90% of cases of Sotos syndrome. Fluorescent in situ hybridization analysis (FISH), MLPA or multiplex quantitative PCR allow detection of total/partial NSD1 deletions and direct sequencing allows detection of NSD1 mutations. We describe two boys with Sotos syndrome in whom PCR amplification and direct sequencing of the NSD1 gene identified two novel mutations not previously described: c.4736dupG in exon 12 and c.3938_3939insT in exon 7. In addition to the cardinal and major features of the syndrome (abnormal facial appearance, overgrowth, cardiac anomalies, renal anomalies, hypotonia, neonatal jaundice, seizures and brain MRI abnormalities) in both patients, one boy also had cryptorchidism and vertebral anomalies, features considered not common. Despite the wide range of possible combinations of phenotypic features, molecular analysis can correctly identify Sotos syndrome.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "da2112b55fe74ffe80afbc48f42143f7", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[5, 6], [72, 73]], "char_spans": [[31, 39], [415, 423]]}]}], "context_tokens": [["Mutations", 0], ["and", 10], ["deletions", 14], ["of", 24], ["the", 27], ["NSD1", 31], ["gene", 36], [",", 40], ["located", 42], ["on", 50], ["chromosome", 53], ["5q35", 64], [",", 68], ["are", 70], ["responsible", 74], ["for", 86], ["over", 90], ["90", 95], ["%", 97], ["of", 99], ["cases", 102], ["of", 108], ["Sotos", 111], ["syndrome", 117], [".", 125], ["Fluorescent", 127], ["in", 139], ["situ", 142], ["hybridization", 147], ["analysis", 161], ["(", 170], ["FISH", 171], [")", 175], [",", 176], ["MLPA", 178], ["or", 183], ["multiplex", 186], ["quantitative", 196], ["PCR", 209], ["allow", 213], ["detection", 219], ["of", 229], ["total", 232], ["/", 237], ["partial", 238], ["NSD1", 246], ["deletions", 251], ["and", 261], ["direct", 265], ["sequencing", 272], ["allows", 283], ["detection", 290], ["of", 300], ["NSD1", 303], ["mutations", 308], [".", 317], ["We", 319], ["describe", 322], ["two", 331], ["boys", 335], ["with", 340], ["Sotos", 345], ["syndrome", 351], ["in", 360], ["whom", 363], ["PCR", 368], ["amplification", 372], ["and", 386], ["direct", 390], ["sequencing", 397], ["of", 408], ["the", 411], ["NSD1", 415], ["gene", 420], ["identified", 425], ["two", 436], ["novel", 440], ["mutations", 446], ["not", 456], ["previously", 460], ["described", 471], [":", 480], ["c.4736dupG", 482], ["in", 493], ["exon", 496], ["12", 501], ["and", 504], ["c.3938_3939insT", 508], ["in", 524], ["exon", 527], ["7", 532], [".", 533], ["In", 535], ["addition", 538], ["to", 547], ["the", 550], ["cardinal", 554], ["and", 563], ["major", 567], ["features", 573], ["of", 582], ["the", 585], ["syndrome", 589], ["(", 598], ["abnormal", 599], ["facial", 608], ["appearance", 615], [",", 625], ["overgrowth", 627], [",", 637], ["cardiac", 639], ["anomalies", 647], [",", 656], ["renal", 658], ["anomalies", 664], [",", 673], ["hypotonia", 675], [",", 684], ["neonatal", 686], ["jaundice", 695], [",", 703], ["seizures", 705], ["and", 714], ["brain", 718], ["MRI", 724], ["abnormalities", 728], [")", 741], ["in", 743], ["both", 746], ["patients", 751], [",", 759], ["one", 761], ["boy", 765], ["also", 769], ["had", 774], ["cryptorchidism", 778], ["and", 793], ["vertebral", 797], ["anomalies", 807], [",", 816], ["features", 818], ["considered", 827], ["not", 838], ["common", 842], [".", 848], ["Despite", 850], ["the", 858], ["wide", 862], ["range", 867], ["of", 873], ["possible", 876], ["combinations", 885], ["of", 898], ["phenotypic", 901], ["features", 912], [",", 920], ["molecular", 922], ["analysis", 932], ["can", 941], ["correctly", 945], ["identify", 955], ["Sotos", 964], ["syndrome", 970], [".", 978]]}
{"context": "Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against the breakpoint cluster region--Abelson murine leukemia (BCR-ABL) tyrosine kinase has been developed for treatment of chronic myelogenous leukemia (CML). Its hematologic and cytogenetic effects have been evaluated in a series of clinical trials. The aim of this study was to report hematologic and cytogenetic response in CML patients during the treatment with imatinib mesylate. A total of 21 patients were treated and observed from July 2006 to December 2008. The median time from CML diagnosis was no more than 12 months, so all the patients received previous treatment with hydroxyurea for which the median time was 3 months. The patients received imatinib mesylate in an effective oral dose of 400 to 800 mg daily, which was followed with peripheral blood counts, bone marrow examination, and cytogenetic studies at 6, 12, 18 and 24 months. Complete hematologic responses were reported for 19 (90.48%) of 21 patients studied. Among 19 patients who had a response, 16 (86%) did so within 3 months. The best cytogenetic response rate at any time during the study treatment with imatinib mesylate, among 14 patients in which cytogenetic response evaluated was: complete cytogenetic response in 7 (50%) patients, partial cytogenetic response in 6 (42.9%) patients and minor cytogenetic response in 1 (7.1%) patient. No patients had progressed to accelerated or blastic phase. The most frequent adverse effects that seemed to be related to treatment with imatinib mesylate were edema and musculoskeletal pain; overall, most were mild. Only one patient discontinued treatment because of hematologic toxic effects. The results obtained in this study confirm that imatinib mesylate induces a complete hematological and cytogenetic response in a high percentage of patients with chronic-phase CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "6a1078ce36c74d609a098b1b566be822", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[20, 22]], "char_spans": [[134, 140]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], [",", 17], ["a", 19], ["tyrosine", 21], ["kinase", 30], ["inhibitor", 37], ["with", 47], ["specific", 52], ["activity", 61], ["against", 70], ["the", 78], ["breakpoint", 82], ["cluster", 93], ["region", 101], ["--", 107], ["Abelson", 109], ["murine", 117], ["leukemia", 124], ["(", 133], ["BCR", 134], ["-", 137], ["ABL", 138], [")", 141], ["tyrosine", 143], ["kinase", 152], ["has", 159], ["been", 163], ["developed", 168], ["for", 178], ["treatment", 182], ["of", 192], ["chronic", 195], ["myelogenous", 203], ["leukemia", 215], ["(", 224], ["CML", 225], [")", 228], [".", 229], ["Its", 231], ["hematologic", 235], ["and", 247], ["cytogenetic", 251], ["effects", 263], ["have", 271], ["been", 276], ["evaluated", 281], ["in", 291], ["a", 294], ["series", 296], ["of", 303], ["clinical", 306], ["trials", 315], [".", 321], ["The", 323], ["aim", 327], ["of", 331], ["this", 334], ["study", 339], ["was", 345], ["to", 349], ["report", 352], ["hematologic", 359], ["and", 371], ["cytogenetic", 375], ["response", 387], ["in", 396], ["CML", 399], ["patients", 403], ["during", 412], ["the", 419], ["treatment", 423], ["with", 433], ["imatinib", 438], ["mesylate", 447], [".", 455], ["A", 457], ["total", 459], ["of", 465], ["21", 468], ["patients", 471], ["were", 480], ["treated", 485], ["and", 493], ["observed", 497], ["from", 506], ["July", 511], ["2006", 516], ["to", 521], ["December", 524], ["2008", 533], [".", 537], ["The", 539], ["median", 543], ["time", 550], ["from", 555], ["CML", 560], ["diagnosis", 564], ["was", 574], ["no", 578], ["more", 581], ["than", 586], ["12", 591], ["months", 594], [",", 600], ["so", 602], ["all", 605], ["the", 609], ["patients", 613], ["received", 622], ["previous", 631], ["treatment", 640], ["with", 650], ["hydroxyurea", 655], ["for", 667], ["which", 671], ["the", 677], ["median", 681], ["time", 688], ["was", 693], ["3", 697], ["months", 699], [".", 705], ["The", 707], ["patients", 711], ["received", 720], ["imatinib", 729], ["mesylate", 738], ["in", 747], ["an", 750], ["effective", 753], ["oral", 763], ["dose", 768], ["of", 773], ["400", 776], ["to", 780], ["800", 783], ["mg", 787], ["daily", 790], [",", 795], ["which", 797], ["was", 803], ["followed", 807], ["with", 816], ["peripheral", 821], ["blood", 832], ["counts", 838], [",", 844], ["bone", 846], ["marrow", 851], ["examination", 858], [",", 869], ["and", 871], ["cytogenetic", 875], ["studies", 887], ["at", 895], ["6", 898], [",", 899], ["12", 901], [",", 903], ["18", 905], ["and", 908], ["24", 912], ["months", 915], [".", 921], ["Complete", 923], ["hematologic", 932], ["responses", 944], ["were", 954], ["reported", 959], ["for", 968], ["19", 972], ["(", 975], ["90.48", 976], ["%", 981], [")", 982], ["of", 984], ["21", 987], ["patients", 990], ["studied", 999], [".", 1006], ["Among", 1008], ["19", 1014], ["patients", 1017], ["who", 1026], ["had", 1030], ["a", 1034], ["response", 1036], [",", 1044], ["16", 1046], ["(", 1049], ["86", 1050], ["%", 1052], [")", 1053], ["did", 1055], ["so", 1059], ["within", 1062], ["3", 1069], ["months", 1071], [".", 1077], ["The", 1079], ["best", 1083], ["cytogenetic", 1088], ["response", 1100], ["rate", 1109], ["at", 1114], ["any", 1117], ["time", 1121], ["during", 1126], ["the", 1133], ["study", 1137], ["treatment", 1143], ["with", 1153], ["imatinib", 1158], ["mesylate", 1167], [",", 1175], ["among", 1177], ["14", 1183], ["patients", 1186], ["in", 1195], ["which", 1198], ["cytogenetic", 1204], ["response", 1216], ["evaluated", 1225], ["was", 1235], [":", 1238], ["complete", 1240], ["cytogenetic", 1249], ["response", 1261], ["in", 1270], ["7", 1273], ["(", 1275], ["50", 1276], ["%", 1278], [")", 1279], ["patients", 1281], [",", 1289], ["partial", 1291], ["cytogenetic", 1299], ["response", 1311], ["in", 1320], ["6", 1323], ["(", 1325], ["42.9", 1326], ["%", 1330], [")", 1331], ["patients", 1333], ["and", 1342], ["minor", 1346], ["cytogenetic", 1352], ["response", 1364], ["in", 1373], ["1", 1376], ["(", 1378], ["7.1", 1379], ["%", 1382], [")", 1383], ["patient", 1385], [".", 1392], ["No", 1394], ["patients", 1397], ["had", 1406], ["progressed", 1410], ["to", 1421], ["accelerated", 1424], ["or", 1436], ["blastic", 1439], ["phase", 1447], [".", 1452], ["The", 1454], ["most", 1458], ["frequent", 1463], ["adverse", 1472], ["effects", 1480], ["that", 1488], ["seemed", 1493], ["to", 1500], ["be", 1503], ["related", 1506], ["to", 1514], ["treatment", 1517], ["with", 1527], ["imatinib", 1532], ["mesylate", 1541], ["were", 1550], ["edema", 1555], ["and", 1561], ["musculoskeletal", 1565], ["pain", 1581], [";", 1585], ["overall", 1587], [",", 1594], ["most", 1596], ["were", 1601], ["mild", 1606], [".", 1610], ["Only", 1612], ["one", 1617], ["patient", 1621], ["discontinued", 1629], ["treatment", 1642], ["because", 1652], ["of", 1660], ["hematologic", 1663], ["toxic", 1675], ["effects", 1681], [".", 1688], ["The", 1690], ["results", 1694], ["obtained", 1702], ["in", 1711], ["this", 1714], ["study", 1719], ["confirm", 1725], ["that", 1733], ["imatinib", 1738], ["mesylate", 1747], ["induces", 1756], ["a", 1764], ["complete", 1766], ["hematological", 1775], ["and", 1789], ["cytogenetic", 1793], ["response", 1805], ["in", 1814], ["a", 1817], ["high", 1819], ["percentage", 1824], ["of", 1835], ["patients", 1838], ["with", 1847], ["chronic", 1852], ["-", 1859], ["phase", 1860], ["CML", 1866], [".", 1869]]}
{"context": "Shprintzen-Goldberg syndrome (SGS) is characterized by craniosynostosis and marfanoid habitus. The clinical findings of SGS include neurological, cardiovascular, connective tissue, and skeletal abnormalities. Among these skeletal findings, developmental scoliosis is recognized in half of all patients with SGS. However, no earlier reports have described the surgical treatment of scoliosis associated with SGS. Four patients (2 boys and 2 girls; mean age at the time of surgery, 7.3\u00b14.4 y) with SGS who underwent surgical treatment for progressive scoliosis were reviewed. The radiologic findings, operative findings, and perioperative complications were evaluated. The mean preoperative Cobb angle was 102.8\u00b116.9 degrees. The curve patterns were a double curve in 2 cases and a triple curve in 2 cases. Local kyphosis at the thoracolumbar area was recognized in all the cases with a mean kyphosis angle of 49\u00b116 degrees. Growing rod procedures were performed in 2 patients, and posterior correction and fusion were performed in 2 patients. The mean correction rate was 45% in the patients who underwent the growing rod procedures at the time of growing rod placement and 51% in the patients who underwent posterior correction and fusion. Dislodgement of the proximal anchors occurred in 3 of the 4 patients. One patient developed pseudoarthrosis. Two patients developed deep wound infections, and implant removal was necessary in 1 patient. Surgical treatment for scoliosis in patients with SGS was associated with a high incidence of perioperative and postoperative complications including implant dislodgements and deep wound infections attributable to poor bone quality and a thin body habitus, which are characteristic clinical features of this syndrome. Careful preoperative surgical planning and postoperative care are critical for the surgical treatment of scoliosis associated with SGS, especially in infants requiring multiple surgeries. Level IV.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "07d30350f8434b48815eaa39fc6cedd9", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[10, 10]], "char_spans": [[55, 70]]}]}], "context_tokens": [["Shprintzen", 0], ["-", 10], ["Goldberg", 11], ["syndrome", 20], ["(", 29], ["SGS", 30], [")", 33], ["is", 35], ["characterized", 38], ["by", 52], ["craniosynostosis", 55], ["and", 72], ["marfanoid", 76], ["habitus", 86], [".", 93], ["The", 95], ["clinical", 99], ["findings", 108], ["of", 117], ["SGS", 120], ["include", 124], ["neurological", 132], [",", 144], ["cardiovascular", 146], [",", 160], ["connective", 162], ["tissue", 173], [",", 179], ["and", 181], ["skeletal", 185], ["abnormalities", 194], [".", 207], ["Among", 209], ["these", 215], ["skeletal", 221], ["findings", 230], [",", 238], ["developmental", 240], ["scoliosis", 254], ["is", 264], ["recognized", 267], ["in", 278], ["half", 281], ["of", 286], ["all", 289], ["patients", 293], ["with", 302], ["SGS", 307], [".", 310], ["However", 312], [",", 319], ["no", 321], ["earlier", 324], ["reports", 332], ["have", 340], ["described", 345], ["the", 355], ["surgical", 359], ["treatment", 368], ["of", 378], ["scoliosis", 381], ["associated", 391], ["with", 402], ["SGS", 407], [".", 410], ["Four", 412], ["patients", 417], ["(", 426], ["2", 427], ["boys", 429], ["and", 434], ["2", 438], ["girls", 440], [";", 445], ["mean", 447], ["age", 452], ["at", 456], ["the", 459], ["time", 463], ["of", 468], ["surgery", 471], [",", 478], ["7.3\u00b14.4", 480], ["y", 488], [")", 489], ["with", 491], ["SGS", 496], ["who", 500], ["underwent", 504], ["surgical", 514], ["treatment", 523], ["for", 533], ["progressive", 537], ["scoliosis", 549], ["were", 559], ["reviewed", 564], [".", 572], ["The", 574], ["radiologic", 578], ["findings", 589], [",", 597], ["operative", 599], ["findings", 609], [",", 617], ["and", 619], ["perioperative", 623], ["complications", 637], ["were", 651], ["evaluated", 656], [".", 665], ["The", 667], ["mean", 671], ["preoperative", 676], ["Cobb", 689], ["angle", 694], ["was", 700], ["102.8\u00b116.9", 704], ["degrees", 715], [".", 722], ["The", 724], ["curve", 728], ["patterns", 734], ["were", 743], ["a", 748], ["double", 750], ["curve", 757], ["in", 763], ["2", 766], ["cases", 768], ["and", 774], ["a", 778], ["triple", 780], ["curve", 787], ["in", 793], ["2", 796], ["cases", 798], [".", 803], ["Local", 805], ["kyphosis", 811], ["at", 820], ["the", 823], ["thoracolumbar", 827], ["area", 841], ["was", 846], ["recognized", 850], ["in", 861], ["all", 864], ["the", 868], ["cases", 872], ["with", 878], ["a", 883], ["mean", 885], ["kyphosis", 890], ["angle", 899], ["of", 905], ["49\u00b116", 908], ["degrees", 914], [".", 921], ["Growing", 923], ["rod", 931], ["procedures", 935], ["were", 946], ["performed", 951], ["in", 961], ["2", 964], ["patients", 966], [",", 974], ["and", 976], ["posterior", 980], ["correction", 990], ["and", 1001], ["fusion", 1005], ["were", 1012], ["performed", 1017], ["in", 1027], ["2", 1030], ["patients", 1032], [".", 1040], ["The", 1042], ["mean", 1046], ["correction", 1051], ["rate", 1062], ["was", 1067], ["45", 1071], ["%", 1073], ["in", 1075], ["the", 1078], ["patients", 1082], ["who", 1091], ["underwent", 1095], ["the", 1105], ["growing", 1109], ["rod", 1117], ["procedures", 1121], ["at", 1132], ["the", 1135], ["time", 1139], ["of", 1144], ["growing", 1147], ["rod", 1155], ["placement", 1159], ["and", 1169], ["51", 1173], ["%", 1175], ["in", 1177], ["the", 1180], ["patients", 1184], ["who", 1193], ["underwent", 1197], ["posterior", 1207], ["correction", 1217], ["and", 1228], ["fusion", 1232], [".", 1238], ["Dislodgement", 1240], ["of", 1253], ["the", 1256], ["proximal", 1260], ["anchors", 1269], ["occurred", 1277], ["in", 1286], ["3", 1289], ["of", 1291], ["the", 1294], ["4", 1298], ["patients", 1300], [".", 1308], ["One", 1310], ["patient", 1314], ["developed", 1322], ["pseudoarthrosis", 1332], [".", 1347], ["Two", 1349], ["patients", 1353], ["developed", 1362], ["deep", 1372], ["wound", 1377], ["infections", 1383], [",", 1393], ["and", 1395], ["implant", 1399], ["removal", 1407], ["was", 1415], ["necessary", 1419], ["in", 1429], ["1", 1432], ["patient", 1434], [".", 1441], ["Surgical", 1443], ["treatment", 1452], ["for", 1462], ["scoliosis", 1466], ["in", 1476], ["patients", 1479], ["with", 1488], ["SGS", 1493], ["was", 1497], ["associated", 1501], ["with", 1512], ["a", 1517], ["high", 1519], ["incidence", 1524], ["of", 1534], ["perioperative", 1537], ["and", 1551], ["postoperative", 1555], ["complications", 1569], ["including", 1583], ["implant", 1593], ["dislodgements", 1601], ["and", 1615], ["deep", 1619], ["wound", 1624], ["infections", 1630], ["attributable", 1641], ["to", 1654], ["poor", 1657], ["bone", 1662], ["quality", 1667], ["and", 1675], ["a", 1679], ["thin", 1681], ["body", 1686], ["habitus", 1691], [",", 1698], ["which", 1700], ["are", 1706], ["characteristic", 1710], ["clinical", 1725], ["features", 1734], ["of", 1743], ["this", 1746], ["syndrome", 1751], [".", 1759], ["Careful", 1761], ["preoperative", 1769], ["surgical", 1782], ["planning", 1791], ["and", 1800], ["postoperative", 1804], ["care", 1818], ["are", 1823], ["critical", 1827], ["for", 1836], ["the", 1840], ["surgical", 1844], ["treatment", 1853], ["of", 1863], ["scoliosis", 1866], ["associated", 1876], ["with", 1887], ["SGS", 1892], [",", 1895], ["especially", 1897], ["in", 1908], ["infants", 1911], ["requiring", 1919], ["multiple", 1929], ["surgeries", 1938], [".", 1947], ["Level", 1949], ["IV", 1955], [".", 1957]]}
{"context": "The precise regulation of microRNA (miRNA) transcription and processing is important for eukaryotic development. Plant miRNAs are first transcribed as stem-loop primary miRNAs (pri-miRNAs) by RNA polymerase II,then cleaved in the nucleus into mature miRNAs by Dicer-like 1 (DCL1). We identified a cycling DOF transcription factor, CDF2, which interacts with DCL1 and regulates the accumulation of a population of miRNAs. CDF2 binds directly to the promoters of some miRNAs and works as a transcription activator or repressor for these miRNA genes. CDF2 binds preferentially to the pri-miRNAs regulated by itself and affects DCL1-mediated processing of these pri-miRNAs. Genetically, CDF2 works in the same pathway as miR156 or miR172 to control flowering. We conclude that CDF2 regulates a group of pri-miRNAs at both the transcriptional and posttranscriptional levels to maintain proper levels of their mature miRNAs to control plant development.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "0d62867611e34119b3f038886614e0ab", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[34, 36]], "char_spans": [[192, 208]]}]}], "context_tokens": [["The", 0], ["precise", 4], ["regulation", 12], ["of", 23], ["microRNA", 26], ["(", 35], ["miRNA", 36], [")", 41], ["transcription", 43], ["and", 57], ["processing", 61], ["is", 72], ["important", 75], ["for", 85], ["eukaryotic", 89], ["development", 100], [".", 111], ["Plant", 113], ["miRNAs", 119], ["are", 126], ["first", 130], ["transcribed", 136], ["as", 148], ["stem", 151], ["-", 155], ["loop", 156], ["primary", 161], ["miRNAs", 169], ["(", 176], ["pri", 177], ["-", 180], ["miRNAs", 181], [")", 187], ["by", 189], ["RNA", 192], ["polymerase", 196], ["II", 207], [",", 209], ["then", 210], ["cleaved", 215], ["in", 223], ["the", 226], ["nucleus", 230], ["into", 238], ["mature", 243], ["miRNAs", 250], ["by", 257], ["Dicer", 260], ["-", 265], ["like", 266], ["1", 271], ["(", 273], ["DCL1", 274], [")", 278], [".", 279], ["We", 281], ["identified", 284], ["a", 295], ["cycling", 297], ["DOF", 305], ["transcription", 309], ["factor", 323], [",", 329], ["CDF2", 331], [",", 335], ["which", 337], ["interacts", 343], ["with", 353], ["DCL1", 358], ["and", 363], ["regulates", 367], ["the", 377], ["accumulation", 381], ["of", 394], ["a", 397], ["population", 399], ["of", 410], ["miRNAs", 413], [".", 419], ["CDF2", 421], ["binds", 426], ["directly", 432], ["to", 441], ["the", 444], ["promoters", 448], ["of", 458], ["some", 461], ["miRNAs", 466], ["and", 473], ["works", 477], ["as", 483], ["a", 486], ["transcription", 488], ["activator", 502], ["or", 512], ["repressor", 515], ["for", 525], ["these", 529], ["miRNA", 535], ["genes", 541], [".", 546], ["CDF2", 548], ["binds", 553], ["preferentially", 559], ["to", 574], ["the", 577], ["pri", 581], ["-", 584], ["miRNAs", 585], ["regulated", 592], ["by", 602], ["itself", 605], ["and", 612], ["affects", 616], ["DCL1-mediated", 624], ["processing", 638], ["of", 649], ["these", 652], ["pri", 658], ["-", 661], ["miRNAs", 662], [".", 668], ["Genetically", 670], [",", 681], ["CDF2", 683], ["works", 688], ["in", 694], ["the", 697], ["same", 701], ["pathway", 706], ["as", 714], ["miR156", 717], ["or", 724], ["miR172", 727], ["to", 734], ["control", 737], ["flowering", 745], [".", 754], ["We", 756], ["conclude", 759], ["that", 768], ["CDF2", 773], ["regulates", 778], ["a", 788], ["group", 790], ["of", 796], ["pri", 799], ["-", 802], ["miRNAs", 803], ["at", 810], ["both", 813], ["the", 818], ["transcriptional", 822], ["and", 838], ["posttranscriptional", 842], ["levels", 862], ["to", 869], ["maintain", 872], ["proper", 881], ["levels", 888], ["of", 895], ["their", 898], ["mature", 904], ["miRNAs", 911], ["to", 918], ["control", 921], ["plant", 929], ["development", 935], [".", 946]]}
{"context": "Batten disease [juvenile-onset neuronal ceroid lipofuscinosis (JNCL)], the most common progressive encephalopathy of childhood, is caused by mutations in a novel lysosomal membrane protein (CLN3) with unknown function. In this study, we have confirmed the lysosomal localization of the CLN3 protein by immunoelectron microscopy by co-localizing it with soluble and membrane-associated lysosomal proteins. We have analysed the intracellular processing and localization of two mutants, 461-677del, which is present in 85% of CLN3 alleles and causes the classical JNCL, and E295K [corrected], which is a rare missense mutation associated with an atypical form of JNCL. Pulse-chase labelling and immunoprecipitation of the two mutant proteins in COS-1-cells indicated that 461-677del is synthesized as an approximately 24 kDa truncated polypeptide, whereas the maturation of E295K [corrected] resembles that of the wild-type CLN3 polypeptide. Transient expression of the two mutants in BHK cells showed that 461-677del is retained in the endoplasmic reticulum, whereas E295K [corrected] was capable of reaching the lysosomal compartment. The CLN3 polypeptides were expressed further in mouse primary neurons where the wild-type CLN3 protein was localized both in the cell soma and in neuronal extensions, whereas the 461-677del mutant was arrested in the cell soma. Interestingly, co-localization of the wild-type CLN3 and E295K [corrected] proteins with a synaptic vesicle marker indicates that the CLN3 protein might participate in synaptic vesicle transport/transmission. The data presented here provide clear evidence for a cellular distinction between classical and atypical forms of Batten disease both in neural and non-neural cells.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "6d7b3c37d90b4259923fc6b4defc1056", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[0, 1], [300, 301]], "char_spans": [[0, 13], [1685, 1698]]}, {"text": "juvenile-onset neuronal ceroid lipofuscinosis", "token_spans": [[3, 8]], "char_spans": [[16, 60]]}, {"text": "JNCL", "token_spans": [[120, 120], [99, 99], [10, 10]], "char_spans": [[660, 663], [561, 564], [63, 66]]}]}], "context_tokens": [["Batten", 0], ["disease", 7], ["[", 15], ["juvenile", 16], ["-", 24], ["onset", 25], ["neuronal", 31], ["ceroid", 40], ["lipofuscinosis", 47], ["(", 62], ["JNCL", 63], [")", 67], ["]", 68], [",", 69], ["the", 71], ["most", 75], ["common", 80], ["progressive", 87], ["encephalopathy", 99], ["of", 114], ["childhood", 117], [",", 126], ["is", 128], ["caused", 131], ["by", 138], ["mutations", 141], ["in", 151], ["a", 154], ["novel", 156], ["lysosomal", 162], ["membrane", 172], ["protein", 181], ["(", 189], ["CLN3", 190], [")", 194], ["with", 196], ["unknown", 201], ["function", 209], [".", 217], ["In", 219], ["this", 222], ["study", 227], [",", 232], ["we", 234], ["have", 237], ["confirmed", 242], ["the", 252], ["lysosomal", 256], ["localization", 266], ["of", 279], ["the", 282], ["CLN3", 286], ["protein", 291], ["by", 299], ["immunoelectron", 302], ["microscopy", 317], ["by", 328], ["co", 331], ["-", 333], ["localizing", 334], ["it", 345], ["with", 348], ["soluble", 353], ["and", 361], ["membrane", 365], ["-", 373], ["associated", 374], ["lysosomal", 385], ["proteins", 395], [".", 403], ["We", 405], ["have", 408], ["analysed", 413], ["the", 422], ["intracellular", 426], ["processing", 440], ["and", 451], ["localization", 455], ["of", 468], ["two", 471], ["mutants", 475], [",", 482], ["461", 484], ["-", 487], ["677del", 488], [",", 494], ["which", 496], ["is", 502], ["present", 505], ["in", 513], ["85", 516], ["%", 518], ["of", 520], ["CLN3", 523], ["alleles", 528], ["and", 536], ["causes", 540], ["the", 547], ["classical", 551], ["JNCL", 561], [",", 565], ["and", 567], ["E295", 571], ["K", 575], ["[", 577], ["corrected", 578], ["]", 587], [",", 588], ["which", 590], ["is", 596], ["a", 599], ["rare", 601], ["missense", 606], ["mutation", 615], ["associated", 624], ["with", 635], ["an", 640], ["atypical", 643], ["form", 652], ["of", 657], ["JNCL", 660], [".", 664], ["Pulse", 666], ["-", 671], ["chase", 672], ["labelling", 678], ["and", 688], ["immunoprecipitation", 692], ["of", 712], ["the", 715], ["two", 719], ["mutant", 723], ["proteins", 730], ["in", 739], ["COS-1-cells", 742], ["indicated", 754], ["that", 764], ["461", 769], ["-", 772], ["677del", 773], ["is", 780], ["synthesized", 783], ["as", 795], ["an", 798], ["approximately", 801], ["24", 815], ["kDa", 818], ["truncated", 822], ["polypeptide", 832], [",", 843], ["whereas", 845], ["the", 853], ["maturation", 857], ["of", 868], ["E295", 871], ["K", 875], ["[", 877], ["corrected", 878], ["]", 887], ["resembles", 889], ["that", 899], ["of", 904], ["the", 907], ["wild", 911], ["-", 915], ["type", 916], ["CLN3", 921], ["polypeptide", 926], [".", 937], ["Transient", 939], ["expression", 949], ["of", 960], ["the", 963], ["two", 967], ["mutants", 971], ["in", 979], ["BHK", 982], ["cells", 986], ["showed", 992], ["that", 999], ["461", 1004], ["-", 1007], ["677del", 1008], ["is", 1015], ["retained", 1018], ["in", 1027], ["the", 1030], ["endoplasmic", 1034], ["reticulum", 1046], [",", 1055], ["whereas", 1057], ["E295", 1065], ["K", 1069], ["[", 1071], ["corrected", 1072], ["]", 1081], ["was", 1083], ["capable", 1087], ["of", 1095], ["reaching", 1098], ["the", 1107], ["lysosomal", 1111], ["compartment", 1121], [".", 1132], ["The", 1134], ["CLN3", 1138], ["polypeptides", 1143], ["were", 1156], ["expressed", 1161], ["further", 1171], ["in", 1179], ["mouse", 1182], ["primary", 1188], ["neurons", 1196], ["where", 1204], ["the", 1210], ["wild", 1214], ["-", 1218], ["type", 1219], ["CLN3", 1224], ["protein", 1229], ["was", 1237], ["localized", 1241], ["both", 1251], ["in", 1256], ["the", 1259], ["cell", 1263], ["soma", 1268], ["and", 1273], ["in", 1277], ["neuronal", 1280], ["extensions", 1289], [",", 1299], ["whereas", 1301], ["the", 1309], ["461", 1313], ["-", 1316], ["677del", 1317], ["mutant", 1324], ["was", 1331], ["arrested", 1335], ["in", 1344], ["the", 1347], ["cell", 1351], ["soma", 1356], [".", 1360], ["Interestingly", 1362], [",", 1375], ["co", 1377], ["-", 1379], ["localization", 1380], ["of", 1393], ["the", 1396], ["wild", 1400], ["-", 1404], ["type", 1405], ["CLN3", 1410], ["and", 1415], ["E295", 1419], ["K", 1423], ["[", 1425], ["corrected", 1426], ["]", 1435], ["proteins", 1437], ["with", 1446], ["a", 1451], ["synaptic", 1453], ["vesicle", 1462], ["marker", 1470], ["indicates", 1477], ["that", 1487], ["the", 1492], ["CLN3", 1496], ["protein", 1501], ["might", 1509], ["participate", 1515], ["in", 1527], ["synaptic", 1530], ["vesicle", 1539], ["transport", 1547], ["/", 1556], ["transmission", 1557], [".", 1569], ["The", 1571], ["data", 1575], ["presented", 1580], ["here", 1590], ["provide", 1595], ["clear", 1603], ["evidence", 1609], ["for", 1618], ["a", 1622], ["cellular", 1624], ["distinction", 1633], ["between", 1645], ["classical", 1653], ["and", 1663], ["atypical", 1667], ["forms", 1676], ["of", 1682], ["Batten", 1685], ["disease", 1692], ["both", 1700], ["in", 1705], ["neural", 1708], ["and", 1715], ["non", 1719], ["-", 1722], ["neural", 1723], ["cells", 1730], [".", 1735]]}
{"context": "Mutations of presenilin 1 (PS1) causing Alzheimer's disease selectively increase the secretion of the amyloidogenic betaA4(1-42), whereas knocking out the gene results in decreased production of both betaA4(1-40) and (1-42) amyloid peptides (De Strooper et al. 1998). Therefore, PS1 function is closely linked to the gamma-secretase processing of the amyloid precursor protein (APP). Given the ongoing controversy on the subcellular localization of PS1, it remains unclear at what level of the secretory and endocytic pathways PS1 exerts its activity on APP and on the APP carboxy-terminal fragments that are the direct substrates for gamma-secretase. Therefore, we have reinvestigated the subcellular localization of endogenously expressed PS1 in neurons in vitro and in vivo using confocal microscopy and fine-tuned subcellular fractionation. We show that uncleaved PS1 holoprotein is recovered in the nuclear envelope fraction, whereas the cleaved PS fragments are found mainly in post-ER membranes including the intermediate compartment (IC). PS1 is concentrated in discrete sec23p- and p58/ERGIC-53-positive patches, suggesting its localization in subdomains involved in ER export. PS1 is not found to significant amounts beyond the cis-Golgi. Surprisingly, we found that APP carboxy-terminal fragments also coenrich in the pre-Golgi membrane fractions, consistent with the idea that these fragments are the real substrates for gamma-secretase. Functional evidence that PS1 exerts its effects on gamma-secretase processing of APP in the ER/IC was obtained using a series of APP trafficking mutants. These mutants were investigated in hippocampal neurons derived from transgenic mice expressing PS1wt or PS1 containing clinical mutations (PS1(M146L) and PS1(L286V)) at physiologically relevant levels. We demonstrate that the APP-London and PS1 mutations have additive effects on the increased secretion of betaA4(1-42) relative to betaA4(1-40), indicating that both mutations operate independently. Overall, our data clearly establish that PS1 controls gamma(42)-secretase activity in pre-Golgi compartments. We discuss models that reconcile this conclusion with the effects of PS1 deficiency on the generation of betaA4(1-40) peptide in the late biosynthetic and endocytic pathways.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "c6a3fb62d44040b1a6fe442b2aadc722", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[8, 10]], "char_spans": [[40, 58]]}]}], "context_tokens": [["Mutations", 0], ["of", 10], ["presenilin", 13], ["1", 24], ["(", 26], ["PS1", 27], [")", 30], ["causing", 32], ["Alzheimer", 40], ["'s", 49], ["disease", 52], ["selectively", 60], ["increase", 72], ["the", 81], ["secretion", 85], ["of", 95], ["the", 98], ["amyloidogenic", 102], ["betaA4(1", 116], ["-", 124], ["42", 125], [")", 127], [",", 128], ["whereas", 130], ["knocking", 138], ["out", 147], ["the", 151], ["gene", 155], ["results", 160], ["in", 168], ["decreased", 171], ["production", 181], ["of", 192], ["both", 195], ["betaA4(1", 200], ["-", 208], ["40", 209], [")", 211], ["and", 213], ["(", 217], ["1", 218], ["-", 219], ["42", 220], [")", 222], ["amyloid", 224], ["peptides", 232], ["(", 241], ["De", 242], ["Strooper", 245], ["et", 254], ["al", 257], [".", 259], ["1998", 261], [")", 265], [".", 266], ["Therefore", 268], [",", 277], ["PS1", 279], ["function", 283], ["is", 292], ["closely", 295], ["linked", 303], ["to", 310], ["the", 313], ["gamma", 317], ["-", 322], ["secretase", 323], ["processing", 333], ["of", 344], ["the", 347], ["amyloid", 351], ["precursor", 359], ["protein", 369], ["(", 377], ["APP", 378], [")", 381], [".", 382], ["Given", 384], ["the", 390], ["ongoing", 394], ["controversy", 402], ["on", 414], ["the", 417], ["subcellular", 421], ["localization", 433], ["of", 446], ["PS1", 449], [",", 452], ["it", 454], ["remains", 457], ["unclear", 465], ["at", 473], ["what", 476], ["level", 481], ["of", 487], ["the", 490], ["secretory", 494], ["and", 504], ["endocytic", 508], ["pathways", 518], ["PS1", 527], ["exerts", 531], ["its", 538], ["activity", 542], ["on", 551], ["APP", 554], ["and", 558], ["on", 562], ["the", 565], ["APP", 569], ["carboxy", 573], ["-", 580], ["terminal", 581], ["fragments", 590], ["that", 600], ["are", 605], ["the", 609], ["direct", 613], ["substrates", 620], ["for", 631], ["gamma", 635], ["-", 640], ["secretase", 641], [".", 650], ["Therefore", 652], [",", 661], ["we", 663], ["have", 666], ["reinvestigated", 671], ["the", 686], ["subcellular", 690], ["localization", 702], ["of", 715], ["endogenously", 718], ["expressed", 731], ["PS1", 741], ["in", 745], ["neurons", 748], ["in", 756], ["vitro", 759], ["and", 765], ["in", 769], ["vivo", 772], ["using", 777], ["confocal", 783], ["microscopy", 792], ["and", 803], ["fine", 807], ["-", 811], ["tuned", 812], ["subcellular", 818], ["fractionation", 830], [".", 843], ["We", 845], ["show", 848], ["that", 853], ["uncleaved", 858], ["PS1", 868], ["holoprotein", 872], ["is", 884], ["recovered", 887], ["in", 897], ["the", 900], ["nuclear", 904], ["envelope", 912], ["fraction", 921], [",", 929], ["whereas", 931], ["the", 939], ["cleaved", 943], ["PS", 951], ["fragments", 954], ["are", 964], ["found", 968], ["mainly", 974], ["in", 981], ["post", 984], ["-", 988], ["ER", 989], ["membranes", 992], ["including", 1002], ["the", 1012], ["intermediate", 1016], ["compartment", 1029], ["(", 1041], ["IC", 1042], [")", 1044], [".", 1045], ["PS1", 1047], ["is", 1051], ["concentrated", 1054], ["in", 1067], ["discrete", 1070], ["sec23p-", 1079], ["and", 1087], ["p58/ERGIC-53-positive", 1091], ["patches", 1113], [",", 1120], ["suggesting", 1122], ["its", 1133], ["localization", 1137], ["in", 1150], ["subdomains", 1153], ["involved", 1164], ["in", 1173], ["ER", 1176], ["export", 1179], [".", 1185], ["PS1", 1187], ["is", 1191], ["not", 1194], ["found", 1198], ["to", 1204], ["significant", 1207], ["amounts", 1219], ["beyond", 1227], ["the", 1234], ["cis", 1238], ["-", 1241], ["Golgi", 1242], [".", 1247], ["Surprisingly", 1249], [",", 1261], ["we", 1263], ["found", 1266], ["that", 1272], ["APP", 1277], ["carboxy", 1281], ["-", 1288], ["terminal", 1289], ["fragments", 1298], ["also", 1308], ["coenrich", 1313], ["in", 1322], ["the", 1325], ["pre", 1329], ["-", 1332], ["Golgi", 1333], ["membrane", 1339], ["fractions", 1348], [",", 1357], ["consistent", 1359], ["with", 1370], ["the", 1375], ["idea", 1379], ["that", 1384], ["these", 1389], ["fragments", 1395], ["are", 1405], ["the", 1409], ["real", 1413], ["substrates", 1418], ["for", 1429], ["gamma", 1433], ["-", 1438], ["secretase", 1439], [".", 1448], ["Functional", 1450], ["evidence", 1461], ["that", 1470], ["PS1", 1475], ["exerts", 1479], ["its", 1486], ["effects", 1490], ["on", 1498], ["gamma", 1501], ["-", 1506], ["secretase", 1507], ["processing", 1517], ["of", 1528], ["APP", 1531], ["in", 1535], ["the", 1538], ["ER", 1542], ["/", 1544], ["IC", 1545], ["was", 1548], ["obtained", 1552], ["using", 1561], ["a", 1567], ["series", 1569], ["of", 1576], ["APP", 1579], ["trafficking", 1583], ["mutants", 1595], [".", 1602], ["These", 1604], ["mutants", 1610], ["were", 1618], ["investigated", 1623], ["in", 1636], ["hippocampal", 1639], ["neurons", 1651], ["derived", 1659], ["from", 1667], ["transgenic", 1672], ["mice", 1683], ["expressing", 1688], ["PS1wt", 1699], ["or", 1705], ["PS1", 1708], ["containing", 1712], ["clinical", 1723], ["mutations", 1732], ["(", 1742], ["PS1(M146L", 1743], [")", 1752], ["and", 1754], ["PS1(L286V", 1758], [")", 1767], [")", 1768], ["at", 1770], ["physiologically", 1773], ["relevant", 1789], ["levels", 1798], [".", 1804], ["We", 1806], ["demonstrate", 1809], ["that", 1821], ["the", 1826], ["APP", 1830], ["-", 1833], ["London", 1834], ["and", 1841], ["PS1", 1845], ["mutations", 1849], ["have", 1859], ["additive", 1864], ["effects", 1873], ["on", 1881], ["the", 1884], ["increased", 1888], ["secretion", 1898], ["of", 1908], ["betaA4(1", 1911], ["-", 1919], ["42", 1920], [")", 1922], ["relative", 1924], ["to", 1933], ["betaA4(1", 1936], ["-", 1944], ["40", 1945], [")", 1947], [",", 1948], ["indicating", 1950], ["that", 1961], ["both", 1966], ["mutations", 1971], ["operate", 1981], ["independently", 1989], [".", 2002], ["Overall", 2004], [",", 2011], ["our", 2013], ["data", 2017], ["clearly", 2022], ["establish", 2030], ["that", 2040], ["PS1", 2045], ["controls", 2049], ["gamma(42)-secretase", 2058], ["activity", 2078], ["in", 2087], ["pre", 2090], ["-", 2093], ["Golgi", 2094], ["compartments", 2100], [".", 2112], ["We", 2114], ["discuss", 2117], ["models", 2125], ["that", 2132], ["reconcile", 2137], ["this", 2147], ["conclusion", 2152], ["with", 2163], ["the", 2168], ["effects", 2172], ["of", 2180], ["PS1", 2183], ["deficiency", 2187], ["on", 2198], ["the", 2201], ["generation", 2205], ["of", 2216], ["betaA4(1", 2219], ["-", 2227], ["40", 2228], [")", 2230], ["peptide", 2232], ["in", 2240], ["the", 2243], ["late", 2247], ["biosynthetic", 2252], ["and", 2265], ["endocytic", 2269], ["pathways", 2279], [".", 2287]]}
{"context": "Turner's syndrome (TS) is a chromosomal disorder that results from the loss of the entire or a part of the X-chromosome and occurs in 1/2,500 female births. According to the majority of specific reports, intelligence in TS is generally found to be normal and the prevalence of mental retardation does not seem to be increased in TS except for those patients with a small ring X-chromosome. We evaluated 33 girls with TS with chronological age from 6-18 years. Intellectual assessment included the WISC III and the WAIS-R scales. Our results showed: 1) mean full scale intelligence quotient (FSIQ) was significantly lower than expected based on normative data (p < 0.0005); 2) no correlation was present between height and general intellectual ability; 3) mean performance intelligence quotient (PIQ) was significantly lower than both mean verbal intelligence quotient (VIQ) and FSIQ (p < 0.0025 and p < 0.01, respectively), and most patients had a VIQ-PIQ discrepancy; 4) the frequency of mental retardation in our study group was significantly higher than that observed in the general population (15.1% vs 2.3%, p < 0.025); 5) a significant association was found between karyotype and VIQ, and the best score was achieved in the subgroup of patients with structural abnormalities of the X-chromosome. In the light of these findings we conclude that the clinical picture in TS may encompass a slightly reduced FSIQ, VIQ and especially an inadequate PIQ, but this neurocognitive profile is not significantly affected by statural impairment. Since these neurocognitive defects can be responsible for misdiagnosed school difficulties, we suggest that girls with TS should receive specialized educational support and multidisciplinary care.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "12fa90a3c056479a92f47b23fd5275bf", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[252, 252], [72, 72], [23, 23]], "char_spans": [[1288, 1288], [376, 376], [107, 107]]}]}], "context_tokens": [["Turner", 0], ["'s", 6], ["syndrome", 9], ["(", 18], ["TS", 19], [")", 21], ["is", 23], ["a", 26], ["chromosomal", 28], ["disorder", 40], ["that", 49], ["results", 54], ["from", 62], ["the", 67], ["loss", 71], ["of", 76], ["the", 79], ["entire", 83], ["or", 90], ["a", 93], ["part", 95], ["of", 100], ["the", 103], ["X", 107], ["-", 108], ["chromosome", 109], ["and", 120], ["occurs", 124], ["in", 131], ["1/2,500", 134], ["female", 142], ["births", 149], [".", 155], ["According", 157], ["to", 167], ["the", 170], ["majority", 174], ["of", 183], ["specific", 186], ["reports", 195], [",", 202], ["intelligence", 204], ["in", 217], ["TS", 220], ["is", 223], ["generally", 226], ["found", 236], ["to", 242], ["be", 245], ["normal", 248], ["and", 255], ["the", 259], ["prevalence", 263], ["of", 274], ["mental", 277], ["retardation", 284], ["does", 296], ["not", 301], ["seem", 305], ["to", 310], ["be", 313], ["increased", 316], ["in", 326], ["TS", 329], ["except", 332], ["for", 339], ["those", 343], ["patients", 349], ["with", 358], ["a", 363], ["small", 365], ["ring", 371], ["X", 376], ["-", 377], ["chromosome", 378], [".", 388], ["We", 390], ["evaluated", 393], ["33", 403], ["girls", 406], ["with", 412], ["TS", 417], ["with", 420], ["chronological", 425], ["age", 439], ["from", 443], ["6", 448], ["-", 449], ["18", 450], ["years", 453], [".", 458], ["Intellectual", 460], ["assessment", 473], ["included", 484], ["the", 493], ["WISC", 497], ["III", 502], ["and", 506], ["the", 510], ["WAIS", 514], ["-", 518], ["R", 519], ["scales", 521], [".", 527], ["Our", 529], ["results", 533], ["showed", 541], [":", 547], ["1", 549], [")", 550], ["mean", 552], ["full", 557], ["scale", 562], ["intelligence", 568], ["quotient", 581], ["(", 590], ["FSIQ", 591], [")", 595], ["was", 597], ["significantly", 601], ["lower", 615], ["than", 621], ["expected", 626], ["based", 635], ["on", 641], ["normative", 644], ["data", 654], ["(", 659], ["p", 660], ["<", 662], ["0.0005", 664], [")", 670], [";", 671], ["2", 673], [")", 674], ["no", 676], ["correlation", 679], ["was", 691], ["present", 695], ["between", 703], ["height", 711], ["and", 718], ["general", 722], ["intellectual", 730], ["ability", 743], [";", 750], ["3", 752], [")", 753], ["mean", 755], ["performance", 760], ["intelligence", 772], ["quotient", 785], ["(", 794], ["PIQ", 795], [")", 798], ["was", 800], ["significantly", 804], ["lower", 818], ["than", 824], ["both", 829], ["mean", 834], ["verbal", 839], ["intelligence", 846], ["quotient", 859], ["(", 868], ["VIQ", 869], [")", 872], ["and", 874], ["FSIQ", 878], ["(", 883], ["p", 884], ["<", 886], ["0.0025", 888], ["and", 895], ["p", 899], ["<", 901], ["0.01", 903], [",", 907], ["respectively", 909], [")", 921], [",", 922], ["and", 924], ["most", 928], ["patients", 933], ["had", 942], ["a", 946], ["VIQ", 948], ["-", 951], ["PIQ", 952], ["discrepancy", 956], [";", 967], ["4", 969], [")", 970], ["the", 972], ["frequency", 976], ["of", 986], ["mental", 989], ["retardation", 996], ["in", 1008], ["our", 1011], ["study", 1015], ["group", 1021], ["was", 1027], ["significantly", 1031], ["higher", 1045], ["than", 1052], ["that", 1057], ["observed", 1062], ["in", 1071], ["the", 1074], ["general", 1078], ["population", 1086], ["(", 1097], ["15.1", 1098], ["%", 1102], ["vs", 1104], ["2.3", 1107], ["%", 1110], [",", 1111], ["p", 1113], ["<", 1115], ["0.025", 1117], [")", 1122], [";", 1123], ["5", 1125], [")", 1126], ["a", 1128], ["significant", 1130], ["association", 1142], ["was", 1154], ["found", 1158], ["between", 1164], ["karyotype", 1172], ["and", 1182], ["VIQ", 1186], [",", 1189], ["and", 1191], ["the", 1195], ["best", 1199], ["score", 1204], ["was", 1210], ["achieved", 1214], ["in", 1223], ["the", 1226], ["subgroup", 1230], ["of", 1239], ["patients", 1242], ["with", 1251], ["structural", 1256], ["abnormalities", 1267], ["of", 1281], ["the", 1284], ["X", 1288], ["-", 1289], ["chromosome", 1290], [".", 1300], ["In", 1302], ["the", 1305], ["light", 1309], ["of", 1315], ["these", 1318], ["findings", 1324], ["we", 1333], ["conclude", 1336], ["that", 1345], ["the", 1350], ["clinical", 1354], ["picture", 1363], ["in", 1371], ["TS", 1374], ["may", 1377], ["encompass", 1381], ["a", 1391], ["slightly", 1393], ["reduced", 1402], ["FSIQ", 1410], [",", 1414], ["VIQ", 1416], ["and", 1420], ["especially", 1424], ["an", 1435], ["inadequate", 1438], ["PIQ", 1449], [",", 1452], ["but", 1454], ["this", 1458], ["neurocognitive", 1463], ["profile", 1478], ["is", 1486], ["not", 1489], ["significantly", 1493], ["affected", 1507], ["by", 1516], ["statural", 1519], ["impairment", 1528], [".", 1538], ["Since", 1540], ["these", 1546], ["neurocognitive", 1552], ["defects", 1567], ["can", 1575], ["be", 1579], ["responsible", 1582], ["for", 1594], ["misdiagnosed", 1598], ["school", 1611], ["difficulties", 1618], [",", 1630], ["we", 1632], ["suggest", 1635], ["that", 1643], ["girls", 1648], ["with", 1654], ["TS", 1659], ["should", 1662], ["receive", 1669], ["specialized", 1677], ["educational", 1689], ["support", 1701], ["and", 1709], ["multidisciplinary", 1713], ["care", 1731], [".", 1735]]}
{"context": "The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis. In the present study, we analyzed the CaSR gene in a Korean family with familial hypocalciuric hypercalcemia (FHH). Genetic studies were performed by direct sequence analysis of the CaSR gene in genomic DNA obtained from peripheral leukocytes. A novel heterozygous G to T substitution at nucleotide position 1711 in exon 6, resulting in the G571W mutation, was identified in the CaSR gene in a 26-year-old female with asymptomatic hypercalcemia, a low calcium/creatinine clearance ratio, and normal intact parathyroid hormone. To study CaSR expression, the mutation was introduced by site-directed mutagenesis into a wild-type (WT) CaSR-expressing pCR3.1 vector, and COS-7 cells were transfected with either the WT or mutant CaSR-containing vector. Transfected cells loaded with Fura-2/AM, a fluorescent indicator of Ca", "qas": [{"question": "What is the function of calcium-sensing receptor (CaSR)?", "answers": ["The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis."], "qid": "1f0adb77304f4c188ae40ccb27db4e56", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["function", 12], ["of", 21], ["calcium", 24], ["-", 31], ["sensing", 32], ["receptor", 40], ["(", 49], ["CaSR", 50], [")", 54], ["?", 55]], "detected_answers": [{"text": "The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis.", "token_spans": [[1, 24]], "char_spans": [[4, 130]]}]}], "context_tokens": [["The", 0], ["calcium", 4], ["-", 11], ["sensing", 12], ["receptor", 20], ["(", 29], ["CaSR", 30], [")", 34], ["is", 36], ["a", 39], ["G", 41], ["-", 42], ["protein", 43], ["-", 50], ["coupled", 51], ["receptor", 59], ["that", 68], ["plays", 73], ["an", 79], ["essential", 82], ["role", 92], ["in", 97], ["maintaining", 100], ["calcium", 112], ["homeostasis", 120], [".", 131], ["In", 133], ["the", 136], ["present", 140], ["study", 148], [",", 153], ["we", 155], ["analyzed", 158], ["the", 167], ["CaSR", 171], ["gene", 176], ["in", 181], ["a", 184], ["Korean", 186], ["family", 193], ["with", 200], ["familial", 205], ["hypocalciuric", 214], ["hypercalcemia", 228], ["(", 242], ["FHH", 243], [")", 246], [".", 247], ["Genetic", 249], ["studies", 257], ["were", 265], ["performed", 270], ["by", 280], ["direct", 283], ["sequence", 290], ["analysis", 299], ["of", 308], ["the", 311], ["CaSR", 315], ["gene", 320], ["in", 325], ["genomic", 328], ["DNA", 336], ["obtained", 340], ["from", 349], ["peripheral", 354], ["leukocytes", 365], [".", 375], ["A", 377], ["novel", 379], ["heterozygous", 385], ["G", 398], ["to", 400], ["T", 403], ["substitution", 405], ["at", 418], ["nucleotide", 421], ["position", 432], ["1711", 441], ["in", 446], ["exon", 449], ["6", 454], [",", 455], ["resulting", 457], ["in", 467], ["the", 470], ["G571W", 474], ["mutation", 480], [",", 488], ["was", 490], ["identified", 494], ["in", 505], ["the", 508], ["CaSR", 512], ["gene", 517], ["in", 522], ["a", 525], ["26-year", 527], ["-", 534], ["old", 535], ["female", 539], ["with", 546], ["asymptomatic", 551], ["hypercalcemia", 564], [",", 577], ["a", 579], ["low", 581], ["calcium", 585], ["/", 592], ["creatinine", 593], ["clearance", 604], ["ratio", 614], [",", 619], ["and", 621], ["normal", 625], ["intact", 632], ["parathyroid", 639], ["hormone", 651], [".", 658], ["To", 660], ["study", 663], ["CaSR", 669], ["expression", 674], [",", 684], ["the", 686], ["mutation", 690], ["was", 699], ["introduced", 703], ["by", 714], ["site", 717], ["-", 721], ["directed", 722], ["mutagenesis", 731], ["into", 743], ["a", 748], ["wild", 750], ["-", 754], ["type", 755], ["(", 760], ["WT", 761], [")", 763], ["CaSR", 765], ["-", 769], ["expressing", 770], ["pCR3.1", 781], ["vector", 788], [",", 794], ["and", 796], ["COS-7", 800], ["cells", 806], ["were", 812], ["transfected", 817], ["with", 829], ["either", 834], ["the", 841], ["WT", 845], ["or", 848], ["mutant", 851], ["CaSR", 858], ["-", 862], ["containing", 863], ["vector", 874], [".", 880], ["Transfected", 882], ["cells", 894], ["loaded", 900], ["with", 907], ["Fura-2/AM", 912], [",", 921], ["a", 923], ["fluorescent", 925], ["indicator", 937], ["of", 947], ["Ca", 950]]}
{"context": "Three isoforms of human plasma apolipoprotein E (apoE) are ligands to lipoprotein receptors and influence in different manner the synthesis and catabolism of pro-atherogenic triglyceride-rich lipoproteins. Among three isoforms, the apoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD). The conformational transitions of beta-amyloid (Abeta) influenced by apoE and serum amyloid P (SAP) component are key events in AD development, the accumulation of intermediate diffusible and soluble oligomers of Abeta being of particular significance. SAP and apoE, in a different manner for the three isoforms, serve as \"pathological\" chaperones during the aggregation of Abeta considered as a conformation-prone process. In turn, apoE consisting of two domains self-associates in solution and intermediate structures differently populated for the three isoforms exist. The different structures of the three isoforms determine their different distribution among various plasma lipoproteins. The structural and metabolic consideration of the common apoE pathway(s) in two pathologies assumes four molecular targets for AD correction: (i) inhibition of the accumulation of diffusible soluble Abeta oligomers; (ii) inhibition of apoE synthesis and secretion by astrocytes, in particular, under lipid-lowering therapy; (iii) inhibition of the binding of apoE and/or SAP to Abeta; (iv) stimulation of the expression of cholesterol transporter ABCA1.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "d2affbf1297d4be7a210c9cbf1cccbba", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[38, 39]], "char_spans": [[232, 244]]}]}], "context_tokens": [["Three", 0], ["isoforms", 6], ["of", 15], ["human", 18], ["plasma", 24], ["apolipoprotein", 31], ["E", 46], ["(", 48], ["apoE", 49], [")", 53], ["are", 55], ["ligands", 59], ["to", 67], ["lipoprotein", 70], ["receptors", 82], ["and", 92], ["influence", 96], ["in", 106], ["different", 109], ["manner", 119], ["the", 126], ["synthesis", 130], ["and", 140], ["catabolism", 144], ["of", 155], ["pro", 158], ["-", 161], ["atherogenic", 162], ["triglyceride", 174], ["-", 186], ["rich", 187], ["lipoproteins", 192], [".", 204], ["Among", 206], ["three", 212], ["isoforms", 218], [",", 226], ["the", 228], ["apoE4", 232], ["isoform", 238], ["is", 246], ["associated", 249], ["with", 260], ["increased", 265], ["frequency", 275], ["of", 285], ["atherosclerosis", 288], ["and", 304], ["Alzheimer", 308], ["'s", 317], ["disease", 320], ["(", 328], ["AD", 329], [")", 331], [".", 332], ["The", 334], ["conformational", 338], ["transitions", 353], ["of", 365], ["beta", 368], ["-", 372], ["amyloid", 373], ["(", 381], ["Abeta", 382], [")", 387], ["influenced", 389], ["by", 400], ["apoE", 403], ["and", 408], ["serum", 412], ["amyloid", 418], ["P", 426], ["(", 428], ["SAP", 429], [")", 432], ["component", 434], ["are", 444], ["key", 448], ["events", 452], ["in", 459], ["AD", 462], ["development", 465], [",", 476], ["the", 478], ["accumulation", 482], ["of", 495], ["intermediate", 498], ["diffusible", 511], ["and", 522], ["soluble", 526], ["oligomers", 534], ["of", 544], ["Abeta", 547], ["being", 553], ["of", 559], ["particular", 562], ["significance", 573], [".", 585], ["SAP", 587], ["and", 591], ["apoE", 595], [",", 599], ["in", 601], ["a", 604], ["different", 606], ["manner", 616], ["for", 623], ["the", 627], ["three", 631], ["isoforms", 637], [",", 645], ["serve", 647], ["as", 653], ["\"", 656], ["pathological", 657], ["\"", 669], ["chaperones", 671], ["during", 682], ["the", 689], ["aggregation", 693], ["of", 705], ["Abeta", 708], ["considered", 714], ["as", 725], ["a", 728], ["conformation", 730], ["-", 742], ["prone", 743], ["process", 749], [".", 756], ["In", 758], ["turn", 761], [",", 765], ["apoE", 767], ["consisting", 772], ["of", 783], ["two", 786], ["domains", 790], ["self", 798], ["-", 802], ["associates", 803], ["in", 814], ["solution", 817], ["and", 826], ["intermediate", 830], ["structures", 843], ["differently", 854], ["populated", 866], ["for", 876], ["the", 880], ["three", 884], ["isoforms", 890], ["exist", 899], [".", 904], ["The", 906], ["different", 910], ["structures", 920], ["of", 931], ["the", 934], ["three", 938], ["isoforms", 944], ["determine", 953], ["their", 963], ["different", 969], ["distribution", 979], ["among", 992], ["various", 998], ["plasma", 1006], ["lipoproteins", 1013], [".", 1025], ["The", 1027], ["structural", 1031], ["and", 1042], ["metabolic", 1046], ["consideration", 1056], ["of", 1070], ["the", 1073], ["common", 1077], ["apoE", 1084], ["pathway(s", 1089], [")", 1098], ["in", 1100], ["two", 1103], ["pathologies", 1107], ["assumes", 1119], ["four", 1127], ["molecular", 1132], ["targets", 1142], ["for", 1150], ["AD", 1154], ["correction", 1157], [":", 1167], ["(", 1169], ["i", 1170], [")", 1171], ["inhibition", 1173], ["of", 1184], ["the", 1187], ["accumulation", 1191], ["of", 1204], ["diffusible", 1207], ["soluble", 1218], ["Abeta", 1226], ["oligomers", 1232], [";", 1241], ["(", 1243], ["ii", 1244], [")", 1246], ["inhibition", 1248], ["of", 1259], ["apoE", 1262], ["synthesis", 1267], ["and", 1277], ["secretion", 1281], ["by", 1291], ["astrocytes", 1294], [",", 1304], ["in", 1306], ["particular", 1309], [",", 1319], ["under", 1321], ["lipid", 1327], ["-", 1332], ["lowering", 1333], ["therapy", 1342], [";", 1349], ["(", 1351], ["iii", 1352], [")", 1355], ["inhibition", 1357], ["of", 1368], ["the", 1371], ["binding", 1375], ["of", 1383], ["apoE", 1386], ["and/or", 1391], ["SAP", 1398], ["to", 1402], ["Abeta", 1405], [";", 1410], ["(", 1412], ["iv", 1413], [")", 1415], ["stimulation", 1417], ["of", 1429], ["the", 1432], ["expression", 1436], ["of", 1447], ["cholesterol", 1450], ["transporter", 1462], ["ABCA1", 1474], [".", 1479]]}
{"context": "Pannexin2 (Panx2) is the largest of three members of the pannexin proteins. Pannexins are topologically related to connexins and innexins, but serve different functional roles than forming gap junctions. We previously showed that pannexins form oligomeric channels but unlike connexins and innexins, they form only single membrane channels. High levels of Panx2 mRNA and protein in the Central Nervous System (CNS) have been documented. Whereas Pannexin1 (Panx1) is fairly ubiquitous and Pannexin3 (Panx3) is found in skin and connective tissue, both are fully glycosylated, traffic to the plasma membrane and have functions correlated with extracellular ATP release. Here, we describe trafficking and subcellular localizations of exogenous Panx2 and Panx1 protein expression in MDCK, HeLa, and HEK 293T cells as well as endogenous Panx1 and Panx2 patterns in the CNS. Panx2 was found in intracellular localizations, was partially N-glycosylated, and localizations were non-overlapping with Panx1. Confocal images of hippocampal sections immunolabeled for the astrocytic protein GFAP, Panx1 and Panx2 demonstrated that the two isoforms, Panx1 and Panx2, localized at different subcellular compartments in both astrocytes and neurons. Using recombinant fusions of Panx2 with appended genetic tags developed for correlated light and electron microscopy and then expressed in different cell lines, we determined that Panx2 is localized in the membrane of intracellular vesicles and not in the endoplasmic reticulum as initially indicated by calnexin colocalization experiments. Dual immunofluorescence imaging with protein markers for specific vesicle compartments showed that Panx2 vesicles are early endosomal in origin. In electron tomographic volumes, cross-sections of these vesicles displayed fine structural details and close proximity to actin filaments. Thus, pannexins expressed at different subcellular compartments likely exert distinct functional roles, particularly in the nervous system.", "qas": [{"question": "Where is the protein Pannexin1 located?", "answers": ["plasma membrane"], "qid": "08b59657cf0b4a05a3b821cb53bc7eeb", "question_tokens": [["Where", 0], ["is", 6], ["the", 9], ["protein", 13], ["Pannexin1", 21], ["located", 31], ["?", 38]], "detected_answers": [{"text": "plasma membrane", "token_spans": [[103, 104]], "char_spans": [[590, 604]]}]}], "context_tokens": [["Pannexin2", 0], ["(", 10], ["Panx2", 11], [")", 16], ["is", 18], ["the", 21], ["largest", 25], ["of", 33], ["three", 36], ["members", 42], ["of", 50], ["the", 53], ["pannexin", 57], ["proteins", 66], [".", 74], ["Pannexins", 76], ["are", 86], ["topologically", 90], ["related", 104], ["to", 112], ["connexins", 115], ["and", 125], ["innexins", 129], [",", 137], ["but", 139], ["serve", 143], ["different", 149], ["functional", 159], ["roles", 170], ["than", 176], ["forming", 181], ["gap", 189], ["junctions", 193], [".", 202], ["We", 204], ["previously", 207], ["showed", 218], ["that", 225], ["pannexins", 230], ["form", 240], ["oligomeric", 245], ["channels", 256], ["but", 265], ["unlike", 269], ["connexins", 276], ["and", 286], ["innexins", 290], [",", 298], ["they", 300], ["form", 305], ["only", 310], ["single", 315], ["membrane", 322], ["channels", 331], [".", 339], ["High", 341], ["levels", 346], ["of", 353], ["Panx2", 356], ["mRNA", 362], ["and", 367], ["protein", 371], ["in", 379], ["the", 382], ["Central", 386], ["Nervous", 394], ["System", 402], ["(", 409], ["CNS", 410], [")", 413], ["have", 415], ["been", 420], ["documented", 425], [".", 435], ["Whereas", 437], ["Pannexin1", 445], ["(", 455], ["Panx1", 456], [")", 461], ["is", 463], ["fairly", 466], ["ubiquitous", 473], ["and", 484], ["Pannexin3", 488], ["(", 498], ["Panx3", 499], [")", 504], ["is", 506], ["found", 509], ["in", 515], ["skin", 518], ["and", 523], ["connective", 527], ["tissue", 538], [",", 544], ["both", 546], ["are", 551], ["fully", 555], ["glycosylated", 561], [",", 573], ["traffic", 575], ["to", 583], ["the", 586], ["plasma", 590], ["membrane", 597], ["and", 606], ["have", 610], ["functions", 615], ["correlated", 625], ["with", 636], ["extracellular", 641], ["ATP", 655], ["release", 659], [".", 666], ["Here", 668], [",", 672], ["we", 674], ["describe", 677], ["trafficking", 686], ["and", 698], ["subcellular", 702], ["localizations", 714], ["of", 728], ["exogenous", 731], ["Panx2", 741], ["and", 747], ["Panx1", 751], ["protein", 757], ["expression", 765], ["in", 776], ["MDCK", 779], [",", 783], ["HeLa", 785], [",", 789], ["and", 791], ["HEK", 795], ["293", 799], ["T", 802], ["cells", 804], ["as", 810], ["well", 813], ["as", 818], ["endogenous", 821], ["Panx1", 832], ["and", 838], ["Panx2", 842], ["patterns", 848], ["in", 857], ["the", 860], ["CNS", 864], [".", 867], ["Panx2", 869], ["was", 875], ["found", 879], ["in", 885], ["intracellular", 888], ["localizations", 902], [",", 915], ["was", 917], ["partially", 921], ["N", 931], ["-", 932], ["glycosylated", 933], [",", 945], ["and", 947], ["localizations", 951], ["were", 965], ["non", 970], ["-", 973], ["overlapping", 974], ["with", 986], ["Panx1", 991], [".", 996], ["Confocal", 998], ["images", 1007], ["of", 1014], ["hippocampal", 1017], ["sections", 1029], ["immunolabeled", 1038], ["for", 1052], ["the", 1056], ["astrocytic", 1060], ["protein", 1071], ["GFAP", 1079], [",", 1083], ["Panx1", 1085], ["and", 1091], ["Panx2", 1095], ["demonstrated", 1101], ["that", 1114], ["the", 1119], ["two", 1123], ["isoforms", 1127], [",", 1135], ["Panx1", 1137], ["and", 1143], ["Panx2", 1147], [",", 1152], ["localized", 1154], ["at", 1164], ["different", 1167], ["subcellular", 1177], ["compartments", 1189], ["in", 1202], ["both", 1205], ["astrocytes", 1210], ["and", 1221], ["neurons", 1225], [".", 1232], ["Using", 1234], ["recombinant", 1240], ["fusions", 1252], ["of", 1260], ["Panx2", 1263], ["with", 1269], ["appended", 1274], ["genetic", 1283], ["tags", 1291], ["developed", 1296], ["for", 1306], ["correlated", 1310], ["light", 1321], ["and", 1327], ["electron", 1331], ["microscopy", 1340], ["and", 1351], ["then", 1355], ["expressed", 1360], ["in", 1370], ["different", 1373], ["cell", 1383], ["lines", 1388], [",", 1393], ["we", 1395], ["determined", 1398], ["that", 1409], ["Panx2", 1414], ["is", 1420], ["localized", 1423], ["in", 1433], ["the", 1436], ["membrane", 1440], ["of", 1449], ["intracellular", 1452], ["vesicles", 1466], ["and", 1475], ["not", 1479], ["in", 1483], ["the", 1486], ["endoplasmic", 1490], ["reticulum", 1502], ["as", 1512], ["initially", 1515], ["indicated", 1525], ["by", 1535], ["calnexin", 1538], ["colocalization", 1547], ["experiments", 1562], [".", 1573], ["Dual", 1575], ["immunofluorescence", 1580], ["imaging", 1599], ["with", 1607], ["protein", 1612], ["markers", 1620], ["for", 1628], ["specific", 1632], ["vesicle", 1641], ["compartments", 1649], ["showed", 1662], ["that", 1669], ["Panx2", 1674], ["vesicles", 1680], ["are", 1689], ["early", 1693], ["endosomal", 1699], ["in", 1709], ["origin", 1712], [".", 1718], ["In", 1720], ["electron", 1723], ["tomographic", 1732], ["volumes", 1744], [",", 1751], ["cross", 1753], ["-", 1758], ["sections", 1759], ["of", 1768], ["these", 1771], ["vesicles", 1777], ["displayed", 1786], ["fine", 1796], ["structural", 1801], ["details", 1812], ["and", 1820], ["close", 1824], ["proximity", 1830], ["to", 1840], ["actin", 1843], ["filaments", 1849], [".", 1858], ["Thus", 1860], [",", 1864], ["pannexins", 1866], ["expressed", 1876], ["at", 1886], ["different", 1889], ["subcellular", 1899], ["compartments", 1911], ["likely", 1924], ["exert", 1931], ["distinct", 1937], ["functional", 1946], ["roles", 1957], [",", 1962], ["particularly", 1964], ["in", 1977], ["the", 1980], ["nervous", 1984], ["system", 1992], [".", 1998]]}
{"context": "To characterise activation of the type I interferon (IFN) pathway in patients with systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid arthritis (RA) and systemic scleroderma (SSc) and to evaluate the potential to develop a molecular diagnostic tool from the peripheral blood that reflects this activation in disease-affected tissues. Overexpressed transcripts were identified in the whole blood (WB) of 262 patients with SLE, 44 with DM, 33 with PM, 28 with SSc and 89 with RA and compared with 24 healthy subjects using Affymetrix microarrays. A five gene type I IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues of each disease and to correlate activation of this pathway in the WB with clinical measurements. A common set of 36 type I IFN inducible transcripts were identified among the most overexpressed in the WB of all subjects. Significant activation of the type I IFN pathway in subgroups of each of the five diseases studied was observed. Baseline disease activity measurements correlated with a type I IFN gene signature in the WB of subjects with SLE, PM and SSc, as did various serum autoantibody levels in subjects with SLE and DM. This signature was also well correlated between disease-affected tissue and WB in subjects with SLE, DM, PM and SSc. The results indicate that the type I IFN pathway is activated in patient subsets of five rheumatic diseases and suggest that these subsets may benefit from anti-IFN therapy.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["Interferon signature", "IFN signature"], "qid": "3d4407ef652d4c23ba87702480b6b50a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "IFN signature", "token_spans": [[115, 116]], "char_spans": [[601, 613]]}]}], "context_tokens": [["To", 0], ["characterise", 3], ["activation", 16], ["of", 27], ["the", 30], ["type", 34], ["I", 39], ["interferon", 41], ["(", 52], ["IFN", 53], [")", 56], ["pathway", 58], ["in", 66], ["patients", 69], ["with", 78], ["systemic", 83], ["lupus", 92], ["erythematosus", 98], ["(", 112], ["SLE", 113], [")", 116], [",", 117], ["dermatomyositis", 119], ["(", 135], ["DM", 136], [")", 138], [",", 139], ["polymyositis", 141], ["(", 154], ["PM", 155], [")", 157], [",", 158], ["rheumatoid", 160], ["arthritis", 171], ["(", 181], ["RA", 182], [")", 184], ["and", 186], ["systemic", 190], ["scleroderma", 199], ["(", 211], ["SSc", 212], [")", 215], ["and", 217], ["to", 221], ["evaluate", 224], ["the", 233], ["potential", 237], ["to", 247], ["develop", 250], ["a", 258], ["molecular", 260], ["diagnostic", 270], ["tool", 281], ["from", 286], ["the", 291], ["peripheral", 295], ["blood", 306], ["that", 312], ["reflects", 317], ["this", 326], ["activation", 331], ["in", 342], ["disease", 345], ["-", 352], ["affected", 353], ["tissues", 362], [".", 369], ["Overexpressed", 371], ["transcripts", 385], ["were", 397], ["identified", 402], ["in", 413], ["the", 416], ["whole", 420], ["blood", 426], ["(", 432], ["WB", 433], [")", 435], ["of", 437], ["262", 440], ["patients", 444], ["with", 453], ["SLE", 458], [",", 461], ["44", 463], ["with", 466], ["DM", 471], [",", 473], ["33", 475], ["with", 478], ["PM", 483], [",", 485], ["28", 487], ["with", 490], ["SSc", 495], ["and", 499], ["89", 503], ["with", 506], ["RA", 511], ["and", 514], ["compared", 518], ["with", 527], ["24", 532], ["healthy", 535], ["subjects", 543], ["using", 552], ["Affymetrix", 558], ["microarrays", 569], [".", 580], ["A", 582], ["five", 584], ["gene", 589], ["type", 594], ["I", 599], ["IFN", 601], ["signature", 605], ["was", 615], ["assessed", 619], ["in", 628], ["these", 631], ["subjects", 637], ["to", 646], ["identify", 649], ["subpopulations", 658], ["showing", 673], ["both", 681], ["activation", 686], ["and", 697], ["concordance", 701], ["of", 713], ["the", 716], ["type", 720], ["I", 725], ["IFN", 727], ["pathway", 731], ["in", 739], ["the", 742], ["peripheral", 746], ["blood", 757], ["and", 763], ["disease", 767], ["-", 774], ["affected", 775], ["tissues", 784], ["of", 792], ["each", 795], ["disease", 800], ["and", 808], ["to", 812], ["correlate", 815], ["activation", 825], ["of", 836], ["this", 839], ["pathway", 844], ["in", 852], ["the", 855], ["WB", 859], ["with", 862], ["clinical", 867], ["measurements", 876], [".", 888], ["A", 890], ["common", 892], ["set", 899], ["of", 903], ["36", 906], ["type", 909], ["I", 914], ["IFN", 916], ["inducible", 920], ["transcripts", 930], ["were", 942], ["identified", 947], ["among", 958], ["the", 964], ["most", 968], ["overexpressed", 973], ["in", 987], ["the", 990], ["WB", 994], ["of", 997], ["all", 1000], ["subjects", 1004], [".", 1012], ["Significant", 1014], ["activation", 1026], ["of", 1037], ["the", 1040], ["type", 1044], ["I", 1049], ["IFN", 1051], ["pathway", 1055], ["in", 1063], ["subgroups", 1066], ["of", 1076], ["each", 1079], ["of", 1084], ["the", 1087], ["five", 1091], ["diseases", 1096], ["studied", 1105], ["was", 1113], ["observed", 1117], [".", 1125], ["Baseline", 1127], ["disease", 1136], ["activity", 1144], ["measurements", 1153], ["correlated", 1166], ["with", 1177], ["a", 1182], ["type", 1184], ["I", 1189], ["IFN", 1191], ["gene", 1195], ["signature", 1200], ["in", 1210], ["the", 1213], ["WB", 1217], ["of", 1220], ["subjects", 1223], ["with", 1232], ["SLE", 1237], [",", 1240], ["PM", 1242], ["and", 1245], ["SSc", 1249], [",", 1252], ["as", 1254], ["did", 1257], ["various", 1261], ["serum", 1269], ["autoantibody", 1275], ["levels", 1288], ["in", 1295], ["subjects", 1298], ["with", 1307], ["SLE", 1312], ["and", 1316], ["DM", 1320], [".", 1322], ["This", 1324], ["signature", 1329], ["was", 1339], ["also", 1343], ["well", 1348], ["correlated", 1353], ["between", 1364], ["disease", 1372], ["-", 1379], ["affected", 1380], ["tissue", 1389], ["and", 1396], ["WB", 1400], ["in", 1403], ["subjects", 1406], ["with", 1415], ["SLE", 1420], [",", 1423], ["DM", 1425], [",", 1427], ["PM", 1429], ["and", 1432], ["SSc", 1436], [".", 1439], ["The", 1441], ["results", 1445], ["indicate", 1453], ["that", 1462], ["the", 1467], ["type", 1471], ["I", 1476], ["IFN", 1478], ["pathway", 1482], ["is", 1490], ["activated", 1493], ["in", 1503], ["patient", 1506], ["subsets", 1514], ["of", 1522], ["five", 1525], ["rheumatic", 1530], ["diseases", 1540], ["and", 1549], ["suggest", 1553], ["that", 1561], ["these", 1566], ["subsets", 1572], ["may", 1580], ["benefit", 1584], ["from", 1592], ["anti", 1597], ["-", 1601], ["IFN", 1602], ["therapy", 1606], [".", 1613]]}
{"context": "The reactive oxygen-generating NADPH oxidases (Noxes) function in a variety of biological roles, and can be broadly classified into those that are regulated by subunit interactions and those that are regulated by calcium. The prototypical subunit-regulated Nox, Nox2, is the membrane-associated catalytic subunit of the phagocyte NADPH-oxidase. Nox2 forms a heterodimer with the integral membrane protein, p22phox, and this heterodimer binds to the regulatory subunits p47phox, p67phox, p40phox and the small GTPase Rac, triggering superoxide generation. Nox-organizer protein 1 (NOXO1) and Nox-activator 1 (NOXA1), respective homologs of p47phox and p67phox, together with p22phox and Rac, activate Nox1, a non-phagocytic homolog of Nox2. NOXO1 and p22phox also regulate Nox3, whereas Nox4 requires only p22phox. In this study, we have assembled and analyzed amino acid sequences of Nox regulatory subunit orthologs from vertebrates, a urochordate, an echinoderm, a mollusc, a cnidarian, a choanoflagellate, fungi and a slime mold amoeba to investigate the evolutionary history of these subunits. Ancestral p47phox, p67phox, and p22phox genes are broadly seen in the metazoa, except for the ecdysozoans. The choanoflagellate Monosiga brevicollis, the unicellular organism that is the closest relatives of multicellular animals, encodes early prototypes of p22phox, p47phox as well as the earliest known Nox2-like ancestor of the Nox1-3 subfamily. p67phox- and p47phox-like genes are seen in the sea urchin Strongylocentrotus purpuratus and the limpet Lottia gigantea that also possess Nox2-like co-orthologs of vertebrate Nox1-3. Duplication of primordial p47phox and p67phox genes occurred in vertebrates, with the duplicated branches evolving into NOXO1 and NOXA1. Analysis of characteristic domains of regulatory subunits suggests a novel view of the evolution of Nox: in fish, p40phox participated in regulating both Nox1 and Nox2, but after the appearance of mammals, Nox1 (but not Nox2) became independent of p40phox. In the fish Oryzias latipes, a NOXO1 ortholog retains an autoinhibitory region that is characteristic of mammalian p47phox, and this was subsequently lost from NOXO1 in later vertebrates. Detailed amino acid sequence comparisons identified both putative key residues conserved in characteristic domains and previously unidentified conserved regions. Also, candidate organizer/activator proteins in fungi and amoeba are identified and hypothetical activation models are suggested. This is the first report to provide the comprehensive view of the molecular evolution of regulatory subunits for Nox enzymes. This approach provides clues for understanding the evolution of biochemical and physiological functions for regulatory-subunit-dependent Nox enzymes.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "c9411266b7014dedb3a042e1c5632fa7", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[128, 128], [288, 288], [349, 349], [338, 338], [255, 255]], "char_spans": [[700, 703], [1623, 1626], [1974, 1977], [1922, 1925], [1430, 1433]]}]}], "context_tokens": [["The", 0], ["reactive", 4], ["oxygen", 13], ["-", 19], ["generating", 20], ["NADPH", 31], ["oxidases", 37], ["(", 46], ["Noxes", 47], [")", 52], ["function", 54], ["in", 63], ["a", 66], ["variety", 68], ["of", 76], ["biological", 79], ["roles", 90], [",", 95], ["and", 97], ["can", 101], ["be", 105], ["broadly", 108], ["classified", 116], ["into", 127], ["those", 132], ["that", 138], ["are", 143], ["regulated", 147], ["by", 157], ["subunit", 160], ["interactions", 168], ["and", 181], ["those", 185], ["that", 191], ["are", 196], ["regulated", 200], ["by", 210], ["calcium", 213], [".", 220], ["The", 222], ["prototypical", 226], ["subunit", 239], ["-", 246], ["regulated", 247], ["Nox", 257], [",", 260], ["Nox2", 262], [",", 266], ["is", 268], ["the", 271], ["membrane", 275], ["-", 283], ["associated", 284], ["catalytic", 295], ["subunit", 305], ["of", 313], ["the", 316], ["phagocyte", 320], ["NADPH", 330], ["-", 335], ["oxidase", 336], [".", 343], ["Nox2", 345], ["forms", 350], ["a", 356], ["heterodimer", 358], ["with", 370], ["the", 375], ["integral", 379], ["membrane", 388], ["protein", 397], [",", 404], ["p22phox", 406], [",", 413], ["and", 415], ["this", 419], ["heterodimer", 424], ["binds", 436], ["to", 442], ["the", 445], ["regulatory", 449], ["subunits", 460], ["p47phox", 469], [",", 476], ["p67phox", 478], [",", 485], ["p40phox", 487], ["and", 495], ["the", 499], ["small", 503], ["GTPase", 509], ["Rac", 516], [",", 519], ["triggering", 521], ["superoxide", 532], ["generation", 543], [".", 553], ["Nox", 555], ["-", 558], ["organizer", 559], ["protein", 569], ["1", 577], ["(", 579], ["NOXO1", 580], [")", 585], ["and", 587], ["Nox", 591], ["-", 594], ["activator", 595], ["1", 605], ["(", 607], ["NOXA1", 608], [")", 613], [",", 614], ["respective", 616], ["homologs", 627], ["of", 636], ["p47phox", 639], ["and", 647], ["p67phox", 651], [",", 658], ["together", 660], ["with", 669], ["p22phox", 674], ["and", 682], ["Rac", 686], [",", 689], ["activate", 691], ["Nox1", 700], [",", 704], ["a", 706], ["non", 708], ["-", 711], ["phagocytic", 712], ["homolog", 723], ["of", 731], ["Nox2", 734], [".", 738], ["NOXO1", 740], ["and", 746], ["p22phox", 750], ["also", 758], ["regulate", 763], ["Nox3", 772], [",", 776], ["whereas", 778], ["Nox4", 786], ["requires", 791], ["only", 800], ["p22phox", 805], [".", 812], ["In", 814], ["this", 817], ["study", 822], [",", 827], ["we", 829], ["have", 832], ["assembled", 837], ["and", 847], ["analyzed", 851], ["amino", 860], ["acid", 866], ["sequences", 871], ["of", 881], ["Nox", 884], ["regulatory", 888], ["subunit", 899], ["orthologs", 907], ["from", 917], ["vertebrates", 922], [",", 933], ["a", 935], ["urochordate", 937], [",", 948], ["an", 950], ["echinoderm", 953], [",", 963], ["a", 965], ["mollusc", 967], [",", 974], ["a", 976], ["cnidarian", 978], [",", 987], ["a", 989], ["choanoflagellate", 991], [",", 1007], ["fungi", 1009], ["and", 1015], ["a", 1019], ["slime", 1021], ["mold", 1027], ["amoeba", 1032], ["to", 1039], ["investigate", 1042], ["the", 1054], ["evolutionary", 1058], ["history", 1071], ["of", 1079], ["these", 1082], ["subunits", 1088], [".", 1096], ["Ancestral", 1098], ["p47phox", 1108], [",", 1115], ["p67phox", 1117], [",", 1124], ["and", 1126], ["p22phox", 1130], ["genes", 1138], ["are", 1144], ["broadly", 1148], ["seen", 1156], ["in", 1161], ["the", 1164], ["metazoa", 1168], [",", 1175], ["except", 1177], ["for", 1184], ["the", 1188], ["ecdysozoans", 1192], [".", 1203], ["The", 1205], ["choanoflagellate", 1209], ["Monosiga", 1226], ["brevicollis", 1235], [",", 1246], ["the", 1248], ["unicellular", 1252], ["organism", 1264], ["that", 1273], ["is", 1278], ["the", 1281], ["closest", 1285], ["relatives", 1293], ["of", 1303], ["multicellular", 1306], ["animals", 1320], [",", 1327], ["encodes", 1329], ["early", 1337], ["prototypes", 1343], ["of", 1354], ["p22phox", 1357], [",", 1364], ["p47phox", 1366], ["as", 1374], ["well", 1377], ["as", 1382], ["the", 1385], ["earliest", 1389], ["known", 1398], ["Nox2-like", 1404], ["ancestor", 1414], ["of", 1423], ["the", 1426], ["Nox1", 1430], ["-", 1434], ["3", 1435], ["subfamily", 1437], [".", 1446], ["p67phox-", 1448], ["and", 1457], ["p47phox", 1461], ["-", 1468], ["like", 1469], ["genes", 1474], ["are", 1480], ["seen", 1484], ["in", 1489], ["the", 1492], ["sea", 1496], ["urchin", 1500], ["Strongylocentrotus", 1507], ["purpuratus", 1526], ["and", 1537], ["the", 1541], ["limpet", 1545], ["Lottia", 1552], ["gigantea", 1559], ["that", 1568], ["also", 1573], ["possess", 1578], ["Nox2-like", 1586], ["co", 1596], ["-", 1598], ["orthologs", 1599], ["of", 1609], ["vertebrate", 1612], ["Nox1", 1623], ["-", 1627], ["3", 1628], [".", 1629], ["Duplication", 1631], ["of", 1643], ["primordial", 1646], ["p47phox", 1657], ["and", 1665], ["p67phox", 1669], ["genes", 1677], ["occurred", 1683], ["in", 1692], ["vertebrates", 1695], [",", 1706], ["with", 1708], ["the", 1713], ["duplicated", 1717], ["branches", 1728], ["evolving", 1737], ["into", 1746], ["NOXO1", 1751], ["and", 1757], ["NOXA1", 1761], [".", 1766], ["Analysis", 1768], ["of", 1777], ["characteristic", 1780], ["domains", 1795], ["of", 1803], ["regulatory", 1806], ["subunits", 1817], ["suggests", 1826], ["a", 1835], ["novel", 1837], ["view", 1843], ["of", 1848], ["the", 1851], ["evolution", 1855], ["of", 1865], ["Nox", 1868], [":", 1871], ["in", 1873], ["fish", 1876], [",", 1880], ["p40phox", 1882], ["participated", 1890], ["in", 1903], ["regulating", 1906], ["both", 1917], ["Nox1", 1922], ["and", 1927], ["Nox2", 1931], [",", 1935], ["but", 1937], ["after", 1941], ["the", 1947], ["appearance", 1951], ["of", 1962], ["mammals", 1965], [",", 1972], ["Nox1", 1974], ["(", 1979], ["but", 1980], ["not", 1984], ["Nox2", 1988], [")", 1992], ["became", 1994], ["independent", 2001], ["of", 2013], ["p40phox", 2016], [".", 2023], ["In", 2025], ["the", 2028], ["fish", 2032], ["Oryzias", 2037], ["latipes", 2045], [",", 2052], ["a", 2054], ["NOXO1", 2056], ["ortholog", 2062], ["retains", 2071], ["an", 2079], ["autoinhibitory", 2082], ["region", 2097], ["that", 2104], ["is", 2109], ["characteristic", 2112], ["of", 2127], ["mammalian", 2130], ["p47phox", 2140], [",", 2147], ["and", 2149], ["this", 2153], ["was", 2158], ["subsequently", 2162], ["lost", 2175], ["from", 2180], ["NOXO1", 2185], ["in", 2191], ["later", 2194], ["vertebrates", 2200], [".", 2211], ["Detailed", 2213], ["amino", 2222], ["acid", 2228], ["sequence", 2233], ["comparisons", 2242], ["identified", 2254], ["both", 2265], ["putative", 2270], ["key", 2279], ["residues", 2283], ["conserved", 2292], ["in", 2302], ["characteristic", 2305], ["domains", 2320], ["and", 2328], ["previously", 2332], ["unidentified", 2343], ["conserved", 2356], ["regions", 2366], [".", 2373], ["Also", 2375], [",", 2379], ["candidate", 2381], ["organizer", 2391], ["/", 2400], ["activator", 2401], ["proteins", 2411], ["in", 2420], ["fungi", 2423], ["and", 2429], ["amoeba", 2433], ["are", 2440], ["identified", 2444], ["and", 2455], ["hypothetical", 2459], ["activation", 2472], ["models", 2483], ["are", 2490], ["suggested", 2494], [".", 2503], ["This", 2505], ["is", 2510], ["the", 2513], ["first", 2517], ["report", 2523], ["to", 2530], ["provide", 2533], ["the", 2541], ["comprehensive", 2545], ["view", 2559], ["of", 2564], ["the", 2567], ["molecular", 2571], ["evolution", 2581], ["of", 2591], ["regulatory", 2594], ["subunits", 2605], ["for", 2614], ["Nox", 2618], ["enzymes", 2622], [".", 2629], ["This", 2631], ["approach", 2636], ["provides", 2645], ["clues", 2654], ["for", 2660], ["understanding", 2664], ["the", 2678], ["evolution", 2682], ["of", 2692], ["biochemical", 2695], ["and", 2707], ["physiological", 2711], ["functions", 2725], ["for", 2735], ["regulatory", 2739], ["-", 2749], ["subunit", 2750], ["-", 2757], ["dependent", 2758], ["Nox", 2768], ["enzymes", 2772], [".", 2779]]}
{"context": "Flumazenil, a potent benzodiazepine antagonist, is a newly synthetic imidazo-benzodiazepine, which blocks the neurological effects of benzodiazepines. The purpose of this study was to evaluate the effects of this agent in reversal of benzodiazepine overdose and differentiation of comatous patients with drug overdose. Fifteen comatous patients with suspected sedatives/hypnotics overdose were included in this study and flumazenil 0.25 mg per dose was administrated intravenously. The average score of Glasgow Coma Scale increased from 7.13 +/- 2.92 to 10.93 +/- 3.67 after one dose of flumazenil. Clear consciousness was restored after multiple doses of flumazenil administration. Three cases with different drug history and variant response after flumazenil treatment were also illustrated and discussed. The dosage of flumazenil used in this study ranged from 0.25 mg to 3 mg (average 0.87 +/- 0.74 mg). We concluded that flumazenil is an excellent antidote for benzodiazepine overdose and valuable for differentiating the patients in comatose.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "ebb1ae34a73c4a5d839b1240da0af1a4", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [96, 96], [106, 106], [154, 154], [119, 119], [130, 130], [65, 65]], "char_spans": [[0, 9], [587, 596], [656, 665], [926, 935], [750, 759], [822, 831], [421, 430]]}]}], "context_tokens": [["Flumazenil", 0], [",", 10], ["a", 12], ["potent", 14], ["benzodiazepine", 21], ["antagonist", 36], [",", 46], ["is", 48], ["a", 51], ["newly", 53], ["synthetic", 59], ["imidazo", 69], ["-", 76], ["benzodiazepine", 77], [",", 91], ["which", 93], ["blocks", 99], ["the", 106], ["neurological", 110], ["effects", 123], ["of", 131], ["benzodiazepines", 134], [".", 149], ["The", 151], ["purpose", 155], ["of", 163], ["this", 166], ["study", 171], ["was", 177], ["to", 181], ["evaluate", 184], ["the", 193], ["effects", 197], ["of", 205], ["this", 208], ["agent", 213], ["in", 219], ["reversal", 222], ["of", 231], ["benzodiazepine", 234], ["overdose", 249], ["and", 258], ["differentiation", 262], ["of", 278], ["comatous", 281], ["patients", 290], ["with", 299], ["drug", 304], ["overdose", 309], [".", 317], ["Fifteen", 319], ["comatous", 327], ["patients", 336], ["with", 345], ["suspected", 350], ["sedatives", 360], ["/", 369], ["hypnotics", 370], ["overdose", 380], ["were", 389], ["included", 394], ["in", 403], ["this", 406], ["study", 411], ["and", 417], ["flumazenil", 421], ["0.25", 432], ["mg", 437], ["per", 440], ["dose", 444], ["was", 449], ["administrated", 453], ["intravenously", 467], [".", 480], ["The", 482], ["average", 486], ["score", 494], ["of", 500], ["Glasgow", 503], ["Coma", 511], ["Scale", 516], ["increased", 522], ["from", 532], ["7.13", 537], ["+", 542], ["/-", 543], ["2.92", 546], ["to", 551], ["10.93", 554], ["+", 560], ["/-", 561], ["3.67", 564], ["after", 569], ["one", 575], ["dose", 579], ["of", 584], ["flumazenil", 587], [".", 597], ["Clear", 599], ["consciousness", 605], ["was", 619], ["restored", 623], ["after", 632], ["multiple", 638], ["doses", 647], ["of", 653], ["flumazenil", 656], ["administration", 667], [".", 681], ["Three", 683], ["cases", 689], ["with", 695], ["different", 700], ["drug", 710], ["history", 715], ["and", 723], ["variant", 727], ["response", 735], ["after", 744], ["flumazenil", 750], ["treatment", 761], ["were", 771], ["also", 776], ["illustrated", 781], ["and", 793], ["discussed", 797], [".", 806], ["The", 808], ["dosage", 812], ["of", 819], ["flumazenil", 822], ["used", 833], ["in", 838], ["this", 841], ["study", 846], ["ranged", 852], ["from", 859], ["0.25", 864], ["mg", 869], ["to", 872], ["3", 875], ["mg", 877], ["(", 880], ["average", 881], ["0.87", 889], ["+", 894], ["/-", 895], ["0.74", 898], ["mg", 903], [")", 905], [".", 906], ["We", 908], ["concluded", 911], ["that", 921], ["flumazenil", 926], ["is", 937], ["an", 940], ["excellent", 943], ["antidote", 953], ["for", 962], ["benzodiazepine", 966], ["overdose", 981], ["and", 990], ["valuable", 994], ["for", 1003], ["differentiating", 1007], ["the", 1023], ["patients", 1027], ["in", 1036], ["comatose", 1039], [".", 1047]]}
{"context": "Turner's syndrome (TS) is a chromosomal defect with partial or total absence of the X chromosome. Our objective is to report our experience in Greece with patients suffering from TS and trying to conceive; therefore, we present four patients with TS, who underwent In vitro fertilization (ICSI) with donor oocytes in order to get pregnant. Three out of four patients managed to conceive and bring pregnancy to completion. It was shown that patients diagnosed in childhood or adolescence with TS have the possibility to undergo hormone replacement therapy (HRT) and thus, secondary sexual characteristics as well as uterus of almost normal size can develop. Assisted reproduction techniques (ART), predominantly with donated oocytes, could give these patients the possibility to have children.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "80b1b799ab8b4a54ad19e73ff5640506", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[17, 17]], "char_spans": [[84, 84]]}]}], "context_tokens": [["Turner", 0], ["'s", 6], ["syndrome", 9], ["(", 18], ["TS", 19], [")", 21], ["is", 23], ["a", 26], ["chromosomal", 28], ["defect", 40], ["with", 47], ["partial", 52], ["or", 60], ["total", 63], ["absence", 69], ["of", 77], ["the", 80], ["X", 84], ["chromosome", 86], [".", 96], ["Our", 98], ["objective", 102], ["is", 112], ["to", 115], ["report", 118], ["our", 125], ["experience", 129], ["in", 140], ["Greece", 143], ["with", 150], ["patients", 155], ["suffering", 164], ["from", 174], ["TS", 179], ["and", 182], ["trying", 186], ["to", 193], ["conceive", 196], [";", 204], ["therefore", 206], [",", 215], ["we", 217], ["present", 220], ["four", 228], ["patients", 233], ["with", 242], ["TS", 247], [",", 249], ["who", 251], ["underwent", 255], ["In", 265], ["vitro", 268], ["fertilization", 274], ["(", 288], ["ICSI", 289], [")", 293], ["with", 295], ["donor", 300], ["oocytes", 306], ["in", 314], ["order", 317], ["to", 323], ["get", 326], ["pregnant", 330], [".", 338], ["Three", 340], ["out", 346], ["of", 350], ["four", 353], ["patients", 358], ["managed", 367], ["to", 375], ["conceive", 378], ["and", 387], ["bring", 391], ["pregnancy", 397], ["to", 407], ["completion", 410], [".", 420], ["It", 422], ["was", 425], ["shown", 429], ["that", 435], ["patients", 440], ["diagnosed", 449], ["in", 459], ["childhood", 462], ["or", 472], ["adolescence", 475], ["with", 487], ["TS", 492], ["have", 495], ["the", 500], ["possibility", 504], ["to", 516], ["undergo", 519], ["hormone", 527], ["replacement", 535], ["therapy", 547], ["(", 555], ["HRT", 556], [")", 559], ["and", 561], ["thus", 565], [",", 569], ["secondary", 571], ["sexual", 581], ["characteristics", 588], ["as", 604], ["well", 607], ["as", 612], ["uterus", 615], ["of", 622], ["almost", 625], ["normal", 632], ["size", 639], ["can", 644], ["develop", 648], [".", 655], ["Assisted", 657], ["reproduction", 666], ["techniques", 679], ["(", 690], ["ART", 691], [")", 694], [",", 695], ["predominantly", 697], ["with", 711], ["donated", 716], ["oocytes", 724], [",", 731], ["could", 733], ["give", 739], ["these", 744], ["patients", 750], ["the", 759], ["possibility", 763], ["to", 775], ["have", 778], ["children", 783], [".", 791]]}
{"context": "Siltuximab, a chimeric monoclonal antibody with high affinity and specificity for interleukin-6, has been shown to enhance anti-multiple myeloma activity of bortezomib and corticosteroid in vitro. We evaluated the safety, pharmacokinetics, immunogenicity, and antitumor effect of siltuximab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. This open-label, phase 1, dose-escalating study used two doses of siltuximab: 5.5 and 11.0 mg/kg (administered on day 1 of each 21-day cycle). In total, nine patients were treated. The most common grade 3/4 adverse events, lymphopenia (89 %) and thrombocytopenia (44 %), occurred in patients receiving both doses of siltuximab; however, no dose-limiting toxicities (DLTs) were observed. Following intravenous administration of siltuximab at 5.5 and 11.0 mg/kg, the maximum serum concentration and the area under the curve from 0 to 21 days and from 0 to infinity increased in an approximately dose-proportional manner. Mean half-life, total systemic clearance, and volume of distribution were similar at doses of 5.5 and 11.0 mg/kg. Across both doses, six of the nine patients had complete or partial response (22 and 44 %, respectively). In conclusion, as no DLT was observed, the recommended dose for this combination is 11.0 mg/kg once every 3 weeks. The study is registered at http://www.clinicaltrials.gov as NCT01309412.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "5cd7ff3ebd7f4aeea91e08b630ebba14", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[12, 12]], "char_spans": [[82, 94]]}]}], "context_tokens": [["Siltuximab", 0], [",", 10], ["a", 12], ["chimeric", 14], ["monoclonal", 23], ["antibody", 34], ["with", 43], ["high", 48], ["affinity", 53], ["and", 62], ["specificity", 66], ["for", 78], ["interleukin-6", 82], [",", 95], ["has", 97], ["been", 101], ["shown", 106], ["to", 112], ["enhance", 115], ["anti", 123], ["-", 127], ["multiple", 128], ["myeloma", 137], ["activity", 145], ["of", 154], ["bortezomib", 157], ["and", 168], ["corticosteroid", 172], ["in", 187], ["vitro", 190], [".", 195], ["We", 197], ["evaluated", 200], ["the", 210], ["safety", 214], [",", 220], ["pharmacokinetics", 222], [",", 238], ["immunogenicity", 240], [",", 254], ["and", 256], ["antitumor", 260], ["effect", 270], ["of", 277], ["siltuximab", 280], ["in", 291], ["combination", 294], ["with", 306], ["bortezomib", 311], ["and", 322], ["dexamethasone", 326], ["in", 340], ["Japanese", 343], ["patients", 352], ["with", 361], ["relapsed", 366], ["or", 375], ["refractory", 378], ["multiple", 389], ["myeloma", 398], [".", 405], ["This", 407], ["open", 412], ["-", 416], ["label", 417], [",", 422], ["phase", 424], ["1", 430], [",", 431], ["dose", 433], ["-", 437], ["escalating", 438], ["study", 449], ["used", 455], ["two", 460], ["doses", 464], ["of", 470], ["siltuximab", 473], [":", 483], ["5.5", 485], ["and", 489], ["11.0", 493], ["mg", 498], ["/", 500], ["kg", 501], ["(", 504], ["administered", 505], ["on", 518], ["day", 521], ["1", 525], ["of", 527], ["each", 530], ["21-day", 535], ["cycle", 542], [")", 547], [".", 548], ["In", 550], ["total", 553], [",", 558], ["nine", 560], ["patients", 565], ["were", 574], ["treated", 579], [".", 586], ["The", 588], ["most", 592], ["common", 597], ["grade", 604], ["3/4", 610], ["adverse", 614], ["events", 622], [",", 628], ["lymphopenia", 630], ["(", 642], ["89", 643], ["%", 646], [")", 647], ["and", 649], ["thrombocytopenia", 653], ["(", 670], ["44", 671], ["%", 674], [")", 675], [",", 676], ["occurred", 678], ["in", 687], ["patients", 690], ["receiving", 699], ["both", 709], ["doses", 714], ["of", 720], ["siltuximab", 723], [";", 733], ["however", 735], [",", 742], ["no", 744], ["dose", 747], ["-", 751], ["limiting", 752], ["toxicities", 761], ["(", 772], ["DLTs", 773], [")", 777], ["were", 779], ["observed", 784], [".", 792], ["Following", 794], ["intravenous", 804], ["administration", 816], ["of", 831], ["siltuximab", 834], ["at", 845], ["5.5", 848], ["and", 852], ["11.0", 856], ["mg", 861], ["/", 863], ["kg", 864], [",", 866], ["the", 868], ["maximum", 872], ["serum", 880], ["concentration", 886], ["and", 900], ["the", 904], ["area", 908], ["under", 913], ["the", 919], ["curve", 923], ["from", 929], ["0", 934], ["to", 936], ["21", 939], ["days", 942], ["and", 947], ["from", 951], ["0", 956], ["to", 958], ["infinity", 961], ["increased", 970], ["in", 980], ["an", 983], ["approximately", 986], ["dose", 1000], ["-", 1004], ["proportional", 1005], ["manner", 1018], [".", 1024], ["Mean", 1026], ["half", 1031], ["-", 1035], ["life", 1036], [",", 1040], ["total", 1042], ["systemic", 1048], ["clearance", 1057], [",", 1066], ["and", 1068], ["volume", 1072], ["of", 1079], ["distribution", 1082], ["were", 1095], ["similar", 1100], ["at", 1108], ["doses", 1111], ["of", 1117], ["5.5", 1120], ["and", 1124], ["11.0", 1128], ["mg", 1133], ["/", 1135], ["kg", 1136], [".", 1138], ["Across", 1140], ["both", 1147], ["doses", 1152], [",", 1157], ["six", 1159], ["of", 1163], ["the", 1166], ["nine", 1170], ["patients", 1175], ["had", 1184], ["complete", 1188], ["or", 1197], ["partial", 1200], ["response", 1208], ["(", 1217], ["22", 1218], ["and", 1221], ["44", 1225], ["%", 1228], [",", 1229], ["respectively", 1231], [")", 1243], [".", 1244], ["In", 1246], ["conclusion", 1249], [",", 1259], ["as", 1261], ["no", 1264], ["DLT", 1267], ["was", 1271], ["observed", 1275], [",", 1283], ["the", 1285], ["recommended", 1289], ["dose", 1301], ["for", 1306], ["this", 1310], ["combination", 1315], ["is", 1327], ["11.0", 1330], ["mg", 1335], ["/", 1337], ["kg", 1338], ["once", 1341], ["every", 1346], ["3", 1352], ["weeks", 1354], [".", 1359], ["The", 1361], ["study", 1365], ["is", 1371], ["registered", 1374], ["at", 1385], ["http://www.clinicaltrials.gov", 1388], ["as", 1418], ["NCT01309412", 1421], [".", 1432]]}
{"context": "A 60-year-old man diagnosed clinically with Becker's muscular dystrophy 20 years ago by another physician presented with gradually progressive proximal muscle weakness since teenage years. Family history revealed a strong paternal familial inheritance pattern of similar distribution of weakness-face, forearm flexion, knee extension and foot dorsiflexion. Work-ups revealed B12 deficiency and allele 1 deletion in fascioscapulohumeral muscular dystrophy (FSHD) DNA testing. FSHD is the third most common muscular dystrophy. Clinical diagnosis is made from the distinctive pattern of weakness, autosomal-dominant inheritance, and confirmed by genetic testing. This case strongly demonstrates the importance of a thorough and careful clinical evaluation even in a case with a long standing diagnosis.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "ff8ede38609d4622af0f985023a70e89", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[95, 97]], "char_spans": [[594, 611]]}]}], "context_tokens": [["A", 0], ["60-year", 2], ["-", 9], ["old", 10], ["man", 14], ["diagnosed", 18], ["clinically", 28], ["with", 39], ["Becker", 44], ["'s", 50], ["muscular", 53], ["dystrophy", 62], ["20", 72], ["years", 75], ["ago", 81], ["by", 85], ["another", 88], ["physician", 96], ["presented", 106], ["with", 116], ["gradually", 121], ["progressive", 131], ["proximal", 143], ["muscle", 152], ["weakness", 159], ["since", 168], ["teenage", 174], ["years", 182], [".", 187], ["Family", 189], ["history", 196], ["revealed", 204], ["a", 213], ["strong", 215], ["paternal", 222], ["familial", 231], ["inheritance", 240], ["pattern", 252], ["of", 260], ["similar", 263], ["distribution", 271], ["of", 284], ["weakness", 287], ["-", 295], ["face", 296], [",", 300], ["forearm", 302], ["flexion", 310], [",", 317], ["knee", 319], ["extension", 324], ["and", 334], ["foot", 338], ["dorsiflexion", 343], [".", 355], ["Work", 357], ["-", 361], ["ups", 362], ["revealed", 366], ["B12", 375], ["deficiency", 379], ["and", 390], ["allele", 394], ["1", 401], ["deletion", 403], ["in", 412], ["fascioscapulohumeral", 415], ["muscular", 436], ["dystrophy", 445], ["(", 455], ["FSHD", 456], [")", 460], ["DNA", 462], ["testing", 466], [".", 473], ["FSHD", 475], ["is", 480], ["the", 483], ["third", 487], ["most", 493], ["common", 498], ["muscular", 505], ["dystrophy", 514], [".", 523], ["Clinical", 525], ["diagnosis", 534], ["is", 544], ["made", 547], ["from", 552], ["the", 557], ["distinctive", 561], ["pattern", 573], ["of", 581], ["weakness", 584], [",", 592], ["autosomal", 594], ["-", 603], ["dominant", 604], ["inheritance", 613], [",", 624], ["and", 626], ["confirmed", 630], ["by", 640], ["genetic", 643], ["testing", 651], [".", 658], ["This", 660], ["case", 665], ["strongly", 670], ["demonstrates", 679], ["the", 692], ["importance", 696], ["of", 707], ["a", 710], ["thorough", 712], ["and", 721], ["careful", 725], ["clinical", 733], ["evaluation", 742], ["even", 753], ["in", 758], ["a", 761], ["case", 763], ["with", 768], ["a", 773], ["long", 775], ["standing", 780], ["diagnosis", 789], [".", 798]]}
{"context": "The Ehlers-Danlos syndrome is a heritable connective-tissue disorder caused by defects in fibrillar-collagen metabolism. Mutations in the type V collagen genes account for up to 50 percent of cases of classic Ehlers-Danlos syndrome, but many other cases are unexplained. We investigated whether the deficiency of the tenascins, extracellular-matrix proteins that are highly expressed in connective tissues, was associated with the Ehlers-Danlos syndrome. We screened serum samples from 151 patients with the classic, hypermobility, or vascular types of the Ehlers-Danlos syndrome; 75 patients with psoriasis; 93 patients with rheumatoid arthritis; and 21 healthy persons for the presence of tenascin-X and tenascin-C by enzyme-linked immunosorbent assay. We examined the expression of tenascins and type V collagen in skin by immunohistochemical methods and sequenced the tenascin-X gene. Tenascin-X was present in serum from all normal subjects, all patients with psoriasis, all patients with rheumatoid arthritis, and 146 of 151 patients with the Ehlers-Danlos syndrome. Tenascin-X was absent from the serum of the 5 remaining patients with Ehlers-Danlos syndrome, who were unrelated. Tenascin-X deficiency was confirmed in these patients by analysis of skin fibroblasts and by immunostaining of skin. The expression of tenascin-C and type V collagen was normal in these patients. All five of these patients had hypermobile joints, hyperelastic skin, and easy bruising, without atrophic scarring. Tenascin-X mutations were identified in all tenascin-X-deficient patients; one patient had a homozygous tenascin-X gene deletion, one was heterozygous for the deletion, and three others had homozygous truncating point mutations, confirming a causative role for tenascin-X and a recessive pattern of inheritance. Tenascin-X deficiency causes a clinically distinct, recessive form of the Ehlers-Danlos syndrome. This finding indicates that factors other than the collagens or collagen-processing enzymes can cause the syndrome and suggests a central role for tenascin-X in maintaining the integrity of collagenous matrix.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective-tissue", "connective tissue"], "qid": "84ecb54e06cc44c78c9482f8b29d119c", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[8, 10]], "char_spans": [[42, 58]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndrome", 18], ["is", 27], ["a", 30], ["heritable", 32], ["connective", 42], ["-", 52], ["tissue", 53], ["disorder", 60], ["caused", 69], ["by", 76], ["defects", 79], ["in", 87], ["fibrillar", 90], ["-", 99], ["collagen", 100], ["metabolism", 109], [".", 119], ["Mutations", 121], ["in", 131], ["the", 134], ["type", 138], ["V", 143], ["collagen", 145], ["genes", 154], ["account", 160], ["for", 168], ["up", 172], ["to", 175], ["50", 178], ["percent", 181], ["of", 189], ["cases", 192], ["of", 198], ["classic", 201], ["Ehlers", 209], ["-", 215], ["Danlos", 216], ["syndrome", 223], [",", 231], ["but", 233], ["many", 237], ["other", 242], ["cases", 248], ["are", 254], ["unexplained", 258], [".", 269], ["We", 271], ["investigated", 274], ["whether", 287], ["the", 295], ["deficiency", 299], ["of", 310], ["the", 313], ["tenascins", 317], [",", 326], ["extracellular", 328], ["-", 341], ["matrix", 342], ["proteins", 349], ["that", 358], ["are", 363], ["highly", 367], ["expressed", 374], ["in", 384], ["connective", 387], ["tissues", 398], [",", 405], ["was", 407], ["associated", 411], ["with", 422], ["the", 427], ["Ehlers", 431], ["-", 437], ["Danlos", 438], ["syndrome", 445], [".", 453], ["We", 455], ["screened", 458], ["serum", 467], ["samples", 473], ["from", 481], ["151", 486], ["patients", 490], ["with", 499], ["the", 504], ["classic", 508], [",", 515], ["hypermobility", 517], [",", 530], ["or", 532], ["vascular", 535], ["types", 544], ["of", 550], ["the", 553], ["Ehlers", 557], ["-", 563], ["Danlos", 564], ["syndrome", 571], [";", 579], ["75", 581], ["patients", 584], ["with", 593], ["psoriasis", 598], [";", 607], ["93", 609], ["patients", 612], ["with", 621], ["rheumatoid", 626], ["arthritis", 637], [";", 646], ["and", 648], ["21", 652], ["healthy", 655], ["persons", 663], ["for", 671], ["the", 675], ["presence", 679], ["of", 688], ["tenascin", 691], ["-", 699], ["X", 700], ["and", 702], ["tenascin", 706], ["-", 714], ["C", 715], ["by", 717], ["enzyme", 720], ["-", 726], ["linked", 727], ["immunosorbent", 734], ["assay", 748], [".", 753], ["We", 755], ["examined", 758], ["the", 767], ["expression", 771], ["of", 782], ["tenascins", 785], ["and", 795], ["type", 799], ["V", 804], ["collagen", 806], ["in", 815], ["skin", 818], ["by", 823], ["immunohistochemical", 826], ["methods", 846], ["and", 854], ["sequenced", 858], ["the", 868], ["tenascin", 872], ["-", 880], ["X", 881], ["gene", 883], [".", 887], ["Tenascin", 889], ["-", 897], ["X", 898], ["was", 900], ["present", 904], ["in", 912], ["serum", 915], ["from", 921], ["all", 926], ["normal", 930], ["subjects", 937], [",", 945], ["all", 947], ["patients", 951], ["with", 960], ["psoriasis", 965], [",", 974], ["all", 976], ["patients", 980], ["with", 989], ["rheumatoid", 994], ["arthritis", 1005], [",", 1014], ["and", 1016], ["146", 1020], ["of", 1024], ["151", 1027], ["patients", 1031], ["with", 1040], ["the", 1045], ["Ehlers", 1049], ["-", 1055], ["Danlos", 1056], ["syndrome", 1063], [".", 1071], ["Tenascin", 1073], ["-", 1081], ["X", 1082], ["was", 1084], ["absent", 1088], ["from", 1095], ["the", 1100], ["serum", 1104], ["of", 1110], ["the", 1113], ["5", 1117], ["remaining", 1119], ["patients", 1129], ["with", 1138], ["Ehlers", 1143], ["-", 1149], ["Danlos", 1150], ["syndrome", 1157], [",", 1165], ["who", 1167], ["were", 1171], ["unrelated", 1176], [".", 1185], ["Tenascin", 1187], ["-", 1195], ["X", 1196], ["deficiency", 1198], ["was", 1209], ["confirmed", 1213], ["in", 1223], ["these", 1226], ["patients", 1232], ["by", 1241], ["analysis", 1244], ["of", 1253], ["skin", 1256], ["fibroblasts", 1261], ["and", 1273], ["by", 1277], ["immunostaining", 1280], ["of", 1295], ["skin", 1298], [".", 1302], ["The", 1304], ["expression", 1308], ["of", 1319], ["tenascin", 1322], ["-", 1330], ["C", 1331], ["and", 1333], ["type", 1337], ["V", 1342], ["collagen", 1344], ["was", 1353], ["normal", 1357], ["in", 1364], ["these", 1367], ["patients", 1373], [".", 1381], ["All", 1383], ["five", 1387], ["of", 1392], ["these", 1395], ["patients", 1401], ["had", 1410], ["hypermobile", 1414], ["joints", 1426], [",", 1432], ["hyperelastic", 1434], ["skin", 1447], [",", 1451], ["and", 1453], ["easy", 1457], ["bruising", 1462], [",", 1470], ["without", 1472], ["atrophic", 1480], ["scarring", 1489], [".", 1497], ["Tenascin", 1499], ["-", 1507], ["X", 1508], ["mutations", 1510], ["were", 1520], ["identified", 1525], ["in", 1536], ["all", 1539], ["tenascin", 1543], ["-", 1551], ["X", 1552], ["-", 1553], ["deficient", 1554], ["patients", 1564], [";", 1572], ["one", 1574], ["patient", 1578], ["had", 1586], ["a", 1590], ["homozygous", 1592], ["tenascin", 1603], ["-", 1611], ["X", 1612], ["gene", 1614], ["deletion", 1619], [",", 1627], ["one", 1629], ["was", 1633], ["heterozygous", 1637], ["for", 1650], ["the", 1654], ["deletion", 1658], [",", 1666], ["and", 1668], ["three", 1672], ["others", 1678], ["had", 1685], ["homozygous", 1689], ["truncating", 1700], ["point", 1711], ["mutations", 1717], [",", 1726], ["confirming", 1728], ["a", 1739], ["causative", 1741], ["role", 1751], ["for", 1756], ["tenascin", 1760], ["-", 1768], ["X", 1769], ["and", 1771], ["a", 1775], ["recessive", 1777], ["pattern", 1787], ["of", 1795], ["inheritance", 1798], [".", 1809], ["Tenascin", 1811], ["-", 1819], ["X", 1820], ["deficiency", 1822], ["causes", 1833], ["a", 1840], ["clinically", 1842], ["distinct", 1853], [",", 1861], ["recessive", 1863], ["form", 1873], ["of", 1878], ["the", 1881], ["Ehlers", 1885], ["-", 1891], ["Danlos", 1892], ["syndrome", 1899], [".", 1907], ["This", 1909], ["finding", 1914], ["indicates", 1922], ["that", 1932], ["factors", 1937], ["other", 1945], ["than", 1951], ["the", 1956], ["collagens", 1960], ["or", 1970], ["collagen", 1973], ["-", 1981], ["processing", 1982], ["enzymes", 1993], ["can", 2001], ["cause", 2005], ["the", 2011], ["syndrome", 2015], ["and", 2024], ["suggests", 2028], ["a", 2037], ["central", 2039], ["role", 2047], ["for", 2052], ["tenascin", 2056], ["-", 2064], ["X", 2065], ["in", 2067], ["maintaining", 2070], ["the", 2082], ["integrity", 2086], ["of", 2096], ["collagenous", 2099], ["matrix", 2111], [".", 2117]]}
{"context": "To evaluate short- and mid-term level of imbalance after vestibular schwannoma (VS) microsurgery by the transpetrosal approach, to search for factors predictive of vestibular compensation, and to determine which patient categories need a postoperative vestibular rehabilitation program. Prospective cohort study at a tertiary referral center. Between 2010 and 2011, patients aged 18 to 75 operated on for VS by transpetrosal approaches were included. VS was characterized by its size (Koos classification) and the presence or not of a cystic component. Hearing was classified according to the Gardner Robertson grading. The preoperative workup included an audiogram, computerized video nystagmography (VNG) with caloric testing, gaze study, rotatory tests, click-evoked cervical vestibular evoked myogenic potential measurements (cVEMPs), and subjective visual vertical test. Patients were asked to complete a Dizziness Handicap Inventory (DHI). Postoperatively, patients were reevaluated on D7 (clinical status), D90 (VNG and DHI), and D180 (DHI). Timing and duration of vestibular rehabilitation were also recorded. Forty-eight patients were included. Preoperatively, 77% experienced mild instability problems with a mean DHI score of 14.1 (range 4-32). Postoperatively, 71% reported stable or even improved perceived stability. Mean DHI scores were 28.1 on D90 and 19.8 on D180. Serviceable hearing, cystic transformation, normal cVEMPs, diplopia, and vestibular syndrome on D7 were found to be predictive of worse equilibrium outcome than when absent. A preoperative caloric deficit greater than 75% seemed to be a good prognostic factor. Vestibular rehabilitation was conducted in 56% of patients. Starting it early (<1 mo) seemed to be beneficial for final equilibrium outcome. VS microsurgery provides good stability results. Some preoperative parameters may be predictive of worse or improved balance recovery, as is clinical status on D7.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "44cd890f1a1b4d6a9b055e363d1c3221", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[11, 12]], "char_spans": [[57, 77]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["short-", 12], ["and", 19], ["mid", 23], ["-", 26], ["term", 27], ["level", 32], ["of", 38], ["imbalance", 41], ["after", 51], ["vestibular", 57], ["schwannoma", 68], ["(", 79], ["VS", 80], [")", 82], ["microsurgery", 84], ["by", 97], ["the", 100], ["transpetrosal", 104], ["approach", 118], [",", 126], ["to", 128], ["search", 131], ["for", 138], ["factors", 142], ["predictive", 150], ["of", 161], ["vestibular", 164], ["compensation", 175], [",", 187], ["and", 189], ["to", 193], ["determine", 196], ["which", 206], ["patient", 212], ["categories", 220], ["need", 231], ["a", 236], ["postoperative", 238], ["vestibular", 252], ["rehabilitation", 263], ["program", 278], [".", 285], ["Prospective", 287], ["cohort", 299], ["study", 306], ["at", 312], ["a", 315], ["tertiary", 317], ["referral", 326], ["center", 335], [".", 341], ["Between", 343], ["2010", 351], ["and", 356], ["2011", 360], [",", 364], ["patients", 366], ["aged", 375], ["18", 380], ["to", 383], ["75", 386], ["operated", 389], ["on", 398], ["for", 401], ["VS", 405], ["by", 408], ["transpetrosal", 411], ["approaches", 425], ["were", 436], ["included", 441], [".", 449], ["VS", 451], ["was", 454], ["characterized", 458], ["by", 472], ["its", 475], ["size", 479], ["(", 484], ["Koos", 485], ["classification", 490], [")", 504], ["and", 506], ["the", 510], ["presence", 514], ["or", 523], ["not", 526], ["of", 530], ["a", 533], ["cystic", 535], ["component", 542], [".", 551], ["Hearing", 553], ["was", 561], ["classified", 565], ["according", 576], ["to", 586], ["the", 589], ["Gardner", 593], ["Robertson", 601], ["grading", 611], [".", 618], ["The", 620], ["preoperative", 624], ["workup", 637], ["included", 644], ["an", 653], ["audiogram", 656], [",", 665], ["computerized", 667], ["video", 680], ["nystagmography", 686], ["(", 701], ["VNG", 702], [")", 705], ["with", 707], ["caloric", 712], ["testing", 720], [",", 727], ["gaze", 729], ["study", 734], [",", 739], ["rotatory", 741], ["tests", 750], [",", 755], ["click", 757], ["-", 762], ["evoked", 763], ["cervical", 770], ["vestibular", 779], ["evoked", 790], ["myogenic", 797], ["potential", 806], ["measurements", 816], ["(", 829], ["cVEMPs", 830], [")", 836], [",", 837], ["and", 839], ["subjective", 843], ["visual", 854], ["vertical", 861], ["test", 870], [".", 874], ["Patients", 876], ["were", 885], ["asked", 890], ["to", 896], ["complete", 899], ["a", 908], ["Dizziness", 910], ["Handicap", 920], ["Inventory", 929], ["(", 939], ["DHI", 940], [")", 943], [".", 944], ["Postoperatively", 946], [",", 961], ["patients", 963], ["were", 972], ["reevaluated", 977], ["on", 989], ["D7", 992], ["(", 995], ["clinical", 996], ["status", 1005], [")", 1011], [",", 1012], ["D90", 1014], ["(", 1018], ["VNG", 1019], ["and", 1023], ["DHI", 1027], [")", 1030], [",", 1031], ["and", 1033], ["D180", 1037], ["(", 1042], ["DHI", 1043], [")", 1046], [".", 1047], ["Timing", 1049], ["and", 1056], ["duration", 1060], ["of", 1069], ["vestibular", 1072], ["rehabilitation", 1083], ["were", 1098], ["also", 1103], ["recorded", 1108], [".", 1116], ["Forty", 1118], ["-", 1123], ["eight", 1124], ["patients", 1130], ["were", 1139], ["included", 1144], [".", 1152], ["Preoperatively", 1154], [",", 1168], ["77", 1170], ["%", 1172], ["experienced", 1174], ["mild", 1186], ["instability", 1191], ["problems", 1203], ["with", 1212], ["a", 1217], ["mean", 1219], ["DHI", 1224], ["score", 1228], ["of", 1234], ["14.1", 1237], ["(", 1242], ["range", 1243], ["4", 1249], ["-", 1250], ["32", 1251], [")", 1253], [".", 1254], ["Postoperatively", 1256], [",", 1271], ["71", 1273], ["%", 1275], ["reported", 1277], ["stable", 1286], ["or", 1293], ["even", 1296], ["improved", 1301], ["perceived", 1310], ["stability", 1320], [".", 1329], ["Mean", 1331], ["DHI", 1336], ["scores", 1340], ["were", 1347], ["28.1", 1352], ["on", 1357], ["D90", 1360], ["and", 1364], ["19.8", 1368], ["on", 1373], ["D180", 1376], [".", 1380], ["Serviceable", 1382], ["hearing", 1394], [",", 1401], ["cystic", 1403], ["transformation", 1410], [",", 1424], ["normal", 1426], ["cVEMPs", 1433], [",", 1439], ["diplopia", 1441], [",", 1449], ["and", 1451], ["vestibular", 1455], ["syndrome", 1466], ["on", 1475], ["D7", 1478], ["were", 1481], ["found", 1486], ["to", 1492], ["be", 1495], ["predictive", 1498], ["of", 1509], ["worse", 1512], ["equilibrium", 1518], ["outcome", 1530], ["than", 1538], ["when", 1543], ["absent", 1548], [".", 1554], ["A", 1556], ["preoperative", 1558], ["caloric", 1571], ["deficit", 1579], ["greater", 1587], ["than", 1595], ["75", 1600], ["%", 1602], ["seemed", 1604], ["to", 1611], ["be", 1614], ["a", 1617], ["good", 1619], ["prognostic", 1624], ["factor", 1635], [".", 1641], ["Vestibular", 1643], ["rehabilitation", 1654], ["was", 1669], ["conducted", 1673], ["in", 1683], ["56", 1686], ["%", 1688], ["of", 1690], ["patients", 1693], [".", 1701], ["Starting", 1703], ["it", 1712], ["early", 1715], ["(", 1721], ["<", 1722], ["1", 1723], ["mo", 1725], [")", 1727], ["seemed", 1729], ["to", 1736], ["be", 1739], ["beneficial", 1742], ["for", 1753], ["final", 1757], ["equilibrium", 1763], ["outcome", 1775], [".", 1782], ["VS", 1784], ["microsurgery", 1787], ["provides", 1800], ["good", 1809], ["stability", 1814], ["results", 1824], [".", 1831], ["Some", 1833], ["preoperative", 1838], ["parameters", 1851], ["may", 1862], ["be", 1866], ["predictive", 1869], ["of", 1880], ["worse", 1883], ["or", 1889], ["improved", 1892], ["balance", 1901], ["recovery", 1909], [",", 1917], ["as", 1919], ["is", 1922], ["clinical", 1925], ["status", 1934], ["on", 1941], ["D7", 1944], [".", 1946]]}
{"context": "Willis-Ekbom disease/restless legs syndrome (WED/RLS) is the most common sleep-related movement disorder in pregnancy. We designed a prospective longitudinal study to investigate the correlates of WED/RLS during and after pregnancy. A total of 138 pregnant women with WED/RLS and a control group of 251 age-matched pregnant women were enrolled prospectively. A questionnaire was administered during a face-to-face interview at first evaluation during pregnancy and three months after delivery. Among all women in the first trimester, 15.6% were diagnosed with WED/RLS, whereas 32.8% of those in the second trimester and 38.8% of those in the third trimester were diagnosed with WED/RLS (p\u2009=\u20090.032). In regression analysis, later gestational age [p\u2009<\u20090.001; odds ratio (OR) 1.054] and previous history of WED/RLS (p\u2009=\u20090.001; OR 2.795) were positively correlated with the presence of WED/RLS, while ferritin levels (p\u2009=\u20090.001; OR 0.956) were negatively correlated with the presence of WED/RLS. Ferritin levels were also negatively correlated with the International RLS Study Group severity index (p\u2009=\u20090.041). Forty-eight patients (34.8%) experienced WED/RLS symptomatology after delivery. The ferritin levels were lower, and the mean number of pregnancies was higher, in women with residual WED/RLS (p\u2009=\u20090.008). Our survey showed that WED/RLS was more common in the second and third trimesters. Emergence of WED/RLS during the second trimester was strongly associated with residual WED/RLS. Lower ferritin levels were associated with both WED/RLS in pregnancy and residual WED/RLS after delivery. A higher number of pregnancies were also associated with a greater likelihood of having residual WED/RLS after delivery.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "c13bddb9e37b47c69428caa895cea7ae", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[5, 7]], "char_spans": [[21, 42]]}]}], "context_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["/", 20], ["restless", 21], ["legs", 30], ["syndrome", 35], ["(", 44], ["WED", 45], ["/", 48], ["RLS", 49], [")", 52], ["is", 54], ["the", 57], ["most", 61], ["common", 66], ["sleep", 73], ["-", 78], ["related", 79], ["movement", 87], ["disorder", 96], ["in", 105], ["pregnancy", 108], [".", 117], ["We", 119], ["designed", 122], ["a", 131], ["prospective", 133], ["longitudinal", 145], ["study", 158], ["to", 164], ["investigate", 167], ["the", 179], ["correlates", 183], ["of", 194], ["WED", 197], ["/", 200], ["RLS", 201], ["during", 205], ["and", 212], ["after", 216], ["pregnancy", 222], [".", 231], ["A", 233], ["total", 235], ["of", 241], ["138", 244], ["pregnant", 248], ["women", 257], ["with", 263], ["WED", 268], ["/", 271], ["RLS", 272], ["and", 276], ["a", 280], ["control", 282], ["group", 290], ["of", 296], ["251", 299], ["age", 303], ["-", 306], ["matched", 307], ["pregnant", 315], ["women", 324], ["were", 330], ["enrolled", 335], ["prospectively", 344], [".", 357], ["A", 359], ["questionnaire", 361], ["was", 375], ["administered", 379], ["during", 392], ["a", 399], ["face", 401], ["-", 405], ["to", 406], ["-", 408], ["face", 409], ["interview", 414], ["at", 424], ["first", 427], ["evaluation", 433], ["during", 444], ["pregnancy", 451], ["and", 461], ["three", 465], ["months", 471], ["after", 478], ["delivery", 484], [".", 492], ["Among", 494], ["all", 500], ["women", 504], ["in", 510], ["the", 513], ["first", 517], ["trimester", 523], [",", 532], ["15.6", 534], ["%", 538], ["were", 540], ["diagnosed", 545], ["with", 555], ["WED", 560], ["/", 563], ["RLS", 564], [",", 567], ["whereas", 569], ["32.8", 577], ["%", 581], ["of", 583], ["those", 586], ["in", 592], ["the", 595], ["second", 599], ["trimester", 606], ["and", 616], ["38.8", 620], ["%", 624], ["of", 626], ["those", 629], ["in", 635], ["the", 638], ["third", 642], ["trimester", 648], ["were", 658], ["diagnosed", 663], ["with", 673], ["WED", 678], ["/", 681], ["RLS", 682], ["(", 686], ["p", 687], ["=", 689], ["0.032", 691], [")", 696], [".", 697], ["In", 699], ["regression", 702], ["analysis", 713], [",", 721], ["later", 723], ["gestational", 729], ["age", 741], ["[", 745], ["p", 746], ["<", 748], ["0.001", 750], [";", 755], ["odds", 757], ["ratio", 762], ["(", 768], ["OR", 769], [")", 771], ["1.054", 773], ["]", 778], ["and", 780], ["previous", 784], ["history", 793], ["of", 801], ["WED", 804], ["/", 807], ["RLS", 808], ["(", 812], ["p", 813], ["=", 815], ["0.001", 817], [";", 822], ["OR", 824], ["2.795", 827], [")", 832], ["were", 834], ["positively", 839], ["correlated", 850], ["with", 861], ["the", 866], ["presence", 870], ["of", 879], ["WED", 882], ["/", 885], ["RLS", 886], [",", 889], ["while", 891], ["ferritin", 897], ["levels", 906], ["(", 913], ["p", 914], ["=", 916], ["0.001", 918], [";", 923], ["OR", 925], ["0.956", 928], [")", 933], ["were", 935], ["negatively", 940], ["correlated", 951], ["with", 962], ["the", 967], ["presence", 971], ["of", 980], ["WED", 983], ["/", 986], ["RLS", 987], [".", 990], ["Ferritin", 992], ["levels", 1001], ["were", 1008], ["also", 1013], ["negatively", 1018], ["correlated", 1029], ["with", 1040], ["the", 1045], ["International", 1049], ["RLS", 1063], ["Study", 1067], ["Group", 1073], ["severity", 1079], ["index", 1088], ["(", 1094], ["p", 1095], ["=", 1097], ["0.041", 1099], [")", 1104], [".", 1105], ["Forty", 1107], ["-", 1112], ["eight", 1113], ["patients", 1119], ["(", 1128], ["34.8", 1129], ["%", 1133], [")", 1134], ["experienced", 1136], ["WED", 1148], ["/", 1151], ["RLS", 1152], ["symptomatology", 1156], ["after", 1171], ["delivery", 1177], [".", 1185], ["The", 1187], ["ferritin", 1191], ["levels", 1200], ["were", 1207], ["lower", 1212], [",", 1217], ["and", 1219], ["the", 1223], ["mean", 1227], ["number", 1232], ["of", 1239], ["pregnancies", 1242], ["was", 1254], ["higher", 1258], [",", 1264], ["in", 1266], ["women", 1269], ["with", 1275], ["residual", 1280], ["WED", 1289], ["/", 1292], ["RLS", 1293], ["(", 1297], ["p", 1298], ["=", 1300], ["0.008", 1302], [")", 1307], [".", 1308], ["Our", 1310], ["survey", 1314], ["showed", 1321], ["that", 1328], ["WED", 1333], ["/", 1336], ["RLS", 1337], ["was", 1341], ["more", 1345], ["common", 1350], ["in", 1357], ["the", 1360], ["second", 1364], ["and", 1371], ["third", 1375], ["trimesters", 1381], [".", 1391], ["Emergence", 1393], ["of", 1403], ["WED", 1406], ["/", 1409], ["RLS", 1410], ["during", 1414], ["the", 1421], ["second", 1425], ["trimester", 1432], ["was", 1442], ["strongly", 1446], ["associated", 1455], ["with", 1466], ["residual", 1471], ["WED", 1480], ["/", 1483], ["RLS", 1484], [".", 1487], ["Lower", 1489], ["ferritin", 1495], ["levels", 1504], ["were", 1511], ["associated", 1516], ["with", 1527], ["both", 1532], ["WED", 1537], ["/", 1540], ["RLS", 1541], ["in", 1545], ["pregnancy", 1548], ["and", 1558], ["residual", 1562], ["WED", 1571], ["/", 1574], ["RLS", 1575], ["after", 1579], ["delivery", 1585], [".", 1593], ["A", 1595], ["higher", 1597], ["number", 1604], ["of", 1611], ["pregnancies", 1614], ["were", 1626], ["also", 1631], ["associated", 1636], ["with", 1647], ["a", 1652], ["greater", 1654], ["likelihood", 1662], ["of", 1673], ["having", 1676], ["residual", 1683], ["WED", 1692], ["/", 1695], ["RLS", 1696], ["after", 1700], ["delivery", 1706], [".", 1714]]}
{"context": "Neuronal loss in specific brain regions and neurons with intracellular inclusions termed Lewy bodies are the pathologic hallmark in both Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Lewy bodies comprise of aggregated intracellular vesicles and proteins and \u03b1-synuclein is reported to be a major protein component. Using human brain tissue from control, PD and DLB and light and confocal immunohistochemistry with antibodies to superoxide dismutase 2 as a marker for mitochondria, \u03b1-synuclein for Lewy bodies and \u03b2III Tubulin for microtubules we have examined the relationship between Lewy bodies and mitochondrial loss. We have shown microtubule regression and mitochondrial and nuclear degradation in neurons with developing Lewy bodies. In PD, multiple Lewy bodies were often observed with \u03b1-synuclein interacting with DNA to cause marked nuclear degradation. In DLB, the mitochondria are drawn into the Lewy body and the mitochondrial integrity is lost. This work suggests that Lewy bodies are cytotoxic. In DLB, we suggest that microtubule regression and mitochondrial loss results in decreased cellular energy and axonal transport that leads to cell death. In PD, \u03b1-synuclein aggregations are associated with intact mitochondria but interacts with and causes nuclear degradation which may be the major cause of cell death.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "a26bb24d46114aeaa1d54858c6340119", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[134, 136], [201, 203], [45, 47], [84, 86]], "char_spans": [[809, 819], [1186, 1196], [274, 284], [497, 507]]}]}], "context_tokens": [["Neuronal", 0], ["loss", 9], ["in", 14], ["specific", 17], ["brain", 26], ["regions", 32], ["and", 40], ["neurons", 44], ["with", 52], ["intracellular", 57], ["inclusions", 71], ["termed", 82], ["Lewy", 89], ["bodies", 94], ["are", 101], ["the", 105], ["pathologic", 109], ["hallmark", 120], ["in", 129], ["both", 132], ["Parkinson", 137], ["'s", 146], ["disease", 149], ["(", 157], ["PD", 158], [")", 160], ["and", 162], ["dementia", 166], ["with", 175], ["Lewy", 180], ["bodies", 185], ["(", 192], ["DLB", 193], [")", 196], [".", 197], ["Lewy", 199], ["bodies", 204], ["comprise", 211], ["of", 220], ["aggregated", 223], ["intracellular", 234], ["vesicles", 248], ["and", 257], ["proteins", 261], ["and", 270], ["\u03b1", 274], ["-", 275], ["synuclein", 276], ["is", 286], ["reported", 289], ["to", 298], ["be", 301], ["a", 304], ["major", 306], ["protein", 312], ["component", 320], [".", 329], ["Using", 331], ["human", 337], ["brain", 343], ["tissue", 349], ["from", 356], ["control", 361], [",", 368], ["PD", 370], ["and", 373], ["DLB", 377], ["and", 381], ["light", 385], ["and", 391], ["confocal", 395], ["immunohistochemistry", 404], ["with", 425], ["antibodies", 430], ["to", 441], ["superoxide", 444], ["dismutase", 455], ["2", 465], ["as", 467], ["a", 470], ["marker", 472], ["for", 479], ["mitochondria", 483], [",", 495], ["\u03b1", 497], ["-", 498], ["synuclein", 499], ["for", 509], ["Lewy", 513], ["bodies", 518], ["and", 525], ["\u03b2III", 529], ["Tubulin", 534], ["for", 542], ["microtubules", 546], ["we", 559], ["have", 562], ["examined", 567], ["the", 576], ["relationship", 580], ["between", 593], ["Lewy", 601], ["bodies", 606], ["and", 613], ["mitochondrial", 617], ["loss", 631], [".", 635], ["We", 637], ["have", 640], ["shown", 645], ["microtubule", 651], ["regression", 663], ["and", 674], ["mitochondrial", 678], ["and", 692], ["nuclear", 696], ["degradation", 704], ["in", 716], ["neurons", 719], ["with", 727], ["developing", 732], ["Lewy", 743], ["bodies", 748], [".", 754], ["In", 756], ["PD", 759], [",", 761], ["multiple", 763], ["Lewy", 772], ["bodies", 777], ["were", 784], ["often", 789], ["observed", 795], ["with", 804], ["\u03b1", 809], ["-", 810], ["synuclein", 811], ["interacting", 821], ["with", 833], ["DNA", 838], ["to", 842], ["cause", 845], ["marked", 851], ["nuclear", 858], ["degradation", 866], [".", 877], ["In", 879], ["DLB", 882], [",", 885], ["the", 887], ["mitochondria", 891], ["are", 904], ["drawn", 908], ["into", 914], ["the", 919], ["Lewy", 923], ["body", 928], ["and", 933], ["the", 937], ["mitochondrial", 941], ["integrity", 955], ["is", 965], ["lost", 968], [".", 972], ["This", 974], ["work", 979], ["suggests", 984], ["that", 993], ["Lewy", 998], ["bodies", 1003], ["are", 1010], ["cytotoxic", 1014], [".", 1023], ["In", 1025], ["DLB", 1028], [",", 1031], ["we", 1033], ["suggest", 1036], ["that", 1044], ["microtubule", 1049], ["regression", 1061], ["and", 1072], ["mitochondrial", 1076], ["loss", 1090], ["results", 1095], ["in", 1103], ["decreased", 1106], ["cellular", 1116], ["energy", 1125], ["and", 1132], ["axonal", 1136], ["transport", 1143], ["that", 1153], ["leads", 1158], ["to", 1164], ["cell", 1167], ["death", 1172], [".", 1177], ["In", 1179], ["PD", 1182], [",", 1184], ["\u03b1", 1186], ["-", 1187], ["synuclein", 1188], ["aggregations", 1198], ["are", 1211], ["associated", 1215], ["with", 1226], ["intact", 1231], ["mitochondria", 1238], ["but", 1251], ["interacts", 1255], ["with", 1265], ["and", 1270], ["causes", 1274], ["nuclear", 1281], ["degradation", 1289], ["which", 1301], ["may", 1307], ["be", 1311], ["the", 1314], ["major", 1318], ["cause", 1324], ["of", 1330], ["cell", 1333], ["death", 1338], [".", 1343]]}
{"context": "Bone pain is a common symptom in bone metastases. The therapies that are currently available include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, steroids and gabapentin which have been demonstrated to improve neuropathic pain. In addition, preclinical studies indicate that agents such as transient receptor potential vanilloid 1 antagonists and cannabinoid 2 receptor agonist could be considered as adjuncts in ameliorating opioid side effects. New drugs are in the clinical phase of development, among which the most promising molecules seem to be anti-nerve growth factor (NGF) antibodies. Anti-NGF antibody therapy may be particularly effective in blocking bone cancer pain because NGF appears to be integrally involved in the upregulation, sensitization and disinhibition of multiple neurotransmitters, ion channels and receptors in the primary afferent nerve. The best way to treat bone metastases pain is to improve the control of skeletal disease burden. Recently, denosumab, a noncytotoxic IgG2 monoclonal antibody with high affinity for human RANKL, has been demonstrated to significantly prevent clinically relevant increase in pain compared with zoledronic acid across the tumor types. Based on these data, it has been suggested that denosumab has the potential to become a new standard of treatment in bone metastases management.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "19f21e68fc4946c181d7758601dee5d5", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[175, 175]], "char_spans": [[1065, 1069]]}]}], "context_tokens": [["Bone", 0], ["pain", 5], ["is", 10], ["a", 13], ["common", 15], ["symptom", 22], ["in", 30], ["bone", 33], ["metastases", 38], [".", 48], ["The", 50], ["therapies", 54], ["that", 64], ["are", 69], ["currently", 73], ["available", 83], ["include", 93], ["nonsteroidal", 101], ["anti", 114], ["-", 118], ["inflammatory", 119], ["drugs", 132], ["(", 138], ["NSAIDs", 139], [")", 145], [",", 146], ["opioids", 148], [",", 155], ["steroids", 157], ["and", 166], ["gabapentin", 170], ["which", 181], ["have", 187], ["been", 192], ["demonstrated", 197], ["to", 210], ["improve", 213], ["neuropathic", 221], ["pain", 233], [".", 237], ["In", 239], ["addition", 242], [",", 250], ["preclinical", 252], ["studies", 264], ["indicate", 272], ["that", 281], ["agents", 286], ["such", 293], ["as", 298], ["transient", 301], ["receptor", 311], ["potential", 320], ["vanilloid", 330], ["1", 340], ["antagonists", 342], ["and", 354], ["cannabinoid", 358], ["2", 370], ["receptor", 372], ["agonist", 381], ["could", 389], ["be", 395], ["considered", 398], ["as", 409], ["adjuncts", 412], ["in", 421], ["ameliorating", 424], ["opioid", 437], ["side", 444], ["effects", 449], [".", 456], ["New", 458], ["drugs", 462], ["are", 468], ["in", 472], ["the", 475], ["clinical", 479], ["phase", 488], ["of", 494], ["development", 497], [",", 508], ["among", 510], ["which", 516], ["the", 522], ["most", 526], ["promising", 531], ["molecules", 541], ["seem", 551], ["to", 556], ["be", 559], ["anti", 562], ["-", 566], ["nerve", 567], ["growth", 573], ["factor", 580], ["(", 587], ["NGF", 588], [")", 591], ["antibodies", 593], [".", 603], ["Anti", 605], ["-", 609], ["NGF", 610], ["antibody", 614], ["therapy", 623], ["may", 631], ["be", 635], ["particularly", 638], ["effective", 651], ["in", 661], ["blocking", 664], ["bone", 673], ["cancer", 678], ["pain", 685], ["because", 690], ["NGF", 698], ["appears", 702], ["to", 710], ["be", 713], ["integrally", 716], ["involved", 727], ["in", 736], ["the", 739], ["upregulation", 743], [",", 755], ["sensitization", 757], ["and", 771], ["disinhibition", 775], ["of", 789], ["multiple", 792], ["neurotransmitters", 801], [",", 818], ["ion", 820], ["channels", 824], ["and", 833], ["receptors", 837], ["in", 847], ["the", 850], ["primary", 854], ["afferent", 862], ["nerve", 871], [".", 876], ["The", 878], ["best", 882], ["way", 887], ["to", 891], ["treat", 894], ["bone", 900], ["metastases", 905], ["pain", 916], ["is", 921], ["to", 924], ["improve", 927], ["the", 935], ["control", 939], ["of", 947], ["skeletal", 950], ["disease", 959], ["burden", 967], [".", 973], ["Recently", 975], [",", 983], ["denosumab", 985], [",", 994], ["a", 996], ["noncytotoxic", 998], ["IgG2", 1011], ["monoclonal", 1016], ["antibody", 1027], ["with", 1036], ["high", 1041], ["affinity", 1046], ["for", 1055], ["human", 1059], ["RANKL", 1065], [",", 1070], ["has", 1072], ["been", 1076], ["demonstrated", 1081], ["to", 1094], ["significantly", 1097], ["prevent", 1111], ["clinically", 1119], ["relevant", 1130], ["increase", 1139], ["in", 1148], ["pain", 1151], ["compared", 1156], ["with", 1165], ["zoledronic", 1170], ["acid", 1181], ["across", 1186], ["the", 1193], ["tumor", 1197], ["types", 1203], [".", 1208], ["Based", 1210], ["on", 1216], ["these", 1219], ["data", 1225], [",", 1229], ["it", 1231], ["has", 1234], ["been", 1238], ["suggested", 1243], ["that", 1253], ["denosumab", 1258], ["has", 1268], ["the", 1272], ["potential", 1276], ["to", 1286], ["become", 1289], ["a", 1296], ["new", 1298], ["standard", 1302], ["of", 1311], ["treatment", 1314], ["in", 1324], ["bone", 1327], ["metastases", 1332], ["management", 1343], [".", 1353]]}
{"context": "The mature central nervous system contains precursor cells in the subventricular zone of the lateral ventricle. In this study we examined the possibility to affect fate of precursor cells through exogenous manipulations. The results indicate that administration of thyroid hormone and retinoic acid increases the expression of Ki67, a nuclear antigen associated with cell proliferation, and of nestin, a marker protein for precursor cells in the subventricular zone of adult male rats. Moreover, retinoic acid increases polysialated-neural cell adhesion molecules (PSA-NCAM)-immunoreactivity. These data suggest that nuclear receptor ligands are potential candidates for fate determination of precursor cells in the subventricular zone also in the adult brain.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "2a963d7335cb4cfa9452f4ded58a357f", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[61, 61]], "char_spans": [[394, 399]]}]}], "context_tokens": [["The", 0], ["mature", 4], ["central", 11], ["nervous", 19], ["system", 27], ["contains", 34], ["precursor", 43], ["cells", 53], ["in", 59], ["the", 62], ["subventricular", 66], ["zone", 81], ["of", 86], ["the", 89], ["lateral", 93], ["ventricle", 101], [".", 110], ["In", 112], ["this", 115], ["study", 120], ["we", 126], ["examined", 129], ["the", 138], ["possibility", 142], ["to", 154], ["affect", 157], ["fate", 164], ["of", 169], ["precursor", 172], ["cells", 182], ["through", 188], ["exogenous", 196], ["manipulations", 206], [".", 219], ["The", 221], ["results", 225], ["indicate", 233], ["that", 242], ["administration", 247], ["of", 262], ["thyroid", 265], ["hormone", 273], ["and", 281], ["retinoic", 285], ["acid", 294], ["increases", 299], ["the", 309], ["expression", 313], ["of", 324], ["Ki67", 327], [",", 331], ["a", 333], ["nuclear", 335], ["antigen", 343], ["associated", 351], ["with", 362], ["cell", 367], ["proliferation", 372], [",", 385], ["and", 387], ["of", 391], ["nestin", 394], [",", 400], ["a", 402], ["marker", 404], ["protein", 411], ["for", 419], ["precursor", 423], ["cells", 433], ["in", 439], ["the", 442], ["subventricular", 446], ["zone", 461], ["of", 466], ["adult", 469], ["male", 475], ["rats", 480], [".", 484], ["Moreover", 486], [",", 494], ["retinoic", 496], ["acid", 505], ["increases", 510], ["polysialated", 520], ["-", 532], ["neural", 533], ["cell", 540], ["adhesion", 545], ["molecules", 554], ["(", 564], ["PSA", 565], ["-", 568], ["NCAM)-immunoreactivity", 569], [".", 591], ["These", 593], ["data", 599], ["suggest", 604], ["that", 612], ["nuclear", 617], ["receptor", 625], ["ligands", 634], ["are", 642], ["potential", 646], ["candidates", 656], ["for", 667], ["fate", 671], ["determination", 676], ["of", 690], ["precursor", 693], ["cells", 703], ["in", 709], ["the", 712], ["subventricular", 716], ["zone", 731], ["also", 736], ["in", 741], ["the", 744], ["adult", 748], ["brain", 754], [".", 759]]}
{"context": "Methylation of lysine 9 (K9) in the N-terminus tail of histone H3 (H3) in chromatin is associated with transcriptionally silenced genes and is mediated by histone methyltransferases. Murine G9a is a 1263 amino acid H3-K9 methyltransferase that possesses characteristic SET domain and ANK repeats. In this paper, we have used a series of green fluorescent protein-tagged deletion constructs to identify two nuclear localization signals (NLS), the first NLS embedded between amino acids 24 and 109 and the second between amino acids 394 and 401 of murine G9a. Our data show that both long and short G9a isoforms were capable of entering the nucleus to methylate chromatin. Full-length or N-terminus-deleted G9a isoforms were also catalytically active enzymes that methylated recombinant H3 or synthetic peptides representing the N-terminus tail of H3. In vitro methylation reactions using N-terminus tail peptides resulted in tri-methylation of K9 that remained processive, even in G9a enzymes that lacked an N-terminus region by deletion. Co-expression of G9a and H3 resulted in di- and tri-methylation of H3-K9, while siRNA-mediated knockdown of G9a in HeLa cells resulted in reduction of global H3-K9 di- and tri-methylation. A recombinant deletion mutant enzyme fused with maltose-binding protein (MBP-G9aDelta634) was used for steady-state kinetic analysis with various substrates and was compared with full-length G9a (G9aFL). Turnover numbers of MBP-G9aDelta634 for various substrates was approximately 3-fold less compared with G9aFL, while their Michaelis constants (K(m)) for recombinant H3 were similar. The K(AdoMet)m for MBP-G9aDelta634 was approximately 2.3-2.65 microM with various substrates. Catalytic efficiencies (kcat/K(m)) for both MBP-G9aDelta634 and G9aFL were similar, suggesting that the N-terminus is not essential for catalysis. Furthermore, mutation of conserved amino acids R1097A, W1103A, Y1120A, Y1138A and R1162A, or the metal binding C1168A in the catalytic region, resulted in catalytically impaired enzymes, thereby confirming the involvement of the C-terminus of G9a in catalysis. Thus, distinct domains modulate nuclear targeting and catalytic functions of G9a.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "e57c68a8293d462f9fdab7bb2767c729", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[46, 47]], "char_spans": [[269, 278]]}]}], "context_tokens": [["Methylation", 0], ["of", 12], ["lysine", 15], ["9", 22], ["(", 24], ["K9", 25], [")", 27], ["in", 29], ["the", 32], ["N", 36], ["-", 37], ["terminus", 38], ["tail", 47], ["of", 52], ["histone", 55], ["H3", 63], ["(", 66], ["H3", 67], [")", 69], ["in", 71], ["chromatin", 74], ["is", 84], ["associated", 87], ["with", 98], ["transcriptionally", 103], ["silenced", 121], ["genes", 130], ["and", 136], ["is", 140], ["mediated", 143], ["by", 152], ["histone", 155], ["methyltransferases", 163], [".", 181], ["Murine", 183], ["G9a", 190], ["is", 194], ["a", 197], ["1263", 199], ["amino", 204], ["acid", 210], ["H3-K9", 215], ["methyltransferase", 221], ["that", 239], ["possesses", 244], ["characteristic", 254], ["SET", 269], ["domain", 273], ["and", 280], ["ANK", 284], ["repeats", 288], [".", 295], ["In", 297], ["this", 300], ["paper", 305], [",", 310], ["we", 312], ["have", 315], ["used", 320], ["a", 325], ["series", 327], ["of", 334], ["green", 337], ["fluorescent", 343], ["protein", 355], ["-", 362], ["tagged", 363], ["deletion", 370], ["constructs", 379], ["to", 390], ["identify", 393], ["two", 402], ["nuclear", 406], ["localization", 414], ["signals", 427], ["(", 435], ["NLS", 436], [")", 439], [",", 440], ["the", 442], ["first", 446], ["NLS", 452], ["embedded", 456], ["between", 465], ["amino", 473], ["acids", 479], ["24", 485], ["and", 488], ["109", 492], ["and", 496], ["the", 500], ["second", 504], ["between", 511], ["amino", 519], ["acids", 525], ["394", 531], ["and", 535], ["401", 539], ["of", 543], ["murine", 546], ["G9a", 553], [".", 556], ["Our", 558], ["data", 562], ["show", 567], ["that", 572], ["both", 577], ["long", 582], ["and", 587], ["short", 591], ["G9a", 597], ["isoforms", 601], ["were", 610], ["capable", 615], ["of", 623], ["entering", 626], ["the", 635], ["nucleus", 639], ["to", 647], ["methylate", 650], ["chromatin", 660], [".", 669], ["Full", 671], ["-", 675], ["length", 676], ["or", 683], ["N", 686], ["-", 687], ["terminus", 688], ["-", 696], ["deleted", 697], ["G9a", 705], ["isoforms", 709], ["were", 718], ["also", 723], ["catalytically", 728], ["active", 742], ["enzymes", 749], ["that", 757], ["methylated", 762], ["recombinant", 773], ["H3", 785], ["or", 788], ["synthetic", 791], ["peptides", 801], ["representing", 810], ["the", 823], ["N", 827], ["-", 828], ["terminus", 829], ["tail", 838], ["of", 843], ["H3", 846], [".", 848], ["In", 850], ["vitro", 853], ["methylation", 859], ["reactions", 871], ["using", 881], ["N", 887], ["-", 888], ["terminus", 889], ["tail", 898], ["peptides", 903], ["resulted", 912], ["in", 921], ["tri", 924], ["-", 927], ["methylation", 928], ["of", 940], ["K9", 943], ["that", 946], ["remained", 951], ["processive", 960], [",", 970], ["even", 972], ["in", 977], ["G9a", 980], ["enzymes", 984], ["that", 992], ["lacked", 997], ["an", 1004], ["N", 1007], ["-", 1008], ["terminus", 1009], ["region", 1018], ["by", 1025], ["deletion", 1028], [".", 1036], ["Co", 1038], ["-", 1040], ["expression", 1041], ["of", 1052], ["G9a", 1055], ["and", 1059], ["H3", 1063], ["resulted", 1066], ["in", 1075], ["di-", 1078], ["and", 1082], ["tri", 1086], ["-", 1089], ["methylation", 1090], ["of", 1102], ["H3-K9", 1105], [",", 1110], ["while", 1112], ["siRNA", 1118], ["-", 1123], ["mediated", 1124], ["knockdown", 1133], ["of", 1143], ["G9a", 1146], ["in", 1150], ["HeLa", 1153], ["cells", 1158], ["resulted", 1164], ["in", 1173], ["reduction", 1176], ["of", 1186], ["global", 1189], ["H3-K9", 1196], ["di-", 1202], ["and", 1206], ["tri", 1210], ["-", 1213], ["methylation", 1214], [".", 1225], ["A", 1227], ["recombinant", 1229], ["deletion", 1241], ["mutant", 1250], ["enzyme", 1257], ["fused", 1264], ["with", 1270], ["maltose", 1275], ["-", 1282], ["binding", 1283], ["protein", 1291], ["(", 1299], ["MBP", 1300], ["-", 1303], ["G9aDelta634", 1304], [")", 1315], ["was", 1317], ["used", 1321], ["for", 1326], ["steady", 1330], ["-", 1336], ["state", 1337], ["kinetic", 1343], ["analysis", 1351], ["with", 1360], ["various", 1365], ["substrates", 1373], ["and", 1384], ["was", 1388], ["compared", 1392], ["with", 1401], ["full", 1406], ["-", 1410], ["length", 1411], ["G9a", 1418], ["(", 1422], ["G9aFL", 1423], [")", 1428], [".", 1429], ["Turnover", 1431], ["numbers", 1440], ["of", 1448], ["MBP", 1451], ["-", 1454], ["G9aDelta634", 1455], ["for", 1467], ["various", 1471], ["substrates", 1479], ["was", 1490], ["approximately", 1494], ["3-fold", 1508], ["less", 1515], ["compared", 1520], ["with", 1529], ["G9aFL", 1534], [",", 1539], ["while", 1541], ["their", 1547], ["Michaelis", 1553], ["constants", 1563], ["(", 1573], ["K(m", 1574], [")", 1577], [")", 1578], ["for", 1580], ["recombinant", 1584], ["H3", 1596], ["were", 1599], ["similar", 1604], [".", 1611], ["The", 1613], ["K(AdoMet)m", 1617], ["for", 1628], ["MBP", 1632], ["-", 1635], ["G9aDelta634", 1636], ["was", 1648], ["approximately", 1652], ["2.3", 1666], ["-", 1669], ["2.65", 1670], ["microM", 1675], ["with", 1682], ["various", 1687], ["substrates", 1695], [".", 1705], ["Catalytic", 1707], ["efficiencies", 1717], ["(", 1730], ["kcat", 1731], ["/", 1735], ["K(m", 1736], [")", 1739], [")", 1740], ["for", 1742], ["both", 1746], ["MBP", 1751], ["-", 1754], ["G9aDelta634", 1755], ["and", 1767], ["G9aFL", 1771], ["were", 1777], ["similar", 1782], [",", 1789], ["suggesting", 1791], ["that", 1802], ["the", 1807], ["N", 1811], ["-", 1812], ["terminus", 1813], ["is", 1822], ["not", 1825], ["essential", 1829], ["for", 1839], ["catalysis", 1843], [".", 1852], ["Furthermore", 1854], [",", 1865], ["mutation", 1867], ["of", 1876], ["conserved", 1879], ["amino", 1889], ["acids", 1895], ["R1097A", 1901], [",", 1907], ["W1103A", 1909], [",", 1915], ["Y1120A", 1917], [",", 1923], ["Y1138A", 1925], ["and", 1932], ["R1162A", 1936], [",", 1942], ["or", 1944], ["the", 1947], ["metal", 1951], ["binding", 1957], ["C1168A", 1965], ["in", 1972], ["the", 1975], ["catalytic", 1979], ["region", 1989], [",", 1995], ["resulted", 1997], ["in", 2006], ["catalytically", 2009], ["impaired", 2023], ["enzymes", 2032], [",", 2039], ["thereby", 2041], ["confirming", 2049], ["the", 2060], ["involvement", 2064], ["of", 2076], ["the", 2079], ["C", 2083], ["-", 2084], ["terminus", 2085], ["of", 2094], ["G9a", 2097], ["in", 2101], ["catalysis", 2104], [".", 2113], ["Thus", 2115], [",", 2119], ["distinct", 2121], ["domains", 2130], ["modulate", 2138], ["nuclear", 2147], ["targeting", 2155], ["and", 2165], ["catalytic", 2169], ["functions", 2179], ["of", 2189], ["G9a", 2192], [".", 2195]]}
{"context": "In yeast, the macromolecular complex Set1/COMPASS is capable of methylating H3K4, a posttranslational modification associated with actively transcribed genes. There is only one Set1 in yeast; yet in mammalian cells there are multiple H3K4 methylases, including Set1A/B, forming human COMPASS complexes, and MLL1-4, forming human COMPASS-like complexes. We have shown that Wdr82, which associates with chromatin in a histone H2B ubiquitination-dependent manner, is a specific component of Set1 complexes but not that of MLL1-4 complexes. RNA interference-mediated knockdown of Wdr82 results in a reduction in the H3K4 trimethylation levels, although these cells still possess active MLL complexes. Comprehensive in vitro enzymatic studies with Set1 and MLL complexes demonstrated that the Set1 complex is a more robust H3K4 trimethylase in vitro than the MLL complexes. Given our in vivo and in vitro observations, it appears that the human Set1 complex plays a more widespread role in H3K4 trimethylation than do the MLL complexes in mammalian cells.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "66e99ba7d17c47c9b3445238952287b4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[37, 37], [173, 173], [11, 11], [142, 142], [110, 110]], "char_spans": [[234, 237], [985, 988], [76, 79], [818, 821], [612, 615]]}]}], "context_tokens": [["In", 0], ["yeast", 3], [",", 8], ["the", 10], ["macromolecular", 14], ["complex", 29], ["Set1/COMPASS", 37], ["is", 50], ["capable", 53], ["of", 61], ["methylating", 64], ["H3K4", 76], [",", 80], ["a", 82], ["posttranslational", 84], ["modification", 102], ["associated", 115], ["with", 126], ["actively", 131], ["transcribed", 140], ["genes", 152], [".", 157], ["There", 159], ["is", 165], ["only", 168], ["one", 173], ["Set1", 177], ["in", 182], ["yeast", 185], [";", 190], ["yet", 192], ["in", 196], ["mammalian", 199], ["cells", 209], ["there", 215], ["are", 221], ["multiple", 225], ["H3K4", 234], ["methylases", 239], [",", 249], ["including", 251], ["Set1A", 261], ["/", 266], ["B", 267], [",", 268], ["forming", 270], ["human", 278], ["COMPASS", 284], ["complexes", 292], [",", 301], ["and", 303], ["MLL1", 307], ["-", 311], ["4", 312], [",", 313], ["forming", 315], ["human", 323], ["COMPASS", 329], ["-", 336], ["like", 337], ["complexes", 342], [".", 351], ["We", 353], ["have", 356], ["shown", 361], ["that", 367], ["Wdr82", 372], [",", 377], ["which", 379], ["associates", 385], ["with", 396], ["chromatin", 401], ["in", 411], ["a", 414], ["histone", 416], ["H2B", 424], ["ubiquitination", 428], ["-", 442], ["dependent", 443], ["manner", 453], [",", 459], ["is", 461], ["a", 464], ["specific", 466], ["component", 475], ["of", 485], ["Set1", 488], ["complexes", 493], ["but", 503], ["not", 507], ["that", 511], ["of", 516], ["MLL1", 519], ["-", 523], ["4", 524], ["complexes", 526], [".", 535], ["RNA", 537], ["interference", 541], ["-", 553], ["mediated", 554], ["knockdown", 563], ["of", 573], ["Wdr82", 576], ["results", 582], ["in", 590], ["a", 593], ["reduction", 595], ["in", 605], ["the", 608], ["H3K4", 612], ["trimethylation", 617], ["levels", 632], [",", 638], ["although", 640], ["these", 649], ["cells", 655], ["still", 661], ["possess", 667], ["active", 675], ["MLL", 682], ["complexes", 686], [".", 695], ["Comprehensive", 697], ["in", 711], ["vitro", 714], ["enzymatic", 720], ["studies", 730], ["with", 738], ["Set1", 743], ["and", 748], ["MLL", 752], ["complexes", 756], ["demonstrated", 766], ["that", 779], ["the", 784], ["Set1", 788], ["complex", 793], ["is", 801], ["a", 804], ["more", 806], ["robust", 811], ["H3K4", 818], ["trimethylase", 823], ["in", 836], ["vitro", 839], ["than", 845], ["the", 850], ["MLL", 854], ["complexes", 858], [".", 867], ["Given", 869], ["our", 875], ["in", 879], ["vivo", 882], ["and", 887], ["in", 891], ["vitro", 894], ["observations", 900], [",", 912], ["it", 914], ["appears", 917], ["that", 925], ["the", 930], ["human", 934], ["Set1", 940], ["complex", 945], ["plays", 953], ["a", 959], ["more", 961], ["widespread", 966], ["role", 977], ["in", 982], ["H3K4", 985], ["trimethylation", 990], ["than", 1005], ["do", 1010], ["the", 1013], ["MLL", 1017], ["complexes", 1021], ["in", 1031], ["mammalian", 1034], ["cells", 1044], [".", 1049]]}
{"context": "The Shprintzen-Goldberg syndrome is an extremely rare syndrome with a characteristic face. This is one of a group of disorders characterized by craniosynostosis and marfanoid features. The aim of this study was to present a new sporadic case of the syndrome and describe in detail the findings at the maxillofacial region.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "0e334455b93e49ba8dc2280657d82443", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[25, 25]], "char_spans": [[144, 159]]}]}], "context_tokens": [["The", 0], ["Shprintzen", 4], ["-", 14], ["Goldberg", 15], ["syndrome", 24], ["is", 33], ["an", 36], ["extremely", 39], ["rare", 49], ["syndrome", 54], ["with", 63], ["a", 68], ["characteristic", 70], ["face", 85], [".", 89], ["This", 91], ["is", 96], ["one", 99], ["of", 103], ["a", 106], ["group", 108], ["of", 114], ["disorders", 117], ["characterized", 127], ["by", 141], ["craniosynostosis", 144], ["and", 161], ["marfanoid", 165], ["features", 175], [".", 183], ["The", 185], ["aim", 189], ["of", 193], ["this", 196], ["study", 201], ["was", 207], ["to", 211], ["present", 214], ["a", 222], ["new", 224], ["sporadic", 228], ["case", 237], ["of", 242], ["the", 245], ["syndrome", 249], ["and", 258], ["describe", 262], ["in", 271], ["detail", 274], ["the", 281], ["findings", 285], ["at", 294], ["the", 297], ["maxillofacial", 301], ["region", 315], [".", 321]]}
{"context": "Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED) is a common condition characterized by an irresistible urge to move the legs, concomitant with an unpleasant sensation in the lower limbs, which is typically relieved by movement. Symptoms occur predominantly at rest and prevail in the afternoon or evening. Treatment of patients with RLS/WED is indicated for those patients who suffer from clinically relevant symptoms. The management of mild forms of RLS/WED is mainly based on dopamine agonists (DA) therapy (including pramipexole and ropinirole) and \u03b1-2-\u03b4 calcium-channel ligand. Nevertheless, with passing of time, symptoms tend to become more severe and the patient can eventually develop pharmacoresistance. Furthermore, long-term treatment with dopaminergic agents may be complicated by the development of augmentation, which is defined by an increase in the severity and frequency of RLS/WED symptoms despite adequate treatment. Here, we discuss which are the best therapeutic options when RLS/WED becomes intractable, with a focus on advantages and side effects of the available medications. Prevention strategies include managing lifestyle changes and a good sleep hygiene. Different drug options are available. Switching to longer-acting dopaminergic agents may be a possibility if the patient is well-tolerating DA treatment. An association with \u03b1-2-\u03b4 calcium-channel ligand is another first-line approach. In refractory RLS/WED, opioids such as oxycodone-naloxone have demonstrated good efficacy. Other pharmacological approaches include IV iron, benzodiazepines such as clonazepam, and antiepileptic drugs, with different level of evidence of efficacy. Therefore, the final decision regarding the agent to use in treating severe RLS/WED symptoms should be tailored to the patient, taking into account the symptomatology, comorbidities, the availability of treatment and the history of the disease.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "57c7f4ca7dcc421f8be58691a3878467", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["Legs", 9], ["Syndrome", 14], ["/", 22], ["Willis", 23], ["-", 29], ["Ekbom", 30], ["Disease", 36], ["(", 44], ["RLS", 45], ["/", 48], ["WED", 49], [")", 52], ["is", 54], ["a", 57], ["common", 59], ["condition", 66], ["characterized", 76], ["by", 90], ["an", 93], ["irresistible", 96], ["urge", 109], ["to", 114], ["move", 117], ["the", 122], ["legs", 126], [",", 130], ["concomitant", 132], ["with", 144], ["an", 149], ["unpleasant", 152], ["sensation", 163], ["in", 173], ["the", 176], ["lower", 180], ["limbs", 186], [",", 191], ["which", 193], ["is", 199], ["typically", 202], ["relieved", 212], ["by", 221], ["movement", 224], [".", 232], ["Symptoms", 234], ["occur", 243], ["predominantly", 249], ["at", 263], ["rest", 266], ["and", 271], ["prevail", 275], ["in", 283], ["the", 286], ["afternoon", 290], ["or", 300], ["evening", 303], [".", 310], ["Treatment", 312], ["of", 322], ["patients", 325], ["with", 334], ["RLS", 339], ["/", 342], ["WED", 343], ["is", 347], ["indicated", 350], ["for", 360], ["those", 364], ["patients", 370], ["who", 379], ["suffer", 383], ["from", 390], ["clinically", 395], ["relevant", 406], ["symptoms", 415], [".", 423], ["The", 425], ["management", 429], ["of", 440], ["mild", 443], ["forms", 448], ["of", 454], ["RLS", 457], ["/", 460], ["WED", 461], ["is", 465], ["mainly", 468], ["based", 475], ["on", 481], ["dopamine", 484], ["agonists", 493], ["(", 502], ["DA", 503], [")", 505], ["therapy", 507], ["(", 515], ["including", 516], ["pramipexole", 526], ["and", 538], ["ropinirole", 542], [")", 552], ["and", 554], ["\u03b1-2-\u03b4", 558], ["calcium", 564], ["-", 571], ["channel", 572], ["ligand", 580], [".", 586], ["Nevertheless", 588], [",", 600], ["with", 602], ["passing", 607], ["of", 615], ["time", 618], [",", 622], ["symptoms", 624], ["tend", 633], ["to", 638], ["become", 641], ["more", 648], ["severe", 653], ["and", 660], ["the", 664], ["patient", 668], ["can", 676], ["eventually", 680], ["develop", 691], ["pharmacoresistance", 699], [".", 717], ["Furthermore", 719], [",", 730], ["long", 732], ["-", 736], ["term", 737], ["treatment", 742], ["with", 752], ["dopaminergic", 757], ["agents", 770], ["may", 777], ["be", 781], ["complicated", 784], ["by", 796], ["the", 799], ["development", 803], ["of", 815], ["augmentation", 818], [",", 830], ["which", 832], ["is", 838], ["defined", 841], ["by", 849], ["an", 852], ["increase", 855], ["in", 864], ["the", 867], ["severity", 871], ["and", 880], ["frequency", 884], ["of", 894], ["RLS", 897], ["/", 900], ["WED", 901], ["symptoms", 905], ["despite", 914], ["adequate", 922], ["treatment", 931], [".", 940], ["Here", 942], [",", 946], ["we", 948], ["discuss", 951], ["which", 959], ["are", 965], ["the", 969], ["best", 973], ["therapeutic", 978], ["options", 990], ["when", 998], ["RLS", 1003], ["/", 1006], ["WED", 1007], ["becomes", 1011], ["intractable", 1019], [",", 1030], ["with", 1032], ["a", 1037], ["focus", 1039], ["on", 1045], ["advantages", 1048], ["and", 1059], ["side", 1063], ["effects", 1068], ["of", 1076], ["the", 1079], ["available", 1083], ["medications", 1093], [".", 1104], ["Prevention", 1106], ["strategies", 1117], ["include", 1128], ["managing", 1136], ["lifestyle", 1145], ["changes", 1155], ["and", 1163], ["a", 1167], ["good", 1169], ["sleep", 1174], ["hygiene", 1180], [".", 1187], ["Different", 1189], ["drug", 1199], ["options", 1204], ["are", 1212], ["available", 1216], [".", 1225], ["Switching", 1227], ["to", 1237], ["longer", 1240], ["-", 1246], ["acting", 1247], ["dopaminergic", 1254], ["agents", 1267], ["may", 1274], ["be", 1278], ["a", 1281], ["possibility", 1283], ["if", 1295], ["the", 1298], ["patient", 1302], ["is", 1310], ["well", 1313], ["-", 1317], ["tolerating", 1318], ["DA", 1329], ["treatment", 1332], [".", 1341], ["An", 1343], ["association", 1346], ["with", 1358], ["\u03b1-2-\u03b4", 1363], ["calcium", 1369], ["-", 1376], ["channel", 1377], ["ligand", 1385], ["is", 1392], ["another", 1395], ["first", 1403], ["-", 1408], ["line", 1409], ["approach", 1414], [".", 1422], ["In", 1424], ["refractory", 1427], ["RLS", 1438], ["/", 1441], ["WED", 1442], [",", 1445], ["opioids", 1447], ["such", 1455], ["as", 1460], ["oxycodone", 1463], ["-", 1472], ["naloxone", 1473], ["have", 1482], ["demonstrated", 1487], ["good", 1500], ["efficacy", 1505], [".", 1513], ["Other", 1515], ["pharmacological", 1521], ["approaches", 1537], ["include", 1548], ["IV", 1556], ["iron", 1559], [",", 1563], ["benzodiazepines", 1565], ["such", 1581], ["as", 1586], ["clonazepam", 1589], [",", 1599], ["and", 1601], ["antiepileptic", 1605], ["drugs", 1619], [",", 1624], ["with", 1626], ["different", 1631], ["level", 1641], ["of", 1647], ["evidence", 1650], ["of", 1659], ["efficacy", 1662], [".", 1670], ["Therefore", 1672], [",", 1681], ["the", 1683], ["final", 1687], ["decision", 1693], ["regarding", 1702], ["the", 1712], ["agent", 1716], ["to", 1722], ["use", 1725], ["in", 1729], ["treating", 1732], ["severe", 1741], ["RLS", 1748], ["/", 1751], ["WED", 1752], ["symptoms", 1756], ["should", 1765], ["be", 1772], ["tailored", 1775], ["to", 1784], ["the", 1787], ["patient", 1791], [",", 1798], ["taking", 1800], ["into", 1807], ["account", 1812], ["the", 1820], ["symptomatology", 1824], [",", 1838], ["comorbidities", 1840], [",", 1853], ["the", 1855], ["availability", 1859], ["of", 1872], ["treatment", 1875], ["and", 1885], ["the", 1889], ["history", 1893], ["of", 1901], ["the", 1904], ["disease", 1908], [".", 1915]]}
{"context": "The gene encoding the ribosomal protein S19 (RPS19) is frequently mutated in Diamond-Blackfan anemia (DBA), a congenital erythroblastopenia. The consequence of these mutations on the onset of the disease remains obscure. Here, we show that RPS19 plays an essential role in biogenesis of the 40S small ribosomal subunit in human cells. Knockdown of RPS19 expression by siRNAs impairs 18S rRNA synthesis and formation of 40S subunits and induces apoptosis in HeLa cells. Pre-rRNA processing is altered, which leads to an arrest in the maturation of precursors to the 18S rRNA. Under these conditions, pre-40S particles are not exported to the cytoplasm and accumulate in the nucleoplasm of the cells in perinuclear dots. Consistently, we find that ribosome biogenesis and nucleolar organization is altered in skin fibroblasts from DBA patients bearing mutations in the RPS19 gene. In addition, maturation of the 18S rRNA is also perturbed in cells from a patient bearing no RPS19-related mutation. These results support the hypothesis that DBA is directly related to a defect in ribosome biogenesis and indicate that yet to be discovered DBA-related genes may be involved in the synthesis of the ribosomal subunits.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "85af34b4c81f4eee8ca3336339fad285", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[14, 17]], "char_spans": [[77, 99]]}, {"text": "DBA", "token_spans": [[182, 182], [19, 19], [199, 199], [146, 146]], "char_spans": [[1038, 1040], [102, 104], [1136, 1138], [829, 831]]}]}], "context_tokens": [["The", 0], ["gene", 4], ["encoding", 9], ["the", 18], ["ribosomal", 22], ["protein", 32], ["S19", 40], ["(", 44], ["RPS19", 45], [")", 50], ["is", 52], ["frequently", 55], ["mutated", 66], ["in", 74], ["Diamond", 77], ["-", 84], ["Blackfan", 85], ["anemia", 94], ["(", 101], ["DBA", 102], [")", 105], [",", 106], ["a", 108], ["congenital", 110], ["erythroblastopenia", 121], [".", 139], ["The", 141], ["consequence", 145], ["of", 157], ["these", 160], ["mutations", 166], ["on", 176], ["the", 179], ["onset", 183], ["of", 189], ["the", 192], ["disease", 196], ["remains", 204], ["obscure", 212], [".", 219], ["Here", 221], [",", 225], ["we", 227], ["show", 230], ["that", 235], ["RPS19", 240], ["plays", 246], ["an", 252], ["essential", 255], ["role", 265], ["in", 270], ["biogenesis", 273], ["of", 284], ["the", 287], ["40S", 291], ["small", 295], ["ribosomal", 301], ["subunit", 311], ["in", 319], ["human", 322], ["cells", 328], [".", 333], ["Knockdown", 335], ["of", 345], ["RPS19", 348], ["expression", 354], ["by", 365], ["siRNAs", 368], ["impairs", 375], ["18S", 383], ["rRNA", 387], ["synthesis", 392], ["and", 402], ["formation", 406], ["of", 416], ["40S", 419], ["subunits", 423], ["and", 432], ["induces", 436], ["apoptosis", 444], ["in", 454], ["HeLa", 457], ["cells", 462], [".", 467], ["Pre", 469], ["-", 472], ["rRNA", 473], ["processing", 478], ["is", 489], ["altered", 492], [",", 499], ["which", 501], ["leads", 507], ["to", 513], ["an", 516], ["arrest", 519], ["in", 526], ["the", 529], ["maturation", 533], ["of", 544], ["precursors", 547], ["to", 558], ["the", 561], ["18S", 565], ["rRNA", 569], [".", 573], ["Under", 575], ["these", 581], ["conditions", 587], [",", 597], ["pre-40S", 599], ["particles", 607], ["are", 617], ["not", 621], ["exported", 625], ["to", 634], ["the", 637], ["cytoplasm", 641], ["and", 651], ["accumulate", 655], ["in", 666], ["the", 669], ["nucleoplasm", 673], ["of", 685], ["the", 688], ["cells", 692], ["in", 698], ["perinuclear", 701], ["dots", 713], [".", 717], ["Consistently", 719], [",", 731], ["we", 733], ["find", 736], ["that", 741], ["ribosome", 746], ["biogenesis", 755], ["and", 766], ["nucleolar", 770], ["organization", 780], ["is", 793], ["altered", 796], ["in", 804], ["skin", 807], ["fibroblasts", 812], ["from", 824], ["DBA", 829], ["patients", 833], ["bearing", 842], ["mutations", 850], ["in", 860], ["the", 863], ["RPS19", 867], ["gene", 873], [".", 877], ["In", 879], ["addition", 882], [",", 890], ["maturation", 892], ["of", 903], ["the", 906], ["18S", 910], ["rRNA", 914], ["is", 919], ["also", 922], ["perturbed", 927], ["in", 937], ["cells", 940], ["from", 946], ["a", 951], ["patient", 953], ["bearing", 961], ["no", 969], ["RPS19-related", 972], ["mutation", 986], [".", 994], ["These", 996], ["results", 1002], ["support", 1010], ["the", 1018], ["hypothesis", 1022], ["that", 1033], ["DBA", 1038], ["is", 1042], ["directly", 1045], ["related", 1054], ["to", 1062], ["a", 1065], ["defect", 1067], ["in", 1074], ["ribosome", 1077], ["biogenesis", 1086], ["and", 1097], ["indicate", 1101], ["that", 1110], ["yet", 1115], ["to", 1119], ["be", 1122], ["discovered", 1125], ["DBA", 1136], ["-", 1139], ["related", 1140], ["genes", 1148], ["may", 1154], ["be", 1158], ["involved", 1161], ["in", 1170], ["the", 1173], ["synthesis", 1177], ["of", 1187], ["the", 1190], ["ribosomal", 1194], ["subunits", 1204], [".", 1212]]}
{"context": "Six persons with the classical Angelman syndrome (AS) phenotype and de novo deletions of chromosome 15q11-q13 were studied to determine the parental origin of the chromosome deletion. Four of the 6 patients had informative cytogenetic studies and all demonstrated maternal inheritance of the deletion. These findings, together with other reported cases of the origin of the chromosome 15 deletion in AS, suggest that deletion of the maternally contributed chromosome leads to the AS phenotype. This contrasts with the Prader-Willi syndrome (PWS) in which a similar deletion of the paternally contributed chromosome 15 is observed. In deletion cases, a parental gamete effect such as genomic imprinting may be the best model to explain why apparently identical 15q11-q13 deletions may develop the different phenotypes of AS or PWS.", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "03aa34b985ac43f7b28e110d51d52e44", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[85, 88]], "char_spans": [[518, 538]]}]}], "context_tokens": [["Six", 0], ["persons", 4], ["with", 12], ["the", 17], ["classical", 21], ["Angelman", 31], ["syndrome", 40], ["(", 49], ["AS", 50], [")", 52], ["phenotype", 54], ["and", 64], ["de", 68], ["novo", 71], ["deletions", 76], ["of", 86], ["chromosome", 89], ["15q11-q13", 100], ["were", 110], ["studied", 115], ["to", 123], ["determine", 126], ["the", 136], ["parental", 140], ["origin", 149], ["of", 156], ["the", 159], ["chromosome", 163], ["deletion", 174], [".", 182], ["Four", 184], ["of", 189], ["the", 192], ["6", 196], ["patients", 198], ["had", 207], ["informative", 211], ["cytogenetic", 223], ["studies", 235], ["and", 243], ["all", 247], ["demonstrated", 251], ["maternal", 264], ["inheritance", 273], ["of", 285], ["the", 288], ["deletion", 292], [".", 300], ["These", 302], ["findings", 308], [",", 316], ["together", 318], ["with", 327], ["other", 332], ["reported", 338], ["cases", 347], ["of", 353], ["the", 356], ["origin", 360], ["of", 367], ["the", 370], ["chromosome", 374], ["15", 385], ["deletion", 388], ["in", 397], ["AS", 400], [",", 402], ["suggest", 404], ["that", 412], ["deletion", 417], ["of", 426], ["the", 429], ["maternally", 433], ["contributed", 444], ["chromosome", 456], ["leads", 467], ["to", 473], ["the", 476], ["AS", 480], ["phenotype", 483], [".", 492], ["This", 494], ["contrasts", 499], ["with", 509], ["the", 514], ["Prader", 518], ["-", 524], ["Willi", 525], ["syndrome", 531], ["(", 540], ["PWS", 541], [")", 544], ["in", 546], ["which", 549], ["a", 555], ["similar", 557], ["deletion", 565], ["of", 574], ["the", 577], ["paternally", 581], ["contributed", 592], ["chromosome", 604], ["15", 615], ["is", 618], ["observed", 621], [".", 629], ["In", 631], ["deletion", 634], ["cases", 643], [",", 648], ["a", 650], ["parental", 652], ["gamete", 661], ["effect", 668], ["such", 675], ["as", 680], ["genomic", 683], ["imprinting", 691], ["may", 702], ["be", 706], ["the", 709], ["best", 713], ["model", 718], ["to", 724], ["explain", 727], ["why", 735], ["apparently", 739], ["identical", 750], ["15q11-q13", 760], ["deletions", 770], ["may", 780], ["develop", 784], ["the", 792], ["different", 796], ["phenotypes", 806], ["of", 817], ["AS", 820], ["or", 823], ["PWS", 826], [".", 829]]}
{"context": "Facioscapulohumeral dystrophy (FSHD) is characterized by chromatin relaxation of the D4Z4 macrosatellite array on chromosome 4 and expression of the D4Z4-encoded DUX4 gene in skeletal muscle. The more common form, autosomal dominant FSHD1, is caused by contraction of the D4Z4 array, whereas the genetic determinants and inheritance of D4Z4 array contraction-independent FSHD2 are unclear. Here, we show that mutations in SMCHD1 (encoding structural maintenance of chromosomes flexible hinge domain containing 1) on chromosome 18 reduce SMCHD1 protein levels and segregate with genome-wide D4Z4 CpG hypomethylation in human kindreds. FSHD2 occurs in individuals who inherited both the SMCHD1 mutation and a normal-sized D4Z4 array on a chromosome 4 haplotype permissive for DUX4 expression. Reducing SMCHD1 levels in skeletal muscle results in D4Z4 contraction-independent DUX4 expression. Our study identifies SMCHD1 as an epigenetic modifier of the D4Z4 metastable epiallele and as a causal genetic determinant of FSHD2 and possibly other human diseases subject to epigenetic regulation.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "a9464ddc76874f33bc3080db5c5c07b9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[34, 35]], "char_spans": [[214, 231]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["dystrophy", 20], ["(", 30], ["FSHD", 31], [")", 35], ["is", 37], ["characterized", 40], ["by", 54], ["chromatin", 57], ["relaxation", 67], ["of", 78], ["the", 81], ["D4Z4", 85], ["macrosatellite", 90], ["array", 105], ["on", 111], ["chromosome", 114], ["4", 125], ["and", 127], ["expression", 131], ["of", 142], ["the", 145], ["D4Z4-encoded", 149], ["DUX4", 162], ["gene", 167], ["in", 172], ["skeletal", 175], ["muscle", 184], [".", 190], ["The", 192], ["more", 196], ["common", 201], ["form", 208], [",", 212], ["autosomal", 214], ["dominant", 224], ["FSHD1", 233], [",", 238], ["is", 240], ["caused", 243], ["by", 250], ["contraction", 253], ["of", 265], ["the", 268], ["D4Z4", 272], ["array", 277], [",", 282], ["whereas", 284], ["the", 292], ["genetic", 296], ["determinants", 304], ["and", 317], ["inheritance", 321], ["of", 333], ["D4Z4", 336], ["array", 341], ["contraction", 347], ["-", 358], ["independent", 359], ["FSHD2", 371], ["are", 377], ["unclear", 381], [".", 388], ["Here", 390], [",", 394], ["we", 396], ["show", 399], ["that", 404], ["mutations", 409], ["in", 419], ["SMCHD1", 422], ["(", 429], ["encoding", 430], ["structural", 439], ["maintenance", 450], ["of", 462], ["chromosomes", 465], ["flexible", 477], ["hinge", 486], ["domain", 492], ["containing", 499], ["1", 510], [")", 511], ["on", 513], ["chromosome", 516], ["18", 527], ["reduce", 530], ["SMCHD1", 537], ["protein", 544], ["levels", 552], ["and", 559], ["segregate", 563], ["with", 573], ["genome", 578], ["-", 584], ["wide", 585], ["D4Z4", 590], ["CpG", 595], ["hypomethylation", 599], ["in", 615], ["human", 618], ["kindreds", 624], [".", 632], ["FSHD2", 634], ["occurs", 640], ["in", 647], ["individuals", 650], ["who", 662], ["inherited", 666], ["both", 676], ["the", 681], ["SMCHD1", 685], ["mutation", 692], ["and", 701], ["a", 705], ["normal", 707], ["-", 713], ["sized", 714], ["D4Z4", 720], ["array", 725], ["on", 731], ["a", 734], ["chromosome", 736], ["4", 747], ["haplotype", 749], ["permissive", 759], ["for", 770], ["DUX4", 774], ["expression", 779], [".", 789], ["Reducing", 791], ["SMCHD1", 800], ["levels", 807], ["in", 814], ["skeletal", 817], ["muscle", 826], ["results", 833], ["in", 841], ["D4Z4", 844], ["contraction", 849], ["-", 860], ["independent", 861], ["DUX4", 873], ["expression", 878], [".", 888], ["Our", 890], ["study", 894], ["identifies", 900], ["SMCHD1", 911], ["as", 918], ["an", 921], ["epigenetic", 924], ["modifier", 935], ["of", 944], ["the", 947], ["D4Z4", 951], ["metastable", 956], ["epiallele", 967], ["and", 977], ["as", 981], ["a", 984], ["causal", 986], ["genetic", 993], ["determinant", 1001], ["of", 1013], ["FSHD2", 1016], ["and", 1022], ["possibly", 1026], ["other", 1035], ["human", 1041], ["diseases", 1047], ["subject", 1056], ["to", 1064], ["epigenetic", 1067], ["regulation", 1078], [".", 1088]]}
{"context": "With the avalanche of biological sequences generated in the post-genomic age, one of the most challenging problems in computational biology is how to effectively formulate the sequence of a biological sample (such as DNA, RNA or protein) with a discrete model or a vector that can effectively reflect its sequence pattern information or capture its key features concerned. Although several web servers and stand-alone tools were developed to address this problem, all these tools, however, can only handle one type of samples. Furthermore, the number of their built-in properties is limited, and hence it is often difficult for users to formulate the biological sequences according to their desired features or properties. In this article, with a much larger number of built-in properties, we are to propose a much more flexible web server called Pse-in-One (http://bioinformatics.hitsz.edu.cn/Pse-in-One/), which can, through its 28 different modes, generate nearly all the possible feature vectors for DNA, RNA and protein sequences. Particularly, it can also generate those feature vectors with the properties defined by users themselves. These feature vectors can be easily combined with machine-learning algorithms to develop computational predictors and analysis methods for various tasks in bioinformatics and system biology. It is anticipated that the Pse-in-One web server will become a very useful tool in computational proteomics, genomics, as well as biological sequence analysis. Moreover, to maximize users' convenience, its stand-alone version can also be downloaded from http://bioinformatics.hitsz.edu.cn/Pse-in-One/download/, and directly run on Windows, Linux, Unix and Mac OS.", "qas": [{"question": "Which server is used for generating modes of pseudo components of DNA, RNA and protein sequences?", "answers": ["Pse-in-One"], "qid": "6f46d726a7c249e68c5a8726f672c870", "question_tokens": [["Which", 0], ["server", 6], ["is", 13], ["used", 16], ["for", 21], ["generating", 25], ["modes", 36], ["of", 42], ["pseudo", 45], ["components", 52], ["of", 63], ["DNA", 66], [",", 69], ["RNA", 71], ["and", 75], ["protein", 79], ["sequences", 87], ["?", 96]], "detected_answers": [{"text": "Pse-in-One", "token_spans": [[155, 159], [238, 242]], "char_spans": [[847, 856], [1360, 1369]]}]}], "context_tokens": [["With", 0], ["the", 5], ["avalanche", 9], ["of", 19], ["biological", 22], ["sequences", 33], ["generated", 43], ["in", 53], ["the", 56], ["post", 60], ["-", 64], ["genomic", 65], ["age", 73], [",", 76], ["one", 78], ["of", 82], ["the", 85], ["most", 89], ["challenging", 94], ["problems", 106], ["in", 115], ["computational", 118], ["biology", 132], ["is", 140], ["how", 143], ["to", 147], ["effectively", 150], ["formulate", 162], ["the", 172], ["sequence", 176], ["of", 185], ["a", 188], ["biological", 190], ["sample", 201], ["(", 208], ["such", 209], ["as", 214], ["DNA", 217], [",", 220], ["RNA", 222], ["or", 226], ["protein", 229], [")", 236], ["with", 238], ["a", 243], ["discrete", 245], ["model", 254], ["or", 260], ["a", 263], ["vector", 265], ["that", 272], ["can", 277], ["effectively", 281], ["reflect", 293], ["its", 301], ["sequence", 305], ["pattern", 314], ["information", 322], ["or", 334], ["capture", 337], ["its", 345], ["key", 349], ["features", 353], ["concerned", 362], [".", 371], ["Although", 373], ["several", 382], ["web", 390], ["servers", 394], ["and", 402], ["stand", 406], ["-", 411], ["alone", 412], ["tools", 418], ["were", 424], ["developed", 429], ["to", 439], ["address", 442], ["this", 450], ["problem", 455], [",", 462], ["all", 464], ["these", 468], ["tools", 474], [",", 479], ["however", 481], [",", 488], ["can", 490], ["only", 494], ["handle", 499], ["one", 506], ["type", 510], ["of", 515], ["samples", 518], [".", 525], ["Furthermore", 527], [",", 538], ["the", 540], ["number", 544], ["of", 551], ["their", 554], ["built", 560], ["-", 565], ["in", 566], ["properties", 569], ["is", 580], ["limited", 583], [",", 590], ["and", 592], ["hence", 596], ["it", 602], ["is", 605], ["often", 608], ["difficult", 614], ["for", 624], ["users", 628], ["to", 634], ["formulate", 637], ["the", 647], ["biological", 651], ["sequences", 662], ["according", 672], ["to", 682], ["their", 685], ["desired", 691], ["features", 699], ["or", 708], ["properties", 711], [".", 721], ["In", 723], ["this", 726], ["article", 731], [",", 738], ["with", 740], ["a", 745], ["much", 747], ["larger", 752], ["number", 759], ["of", 766], ["built", 769], ["-", 774], ["in", 775], ["properties", 778], [",", 788], ["we", 790], ["are", 793], ["to", 797], ["propose", 800], ["a", 808], ["much", 810], ["more", 815], ["flexible", 820], ["web", 829], ["server", 833], ["called", 840], ["Pse", 847], ["-", 850], ["in", 851], ["-", 853], ["One", 854], ["(", 858], ["http://bioinformatics.hitsz.edu.cn/Pse-in-One/", 859], [")", 905], [",", 906], ["which", 908], ["can", 914], [",", 917], ["through", 919], ["its", 927], ["28", 931], ["different", 934], ["modes", 944], [",", 949], ["generate", 951], ["nearly", 960], ["all", 967], ["the", 971], ["possible", 975], ["feature", 984], ["vectors", 992], ["for", 1000], ["DNA", 1004], [",", 1007], ["RNA", 1009], ["and", 1013], ["protein", 1017], ["sequences", 1025], [".", 1034], ["Particularly", 1036], [",", 1048], ["it", 1050], ["can", 1053], ["also", 1057], ["generate", 1062], ["those", 1071], ["feature", 1077], ["vectors", 1085], ["with", 1093], ["the", 1098], ["properties", 1102], ["defined", 1113], ["by", 1121], ["users", 1124], ["themselves", 1130], [".", 1140], ["These", 1142], ["feature", 1148], ["vectors", 1156], ["can", 1164], ["be", 1168], ["easily", 1171], ["combined", 1178], ["with", 1187], ["machine", 1192], ["-", 1199], ["learning", 1200], ["algorithms", 1209], ["to", 1220], ["develop", 1223], ["computational", 1231], ["predictors", 1245], ["and", 1256], ["analysis", 1260], ["methods", 1269], ["for", 1277], ["various", 1281], ["tasks", 1289], ["in", 1295], ["bioinformatics", 1298], ["and", 1313], ["system", 1317], ["biology", 1324], [".", 1331], ["It", 1333], ["is", 1336], ["anticipated", 1339], ["that", 1351], ["the", 1356], ["Pse", 1360], ["-", 1363], ["in", 1364], ["-", 1366], ["One", 1367], ["web", 1371], ["server", 1375], ["will", 1382], ["become", 1387], ["a", 1394], ["very", 1396], ["useful", 1401], ["tool", 1408], ["in", 1413], ["computational", 1416], ["proteomics", 1430], [",", 1440], ["genomics", 1442], [",", 1450], ["as", 1452], ["well", 1455], ["as", 1460], ["biological", 1463], ["sequence", 1474], ["analysis", 1483], [".", 1491], ["Moreover", 1493], [",", 1501], ["to", 1503], ["maximize", 1506], ["users", 1515], ["'", 1520], ["convenience", 1522], [",", 1533], ["its", 1535], ["stand", 1539], ["-", 1544], ["alone", 1545], ["version", 1551], ["can", 1559], ["also", 1563], ["be", 1568], ["downloaded", 1571], ["from", 1582], ["http://bioinformatics.hitsz.edu.cn/Pse-in-One/download/", 1587], [",", 1642], ["and", 1644], ["directly", 1648], ["run", 1657], ["on", 1661], ["Windows", 1664], [",", 1671], ["Linux", 1673], [",", 1678], ["Unix", 1680], ["and", 1685], ["Mac", 1689], ["OS", 1693], [".", 1695]]}
{"context": "Past studies have documented a crosstalk between H2B ubiquitylation (H2Bub) and H3K4 methylation, but little (if any) direct evidence exists explaining the mechanism underlying H2Bub-dependent H3K4 methylation on chromatin templates. Here, we took advantage of an in vitro histone methyltransferase assay employing a reconstituted yeast Set1 complex (ySet1C) and a recombinant chromatin template containing fully ubiquitylated H2B to gain valuable insights. Combined with genetic analyses, we demonstrate that the n-SET domain within Set1, but not Swd2, is essential for H2Bub-dependent H3K4 methylation. Spp1, a homolog of human CFP1, is conditionally involved in this crosstalk. Our findings extend to the human Set1 complex, underscoring the conserved nature of this disease-relevant crosstalk pathway. As not all members of the H3K4 methyltransferase family contain n-SET domains, our studies draw attention to the n-SET domain as a predictor of an H2B ubiquitylation-sensing mechanism that leads to downstream H3K4 methylation.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "0e9ad5ae9db7422d92338cea8e52e210", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[84, 85], [161, 162]], "char_spans": [[516, 525], [921, 930]]}]}], "context_tokens": [["Past", 0], ["studies", 5], ["have", 13], ["documented", 18], ["a", 29], ["crosstalk", 31], ["between", 41], ["H2B", 49], ["ubiquitylation", 53], ["(", 68], ["H2Bub", 69], [")", 74], ["and", 76], ["H3K4", 80], ["methylation", 85], [",", 96], ["but", 98], ["little", 102], ["(", 109], ["if", 110], ["any", 113], [")", 116], ["direct", 118], ["evidence", 125], ["exists", 134], ["explaining", 141], ["the", 152], ["mechanism", 156], ["underlying", 166], ["H2Bub", 177], ["-", 182], ["dependent", 183], ["H3K4", 193], ["methylation", 198], ["on", 210], ["chromatin", 213], ["templates", 223], [".", 232], ["Here", 234], [",", 238], ["we", 240], ["took", 243], ["advantage", 248], ["of", 258], ["an", 261], ["in", 264], ["vitro", 267], ["histone", 273], ["methyltransferase", 281], ["assay", 299], ["employing", 305], ["a", 315], ["reconstituted", 317], ["yeast", 331], ["Set1", 337], ["complex", 342], ["(", 350], ["ySet1C", 351], [")", 357], ["and", 359], ["a", 363], ["recombinant", 365], ["chromatin", 377], ["template", 387], ["containing", 396], ["fully", 407], ["ubiquitylated", 413], ["H2B", 427], ["to", 431], ["gain", 434], ["valuable", 439], ["insights", 448], [".", 456], ["Combined", 458], ["with", 467], ["genetic", 472], ["analyses", 480], [",", 488], ["we", 490], ["demonstrate", 493], ["that", 505], ["the", 510], ["n", 514], ["-", 515], ["SET", 516], ["domain", 520], ["within", 527], ["Set1", 534], [",", 538], ["but", 540], ["not", 544], ["Swd2", 548], [",", 552], ["is", 554], ["essential", 557], ["for", 567], ["H2Bub", 571], ["-", 576], ["dependent", 577], ["H3K4", 587], ["methylation", 592], [".", 603], ["Spp1", 605], [",", 609], ["a", 611], ["homolog", 613], ["of", 621], ["human", 624], ["CFP1", 630], [",", 634], ["is", 636], ["conditionally", 639], ["involved", 653], ["in", 662], ["this", 665], ["crosstalk", 670], [".", 679], ["Our", 681], ["findings", 685], ["extend", 694], ["to", 701], ["the", 704], ["human", 708], ["Set1", 714], ["complex", 719], [",", 726], ["underscoring", 728], ["the", 741], ["conserved", 745], ["nature", 755], ["of", 762], ["this", 765], ["disease", 770], ["-", 777], ["relevant", 778], ["crosstalk", 787], ["pathway", 797], [".", 804], ["As", 806], ["not", 809], ["all", 813], ["members", 817], ["of", 825], ["the", 828], ["H3K4", 832], ["methyltransferase", 837], ["family", 855], ["contain", 862], ["n", 870], ["-", 871], ["SET", 872], ["domains", 876], [",", 883], ["our", 885], ["studies", 889], ["draw", 897], ["attention", 902], ["to", 912], ["the", 915], ["n", 919], ["-", 920], ["SET", 921], ["domain", 925], ["as", 932], ["a", 935], ["predictor", 937], ["of", 947], ["an", 950], ["H2B", 953], ["ubiquitylation", 957], ["-", 971], ["sensing", 972], ["mechanism", 980], ["that", 990], ["leads", 995], ["to", 1001], ["downstream", 1004], ["H3K4", 1015], ["methylation", 1020], [".", 1031]]}
{"context": "The X-linked McLeod neuroacanthocytosis syndrome is a multisystem disorder with hematologic, neuromuscular, and central nervous system (CNS) manifestations. All carriers of the McLeod blood group phenotype examined so far had at least subclinical signs of systemic involvement. Evaluation of two brothers carrying the McLeod phenotype with neurologic examination, immunohematology, RBC membrane protein Western blotting, analysis of XK DNA sequence and RNA levels, muscle histology including XK/Kell immunohistochemistry, cerebral magnetic resonance imaging (MRI), and quantified positron emission tomography (PET). Immunohematology and Western blotting confirmed presence of the McLeod blood group phenotype. No acanthocytosis or other hematologic anomalies were found. XK gene sequence analysis revealed a missense mutation in exon 3 (E327K). WBC XK RNA levels were not decreased. There were no neuromuscular and CNS signs or symptoms. In addition, no subclinical involvement was discovered on the basis of normal muscle histology with a physiologic pattern of XK and Kell immunohistochemistry, normal cerebral MRI, and quantified PET. Known disease-causing XK gene mutations comprised deletions, nonsense, or splice-site mutations predicting absent or truncated XK protein devoid of the Kell-protein binding site. Although the E327K missense mutation was associated with the immunohematologic characteristics of McLeod syndrome, the mutated XK protein seemed to be largely functional. These findings contribute to the understanding of the physiology of XK and Kell proteins, and the pathogenetic mechanisms of acanthocytosis, myopathy, and striatal neurodegeneration in McLeod syndrome.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "9019bb534c7b4632b5c84114049ce836", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[192, 192], [256, 256], [67, 67], [77, 77], [138, 138], [121, 121], [209, 209], [238, 238], [175, 175]], "char_spans": [[1160, 1161], [1556, 1557], [433, 434], [492, 493], [849, 850], [771, 772], [1265, 1266], [1444, 1445], [1063, 1064]]}]}], "context_tokens": [["The", 0], ["X", 4], ["-", 5], ["linked", 6], ["McLeod", 13], ["neuroacanthocytosis", 20], ["syndrome", 40], ["is", 49], ["a", 52], ["multisystem", 54], ["disorder", 66], ["with", 75], ["hematologic", 80], [",", 91], ["neuromuscular", 93], [",", 106], ["and", 108], ["central", 112], ["nervous", 120], ["system", 128], ["(", 135], ["CNS", 136], [")", 139], ["manifestations", 141], [".", 155], ["All", 157], ["carriers", 161], ["of", 170], ["the", 173], ["McLeod", 177], ["blood", 184], ["group", 190], ["phenotype", 196], ["examined", 206], ["so", 215], ["far", 218], ["had", 222], ["at", 226], ["least", 229], ["subclinical", 235], ["signs", 247], ["of", 253], ["systemic", 256], ["involvement", 265], [".", 276], ["Evaluation", 278], ["of", 289], ["two", 292], ["brothers", 296], ["carrying", 305], ["the", 314], ["McLeod", 318], ["phenotype", 325], ["with", 335], ["neurologic", 340], ["examination", 351], [",", 362], ["immunohematology", 364], [",", 380], ["RBC", 382], ["membrane", 386], ["protein", 395], ["Western", 403], ["blotting", 411], [",", 419], ["analysis", 421], ["of", 430], ["XK", 433], ["DNA", 436], ["sequence", 440], ["and", 449], ["RNA", 453], ["levels", 457], [",", 463], ["muscle", 465], ["histology", 472], ["including", 482], ["XK", 492], ["/", 494], ["Kell", 495], ["immunohistochemistry", 500], [",", 520], ["cerebral", 522], ["magnetic", 531], ["resonance", 540], ["imaging", 550], ["(", 558], ["MRI", 559], [")", 562], [",", 563], ["and", 565], ["quantified", 569], ["positron", 580], ["emission", 589], ["tomography", 598], ["(", 609], ["PET", 610], [")", 613], [".", 614], ["Immunohematology", 616], ["and", 633], ["Western", 637], ["blotting", 645], ["confirmed", 654], ["presence", 664], ["of", 673], ["the", 676], ["McLeod", 680], ["blood", 687], ["group", 693], ["phenotype", 699], [".", 708], ["No", 710], ["acanthocytosis", 713], ["or", 728], ["other", 731], ["hematologic", 737], ["anomalies", 749], ["were", 759], ["found", 764], [".", 769], ["XK", 771], ["gene", 774], ["sequence", 779], ["analysis", 788], ["revealed", 797], ["a", 806], ["missense", 808], ["mutation", 817], ["in", 826], ["exon", 829], ["3", 834], ["(", 836], ["E327", 837], ["K", 841], [")", 842], [".", 843], ["WBC", 845], ["XK", 849], ["RNA", 852], ["levels", 856], ["were", 863], ["not", 868], ["decreased", 872], [".", 881], ["There", 883], ["were", 889], ["no", 894], ["neuromuscular", 897], ["and", 911], ["CNS", 915], ["signs", 919], ["or", 925], ["symptoms", 928], [".", 936], ["In", 938], ["addition", 941], [",", 949], ["no", 951], ["subclinical", 954], ["involvement", 966], ["was", 978], ["discovered", 982], ["on", 993], ["the", 996], ["basis", 1000], ["of", 1006], ["normal", 1009], ["muscle", 1016], ["histology", 1023], ["with", 1033], ["a", 1038], ["physiologic", 1040], ["pattern", 1052], ["of", 1060], ["XK", 1063], ["and", 1066], ["Kell", 1070], ["immunohistochemistry", 1075], [",", 1095], ["normal", 1097], ["cerebral", 1104], ["MRI", 1113], [",", 1116], ["and", 1118], ["quantified", 1122], ["PET", 1133], [".", 1136], ["Known", 1138], ["disease", 1144], ["-", 1151], ["causing", 1152], ["XK", 1160], ["gene", 1163], ["mutations", 1168], ["comprised", 1178], ["deletions", 1188], [",", 1197], ["nonsense", 1199], [",", 1207], ["or", 1209], ["splice", 1212], ["-", 1218], ["site", 1219], ["mutations", 1224], ["predicting", 1234], ["absent", 1245], ["or", 1252], ["truncated", 1255], ["XK", 1265], ["protein", 1268], ["devoid", 1276], ["of", 1283], ["the", 1286], ["Kell", 1290], ["-", 1294], ["protein", 1295], ["binding", 1303], ["site", 1311], [".", 1315], ["Although", 1317], ["the", 1326], ["E327", 1330], ["K", 1334], ["missense", 1336], ["mutation", 1345], ["was", 1354], ["associated", 1358], ["with", 1369], ["the", 1374], ["immunohematologic", 1378], ["characteristics", 1396], ["of", 1412], ["McLeod", 1415], ["syndrome", 1422], [",", 1430], ["the", 1432], ["mutated", 1436], ["XK", 1444], ["protein", 1447], ["seemed", 1455], ["to", 1462], ["be", 1465], ["largely", 1468], ["functional", 1476], [".", 1486], ["These", 1488], ["findings", 1494], ["contribute", 1503], ["to", 1514], ["the", 1517], ["understanding", 1521], ["of", 1535], ["the", 1538], ["physiology", 1542], ["of", 1553], ["XK", 1556], ["and", 1559], ["Kell", 1563], ["proteins", 1568], [",", 1576], ["and", 1578], ["the", 1582], ["pathogenetic", 1586], ["mechanisms", 1599], ["of", 1610], ["acanthocytosis", 1613], [",", 1627], ["myopathy", 1629], [",", 1637], ["and", 1639], ["striatal", 1643], ["neurodegeneration", 1652], ["in", 1670], ["McLeod", 1673], ["syndrome", 1680], [".", 1688]]}
{"context": "Viroids, satellite RNAs, satellites viruses and the human hepatitis delta virus form the 'brotherhood' of the smallest known infectious RNA agents, known as the subviral RNAs. For most of these species, it is generally accepted that characteristics such as cell movement, replication, host specificity and pathogenicity are encoded in their RNA sequences and their resulting RNA structures. Although many sequences are indexed in publicly available databases, these sequence annotation databases do not provide the advanced searches and data manipulation capability for identifying and characterizing subviral RNA motifs. The Subviral RNA database is a web-based environment that facilitates the research and analysis of viroids, satellite RNAs, satellites viruses, the human hepatitis delta virus, and related RNA sequences. It integrates a large number of Subviral RNA sequences, their respective RNA motifs, analysis tools, related publication links and additional pertinent information (ex. links, conferences, announcements), allowing users to efficiently retrieve and analyze relevant information about these small RNA agents. With its design, the Subviral RNA Database could be considered as a fundamental building block for the study of these related RNAs. It is freely available via a web browser at the URL: http://subviral.med.uottawa.ca.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "2617acecfbd24533a69a8513130d6dde", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[116, 116], [0, 0]], "char_spans": [[721, 727], [0, 6]]}]}], "context_tokens": [["Viroids", 0], [",", 7], ["satellite", 9], ["RNAs", 19], [",", 23], ["satellites", 25], ["viruses", 36], ["and", 44], ["the", 48], ["human", 52], ["hepatitis", 58], ["delta", 68], ["virus", 74], ["form", 80], ["the", 85], ["'", 89], ["brotherhood", 90], ["'", 101], ["of", 103], ["the", 106], ["smallest", 110], ["known", 119], ["infectious", 125], ["RNA", 136], ["agents", 140], [",", 146], ["known", 148], ["as", 154], ["the", 157], ["subviral", 161], ["RNAs", 170], [".", 174], ["For", 176], ["most", 180], ["of", 185], ["these", 188], ["species", 194], [",", 201], ["it", 203], ["is", 206], ["generally", 209], ["accepted", 219], ["that", 228], ["characteristics", 233], ["such", 249], ["as", 254], ["cell", 257], ["movement", 262], [",", 270], ["replication", 272], [",", 283], ["host", 285], ["specificity", 290], ["and", 302], ["pathogenicity", 306], ["are", 320], ["encoded", 324], ["in", 332], ["their", 335], ["RNA", 341], ["sequences", 345], ["and", 355], ["their", 359], ["resulting", 365], ["RNA", 375], ["structures", 379], [".", 389], ["Although", 391], ["many", 400], ["sequences", 405], ["are", 415], ["indexed", 419], ["in", 427], ["publicly", 430], ["available", 439], ["databases", 449], [",", 458], ["these", 460], ["sequence", 466], ["annotation", 475], ["databases", 486], ["do", 496], ["not", 499], ["provide", 503], ["the", 511], ["advanced", 515], ["searches", 524], ["and", 533], ["data", 537], ["manipulation", 542], ["capability", 555], ["for", 566], ["identifying", 570], ["and", 582], ["characterizing", 586], ["subviral", 601], ["RNA", 610], ["motifs", 614], [".", 620], ["The", 622], ["Subviral", 626], ["RNA", 635], ["database", 639], ["is", 648], ["a", 651], ["web", 653], ["-", 656], ["based", 657], ["environment", 663], ["that", 675], ["facilitates", 680], ["the", 692], ["research", 696], ["and", 705], ["analysis", 709], ["of", 718], ["viroids", 721], [",", 728], ["satellite", 730], ["RNAs", 740], [",", 744], ["satellites", 746], ["viruses", 757], [",", 764], ["the", 766], ["human", 770], ["hepatitis", 776], ["delta", 786], ["virus", 792], [",", 797], ["and", 799], ["related", 803], ["RNA", 811], ["sequences", 815], [".", 824], ["It", 826], ["integrates", 829], ["a", 840], ["large", 842], ["number", 848], ["of", 855], ["Subviral", 858], ["RNA", 867], ["sequences", 871], [",", 880], ["their", 882], ["respective", 888], ["RNA", 899], ["motifs", 903], [",", 909], ["analysis", 911], ["tools", 920], [",", 925], ["related", 927], ["publication", 935], ["links", 947], ["and", 953], ["additional", 957], ["pertinent", 968], ["information", 978], ["(", 990], ["ex", 991], [".", 993], ["links", 995], [",", 1000], ["conferences", 1002], [",", 1013], ["announcements", 1015], [")", 1028], [",", 1029], ["allowing", 1031], ["users", 1040], ["to", 1046], ["efficiently", 1049], ["retrieve", 1061], ["and", 1070], ["analyze", 1074], ["relevant", 1082], ["information", 1091], ["about", 1103], ["these", 1109], ["small", 1115], ["RNA", 1121], ["agents", 1125], [".", 1131], ["With", 1133], ["its", 1138], ["design", 1142], [",", 1148], ["the", 1150], ["Subviral", 1154], ["RNA", 1163], ["Database", 1167], ["could", 1176], ["be", 1182], ["considered", 1185], ["as", 1196], ["a", 1199], ["fundamental", 1201], ["building", 1213], ["block", 1222], ["for", 1228], ["the", 1232], ["study", 1236], ["of", 1242], ["these", 1245], ["related", 1251], ["RNAs", 1259], [".", 1263], ["It", 1265], ["is", 1268], ["freely", 1271], ["available", 1278], ["via", 1288], ["a", 1292], ["web", 1294], ["browser", 1298], ["at", 1306], ["the", 1309], ["URL", 1313], [":", 1316], ["http://subviral.med.uottawa.ca", 1318], [".", 1348]]}
{"context": "Centrosomes are composed of a centriole pair surrounded by an intricate proteinaceous matrix referred to as pericentriolar material. Although the mechanisms underpinning the control of centriole duplication are now well understood, we know relatively little about the control of centrosome size and shape. Here we used interaction proteomics to identify the E3 ligase HERC2 and the neuralized homologue NEURL4 as novel interaction partners of the centrosomal protein CP110. Using high resolution imaging, we find that HERC2 and NEURL4 localize to the centrosome and that interfering with their function alters centrosome morphology through the appearance of aberrant filamentous structures that stain for a subset of pericentriolar material proteins including pericentrin and CEP135. Using an RNA interference-resistant transgene approach in combination with structure-function analyses, we show that the association between CP110 and HERC2 depends on nonoverlapping regions of NEURL4. Whereas CP110 binding to NEURL4 is dispensable for the regulation of pericentriolar material architecture, its association with HERC2 is required to maintain normal centrosome integrity. NEURL4 is a substrate of HERC2, and together these results indicate that the NEURL4-HERC2 complex participates in the ubiquitin-dependent regulation of centrosome architecture.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "edb15e5cd3594668933fa0a9f6c83206", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[173, 173], [86, 86], [41, 41], [200, 200], [94, 94]], "char_spans": [[1151, 1160], [551, 560], [279, 288], [1325, 1334], [610, 619]]}]}], "context_tokens": [["Centrosomes", 0], ["are", 12], ["composed", 16], ["of", 25], ["a", 28], ["centriole", 30], ["pair", 40], ["surrounded", 45], ["by", 56], ["an", 59], ["intricate", 62], ["proteinaceous", 72], ["matrix", 86], ["referred", 93], ["to", 102], ["as", 105], ["pericentriolar", 108], ["material", 123], [".", 131], ["Although", 133], ["the", 142], ["mechanisms", 146], ["underpinning", 157], ["the", 170], ["control", 174], ["of", 182], ["centriole", 185], ["duplication", 195], ["are", 207], ["now", 211], ["well", 215], ["understood", 220], [",", 230], ["we", 232], ["know", 235], ["relatively", 240], ["little", 251], ["about", 258], ["the", 264], ["control", 268], ["of", 276], ["centrosome", 279], ["size", 290], ["and", 295], ["shape", 299], [".", 304], ["Here", 306], ["we", 311], ["used", 314], ["interaction", 319], ["proteomics", 331], ["to", 342], ["identify", 345], ["the", 354], ["E3", 358], ["ligase", 361], ["HERC2", 368], ["and", 374], ["the", 378], ["neuralized", 382], ["homologue", 393], ["NEURL4", 403], ["as", 410], ["novel", 413], ["interaction", 419], ["partners", 431], ["of", 440], ["the", 443], ["centrosomal", 447], ["protein", 459], ["CP110", 467], [".", 472], ["Using", 474], ["high", 480], ["resolution", 485], ["imaging", 496], [",", 503], ["we", 505], ["find", 508], ["that", 513], ["HERC2", 518], ["and", 524], ["NEURL4", 528], ["localize", 535], ["to", 544], ["the", 547], ["centrosome", 551], ["and", 562], ["that", 566], ["interfering", 571], ["with", 583], ["their", 588], ["function", 594], ["alters", 603], ["centrosome", 610], ["morphology", 621], ["through", 632], ["the", 640], ["appearance", 644], ["of", 655], ["aberrant", 658], ["filamentous", 667], ["structures", 679], ["that", 690], ["stain", 695], ["for", 701], ["a", 705], ["subset", 707], ["of", 714], ["pericentriolar", 717], ["material", 732], ["proteins", 741], ["including", 750], ["pericentrin", 760], ["and", 772], ["CEP135", 776], [".", 782], ["Using", 784], ["an", 790], ["RNA", 793], ["interference", 797], ["-", 809], ["resistant", 810], ["transgene", 820], ["approach", 830], ["in", 839], ["combination", 842], ["with", 854], ["structure", 859], ["-", 868], ["function", 869], ["analyses", 878], [",", 886], ["we", 888], ["show", 891], ["that", 896], ["the", 901], ["association", 905], ["between", 917], ["CP110", 925], ["and", 931], ["HERC2", 935], ["depends", 941], ["on", 949], ["nonoverlapping", 952], ["regions", 967], ["of", 975], ["NEURL4", 978], [".", 984], ["Whereas", 986], ["CP110", 994], ["binding", 1000], ["to", 1008], ["NEURL4", 1011], ["is", 1018], ["dispensable", 1021], ["for", 1033], ["the", 1037], ["regulation", 1041], ["of", 1052], ["pericentriolar", 1055], ["material", 1070], ["architecture", 1079], [",", 1091], ["its", 1093], ["association", 1097], ["with", 1109], ["HERC2", 1114], ["is", 1120], ["required", 1123], ["to", 1132], ["maintain", 1135], ["normal", 1144], ["centrosome", 1151], ["integrity", 1162], [".", 1171], ["NEURL4", 1173], ["is", 1180], ["a", 1183], ["substrate", 1185], ["of", 1195], ["HERC2", 1198], [",", 1203], ["and", 1205], ["together", 1209], ["these", 1218], ["results", 1224], ["indicate", 1232], ["that", 1241], ["the", 1246], ["NEURL4-HERC2", 1250], ["complex", 1263], ["participates", 1271], ["in", 1284], ["the", 1287], ["ubiquitin", 1291], ["-", 1300], ["dependent", 1301], ["regulation", 1311], ["of", 1322], ["centrosome", 1325], ["architecture", 1336], [".", 1348]]}
{"context": "The membranous structure of vestibular schwannoma is an important factor in its surgical treatment. Herein, we report intraoperative and microscopic findings relating to an outermost dura-like membrane in cases of vestibular schwannoma and the importance of these findings. Intraoperative findings of 16 cases of vestibular schwannoma treated with an initial surgery were studied with an aim to determine if the cases had a dura-like membrane. Then we studied microscopic findings of the dura-like membrane using hematoxylin and eosin, Masson trichrome, and immunohistochemical staining in 2 cases. The dura-like membrane was observed in 8 out of 16 cases. The average tumor size of the cases that had a dura-like membrane was 30 \u00b1 8.1 mm, and Koos grading 4 was in 7 out of 8 cases, and one was grade 3. In cases without a dura-like membrane, these values were significantly smaller, with an average tumor size of 12.8 \u00b1 5.2 mm, and Koos grading 4 was only in 1 of 8 cases, grade 3 was in 2 cases, and other 5 cases were grade 2. The outermost dura-like membrane enveloped the vestibular schwannoma around the internal acoustic meatus and was continuous with the dura mater. Reactive angiogenesis was observed in the dura mater. Microscopic findings proved its continuity with the dura mater. In one case, the facial nerve was damaged before it was identified during subcapsular dissection. In that case, the dura-like membrane negatively affected our ability to identify the facial nerve. A dura-like membrane sometimes envelops vestibular schwannoma around the internal acoustic meatus. Recognition of this membranous structure is important for the surgical preservation of facial and acoustic nerves.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "49b937d0ed614da79079221407d48ab8", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[49, 50], [289, 290], [4, 5], [212, 213], [34, 35]], "char_spans": [[313, 333], [1531, 1551], [28, 48], [1078, 1098], [214, 234]]}]}], "context_tokens": [["The", 0], ["membranous", 4], ["structure", 15], ["of", 25], ["vestibular", 28], ["schwannoma", 39], ["is", 50], ["an", 53], ["important", 56], ["factor", 66], ["in", 73], ["its", 76], ["surgical", 80], ["treatment", 89], [".", 98], ["Herein", 100], [",", 106], ["we", 108], ["report", 111], ["intraoperative", 118], ["and", 133], ["microscopic", 137], ["findings", 149], ["relating", 158], ["to", 167], ["an", 170], ["outermost", 173], ["dura", 183], ["-", 187], ["like", 188], ["membrane", 193], ["in", 202], ["cases", 205], ["of", 211], ["vestibular", 214], ["schwannoma", 225], ["and", 236], ["the", 240], ["importance", 244], ["of", 255], ["these", 258], ["findings", 264], [".", 272], ["Intraoperative", 274], ["findings", 289], ["of", 298], ["16", 301], ["cases", 304], ["of", 310], ["vestibular", 313], ["schwannoma", 324], ["treated", 335], ["with", 343], ["an", 348], ["initial", 351], ["surgery", 359], ["were", 367], ["studied", 372], ["with", 380], ["an", 385], ["aim", 388], ["to", 392], ["determine", 395], ["if", 405], ["the", 408], ["cases", 412], ["had", 418], ["a", 422], ["dura", 424], ["-", 428], ["like", 429], ["membrane", 434], [".", 442], ["Then", 444], ["we", 449], ["studied", 452], ["microscopic", 460], ["findings", 472], ["of", 481], ["the", 484], ["dura", 488], ["-", 492], ["like", 493], ["membrane", 498], ["using", 507], ["hematoxylin", 513], ["and", 525], ["eosin", 529], [",", 534], ["Masson", 536], ["trichrome", 543], [",", 552], ["and", 554], ["immunohistochemical", 558], ["staining", 578], ["in", 587], ["2", 590], ["cases", 592], [".", 597], ["The", 599], ["dura", 603], ["-", 607], ["like", 608], ["membrane", 613], ["was", 622], ["observed", 626], ["in", 635], ["8", 638], ["out", 640], ["of", 644], ["16", 647], ["cases", 650], [".", 655], ["The", 657], ["average", 661], ["tumor", 669], ["size", 675], ["of", 680], ["the", 683], ["cases", 687], ["that", 693], ["had", 698], ["a", 702], ["dura", 704], ["-", 708], ["like", 709], ["membrane", 714], ["was", 723], ["30", 727], ["\u00b1", 730], ["8.1", 732], ["mm", 736], [",", 738], ["and", 740], ["Koos", 744], ["grading", 749], ["4", 757], ["was", 759], ["in", 763], ["7", 766], ["out", 768], ["of", 772], ["8", 775], ["cases", 777], [",", 782], ["and", 784], ["one", 788], ["was", 792], ["grade", 796], ["3", 802], [".", 803], ["In", 805], ["cases", 808], ["without", 814], ["a", 822], ["dura", 824], ["-", 828], ["like", 829], ["membrane", 834], [",", 842], ["these", 844], ["values", 850], ["were", 857], ["significantly", 862], ["smaller", 876], [",", 883], ["with", 885], ["an", 890], ["average", 893], ["tumor", 901], ["size", 907], ["of", 912], ["12.8", 915], ["\u00b1", 920], ["5.2", 922], ["mm", 926], [",", 928], ["and", 930], ["Koos", 934], ["grading", 939], ["4", 947], ["was", 949], ["only", 953], ["in", 958], ["1", 961], ["of", 963], ["8", 966], ["cases", 968], [",", 973], ["grade", 975], ["3", 981], ["was", 983], ["in", 987], ["2", 990], ["cases", 992], [",", 997], ["and", 999], ["other", 1003], ["5", 1009], ["cases", 1011], ["were", 1017], ["grade", 1022], ["2", 1028], [".", 1029], ["The", 1031], ["outermost", 1035], ["dura", 1045], ["-", 1049], ["like", 1050], ["membrane", 1055], ["enveloped", 1064], ["the", 1074], ["vestibular", 1078], ["schwannoma", 1089], ["around", 1100], ["the", 1107], ["internal", 1111], ["acoustic", 1120], ["meatus", 1129], ["and", 1136], ["was", 1140], ["continuous", 1144], ["with", 1155], ["the", 1160], ["dura", 1164], ["mater", 1169], [".", 1174], ["Reactive", 1176], ["angiogenesis", 1185], ["was", 1198], ["observed", 1202], ["in", 1211], ["the", 1214], ["dura", 1218], ["mater", 1223], [".", 1228], ["Microscopic", 1230], ["findings", 1242], ["proved", 1251], ["its", 1258], ["continuity", 1262], ["with", 1273], ["the", 1278], ["dura", 1282], ["mater", 1287], [".", 1292], ["In", 1294], ["one", 1297], ["case", 1301], [",", 1305], ["the", 1307], ["facial", 1311], ["nerve", 1318], ["was", 1324], ["damaged", 1328], ["before", 1336], ["it", 1343], ["was", 1346], ["identified", 1350], ["during", 1361], ["subcapsular", 1368], ["dissection", 1380], [".", 1390], ["In", 1392], ["that", 1395], ["case", 1400], [",", 1404], ["the", 1406], ["dura", 1410], ["-", 1414], ["like", 1415], ["membrane", 1420], ["negatively", 1429], ["affected", 1440], ["our", 1449], ["ability", 1453], ["to", 1461], ["identify", 1464], ["the", 1473], ["facial", 1477], ["nerve", 1484], [".", 1489], ["A", 1491], ["dura", 1493], ["-", 1497], ["like", 1498], ["membrane", 1503], ["sometimes", 1512], ["envelops", 1522], ["vestibular", 1531], ["schwannoma", 1542], ["around", 1553], ["the", 1560], ["internal", 1564], ["acoustic", 1573], ["meatus", 1582], [".", 1588], ["Recognition", 1590], ["of", 1602], ["this", 1605], ["membranous", 1610], ["structure", 1621], ["is", 1631], ["important", 1634], ["for", 1644], ["the", 1648], ["surgical", 1652], ["preservation", 1661], ["of", 1674], ["facial", 1677], ["and", 1684], ["acoustic", 1688], ["nerves", 1697], [".", 1703]]}
{"context": "In eukaryotic cells, there are two sub-pathways of nucleotide excision repair (NER), the global genome (gg) NER and the transcription-coupled repair (TCR). TCR can preferentially remove the bulky DNA lesions located at the transcribed strand of a transcriptional active gene more rapidly than those at the untranscribed strand or overall genomic DNA. This strand-specific repair in a suitable restriction fragment is usually determined by alkaline gel electrophoresis followed by Southern blotting transfer and hybridization with an indirect end-labeled single-stranded probe. Here we describe a new method of TCR assay based on strand-specific-PCR (SS-PCR). Using this method, we have investigated the role of DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a member of the phosphatidylinositol 3-kinase-related protein kinases (PIKK) family, in the TCR pathway of UV-induced DNA damage. Although depletion of DNA-PKcs sensitized HeLa cells to UV radiation, it did not affect the ggNER efficiency of UV-induced cyclobutane pyrimidine dimers (CPD) damage. We postulated that DNA-PKcs may involve in the TCR process. To test this hypothesis, we have firstly developed a novel method of TCR assay based on the strand-specific PCR technology with a set of smart primers, which allows the strand-specific amplification of a restricted gene fragment of UV radiation-damaged genomic DNA in mammalian cells. Using this new method, we confirmed that siRNA-mediated downregulation of Cockayne syndrome B resulted in a deficiency of TCR of the UV-damaged dihydrofolate reductase (DHFR) gene. In addition, DMSO-induced silencing of the c-myc gene led to a decreased TCR efficiency of UV radiation-damaged c-myc gene in HL60 cells. On the basis of the above methodology verification, we found that the depletion of DNA-PKcs mediated by siRNA significantly decreased the TCR capacity of repairing the UV-induced CPDs damage in DHFR gene in HeLa cells, indicating that DNA-PKcs may also be involved in the TCR pathway of DNA damage repair. By means of immunoprecipitation and MALDI-TOF-Mass spectrometric analysis, we have revealed the interaction of DNA-PKcs and cyclin T2, which is a subunit of the human transcription elongation factor (P-TEFb). While the P-TEFb complex can phosphorylate the serine 2 of the carboxyl-terminal domain (CTD) of RNA polymerase II and promote transcription elongation. A new method of TCR assay was developed based the strand-specific-PCR (SS-PCR). Our data suggest that DNA-PKcs plays a role in the TCR pathway of UV-damaged DNA. One possible mechanistic hypothesis is that DNA-PKcs may function through associating with CyclinT2/CDK9 (P-TEFb) to modulate the activity of RNA Pol II, which has already been identified as a key molecule recognizing and initializing TCR.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "bdc9cd8b282d4eb29e42242885c5b466", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[46, 47]], "char_spans": [[223, 240]]}]}], "context_tokens": [["In", 0], ["eukaryotic", 3], ["cells", 14], [",", 19], ["there", 21], ["are", 27], ["two", 31], ["sub", 35], ["-", 38], ["pathways", 39], ["of", 48], ["nucleotide", 51], ["excision", 62], ["repair", 71], ["(", 78], ["NER", 79], [")", 82], [",", 83], ["the", 85], ["global", 89], ["genome", 96], ["(", 103], ["gg", 104], [")", 106], ["NER", 108], ["and", 112], ["the", 116], ["transcription", 120], ["-", 133], ["coupled", 134], ["repair", 142], ["(", 149], ["TCR", 150], [")", 153], [".", 154], ["TCR", 156], ["can", 160], ["preferentially", 164], ["remove", 179], ["the", 186], ["bulky", 190], ["DNA", 196], ["lesions", 200], ["located", 208], ["at", 216], ["the", 219], ["transcribed", 223], ["strand", 235], ["of", 242], ["a", 245], ["transcriptional", 247], ["active", 263], ["gene", 270], ["more", 275], ["rapidly", 280], ["than", 288], ["those", 293], ["at", 299], ["the", 302], ["untranscribed", 306], ["strand", 320], ["or", 327], ["overall", 330], ["genomic", 338], ["DNA", 346], [".", 349], ["This", 351], ["strand", 356], ["-", 362], ["specific", 363], ["repair", 372], ["in", 379], ["a", 382], ["suitable", 384], ["restriction", 393], ["fragment", 405], ["is", 414], ["usually", 417], ["determined", 425], ["by", 436], ["alkaline", 439], ["gel", 448], ["electrophoresis", 452], ["followed", 468], ["by", 477], ["Southern", 480], ["blotting", 489], ["transfer", 498], ["and", 507], ["hybridization", 511], ["with", 525], ["an", 530], ["indirect", 533], ["end", 542], ["-", 545], ["labeled", 546], ["single", 554], ["-", 560], ["stranded", 561], ["probe", 570], [".", 575], ["Here", 577], ["we", 582], ["describe", 585], ["a", 594], ["new", 596], ["method", 600], ["of", 607], ["TCR", 610], ["assay", 614], ["based", 620], ["on", 626], ["strand", 629], ["-", 635], ["specific", 636], ["-", 644], ["PCR", 645], ["(", 649], ["SS", 650], ["-", 652], ["PCR", 653], [")", 656], [".", 657], ["Using", 659], ["this", 665], ["method", 670], [",", 676], ["we", 678], ["have", 681], ["investigated", 686], ["the", 699], ["role", 703], ["of", 708], ["DNA", 711], ["-", 714], ["dependent", 715], ["protein", 725], ["kinase", 733], ["catalytic", 740], ["subunit", 750], ["(", 758], ["DNA", 759], ["-", 762], ["PKcs", 763], [")", 767], [",", 768], ["a", 770], ["member", 772], ["of", 779], ["the", 782], ["phosphatidylinositol", 786], ["3-kinase", 807], ["-", 815], ["related", 816], ["protein", 824], ["kinases", 832], ["(", 840], ["PIKK", 841], [")", 845], ["family", 847], [",", 853], ["in", 855], ["the", 858], ["TCR", 862], ["pathway", 866], ["of", 874], ["UV", 877], ["-", 879], ["induced", 880], ["DNA", 888], ["damage", 892], [".", 898], ["Although", 900], ["depletion", 909], ["of", 919], ["DNA", 922], ["-", 925], ["PKcs", 926], ["sensitized", 931], ["HeLa", 942], ["cells", 947], ["to", 953], ["UV", 956], ["radiation", 959], [",", 968], ["it", 970], ["did", 973], ["not", 977], ["affect", 981], ["the", 988], ["ggNER", 992], ["efficiency", 998], ["of", 1009], ["UV", 1012], ["-", 1014], ["induced", 1015], ["cyclobutane", 1023], ["pyrimidine", 1035], ["dimers", 1046], ["(", 1053], ["CPD", 1054], [")", 1057], ["damage", 1059], [".", 1065], ["We", 1067], ["postulated", 1070], ["that", 1081], ["DNA", 1086], ["-", 1089], ["PKcs", 1090], ["may", 1095], ["involve", 1099], ["in", 1107], ["the", 1110], ["TCR", 1114], ["process", 1118], [".", 1125], ["To", 1127], ["test", 1130], ["this", 1135], ["hypothesis", 1140], [",", 1150], ["we", 1152], ["have", 1155], ["firstly", 1160], ["developed", 1168], ["a", 1178], ["novel", 1180], ["method", 1186], ["of", 1193], ["TCR", 1196], ["assay", 1200], ["based", 1206], ["on", 1212], ["the", 1215], ["strand", 1219], ["-", 1225], ["specific", 1226], ["PCR", 1235], ["technology", 1239], ["with", 1250], ["a", 1255], ["set", 1257], ["of", 1261], ["smart", 1264], ["primers", 1270], [",", 1277], ["which", 1279], ["allows", 1285], ["the", 1292], ["strand", 1296], ["-", 1302], ["specific", 1303], ["amplification", 1312], ["of", 1326], ["a", 1329], ["restricted", 1331], ["gene", 1342], ["fragment", 1347], ["of", 1356], ["UV", 1359], ["radiation", 1362], ["-", 1371], ["damaged", 1372], ["genomic", 1380], ["DNA", 1388], ["in", 1392], ["mammalian", 1395], ["cells", 1405], [".", 1410], ["Using", 1412], ["this", 1418], ["new", 1423], ["method", 1427], [",", 1433], ["we", 1435], ["confirmed", 1438], ["that", 1448], ["siRNA", 1453], ["-", 1458], ["mediated", 1459], ["downregulation", 1468], ["of", 1483], ["Cockayne", 1486], ["syndrome", 1495], ["B", 1504], ["resulted", 1506], ["in", 1515], ["a", 1518], ["deficiency", 1520], ["of", 1531], ["TCR", 1534], ["of", 1538], ["the", 1541], ["UV", 1545], ["-", 1547], ["damaged", 1548], ["dihydrofolate", 1556], ["reductase", 1570], ["(", 1580], ["DHFR", 1581], [")", 1585], ["gene", 1587], [".", 1591], ["In", 1593], ["addition", 1596], [",", 1604], ["DMSO", 1606], ["-", 1610], ["induced", 1611], ["silencing", 1619], ["of", 1629], ["the", 1632], ["c", 1636], ["-", 1637], ["myc", 1638], ["gene", 1642], ["led", 1647], ["to", 1651], ["a", 1654], ["decreased", 1656], ["TCR", 1666], ["efficiency", 1670], ["of", 1681], ["UV", 1684], ["radiation", 1687], ["-", 1696], ["damaged", 1697], ["c", 1705], ["-", 1706], ["myc", 1707], ["gene", 1711], ["in", 1716], ["HL60", 1719], ["cells", 1724], [".", 1729], ["On", 1731], ["the", 1734], ["basis", 1738], ["of", 1744], ["the", 1747], ["above", 1751], ["methodology", 1757], ["verification", 1769], [",", 1781], ["we", 1783], ["found", 1786], ["that", 1792], ["the", 1797], ["depletion", 1801], ["of", 1811], ["DNA", 1814], ["-", 1817], ["PKcs", 1818], ["mediated", 1823], ["by", 1832], ["siRNA", 1835], ["significantly", 1841], ["decreased", 1855], ["the", 1865], ["TCR", 1869], ["capacity", 1873], ["of", 1882], ["repairing", 1885], ["the", 1895], ["UV", 1899], ["-", 1901], ["induced", 1902], ["CPDs", 1910], ["damage", 1915], ["in", 1922], ["DHFR", 1925], ["gene", 1930], ["in", 1935], ["HeLa", 1938], ["cells", 1943], [",", 1948], ["indicating", 1950], ["that", 1961], ["DNA", 1966], ["-", 1969], ["PKcs", 1970], ["may", 1975], ["also", 1979], ["be", 1984], ["involved", 1987], ["in", 1996], ["the", 1999], ["TCR", 2003], ["pathway", 2007], ["of", 2015], ["DNA", 2018], ["damage", 2022], ["repair", 2029], [".", 2035], ["By", 2037], ["means", 2040], ["of", 2046], ["immunoprecipitation", 2049], ["and", 2069], ["MALDI", 2073], ["-", 2078], ["TOF", 2079], ["-", 2082], ["Mass", 2083], ["spectrometric", 2088], ["analysis", 2102], [",", 2110], ["we", 2112], ["have", 2115], ["revealed", 2120], ["the", 2129], ["interaction", 2133], ["of", 2145], ["DNA", 2148], ["-", 2151], ["PKcs", 2152], ["and", 2157], ["cyclin", 2161], ["T2", 2168], [",", 2170], ["which", 2172], ["is", 2178], ["a", 2181], ["subunit", 2183], ["of", 2191], ["the", 2194], ["human", 2198], ["transcription", 2204], ["elongation", 2218], ["factor", 2229], ["(", 2236], ["P", 2237], ["-", 2238], ["TEFb", 2239], [")", 2243], [".", 2244], ["While", 2246], ["the", 2252], ["P", 2256], ["-", 2257], ["TEFb", 2258], ["complex", 2263], ["can", 2271], ["phosphorylate", 2275], ["the", 2289], ["serine", 2293], ["2", 2300], ["of", 2302], ["the", 2305], ["carboxyl", 2309], ["-", 2317], ["terminal", 2318], ["domain", 2327], ["(", 2334], ["CTD", 2335], [")", 2338], ["of", 2340], ["RNA", 2343], ["polymerase", 2347], ["II", 2358], ["and", 2361], ["promote", 2365], ["transcription", 2373], ["elongation", 2387], [".", 2397], ["A", 2399], ["new", 2401], ["method", 2405], ["of", 2412], ["TCR", 2415], ["assay", 2419], ["was", 2425], ["developed", 2429], ["based", 2439], ["the", 2445], ["strand", 2449], ["-", 2455], ["specific", 2456], ["-", 2464], ["PCR", 2465], ["(", 2469], ["SS", 2470], ["-", 2472], ["PCR", 2473], [")", 2476], [".", 2477], ["Our", 2479], ["data", 2483], ["suggest", 2488], ["that", 2496], ["DNA", 2501], ["-", 2504], ["PKcs", 2505], ["plays", 2510], ["a", 2516], ["role", 2518], ["in", 2523], ["the", 2526], ["TCR", 2530], ["pathway", 2534], ["of", 2542], ["UV", 2545], ["-", 2547], ["damaged", 2548], ["DNA", 2556], [".", 2559], ["One", 2561], ["possible", 2565], ["mechanistic", 2574], ["hypothesis", 2586], ["is", 2597], ["that", 2600], ["DNA", 2605], ["-", 2608], ["PKcs", 2609], ["may", 2614], ["function", 2618], ["through", 2627], ["associating", 2635], ["with", 2647], ["CyclinT2/CDK9", 2652], ["(", 2666], ["P", 2667], ["-", 2668], ["TEFb", 2669], [")", 2673], ["to", 2675], ["modulate", 2678], ["the", 2687], ["activity", 2691], ["of", 2700], ["RNA", 2703], ["Pol", 2707], ["II", 2711], [",", 2713], ["which", 2715], ["has", 2721], ["already", 2725], ["been", 2733], ["identified", 2738], ["as", 2749], ["a", 2752], ["key", 2754], ["molecule", 2758], ["recognizing", 2767], ["and", 2779], ["initializing", 2783], ["TCR", 2796], [".", 2799]]}
{"context": "Interleukin-1\u03b2 (IL-1\u03b2) is a proinflammatory cytokine that is implicated in many autoinflammatory disorders, but is also important in defense against pathogens. Thus, there is a need to safely and effectively modulate IL-1\u03b2 activity to reduce pathology while maintaining function. Gevokizumab is a potent anti-IL-1\u03b2 antibody being developed as a treatment for diseases in which IL-1\u03b2 has been associated with pathogenesis. Previous data indicated that gevokizumab negatively modulates IL-1\u03b2 signaling through an allosteric mechanism. Because IL-1\u03b2 signaling is a complex, dynamic process involving multiple components, it is important to understand the kinetics of IL-1\u03b2 signaling and the impact of gevokizumab on this process. In the present study, we measured the impact of gevokizumab on the IL-1\u03b2 system using Schild analysis and surface plasmon resonance studies, both of which demonstrated that gevokizumab decreases the binding affinity of IL-1\u03b2 for the IL-1 receptor type I (IL-1RI) signaling receptor, but not the IL-1 counter-regulatory decoy receptor (IL-1 receptor type II). Gevokizumab inhibits both the binding of IL-1\u03b2 to IL-1RI and the subsequent recruitment of IL-1 accessory protein primarily by reducing the association rates of these interactions. Based on this information and recently published structural data, we propose that gevokizumab decreases the association rate for binding of IL-1\u03b2 to its receptor by altering the electrostatic surface potential of IL-1\u03b2, thus reducing the contribution of electrostatic steering to the rapid association rate. These data indicate, therefore, that gevokizumab is a unique inhibitor of IL-1\u03b2 signaling that may offer an alternative to current therapies for IL-1\u03b2-associated autoinflammatory diseases.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "5389373ddbe048119c1dbeb0494dd528", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[128, 128], [51, 51], [227, 227], [150, 150], [266, 266], [2, 2], [277, 277], [36, 36], [76, 76], [84, 84], [185, 185], [238, 238], [104, 104], [62, 62]], "char_spans": [[794, 798], [309, 313], [1407, 1411], [946, 950], [1649, 1653], [16, 20], [1720, 1724], [217, 221], [484, 488], [541, 545], [1127, 1131], [1480, 1484], [664, 668], [377, 381]]}]}], "context_tokens": [["Interleukin-1\u03b2", 0], ["(", 15], ["IL-1\u03b2", 16], [")", 21], ["is", 23], ["a", 26], ["proinflammatory", 28], ["cytokine", 44], ["that", 53], ["is", 58], ["implicated", 61], ["in", 72], ["many", 75], ["autoinflammatory", 80], ["disorders", 97], [",", 106], ["but", 108], ["is", 112], ["also", 115], ["important", 120], ["in", 130], ["defense", 133], ["against", 141], ["pathogens", 149], [".", 158], ["Thus", 160], [",", 164], ["there", 166], ["is", 172], ["a", 175], ["need", 177], ["to", 182], ["safely", 185], ["and", 192], ["effectively", 196], ["modulate", 208], ["IL-1\u03b2", 217], ["activity", 223], ["to", 232], ["reduce", 235], ["pathology", 242], ["while", 252], ["maintaining", 258], ["function", 270], [".", 278], ["Gevokizumab", 280], ["is", 292], ["a", 295], ["potent", 297], ["anti", 304], ["-", 308], ["IL-1\u03b2", 309], ["antibody", 315], ["being", 324], ["developed", 330], ["as", 340], ["a", 343], ["treatment", 345], ["for", 355], ["diseases", 359], ["in", 368], ["which", 371], ["IL-1\u03b2", 377], ["has", 383], ["been", 387], ["associated", 392], ["with", 403], ["pathogenesis", 408], [".", 420], ["Previous", 422], ["data", 431], ["indicated", 436], ["that", 446], ["gevokizumab", 451], ["negatively", 463], ["modulates", 474], ["IL-1\u03b2", 484], ["signaling", 490], ["through", 500], ["an", 508], ["allosteric", 511], ["mechanism", 522], [".", 531], ["Because", 533], ["IL-1\u03b2", 541], ["signaling", 547], ["is", 557], ["a", 560], ["complex", 562], [",", 569], ["dynamic", 571], ["process", 579], ["involving", 587], ["multiple", 597], ["components", 606], [",", 616], ["it", 618], ["is", 621], ["important", 624], ["to", 634], ["understand", 637], ["the", 648], ["kinetics", 652], ["of", 661], ["IL-1\u03b2", 664], ["signaling", 670], ["and", 680], ["the", 684], ["impact", 688], ["of", 695], ["gevokizumab", 698], ["on", 710], ["this", 713], ["process", 718], [".", 725], ["In", 727], ["the", 730], ["present", 734], ["study", 742], [",", 747], ["we", 749], ["measured", 752], ["the", 761], ["impact", 765], ["of", 772], ["gevokizumab", 775], ["on", 787], ["the", 790], ["IL-1\u03b2", 794], ["system", 800], ["using", 807], ["Schild", 813], ["analysis", 820], ["and", 829], ["surface", 833], ["plasmon", 841], ["resonance", 849], ["studies", 859], [",", 866], ["both", 868], ["of", 873], ["which", 876], ["demonstrated", 882], ["that", 895], ["gevokizumab", 900], ["decreases", 912], ["the", 922], ["binding", 926], ["affinity", 934], ["of", 943], ["IL-1\u03b2", 946], ["for", 952], ["the", 956], ["IL-1", 960], ["receptor", 965], ["type", 974], ["I", 979], ["(", 981], ["IL-1RI", 982], [")", 988], ["signaling", 990], ["receptor", 1000], [",", 1008], ["but", 1010], ["not", 1014], ["the", 1018], ["IL-1", 1022], ["counter", 1027], ["-", 1034], ["regulatory", 1035], ["decoy", 1046], ["receptor", 1052], ["(", 1061], ["IL-1", 1062], ["receptor", 1067], ["type", 1076], ["II", 1081], [")", 1083], [".", 1084], ["Gevokizumab", 1086], ["inhibits", 1098], ["both", 1107], ["the", 1112], ["binding", 1116], ["of", 1124], ["IL-1\u03b2", 1127], ["to", 1133], ["IL-1RI", 1136], ["and", 1143], ["the", 1147], ["subsequent", 1151], ["recruitment", 1162], ["of", 1174], ["IL-1", 1177], ["accessory", 1182], ["protein", 1192], ["primarily", 1200], ["by", 1210], ["reducing", 1213], ["the", 1222], ["association", 1226], ["rates", 1238], ["of", 1244], ["these", 1247], ["interactions", 1253], [".", 1265], ["Based", 1267], ["on", 1273], ["this", 1276], ["information", 1281], ["and", 1293], ["recently", 1297], ["published", 1306], ["structural", 1316], ["data", 1327], [",", 1331], ["we", 1333], ["propose", 1336], ["that", 1344], ["gevokizumab", 1349], ["decreases", 1361], ["the", 1371], ["association", 1375], ["rate", 1387], ["for", 1392], ["binding", 1396], ["of", 1404], ["IL-1\u03b2", 1407], ["to", 1413], ["its", 1416], ["receptor", 1420], ["by", 1429], ["altering", 1432], ["the", 1441], ["electrostatic", 1445], ["surface", 1459], ["potential", 1467], ["of", 1477], ["IL-1\u03b2", 1480], [",", 1485], ["thus", 1487], ["reducing", 1492], ["the", 1501], ["contribution", 1505], ["of", 1518], ["electrostatic", 1521], ["steering", 1535], ["to", 1544], ["the", 1547], ["rapid", 1551], ["association", 1557], ["rate", 1569], [".", 1573], ["These", 1575], ["data", 1581], ["indicate", 1586], [",", 1594], ["therefore", 1596], [",", 1605], ["that", 1607], ["gevokizumab", 1612], ["is", 1624], ["a", 1627], ["unique", 1629], ["inhibitor", 1636], ["of", 1646], ["IL-1\u03b2", 1649], ["signaling", 1655], ["that", 1665], ["may", 1670], ["offer", 1674], ["an", 1680], ["alternative", 1683], ["to", 1695], ["current", 1698], ["therapies", 1706], ["for", 1716], ["IL-1\u03b2", 1720], ["-", 1725], ["associated", 1726], ["autoinflammatory", 1737], ["diseases", 1754], [".", 1762]]}
{"context": "Community-associated methicillin-resistant Staphylococcus aureus-(CA-MRSA) strains have emerged in Argentina. We investigated the clinical and molecular evolution of community-onset MRSA infections (CO-MRSA) in children of C\u00f3rdoba, Argentina, 2005-2008. Additionally, data from 2007 were compared with the epidemiology of these infections in other regions of the country. Two datasets were used: i) lab-based prospective surveillance of CA-MRSA isolates from 3 C\u00f3rdoba pediatric hospitals-(CBAH1-H3) in 2007-2008 (compared to previously published data of 2005) and ii) a sampling of CO-MRSA from a study involving both, healthcare-associated community-onset-(HACO) infections in children with risk-factors for healthcare-associated infections-(HRFs), and CA-MRSA infections in patients without HRFs detected in multiple centers of Argentina in 2007. Molecular typing was performed on the CA-MRSA-(n: 99) isolates from the CBAH1-H3-dataset and on the HACO-MRSA-(n: 51) and CA-MRSA-(n: 213) isolates from other regions. Between 2005-2008, the annual proportion of CA-MRSA/CA-S. aureus in C\u00f3rdoba hospitals increased from 25% to 49%, P<0.01. Total CA-MRSA infections increased 3.6 fold-(5.1 to 18.6 cases/100,000 annual-visits, P<0.0001), associated with an important increase of invasive CA-MRSA infections-(8.5 fold). In all regions analyzed, a single genotype prevailed in both CA-MRSA (82%) and HACO-MRSA(57%), which showed pulsed-field-gel electrophoresis-(PFGE)-type-\"I\", sequence-type-5-(ST5), SCCmec-type-IVa, spa-t311, and was positive for PVL. The second clone, pulsotype-N/ST30/CC30/SCCmecIVc/t019/PVL(+), accounted for 11.5% of total CA-MRSA infections. Importantly, the first 4 isolates of Argentina belonging to South American-USA300 clone-(USA300/ST8/CC8/SCCmecIVc/t008/PVL(+)/ACME(-)) were detected. We also demonstrated that a HA-MRSA clone-(pulsotype-C/ST100/CC5) caused 2% and 10% of CA-MRSA and HACO-MRSA infections respectively and was associated with a SCCmec type closely related to SCCmecIV(2B&5). The dissemination of epidemic MRSA clone, ST5-IV-PVL(+) was the main cause of increasing staphylococcal community-onset infections in Argentinean children (2003-2008), conversely to other countries. The predominance of this clone, which has capacity to express the h-VISA phenotype, in healthcare-associated community-onset cases suggests that it has infiltrated into hospital-settings.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "e471eaad8b7f456298a4d3d189d07e9f", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[226, 226], [384, 384], [141, 141], [250, 250], [28, 28], [204, 204], [9, 9], [268, 268], [332, 332], [364, 364], [380, 380], [404, 404], [110, 110], [33, 33], [81, 81]], "char_spans": [[1148, 1151], [1917, 1920], [758, 761], [1289, 1292], [182, 185], [1065, 1068], [69, 72], [1381, 1384], [1646, 1649], [1844, 1847], [1903, 1906], [2049, 2052], [586, 589], [202, 205], [440, 443]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["associated", 10], ["methicillin", 21], ["-", 32], ["resistant", 33], ["Staphylococcus", 43], ["aureus-(CA", 58], ["-", 68], ["MRSA", 69], [")", 73], ["strains", 75], ["have", 83], ["emerged", 88], ["in", 96], ["Argentina", 99], [".", 108], ["We", 110], ["investigated", 113], ["the", 126], ["clinical", 130], ["and", 139], ["molecular", 143], ["evolution", 153], ["of", 163], ["community", 166], ["-", 175], ["onset", 176], ["MRSA", 182], ["infections", 187], ["(", 198], ["CO", 199], ["-", 201], ["MRSA", 202], [")", 206], ["in", 208], ["children", 211], ["of", 220], ["C\u00f3rdoba", 223], [",", 230], ["Argentina", 232], [",", 241], ["2005", 243], ["-", 247], ["2008", 248], [".", 252], ["Additionally", 254], [",", 266], ["data", 268], ["from", 273], ["2007", 278], ["were", 283], ["compared", 288], ["with", 297], ["the", 302], ["epidemiology", 306], ["of", 319], ["these", 322], ["infections", 328], ["in", 339], ["other", 342], ["regions", 348], ["of", 356], ["the", 359], ["country", 363], [".", 370], ["Two", 372], ["datasets", 376], ["were", 385], ["used", 390], [":", 394], ["i", 396], [")", 397], ["lab", 399], ["-", 402], ["based", 403], ["prospective", 409], ["surveillance", 421], ["of", 434], ["CA", 437], ["-", 439], ["MRSA", 440], ["isolates", 445], ["from", 454], ["3", 459], ["C\u00f3rdoba", 461], ["pediatric", 469], ["hospitals-(CBAH1-H3", 479], [")", 498], ["in", 500], ["2007", 503], ["-", 507], ["2008", 508], ["(", 513], ["compared", 514], ["to", 523], ["previously", 526], ["published", 537], ["data", 547], ["of", 552], ["2005", 555], [")", 559], ["and", 561], ["ii", 565], [")", 567], ["a", 569], ["sampling", 571], ["of", 580], ["CO", 583], ["-", 585], ["MRSA", 586], ["from", 591], ["a", 596], ["study", 598], ["involving", 604], ["both", 614], [",", 618], ["healthcare", 620], ["-", 630], ["associated", 631], ["community", 642], ["-", 651], ["onset-(HACO", 652], [")", 663], ["infections", 665], ["in", 676], ["children", 679], ["with", 688], ["risk", 693], ["-", 697], ["factors", 698], ["for", 706], ["healthcare", 710], ["-", 720], ["associated", 721], ["infections-(HRFs", 732], [")", 748], [",", 749], ["and", 751], ["CA", 755], ["-", 757], ["MRSA", 758], ["infections", 763], ["in", 774], ["patients", 777], ["without", 786], ["HRFs", 794], ["detected", 799], ["in", 808], ["multiple", 811], ["centers", 820], ["of", 828], ["Argentina", 831], ["in", 841], ["2007", 844], [".", 848], ["Molecular", 850], ["typing", 860], ["was", 867], ["performed", 871], ["on", 881], ["the", 884], ["CA", 888], ["-", 890], ["MRSA-(n", 891], [":", 898], ["99", 900], [")", 902], ["isolates", 904], ["from", 913], ["the", 918], ["CBAH1-H3-dataset", 922], ["and", 939], ["on", 943], ["the", 946], ["HACO", 950], ["-", 954], ["MRSA-(n", 955], [":", 962], ["51", 964], [")", 966], ["and", 968], ["CA", 972], ["-", 974], ["MRSA-(n", 975], [":", 982], ["213", 984], [")", 987], ["isolates", 989], ["from", 998], ["other", 1003], ["regions", 1009], [".", 1016], ["Between", 1018], ["2005", 1026], ["-", 1030], ["2008", 1031], [",", 1035], ["the", 1037], ["annual", 1041], ["proportion", 1048], ["of", 1059], ["CA", 1062], ["-", 1064], ["MRSA", 1065], ["/", 1069], ["CA", 1070], ["-", 1072], ["S.", 1073], ["aureus", 1076], ["in", 1083], ["C\u00f3rdoba", 1086], ["hospitals", 1094], ["increased", 1104], ["from", 1114], ["25", 1119], ["%", 1121], ["to", 1123], ["49", 1126], ["%", 1128], [",", 1129], ["P<0.01", 1131], [".", 1137], ["Total", 1139], ["CA", 1145], ["-", 1147], ["MRSA", 1148], ["infections", 1153], ["increased", 1164], ["3.6", 1174], ["fold-(5.1", 1178], ["to", 1188], ["18.6", 1191], ["cases/100,000", 1196], ["annual", 1210], ["-", 1216], ["visits", 1217], [",", 1223], ["P<0.0001", 1225], [")", 1233], [",", 1234], ["associated", 1236], ["with", 1247], ["an", 1252], ["important", 1255], ["increase", 1265], ["of", 1274], ["invasive", 1277], ["CA", 1286], ["-", 1288], ["MRSA", 1289], ["infections-(8.5", 1294], ["fold", 1310], [")", 1314], [".", 1315], ["In", 1317], ["all", 1320], ["regions", 1324], ["analyzed", 1332], [",", 1340], ["a", 1342], ["single", 1344], ["genotype", 1351], ["prevailed", 1360], ["in", 1370], ["both", 1373], ["CA", 1378], ["-", 1380], ["MRSA", 1381], ["(", 1386], ["82", 1387], ["%", 1389], [")", 1390], ["and", 1392], ["HACO", 1396], ["-", 1400], ["MRSA(57", 1401], ["%", 1408], [")", 1409], [",", 1410], ["which", 1412], ["showed", 1418], ["pulsed", 1425], ["-", 1431], ["field", 1432], ["-", 1437], ["gel", 1438], ["electrophoresis-(PFGE)-type-\"I", 1442], ["\"", 1472], [",", 1473], ["sequence", 1475], ["-", 1483], ["type-5-(ST5", 1484], [")", 1495], [",", 1496], ["SCCmec", 1498], ["-", 1504], ["type", 1505], ["-", 1509], ["IVa", 1510], [",", 1513], ["spa", 1515], ["-", 1518], ["t311", 1519], [",", 1523], ["and", 1525], ["was", 1529], ["positive", 1533], ["for", 1542], ["PVL", 1546], [".", 1549], ["The", 1551], ["second", 1555], ["clone", 1562], [",", 1567], ["pulsotype", 1569], ["-", 1578], ["N", 1579], ["/", 1580], ["ST30/CC30/SCCmecIVc", 1581], ["/", 1600], ["t019/PVL(+", 1601], [")", 1611], [",", 1612], ["accounted", 1614], ["for", 1624], ["11.5", 1628], ["%", 1632], ["of", 1634], ["total", 1637], ["CA", 1643], ["-", 1645], ["MRSA", 1646], ["infections", 1651], [".", 1661], ["Importantly", 1663], [",", 1674], ["the", 1676], ["first", 1680], ["4", 1686], ["isolates", 1688], ["of", 1697], ["Argentina", 1700], ["belonging", 1710], ["to", 1720], ["South", 1723], ["American", 1729], ["-", 1737], ["USA300", 1738], ["clone-(USA300/ST8/CC8/SCCmecIVc", 1745], ["/", 1776], ["t008/PVL(+)/ACME(-", 1777], [")", 1795], [")", 1796], ["were", 1798], ["detected", 1803], [".", 1811], ["We", 1813], ["also", 1816], ["demonstrated", 1821], ["that", 1834], ["a", 1839], ["HA", 1841], ["-", 1843], ["MRSA", 1844], ["clone-(pulsotype", 1849], ["-", 1865], ["C", 1866], ["/", 1867], ["ST100/CC5", 1868], [")", 1877], ["caused", 1879], ["2", 1886], ["%", 1887], ["and", 1889], ["10", 1893], ["%", 1895], ["of", 1897], ["CA", 1900], ["-", 1902], ["MRSA", 1903], ["and", 1908], ["HACO", 1912], ["-", 1916], ["MRSA", 1917], ["infections", 1922], ["respectively", 1933], ["and", 1946], ["was", 1950], ["associated", 1954], ["with", 1965], ["a", 1970], ["SCCmec", 1972], ["type", 1979], ["closely", 1984], ["related", 1992], ["to", 2000], ["SCCmecIV(2B&5", 2003], [")", 2016], [".", 2017], ["The", 2019], ["dissemination", 2023], ["of", 2037], ["epidemic", 2040], ["MRSA", 2049], ["clone", 2054], [",", 2059], ["ST5-IV", 2061], ["-", 2067], ["PVL(+", 2068], [")", 2073], ["was", 2075], ["the", 2079], ["main", 2083], ["cause", 2088], ["of", 2094], ["increasing", 2097], ["staphylococcal", 2108], ["community", 2123], ["-", 2132], ["onset", 2133], ["infections", 2139], ["in", 2150], ["Argentinean", 2153], ["children", 2165], ["(", 2174], ["2003", 2175], ["-", 2179], ["2008", 2180], [")", 2184], [",", 2185], ["conversely", 2187], ["to", 2198], ["other", 2201], ["countries", 2207], [".", 2216], ["The", 2218], ["predominance", 2222], ["of", 2235], ["this", 2238], ["clone", 2243], [",", 2248], ["which", 2250], ["has", 2256], ["capacity", 2260], ["to", 2269], ["express", 2272], ["the", 2280], ["h", 2284], ["-", 2285], ["VISA", 2286], ["phenotype", 2291], [",", 2300], ["in", 2302], ["healthcare", 2305], ["-", 2315], ["associated", 2316], ["community", 2327], ["-", 2336], ["onset", 2337], ["cases", 2343], ["suggests", 2349], ["that", 2358], ["it", 2363], ["has", 2366], ["infiltrated", 2370], ["into", 2382], ["hospital", 2387], ["-", 2395], ["settings", 2396], [".", 2404]]}
{"context": "Secretory phospholipase A2 (sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2 inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. To determine the effects of sPLA2 inhibition with varespladib on cardiovascular outcomes. A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n\u2009=\u20092572) or placebo (n\u2009=\u20092573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. The primary efficacy measure was a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95% CI, 0.97-1.61; log-rank P\u2009=\u2009.08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95% CI, 1.16-2.39; log-rank P\u2009=\u2009.005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P\u2009=\u2009.04). In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2 inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. clinicaltrials.gov Identifier: NCT01130246.", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "9b9bcd725a354906b933c55de76f23a8", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[0, 2]], "char_spans": [[0, 25]]}]}], "context_tokens": [["Secretory", 0], ["phospholipase", 10], ["A2", 24], ["(", 27], ["sPLA2", 28], [")", 33], ["generates", 35], ["bioactive", 45], ["phospholipid", 55], ["products", 68], ["implicated", 77], ["in", 88], ["atherosclerosis", 91], [".", 106], ["The", 108], ["sPLA2", 112], ["inhibitor", 118], ["varespladib", 128], ["has", 140], ["favorable", 144], ["effects", 154], ["on", 162], ["lipid", 165], ["and", 171], ["inflammatory", 175], ["markers", 188], [";", 195], ["however", 197], [",", 204], ["its", 206], ["effect", 210], ["on", 217], ["cardiovascular", 220], ["outcomes", 235], ["is", 244], ["unknown", 247], [".", 254], ["To", 256], ["determine", 259], ["the", 269], ["effects", 273], ["of", 281], ["sPLA2", 284], ["inhibition", 290], ["with", 301], ["varespladib", 306], ["on", 318], ["cardiovascular", 321], ["outcomes", 336], [".", 344], ["A", 346], ["double", 348], ["-", 354], ["blind", 355], [",", 360], ["randomized", 362], [",", 372], ["multicenter", 374], ["trial", 386], ["at", 392], ["362", 395], ["academic", 399], ["and", 408], ["community", 412], ["hospitals", 422], ["in", 432], ["Europe", 435], [",", 441], ["Australia", 443], [",", 452], ["New", 454], ["Zealand", 458], [",", 465], ["India", 467], [",", 472], ["and", 474], ["North", 478], ["America", 484], ["of", 492], ["5145", 495], ["patients", 500], ["randomized", 509], ["within", 520], ["96", 527], ["hours", 530], ["of", 536], ["presentation", 539], ["of", 552], ["an", 555], ["acute", 558], ["coronary", 564], ["syndrome", 573], ["(", 582], ["ACS", 583], [")", 586], ["to", 588], ["either", 591], ["varespladib", 598], ["(", 610], ["n", 611], ["=", 613], ["2572", 615], [")", 619], ["or", 621], ["placebo", 624], ["(", 632], ["n", 633], ["=", 635], ["2573", 637], [")", 641], ["with", 643], ["enrollment", 648], ["between", 659], ["June", 667], ["1", 672], [",", 673], ["2010", 675], [",", 679], ["and", 681], ["March", 685], ["7", 691], [",", 692], ["2012", 694], ["(", 699], ["study", 700], ["termination", 706], ["on", 718], ["March", 721], ["9", 727], [",", 728], ["2012", 730], [")", 734], [".", 735], ["Participants", 737], ["were", 750], ["randomized", 755], ["to", 766], ["receive", 769], ["varespladib", 777], ["(", 789], ["500", 790], ["mg", 794], [")", 796], ["or", 798], ["placebo", 801], ["daily", 809], ["for", 815], ["16", 819], ["weeks", 822], [",", 827], ["in", 829], ["addition", 832], ["to", 841], ["atorvastatin", 844], ["and", 857], ["other", 861], ["established", 867], ["therapies", 879], [".", 888], ["The", 890], ["primary", 894], ["efficacy", 902], ["measure", 911], ["was", 919], ["a", 923], ["composite", 925], ["of", 935], ["cardiovascular", 938], ["mortality", 953], [",", 962], ["nonfatal", 964], ["myocardial", 973], ["infarction", 984], ["(", 995], ["MI", 996], [")", 998], [",", 999], ["nonfatal", 1001], ["stroke", 1010], [",", 1016], ["or", 1018], ["unstable", 1021], ["angina", 1030], ["with", 1037], ["evidence", 1042], ["of", 1051], ["ischemia", 1054], ["requiring", 1063], ["hospitalization", 1073], ["at", 1089], ["16", 1092], ["weeks", 1095], [".", 1100], ["Six", 1102], ["-", 1105], ["month", 1106], ["survival", 1112], ["status", 1121], ["was", 1128], ["also", 1132], ["evaluated", 1137], [".", 1146], ["At", 1148], ["a", 1151], ["prespecified", 1153], ["interim", 1166], ["analysis", 1174], [",", 1182], ["including", 1184], ["212", 1194], ["primary", 1198], ["end", 1206], ["point", 1210], ["events", 1216], [",", 1222], ["the", 1224], ["independent", 1228], ["data", 1240], ["and", 1245], ["safety", 1249], ["monitoring", 1256], ["board", 1267], ["recommended", 1273], ["termination", 1285], ["of", 1297], ["the", 1300], ["trial", 1304], ["for", 1310], ["futility", 1314], ["and", 1323], ["possible", 1327], ["harm", 1336], [".", 1340], ["The", 1342], ["primary", 1346], ["end", 1354], ["point", 1358], ["occurred", 1364], ["in", 1373], ["136", 1376], ["patients", 1380], ["(", 1389], ["6.1", 1390], ["%", 1393], [")", 1394], ["treated", 1396], ["with", 1404], ["varespladib", 1409], ["compared", 1421], ["with", 1430], ["109", 1435], ["patients", 1439], ["(", 1448], ["5.1", 1449], ["%", 1452], [")", 1453], ["treated", 1455], ["with", 1463], ["placebo", 1468], ["(", 1476], ["hazard", 1477], ["ratio", 1484], ["[", 1490], ["HR", 1491], ["]", 1493], [",", 1494], ["1.25", 1496], [";", 1500], ["95", 1502], ["%", 1504], ["CI", 1506], [",", 1508], ["0.97", 1510], ["-", 1514], ["1.61", 1515], [";", 1519], ["log", 1521], ["-", 1524], ["rank", 1525], ["P", 1530], ["=", 1532], [".08", 1534], [")", 1537], [".", 1538], ["Varespladib", 1540], ["was", 1552], ["associated", 1556], ["with", 1567], ["a", 1572], ["greater", 1574], ["risk", 1582], ["of", 1587], ["MI", 1590], ["(", 1593], ["78", 1594], ["[", 1597], ["3.4", 1598], ["%", 1601], ["]", 1602], ["vs", 1604], ["47", 1607], ["[", 1610], ["2.2", 1611], ["%", 1614], ["]", 1615], [";", 1616], ["HR", 1618], [",", 1620], ["1.66", 1622], [";", 1626], ["95", 1628], ["%", 1630], ["CI", 1632], [",", 1634], ["1.16", 1636], ["-", 1640], ["2.39", 1641], [";", 1645], ["log", 1647], ["-", 1650], ["rank", 1651], ["P", 1656], ["=", 1658], [".005", 1660], [")", 1664], [".", 1665], ["The", 1667], ["composite", 1671], ["secondary", 1681], ["end", 1691], ["point", 1695], ["of", 1701], ["cardiovascular", 1704], ["mortality", 1719], [",", 1728], ["MI", 1730], [",", 1732], ["and", 1734], ["stroke", 1738], ["was", 1745], ["observed", 1749], ["in", 1758], ["107", 1761], ["patients", 1765], ["(", 1774], ["4.6", 1775], ["%", 1778], [")", 1779], ["in", 1781], ["the", 1784], ["varespladib", 1788], ["group", 1800], ["and", 1806], ["79", 1810], ["patients", 1813], ["(", 1822], ["3.8", 1823], ["%", 1826], [")", 1827], ["in", 1829], ["the", 1832], ["placebo", 1836], ["group", 1844], ["(", 1850], ["HR", 1851], [",", 1853], ["1.36", 1855], [";", 1859], ["95", 1861], ["%", 1863], ["CI", 1865], [",", 1867], ["1.02", 1869], ["-", 1873], ["1.82", 1874], [";", 1878], ["P", 1880], ["=", 1882], [".04", 1884], [")", 1887], [".", 1888], ["In", 1890], ["patients", 1893], ["with", 1902], ["recent", 1907], ["ACS", 1914], [",", 1917], ["varespladib", 1919], ["did", 1931], ["not", 1935], ["reduce", 1939], ["the", 1946], ["risk", 1950], ["of", 1955], ["recurrent", 1958], ["cardiovascular", 1968], ["events", 1983], ["and", 1990], ["significantly", 1994], ["increased", 2008], ["the", 2018], ["risk", 2022], ["of", 2027], ["MI", 2030], [".", 2032], ["The", 2034], ["sPLA2", 2038], ["inhibition", 2044], ["with", 2055], ["varespladib", 2060], ["may", 2072], ["be", 2076], ["harmful", 2079], ["and", 2087], ["is", 2091], ["not", 2094], ["a", 2098], ["useful", 2100], ["strategy", 2107], ["to", 2116], ["reduce", 2119], ["adverse", 2126], ["cardiovascular", 2134], ["outcomes", 2149], ["after", 2158], ["ACS", 2164], [".", 2167], ["clinicaltrials.gov", 2169], ["Identifier", 2188], [":", 2198], ["NCT01130246", 2200], [".", 2211]]}
{"context": "The gangliosidoses comprise a family of lysosomal storage diseases characterized by the accumulation of complex glycosphingolipids in the nervous system and other tissues, secondary to the deficient activity of lysosomal hydrolases or their associated activator proteins. GM1 and GM2 gangliosidosis are associated with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase respectively. All gangliosidoses are characterized by progressive neurodegeneration, the severity of which is proportional to the residual enzyme activity. The GM1 gangliosidoses are characterized by dysostosis, organomegaly and coarsening in their most severe forms, whereas children with classic infantile GM2 gangliosidosis (Tay-Sachs disease) are usually spared systemic involvement, except in the case of the Sandhoff variant, in which organomegaly may occur. Cherry-red macular spots occur in the early onset forms of the gangliosidoses, but are less frequently seen in the less severe, later onset phenotypes. Macrocephaly, an exaggerated startle response, cognitive decline, seizures, ataxia, and progressive muscular atrophy may occur in different forms of gangliosidosis. The diagnosis is made by assay of enzyme activity, and can be confirmed by mutation analysis. Carrier screening for Tay-Sachs disease has been remarkably successful in reducing the incidence of this disease in the at-risk Ashkenazi population. There are no proven disease-modifying therapies for the gangliosidoses.", "qas": [{"question": "Which enzyme deficiency can cause GM1 gangliosidoses?", "answers": ["\u03b2-galactosidase"], "qid": "91ba5f0e9cdb420b8e49daf63935d388", "question_tokens": [["Which", 0], ["enzyme", 6], ["deficiency", 13], ["can", 24], ["cause", 28], ["GM1", 34], ["gangliosidoses", 38], ["?", 52]], "detected_answers": [{"text": "\u03b2-galactosidase", "token_spans": [[47, 49]], "char_spans": [[333, 347]]}]}], "context_tokens": [["The", 0], ["gangliosidoses", 4], ["comprise", 19], ["a", 28], ["family", 30], ["of", 37], ["lysosomal", 40], ["storage", 50], ["diseases", 58], ["characterized", 67], ["by", 81], ["the", 84], ["accumulation", 88], ["of", 101], ["complex", 104], ["glycosphingolipids", 112], ["in", 131], ["the", 134], ["nervous", 138], ["system", 146], ["and", 153], ["other", 157], ["tissues", 163], [",", 170], ["secondary", 172], ["to", 182], ["the", 185], ["deficient", 189], ["activity", 199], ["of", 208], ["lysosomal", 211], ["hydrolases", 221], ["or", 232], ["their", 235], ["associated", 241], ["activator", 252], ["proteins", 262], [".", 270], ["GM1", 272], ["and", 276], ["GM2", 280], ["gangliosidosis", 284], ["are", 299], ["associated", 303], ["with", 314], ["deficiency", 319], ["of", 330], ["\u03b2", 333], ["-", 334], ["galactosidase", 335], ["and", 349], ["\u03b2", 353], ["-", 354], ["hexosaminidase", 355], ["respectively", 370], [".", 382], ["All", 384], ["gangliosidoses", 388], ["are", 403], ["characterized", 407], ["by", 421], ["progressive", 424], ["neurodegeneration", 436], [",", 453], ["the", 455], ["severity", 459], ["of", 468], ["which", 471], ["is", 477], ["proportional", 480], ["to", 493], ["the", 496], ["residual", 500], ["enzyme", 509], ["activity", 516], [".", 524], ["The", 526], ["GM1", 530], ["gangliosidoses", 534], ["are", 549], ["characterized", 553], ["by", 567], ["dysostosis", 570], [",", 580], ["organomegaly", 582], ["and", 595], ["coarsening", 599], ["in", 610], ["their", 613], ["most", 619], ["severe", 624], ["forms", 631], [",", 636], ["whereas", 638], ["children", 646], ["with", 655], ["classic", 660], ["infantile", 668], ["GM2", 678], ["gangliosidosis", 682], ["(", 697], ["Tay", 698], ["-", 701], ["Sachs", 702], ["disease", 708], [")", 715], ["are", 717], ["usually", 721], ["spared", 729], ["systemic", 736], ["involvement", 745], [",", 756], ["except", 758], ["in", 765], ["the", 768], ["case", 772], ["of", 777], ["the", 780], ["Sandhoff", 784], ["variant", 793], [",", 800], ["in", 802], ["which", 805], ["organomegaly", 811], ["may", 824], ["occur", 828], [".", 833], ["Cherry", 835], ["-", 841], ["red", 842], ["macular", 846], ["spots", 854], ["occur", 860], ["in", 866], ["the", 869], ["early", 873], ["onset", 879], ["forms", 885], ["of", 891], ["the", 894], ["gangliosidoses", 898], [",", 912], ["but", 914], ["are", 918], ["less", 922], ["frequently", 927], ["seen", 938], ["in", 943], ["the", 946], ["less", 950], ["severe", 955], [",", 961], ["later", 963], ["onset", 969], ["phenotypes", 975], [".", 985], ["Macrocephaly", 987], [",", 999], ["an", 1001], ["exaggerated", 1004], ["startle", 1016], ["response", 1024], [",", 1032], ["cognitive", 1034], ["decline", 1044], [",", 1051], ["seizures", 1053], [",", 1061], ["ataxia", 1063], [",", 1069], ["and", 1071], ["progressive", 1075], ["muscular", 1087], ["atrophy", 1096], ["may", 1104], ["occur", 1108], ["in", 1114], ["different", 1117], ["forms", 1127], ["of", 1133], ["gangliosidosis", 1136], [".", 1150], ["The", 1152], ["diagnosis", 1156], ["is", 1166], ["made", 1169], ["by", 1174], ["assay", 1177], ["of", 1183], ["enzyme", 1186], ["activity", 1193], [",", 1201], ["and", 1203], ["can", 1207], ["be", 1211], ["confirmed", 1214], ["by", 1224], ["mutation", 1227], ["analysis", 1236], [".", 1244], ["Carrier", 1246], ["screening", 1254], ["for", 1264], ["Tay", 1268], ["-", 1271], ["Sachs", 1272], ["disease", 1278], ["has", 1286], ["been", 1290], ["remarkably", 1295], ["successful", 1306], ["in", 1317], ["reducing", 1320], ["the", 1329], ["incidence", 1333], ["of", 1343], ["this", 1346], ["disease", 1351], ["in", 1359], ["the", 1362], ["at", 1366], ["-", 1368], ["risk", 1369], ["Ashkenazi", 1374], ["population", 1384], [".", 1394], ["There", 1396], ["are", 1402], ["no", 1406], ["proven", 1409], ["disease", 1416], ["-", 1423], ["modifying", 1424], ["therapies", 1434], ["for", 1444], ["the", 1448], ["gangliosidoses", 1452], [".", 1466]]}
{"context": "High circulating levels of group IIA secretory phospholipase A2 (sPLA2-IIA) activity and mass are independent cardiovascular risk factors. Therefore, inhibition of sPLA2-IIA may be a target for the treatment of atherosclerotic cardiovascular disease. The present study evaluated the effects of sPLA2-IIA inhibition with varespladib acid in a novel mouse model, human apolipoprotein B (apoB)/human cholesteryl ester transfer protein (CETP)/human sPLA2-IIA triple transgenic mice (TTT) fed a Western-type diet. sPLA2-IIA expression increased atherosclerotic lesion formation in TTT compared with human apoB/human CETP double transgenic mice (P<0.01). Varespladib acid effectively inhibited plasma sPLA2-IIA activity. Surprisingly, however, administration of varespladib acid to TTT had no impact on atherosclerosis, which could be attributed to a proatherogenic plasma lipoprotein profile that appears in response to sPLA2-IIA inhibition because of increased plasma CETP activity. In the TTT model, sPLA2-IIA decreased CETP activity by reducing the acceptor properties of sPLA2-IIA-modified very low-density lipoproteins specifically because of a significantly lower apoE content. Increasing very low-density lipoprotein-apoE content by means of adenovirus-mediated gene transfer in sPLA2-IIA transgenic mice restored the acceptor properties for CETP. These data show that in a humanized triple transgenic mouse model with hypercholesterolemia, sPLA2-IIA inhibition increases CETP activity via increasing the very low-density lipoprotein-apoE content, resulting in a proatherogenic lipoprotein profile.", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "9f57803776af4b0bbe0deae68fbd40b0", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[6, 8]], "char_spans": [[37, 62]]}]}], "context_tokens": [["High", 0], ["circulating", 5], ["levels", 17], ["of", 24], ["group", 27], ["IIA", 33], ["secretory", 37], ["phospholipase", 47], ["A2", 61], ["(", 64], ["sPLA2-IIA", 65], [")", 74], ["activity", 76], ["and", 85], ["mass", 89], ["are", 94], ["independent", 98], ["cardiovascular", 110], ["risk", 125], ["factors", 130], [".", 137], ["Therefore", 139], [",", 148], ["inhibition", 150], ["of", 161], ["sPLA2-IIA", 164], ["may", 174], ["be", 178], ["a", 181], ["target", 183], ["for", 190], ["the", 194], ["treatment", 198], ["of", 208], ["atherosclerotic", 211], ["cardiovascular", 227], ["disease", 242], [".", 249], ["The", 251], ["present", 255], ["study", 263], ["evaluated", 269], ["the", 279], ["effects", 283], ["of", 291], ["sPLA2-IIA", 294], ["inhibition", 304], ["with", 315], ["varespladib", 320], ["acid", 332], ["in", 337], ["a", 340], ["novel", 342], ["mouse", 348], ["model", 354], [",", 359], ["human", 361], ["apolipoprotein", 367], ["B", 382], ["(", 384], ["apoB)/human", 385], ["cholesteryl", 397], ["ester", 409], ["transfer", 415], ["protein", 424], ["(", 432], ["CETP)/human", 433], ["sPLA2-IIA", 445], ["triple", 455], ["transgenic", 462], ["mice", 473], ["(", 478], ["TTT", 479], [")", 482], ["fed", 484], ["a", 488], ["Western", 490], ["-", 497], ["type", 498], ["diet", 503], [".", 507], ["sPLA2-IIA", 509], ["expression", 519], ["increased", 530], ["atherosclerotic", 540], ["lesion", 556], ["formation", 563], ["in", 573], ["TTT", 576], ["compared", 580], ["with", 589], ["human", 594], ["apoB", 600], ["/", 604], ["human", 605], ["CETP", 611], ["double", 616], ["transgenic", 623], ["mice", 634], ["(", 639], ["P<0.01", 640], [")", 646], [".", 647], ["Varespladib", 649], ["acid", 661], ["effectively", 666], ["inhibited", 678], ["plasma", 688], ["sPLA2-IIA", 695], ["activity", 705], [".", 713], ["Surprisingly", 715], [",", 727], ["however", 729], [",", 736], ["administration", 738], ["of", 753], ["varespladib", 756], ["acid", 768], ["to", 773], ["TTT", 776], ["had", 780], ["no", 784], ["impact", 787], ["on", 794], ["atherosclerosis", 797], [",", 812], ["which", 814], ["could", 820], ["be", 826], ["attributed", 829], ["to", 840], ["a", 843], ["proatherogenic", 845], ["plasma", 860], ["lipoprotein", 867], ["profile", 879], ["that", 887], ["appears", 892], ["in", 900], ["response", 903], ["to", 912], ["sPLA2-IIA", 915], ["inhibition", 925], ["because", 936], ["of", 944], ["increased", 947], ["plasma", 957], ["CETP", 964], ["activity", 969], [".", 977], ["In", 979], ["the", 982], ["TTT", 986], ["model", 990], [",", 995], ["sPLA2-IIA", 997], ["decreased", 1007], ["CETP", 1017], ["activity", 1022], ["by", 1031], ["reducing", 1034], ["the", 1043], ["acceptor", 1047], ["properties", 1056], ["of", 1067], ["sPLA2-IIA", 1070], ["-", 1079], ["modified", 1080], ["very", 1089], ["low", 1094], ["-", 1097], ["density", 1098], ["lipoproteins", 1106], ["specifically", 1119], ["because", 1132], ["of", 1140], ["a", 1143], ["significantly", 1145], ["lower", 1159], ["apoE", 1165], ["content", 1170], [".", 1177], ["Increasing", 1179], ["very", 1190], ["low", 1195], ["-", 1198], ["density", 1199], ["lipoprotein", 1207], ["-", 1218], ["apoE", 1219], ["content", 1224], ["by", 1232], ["means", 1235], ["of", 1241], ["adenovirus", 1244], ["-", 1254], ["mediated", 1255], ["gene", 1264], ["transfer", 1269], ["in", 1278], ["sPLA2-IIA", 1281], ["transgenic", 1291], ["mice", 1302], ["restored", 1307], ["the", 1316], ["acceptor", 1320], ["properties", 1329], ["for", 1340], ["CETP", 1344], [".", 1348], ["These", 1350], ["data", 1356], ["show", 1361], ["that", 1366], ["in", 1371], ["a", 1374], ["humanized", 1376], ["triple", 1386], ["transgenic", 1393], ["mouse", 1404], ["model", 1410], ["with", 1416], ["hypercholesterolemia", 1421], [",", 1441], ["sPLA2-IIA", 1443], ["inhibition", 1453], ["increases", 1464], ["CETP", 1474], ["activity", 1479], ["via", 1488], ["increasing", 1492], ["the", 1503], ["very", 1507], ["low", 1512], ["-", 1515], ["density", 1516], ["lipoprotein", 1524], ["-", 1535], ["apoE", 1536], ["content", 1541], [",", 1548], ["resulting", 1550], ["in", 1560], ["a", 1563], ["proatherogenic", 1565], ["lipoprotein", 1580], ["profile", 1592], [".", 1599]]}
{"context": "In order to determine the prevalence of latent infection due to Mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the Monotest and, for reference purposes, to the Mantoux test. The overall prevalence of subjects with a tuberculin skin reaction size > or = 5 mm in the Mantoux test was 25.7%; utilizing a cut-off of > or = 10 mm, the prevalence was 11.4%. Irrespective of cut-off, the Monotest showed a sensitivity of > 90% and a specificity of > 80%. At a prevalence of 25.7%, and with cut-offs of > or = 5 or > or = 10 mm, the positive predictive value was 83% or 62.2%, respectively. Irrespective of cut-off, the negative predictive value was > 97%. In conclusion, the Monotest proved satisfactory as a tool for epidemiological screening in a population with a high prevalence for latent tuberculosis, namely drug users.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "36caa3ccb74340beb0182b812e4fbc13", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[12, 12], [189, 189], [28, 28]], "char_spans": [[78, 89], [902, 913], [169, 180]]}]}], "context_tokens": [["In", 0], ["order", 3], ["to", 9], ["determine", 12], ["the", 22], ["prevalence", 26], ["of", 37], ["latent", 40], ["infection", 47], ["due", 57], ["to", 61], ["Mycobacterium", 64], ["tuberculosis", 78], ["in", 91], ["drug", 94], ["users", 99], ["and", 105], ["to", 109], ["provide", 112], ["centres", 120], ["for", 128], ["drug", 132], ["users", 137], ["with", 143], ["a", 148], ["practical", 150], ["tool", 160], ["for", 165], ["tuberculosis", 169], ["screening", 182], [",", 191], ["237", 193], ["drug", 197], ["users", 202], ["were", 208], ["subjected", 213], ["to", 223], ["the", 226], ["Monotest", 230], ["and", 239], [",", 242], ["for", 244], ["reference", 248], ["purposes", 258], [",", 266], ["to", 268], ["the", 271], ["Mantoux", 275], ["test", 283], [".", 287], ["The", 289], ["overall", 293], ["prevalence", 301], ["of", 312], ["subjects", 315], ["with", 324], ["a", 329], ["tuberculin", 331], ["skin", 342], ["reaction", 347], ["size", 356], [">", 361], ["or", 363], ["=", 366], ["5", 368], ["mm", 370], ["in", 373], ["the", 376], ["Mantoux", 380], ["test", 388], ["was", 393], ["25.7", 397], ["%", 401], [";", 402], ["utilizing", 404], ["a", 414], ["cut", 416], ["-", 419], ["off", 420], ["of", 424], [">", 427], ["or", 429], ["=", 432], ["10", 434], ["mm", 437], [",", 439], ["the", 441], ["prevalence", 445], ["was", 456], ["11.4", 460], ["%", 464], [".", 465], ["Irrespective", 467], ["of", 480], ["cut", 483], ["-", 486], ["off", 487], [",", 490], ["the", 492], ["Monotest", 496], ["showed", 505], ["a", 512], ["sensitivity", 514], ["of", 526], [">", 529], ["90", 531], ["%", 533], ["and", 535], ["a", 539], ["specificity", 541], ["of", 553], [">", 556], ["80", 558], ["%", 560], [".", 561], ["At", 563], ["a", 566], ["prevalence", 568], ["of", 579], ["25.7", 582], ["%", 586], [",", 587], ["and", 589], ["with", 593], ["cut", 598], ["-", 601], ["offs", 602], ["of", 607], [">", 610], ["or", 612], ["=", 615], ["5", 617], ["or", 619], [">", 622], ["or", 624], ["=", 627], ["10", 629], ["mm", 632], [",", 634], ["the", 636], ["positive", 640], ["predictive", 649], ["value", 660], ["was", 666], ["83", 670], ["%", 672], ["or", 674], ["62.2", 677], ["%", 681], [",", 682], ["respectively", 684], [".", 696], ["Irrespective", 698], ["of", 711], ["cut", 714], ["-", 717], ["off", 718], [",", 721], ["the", 723], ["negative", 727], ["predictive", 736], ["value", 747], ["was", 753], [">", 757], ["97", 759], ["%", 761], [".", 762], ["In", 764], ["conclusion", 767], [",", 777], ["the", 779], ["Monotest", 783], ["proved", 792], ["satisfactory", 799], ["as", 812], ["a", 815], ["tool", 817], ["for", 822], ["epidemiological", 826], ["screening", 842], ["in", 852], ["a", 855], ["population", 857], ["with", 868], ["a", 873], ["high", 875], ["prevalence", 880], ["for", 891], ["latent", 895], ["tuberculosis", 902], [",", 914], ["namely", 916], ["drug", 923], ["users", 928], [".", 933]]}
{"context": "This report describes the reliability, validity, treatment sensitivity, diagnostic performance and normative values for the Short Post-Traumatic Stress Disorder (PTSD) Rating Interview (SPRINT), a brief, global assessment for PTSD. The SPRINT was administered to subjects participating in a clinical trial of PTSD and in a population survey assessing PTSD prevalence. The 8-item SPRINT includes questions assessing the core symptoms of PTSD, as well as related aspects of somatic malaise, stress vulnerability and functional impairment. Validity was assessed against the MINI structured interview, the Davidson Trauma Scale, Treatment Outcome for PTSD Scale, Connor-Davidson Resilience Scale, Sheehan Stress Vulnerability Scale, Sheehan Disability Scale and Clinical Global Impressions of Severity and Improvement Scales. Good test-retest reliability, internal consistency, convergent and divergent validity were obtained. The SPRINT was responsive to symptom change over time and correlated with comparable PTSD symptom measures. In victims of trauma, a score of 14-17 was associated with 96% diagnostic accuracy, whereas in those with PTSD, highest efficiency corresponded to a range of 11-13. The SPRINT demonstrates solid psychometric properties and can serve as a reliable, valid and homogeneous measure of PTSD illness severity and of global improvement.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "4426d2042a6d4887bdddfa6bb9150c20", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[19, 23]], "char_spans": [[130, 159]]}, {"text": "PTSD", "token_spans": [[53, 53], [107, 107], [163, 163], [221, 221], [60, 60], [39, 39], [25, 25], [73, 73], [190, 190]], "char_spans": [[309, 312], [647, 650], [1008, 1011], [1312, 1315], [351, 354], [226, 229], [162, 165], [436, 439], [1137, 1140]]}]}], "context_tokens": [["This", 0], ["report", 5], ["describes", 12], ["the", 22], ["reliability", 26], [",", 37], ["validity", 39], [",", 47], ["treatment", 49], ["sensitivity", 59], [",", 70], ["diagnostic", 72], ["performance", 83], ["and", 95], ["normative", 99], ["values", 109], ["for", 116], ["the", 120], ["Short", 124], ["Post", 130], ["-", 134], ["Traumatic", 135], ["Stress", 145], ["Disorder", 152], ["(", 161], ["PTSD", 162], [")", 166], ["Rating", 168], ["Interview", 175], ["(", 185], ["SPRINT", 186], [")", 192], [",", 193], ["a", 195], ["brief", 197], [",", 202], ["global", 204], ["assessment", 211], ["for", 222], ["PTSD", 226], [".", 230], ["The", 232], ["SPRINT", 236], ["was", 243], ["administered", 247], ["to", 260], ["subjects", 263], ["participating", 272], ["in", 286], ["a", 289], ["clinical", 291], ["trial", 300], ["of", 306], ["PTSD", 309], ["and", 314], ["in", 318], ["a", 321], ["population", 323], ["survey", 334], ["assessing", 341], ["PTSD", 351], ["prevalence", 356], [".", 366], ["The", 368], ["8-item", 372], ["SPRINT", 379], ["includes", 386], ["questions", 395], ["assessing", 405], ["the", 415], ["core", 419], ["symptoms", 424], ["of", 433], ["PTSD", 436], [",", 440], ["as", 442], ["well", 445], ["as", 450], ["related", 453], ["aspects", 461], ["of", 469], ["somatic", 472], ["malaise", 480], [",", 487], ["stress", 489], ["vulnerability", 496], ["and", 510], ["functional", 514], ["impairment", 525], [".", 535], ["Validity", 537], ["was", 546], ["assessed", 550], ["against", 559], ["the", 567], ["MINI", 571], ["structured", 576], ["interview", 587], [",", 596], ["the", 598], ["Davidson", 602], ["Trauma", 611], ["Scale", 618], [",", 623], ["Treatment", 625], ["Outcome", 635], ["for", 643], ["PTSD", 647], ["Scale", 652], [",", 657], ["Connor", 659], ["-", 665], ["Davidson", 666], ["Resilience", 675], ["Scale", 686], [",", 691], ["Sheehan", 693], ["Stress", 701], ["Vulnerability", 708], ["Scale", 722], [",", 727], ["Sheehan", 729], ["Disability", 737], ["Scale", 748], ["and", 754], ["Clinical", 758], ["Global", 767], ["Impressions", 774], ["of", 786], ["Severity", 789], ["and", 798], ["Improvement", 802], ["Scales", 814], [".", 820], ["Good", 822], ["test", 827], ["-", 831], ["retest", 832], ["reliability", 839], [",", 850], ["internal", 852], ["consistency", 861], [",", 872], ["convergent", 874], ["and", 885], ["divergent", 889], ["validity", 899], ["were", 908], ["obtained", 913], [".", 921], ["The", 923], ["SPRINT", 927], ["was", 934], ["responsive", 938], ["to", 949], ["symptom", 952], ["change", 960], ["over", 967], ["time", 972], ["and", 977], ["correlated", 981], ["with", 992], ["comparable", 997], ["PTSD", 1008], ["symptom", 1013], ["measures", 1021], [".", 1029], ["In", 1031], ["victims", 1034], ["of", 1042], ["trauma", 1045], [",", 1051], ["a", 1053], ["score", 1055], ["of", 1061], ["14", 1064], ["-", 1066], ["17", 1067], ["was", 1070], ["associated", 1074], ["with", 1085], ["96", 1090], ["%", 1092], ["diagnostic", 1094], ["accuracy", 1105], [",", 1113], ["whereas", 1115], ["in", 1123], ["those", 1126], ["with", 1132], ["PTSD", 1137], [",", 1141], ["highest", 1143], ["efficiency", 1151], ["corresponded", 1162], ["to", 1175], ["a", 1178], ["range", 1180], ["of", 1186], ["11", 1189], ["-", 1191], ["13", 1192], [".", 1194], ["The", 1196], ["SPRINT", 1200], ["demonstrates", 1207], ["solid", 1220], ["psychometric", 1226], ["properties", 1239], ["and", 1250], ["can", 1254], ["serve", 1258], ["as", 1264], ["a", 1267], ["reliable", 1269], [",", 1277], ["valid", 1279], ["and", 1285], ["homogeneous", 1289], ["measure", 1301], ["of", 1309], ["PTSD", 1312], ["illness", 1317], ["severity", 1325], ["and", 1334], ["of", 1338], ["global", 1341], ["improvement", 1348], [".", 1359]]}
{"context": "Ehlers-Danlos syndrome type 4, the vascular type, is a rare, life-threatening inherited disorder of the connective tissue. Affected patients are at risk of arterial, bowel and uterine rupture during pregnancy. Generally, this syndrome remains undiagnosed until a sudden, acute presentation with organ rupture, and results in premature death, even if the patients survive the first and second major complications. An early diagnosis with genetic assays can help to plan the best treatment, which is often challenging due to the frailty of the arterial tissue. We report on a 28-year-old lady who presented with spontaneous rupture of a pseudoaneurysm of the posterior tibial artery.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "1a2e7aaf9e9148c98bfc8b68db1ea274", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[22, 23]], "char_spans": [[104, 120]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["type", 23], ["4", 28], [",", 29], ["the", 31], ["vascular", 35], ["type", 44], [",", 48], ["is", 50], ["a", 53], ["rare", 55], [",", 59], ["life", 61], ["-", 65], ["threatening", 66], ["inherited", 78], ["disorder", 88], ["of", 97], ["the", 100], ["connective", 104], ["tissue", 115], [".", 121], ["Affected", 123], ["patients", 132], ["are", 141], ["at", 145], ["risk", 148], ["of", 153], ["arterial", 156], [",", 164], ["bowel", 166], ["and", 172], ["uterine", 176], ["rupture", 184], ["during", 192], ["pregnancy", 199], [".", 208], ["Generally", 210], [",", 219], ["this", 221], ["syndrome", 226], ["remains", 235], ["undiagnosed", 243], ["until", 255], ["a", 261], ["sudden", 263], [",", 269], ["acute", 271], ["presentation", 277], ["with", 290], ["organ", 295], ["rupture", 301], [",", 308], ["and", 310], ["results", 314], ["in", 322], ["premature", 325], ["death", 335], [",", 340], ["even", 342], ["if", 347], ["the", 350], ["patients", 354], ["survive", 363], ["the", 371], ["first", 375], ["and", 381], ["second", 385], ["major", 392], ["complications", 398], [".", 411], ["An", 413], ["early", 416], ["diagnosis", 422], ["with", 432], ["genetic", 437], ["assays", 445], ["can", 452], ["help", 456], ["to", 461], ["plan", 464], ["the", 469], ["best", 473], ["treatment", 478], [",", 487], ["which", 489], ["is", 495], ["often", 498], ["challenging", 504], ["due", 516], ["to", 520], ["the", 523], ["frailty", 527], ["of", 535], ["the", 538], ["arterial", 542], ["tissue", 551], [".", 557], ["We", 559], ["report", 562], ["on", 569], ["a", 572], ["28-year", 574], ["-", 581], ["old", 582], ["lady", 586], ["who", 591], ["presented", 595], ["with", 605], ["spontaneous", 610], ["rupture", 622], ["of", 630], ["a", 633], ["pseudoaneurysm", 635], ["of", 650], ["the", 653], ["posterior", 657], ["tibial", 667], ["artery", 674], [".", 680]]}
{"context": "Idarucizumab is a monoclonal antibody fragment that binds dabigatran with high affinity in a 1:1 molar ratio. We investigated the safety, tolerability, and efficacy of increasing doses of idarucizumab for the reversal of anticoagulant effects of dabigatran in a two-part phase 1 study (rising-dose assessment and dose-finding, proof-of-concept investigation). Here we present the results of the proof-of-concept part of the study. In this randomised, placebo-controlled, double-blind, proof-of-concept phase 1 study, we enrolled healthy volunteers (aged 18-45 years) with a body-mass index of 18\u00b75-29\u00b79 kg/m(2) into one of four dose groups at SGS Life Sciences Clinical Research Services, Belgium. Participants were randomly assigned within groups in a 3:1 ratio to idarucizumab or placebo using a pseudorandom number generator and a supplied seed number. Participants and care providers were masked to treatment assignment. All participants received oral dabigatran etexilate 220 mg twice daily for 3 days and a final dose on day 4. Idarucizumab (1 g, 2 g, or 4 g 5-min infusion, or 5 g plus 2\u00b75 g in two 5-min infusions given 1 h apart) was administered about 2 h after the final dabigatran etexilate dose. The primary endpoint was incidence of drug-related adverse events, analysed in all randomly assigned participants who received at least one dose of dabigatran etexilate. Reversal of diluted thrombin time (dTT), ecarin clotting time (ECT), activated partial thromboplastin time (aPTT), and thrombin time (TT) were secondary endpoints assessed by measuring the area under the effect curve from 2 h to 12 h (AUEC2-12) after dabigatran etexilate ingestion on days 3 and 4. This trial is registered with ClinicalTrials.gov, number NCT01688830. Between Feb 23, and Nov 29, 2013, 47 men completed this part of the study. 12 were enrolled into each of the 1 g, 2 g, or 5 g plus 2\u00b75 g idarucizumab groups (nine to idarucizumab and three to placebo in each group), and 11 were enrolled into the 4 g idarucizumab group (eight to idarucizumab and three to placebo). Drug-related adverse events were all of mild intensity and reported in seven participants: one in the 1 g idarucizumab group (infusion site erythema and hot flushes), one in the 5 g plus 2\u00b75 g idarucizumab group (epistaxis); one receiving placebo (infusion site haematoma), and four during dabigatran etexilate pretreatment (three haematuria and one epistaxis). Idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 AUEC2-12 to day 3 AUEC2-12 for dTT was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction). No serious or severe adverse events were reported, no adverse event led to discontinuation of treatment, and no clinically relevant difference in incidence of adverse events was noted between treatment groups. These phase 1 results show that idarucizumab was associated with immediate, complete, and sustained reversal of dabigatran-induced anticoagulation in healthy men, and was well tolerated with no unexpected or clinically relevant safety concerns, supporting further testing. Further clinical studies are in progress. Boehringer Ingelheim Pharma GmbH & Co KG.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "2997ce0116fe4da1afc9fa4cdf7e48d6", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[267, 267], [474, 474], [490, 490], [324, 324], [39, 39], [184, 184], [8, 8], [238, 238], [623, 623]], "char_spans": [[1357, 1366], [2353, 2362], [2474, 2483], [1630, 1639], [246, 255], [956, 965], [58, 67], [1182, 1191], [3132, 3141]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["a", 16], ["monoclonal", 18], ["antibody", 29], ["fragment", 38], ["that", 47], ["binds", 52], ["dabigatran", 58], ["with", 69], ["high", 74], ["affinity", 79], ["in", 88], ["a", 91], ["1:1", 93], ["molar", 97], ["ratio", 103], [".", 108], ["We", 110], ["investigated", 113], ["the", 126], ["safety", 130], [",", 136], ["tolerability", 138], [",", 150], ["and", 152], ["efficacy", 156], ["of", 165], ["increasing", 168], ["doses", 179], ["of", 185], ["idarucizumab", 188], ["for", 201], ["the", 205], ["reversal", 209], ["of", 218], ["anticoagulant", 221], ["effects", 235], ["of", 243], ["dabigatran", 246], ["in", 257], ["a", 260], ["two", 262], ["-", 265], ["part", 266], ["phase", 271], ["1", 277], ["study", 279], ["(", 285], ["rising", 286], ["-", 292], ["dose", 293], ["assessment", 298], ["and", 309], ["dose", 313], ["-", 317], ["finding", 318], [",", 325], ["proof", 327], ["-", 332], ["of", 333], ["-", 335], ["concept", 336], ["investigation", 344], [")", 357], [".", 358], ["Here", 360], ["we", 365], ["present", 368], ["the", 376], ["results", 380], ["of", 388], ["the", 391], ["proof", 395], ["-", 400], ["of", 401], ["-", 403], ["concept", 404], ["part", 412], ["of", 417], ["the", 420], ["study", 424], [".", 429], ["In", 431], ["this", 434], ["randomised", 439], [",", 449], ["placebo", 451], ["-", 458], ["controlled", 459], [",", 469], ["double", 471], ["-", 477], ["blind", 478], [",", 483], ["proof", 485], ["-", 490], ["of", 491], ["-", 493], ["concept", 494], ["phase", 502], ["1", 508], ["study", 510], [",", 515], ["we", 517], ["enrolled", 520], ["healthy", 529], ["volunteers", 537], ["(", 548], ["aged", 549], ["18", 554], ["-", 556], ["45", 557], ["years", 560], [")", 565], ["with", 567], ["a", 572], ["body", 574], ["-", 578], ["mass", 579], ["index", 584], ["of", 590], ["18\u00b75", 593], ["-", 597], ["29\u00b79", 598], ["kg", 603], ["/", 605], ["m(2", 606], [")", 609], ["into", 611], ["one", 616], ["of", 620], ["four", 623], ["dose", 628], ["groups", 633], ["at", 640], ["SGS", 643], ["Life", 647], ["Sciences", 652], ["Clinical", 661], ["Research", 670], ["Services", 679], [",", 687], ["Belgium", 689], [".", 696], ["Participants", 698], ["were", 711], ["randomly", 716], ["assigned", 725], ["within", 734], ["groups", 741], ["in", 748], ["a", 751], ["3:1", 753], ["ratio", 757], ["to", 763], ["idarucizumab", 766], ["or", 779], ["placebo", 782], ["using", 790], ["a", 796], ["pseudorandom", 798], ["number", 811], ["generator", 818], ["and", 828], ["a", 832], ["supplied", 834], ["seed", 843], ["number", 848], [".", 854], ["Participants", 856], ["and", 869], ["care", 873], ["providers", 878], ["were", 888], ["masked", 893], ["to", 900], ["treatment", 903], ["assignment", 913], [".", 923], ["All", 925], ["participants", 929], ["received", 942], ["oral", 951], ["dabigatran", 956], ["etexilate", 967], ["220", 977], ["mg", 981], ["twice", 984], ["daily", 990], ["for", 996], ["3", 1000], ["days", 1002], ["and", 1007], ["a", 1011], ["final", 1013], ["dose", 1019], ["on", 1024], ["day", 1027], ["4", 1031], [".", 1032], ["Idarucizumab", 1034], ["(", 1047], ["1", 1048], ["g", 1050], [",", 1051], ["2", 1053], ["g", 1055], [",", 1056], ["or", 1058], ["4", 1061], ["g", 1063], ["5-min", 1065], ["infusion", 1071], [",", 1079], ["or", 1081], ["5", 1084], ["g", 1086], ["plus", 1088], ["2\u00b75", 1093], ["g", 1097], ["in", 1099], ["two", 1102], ["5-min", 1106], ["infusions", 1112], ["given", 1122], ["1", 1128], ["h", 1130], ["apart", 1132], [")", 1137], ["was", 1139], ["administered", 1143], ["about", 1156], ["2", 1162], ["h", 1164], ["after", 1166], ["the", 1172], ["final", 1176], ["dabigatran", 1182], ["etexilate", 1193], ["dose", 1203], [".", 1207], ["The", 1209], ["primary", 1213], ["endpoint", 1221], ["was", 1230], ["incidence", 1234], ["of", 1244], ["drug", 1247], ["-", 1251], ["related", 1252], ["adverse", 1260], ["events", 1268], [",", 1274], ["analysed", 1276], ["in", 1285], ["all", 1288], ["randomly", 1292], ["assigned", 1301], ["participants", 1310], ["who", 1323], ["received", 1327], ["at", 1336], ["least", 1339], ["one", 1345], ["dose", 1349], ["of", 1354], ["dabigatran", 1357], ["etexilate", 1368], [".", 1377], ["Reversal", 1379], ["of", 1388], ["diluted", 1391], ["thrombin", 1399], ["time", 1408], ["(", 1413], ["dTT", 1414], [")", 1417], [",", 1418], ["ecarin", 1420], ["clotting", 1427], ["time", 1436], ["(", 1441], ["ECT", 1442], [")", 1445], [",", 1446], ["activated", 1448], ["partial", 1458], ["thromboplastin", 1466], ["time", 1481], ["(", 1486], ["aPTT", 1487], [")", 1491], [",", 1492], ["and", 1494], ["thrombin", 1498], ["time", 1507], ["(", 1512], ["TT", 1513], [")", 1515], ["were", 1517], ["secondary", 1522], ["endpoints", 1532], ["assessed", 1542], ["by", 1551], ["measuring", 1554], ["the", 1564], ["area", 1568], ["under", 1573], ["the", 1579], ["effect", 1583], ["curve", 1590], ["from", 1596], ["2", 1601], ["h", 1603], ["to", 1605], ["12", 1608], ["h", 1611], ["(", 1613], ["AUEC2", 1614], ["-", 1619], ["12", 1620], [")", 1622], ["after", 1624], ["dabigatran", 1630], ["etexilate", 1641], ["ingestion", 1651], ["on", 1661], ["days", 1664], ["3", 1669], ["and", 1671], ["4", 1675], [".", 1676], ["This", 1678], ["trial", 1683], ["is", 1689], ["registered", 1692], ["with", 1703], ["ClinicalTrials.gov", 1708], [",", 1726], ["number", 1728], ["NCT01688830", 1735], [".", 1746], ["Between", 1748], ["Feb", 1756], ["23", 1760], [",", 1762], ["and", 1764], ["Nov", 1768], ["29", 1772], [",", 1774], ["2013", 1776], [",", 1780], ["47", 1782], ["men", 1785], ["completed", 1789], ["this", 1799], ["part", 1804], ["of", 1809], ["the", 1812], ["study", 1816], [".", 1821], ["12", 1823], ["were", 1826], ["enrolled", 1831], ["into", 1840], ["each", 1845], ["of", 1850], ["the", 1853], ["1", 1857], ["g", 1859], [",", 1860], ["2", 1862], ["g", 1864], [",", 1865], ["or", 1867], ["5", 1870], ["g", 1872], ["plus", 1874], ["2\u00b75", 1879], ["g", 1883], ["idarucizumab", 1885], ["groups", 1898], ["(", 1905], ["nine", 1906], ["to", 1911], ["idarucizumab", 1914], ["and", 1927], ["three", 1931], ["to", 1937], ["placebo", 1940], ["in", 1948], ["each", 1951], ["group", 1956], [")", 1961], [",", 1962], ["and", 1964], ["11", 1968], ["were", 1971], ["enrolled", 1976], ["into", 1985], ["the", 1990], ["4", 1994], ["g", 1996], ["idarucizumab", 1998], ["group", 2011], ["(", 2017], ["eight", 2018], ["to", 2024], ["idarucizumab", 2027], ["and", 2040], ["three", 2044], ["to", 2050], ["placebo", 2053], [")", 2060], [".", 2061], ["Drug", 2063], ["-", 2067], ["related", 2068], ["adverse", 2076], ["events", 2084], ["were", 2091], ["all", 2096], ["of", 2100], ["mild", 2103], ["intensity", 2108], ["and", 2118], ["reported", 2122], ["in", 2131], ["seven", 2134], ["participants", 2140], [":", 2152], ["one", 2154], ["in", 2158], ["the", 2161], ["1", 2165], ["g", 2167], ["idarucizumab", 2169], ["group", 2182], ["(", 2188], ["infusion", 2189], ["site", 2198], ["erythema", 2203], ["and", 2212], ["hot", 2216], ["flushes", 2220], [")", 2227], [",", 2228], ["one", 2230], ["in", 2234], ["the", 2237], ["5", 2241], ["g", 2243], ["plus", 2245], ["2\u00b75", 2250], ["g", 2254], ["idarucizumab", 2256], ["group", 2269], ["(", 2275], ["epistaxis", 2276], [")", 2285], [";", 2286], ["one", 2288], ["receiving", 2292], ["placebo", 2302], ["(", 2310], ["infusion", 2311], ["site", 2320], ["haematoma", 2325], [")", 2334], [",", 2335], ["and", 2337], ["four", 2341], ["during", 2346], ["dabigatran", 2353], ["etexilate", 2364], ["pretreatment", 2374], ["(", 2387], ["three", 2388], ["haematuria", 2394], ["and", 2405], ["one", 2409], ["epistaxis", 2413], [")", 2422], [".", 2423], ["Idarucizumab", 2425], ["immediately", 2438], ["and", 2450], ["completely", 2454], ["reversed", 2465], ["dabigatran", 2474], ["-", 2484], ["induced", 2485], ["anticoagulation", 2493], ["in", 2509], ["a", 2512], ["dose", 2514], ["-", 2518], ["dependent", 2519], ["manner", 2529], [";", 2535], ["the", 2537], ["mean", 2541], ["ratio", 2546], ["of", 2552], ["day", 2555], ["4", 2559], ["AUEC2", 2561], ["-", 2566], ["12", 2567], ["to", 2570], ["day", 2573], ["3", 2577], ["AUEC2", 2579], ["-", 2584], ["12", 2585], ["for", 2588], ["dTT", 2592], ["was", 2596], ["1\u00b701", 2600], ["with", 2605], ["placebo", 2610], [",", 2617], ["0\u00b726", 2619], ["with", 2624], ["1", 2629], ["g", 2631], ["idarucizumab", 2633], ["(", 2646], ["74", 2647], ["%", 2649], ["reduction", 2651], [")", 2660], [",", 2661], ["0\u00b706", 2663], ["with", 2668], ["2", 2673], ["g", 2675], ["idarucizumab", 2677], ["(", 2690], ["94", 2691], ["%", 2693], ["reduction", 2695], [")", 2704], [",", 2705], ["0\u00b702", 2707], ["with", 2712], ["4", 2717], ["g", 2719], ["idarucizumab", 2721], ["(", 2734], ["98", 2735], ["%", 2737], ["reduction", 2739], [")", 2748], [",", 2749], ["and", 2751], ["0\u00b701", 2755], ["with", 2760], ["5", 2765], ["g", 2767], ["plus", 2769], ["2\u00b75", 2774], ["g", 2778], ["idarucizumab", 2780], ["(", 2793], ["99", 2794], ["%", 2796], ["reduction", 2798], [")", 2807], [".", 2808], ["No", 2810], ["serious", 2813], ["or", 2821], ["severe", 2824], ["adverse", 2831], ["events", 2839], ["were", 2846], ["reported", 2851], [",", 2859], ["no", 2861], ["adverse", 2864], ["event", 2872], ["led", 2878], ["to", 2882], ["discontinuation", 2885], ["of", 2901], ["treatment", 2904], [",", 2913], ["and", 2915], ["no", 2919], ["clinically", 2922], ["relevant", 2933], ["difference", 2942], ["in", 2953], ["incidence", 2956], ["of", 2966], ["adverse", 2969], ["events", 2977], ["was", 2984], ["noted", 2988], ["between", 2994], ["treatment", 3002], ["groups", 3012], [".", 3018], ["These", 3020], ["phase", 3026], ["1", 3032], ["results", 3034], ["show", 3042], ["that", 3047], ["idarucizumab", 3052], ["was", 3065], ["associated", 3069], ["with", 3080], ["immediate", 3085], [",", 3094], ["complete", 3096], [",", 3104], ["and", 3106], ["sustained", 3110], ["reversal", 3120], ["of", 3129], ["dabigatran", 3132], ["-", 3142], ["induced", 3143], ["anticoagulation", 3151], ["in", 3167], ["healthy", 3170], ["men", 3178], [",", 3181], ["and", 3183], ["was", 3187], ["well", 3191], ["tolerated", 3196], ["with", 3206], ["no", 3211], ["unexpected", 3214], ["or", 3225], ["clinically", 3228], ["relevant", 3239], ["safety", 3248], ["concerns", 3255], [",", 3263], ["supporting", 3265], ["further", 3276], ["testing", 3284], [".", 3291], ["Further", 3293], ["clinical", 3301], ["studies", 3310], ["are", 3318], ["in", 3322], ["progress", 3325], [".", 3333], ["Boehringer", 3335], ["Ingelheim", 3346], ["Pharma", 3356], ["GmbH", 3363], ["&", 3368], ["Co", 3370], ["KG", 3373], [".", 3375]]}
{"context": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic. In search for the pathophysiology and causative agent of VE, we performed a cross-sectional study on clinical, serological and neuroimaging data on chronic VE patients during two medical expeditions to three villages within the Viliuiski river basin in the Republic of Sakha in 2000 and to the capital Yakutsk in 2006. The severity of the core clinical picture with predominant sensory ataxia, gait apraxia, lower limb spasticity, cognitive impairment and bladder dysfunction correlated with the degree of MRI findings showing enlargement of inner ventricular spaces as in communicating hydrocephalus. Laboratory studies revealed transient eosinophilia during the preceding acute meningitis-like phase, but no ongoing inflammatory process in the CSF. We found immune reactions against Toxocara canis in the majority of chronic VE patients but rarely in controls (P = 0.025; Fisher's exact test). Histological analysis of subacute to subchronic VE brain samples showed eosinophilic infiltrations with no signs of persistent Toxocara canis infection. Our data showed that pressure by the communicating hydrocephalus as a mechanical factor is the major pathogenic mechanism in chronic VE, most likely triggered by eosinophilic meningitis. There are no signs for an ongoing inflammatory process in chronic VE. The past eosinophilic reaction in VE might be caused by Toxocara ssp. infection and might therefore represent the first hint for an initial cause leading to the development of chronic VE. Our data provide a framework for future studies and potential therapeutic interventions for this enigmatic epidemic neurological disease potentially spreading in Sakha Republic.", "qas": [{"question": "Viliuisk encephalomyelitis is diagnosed in which geographical area?", "answers": ["Northeast Siberia"], "qid": "15bd193287ec4c43b761c54699d4ca55", "question_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["is", 27], ["diagnosed", 30], ["in", 40], ["which", 43], ["geographical", 49], ["area", 62], ["?", 66]], "detected_answers": [{"text": "Northeast Siberia", "token_spans": [[11, 12]], "char_spans": [[70, 86]]}]}], "context_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["(", 27], ["VE", 28], [")", 30], ["is", 32], ["an", 35], ["endemic", 38], ["neurological", 46], ["disease", 59], ["in", 67], ["Northeast", 70], ["Siberia", 80], ["and", 88], ["generally", 92], ["considered", 102], ["to", 113], ["be", 116], ["a", 119], ["chronic", 121], ["encephalomyelitis", 129], ["of", 147], ["unknown", 150], ["origin", 158], ["actually", 165], ["spreading", 174], ["in", 184], ["the", 187], ["Sakha", 191], ["(", 197], ["Yakutian", 198], [")", 206], ["Republic", 208], [".", 216], ["In", 218], ["search", 221], ["for", 228], ["the", 232], ["pathophysiology", 236], ["and", 252], ["causative", 256], ["agent", 266], ["of", 272], ["VE", 275], [",", 277], ["we", 279], ["performed", 282], ["a", 292], ["cross", 294], ["-", 299], ["sectional", 300], ["study", 310], ["on", 316], ["clinical", 319], [",", 327], ["serological", 329], ["and", 341], ["neuroimaging", 345], ["data", 358], ["on", 363], ["chronic", 366], ["VE", 374], ["patients", 377], ["during", 386], ["two", 393], ["medical", 397], ["expeditions", 405], ["to", 417], ["three", 420], ["villages", 426], ["within", 435], ["the", 442], ["Viliuiski", 446], ["river", 456], ["basin", 462], ["in", 468], ["the", 471], ["Republic", 475], ["of", 484], ["Sakha", 487], ["in", 493], ["2000", 496], ["and", 501], ["to", 505], ["the", 508], ["capital", 512], ["Yakutsk", 520], ["in", 528], ["2006", 531], [".", 535], ["The", 537], ["severity", 541], ["of", 550], ["the", 553], ["core", 557], ["clinical", 562], ["picture", 571], ["with", 579], ["predominant", 584], ["sensory", 596], ["ataxia", 604], [",", 610], ["gait", 612], ["apraxia", 617], [",", 624], ["lower", 626], ["limb", 632], ["spasticity", 637], [",", 647], ["cognitive", 649], ["impairment", 659], ["and", 670], ["bladder", 674], ["dysfunction", 682], ["correlated", 694], ["with", 705], ["the", 710], ["degree", 714], ["of", 721], ["MRI", 724], ["findings", 728], ["showing", 737], ["enlargement", 745], ["of", 757], ["inner", 760], ["ventricular", 766], ["spaces", 778], ["as", 785], ["in", 788], ["communicating", 791], ["hydrocephalus", 805], [".", 818], ["Laboratory", 820], ["studies", 831], ["revealed", 839], ["transient", 848], ["eosinophilia", 858], ["during", 871], ["the", 878], ["preceding", 882], ["acute", 892], ["meningitis", 898], ["-", 908], ["like", 909], ["phase", 914], [",", 919], ["but", 921], ["no", 925], ["ongoing", 928], ["inflammatory", 936], ["process", 949], ["in", 957], ["the", 960], ["CSF", 964], [".", 967], ["We", 969], ["found", 972], ["immune", 978], ["reactions", 985], ["against", 995], ["Toxocara", 1003], ["canis", 1012], ["in", 1018], ["the", 1021], ["majority", 1025], ["of", 1034], ["chronic", 1037], ["VE", 1045], ["patients", 1048], ["but", 1057], ["rarely", 1061], ["in", 1068], ["controls", 1071], ["(", 1080], ["P", 1081], ["=", 1083], ["0.025", 1085], [";", 1090], ["Fisher", 1092], ["'s", 1098], ["exact", 1101], ["test", 1107], [")", 1111], [".", 1112], ["Histological", 1114], ["analysis", 1127], ["of", 1136], ["subacute", 1139], ["to", 1148], ["subchronic", 1151], ["VE", 1162], ["brain", 1165], ["samples", 1171], ["showed", 1179], ["eosinophilic", 1186], ["infiltrations", 1199], ["with", 1213], ["no", 1218], ["signs", 1221], ["of", 1227], ["persistent", 1230], ["Toxocara", 1241], ["canis", 1250], ["infection", 1256], [".", 1265], ["Our", 1267], ["data", 1271], ["showed", 1276], ["that", 1283], ["pressure", 1288], ["by", 1297], ["the", 1300], ["communicating", 1304], ["hydrocephalus", 1318], ["as", 1332], ["a", 1335], ["mechanical", 1337], ["factor", 1348], ["is", 1355], ["the", 1358], ["major", 1362], ["pathogenic", 1368], ["mechanism", 1379], ["in", 1389], ["chronic", 1392], ["VE", 1400], [",", 1402], ["most", 1404], ["likely", 1409], ["triggered", 1416], ["by", 1426], ["eosinophilic", 1429], ["meningitis", 1442], [".", 1452], ["There", 1454], ["are", 1460], ["no", 1464], ["signs", 1467], ["for", 1473], ["an", 1477], ["ongoing", 1480], ["inflammatory", 1488], ["process", 1501], ["in", 1509], ["chronic", 1512], ["VE", 1520], [".", 1522], ["The", 1524], ["past", 1528], ["eosinophilic", 1533], ["reaction", 1546], ["in", 1555], ["VE", 1558], ["might", 1561], ["be", 1567], ["caused", 1570], ["by", 1577], ["Toxocara", 1580], ["ssp", 1589], [".", 1592], ["infection", 1594], ["and", 1604], ["might", 1608], ["therefore", 1614], ["represent", 1624], ["the", 1634], ["first", 1638], ["hint", 1644], ["for", 1649], ["an", 1653], ["initial", 1656], ["cause", 1664], ["leading", 1670], ["to", 1678], ["the", 1681], ["development", 1685], ["of", 1697], ["chronic", 1700], ["VE", 1708], [".", 1710], ["Our", 1712], ["data", 1716], ["provide", 1721], ["a", 1729], ["framework", 1731], ["for", 1741], ["future", 1745], ["studies", 1752], ["and", 1760], ["potential", 1764], ["therapeutic", 1774], ["interventions", 1786], ["for", 1800], ["this", 1804], ["enigmatic", 1809], ["epidemic", 1819], ["neurological", 1828], ["disease", 1841], ["potentially", 1849], ["spreading", 1861], ["in", 1871], ["Sakha", 1874], ["Republic", 1880], [".", 1888]]}
{"context": "Mammalian selenium-containing proteins identified thus far contain selenium in the form of a selenocysteine residue encoded by UGA. These proteins lack common amino acid sequence motifs, but 3'-untranslated regions of selenoprotein genes contain a common stem-loop structure, selenocysteine insertion sequence (SECIS) element, that is necessary for decoding UGA as selenocysteine rather than a stop signal. We describe here a computer program, SECISearch, that identifies mammalian selenoprotein genes by recognizing SECIS elements on the basis of their primary and secondary structures and free energy requirements. When SECISearch was applied to search human dbEST, two new mammalian selenoproteins, designated SelT and SelR, were identified. We determined their cDNA sequences and expressed them in a monkey cell line as fusion proteins with a green fluorescent protein. Incorporation of selenium into new proteins was confirmed by metabolic labeling with (75)Se, and expression of SelT was additionally documented in immunoblot assays. SelT and SelR did not have homology to previously characterized proteins, but their putative homologs were detected in various organisms. SelR homologs were present in every organism characterized by complete genome sequencing. The data suggest applicability of SECISearch for identification of new selenoprotein genes in nucleotide data bases.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "0d1597667c614526ba0ceede9a3ecc54", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[48, 48], [82, 82]], "char_spans": [[311, 315], [517, 521]]}]}], "context_tokens": [["Mammalian", 0], ["selenium", 10], ["-", 18], ["containing", 19], ["proteins", 30], ["identified", 39], ["thus", 50], ["far", 55], ["contain", 59], ["selenium", 67], ["in", 76], ["the", 79], ["form", 83], ["of", 88], ["a", 91], ["selenocysteine", 93], ["residue", 108], ["encoded", 116], ["by", 124], ["UGA", 127], [".", 130], ["These", 132], ["proteins", 138], ["lack", 147], ["common", 152], ["amino", 159], ["acid", 165], ["sequence", 170], ["motifs", 179], [",", 185], ["but", 187], ["3'-untranslated", 191], ["regions", 207], ["of", 215], ["selenoprotein", 218], ["genes", 232], ["contain", 238], ["a", 246], ["common", 248], ["stem", 255], ["-", 259], ["loop", 260], ["structure", 265], [",", 274], ["selenocysteine", 276], ["insertion", 291], ["sequence", 301], ["(", 310], ["SECIS", 311], [")", 316], ["element", 318], [",", 325], ["that", 327], ["is", 332], ["necessary", 335], ["for", 345], ["decoding", 349], ["UGA", 358], ["as", 362], ["selenocysteine", 365], ["rather", 380], ["than", 387], ["a", 392], ["stop", 394], ["signal", 399], [".", 405], ["We", 407], ["describe", 410], ["here", 419], ["a", 424], ["computer", 426], ["program", 435], [",", 442], ["SECISearch", 444], [",", 454], ["that", 456], ["identifies", 461], ["mammalian", 472], ["selenoprotein", 482], ["genes", 496], ["by", 502], ["recognizing", 505], ["SECIS", 517], ["elements", 523], ["on", 532], ["the", 535], ["basis", 539], ["of", 545], ["their", 548], ["primary", 554], ["and", 562], ["secondary", 566], ["structures", 576], ["and", 587], ["free", 591], ["energy", 596], ["requirements", 603], [".", 615], ["When", 617], ["SECISearch", 622], ["was", 633], ["applied", 637], ["to", 645], ["search", 648], ["human", 655], ["dbEST", 661], [",", 666], ["two", 668], ["new", 672], ["mammalian", 676], ["selenoproteins", 686], [",", 700], ["designated", 702], ["SelT", 713], ["and", 718], ["SelR", 722], [",", 726], ["were", 728], ["identified", 733], [".", 743], ["We", 745], ["determined", 748], ["their", 759], ["cDNA", 765], ["sequences", 770], ["and", 780], ["expressed", 784], ["them", 794], ["in", 799], ["a", 802], ["monkey", 804], ["cell", 811], ["line", 816], ["as", 821], ["fusion", 824], ["proteins", 831], ["with", 840], ["a", 845], ["green", 847], ["fluorescent", 853], ["protein", 865], [".", 872], ["Incorporation", 874], ["of", 888], ["selenium", 891], ["into", 900], ["new", 905], ["proteins", 909], ["was", 918], ["confirmed", 922], ["by", 932], ["metabolic", 935], ["labeling", 945], ["with", 954], ["(", 959], ["75)Se", 960], [",", 965], ["and", 967], ["expression", 971], ["of", 982], ["SelT", 985], ["was", 990], ["additionally", 994], ["documented", 1007], ["in", 1018], ["immunoblot", 1021], ["assays", 1032], [".", 1038], ["SelT", 1040], ["and", 1045], ["SelR", 1049], ["did", 1054], ["not", 1058], ["have", 1062], ["homology", 1067], ["to", 1076], ["previously", 1079], ["characterized", 1090], ["proteins", 1104], [",", 1112], ["but", 1114], ["their", 1118], ["putative", 1124], ["homologs", 1133], ["were", 1142], ["detected", 1147], ["in", 1156], ["various", 1159], ["organisms", 1167], [".", 1176], ["SelR", 1178], ["homologs", 1183], ["were", 1192], ["present", 1197], ["in", 1205], ["every", 1208], ["organism", 1214], ["characterized", 1223], ["by", 1237], ["complete", 1240], ["genome", 1249], ["sequencing", 1256], [".", 1266], ["The", 1268], ["data", 1272], ["suggest", 1277], ["applicability", 1285], ["of", 1299], ["SECISearch", 1302], ["for", 1313], ["identification", 1317], ["of", 1332], ["new", 1335], ["selenoprotein", 1339], ["genes", 1353], ["in", 1359], ["nucleotide", 1362], ["data", 1373], ["bases", 1378], [".", 1383]]}
{"context": "Recently, deletions encompassing the nuclear receptor binding SET-Domain 1 (NSD1) gene have been described as the major cause of Japanese patients with the Sotos syndrome, whereas point mutations have been identified in the majority of European Sotos syndrome patients. In order to investigate a possible phenotype-genotype correlation and to further define the predictive value of NSD1 mutations, we performed mutational analysis of the NSD1 gene in 20 patients and one familial case with Sotos syndrome, five patients with Weaver syndrome, six patients with unclassified overgrowth/mental retardation, and six patients with macrocephaly/mental retardation. We were able to identify mutations within the NSD1 gene in 18 patients and the familial case with Sotos syndrome (90%). The mutations (six nonsense, eight frame shifts, three splice site, one missense, one in-frame deletion) are expected to result in an impairment of NSD1 function. The best correlation between clinical assessment and molecular results was obtained for the Sotos facial gestalt in conjunction with overgrowth, macrocephaly, and developmental delay. In contrast to the high mutation detection rate in Sotos syndrome, none of the patients with Weaver syndrome, unclassified overgrowth/mental retardation and macrocephaly/mental retardation, harbored NSD1 mutations. We tested for large deletions by FISH analysis but were not able to identify any deletion cases. The results indicate that the great majority of patients with Sotos syndrome are caused by mutations in NSD1. Deletions covering the NSD1 locus were not found in the patients analyzed here.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "c0eee31746d343f19dcd03ff0c8496b2", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[73, 74], [13, 15], [118, 119]], "char_spans": [[438, 446], [76, 85], [705, 713]]}]}], "context_tokens": [["Recently", 0], [",", 8], ["deletions", 10], ["encompassing", 20], ["the", 33], ["nuclear", 37], ["receptor", 45], ["binding", 54], ["SET", 62], ["-", 65], ["Domain", 66], ["1", 73], ["(", 75], ["NSD1", 76], [")", 80], ["gene", 82], ["have", 87], ["been", 92], ["described", 97], ["as", 107], ["the", 110], ["major", 114], ["cause", 120], ["of", 126], ["Japanese", 129], ["patients", 138], ["with", 147], ["the", 152], ["Sotos", 156], ["syndrome", 162], [",", 170], ["whereas", 172], ["point", 180], ["mutations", 186], ["have", 196], ["been", 201], ["identified", 206], ["in", 217], ["the", 220], ["majority", 224], ["of", 233], ["European", 236], ["Sotos", 245], ["syndrome", 251], ["patients", 260], [".", 268], ["In", 270], ["order", 273], ["to", 279], ["investigate", 282], ["a", 294], ["possible", 296], ["phenotype", 305], ["-", 314], ["genotype", 315], ["correlation", 324], ["and", 336], ["to", 340], ["further", 343], ["define", 351], ["the", 358], ["predictive", 362], ["value", 373], ["of", 379], ["NSD1", 382], ["mutations", 387], [",", 396], ["we", 398], ["performed", 401], ["mutational", 411], ["analysis", 422], ["of", 431], ["the", 434], ["NSD1", 438], ["gene", 443], ["in", 448], ["20", 451], ["patients", 454], ["and", 463], ["one", 467], ["familial", 471], ["case", 480], ["with", 485], ["Sotos", 490], ["syndrome", 496], [",", 504], ["five", 506], ["patients", 511], ["with", 520], ["Weaver", 525], ["syndrome", 532], [",", 540], ["six", 542], ["patients", 546], ["with", 555], ["unclassified", 560], ["overgrowth", 573], ["/", 583], ["mental", 584], ["retardation", 591], [",", 602], ["and", 604], ["six", 608], ["patients", 612], ["with", 621], ["macrocephaly", 626], ["/", 638], ["mental", 639], ["retardation", 646], [".", 657], ["We", 659], ["were", 662], ["able", 667], ["to", 672], ["identify", 675], ["mutations", 684], ["within", 694], ["the", 701], ["NSD1", 705], ["gene", 710], ["in", 715], ["18", 718], ["patients", 721], ["and", 730], ["the", 734], ["familial", 738], ["case", 747], ["with", 752], ["Sotos", 757], ["syndrome", 763], ["(", 772], ["90", 773], ["%", 775], [")", 776], [".", 777], ["The", 779], ["mutations", 783], ["(", 793], ["six", 794], ["nonsense", 798], [",", 806], ["eight", 808], ["frame", 814], ["shifts", 820], [",", 826], ["three", 828], ["splice", 834], ["site", 841], [",", 845], ["one", 847], ["missense", 851], [",", 859], ["one", 861], ["in", 865], ["-", 867], ["frame", 868], ["deletion", 874], [")", 882], ["are", 884], ["expected", 888], ["to", 897], ["result", 900], ["in", 907], ["an", 910], ["impairment", 913], ["of", 924], ["NSD1", 927], ["function", 932], [".", 940], ["The", 942], ["best", 946], ["correlation", 951], ["between", 963], ["clinical", 971], ["assessment", 980], ["and", 991], ["molecular", 995], ["results", 1005], ["was", 1013], ["obtained", 1017], ["for", 1026], ["the", 1030], ["Sotos", 1034], ["facial", 1040], ["gestalt", 1047], ["in", 1055], ["conjunction", 1058], ["with", 1070], ["overgrowth", 1075], [",", 1085], ["macrocephaly", 1087], [",", 1099], ["and", 1101], ["developmental", 1105], ["delay", 1119], [".", 1124], ["In", 1126], ["contrast", 1129], ["to", 1138], ["the", 1141], ["high", 1145], ["mutation", 1150], ["detection", 1159], ["rate", 1169], ["in", 1174], ["Sotos", 1177], ["syndrome", 1183], [",", 1191], ["none", 1193], ["of", 1198], ["the", 1201], ["patients", 1205], ["with", 1214], ["Weaver", 1219], ["syndrome", 1226], [",", 1234], ["unclassified", 1236], ["overgrowth", 1249], ["/", 1259], ["mental", 1260], ["retardation", 1267], ["and", 1279], ["macrocephaly", 1283], ["/", 1295], ["mental", 1296], ["retardation", 1303], [",", 1314], ["harbored", 1316], ["NSD1", 1325], ["mutations", 1330], [".", 1339], ["We", 1341], ["tested", 1344], ["for", 1351], ["large", 1355], ["deletions", 1361], ["by", 1371], ["FISH", 1374], ["analysis", 1379], ["but", 1388], ["were", 1392], ["not", 1397], ["able", 1401], ["to", 1406], ["identify", 1409], ["any", 1418], ["deletion", 1422], ["cases", 1431], [".", 1436], ["The", 1438], ["results", 1442], ["indicate", 1450], ["that", 1459], ["the", 1464], ["great", 1468], ["majority", 1474], ["of", 1483], ["patients", 1486], ["with", 1495], ["Sotos", 1500], ["syndrome", 1506], ["are", 1515], ["caused", 1519], ["by", 1526], ["mutations", 1529], ["in", 1539], ["NSD1", 1542], [".", 1546], ["Deletions", 1548], ["covering", 1558], ["the", 1567], ["NSD1", 1571], ["locus", 1576], ["were", 1582], ["not", 1587], ["found", 1591], ["in", 1597], ["the", 1600], ["patients", 1604], ["analyzed", 1613], ["here", 1622], [".", 1626]]}
{"context": "Monosomy for the X chromosome is the most frequent cause of Turner's syndrome, a common clinical syndrome associated with particular physical and neurobehavioral features. The results from comprehensive assessment of prepubertal monozygotic female twins discordant for X monosomy are presented. Zygosity was established with DNA Fingerprinting and no evidence of chromosomal mosaicism was seen in either child. Physical features in the affected twin were relatively mild with respect to the full spectrum of physical malformations and disabilities associated with Turner's syndrome. The neurobehavioral phenotypes of the twins were compared. Although both sisters scored in the superior range of intelligence, the affected twin's Performance IQ was 18 points less than her sister, whereas Verbal IQ showed only a 3-point difference between the sisters. Other relative differences were noted within the executive, visuospatial, and visuomotor domains of function. Behavioral evaluation indicated greater problems with attention, hyperactivity, and anxiety in the affected twin. Quantitative analysis of brain anatomy revealed evidence of both general and regional effects of X monosomy on neurodevelopment. Cerebrospinal fluid volume was increased by 25% in the affected twin compared with her sister with a corresponding decrease in gray matter volume. The right frontal, right parietal-occipital, and left parietal-perisylvian regions showed the greatest discrepancy between the sisters with respect to increased cerebrospinal fluid and decreased gray matter volumes in twin with X monosomy. Differences in the posterior fossa were also noted with a 50% relative increase in the volumes of the fourth ventricle and cisterna magna and a 10 to 15% relative reduction in size of the cerebellar vermis, pons, and medulla in the affected twin. The association between the neurobehavioral and neuroanatomical findings in the affected twin is discussed. The unique nature of the naturally occurring genetic phenomenon seen in this twin pair provides an opportunity to more fully elucidate the neurobehavioral phenotype associated with X monosomy and Turner's syndrome.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "7e00d62adabb4717889af97b4ed46c4c", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[3, 3], [182, 182], [340, 340], [39, 39], [248, 248]], "char_spans": [[17, 17], [1174, 1174], [2129, 2129], [269, 269], [1581, 1581]]}]}], "context_tokens": [["Monosomy", 0], ["for", 9], ["the", 13], ["X", 17], ["chromosome", 19], ["is", 30], ["the", 33], ["most", 37], ["frequent", 42], ["cause", 51], ["of", 57], ["Turner", 60], ["'s", 66], ["syndrome", 69], [",", 77], ["a", 79], ["common", 81], ["clinical", 88], ["syndrome", 97], ["associated", 106], ["with", 117], ["particular", 122], ["physical", 133], ["and", 142], ["neurobehavioral", 146], ["features", 162], [".", 170], ["The", 172], ["results", 176], ["from", 184], ["comprehensive", 189], ["assessment", 203], ["of", 214], ["prepubertal", 217], ["monozygotic", 229], ["female", 241], ["twins", 248], ["discordant", 254], ["for", 265], ["X", 269], ["monosomy", 271], ["are", 280], ["presented", 284], [".", 293], ["Zygosity", 295], ["was", 304], ["established", 308], ["with", 320], ["DNA", 325], ["Fingerprinting", 329], ["and", 344], ["no", 348], ["evidence", 351], ["of", 360], ["chromosomal", 363], ["mosaicism", 375], ["was", 385], ["seen", 389], ["in", 394], ["either", 397], ["child", 404], [".", 409], ["Physical", 411], ["features", 420], ["in", 429], ["the", 432], ["affected", 436], ["twin", 445], ["were", 450], ["relatively", 455], ["mild", 466], ["with", 471], ["respect", 476], ["to", 484], ["the", 487], ["full", 491], ["spectrum", 496], ["of", 505], ["physical", 508], ["malformations", 517], ["and", 531], ["disabilities", 535], ["associated", 548], ["with", 559], ["Turner", 564], ["'s", 570], ["syndrome", 573], [".", 581], ["The", 583], ["neurobehavioral", 587], ["phenotypes", 603], ["of", 614], ["the", 617], ["twins", 621], ["were", 627], ["compared", 632], [".", 640], ["Although", 642], ["both", 651], ["sisters", 656], ["scored", 664], ["in", 671], ["the", 674], ["superior", 678], ["range", 687], ["of", 693], ["intelligence", 696], [",", 708], ["the", 710], ["affected", 714], ["twin", 723], ["'s", 727], ["Performance", 730], ["IQ", 742], ["was", 745], ["18", 749], ["points", 752], ["less", 759], ["than", 764], ["her", 769], ["sister", 773], [",", 779], ["whereas", 781], ["Verbal", 789], ["IQ", 796], ["showed", 799], ["only", 806], ["a", 811], ["3-point", 813], ["difference", 821], ["between", 832], ["the", 840], ["sisters", 844], [".", 851], ["Other", 853], ["relative", 859], ["differences", 868], ["were", 880], ["noted", 885], ["within", 891], ["the", 898], ["executive", 902], [",", 911], ["visuospatial", 913], [",", 925], ["and", 927], ["visuomotor", 931], ["domains", 942], ["of", 950], ["function", 953], [".", 961], ["Behavioral", 963], ["evaluation", 974], ["indicated", 985], ["greater", 995], ["problems", 1003], ["with", 1012], ["attention", 1017], [",", 1026], ["hyperactivity", 1028], [",", 1041], ["and", 1043], ["anxiety", 1047], ["in", 1055], ["the", 1058], ["affected", 1062], ["twin", 1071], [".", 1075], ["Quantitative", 1077], ["analysis", 1090], ["of", 1099], ["brain", 1102], ["anatomy", 1108], ["revealed", 1116], ["evidence", 1125], ["of", 1134], ["both", 1137], ["general", 1142], ["and", 1150], ["regional", 1154], ["effects", 1163], ["of", 1171], ["X", 1174], ["monosomy", 1176], ["on", 1185], ["neurodevelopment", 1188], [".", 1204], ["Cerebrospinal", 1206], ["fluid", 1220], ["volume", 1226], ["was", 1233], ["increased", 1237], ["by", 1247], ["25", 1250], ["%", 1252], ["in", 1254], ["the", 1257], ["affected", 1261], ["twin", 1270], ["compared", 1275], ["with", 1284], ["her", 1289], ["sister", 1293], ["with", 1300], ["a", 1305], ["corresponding", 1307], ["decrease", 1321], ["in", 1330], ["gray", 1333], ["matter", 1338], ["volume", 1345], [".", 1351], ["The", 1353], ["right", 1357], ["frontal", 1363], [",", 1370], ["right", 1372], ["parietal", 1378], ["-", 1386], ["occipital", 1387], [",", 1396], ["and", 1398], ["left", 1402], ["parietal", 1407], ["-", 1415], ["perisylvian", 1416], ["regions", 1428], ["showed", 1436], ["the", 1443], ["greatest", 1447], ["discrepancy", 1456], ["between", 1468], ["the", 1476], ["sisters", 1480], ["with", 1488], ["respect", 1493], ["to", 1501], ["increased", 1504], ["cerebrospinal", 1514], ["fluid", 1528], ["and", 1534], ["decreased", 1538], ["gray", 1548], ["matter", 1553], ["volumes", 1560], ["in", 1568], ["twin", 1571], ["with", 1576], ["X", 1581], ["monosomy", 1583], [".", 1591], ["Differences", 1593], ["in", 1605], ["the", 1608], ["posterior", 1612], ["fossa", 1622], ["were", 1628], ["also", 1633], ["noted", 1638], ["with", 1644], ["a", 1649], ["50", 1651], ["%", 1653], ["relative", 1655], ["increase", 1664], ["in", 1673], ["the", 1676], ["volumes", 1680], ["of", 1688], ["the", 1691], ["fourth", 1695], ["ventricle", 1702], ["and", 1712], ["cisterna", 1716], ["magna", 1725], ["and", 1731], ["a", 1735], ["10", 1737], ["to", 1740], ["15", 1743], ["%", 1745], ["relative", 1747], ["reduction", 1756], ["in", 1766], ["size", 1769], ["of", 1774], ["the", 1777], ["cerebellar", 1781], ["vermis", 1792], [",", 1798], ["pons", 1800], [",", 1804], ["and", 1806], ["medulla", 1810], ["in", 1818], ["the", 1821], ["affected", 1825], ["twin", 1834], [".", 1838], ["The", 1840], ["association", 1844], ["between", 1856], ["the", 1864], ["neurobehavioral", 1868], ["and", 1884], ["neuroanatomical", 1888], ["findings", 1904], ["in", 1913], ["the", 1916], ["affected", 1920], ["twin", 1929], ["is", 1934], ["discussed", 1937], [".", 1946], ["The", 1948], ["unique", 1952], ["nature", 1959], ["of", 1966], ["the", 1969], ["naturally", 1973], ["occurring", 1983], ["genetic", 1993], ["phenomenon", 2001], ["seen", 2012], ["in", 2017], ["this", 2020], ["twin", 2025], ["pair", 2030], ["provides", 2035], ["an", 2044], ["opportunity", 2047], ["to", 2059], ["more", 2062], ["fully", 2067], ["elucidate", 2073], ["the", 2083], ["neurobehavioral", 2087], ["phenotype", 2103], ["associated", 2113], ["with", 2124], ["X", 2129], ["monosomy", 2131], ["and", 2140], ["Turner", 2144], ["'s", 2150], ["syndrome", 2153], [".", 2161]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a small vessel disease of the brain caused by mutations in the NOTCH3 gene. CADASIL progresses, in some cases, to subcortical dementia with a particular cognitive impairment. Different diseases in the dementia spectrum share a central cholinergic and sensorimotor plasticity alteration. We aimed to study different intracortical circuits and sensorimotor plasticity in CADASIL patients using transcranial magnetic stimulation protocols, and to determine whether these characteristics correlated with the results of clinical neuropsychological evaluation. Ten CADASIL patients and 10 healthy subjects were included in the study. All subjects underwent a transcranial magnetic stimulation study examining different intracortical circuits. Sensorimotor plasticity was also assessed using a paired associative stimulation and extensive neuropsychological tests. CADASIL patients showed a lack of intracortical facilitation, short latency afferent inhibition and sensorimotor plasticity when compared with control subjects. CADASIL patients also showed an altered neuropsychological profile. Correlation between sensorimotor plasticity and neuropsychological alterations was observed in CADASIL patients. These results suggest that acetylcholine and glutamate could be involved in the dementia process in CADASIL and that abnormal sensorimotor plasticity correlates with the neuropsychological profile in CADASIL patients.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "27c99f3d44a94401b785406bd2f20967", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[25, 26]], "char_spans": [[167, 177]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["a", 104], ["small", 106], ["vessel", 112], ["disease", 119], ["of", 127], ["the", 130], ["brain", 134], ["caused", 140], ["by", 147], ["mutations", 150], ["in", 160], ["the", 163], ["NOTCH3", 167], ["gene", 174], [".", 178], ["CADASIL", 180], ["progresses", 188], [",", 198], ["in", 200], ["some", 203], ["cases", 208], [",", 213], ["to", 215], ["subcortical", 218], ["dementia", 230], ["with", 239], ["a", 244], ["particular", 246], ["cognitive", 257], ["impairment", 267], [".", 277], ["Different", 279], ["diseases", 289], ["in", 298], ["the", 301], ["dementia", 305], ["spectrum", 314], ["share", 323], ["a", 329], ["central", 331], ["cholinergic", 339], ["and", 351], ["sensorimotor", 355], ["plasticity", 368], ["alteration", 379], [".", 389], ["We", 391], ["aimed", 394], ["to", 400], ["study", 403], ["different", 409], ["intracortical", 419], ["circuits", 433], ["and", 442], ["sensorimotor", 446], ["plasticity", 459], ["in", 470], ["CADASIL", 473], ["patients", 481], ["using", 490], ["transcranial", 496], ["magnetic", 509], ["stimulation", 518], ["protocols", 530], [",", 539], ["and", 541], ["to", 545], ["determine", 548], ["whether", 558], ["these", 566], ["characteristics", 572], ["correlated", 588], ["with", 599], ["the", 604], ["results", 608], ["of", 616], ["clinical", 619], ["neuropsychological", 628], ["evaluation", 647], [".", 657], ["Ten", 659], ["CADASIL", 663], ["patients", 671], ["and", 680], ["10", 684], ["healthy", 687], ["subjects", 695], ["were", 704], ["included", 709], ["in", 718], ["the", 721], ["study", 725], [".", 730], ["All", 732], ["subjects", 736], ["underwent", 745], ["a", 755], ["transcranial", 757], ["magnetic", 770], ["stimulation", 779], ["study", 791], ["examining", 797], ["different", 807], ["intracortical", 817], ["circuits", 831], [".", 839], ["Sensorimotor", 841], ["plasticity", 854], ["was", 865], ["also", 869], ["assessed", 874], ["using", 883], ["a", 889], ["paired", 891], ["associative", 898], ["stimulation", 910], ["and", 922], ["extensive", 926], ["neuropsychological", 936], ["tests", 955], [".", 960], ["CADASIL", 962], ["patients", 970], ["showed", 979], ["a", 986], ["lack", 988], ["of", 993], ["intracortical", 996], ["facilitation", 1010], [",", 1022], ["short", 1024], ["latency", 1030], ["afferent", 1038], ["inhibition", 1047], ["and", 1058], ["sensorimotor", 1062], ["plasticity", 1075], ["when", 1086], ["compared", 1091], ["with", 1100], ["control", 1105], ["subjects", 1113], [".", 1121], ["CADASIL", 1123], ["patients", 1131], ["also", 1140], ["showed", 1145], ["an", 1152], ["altered", 1155], ["neuropsychological", 1163], ["profile", 1182], [".", 1189], ["Correlation", 1191], ["between", 1203], ["sensorimotor", 1211], ["plasticity", 1224], ["and", 1235], ["neuropsychological", 1239], ["alterations", 1258], ["was", 1270], ["observed", 1274], ["in", 1283], ["CADASIL", 1286], ["patients", 1294], [".", 1302], ["These", 1304], ["results", 1310], ["suggest", 1318], ["that", 1326], ["acetylcholine", 1331], ["and", 1345], ["glutamate", 1349], ["could", 1359], ["be", 1365], ["involved", 1368], ["in", 1377], ["the", 1380], ["dementia", 1384], ["process", 1393], ["in", 1401], ["CADASIL", 1404], ["and", 1412], ["that", 1416], ["abnormal", 1421], ["sensorimotor", 1430], ["plasticity", 1443], ["correlates", 1454], ["with", 1465], ["the", 1470], ["neuropsychological", 1474], ["profile", 1493], ["in", 1501], ["CADASIL", 1504], ["patients", 1512], [".", 1520]]}
{"context": "Na\u00efve and primed pluripotent states retain distinct molecular properties, yet limited knowledge exists on how their state transitions are regulated. Here, we identify Mettl3, an N(6)-methyladenosine (m(6)A) transferase, as a regulator for terminating murine na\u00efve pluripotency. Mettl3 knockout preimplantation epiblasts and na\u00efve embryonic stem cells are depleted for m(6)A in mRNAs, yet are viable. However, they fail to adequately terminate their na\u00efve state and, subsequently, undergo aberrant and restricted lineage priming at the postimplantation stage, which leads to early embryonic lethality. m(6)A predominantly and directly reduces mRNA stability, including that of key na\u00efve pluripotency-promoting transcripts. This study highlights a critical role for an mRNA epigenetic modification in vivo and identifies regulatory modules that functionally influence na\u00efve and primed pluripotency in an opposing manner.", "qas": [{"question": "Which properties of the mRNA does N6-methyladenosine (m6A) affect?", "answers": ["mRNA stability"], "qid": "e2dccc6fa3a84b67a72cd87b03a0db2e", "question_tokens": [["Which", 0], ["properties", 6], ["of", 17], ["the", 20], ["mRNA", 24], ["does", 29], ["N6-methyladenosine", 34], ["(", 53], ["m6A", 54], [")", 57], ["affect", 59], ["?", 65]], "detected_answers": [{"text": "mRNA stability", "token_spans": [[101, 102]], "char_spans": [[642, 655]]}]}], "context_tokens": [["Na\u00efve", 0], ["and", 6], ["primed", 10], ["pluripotent", 17], ["states", 29], ["retain", 36], ["distinct", 43], ["molecular", 52], ["properties", 62], [",", 72], ["yet", 74], ["limited", 78], ["knowledge", 86], ["exists", 96], ["on", 103], ["how", 106], ["their", 110], ["state", 116], ["transitions", 122], ["are", 134], ["regulated", 138], [".", 147], ["Here", 149], [",", 153], ["we", 155], ["identify", 158], ["Mettl3", 167], [",", 173], ["an", 175], ["N(6)-methyladenosine", 178], ["(", 199], ["m(6)A", 200], [")", 205], ["transferase", 207], [",", 218], ["as", 220], ["a", 223], ["regulator", 225], ["for", 235], ["terminating", 239], ["murine", 251], ["na\u00efve", 258], ["pluripotency", 264], [".", 276], ["Mettl3", 278], ["knockout", 285], ["preimplantation", 294], ["epiblasts", 310], ["and", 320], ["na\u00efve", 324], ["embryonic", 330], ["stem", 340], ["cells", 345], ["are", 351], ["depleted", 355], ["for", 364], ["m(6)A", 368], ["in", 374], ["mRNAs", 377], [",", 382], ["yet", 384], ["are", 388], ["viable", 392], [".", 398], ["However", 400], [",", 407], ["they", 409], ["fail", 414], ["to", 419], ["adequately", 422], ["terminate", 433], ["their", 443], ["na\u00efve", 449], ["state", 455], ["and", 461], [",", 464], ["subsequently", 466], [",", 478], ["undergo", 480], ["aberrant", 488], ["and", 497], ["restricted", 501], ["lineage", 512], ["priming", 520], ["at", 528], ["the", 531], ["postimplantation", 535], ["stage", 552], [",", 557], ["which", 559], ["leads", 565], ["to", 571], ["early", 574], ["embryonic", 580], ["lethality", 590], [".", 599], ["m(6)A", 601], ["predominantly", 607], ["and", 621], ["directly", 625], ["reduces", 634], ["mRNA", 642], ["stability", 647], [",", 656], ["including", 658], ["that", 668], ["of", 673], ["key", 676], ["na\u00efve", 680], ["pluripotency", 686], ["-", 698], ["promoting", 699], ["transcripts", 709], [".", 720], ["This", 722], ["study", 727], ["highlights", 733], ["a", 744], ["critical", 746], ["role", 755], ["for", 760], ["an", 764], ["mRNA", 767], ["epigenetic", 772], ["modification", 783], ["in", 796], ["vivo", 799], ["and", 804], ["identifies", 808], ["regulatory", 819], ["modules", 830], ["that", 838], ["functionally", 843], ["influence", 856], ["na\u00efve", 866], ["and", 872], ["primed", 876], ["pluripotency", 883], ["in", 896], ["an", 899], ["opposing", 902], ["manner", 911], [".", 917]]}
{"context": "Many neurodegenerative diseases are associated with the aggregation of misfolded proteins into amyloid oligomers or fibrils that are deposited as pathological lesions within areas of the brain. An attractive therapeutic strategy for preventing or ameliorating amyloid formation is to identify agents that inhibit the onset or propagation of protein aggregation. Here we demonstrate how solid-state nuclear magnetic resonance (ssNMR) may be used to identify key residues within amyloidogenic protein sequences that may be targeted to inhibit the aggregation of the host protein. For alpha-synuclein, the major protein component of Lewy bodies associated with Parkinson's disease, we have used a combination of ssNMR and biochemical data to identify the key region for self-aggregation of the protein as residues 77-82 (VAQKTV). We used our new structural information to design a peptide derived from residues 77 to 82 of alpha-synuclein with an N-methyl group at the C-terminal residue, which was able to disrupt the aggregation of alpha-synuclein. Thus, we have shown how structural data obtained from ssNMR can guide the design of modified peptides for use as amyloid inhibitors, as a primary step toward developing therapeutic compounds for prevention and/or treatment of amyloid diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "ec3fbfeea1b541fd86801d3f230fe7ac", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[179, 181], [90, 92], [155, 157]], "char_spans": [[1031, 1045], [582, 596], [920, 934]]}]}], "context_tokens": [["Many", 0], ["neurodegenerative", 5], ["diseases", 23], ["are", 32], ["associated", 36], ["with", 47], ["the", 52], ["aggregation", 56], ["of", 68], ["misfolded", 71], ["proteins", 81], ["into", 90], ["amyloid", 95], ["oligomers", 103], ["or", 113], ["fibrils", 116], ["that", 124], ["are", 129], ["deposited", 133], ["as", 143], ["pathological", 146], ["lesions", 159], ["within", 167], ["areas", 174], ["of", 180], ["the", 183], ["brain", 187], [".", 192], ["An", 194], ["attractive", 197], ["therapeutic", 208], ["strategy", 220], ["for", 229], ["preventing", 233], ["or", 244], ["ameliorating", 247], ["amyloid", 260], ["formation", 268], ["is", 278], ["to", 281], ["identify", 284], ["agents", 293], ["that", 300], ["inhibit", 305], ["the", 313], ["onset", 317], ["or", 323], ["propagation", 326], ["of", 338], ["protein", 341], ["aggregation", 349], [".", 360], ["Here", 362], ["we", 367], ["demonstrate", 370], ["how", 382], ["solid", 386], ["-", 391], ["state", 392], ["nuclear", 398], ["magnetic", 406], ["resonance", 415], ["(", 425], ["ssNMR", 426], [")", 431], ["may", 433], ["be", 437], ["used", 440], ["to", 445], ["identify", 448], ["key", 457], ["residues", 461], ["within", 470], ["amyloidogenic", 477], ["protein", 491], ["sequences", 499], ["that", 509], ["may", 514], ["be", 518], ["targeted", 521], ["to", 530], ["inhibit", 533], ["the", 541], ["aggregation", 545], ["of", 557], ["the", 560], ["host", 564], ["protein", 569], [".", 576], ["For", 578], ["alpha", 582], ["-", 587], ["synuclein", 588], [",", 597], ["the", 599], ["major", 603], ["protein", 609], ["component", 617], ["of", 627], ["Lewy", 630], ["bodies", 635], ["associated", 642], ["with", 653], ["Parkinson", 658], ["'s", 667], ["disease", 670], [",", 677], ["we", 679], ["have", 682], ["used", 687], ["a", 692], ["combination", 694], ["of", 706], ["ssNMR", 709], ["and", 715], ["biochemical", 719], ["data", 731], ["to", 736], ["identify", 739], ["the", 748], ["key", 752], ["region", 756], ["for", 763], ["self", 767], ["-", 771], ["aggregation", 772], ["of", 784], ["the", 787], ["protein", 791], ["as", 799], ["residues", 802], ["77", 811], ["-", 813], ["82", 814], ["(", 817], ["VAQKTV", 818], [")", 824], [".", 825], ["We", 827], ["used", 830], ["our", 835], ["new", 839], ["structural", 843], ["information", 854], ["to", 866], ["design", 869], ["a", 876], ["peptide", 878], ["derived", 886], ["from", 894], ["residues", 899], ["77", 908], ["to", 911], ["82", 914], ["of", 917], ["alpha", 920], ["-", 925], ["synuclein", 926], ["with", 936], ["an", 941], ["N", 944], ["-", 945], ["methyl", 946], ["group", 953], ["at", 959], ["the", 962], ["C", 966], ["-", 967], ["terminal", 968], ["residue", 977], [",", 984], ["which", 986], ["was", 992], ["able", 996], ["to", 1001], ["disrupt", 1004], ["the", 1012], ["aggregation", 1016], ["of", 1028], ["alpha", 1031], ["-", 1036], ["synuclein", 1037], [".", 1046], ["Thus", 1048], [",", 1052], ["we", 1054], ["have", 1057], ["shown", 1062], ["how", 1068], ["structural", 1072], ["data", 1083], ["obtained", 1088], ["from", 1097], ["ssNMR", 1102], ["can", 1108], ["guide", 1112], ["the", 1118], ["design", 1122], ["of", 1129], ["modified", 1132], ["peptides", 1141], ["for", 1150], ["use", 1154], ["as", 1158], ["amyloid", 1161], ["inhibitors", 1169], [",", 1179], ["as", 1181], ["a", 1184], ["primary", 1186], ["step", 1194], ["toward", 1199], ["developing", 1206], ["therapeutic", 1217], ["compounds", 1229], ["for", 1239], ["prevention", 1243], ["and/or", 1254], ["treatment", 1261], ["of", 1271], ["amyloid", 1274], ["diseases", 1282], [".", 1290]]}
{"context": "McLeod syndrome and chorea-acanthocytosis are classified with the so-called neuroacanthocytosis group of syndromes. Both lead to progressive basal ganglia degeneration and were not easily distinguished in the past. With the discovery of their molecular bases, mutations of the X-linked gene XK and autosomal recessive mutations of the gene coding for chorein, respectively, the two phenotypes can now be differentiated and extend the diagnostic spectrum in patients presenting with chorea. The present review compares the two conditions and proposes a practical approach to diagnosis and treatment. Better-defined disease concepts should eventually replace the umbrella term of \"neuroacanthocytosis.\" Animal models are needed to understand the underlying mechanisms. A final common pathway is likely for the pathogenesis of these conditions and is most probably shared with Huntington's disease.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "4678fd2baf4f4fc2a3d6a5f6d70178ed", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[49, 49]], "char_spans": [[291, 292]]}]}], "context_tokens": [["McLeod", 0], ["syndrome", 7], ["and", 16], ["chorea", 20], ["-", 26], ["acanthocytosis", 27], ["are", 42], ["classified", 46], ["with", 57], ["the", 62], ["so", 66], ["-", 68], ["called", 69], ["neuroacanthocytosis", 76], ["group", 96], ["of", 102], ["syndromes", 105], [".", 114], ["Both", 116], ["lead", 121], ["to", 126], ["progressive", 129], ["basal", 141], ["ganglia", 147], ["degeneration", 155], ["and", 168], ["were", 172], ["not", 177], ["easily", 181], ["distinguished", 188], ["in", 202], ["the", 205], ["past", 209], [".", 213], ["With", 215], ["the", 220], ["discovery", 224], ["of", 234], ["their", 237], ["molecular", 243], ["bases", 253], [",", 258], ["mutations", 260], ["of", 270], ["the", 273], ["X", 277], ["-", 278], ["linked", 279], ["gene", 286], ["XK", 291], ["and", 294], ["autosomal", 298], ["recessive", 308], ["mutations", 318], ["of", 328], ["the", 331], ["gene", 335], ["coding", 340], ["for", 347], ["chorein", 351], [",", 358], ["respectively", 360], [",", 372], ["the", 374], ["two", 378], ["phenotypes", 382], ["can", 393], ["now", 397], ["be", 401], ["differentiated", 404], ["and", 419], ["extend", 423], ["the", 430], ["diagnostic", 434], ["spectrum", 445], ["in", 454], ["patients", 457], ["presenting", 466], ["with", 477], ["chorea", 482], [".", 488], ["The", 490], ["present", 494], ["review", 502], ["compares", 509], ["the", 518], ["two", 522], ["conditions", 526], ["and", 537], ["proposes", 541], ["a", 550], ["practical", 552], ["approach", 562], ["to", 571], ["diagnosis", 574], ["and", 584], ["treatment", 588], [".", 597], ["Better", 599], ["-", 605], ["defined", 606], ["disease", 614], ["concepts", 622], ["should", 631], ["eventually", 638], ["replace", 649], ["the", 657], ["umbrella", 661], ["term", 670], ["of", 675], ["\"", 678], ["neuroacanthocytosis", 679], [".", 698], ["\"", 699], ["Animal", 701], ["models", 708], ["are", 715], ["needed", 719], ["to", 726], ["understand", 729], ["the", 740], ["underlying", 744], ["mechanisms", 755], [".", 765], ["A", 767], ["final", 769], ["common", 775], ["pathway", 782], ["is", 790], ["likely", 793], ["for", 800], ["the", 804], ["pathogenesis", 808], ["of", 821], ["these", 824], ["conditions", 830], ["and", 841], ["is", 845], ["most", 848], ["probably", 853], ["shared", 862], ["with", 869], ["Huntington", 874], ["'s", 884], ["disease", 887], [".", 894]]}
{"context": "Empagliflozin is an orally available, potent and highly selective inhibitor of the sodium glucose cotransporter 2 (SGLT2). This study was undertaken to investigate the effect of food on the pharmacokinetics of 25 mg empagliflozin and to assess dose proportionality between 10 mg and 25 mg empagliflozin under fasted conditions. In this open-label, 3-way, cross-over study, 18 healthy volunteers received 3 single doses of empagliflozin in a randomized sequence (25 mg empagliflozin under fasted conditions, 25 mg empagliflozin after a high-fat, high-calorie breakfast and 10 mg empagliflozin under fasted conditions), each separated by a washout period of at least 7 days. Serial plasma samples were collected at selected time points over a period of 72 hours. Administration with food had no clinically relevant effect on the area under the plasma concentration-time curve (AUC0-\u221e) of empagliflozin (geometric mean ratio (GMR): 84.04, 90% confidence interval (CI): 80.86 - 87.34). The decrease observed in the maximum plasma concentrations (Cmax) of empagliflozin (GMR: 63.22, 90% CI: 56.74 - 70.44) when administered with food was not considered clinically meaningful. The increases in AUC0-\u221e and Cmax for 10 mg vs. 25 mg empagliflozin administered under fasting conditions were roughly dose-proportional, as demonstrated by the slope \u03b2 of the regression lines being slightly less than 1 (slope \u03b2 for AUC0-\u221e: 0.94, 95% CI: 0.90 - 0.97; slope \u03b2 for Cmax: 0.91, 95% CI: 0.80 - 1.01). Empagliflozin was well tolerated under fed and fasting conditions. The results support administration of empagliflozin tablets independently of food. Increases in empagliflozin exposure under fasting conditions were roughly dose-proportional between 10 mg and 25 mg empagliflozin.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "1ac6a774b34748d0b2f90a6dd51379eb", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[18, 18]], "char_spans": [[115, 119]]}]}], "context_tokens": [["Empagliflozin", 0], ["is", 14], ["an", 17], ["orally", 20], ["available", 27], [",", 36], ["potent", 38], ["and", 45], ["highly", 49], ["selective", 56], ["inhibitor", 66], ["of", 76], ["the", 79], ["sodium", 83], ["glucose", 90], ["cotransporter", 98], ["2", 112], ["(", 114], ["SGLT2", 115], [")", 120], [".", 121], ["This", 123], ["study", 128], ["was", 134], ["undertaken", 138], ["to", 149], ["investigate", 152], ["the", 164], ["effect", 168], ["of", 175], ["food", 178], ["on", 183], ["the", 186], ["pharmacokinetics", 190], ["of", 207], ["25", 210], ["mg", 213], ["empagliflozin", 216], ["and", 230], ["to", 234], ["assess", 237], ["dose", 244], ["proportionality", 249], ["between", 265], ["10", 273], ["mg", 276], ["and", 279], ["25", 283], ["mg", 286], ["empagliflozin", 289], ["under", 303], ["fasted", 309], ["conditions", 316], [".", 326], ["In", 328], ["this", 331], ["open", 336], ["-", 340], ["label", 341], [",", 346], ["3-way", 348], [",", 353], ["cross", 355], ["-", 360], ["over", 361], ["study", 366], [",", 371], ["18", 373], ["healthy", 376], ["volunteers", 384], ["received", 395], ["3", 404], ["single", 406], ["doses", 413], ["of", 419], ["empagliflozin", 422], ["in", 436], ["a", 439], ["randomized", 441], ["sequence", 452], ["(", 461], ["25", 462], ["mg", 465], ["empagliflozin", 468], ["under", 482], ["fasted", 488], ["conditions", 495], [",", 505], ["25", 507], ["mg", 510], ["empagliflozin", 513], ["after", 527], ["a", 533], ["high", 535], ["-", 539], ["fat", 540], [",", 543], ["high", 545], ["-", 549], ["calorie", 550], ["breakfast", 558], ["and", 568], ["10", 572], ["mg", 575], ["empagliflozin", 578], ["under", 592], ["fasted", 598], ["conditions", 605], [")", 615], [",", 616], ["each", 618], ["separated", 623], ["by", 633], ["a", 636], ["washout", 638], ["period", 646], ["of", 653], ["at", 656], ["least", 659], ["7", 665], ["days", 667], [".", 671], ["Serial", 673], ["plasma", 680], ["samples", 687], ["were", 695], ["collected", 700], ["at", 710], ["selected", 713], ["time", 722], ["points", 727], ["over", 734], ["a", 739], ["period", 741], ["of", 748], ["72", 751], ["hours", 754], [".", 759], ["Administration", 761], ["with", 776], ["food", 781], ["had", 786], ["no", 790], ["clinically", 793], ["relevant", 804], ["effect", 813], ["on", 820], ["the", 823], ["area", 827], ["under", 832], ["the", 838], ["plasma", 842], ["concentration", 849], ["-", 862], ["time", 863], ["curve", 868], ["(", 874], ["AUC0-\u221e", 875], [")", 881], ["of", 883], ["empagliflozin", 886], ["(", 900], ["geometric", 901], ["mean", 911], ["ratio", 916], ["(", 922], ["GMR", 923], [")", 926], [":", 927], ["84.04", 929], [",", 934], ["90", 936], ["%", 938], ["confidence", 940], ["interval", 951], ["(", 960], ["CI", 961], [")", 963], [":", 964], ["80.86", 966], ["-", 972], ["87.34", 974], [")", 979], [".", 980], ["The", 982], ["decrease", 986], ["observed", 995], ["in", 1004], ["the", 1007], ["maximum", 1011], ["plasma", 1019], ["concentrations", 1026], ["(", 1041], ["Cmax", 1042], [")", 1046], ["of", 1048], ["empagliflozin", 1051], ["(", 1065], ["GMR", 1066], [":", 1069], ["63.22", 1071], [",", 1076], ["90", 1078], ["%", 1080], ["CI", 1082], [":", 1084], ["56.74", 1086], ["-", 1092], ["70.44", 1094], [")", 1099], ["when", 1101], ["administered", 1106], ["with", 1119], ["food", 1124], ["was", 1129], ["not", 1133], ["considered", 1137], ["clinically", 1148], ["meaningful", 1159], [".", 1169], ["The", 1171], ["increases", 1175], ["in", 1185], ["AUC0-\u221e", 1188], ["and", 1195], ["Cmax", 1199], ["for", 1204], ["10", 1208], ["mg", 1211], ["vs.", 1214], ["25", 1218], ["mg", 1221], ["empagliflozin", 1224], ["administered", 1238], ["under", 1251], ["fasting", 1257], ["conditions", 1265], ["were", 1276], ["roughly", 1281], ["dose", 1289], ["-", 1293], ["proportional", 1294], [",", 1306], ["as", 1308], ["demonstrated", 1311], ["by", 1324], ["the", 1327], ["slope", 1331], ["\u03b2", 1337], ["of", 1339], ["the", 1342], ["regression", 1346], ["lines", 1357], ["being", 1363], ["slightly", 1369], ["less", 1378], ["than", 1383], ["1", 1388], ["(", 1390], ["slope", 1391], ["\u03b2", 1397], ["for", 1399], ["AUC0-\u221e", 1403], [":", 1409], ["0.94", 1411], [",", 1415], ["95", 1417], ["%", 1419], ["CI", 1421], [":", 1423], ["0.90", 1425], ["-", 1430], ["0.97", 1432], [";", 1436], ["slope", 1438], ["\u03b2", 1444], ["for", 1446], ["Cmax", 1450], [":", 1454], ["0.91", 1456], [",", 1460], ["95", 1462], ["%", 1464], ["CI", 1466], [":", 1468], ["0.80", 1470], ["-", 1475], ["1.01", 1477], [")", 1481], [".", 1482], ["Empagliflozin", 1484], ["was", 1498], ["well", 1502], ["tolerated", 1507], ["under", 1517], ["fed", 1523], ["and", 1527], ["fasting", 1531], ["conditions", 1539], [".", 1549], ["The", 1551], ["results", 1555], ["support", 1563], ["administration", 1571], ["of", 1586], ["empagliflozin", 1589], ["tablets", 1603], ["independently", 1611], ["of", 1625], ["food", 1628], [".", 1632], ["Increases", 1634], ["in", 1644], ["empagliflozin", 1647], ["exposure", 1661], ["under", 1670], ["fasting", 1676], ["conditions", 1684], ["were", 1695], ["roughly", 1700], ["dose", 1708], ["-", 1712], ["proportional", 1713], ["between", 1726], ["10", 1734], ["mg", 1737], ["and", 1740], ["25", 1744], ["mg", 1747], ["empagliflozin", 1750], [".", 1763]]}
{"context": "Most previously reported mutations in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) result in an odd number of cysteine residues within the epidermal growth factor (EGF)-like repeats in Notch3. We report here R75P mutation in two Japanese CADASIL families not directly involving cysteine residues located within the first EGF-like repeats. Probands in both families had repeated episodes of stroke, depression, dementia as well as T2 high-intensity lesions in the basal ganglia and periventricular white matter, but fewer white matter lesions in the temporal pole on MRI. These families provide new insights into the diagnosis and pathomechanisms of CADASIL.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "bcde6357432f432684078b4f2374b9d8", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[23, 23], [49, 49]], "char_spans": [[166, 173], [334, 341]]}]}], "context_tokens": [["Most", 0], ["previously", 5], ["reported", 16], ["mutations", 25], ["in", 35], ["cerebral", 38], ["autosomal", 47], ["dominant", 57], ["arteriopathy", 66], ["with", 79], ["subcortical", 84], ["infarcts", 96], ["and", 105], ["leukoencephalopathy", 109], ["(", 129], ["CADASIL", 130], [")", 137], ["result", 139], ["in", 146], ["an", 149], ["odd", 152], ["number", 156], ["of", 163], ["cysteine", 166], ["residues", 175], ["within", 184], ["the", 191], ["epidermal", 195], ["growth", 205], ["factor", 212], ["(", 219], ["EGF)-like", 220], ["repeats", 230], ["in", 238], ["Notch3", 241], [".", 247], ["We", 249], ["report", 252], ["here", 259], ["R75P", 264], ["mutation", 269], ["in", 278], ["two", 281], ["Japanese", 285], ["CADASIL", 294], ["families", 302], ["not", 311], ["directly", 315], ["involving", 324], ["cysteine", 334], ["residues", 343], ["located", 352], ["within", 360], ["the", 367], ["first", 371], ["EGF", 377], ["-", 380], ["like", 381], ["repeats", 386], [".", 393], ["Probands", 395], ["in", 404], ["both", 407], ["families", 412], ["had", 421], ["repeated", 425], ["episodes", 434], ["of", 443], ["stroke", 446], [",", 452], ["depression", 454], [",", 464], ["dementia", 466], ["as", 475], ["well", 478], ["as", 483], ["T2", 486], ["high", 489], ["-", 493], ["intensity", 494], ["lesions", 504], ["in", 512], ["the", 515], ["basal", 519], ["ganglia", 525], ["and", 533], ["periventricular", 537], ["white", 553], ["matter", 559], [",", 565], ["but", 567], ["fewer", 571], ["white", 577], ["matter", 583], ["lesions", 590], ["in", 598], ["the", 601], ["temporal", 605], ["pole", 614], ["on", 619], ["MRI", 622], [".", 625], ["These", 627], ["families", 633], ["provide", 642], ["new", 650], ["insights", 654], ["into", 663], ["the", 668], ["diagnosis", 672], ["and", 682], ["pathomechanisms", 686], ["of", 702], ["CADASIL", 705], [".", 712]]}
{"context": "Mowat-Wilson syndrome (MWS) is a rare genetic condition where variable and multiple congenital anomalies including Hirschsprung's disease, intellectual disability, and prominent facial features are present. At molecular level, MWS is characterized by many different described mutations in the zinc finger E-box protein 2 (ZEB2) gene, ultimately leading to loss of gene function. This report is the first to describe the association of MWS with two different asynchronous malignant brain tumors (medulloblastoma and glioblastoma) occurring in a child.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "1d067f852f5b46409f02c83de355022e", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[55, 55]], "char_spans": [[322, 325]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["rare", 33], ["genetic", 38], ["condition", 46], ["where", 56], ["variable", 62], ["and", 71], ["multiple", 75], ["congenital", 84], ["anomalies", 95], ["including", 105], ["Hirschsprung", 115], ["'s", 127], ["disease", 130], [",", 137], ["intellectual", 139], ["disability", 152], [",", 162], ["and", 164], ["prominent", 168], ["facial", 178], ["features", 185], ["are", 194], ["present", 198], [".", 205], ["At", 207], ["molecular", 210], ["level", 220], [",", 225], ["MWS", 227], ["is", 231], ["characterized", 234], ["by", 248], ["many", 251], ["different", 256], ["described", 266], ["mutations", 276], ["in", 286], ["the", 289], ["zinc", 293], ["finger", 298], ["E", 305], ["-", 306], ["box", 307], ["protein", 311], ["2", 319], ["(", 321], ["ZEB2", 322], [")", 326], ["gene", 328], [",", 332], ["ultimately", 334], ["leading", 345], ["to", 353], ["loss", 356], ["of", 361], ["gene", 364], ["function", 369], [".", 377], ["This", 379], ["report", 384], ["is", 391], ["the", 394], ["first", 398], ["to", 404], ["describe", 407], ["the", 416], ["association", 420], ["of", 432], ["MWS", 435], ["with", 439], ["two", 444], ["different", 448], ["asynchronous", 458], ["malignant", 471], ["brain", 481], ["tumors", 487], ["(", 494], ["medulloblastoma", 495], ["and", 511], ["glioblastoma", 515], [")", 527], ["occurring", 529], ["in", 539], ["a", 542], ["child", 544], [".", 549]]}
{"context": "Gefitinib is a specific inhibitor of the epidermal growth factor receptor (EGFR) that causes growth delay in cancer cell lines and human tumor xenografts expressing high levels of EGFR. An understanding of the downstream cellular targets of gefitinib will allow the discovery of biomarkers for predicting outcomes and monitoring anti-EGFR therapies and provide information for key targets for therapeutic intervention. In this study, we investigated the role of FOXO3a in gefitinib action and resistance. Using two gefitinib-sensitive (i.e., BT474 and SKBR3) as well as three other resistant breast carcinoma cell lines (i.e., MCF-7, MDA-MB-231, and MDA-MB-453), we showed that gefitinib targets the transcription factor FOXO3a to mediate cell cycle arrest and cell death in sensitive breast cancer cells. In the sensitive cells, gefitinib treatment causes cell cycle arrest predominantly at the G(0)-G(1) phase and apoptosis, which is associated with FOXO3a dephosphorylation at Akt sites and nuclear translocation, whereas in the resistant cells, FOXO3a stays phosphorylated and remains in the cytoplasm. The nuclear accumulation of FOXO3a in response to gefitinib was confirmed in tumor tissue sections from breast cancer patients presurgically treated with gefitinib as monotherapy. We also showed that knockdown of FOXO3a expression using small interfering RNA (siRNA) can rescue sensitive BT474 cells from gefitinib-induced cell-proliferative arrest, whereas reintroduction of active FOXO3a in resistant MDA-MB-231 cells can at least partially restore cell-proliferative arrest and sensitivity to gefitinib. These results suggest that the FOXO3a dephosphorylation and nuclear localization have a direct role in mediating the gefitinib-induced proliferative arrest and in determining sensitivity to gefitinib.", "qas": [{"question": "Which is the cellular target of gefitinib?", "answers": ["Epidermal growth factor receptor (EGFR)"], "qid": "5ad5edb13de04cb2b3191b68d0eab76d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["target", 22], ["of", 29], ["gefitinib", 32], ["?", 41]], "detected_answers": [{"text": "Epidermal growth factor receptor (EGFR)", "token_spans": [[7, 12]], "char_spans": [[41, 78]]}]}], "context_tokens": [["Gefitinib", 0], ["is", 10], ["a", 13], ["specific", 15], ["inhibitor", 24], ["of", 34], ["the", 37], ["epidermal", 41], ["growth", 51], ["factor", 58], ["receptor", 65], ["(", 74], ["EGFR", 75], [")", 79], ["that", 81], ["causes", 86], ["growth", 93], ["delay", 100], ["in", 106], ["cancer", 109], ["cell", 116], ["lines", 121], ["and", 127], ["human", 131], ["tumor", 137], ["xenografts", 143], ["expressing", 154], ["high", 165], ["levels", 170], ["of", 177], ["EGFR", 180], [".", 184], ["An", 186], ["understanding", 189], ["of", 203], ["the", 206], ["downstream", 210], ["cellular", 221], ["targets", 230], ["of", 238], ["gefitinib", 241], ["will", 251], ["allow", 256], ["the", 262], ["discovery", 266], ["of", 276], ["biomarkers", 279], ["for", 290], ["predicting", 294], ["outcomes", 305], ["and", 314], ["monitoring", 318], ["anti", 329], ["-", 333], ["EGFR", 334], ["therapies", 339], ["and", 349], ["provide", 353], ["information", 361], ["for", 373], ["key", 377], ["targets", 381], ["for", 389], ["therapeutic", 393], ["intervention", 405], [".", 417], ["In", 419], ["this", 422], ["study", 427], [",", 432], ["we", 434], ["investigated", 437], ["the", 450], ["role", 454], ["of", 459], ["FOXO3a", 462], ["in", 469], ["gefitinib", 472], ["action", 482], ["and", 489], ["resistance", 493], [".", 503], ["Using", 505], ["two", 511], ["gefitinib", 515], ["-", 524], ["sensitive", 525], ["(", 535], ["i.e.", 536], [",", 540], ["BT474", 542], ["and", 548], ["SKBR3", 552], [")", 557], ["as", 559], ["well", 562], ["as", 567], ["three", 570], ["other", 576], ["resistant", 582], ["breast", 592], ["carcinoma", 599], ["cell", 609], ["lines", 614], ["(", 620], ["i.e.", 621], [",", 625], ["MCF-7", 627], [",", 632], ["MDA", 634], ["-", 637], ["MB-231", 638], [",", 644], ["and", 646], ["MDA", 650], ["-", 653], ["MB-453", 654], [")", 660], [",", 661], ["we", 663], ["showed", 666], ["that", 673], ["gefitinib", 678], ["targets", 688], ["the", 696], ["transcription", 700], ["factor", 714], ["FOXO3a", 721], ["to", 728], ["mediate", 731], ["cell", 739], ["cycle", 744], ["arrest", 750], ["and", 757], ["cell", 761], ["death", 766], ["in", 772], ["sensitive", 775], ["breast", 785], ["cancer", 792], ["cells", 799], [".", 804], ["In", 806], ["the", 809], ["sensitive", 813], ["cells", 823], [",", 828], ["gefitinib", 830], ["treatment", 840], ["causes", 850], ["cell", 857], ["cycle", 862], ["arrest", 868], ["predominantly", 875], ["at", 889], ["the", 892], ["G(0)-G(1", 896], [")", 904], ["phase", 906], ["and", 912], ["apoptosis", 916], [",", 925], ["which", 927], ["is", 933], ["associated", 936], ["with", 947], ["FOXO3a", 952], ["dephosphorylation", 959], ["at", 977], ["Akt", 980], ["sites", 984], ["and", 990], ["nuclear", 994], ["translocation", 1002], [",", 1015], ["whereas", 1017], ["in", 1025], ["the", 1028], ["resistant", 1032], ["cells", 1042], [",", 1047], ["FOXO3a", 1049], ["stays", 1056], ["phosphorylated", 1062], ["and", 1077], ["remains", 1081], ["in", 1089], ["the", 1092], ["cytoplasm", 1096], [".", 1105], ["The", 1107], ["nuclear", 1111], ["accumulation", 1119], ["of", 1132], ["FOXO3a", 1135], ["in", 1142], ["response", 1145], ["to", 1154], ["gefitinib", 1157], ["was", 1167], ["confirmed", 1171], ["in", 1181], ["tumor", 1184], ["tissue", 1190], ["sections", 1197], ["from", 1206], ["breast", 1211], ["cancer", 1218], ["patients", 1225], ["presurgically", 1234], ["treated", 1248], ["with", 1256], ["gefitinib", 1261], ["as", 1271], ["monotherapy", 1274], [".", 1285], ["We", 1287], ["also", 1290], ["showed", 1295], ["that", 1302], ["knockdown", 1307], ["of", 1317], ["FOXO3a", 1320], ["expression", 1327], ["using", 1338], ["small", 1344], ["interfering", 1350], ["RNA", 1362], ["(", 1366], ["siRNA", 1367], [")", 1372], ["can", 1374], ["rescue", 1378], ["sensitive", 1385], ["BT474", 1395], ["cells", 1401], ["from", 1407], ["gefitinib", 1412], ["-", 1421], ["induced", 1422], ["cell", 1430], ["-", 1434], ["proliferative", 1435], ["arrest", 1449], [",", 1455], ["whereas", 1457], ["reintroduction", 1465], ["of", 1480], ["active", 1483], ["FOXO3a", 1490], ["in", 1497], ["resistant", 1500], ["MDA", 1510], ["-", 1513], ["MB-231", 1514], ["cells", 1521], ["can", 1527], ["at", 1531], ["least", 1534], ["partially", 1540], ["restore", 1550], ["cell", 1558], ["-", 1562], ["proliferative", 1563], ["arrest", 1577], ["and", 1584], ["sensitivity", 1588], ["to", 1600], ["gefitinib", 1603], [".", 1612], ["These", 1614], ["results", 1620], ["suggest", 1628], ["that", 1636], ["the", 1641], ["FOXO3a", 1645], ["dephosphorylation", 1652], ["and", 1670], ["nuclear", 1674], ["localization", 1682], ["have", 1695], ["a", 1700], ["direct", 1702], ["role", 1709], ["in", 1714], ["mediating", 1717], ["the", 1727], ["gefitinib", 1731], ["-", 1740], ["induced", 1741], ["proliferative", 1749], ["arrest", 1763], ["and", 1770], ["in", 1774], ["determining", 1777], ["sensitivity", 1789], ["to", 1801], ["gefitinib", 1804], [".", 1813]]}
{"context": "Patients with splenomegaly and abnormally high leukocyte counts were first recognized in France, Germany, and Scotland in the 1840s. The only well-documented therapy in the 19th century was use of arsenic in one or other form, which did undoubtedly reduce the leukocyte count but probably did little or nothing to prolong life. These early cases were probably examples of chronic myeloid leukemia (CML) (then called chronic granulocytic leukemia). In the 20th century important steps in unraveling the pathogenesis of CML were the discovery of the Philadelphia chromosome in 1960, and of the (9;22) translocation in 1973. There followed definition of the breakpoint cluster region on chromosome 22 in 1984 and the demonstration of the BCR-ABL transcript in CML in 1985. In the first half of the 20th century patients were treated predominantly with radiotherapy, and later on with busulfan, hydroxycarbamide, or interferon-alfa (IFN-\u03b1). From 1980 onwards allogeneic stem cell transplantation (SCT) became the treatment of choice for eligible patients. The era of tyrosine kinase inhibitors (TKI) began in 1998 and today the use of the original TKI, imatinib, has replaced SCT as initial therapy for patients who present with CML in chronic phase.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7a34cd7025714d5fa78883088d8a1b82", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[130, 132]], "char_spans": [[735, 741]]}]}], "context_tokens": [["Patients", 0], ["with", 9], ["splenomegaly", 14], ["and", 27], ["abnormally", 31], ["high", 42], ["leukocyte", 47], ["counts", 57], ["were", 64], ["first", 69], ["recognized", 75], ["in", 86], ["France", 89], [",", 95], ["Germany", 97], [",", 104], ["and", 106], ["Scotland", 110], ["in", 119], ["the", 122], ["1840s", 126], [".", 131], ["The", 133], ["only", 137], ["well", 142], ["-", 146], ["documented", 147], ["therapy", 158], ["in", 166], ["the", 169], ["19th", 173], ["century", 178], ["was", 186], ["use", 190], ["of", 194], ["arsenic", 197], ["in", 205], ["one", 208], ["or", 212], ["other", 215], ["form", 221], [",", 225], ["which", 227], ["did", 233], ["undoubtedly", 237], ["reduce", 249], ["the", 256], ["leukocyte", 260], ["count", 270], ["but", 276], ["probably", 280], ["did", 289], ["little", 293], ["or", 300], ["nothing", 303], ["to", 311], ["prolong", 314], ["life", 322], [".", 326], ["These", 328], ["early", 334], ["cases", 340], ["were", 346], ["probably", 351], ["examples", 360], ["of", 369], ["chronic", 372], ["myeloid", 380], ["leukemia", 388], ["(", 397], ["CML", 398], [")", 401], ["(", 403], ["then", 404], ["called", 409], ["chronic", 416], ["granulocytic", 424], ["leukemia", 437], [")", 445], [".", 446], ["In", 448], ["the", 451], ["20th", 455], ["century", 460], ["important", 468], ["steps", 478], ["in", 484], ["unraveling", 487], ["the", 498], ["pathogenesis", 502], ["of", 515], ["CML", 518], ["were", 522], ["the", 527], ["discovery", 531], ["of", 541], ["the", 544], ["Philadelphia", 548], ["chromosome", 561], ["in", 572], ["1960", 575], [",", 579], ["and", 581], ["of", 585], ["the", 588], ["(", 592], ["9;22", 593], [")", 597], ["translocation", 599], ["in", 613], ["1973", 616], [".", 620], ["There", 622], ["followed", 628], ["definition", 637], ["of", 648], ["the", 651], ["breakpoint", 655], ["cluster", 666], ["region", 674], ["on", 681], ["chromosome", 684], ["22", 695], ["in", 698], ["1984", 701], ["and", 706], ["the", 710], ["demonstration", 714], ["of", 728], ["the", 731], ["BCR", 735], ["-", 738], ["ABL", 739], ["transcript", 743], ["in", 754], ["CML", 757], ["in", 761], ["1985", 764], [".", 768], ["In", 770], ["the", 773], ["first", 777], ["half", 783], ["of", 788], ["the", 791], ["20th", 795], ["century", 800], ["patients", 808], ["were", 817], ["treated", 822], ["predominantly", 830], ["with", 844], ["radiotherapy", 849], [",", 861], ["and", 863], ["later", 867], ["on", 873], ["with", 876], ["busulfan", 881], [",", 889], ["hydroxycarbamide", 891], [",", 907], ["or", 909], ["interferon", 912], ["-", 922], ["alfa", 923], ["(", 928], ["IFN", 929], ["-", 932], ["\u03b1", 933], [")", 934], [".", 935], ["From", 937], ["1980", 942], ["onwards", 947], ["allogeneic", 955], ["stem", 966], ["cell", 971], ["transplantation", 976], ["(", 992], ["SCT", 993], [")", 996], ["became", 998], ["the", 1005], ["treatment", 1009], ["of", 1019], ["choice", 1022], ["for", 1029], ["eligible", 1033], ["patients", 1042], [".", 1050], ["The", 1052], ["era", 1056], ["of", 1060], ["tyrosine", 1063], ["kinase", 1072], ["inhibitors", 1079], ["(", 1090], ["TKI", 1091], [")", 1094], ["began", 1096], ["in", 1102], ["1998", 1105], ["and", 1110], ["today", 1114], ["the", 1120], ["use", 1124], ["of", 1128], ["the", 1131], ["original", 1135], ["TKI", 1144], [",", 1147], ["imatinib", 1149], [",", 1157], ["has", 1159], ["replaced", 1163], ["SCT", 1172], ["as", 1176], ["initial", 1179], ["therapy", 1187], ["for", 1195], ["patients", 1199], ["who", 1208], ["present", 1212], ["with", 1220], ["CML", 1225], ["in", 1229], ["chronic", 1232], ["phase", 1240], [".", 1245]]}
{"context": "Groucho (Gro) is a Drosophila melanogaster transcriptional corepressor that directly interacts with the histone deacetylase Rpd3. Although previous studies suggest that this interaction is required for repression of Gro-responsive reporters in cultured cells, the in vivo significance of this interaction and the mechanism by which it leads to repression remain largely unexplored. In this study, we show that Gro is partially dependent on Rpd3 for repression, supporting the idea that Rpd3-mediated repression is one mode of Gro-mediated repression. We demonstrate that Gro colocalizes with Rpd3 to the chromatin of a target gene and that this is accompanied by the deacetylation of specific lysines within the N-terminal tails of histones H3 and H4. Gro overexpression leads to wing patterning defects and ectopic repression in the wing disc of transcription directed by the vestigial quadrant enhancer. These effects are reversed by the histone deacetylase inhibitors TSA and HC-Toxin and by the reduction of Rpd3 gene dosage. Furthermore, repression of the vestigial quadrant enhancer is accompanied by a Gro-mediated increase in nucleosome density, an effect that is reversed by histone deacetylase inhibitors. We propose a model in which Gro-mediated histone deacetylation results in increased nucleosome density leading to transcriptional repression.", "qas": [{"question": "What is the Drosophila melanogaster Groucho protein?", "answers": ["Groucho (Gro) is a Drosophila melanogaster transcriptional corepressor"], "qid": "cb1860ac490e4c2cb4db0aaf636faa83", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["Drosophila", 12], ["melanogaster", 23], ["Groucho", 36], ["protein", 44], ["?", 51]], "detected_answers": [{"text": "Groucho (Gro) is a Drosophila melanogaster transcriptional corepressor", "token_spans": [[0, 9]], "char_spans": [[0, 69]]}]}], "context_tokens": [["Groucho", 0], ["(", 8], ["Gro", 9], [")", 12], ["is", 14], ["a", 17], ["Drosophila", 19], ["melanogaster", 30], ["transcriptional", 43], ["corepressor", 59], ["that", 71], ["directly", 76], ["interacts", 85], ["with", 95], ["the", 100], ["histone", 104], ["deacetylase", 112], ["Rpd3", 124], [".", 128], ["Although", 130], ["previous", 139], ["studies", 148], ["suggest", 156], ["that", 164], ["this", 169], ["interaction", 174], ["is", 186], ["required", 189], ["for", 198], ["repression", 202], ["of", 213], ["Gro", 216], ["-", 219], ["responsive", 220], ["reporters", 231], ["in", 241], ["cultured", 244], ["cells", 253], [",", 258], ["the", 260], ["in", 264], ["vivo", 267], ["significance", 272], ["of", 285], ["this", 288], ["interaction", 293], ["and", 305], ["the", 309], ["mechanism", 313], ["by", 323], ["which", 326], ["it", 332], ["leads", 335], ["to", 341], ["repression", 344], ["remain", 355], ["largely", 362], ["unexplored", 370], [".", 380], ["In", 382], ["this", 385], ["study", 390], [",", 395], ["we", 397], ["show", 400], ["that", 405], ["Gro", 410], ["is", 414], ["partially", 417], ["dependent", 427], ["on", 437], ["Rpd3", 440], ["for", 445], ["repression", 449], [",", 459], ["supporting", 461], ["the", 472], ["idea", 476], ["that", 481], ["Rpd3-mediated", 486], ["repression", 500], ["is", 511], ["one", 514], ["mode", 518], ["of", 523], ["Gro", 526], ["-", 529], ["mediated", 530], ["repression", 539], [".", 549], ["We", 551], ["demonstrate", 554], ["that", 566], ["Gro", 571], ["colocalizes", 575], ["with", 587], ["Rpd3", 592], ["to", 597], ["the", 600], ["chromatin", 604], ["of", 614], ["a", 617], ["target", 619], ["gene", 626], ["and", 631], ["that", 635], ["this", 640], ["is", 645], ["accompanied", 648], ["by", 660], ["the", 663], ["deacetylation", 667], ["of", 681], ["specific", 684], ["lysines", 693], ["within", 701], ["the", 708], ["N", 712], ["-", 713], ["terminal", 714], ["tails", 723], ["of", 729], ["histones", 732], ["H3", 741], ["and", 744], ["H4", 748], [".", 750], ["Gro", 752], ["overexpression", 756], ["leads", 771], ["to", 777], ["wing", 780], ["patterning", 785], ["defects", 796], ["and", 804], ["ectopic", 808], ["repression", 816], ["in", 827], ["the", 830], ["wing", 834], ["disc", 839], ["of", 844], ["transcription", 847], ["directed", 861], ["by", 870], ["the", 873], ["vestigial", 877], ["quadrant", 887], ["enhancer", 896], [".", 904], ["These", 906], ["effects", 912], ["are", 920], ["reversed", 924], ["by", 933], ["the", 936], ["histone", 940], ["deacetylase", 948], ["inhibitors", 960], ["TSA", 971], ["and", 975], ["HC", 979], ["-", 981], ["Toxin", 982], ["and", 988], ["by", 992], ["the", 995], ["reduction", 999], ["of", 1009], ["Rpd3", 1012], ["gene", 1017], ["dosage", 1022], [".", 1028], ["Furthermore", 1030], [",", 1041], ["repression", 1043], ["of", 1054], ["the", 1057], ["vestigial", 1061], ["quadrant", 1071], ["enhancer", 1080], ["is", 1089], ["accompanied", 1092], ["by", 1104], ["a", 1107], ["Gro", 1109], ["-", 1112], ["mediated", 1113], ["increase", 1122], ["in", 1131], ["nucleosome", 1134], ["density", 1145], [",", 1152], ["an", 1154], ["effect", 1157], ["that", 1164], ["is", 1169], ["reversed", 1172], ["by", 1181], ["histone", 1184], ["deacetylase", 1192], ["inhibitors", 1204], [".", 1214], ["We", 1216], ["propose", 1219], ["a", 1227], ["model", 1229], ["in", 1235], ["which", 1238], ["Gro", 1244], ["-", 1247], ["mediated", 1248], ["histone", 1257], ["deacetylation", 1265], ["results", 1279], ["in", 1287], ["increased", 1290], ["nucleosome", 1300], ["density", 1311], ["leading", 1319], ["to", 1327], ["transcriptional", 1330], ["repression", 1346], [".", 1356]]}
{"context": "The SP790 study (ClinicalTrials.gov, NCT00136045) showed benefits of rotigotine over placebo in improving symptom severity of restless legs syndrome (RLS), also known as Willis-Ekbom disease, on the International Restless Legs Syndrome Study Group rating scale (IRLS), Clinical Global Impression item 1 (CGI-1), RLS 6-item questionnaire (RLS-6), and the RLS-quality of life questionnaire (RLS-QoL) in patients with moderate to severe idiopathic RLS. To provide clinical context for the IRLS and to guide the choice of assessment scales for RLS studies, our post hoc analysis of SP790 data evaluated associations between the IRLS and the CGI-1, IRLS and RLS-6, and the IRLS and RLS-QoL. Scale associations were analyzed at baseline and at the end of maintenance (EoM) using data from the safety set (rotigotine and placebo groups combined [n=458]). Changes from baseline to EoM in IRLS score vs comparator scale scores also were analyzed. There was a trend towards increasing IRLS severity category with increasing CGI-1, RLS-6, and RLS-QoL score. Pearson product moment correlation coefficients showed correlations between IRLS and comparator scale scores at baseline and EoM as well as correlations for change from baseline to EoM. Correlations between the IRLS and comparator scales were substantial. These data indicate that the IRLS is clinically meaningful. The IRLS and CGI-1 are generally sufficient to evaluate the overall severity and impact of RLS symptoms in clinical trials.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "ad2342b8121d4fafa653d33df74f5afc", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[37, 39], [19, 21]], "char_spans": [[213, 234], [126, 147]]}]}], "context_tokens": [["The", 0], ["SP790", 4], ["study", 10], ["(", 16], ["ClinicalTrials.gov", 17], [",", 35], ["NCT00136045", 37], [")", 48], ["showed", 50], ["benefits", 57], ["of", 66], ["rotigotine", 69], ["over", 80], ["placebo", 85], ["in", 93], ["improving", 96], ["symptom", 106], ["severity", 114], ["of", 123], ["restless", 126], ["legs", 135], ["syndrome", 140], ["(", 149], ["RLS", 150], [")", 153], [",", 154], ["also", 156], ["known", 161], ["as", 167], ["Willis", 170], ["-", 176], ["Ekbom", 177], ["disease", 183], [",", 190], ["on", 192], ["the", 195], ["International", 199], ["Restless", 213], ["Legs", 222], ["Syndrome", 227], ["Study", 236], ["Group", 242], ["rating", 248], ["scale", 255], ["(", 261], ["IRLS", 262], [")", 266], [",", 267], ["Clinical", 269], ["Global", 278], ["Impression", 285], ["item", 296], ["1", 301], ["(", 303], ["CGI-1", 304], [")", 309], [",", 310], ["RLS", 312], ["6-item", 316], ["questionnaire", 323], ["(", 337], ["RLS-6", 338], [")", 343], [",", 344], ["and", 346], ["the", 350], ["RLS", 354], ["-", 357], ["quality", 358], ["of", 366], ["life", 369], ["questionnaire", 374], ["(", 388], ["RLS", 389], ["-", 392], ["QoL", 393], [")", 396], ["in", 398], ["patients", 401], ["with", 410], ["moderate", 415], ["to", 424], ["severe", 427], ["idiopathic", 434], ["RLS", 445], [".", 448], ["To", 450], ["provide", 453], ["clinical", 461], ["context", 470], ["for", 478], ["the", 482], ["IRLS", 486], ["and", 491], ["to", 495], ["guide", 498], ["the", 504], ["choice", 508], ["of", 515], ["assessment", 518], ["scales", 529], ["for", 536], ["RLS", 540], ["studies", 544], [",", 551], ["our", 553], ["post", 557], ["hoc", 562], ["analysis", 566], ["of", 575], ["SP790", 578], ["data", 584], ["evaluated", 589], ["associations", 599], ["between", 612], ["the", 620], ["IRLS", 624], ["and", 629], ["the", 633], ["CGI-1", 637], [",", 642], ["IRLS", 644], ["and", 649], ["RLS-6", 653], [",", 658], ["and", 660], ["the", 664], ["IRLS", 668], ["and", 673], ["RLS", 677], ["-", 680], ["QoL.", 681], ["Scale", 686], ["associations", 692], ["were", 705], ["analyzed", 710], ["at", 719], ["baseline", 722], ["and", 731], ["at", 735], ["the", 738], ["end", 742], ["of", 746], ["maintenance", 749], ["(", 761], ["EoM", 762], [")", 765], ["using", 767], ["data", 773], ["from", 778], ["the", 783], ["safety", 787], ["set", 794], ["(", 798], ["rotigotine", 799], ["and", 810], ["placebo", 814], ["groups", 822], ["combined", 829], ["[", 838], ["n=458", 839], ["]", 844], [")", 845], [".", 846], ["Changes", 848], ["from", 856], ["baseline", 861], ["to", 870], ["EoM", 873], ["in", 877], ["IRLS", 880], ["score", 885], ["vs", 891], ["comparator", 894], ["scale", 905], ["scores", 911], ["also", 918], ["were", 923], ["analyzed", 928], [".", 936], ["There", 938], ["was", 944], ["a", 948], ["trend", 950], ["towards", 956], ["increasing", 964], ["IRLS", 975], ["severity", 980], ["category", 989], ["with", 998], ["increasing", 1003], ["CGI-1", 1014], [",", 1019], ["RLS-6", 1021], [",", 1026], ["and", 1028], ["RLS", 1032], ["-", 1035], ["QoL", 1036], ["score", 1040], [".", 1045], ["Pearson", 1047], ["product", 1055], ["moment", 1063], ["correlation", 1070], ["coefficients", 1082], ["showed", 1095], ["correlations", 1102], ["between", 1115], ["IRLS", 1123], ["and", 1128], ["comparator", 1132], ["scale", 1143], ["scores", 1149], ["at", 1156], ["baseline", 1159], ["and", 1168], ["EoM", 1172], ["as", 1176], ["well", 1179], ["as", 1184], ["correlations", 1187], ["for", 1200], ["change", 1204], ["from", 1211], ["baseline", 1216], ["to", 1225], ["EoM.", 1228], ["Correlations", 1233], ["between", 1246], ["the", 1254], ["IRLS", 1258], ["and", 1263], ["comparator", 1267], ["scales", 1278], ["were", 1285], ["substantial", 1290], [".", 1301], ["These", 1303], ["data", 1309], ["indicate", 1314], ["that", 1323], ["the", 1328], ["IRLS", 1332], ["is", 1337], ["clinically", 1340], ["meaningful", 1351], [".", 1361], ["The", 1363], ["IRLS", 1367], ["and", 1372], ["CGI-1", 1376], ["are", 1382], ["generally", 1386], ["sufficient", 1396], ["to", 1407], ["evaluate", 1410], ["the", 1419], ["overall", 1423], ["severity", 1431], ["and", 1440], ["impact", 1444], ["of", 1451], ["RLS", 1454], ["symptoms", 1458], ["in", 1467], ["clinical", 1470], ["trials", 1479], [".", 1485]]}
{"context": "The conserved histone variant H2A.Z functions in euchromatin to antagonize the spread of heterochromatin. The mechanism by which histone H2A is replaced by H2A.Z in the nucleosome is unknown. We identified a complex containing 13 different polypeptides associated with a soluble pool of H2A.Z in Saccharomyces cerevisiae. This complex was designated SWR1-Com in reference to the Swr1p subunit, a Swi2/Snf2-paralog. Swr1p and six other subunits were found only in SWR1-Com, whereas six other subunits were also found in the NuA4 histone acetyltransferase and/or the Ino80 chromatin remodeling complex. H2A.Z and SWR1 were essential for viability of cells lacking the EAF1 component of NuA4, pointing to a close functional connection between these two complexes. Strikingly, chromatin immunoprecipitation analysis of cells lacking Swr1p, the presumed ATPase of the complex, revealed a profound defect in the deposition of H2A.Z at euchromatic regions that flank the silent mating type cassette HMR and at 12 other chromosomal sites tested. Consistent with a specialized role for Swr1p in H2A.Z deposition, the majority of the genome-wide transcriptional defects seen in swr1Delta cells were also found in htz1Delta cells. These studies revealed a novel role for a member of the ATP-dependent chromatin remodeling enzyme family in determining the region-specific histone subunit composition of chromatin in vivo and controlling the epigenetic state of chromatin. Metazoan orthologs of Swr1p (Drosophila Domino; human SRCAP and p400) may have analogous functions.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "30f3fe33aa974d54aa12ad555cb22644", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[97, 97]], "char_spans": [[611, 614]]}]}], "context_tokens": [["The", 0], ["conserved", 4], ["histone", 14], ["variant", 22], ["H2A.Z", 30], ["functions", 36], ["in", 46], ["euchromatin", 49], ["to", 61], ["antagonize", 64], ["the", 75], ["spread", 79], ["of", 86], ["heterochromatin", 89], [".", 104], ["The", 106], ["mechanism", 110], ["by", 120], ["which", 123], ["histone", 129], ["H2A", 137], ["is", 141], ["replaced", 144], ["by", 153], ["H2A.Z", 156], ["in", 162], ["the", 165], ["nucleosome", 169], ["is", 180], ["unknown", 183], [".", 190], ["We", 192], ["identified", 195], ["a", 206], ["complex", 208], ["containing", 216], ["13", 227], ["different", 230], ["polypeptides", 240], ["associated", 253], ["with", 264], ["a", 269], ["soluble", 271], ["pool", 279], ["of", 284], ["H2A.Z", 287], ["in", 293], ["Saccharomyces", 296], ["cerevisiae", 310], [".", 320], ["This", 322], ["complex", 327], ["was", 335], ["designated", 339], ["SWR1-Com", 350], ["in", 359], ["reference", 362], ["to", 372], ["the", 375], ["Swr1p", 379], ["subunit", 385], [",", 392], ["a", 394], ["Swi2/Snf2-paralog", 396], [".", 413], ["Swr1p", 415], ["and", 421], ["six", 425], ["other", 429], ["subunits", 435], ["were", 444], ["found", 449], ["only", 455], ["in", 460], ["SWR1-Com", 463], [",", 471], ["whereas", 473], ["six", 481], ["other", 485], ["subunits", 491], ["were", 500], ["also", 505], ["found", 510], ["in", 516], ["the", 519], ["NuA4", 523], ["histone", 528], ["acetyltransferase", 536], ["and/or", 554], ["the", 561], ["Ino80", 565], ["chromatin", 571], ["remodeling", 581], ["complex", 592], [".", 599], ["H2A.Z", 601], ["and", 607], ["SWR1", 611], ["were", 616], ["essential", 621], ["for", 631], ["viability", 635], ["of", 645], ["cells", 648], ["lacking", 654], ["the", 662], ["EAF1", 666], ["component", 671], ["of", 681], ["NuA4", 684], [",", 688], ["pointing", 690], ["to", 699], ["a", 702], ["close", 704], ["functional", 710], ["connection", 721], ["between", 732], ["these", 740], ["two", 746], ["complexes", 750], [".", 759], ["Strikingly", 761], [",", 771], ["chromatin", 773], ["immunoprecipitation", 783], ["analysis", 803], ["of", 812], ["cells", 815], ["lacking", 821], ["Swr1p", 829], [",", 834], ["the", 836], ["presumed", 840], ["ATPase", 849], ["of", 856], ["the", 859], ["complex", 863], [",", 870], ["revealed", 872], ["a", 881], ["profound", 883], ["defect", 892], ["in", 899], ["the", 902], ["deposition", 906], ["of", 917], ["H2A.Z", 920], ["at", 926], ["euchromatic", 929], ["regions", 941], ["that", 949], ["flank", 954], ["the", 960], ["silent", 964], ["mating", 971], ["type", 978], ["cassette", 983], ["HMR", 992], ["and", 996], ["at", 1000], ["12", 1003], ["other", 1006], ["chromosomal", 1012], ["sites", 1024], ["tested", 1030], [".", 1036], ["Consistent", 1038], ["with", 1049], ["a", 1054], ["specialized", 1056], ["role", 1068], ["for", 1073], ["Swr1p", 1077], ["in", 1083], ["H2A.Z", 1086], ["deposition", 1092], [",", 1102], ["the", 1104], ["majority", 1108], ["of", 1117], ["the", 1120], ["genome", 1124], ["-", 1130], ["wide", 1131], ["transcriptional", 1136], ["defects", 1152], ["seen", 1160], ["in", 1165], ["swr1Delta", 1168], ["cells", 1178], ["were", 1184], ["also", 1189], ["found", 1194], ["in", 1200], ["htz1Delta", 1203], ["cells", 1213], [".", 1218], ["These", 1220], ["studies", 1226], ["revealed", 1234], ["a", 1243], ["novel", 1245], ["role", 1251], ["for", 1256], ["a", 1260], ["member", 1262], ["of", 1269], ["the", 1272], ["ATP", 1276], ["-", 1279], ["dependent", 1280], ["chromatin", 1290], ["remodeling", 1300], ["enzyme", 1311], ["family", 1318], ["in", 1325], ["determining", 1328], ["the", 1340], ["region", 1344], ["-", 1350], ["specific", 1351], ["histone", 1360], ["subunit", 1368], ["composition", 1376], ["of", 1388], ["chromatin", 1391], ["in", 1401], ["vivo", 1404], ["and", 1409], ["controlling", 1413], ["the", 1425], ["epigenetic", 1429], ["state", 1440], ["of", 1446], ["chromatin", 1449], [".", 1458], ["Metazoan", 1460], ["orthologs", 1469], ["of", 1479], ["Swr1p", 1482], ["(", 1488], ["Drosophila", 1489], ["Domino", 1500], [";", 1506], ["human", 1508], ["SRCAP", 1514], ["and", 1520], ["p400", 1524], [")", 1528], ["may", 1530], ["have", 1534], ["analogous", 1539], ["functions", 1549], [".", 1558]]}
{"context": "Research is ongoing to develop multipurpose vaginal rings to be used continuously for contraception and to prevent Human Immunodeficiency Virus (HIV) infection. Contraceptive vaginal rings (CVRs) are available in a number of countries and are most of the time used intermittently i.e. three weeks out of a 4-week cycle. Efficacy trials with a dapivirine-containing vaginal ring for HIV prevention are ongoing and plans to develop multi-purpose vaginal rings for prevention of both HIV and pregnancy have been elaborated. In contrast with the CVRs, multi-purpose vaginal rings will have to be used continuously. Women who continuously use a CVR will no longer have menses. Furthermore, some safety aspects of CVR use have never been studied in-depth in the past, such as the impact of the vaginal ring on the vaginal microbiota, biofilm formation and induction of inflammation. We studied acceptability and these novel aspects of safety in Rwandan women. Although significant progress has been made over the past decade, Rwanda still has a high unmet need for contraception (with 47% unplanned births) and a generalized HIV epidemic, and CVRs are not yet available. We will conduct an open label, single centre, randomized controlled trial. A total of 120 HIV-negative women will be randomized to intermittent CVR use (to allow menstruation) or continuous CVR use. Women will be followed for a maximum of 14 weeks. In parallel, we will conduct a qualitative study using in-depth interview and focus group discussion methodology. In addition to evaluating the safety and acceptability of intermittent and continuous CVR use in Rwandan women, we hope that our findings will inform the development of future multipurpose vaginal rings, will prepare Rwandan study populations for future clinical trials of multipurpose vaginal rings, and will pave the way for introduction of CVRs on African markets. Clinicaltrials.gov NCT01796613 . Registered 14 February 2013.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "bf0da804130241878073b33d36565f05", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[229, 229], [21, 21], [201, 201], [82, 82], [65, 65]], "char_spans": [[1255, 1257], [145, 147], [1119, 1121], [481, 483], [382, 384]]}]}], "context_tokens": [["Research", 0], ["is", 9], ["ongoing", 12], ["to", 20], ["develop", 23], ["multipurpose", 31], ["vaginal", 44], ["rings", 52], ["to", 58], ["be", 61], ["used", 64], ["continuously", 69], ["for", 82], ["contraception", 86], ["and", 100], ["to", 104], ["prevent", 107], ["Human", 115], ["Immunodeficiency", 121], ["Virus", 138], ["(", 144], ["HIV", 145], [")", 148], ["infection", 150], [".", 159], ["Contraceptive", 161], ["vaginal", 175], ["rings", 183], ["(", 189], ["CVRs", 190], [")", 194], ["are", 196], ["available", 200], ["in", 210], ["a", 213], ["number", 215], ["of", 222], ["countries", 225], ["and", 235], ["are", 239], ["most", 243], ["of", 248], ["the", 251], ["time", 255], ["used", 260], ["intermittently", 265], ["i.e.", 280], ["three", 285], ["weeks", 291], ["out", 297], ["of", 301], ["a", 304], ["4-week", 306], ["cycle", 313], [".", 318], ["Efficacy", 320], ["trials", 329], ["with", 336], ["a", 341], ["dapivirine", 343], ["-", 353], ["containing", 354], ["vaginal", 365], ["ring", 373], ["for", 378], ["HIV", 382], ["prevention", 386], ["are", 397], ["ongoing", 401], ["and", 409], ["plans", 413], ["to", 419], ["develop", 422], ["multi", 430], ["-", 435], ["purpose", 436], ["vaginal", 444], ["rings", 452], ["for", 458], ["prevention", 462], ["of", 473], ["both", 476], ["HIV", 481], ["and", 485], ["pregnancy", 489], ["have", 499], ["been", 504], ["elaborated", 509], [".", 519], ["In", 521], ["contrast", 524], ["with", 533], ["the", 538], ["CVRs", 542], [",", 546], ["multi", 548], ["-", 553], ["purpose", 554], ["vaginal", 562], ["rings", 570], ["will", 576], ["have", 581], ["to", 586], ["be", 589], ["used", 592], ["continuously", 597], [".", 609], ["Women", 611], ["who", 617], ["continuously", 621], ["use", 634], ["a", 638], ["CVR", 640], ["will", 644], ["no", 649], ["longer", 652], ["have", 659], ["menses", 664], [".", 670], ["Furthermore", 672], [",", 683], ["some", 685], ["safety", 690], ["aspects", 697], ["of", 705], ["CVR", 708], ["use", 712], ["have", 716], ["never", 721], ["been", 727], ["studied", 732], ["in", 740], ["-", 742], ["depth", 743], ["in", 749], ["the", 752], ["past", 756], [",", 760], ["such", 762], ["as", 767], ["the", 770], ["impact", 774], ["of", 781], ["the", 784], ["vaginal", 788], ["ring", 796], ["on", 801], ["the", 804], ["vaginal", 808], ["microbiota", 816], [",", 826], ["biofilm", 828], ["formation", 836], ["and", 846], ["induction", 850], ["of", 860], ["inflammation", 863], [".", 875], ["We", 877], ["studied", 880], ["acceptability", 888], ["and", 902], ["these", 906], ["novel", 912], ["aspects", 918], ["of", 926], ["safety", 929], ["in", 936], ["Rwandan", 939], ["women", 947], [".", 952], ["Although", 954], ["significant", 963], ["progress", 975], ["has", 984], ["been", 988], ["made", 993], ["over", 998], ["the", 1003], ["past", 1007], ["decade", 1012], [",", 1018], ["Rwanda", 1020], ["still", 1027], ["has", 1033], ["a", 1037], ["high", 1039], ["unmet", 1044], ["need", 1050], ["for", 1055], ["contraception", 1059], ["(", 1073], ["with", 1074], ["47", 1079], ["%", 1081], ["unplanned", 1083], ["births", 1093], [")", 1099], ["and", 1101], ["a", 1105], ["generalized", 1107], ["HIV", 1119], ["epidemic", 1123], [",", 1131], ["and", 1133], ["CVRs", 1137], ["are", 1142], ["not", 1146], ["yet", 1150], ["available", 1154], [".", 1163], ["We", 1165], ["will", 1168], ["conduct", 1173], ["an", 1181], ["open", 1184], ["label", 1189], [",", 1194], ["single", 1196], ["centre", 1203], [",", 1209], ["randomized", 1211], ["controlled", 1222], ["trial", 1233], [".", 1238], ["A", 1240], ["total", 1242], ["of", 1248], ["120", 1251], ["HIV", 1255], ["-", 1258], ["negative", 1259], ["women", 1268], ["will", 1274], ["be", 1279], ["randomized", 1282], ["to", 1293], ["intermittent", 1296], ["CVR", 1309], ["use", 1313], ["(", 1317], ["to", 1318], ["allow", 1321], ["menstruation", 1327], [")", 1339], ["or", 1341], ["continuous", 1344], ["CVR", 1355], ["use", 1359], [".", 1362], ["Women", 1364], ["will", 1370], ["be", 1375], ["followed", 1378], ["for", 1387], ["a", 1391], ["maximum", 1393], ["of", 1401], ["14", 1404], ["weeks", 1407], [".", 1412], ["In", 1414], ["parallel", 1417], [",", 1425], ["we", 1427], ["will", 1430], ["conduct", 1435], ["a", 1443], ["qualitative", 1445], ["study", 1457], ["using", 1463], ["in", 1469], ["-", 1471], ["depth", 1472], ["interview", 1478], ["and", 1488], ["focus", 1492], ["group", 1498], ["discussion", 1504], ["methodology", 1515], [".", 1526], ["In", 1528], ["addition", 1531], ["to", 1540], ["evaluating", 1543], ["the", 1554], ["safety", 1558], ["and", 1565], ["acceptability", 1569], ["of", 1583], ["intermittent", 1586], ["and", 1599], ["continuous", 1603], ["CVR", 1614], ["use", 1618], ["in", 1622], ["Rwandan", 1625], ["women", 1633], [",", 1638], ["we", 1640], ["hope", 1643], ["that", 1648], ["our", 1653], ["findings", 1657], ["will", 1666], ["inform", 1671], ["the", 1678], ["development", 1682], ["of", 1694], ["future", 1697], ["multipurpose", 1704], ["vaginal", 1717], ["rings", 1725], [",", 1730], ["will", 1732], ["prepare", 1737], ["Rwandan", 1745], ["study", 1753], ["populations", 1759], ["for", 1771], ["future", 1775], ["clinical", 1782], ["trials", 1791], ["of", 1798], ["multipurpose", 1801], ["vaginal", 1814], ["rings", 1822], [",", 1827], ["and", 1829], ["will", 1833], ["pave", 1838], ["the", 1843], ["way", 1847], ["for", 1851], ["introduction", 1855], ["of", 1868], ["CVRs", 1871], ["on", 1876], ["African", 1879], ["markets", 1887], [".", 1894], ["Clinicaltrials.gov", 1896], ["NCT01796613", 1915], [".", 1927], ["Registered", 1929], ["14", 1940], ["February", 1943], ["2013", 1952], [".", 1956]]}
{"context": "Lewy bodies and coarse Lewy neurites are the pathological hallmarks of degenerating neurons in the brains of patients suffering from Parkinson's disease (PD). Recently, the presynaptic protein alpha-synuclein was shown to be a major component of Lewy bodies and Lewy neurites. This study demonstrates for the first time that extensive and thin alpha-synuclein-immunoreactive inclusions are present in the axonal processes of neurons.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "62d0c93b45ca401ca522395ff2d09c8b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[60, 62], [32, 34]], "char_spans": [[344, 358], [193, 207]]}]}], "context_tokens": [["Lewy", 0], ["bodies", 5], ["and", 12], ["coarse", 16], ["Lewy", 23], ["neurites", 28], ["are", 37], ["the", 41], ["pathological", 45], ["hallmarks", 58], ["of", 68], ["degenerating", 71], ["neurons", 84], ["in", 92], ["the", 95], ["brains", 99], ["of", 106], ["patients", 109], ["suffering", 118], ["from", 128], ["Parkinson", 133], ["'s", 142], ["disease", 145], ["(", 153], ["PD", 154], [")", 156], [".", 157], ["Recently", 159], [",", 167], ["the", 169], ["presynaptic", 173], ["protein", 185], ["alpha", 193], ["-", 198], ["synuclein", 199], ["was", 209], ["shown", 213], ["to", 219], ["be", 222], ["a", 225], ["major", 227], ["component", 233], ["of", 243], ["Lewy", 246], ["bodies", 251], ["and", 258], ["Lewy", 262], ["neurites", 267], [".", 275], ["This", 277], ["study", 282], ["demonstrates", 288], ["for", 301], ["the", 305], ["first", 309], ["time", 315], ["that", 320], ["extensive", 325], ["and", 335], ["thin", 339], ["alpha", 344], ["-", 349], ["synuclein", 350], ["-", 359], ["immunoreactive", 360], ["inclusions", 375], ["are", 386], ["present", 390], ["in", 398], ["the", 401], ["axonal", 405], ["processes", 412], ["of", 422], ["neurons", 425], [".", 432]]}
{"context": "Acrokeratosis paraneoplastic (Bazex syndrome) is a rare, but distinctive paraneoplastic dermatosis characterized by erythematosquamous lesions located at the acral sites and is most commonly associated with carcinomas of the upper aerodigestive tract. We report a 58-year-old female with a history of a pigmented rash on her extremities, thick keratotic plaques on her hands, and brittle nails. Chest imaging revealed a right upper lobe mass that was proven to be small cell lung carcinoma. While Bazex syndrome has been described in the dermatology literature, it is also important for the radiologist to be aware of this entity and its common presentations.", "qas": [{"question": "Name synonym of Acrokeratosis paraneoplastica.", "answers": ["Bazex syndrome"], "qid": "17fe85e739194ecda4e790b9d6224dc0", "question_tokens": [["Name", 0], ["synonym", 5], ["of", 13], ["Acrokeratosis", 16], ["paraneoplastica", 30], [".", 45]], "detected_answers": [{"text": "Bazex syndrome", "token_spans": [[84, 85], [3, 4]], "char_spans": [[497, 510], [30, 43]]}]}], "context_tokens": [["Acrokeratosis", 0], ["paraneoplastic", 14], ["(", 29], ["Bazex", 30], ["syndrome", 36], [")", 44], ["is", 46], ["a", 49], ["rare", 51], [",", 55], ["but", 57], ["distinctive", 61], ["paraneoplastic", 73], ["dermatosis", 88], ["characterized", 99], ["by", 113], ["erythematosquamous", 116], ["lesions", 135], ["located", 143], ["at", 151], ["the", 154], ["acral", 158], ["sites", 164], ["and", 170], ["is", 174], ["most", 177], ["commonly", 182], ["associated", 191], ["with", 202], ["carcinomas", 207], ["of", 218], ["the", 221], ["upper", 225], ["aerodigestive", 231], ["tract", 245], [".", 250], ["We", 252], ["report", 255], ["a", 262], ["58-year", 264], ["-", 271], ["old", 272], ["female", 276], ["with", 283], ["a", 288], ["history", 290], ["of", 298], ["a", 301], ["pigmented", 303], ["rash", 313], ["on", 318], ["her", 321], ["extremities", 325], [",", 336], ["thick", 338], ["keratotic", 344], ["plaques", 354], ["on", 362], ["her", 365], ["hands", 369], [",", 374], ["and", 376], ["brittle", 380], ["nails", 388], [".", 393], ["Chest", 395], ["imaging", 401], ["revealed", 409], ["a", 418], ["right", 420], ["upper", 426], ["lobe", 432], ["mass", 437], ["that", 442], ["was", 447], ["proven", 451], ["to", 458], ["be", 461], ["small", 464], ["cell", 470], ["lung", 475], ["carcinoma", 480], [".", 489], ["While", 491], ["Bazex", 497], ["syndrome", 503], ["has", 512], ["been", 516], ["described", 521], ["in", 531], ["the", 534], ["dermatology", 538], ["literature", 550], [",", 560], ["it", 562], ["is", 565], ["also", 568], ["important", 573], ["for", 583], ["the", 587], ["radiologist", 591], ["to", 603], ["be", 606], ["aware", 609], ["of", 615], ["this", 618], ["entity", 623], ["and", 630], ["its", 634], ["common", 638], ["presentations", 645], [".", 658]]}
{"context": "It was found in the present study that combined use of fusidic acid (FA) and berberine chloride (BBR) offered an in vitro synergistic action against 7 of the 30 clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, with a fractional inhibitory concentration (FIC) index ranging from 0.5 to 0.19. This synergistic effect was most pronounced on MRSA 4806, an FA-resistant isolate, with a minimum inhibitory concentration (MIC) value of 1,024 \u03bcg/ml. The time-kill curve experiment showed that FA plus BBR yielded a 4.2 log10 c.f.u./ml reduction in the number of MRSA 4806 bacteria after 24-h incubation as compared with BBR alone. Viable count analysis showed that FA plus BBR produced a 3.0 log10 c.f.u./ml decrease in biofilm formation and a 1.5 log10 c.f.u./ml decrease in mature biofilm in viable cell density as compared with BBR alone. In addition, phase contrast micrographs confirmed that biofilm formation was significantly inhibited and mature biofilm was obviously destructed when FA was used in combination with BBR. These results provide evidence that combined use of FA and BBR may prove to be a promising clinical therapeutic strategy against MRSA.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "4cf67c0ee39c479999455e6a1bb0566a", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[40, 40], [208, 208], [111, 111], [66, 66]], "char_spans": [[215, 218], [1170, 1173], [574, 577], [358, 361]]}]}], "context_tokens": [["It", 0], ["was", 3], ["found", 7], ["in", 13], ["the", 16], ["present", 20], ["study", 28], ["that", 34], ["combined", 39], ["use", 48], ["of", 52], ["fusidic", 55], ["acid", 63], ["(", 68], ["FA", 69], [")", 71], ["and", 73], ["berberine", 77], ["chloride", 87], ["(", 96], ["BBR", 97], [")", 100], ["offered", 102], ["an", 110], ["in", 113], ["vitro", 116], ["synergistic", 122], ["action", 134], ["against", 141], ["7", 149], ["of", 151], ["the", 154], ["30", 158], ["clinical", 161], ["methicillin", 170], ["-", 181], ["resistant", 182], ["Staphylococcus", 192], ["aureus", 207], ["(", 214], ["MRSA", 215], [")", 219], ["strains", 221], [",", 228], ["with", 230], ["a", 235], ["fractional", 237], ["inhibitory", 248], ["concentration", 259], ["(", 273], ["FIC", 274], [")", 277], ["index", 279], ["ranging", 285], ["from", 293], ["0.5", 298], ["to", 302], ["0.19", 305], [".", 309], ["This", 311], ["synergistic", 316], ["effect", 328], ["was", 335], ["most", 339], ["pronounced", 344], ["on", 355], ["MRSA", 358], ["4806", 363], [",", 367], ["an", 369], ["FA", 372], ["-", 374], ["resistant", 375], ["isolate", 385], [",", 392], ["with", 394], ["a", 399], ["minimum", 401], ["inhibitory", 409], ["concentration", 420], ["(", 434], ["MIC", 435], [")", 438], ["value", 440], ["of", 446], ["1,024", 449], ["\u03bcg", 455], ["/", 457], ["ml", 458], [".", 460], ["The", 462], ["time", 466], ["-", 470], ["kill", 471], ["curve", 476], ["experiment", 482], ["showed", 493], ["that", 500], ["FA", 505], ["plus", 508], ["BBR", 513], ["yielded", 517], ["a", 525], ["4.2", 527], ["log10", 531], ["c.f.u./ml", 537], ["reduction", 547], ["in", 557], ["the", 560], ["number", 564], ["of", 571], ["MRSA", 574], ["4806", 579], ["bacteria", 584], ["after", 593], ["24-h", 599], ["incubation", 604], ["as", 615], ["compared", 618], ["with", 627], ["BBR", 632], ["alone", 636], [".", 641], ["Viable", 643], ["count", 650], ["analysis", 656], ["showed", 665], ["that", 672], ["FA", 677], ["plus", 680], ["BBR", 685], ["produced", 689], ["a", 698], ["3.0", 700], ["log10", 704], ["c.f.u./ml", 710], ["decrease", 720], ["in", 729], ["biofilm", 732], ["formation", 740], ["and", 750], ["a", 754], ["1.5", 756], ["log10", 760], ["c.f.u./ml", 766], ["decrease", 776], ["in", 785], ["mature", 788], ["biofilm", 795], ["in", 803], ["viable", 806], ["cell", 813], ["density", 818], ["as", 826], ["compared", 829], ["with", 838], ["BBR", 843], ["alone", 847], [".", 852], ["In", 854], ["addition", 857], [",", 865], ["phase", 867], ["contrast", 873], ["micrographs", 882], ["confirmed", 894], ["that", 904], ["biofilm", 909], ["formation", 917], ["was", 927], ["significantly", 931], ["inhibited", 945], ["and", 955], ["mature", 959], ["biofilm", 966], ["was", 974], ["obviously", 978], ["destructed", 988], ["when", 999], ["FA", 1004], ["was", 1007], ["used", 1011], ["in", 1016], ["combination", 1019], ["with", 1031], ["BBR", 1036], [".", 1039], ["These", 1041], ["results", 1047], ["provide", 1055], ["evidence", 1063], ["that", 1072], ["combined", 1077], ["use", 1086], ["of", 1090], ["FA", 1093], ["and", 1096], ["BBR", 1100], ["may", 1104], ["prove", 1108], ["to", 1114], ["be", 1117], ["a", 1120], ["promising", 1122], ["clinical", 1132], ["therapeutic", 1141], ["strategy", 1153], ["against", 1162], ["MRSA", 1170], [".", 1174]]}
{"context": "Magnetic resonance imaging (MRI) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. MRI performs somewhat better than any of several common tests--probe to bone (PTB), erythrocyte sedimentation rate (ESR) >70 mm/hr, C-reactive protein (CRP) >14 mg/L, procalcitonin >0.3 ng/mL, and ulcer size >2 cm\u00b2--although PTB has the highest specificity of any test and is commonly used together with MRI. No studies have directly compared MRI with a combination of these tests, which may assist in diagnosis.", "qas": [{"question": "Which disease can be diagnosed with the \"probe to bone\" test?", "answers": ["diabetic foot osteomyelitis"], "qid": "63e453c58aac4f2abda1af843d1f2c50", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["diagnosed", 21], ["with", 31], ["the", 36], ["\"", 40], ["probe", 41], ["to", 47], ["bone", 50], ["\"", 54], ["test", 56], ["?", 60]], "detected_answers": [{"text": "diabetic foot osteomyelitis", "token_spans": [[31, 33]], "char_spans": [[140, 166]]}]}], "context_tokens": [["Magnetic", 0], ["resonance", 9], ["imaging", 19], ["(", 27], ["MRI", 28], [")", 31], ["has", 33], ["a", 37], ["higher", 39], ["sensitivity", 46], ["and", 58], ["specificity", 62], ["(", 74], ["90", 75], ["%", 77], ["and", 79], ["79", 83], ["%", 85], [")", 86], ["than", 88], ["plain", 93], ["radiography", 99], ["(", 111], ["54", 112], ["%", 114], ["and", 116], ["68", 120], ["%", 122], [")", 123], ["for", 125], ["diagnosing", 129], ["diabetic", 140], ["foot", 149], ["osteomyelitis", 154], [".", 167], ["MRI", 169], ["performs", 173], ["somewhat", 182], ["better", 191], ["than", 198], ["any", 203], ["of", 207], ["several", 210], ["common", 218], ["tests", 225], ["--", 230], ["probe", 232], ["to", 238], ["bone", 241], ["(", 246], ["PTB", 247], [")", 250], [",", 251], ["erythrocyte", 253], ["sedimentation", 265], ["rate", 279], ["(", 284], ["ESR", 285], [")", 288], [">", 290], ["70", 291], ["mm", 294], ["/", 296], ["hr", 297], [",", 299], ["C", 301], ["-", 302], ["reactive", 303], ["protein", 312], ["(", 320], ["CRP", 321], [")", 324], [">", 326], ["14", 327], ["mg", 330], ["/", 332], ["L", 333], [",", 334], ["procalcitonin", 336], [">", 350], ["0.3", 351], ["ng", 355], ["/", 357], ["mL", 358], [",", 360], ["and", 362], ["ulcer", 366], ["size", 372], [">", 377], ["2", 378], ["cm\u00b2--although", 380], ["PTB", 394], ["has", 398], ["the", 402], ["highest", 406], ["specificity", 414], ["of", 426], ["any", 429], ["test", 433], ["and", 438], ["is", 442], ["commonly", 445], ["used", 454], ["together", 459], ["with", 468], ["MRI", 473], [".", 476], ["No", 478], ["studies", 481], ["have", 489], ["directly", 494], ["compared", 503], ["MRI", 512], ["with", 516], ["a", 521], ["combination", 523], ["of", 535], ["these", 538], ["tests", 544], [",", 549], ["which", 551], ["may", 557], ["assist", 561], ["in", 568], ["diagnosis", 571], [".", 580]]}
{"context": "Polyglutamine diseases, including Huntington's disease, designate a group of nine neurodegenerative disorders characterized by the presence of a toxic polyglutamine expansion in specific target proteins. Using cell and mouse models, we have shown that expanded polyglutamine led to activation of the stress kinase JNK and the transcription factor AP-1, which are implicated in neuronal death. Polyglutamine expansion-induced stress shared common features with protein-damaging stress such as heat shock, because activation of JNK involved inhibition of JNK phosphatase activities. Indeed, expanded polyglutamine impaired the solubility of the dual-specificity JNK phosphatase M3/6. Aggregation of M3/6 by polyglutamine expansion appeared to be indirect, because M3/6 was not recruited into polyglutamine inclusions. The heat shock protein HSP70, which is known to inhibit JNK during the heat shock response, suppressed polyglutamine-mediated aggregation of M3/6 and activation of JNK. Interestingly, levels of HSP70 were down-regulated by polyglutamine expansion. We suggest that reduction of HSP70 by expanded polyglutamine is implicated in aggregation and inhibition of M3/6 and in activation of JNK and AP-1.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "db7adf06a3c547ec93d26a22ee2e1de9", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[48, 48], [83, 83], [155, 155], [138, 138], [103, 103], [87, 87], [191, 191]], "char_spans": [[314, 316], [526, 528], [980, 982], [872, 874], [660, 662], [553, 555], [1198, 1200]]}]}], "context_tokens": [["Polyglutamine", 0], ["diseases", 14], [",", 22], ["including", 24], ["Huntington", 34], ["'s", 44], ["disease", 47], [",", 54], ["designate", 56], ["a", 66], ["group", 68], ["of", 74], ["nine", 77], ["neurodegenerative", 82], ["disorders", 100], ["characterized", 110], ["by", 124], ["the", 127], ["presence", 131], ["of", 140], ["a", 143], ["toxic", 145], ["polyglutamine", 151], ["expansion", 165], ["in", 175], ["specific", 178], ["target", 187], ["proteins", 194], [".", 202], ["Using", 204], ["cell", 210], ["and", 215], ["mouse", 219], ["models", 225], [",", 231], ["we", 233], ["have", 236], ["shown", 241], ["that", 247], ["expanded", 252], ["polyglutamine", 261], ["led", 275], ["to", 279], ["activation", 282], ["of", 293], ["the", 296], ["stress", 300], ["kinase", 307], ["JNK", 314], ["and", 318], ["the", 322], ["transcription", 326], ["factor", 340], ["AP-1", 347], [",", 351], ["which", 353], ["are", 359], ["implicated", 363], ["in", 374], ["neuronal", 377], ["death", 386], [".", 391], ["Polyglutamine", 393], ["expansion", 407], ["-", 416], ["induced", 417], ["stress", 425], ["shared", 432], ["common", 439], ["features", 446], ["with", 455], ["protein", 460], ["-", 467], ["damaging", 468], ["stress", 477], ["such", 484], ["as", 489], ["heat", 492], ["shock", 497], [",", 502], ["because", 504], ["activation", 512], ["of", 523], ["JNK", 526], ["involved", 530], ["inhibition", 539], ["of", 550], ["JNK", 553], ["phosphatase", 557], ["activities", 569], [".", 579], ["Indeed", 581], [",", 587], ["expanded", 589], ["polyglutamine", 598], ["impaired", 612], ["the", 621], ["solubility", 625], ["of", 636], ["the", 639], ["dual", 643], ["-", 647], ["specificity", 648], ["JNK", 660], ["phosphatase", 664], ["M3/6", 676], [".", 680], ["Aggregation", 682], ["of", 694], ["M3/6", 697], ["by", 702], ["polyglutamine", 705], ["expansion", 719], ["appeared", 729], ["to", 738], ["be", 741], ["indirect", 744], [",", 752], ["because", 754], ["M3/6", 762], ["was", 767], ["not", 771], ["recruited", 775], ["into", 785], ["polyglutamine", 790], ["inclusions", 804], [".", 814], ["The", 816], ["heat", 820], ["shock", 825], ["protein", 831], ["HSP70", 839], [",", 844], ["which", 846], ["is", 852], ["known", 855], ["to", 861], ["inhibit", 864], ["JNK", 872], ["during", 876], ["the", 883], ["heat", 887], ["shock", 892], ["response", 898], [",", 906], ["suppressed", 908], ["polyglutamine", 919], ["-", 932], ["mediated", 933], ["aggregation", 942], ["of", 954], ["M3/6", 957], ["and", 962], ["activation", 966], ["of", 977], ["JNK", 980], [".", 983], ["Interestingly", 985], [",", 998], ["levels", 1000], ["of", 1007], ["HSP70", 1010], ["were", 1016], ["down", 1021], ["-", 1025], ["regulated", 1026], ["by", 1036], ["polyglutamine", 1039], ["expansion", 1053], [".", 1062], ["We", 1064], ["suggest", 1067], ["that", 1075], ["reduction", 1080], ["of", 1090], ["HSP70", 1093], ["by", 1099], ["expanded", 1102], ["polyglutamine", 1111], ["is", 1125], ["implicated", 1128], ["in", 1139], ["aggregation", 1142], ["and", 1154], ["inhibition", 1158], ["of", 1169], ["M3/6", 1172], ["and", 1177], ["in", 1181], ["activation", 1184], ["of", 1195], ["JNK", 1198], ["and", 1202], ["AP-1", 1206], [".", 1210]]}
{"context": "Many different cellular pathways have evolved to protect the genome from the deleterious effects of DNA damage that result from exposure to chemical and physical agents. Among these is a process called transcription-coupled repair (TCR) that catalyzes the removal of DNA lesions from the transcribed strand of expressed genes, often resulting in a preferential bias of damage clearance from this strand relative to its non-transcribed counterpart. Lesions subject to this type of repair include cyclobutane pyrimidine dimers that are normally repaired by nucleotide excision repair (NER) and thymine glycols (TGs) that are removed primarily by base excision repair (BER). While the mechanism underlying TCR is not completely clear, it is known that its facilitation requires proteins used by other repair pathways like NER. It is also believed that the signal for TCR is the stalled RNA polymerase that results when DNA damage prevents its translocation during transcription elongation. While there is a clear role for some NER proteins in TCR, the involvement of BER proteins is less clear. To explore this further, we studied the removal of 7-methylguanine (7MeG) and 3-methyladenine (3MeA) from the dihydrofolate reductase (dhfr) gene of murine cell lines that vary in their repair phenotypes. 7MeG and 3MeA constitute the two principal N-methylpurines formed in DNA following exposure to methylating agents. In mammalian cells, alkyladenine DNA alkyladenine glycosylase (Aag) is the major enzyme required for the repair of these lesions via BER, and their removal from the total genome is quite rapid. There is no observable TCR of these lesions in specific genes in DNA repair proficient cells; however, it is possible that the rapid repair of these adducts by BER masks any TCR. The repair of 3MeA and 7MeG was examined in cells lacking Aag, NER, or both Aag and NER to determine if rapid overall repair masks TCR. The results show that both 3MeA and 7MeG are removed without strand bias from the dhfr gene of BER deficient (Aag deficient) and NER deficient murine cell lines. Furthermore, repair of 3MeA in this region is highly dependent on Aag, but repair of 7MeG is equally efficient in the repair proficient, BER deficient, and NER deficient cell lines. Strikingly, in the absence of both BER and NER, neither 7MeG nor 3MeA is repaired. These results demonstrate that NER, but not TCR, contributes to the repair of 7MeG, and to a lesser extent 3MeA.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "1cde295a27944b1b94e1e91a3f0c2a84", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[49, 50]], "char_spans": [[288, 305]]}]}], "context_tokens": [["Many", 0], ["different", 5], ["cellular", 15], ["pathways", 24], ["have", 33], ["evolved", 38], ["to", 46], ["protect", 49], ["the", 57], ["genome", 61], ["from", 68], ["the", 73], ["deleterious", 77], ["effects", 89], ["of", 97], ["DNA", 100], ["damage", 104], ["that", 111], ["result", 116], ["from", 123], ["exposure", 128], ["to", 137], ["chemical", 140], ["and", 149], ["physical", 153], ["agents", 162], [".", 168], ["Among", 170], ["these", 176], ["is", 182], ["a", 185], ["process", 187], ["called", 195], ["transcription", 202], ["-", 215], ["coupled", 216], ["repair", 224], ["(", 231], ["TCR", 232], [")", 235], ["that", 237], ["catalyzes", 242], ["the", 252], ["removal", 256], ["of", 264], ["DNA", 267], ["lesions", 271], ["from", 279], ["the", 284], ["transcribed", 288], ["strand", 300], ["of", 307], ["expressed", 310], ["genes", 320], [",", 325], ["often", 327], ["resulting", 333], ["in", 343], ["a", 346], ["preferential", 348], ["bias", 361], ["of", 366], ["damage", 369], ["clearance", 376], ["from", 386], ["this", 391], ["strand", 396], ["relative", 403], ["to", 412], ["its", 415], ["non", 419], ["-", 422], ["transcribed", 423], ["counterpart", 435], [".", 446], ["Lesions", 448], ["subject", 456], ["to", 464], ["this", 467], ["type", 472], ["of", 477], ["repair", 480], ["include", 487], ["cyclobutane", 495], ["pyrimidine", 507], ["dimers", 518], ["that", 525], ["are", 530], ["normally", 534], ["repaired", 543], ["by", 552], ["nucleotide", 555], ["excision", 566], ["repair", 575], ["(", 582], ["NER", 583], [")", 586], ["and", 588], ["thymine", 592], ["glycols", 600], ["(", 608], ["TGs", 609], [")", 612], ["that", 614], ["are", 619], ["removed", 623], ["primarily", 631], ["by", 641], ["base", 644], ["excision", 649], ["repair", 658], ["(", 665], ["BER", 666], [")", 669], [".", 670], ["While", 672], ["the", 678], ["mechanism", 682], ["underlying", 692], ["TCR", 703], ["is", 707], ["not", 710], ["completely", 714], ["clear", 725], [",", 730], ["it", 732], ["is", 735], ["known", 738], ["that", 744], ["its", 749], ["facilitation", 753], ["requires", 766], ["proteins", 775], ["used", 784], ["by", 789], ["other", 792], ["repair", 798], ["pathways", 805], ["like", 814], ["NER", 819], [".", 822], ["It", 824], ["is", 827], ["also", 830], ["believed", 835], ["that", 844], ["the", 849], ["signal", 853], ["for", 860], ["TCR", 864], ["is", 868], ["the", 871], ["stalled", 875], ["RNA", 883], ["polymerase", 887], ["that", 898], ["results", 903], ["when", 911], ["DNA", 916], ["damage", 920], ["prevents", 927], ["its", 936], ["translocation", 940], ["during", 954], ["transcription", 961], ["elongation", 975], [".", 985], ["While", 987], ["there", 993], ["is", 999], ["a", 1002], ["clear", 1004], ["role", 1010], ["for", 1015], ["some", 1019], ["NER", 1024], ["proteins", 1028], ["in", 1037], ["TCR", 1040], [",", 1043], ["the", 1045], ["involvement", 1049], ["of", 1061], ["BER", 1064], ["proteins", 1068], ["is", 1077], ["less", 1080], ["clear", 1085], [".", 1090], ["To", 1092], ["explore", 1095], ["this", 1103], ["further", 1108], [",", 1115], ["we", 1117], ["studied", 1120], ["the", 1128], ["removal", 1132], ["of", 1140], ["7-methylguanine", 1143], ["(", 1159], ["7MeG", 1160], [")", 1164], ["and", 1166], ["3-methyladenine", 1170], ["(", 1186], ["3MeA", 1187], [")", 1191], ["from", 1193], ["the", 1198], ["dihydrofolate", 1202], ["reductase", 1216], ["(", 1226], ["dhfr", 1227], [")", 1231], ["gene", 1233], ["of", 1238], ["murine", 1241], ["cell", 1248], ["lines", 1253], ["that", 1259], ["vary", 1264], ["in", 1269], ["their", 1272], ["repair", 1278], ["phenotypes", 1285], [".", 1295], ["7MeG", 1297], ["and", 1302], ["3MeA", 1306], ["constitute", 1311], ["the", 1322], ["two", 1326], ["principal", 1330], ["N", 1340], ["-", 1341], ["methylpurines", 1342], ["formed", 1356], ["in", 1363], ["DNA", 1366], ["following", 1370], ["exposure", 1380], ["to", 1389], ["methylating", 1392], ["agents", 1404], [".", 1410], ["In", 1412], ["mammalian", 1415], ["cells", 1425], [",", 1430], ["alkyladenine", 1432], ["DNA", 1445], ["alkyladenine", 1449], ["glycosylase", 1462], ["(", 1474], ["Aag", 1475], [")", 1478], ["is", 1480], ["the", 1483], ["major", 1487], ["enzyme", 1493], ["required", 1500], ["for", 1509], ["the", 1513], ["repair", 1517], ["of", 1524], ["these", 1527], ["lesions", 1533], ["via", 1541], ["BER", 1545], [",", 1548], ["and", 1550], ["their", 1554], ["removal", 1560], ["from", 1568], ["the", 1573], ["total", 1577], ["genome", 1583], ["is", 1590], ["quite", 1593], ["rapid", 1599], [".", 1604], ["There", 1606], ["is", 1612], ["no", 1615], ["observable", 1618], ["TCR", 1629], ["of", 1633], ["these", 1636], ["lesions", 1642], ["in", 1650], ["specific", 1653], ["genes", 1662], ["in", 1668], ["DNA", 1671], ["repair", 1675], ["proficient", 1682], ["cells", 1693], [";", 1698], ["however", 1700], [",", 1707], ["it", 1709], ["is", 1712], ["possible", 1715], ["that", 1724], ["the", 1729], ["rapid", 1733], ["repair", 1739], ["of", 1746], ["these", 1749], ["adducts", 1755], ["by", 1763], ["BER", 1766], ["masks", 1770], ["any", 1776], ["TCR", 1780], [".", 1783], ["The", 1785], ["repair", 1789], ["of", 1796], ["3MeA", 1799], ["and", 1804], ["7MeG", 1808], ["was", 1813], ["examined", 1817], ["in", 1826], ["cells", 1829], ["lacking", 1835], ["Aag", 1843], [",", 1846], ["NER", 1848], [",", 1851], ["or", 1853], ["both", 1856], ["Aag", 1861], ["and", 1865], ["NER", 1869], ["to", 1873], ["determine", 1876], ["if", 1886], ["rapid", 1889], ["overall", 1895], ["repair", 1903], ["masks", 1910], ["TCR", 1916], [".", 1919], ["The", 1921], ["results", 1925], ["show", 1933], ["that", 1938], ["both", 1943], ["3MeA", 1948], ["and", 1953], ["7MeG", 1957], ["are", 1962], ["removed", 1966], ["without", 1974], ["strand", 1982], ["bias", 1989], ["from", 1994], ["the", 1999], ["dhfr", 2003], ["gene", 2008], ["of", 2013], ["BER", 2016], ["deficient", 2020], ["(", 2030], ["Aag", 2031], ["deficient", 2035], [")", 2044], ["and", 2046], ["NER", 2050], ["deficient", 2054], ["murine", 2064], ["cell", 2071], ["lines", 2076], [".", 2081], ["Furthermore", 2083], [",", 2094], ["repair", 2096], ["of", 2103], ["3MeA", 2106], ["in", 2111], ["this", 2114], ["region", 2119], ["is", 2126], ["highly", 2129], ["dependent", 2136], ["on", 2146], ["Aag", 2149], [",", 2152], ["but", 2154], ["repair", 2158], ["of", 2165], ["7MeG", 2168], ["is", 2173], ["equally", 2176], ["efficient", 2184], ["in", 2194], ["the", 2197], ["repair", 2201], ["proficient", 2208], [",", 2218], ["BER", 2220], ["deficient", 2224], [",", 2233], ["and", 2235], ["NER", 2239], ["deficient", 2243], ["cell", 2253], ["lines", 2258], [".", 2263], ["Strikingly", 2265], [",", 2275], ["in", 2277], ["the", 2280], ["absence", 2284], ["of", 2292], ["both", 2295], ["BER", 2300], ["and", 2304], ["NER", 2308], [",", 2311], ["neither", 2313], ["7MeG", 2321], ["nor", 2326], ["3MeA", 2330], ["is", 2335], ["repaired", 2338], [".", 2346], ["These", 2348], ["results", 2354], ["demonstrate", 2362], ["that", 2374], ["NER", 2379], [",", 2382], ["but", 2384], ["not", 2388], ["TCR", 2392], [",", 2395], ["contributes", 2397], ["to", 2409], ["the", 2412], ["repair", 2416], ["of", 2423], ["7MeG", 2426], [",", 2430], ["and", 2432], ["to", 2436], ["a", 2439], ["lesser", 2441], ["extent", 2448], ["3MeA.", 2455]]}
{"context": "Prominin-1 (CD133) is commonly used to isolate stem and progenitor cells from the developing and adult nervous system and to identify cancer stem cells in brain tumors. However, despite extensive characterization of Prominin-1(+) precursor cells from the adult subventricular zone, no information about the expression of Prominin-1 by precursor cells in the subgranular zone (SGZ) of the adult hippocampus has been available. We show here that Prominin-1 is expressed by a significant number of cells in the SGZ of adult mice in vivo and ex vivo, including postmitotic astrocytes. A small subset of Prominin-1(+) cells coexpressed the nonspecific precursor cell marker Nestin as well as GFAP and Sox2. Upon fluorescence-activated cell sorting, only Prominin-1/Nestin double-positive cells fulfilled the defining stem cell criteria of proliferation, self-renewal, and multipotentiality as assessed by a neurosphere assay. In addition, isolated primary Prominin-1(+) cells preferentially migrated to the neurogenic niche in the SGZ upon transplantation in vivo. Finally, despite its expression by various stem and progenitor cells, Prominin-1 turned out to be dispensable for precursor cell proliferation in vitro and in vivo. Nevertheless, a net decrease in hippocampal neurogenesis, by \u223c30% was found in Prominin-1 knock-out mice, suggesting other roles in controlling adult hippocampal neurogenesis. Remarkably, an upregulation of Prominin-2 was detected in Prominin-1-deficient mice highlighting a potential compensatory mechanism, which might explain the lack of severe symptoms in individuals carrying mutations in the Prom1 gene.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "6cc9877ac4fc485b8865be0daa1ae5a3", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[113, 113]], "char_spans": [[669, 674]]}]}], "context_tokens": [["Prominin-1", 0], ["(", 11], ["CD133", 12], [")", 17], ["is", 19], ["commonly", 22], ["used", 31], ["to", 36], ["isolate", 39], ["stem", 47], ["and", 52], ["progenitor", 56], ["cells", 67], ["from", 73], ["the", 78], ["developing", 82], ["and", 93], ["adult", 97], ["nervous", 103], ["system", 111], ["and", 118], ["to", 122], ["identify", 125], ["cancer", 134], ["stem", 141], ["cells", 146], ["in", 152], ["brain", 155], ["tumors", 161], [".", 167], ["However", 169], [",", 176], ["despite", 178], ["extensive", 186], ["characterization", 196], ["of", 213], ["Prominin-1(+", 216], [")", 228], ["precursor", 230], ["cells", 240], ["from", 246], ["the", 251], ["adult", 255], ["subventricular", 261], ["zone", 276], [",", 280], ["no", 282], ["information", 285], ["about", 297], ["the", 303], ["expression", 307], ["of", 318], ["Prominin-1", 321], ["by", 332], ["precursor", 335], ["cells", 345], ["in", 351], ["the", 354], ["subgranular", 358], ["zone", 370], ["(", 375], ["SGZ", 376], [")", 379], ["of", 381], ["the", 384], ["adult", 388], ["hippocampus", 394], ["has", 406], ["been", 410], ["available", 415], [".", 424], ["We", 426], ["show", 429], ["here", 434], ["that", 439], ["Prominin-1", 444], ["is", 455], ["expressed", 458], ["by", 468], ["a", 471], ["significant", 473], ["number", 485], ["of", 492], ["cells", 495], ["in", 501], ["the", 504], ["SGZ", 508], ["of", 512], ["adult", 515], ["mice", 521], ["in", 526], ["vivo", 529], ["and", 534], ["ex", 538], ["vivo", 541], [",", 545], ["including", 547], ["postmitotic", 557], ["astrocytes", 569], [".", 579], ["A", 581], ["small", 583], ["subset", 589], ["of", 596], ["Prominin-1(+", 599], [")", 611], ["cells", 613], ["coexpressed", 619], ["the", 631], ["nonspecific", 635], ["precursor", 647], ["cell", 657], ["marker", 662], ["Nestin", 669], ["as", 676], ["well", 679], ["as", 684], ["GFAP", 687], ["and", 692], ["Sox2", 696], [".", 700], ["Upon", 702], ["fluorescence", 707], ["-", 719], ["activated", 720], ["cell", 730], ["sorting", 735], [",", 742], ["only", 744], ["Prominin-1/Nestin", 749], ["double", 767], ["-", 773], ["positive", 774], ["cells", 783], ["fulfilled", 789], ["the", 799], ["defining", 803], ["stem", 812], ["cell", 817], ["criteria", 822], ["of", 831], ["proliferation", 834], [",", 847], ["self", 849], ["-", 853], ["renewal", 854], [",", 861], ["and", 863], ["multipotentiality", 867], ["as", 885], ["assessed", 888], ["by", 897], ["a", 900], ["neurosphere", 902], ["assay", 914], [".", 919], ["In", 921], ["addition", 924], [",", 932], ["isolated", 934], ["primary", 943], ["Prominin-1(+", 951], [")", 963], ["cells", 965], ["preferentially", 971], ["migrated", 986], ["to", 995], ["the", 998], ["neurogenic", 1002], ["niche", 1013], ["in", 1019], ["the", 1022], ["SGZ", 1026], ["upon", 1030], ["transplantation", 1035], ["in", 1051], ["vivo", 1054], [".", 1058], ["Finally", 1060], [",", 1067], ["despite", 1069], ["its", 1077], ["expression", 1081], ["by", 1092], ["various", 1095], ["stem", 1103], ["and", 1108], ["progenitor", 1112], ["cells", 1123], [",", 1128], ["Prominin-1", 1130], ["turned", 1141], ["out", 1148], ["to", 1152], ["be", 1155], ["dispensable", 1158], ["for", 1170], ["precursor", 1174], ["cell", 1184], ["proliferation", 1189], ["in", 1203], ["vitro", 1206], ["and", 1212], ["in", 1216], ["vivo", 1219], [".", 1223], ["Nevertheless", 1225], [",", 1237], ["a", 1239], ["net", 1241], ["decrease", 1245], ["in", 1254], ["hippocampal", 1257], ["neurogenesis", 1269], [",", 1281], ["by", 1283], ["\u223c30", 1286], ["%", 1289], ["was", 1291], ["found", 1295], ["in", 1301], ["Prominin-1", 1304], ["knock", 1315], ["-", 1320], ["out", 1321], ["mice", 1325], [",", 1329], ["suggesting", 1331], ["other", 1342], ["roles", 1348], ["in", 1354], ["controlling", 1357], ["adult", 1369], ["hippocampal", 1375], ["neurogenesis", 1387], [".", 1399], ["Remarkably", 1401], [",", 1411], ["an", 1413], ["upregulation", 1416], ["of", 1429], ["Prominin-2", 1432], ["was", 1443], ["detected", 1447], ["in", 1456], ["Prominin-1-deficient", 1459], ["mice", 1480], ["highlighting", 1485], ["a", 1498], ["potential", 1500], ["compensatory", 1510], ["mechanism", 1523], [",", 1532], ["which", 1534], ["might", 1540], ["explain", 1546], ["the", 1554], ["lack", 1558], ["of", 1563], ["severe", 1566], ["symptoms", 1573], ["in", 1582], ["individuals", 1585], ["carrying", 1597], ["mutations", 1606], ["in", 1616], ["the", 1619], ["Prom1", 1623], ["gene", 1629], [".", 1633]]}
{"context": "Cyclosporine mediates its immunosuppressive effect by preventing the synthesis of lymphokine mRNA during the process of T lymphocyte activation. Although the detailed molecular mechanism by which CsA achieves this effect is unknown, two proteins have been identified as putative intracellular CsA-receptor proteins. One of these, calmodulin, is an important Ca++-binding protein and enzyme cofactor and the other, cyclophilin, is a novel protein that is reported to have protein kinase activity. In this study the CsA-binding capacity of both these proteins has been assessed using CsA-coated ELISA plates and CsA-affinity gel matrices. CsA binding was shown by cyclophilin whereas no CsA-calmodulin binding could be detected under identical conditions. However, it was not possible to demonstrate any cyclophilin-associated protein kinase activity. Jurkat cells were probed for the presence of CsA-binding proteins using the CsA-affinity gel matrix; a 17 KD protein, most probably cyclophilin, was identified as the major CsA-binding protein. In addition, a previously unidentified CsA-binding 45 KD phosphoprotein was precipitated from 32P-labeled Jurkat cells. These results would support cyclophilin as the major, if not only, intracellular receptor protein for CsA. However, the relationship between binding of CsA to cyclophilin and/or the 45 KD phosphoprotein and the immunosuppressive effects of CsA is still unknown.", "qas": [{"question": "Which is the receptor for the immunosuppressive drug cyclosporin A (CsA)?", "answers": ["cyclophilin"], "qid": "085511319724479098fd99f2b10f8fe5", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["the", 26], ["immunosuppressive", 30], ["drug", 48], ["cyclosporin", 53], ["A", 65], ["(", 67], ["CsA", 68], [")", 71], ["?", 72]], "detected_answers": [{"text": "cyclophilin", "token_spans": [[170, 170], [230, 230], [65, 65], [136, 136], [113, 113], [207, 207]], "char_spans": [[982, 992], [1323, 1333], [414, 424], [802, 812], [662, 672], [1192, 1202]]}]}], "context_tokens": [["Cyclosporine", 0], ["mediates", 13], ["its", 22], ["immunosuppressive", 26], ["effect", 44], ["by", 51], ["preventing", 54], ["the", 65], ["synthesis", 69], ["of", 79], ["lymphokine", 82], ["mRNA", 93], ["during", 98], ["the", 105], ["process", 109], ["of", 117], ["T", 120], ["lymphocyte", 122], ["activation", 133], [".", 143], ["Although", 145], ["the", 154], ["detailed", 158], ["molecular", 167], ["mechanism", 177], ["by", 187], ["which", 190], ["CsA", 196], ["achieves", 200], ["this", 209], ["effect", 214], ["is", 221], ["unknown", 224], [",", 231], ["two", 233], ["proteins", 237], ["have", 246], ["been", 251], ["identified", 256], ["as", 267], ["putative", 270], ["intracellular", 279], ["CsA", 293], ["-", 296], ["receptor", 297], ["proteins", 306], [".", 314], ["One", 316], ["of", 320], ["these", 323], [",", 328], ["calmodulin", 330], [",", 340], ["is", 342], ["an", 345], ["important", 348], ["Ca++-binding", 358], ["protein", 371], ["and", 379], ["enzyme", 383], ["cofactor", 390], ["and", 399], ["the", 403], ["other", 407], [",", 412], ["cyclophilin", 414], [",", 425], ["is", 427], ["a", 430], ["novel", 432], ["protein", 438], ["that", 446], ["is", 451], ["reported", 454], ["to", 463], ["have", 466], ["protein", 471], ["kinase", 479], ["activity", 486], [".", 494], ["In", 496], ["this", 499], ["study", 504], ["the", 510], ["CsA", 514], ["-", 517], ["binding", 518], ["capacity", 526], ["of", 535], ["both", 538], ["these", 543], ["proteins", 549], ["has", 558], ["been", 562], ["assessed", 567], ["using", 576], ["CsA", 582], ["-", 585], ["coated", 586], ["ELISA", 593], ["plates", 599], ["and", 606], ["CsA", 610], ["-", 613], ["affinity", 614], ["gel", 623], ["matrices", 627], [".", 635], ["CsA", 637], ["binding", 641], ["was", 649], ["shown", 653], ["by", 659], ["cyclophilin", 662], ["whereas", 674], ["no", 682], ["CsA", 685], ["-", 688], ["calmodulin", 689], ["binding", 700], ["could", 708], ["be", 714], ["detected", 717], ["under", 726], ["identical", 732], ["conditions", 742], [".", 752], ["However", 754], [",", 761], ["it", 763], ["was", 766], ["not", 770], ["possible", 774], ["to", 783], ["demonstrate", 786], ["any", 798], ["cyclophilin", 802], ["-", 813], ["associated", 814], ["protein", 825], ["kinase", 833], ["activity", 840], [".", 848], ["Jurkat", 850], ["cells", 857], ["were", 863], ["probed", 868], ["for", 875], ["the", 879], ["presence", 883], ["of", 892], ["CsA", 895], ["-", 898], ["binding", 899], ["proteins", 907], ["using", 916], ["the", 922], ["CsA", 926], ["-", 929], ["affinity", 930], ["gel", 939], ["matrix", 943], [";", 949], ["a", 951], ["17", 953], ["KD", 956], ["protein", 959], [",", 966], ["most", 968], ["probably", 973], ["cyclophilin", 982], [",", 993], ["was", 995], ["identified", 999], ["as", 1010], ["the", 1013], ["major", 1017], ["CsA", 1023], ["-", 1026], ["binding", 1027], ["protein", 1035], [".", 1042], ["In", 1044], ["addition", 1047], [",", 1055], ["a", 1057], ["previously", 1059], ["unidentified", 1070], ["CsA", 1083], ["-", 1086], ["binding", 1087], ["45", 1095], ["KD", 1098], ["phosphoprotein", 1101], ["was", 1116], ["precipitated", 1120], ["from", 1133], ["32P", 1138], ["-", 1141], ["labeled", 1142], ["Jurkat", 1150], ["cells", 1157], [".", 1162], ["These", 1164], ["results", 1170], ["would", 1178], ["support", 1184], ["cyclophilin", 1192], ["as", 1204], ["the", 1207], ["major", 1211], [",", 1216], ["if", 1218], ["not", 1221], ["only", 1225], [",", 1229], ["intracellular", 1231], ["receptor", 1245], ["protein", 1254], ["for", 1262], ["CsA.", 1266], ["However", 1271], [",", 1278], ["the", 1280], ["relationship", 1284], ["between", 1297], ["binding", 1305], ["of", 1313], ["CsA", 1316], ["to", 1320], ["cyclophilin", 1323], ["and/or", 1335], ["the", 1342], ["45", 1346], ["KD", 1349], ["phosphoprotein", 1352], ["and", 1367], ["the", 1371], ["immunosuppressive", 1375], ["effects", 1393], ["of", 1401], ["CsA", 1404], ["is", 1408], ["still", 1411], ["unknown", 1417], [".", 1424]]}
{"context": "MicroRNAs (miRNAs) are 21 nt RNAs that regulate many biological processes in plants by mediating translational inhibition or cleavage of target transcripts. Arabidopsis mutants defective in miRNA biogenesis have overlapping and highly pleiotropic phenotypes including serrated leaves and ABA hypersensitivity. Recent evidence indicates that miRNA genes are transcribed by RNA polymerase II (Pol II). Since Pol II transcripts are capped, we hypothesized that CBP (cap-binding protein) 20 and 80 may bind to capped primary miRNA (pri-miRNA) transcripts and play a role in their processing. Here, we show that cbp20 and cbp80 mutants have reduced miRNA levels and increased pri-miRNA levels. Co-immunoprecipitation experiments revealed that pri-miRNAs 159, 166, 168 and 172 could be associated with CBP20 and CBP80. We found that CBP20 and CBP80 are stabilized by ABA by a post-translational mechanism, and these proteins are needed for ABA induction of miR159 during seed germination. The lack of miR159 accumulation in ABA-treated seeds of cbp20/80 mutants leads to increased MYB33 and MYB101 transcript levels, and presumably higher levels of these positive regulators result in ABA hypersensitivity. Genetic and molecular analyses show that CBP20 and 80 have overlapping function in the same developmental pathway as SE and HYL1. Our results identify new components in miRNA biogenesis.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "f8691bdd04254433a162cdef7998689e", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[53, 55]], "char_spans": [[372, 388]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["are", 19], ["21", 23], ["nt", 26], ["RNAs", 29], ["that", 34], ["regulate", 39], ["many", 48], ["biological", 53], ["processes", 64], ["in", 74], ["plants", 77], ["by", 84], ["mediating", 87], ["translational", 97], ["inhibition", 111], ["or", 122], ["cleavage", 125], ["of", 134], ["target", 137], ["transcripts", 144], [".", 155], ["Arabidopsis", 157], ["mutants", 169], ["defective", 177], ["in", 187], ["miRNA", 190], ["biogenesis", 196], ["have", 207], ["overlapping", 212], ["and", 224], ["highly", 228], ["pleiotropic", 235], ["phenotypes", 247], ["including", 258], ["serrated", 268], ["leaves", 277], ["and", 284], ["ABA", 288], ["hypersensitivity", 292], [".", 308], ["Recent", 310], ["evidence", 317], ["indicates", 326], ["that", 336], ["miRNA", 341], ["genes", 347], ["are", 353], ["transcribed", 357], ["by", 369], ["RNA", 372], ["polymerase", 376], ["II", 387], ["(", 390], ["Pol", 391], ["II", 395], [")", 397], [".", 398], ["Since", 400], ["Pol", 406], ["II", 410], ["transcripts", 413], ["are", 425], ["capped", 429], [",", 435], ["we", 437], ["hypothesized", 440], ["that", 453], ["CBP", 458], ["(", 462], ["cap", 463], ["-", 466], ["binding", 467], ["protein", 475], [")", 482], ["20", 484], ["and", 487], ["80", 491], ["may", 494], ["bind", 498], ["to", 503], ["capped", 506], ["primary", 513], ["miRNA", 521], ["(", 527], ["pri", 528], ["-", 531], ["miRNA", 532], [")", 537], ["transcripts", 539], ["and", 551], ["play", 555], ["a", 560], ["role", 562], ["in", 567], ["their", 570], ["processing", 576], [".", 586], ["Here", 588], [",", 592], ["we", 594], ["show", 597], ["that", 602], ["cbp20", 607], ["and", 613], ["cbp80", 617], ["mutants", 623], ["have", 631], ["reduced", 636], ["miRNA", 644], ["levels", 650], ["and", 657], ["increased", 661], ["pri", 671], ["-", 674], ["miRNA", 675], ["levels", 681], [".", 687], ["Co", 689], ["-", 691], ["immunoprecipitation", 692], ["experiments", 712], ["revealed", 724], ["that", 733], ["pri", 738], ["-", 741], ["miRNAs", 742], ["159", 749], [",", 752], ["166", 754], [",", 757], ["168", 759], ["and", 763], ["172", 767], ["could", 771], ["be", 777], ["associated", 780], ["with", 791], ["CBP20", 796], ["and", 802], ["CBP80", 806], [".", 811], ["We", 813], ["found", 816], ["that", 822], ["CBP20", 827], ["and", 833], ["CBP80", 837], ["are", 843], ["stabilized", 847], ["by", 858], ["ABA", 861], ["by", 865], ["a", 868], ["post", 870], ["-", 874], ["translational", 875], ["mechanism", 889], [",", 898], ["and", 900], ["these", 904], ["proteins", 910], ["are", 919], ["needed", 923], ["for", 930], ["ABA", 934], ["induction", 938], ["of", 948], ["miR159", 951], ["during", 958], ["seed", 965], ["germination", 970], [".", 981], ["The", 983], ["lack", 987], ["of", 992], ["miR159", 995], ["accumulation", 1002], ["in", 1015], ["ABA", 1018], ["-", 1021], ["treated", 1022], ["seeds", 1030], ["of", 1036], ["cbp20/80", 1039], ["mutants", 1048], ["leads", 1056], ["to", 1062], ["increased", 1065], ["MYB33", 1075], ["and", 1081], ["MYB101", 1085], ["transcript", 1092], ["levels", 1103], [",", 1109], ["and", 1111], ["presumably", 1115], ["higher", 1126], ["levels", 1133], ["of", 1140], ["these", 1143], ["positive", 1149], ["regulators", 1158], ["result", 1169], ["in", 1176], ["ABA", 1179], ["hypersensitivity", 1183], [".", 1199], ["Genetic", 1201], ["and", 1209], ["molecular", 1213], ["analyses", 1223], ["show", 1232], ["that", 1237], ["CBP20", 1242], ["and", 1248], ["80", 1252], ["have", 1255], ["overlapping", 1260], ["function", 1272], ["in", 1281], ["the", 1284], ["same", 1288], ["developmental", 1293], ["pathway", 1307], ["as", 1315], ["SE", 1318], ["and", 1321], ["HYL1", 1325], [".", 1329], ["Our", 1331], ["results", 1335], ["identify", 1343], ["new", 1352], ["components", 1356], ["in", 1367], ["miRNA", 1370], ["biogenesis", 1376], [".", 1386]]}
{"context": "The Shprintzen-Goldberg syndrome (SGS) is a disorder of unknown cause comprising craniosynostosis, a marfanoid habitus and skeletal, neurological, cardiovascular, and connective-tissue anomalies. There are no pathognomonic signs of SGS and diagnosis depends on recognition of a characteristic combination of anomalies. Here, we describe 14 persons with SGS and compare their clinical findings with those of 23 previously reported individuals, including two families with more than one affected individual. Our analysis suggests that there is a characteristic facial appearance, with more than two thirds of all individuals having hypertelorism, down-slanting palpebral fissures, a high-arched palate, micrognathia, and apparently low-set and posteriorly rotated ears. Other commonly reported manifestations include hypotonia in at least the neonatal period, developmental delay, and inguinal or umbilical hernia. The degree of reported intellectual impairment ranges from mild to severe. The most common skeletal manifestations in SGS were arachnodactyly, pectus deformity, camptodactyly, scoliosis, and joint hypermobility. None of the skeletal signs alone is specific for SGS. Our study includes 14 mainly German individuals with SGS evaluated over a period of 10 years. Given that only 23 other persons with SGS have been reported to date worldwide, we suggest that SGS may be more common than previously assumed.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "2406a794568840628014804927e40975", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[15, 15]], "char_spans": [[81, 96]]}]}], "context_tokens": [["The", 0], ["Shprintzen", 4], ["-", 14], ["Goldberg", 15], ["syndrome", 24], ["(", 33], ["SGS", 34], [")", 37], ["is", 39], ["a", 42], ["disorder", 44], ["of", 53], ["unknown", 56], ["cause", 64], ["comprising", 70], ["craniosynostosis", 81], [",", 97], ["a", 99], ["marfanoid", 101], ["habitus", 111], ["and", 119], ["skeletal", 123], [",", 131], ["neurological", 133], [",", 145], ["cardiovascular", 147], [",", 161], ["and", 163], ["connective", 167], ["-", 177], ["tissue", 178], ["anomalies", 185], [".", 194], ["There", 196], ["are", 202], ["no", 206], ["pathognomonic", 209], ["signs", 223], ["of", 229], ["SGS", 232], ["and", 236], ["diagnosis", 240], ["depends", 250], ["on", 258], ["recognition", 261], ["of", 273], ["a", 276], ["characteristic", 278], ["combination", 293], ["of", 305], ["anomalies", 308], [".", 317], ["Here", 319], [",", 323], ["we", 325], ["describe", 328], ["14", 337], ["persons", 340], ["with", 348], ["SGS", 353], ["and", 357], ["compare", 361], ["their", 369], ["clinical", 375], ["findings", 384], ["with", 393], ["those", 398], ["of", 404], ["23", 407], ["previously", 410], ["reported", 421], ["individuals", 430], [",", 441], ["including", 443], ["two", 453], ["families", 457], ["with", 466], ["more", 471], ["than", 476], ["one", 481], ["affected", 485], ["individual", 494], [".", 504], ["Our", 506], ["analysis", 510], ["suggests", 519], ["that", 528], ["there", 533], ["is", 539], ["a", 542], ["characteristic", 544], ["facial", 559], ["appearance", 566], [",", 576], ["with", 578], ["more", 583], ["than", 588], ["two", 593], ["thirds", 597], ["of", 604], ["all", 607], ["individuals", 611], ["having", 623], ["hypertelorism", 630], [",", 643], ["down", 645], ["-", 649], ["slanting", 650], ["palpebral", 659], ["fissures", 669], [",", 677], ["a", 679], ["high", 681], ["-", 685], ["arched", 686], ["palate", 693], [",", 699], ["micrognathia", 701], [",", 713], ["and", 715], ["apparently", 719], ["low", 730], ["-", 733], ["set", 734], ["and", 738], ["posteriorly", 742], ["rotated", 754], ["ears", 762], [".", 766], ["Other", 768], ["commonly", 774], ["reported", 783], ["manifestations", 792], ["include", 807], ["hypotonia", 815], ["in", 825], ["at", 828], ["least", 831], ["the", 837], ["neonatal", 841], ["period", 850], [",", 856], ["developmental", 858], ["delay", 872], [",", 877], ["and", 879], ["inguinal", 883], ["or", 892], ["umbilical", 895], ["hernia", 905], [".", 911], ["The", 913], ["degree", 917], ["of", 924], ["reported", 927], ["intellectual", 936], ["impairment", 949], ["ranges", 960], ["from", 967], ["mild", 972], ["to", 977], ["severe", 980], [".", 986], ["The", 988], ["most", 992], ["common", 997], ["skeletal", 1004], ["manifestations", 1013], ["in", 1028], ["SGS", 1031], ["were", 1035], ["arachnodactyly", 1040], [",", 1054], ["pectus", 1056], ["deformity", 1063], [",", 1072], ["camptodactyly", 1074], [",", 1087], ["scoliosis", 1089], [",", 1098], ["and", 1100], ["joint", 1104], ["hypermobility", 1110], [".", 1123], ["None", 1125], ["of", 1130], ["the", 1133], ["skeletal", 1137], ["signs", 1146], ["alone", 1152], ["is", 1158], ["specific", 1161], ["for", 1170], ["SGS", 1174], [".", 1177], ["Our", 1179], ["study", 1183], ["includes", 1189], ["14", 1198], ["mainly", 1201], ["German", 1208], ["individuals", 1215], ["with", 1227], ["SGS", 1232], ["evaluated", 1236], ["over", 1246], ["a", 1251], ["period", 1253], ["of", 1260], ["10", 1263], ["years", 1266], [".", 1271], ["Given", 1273], ["that", 1279], ["only", 1284], ["23", 1289], ["other", 1292], ["persons", 1298], ["with", 1306], ["SGS", 1311], ["have", 1315], ["been", 1320], ["reported", 1325], ["to", 1334], ["date", 1337], ["worldwide", 1342], [",", 1351], ["we", 1353], ["suggest", 1356], ["that", 1364], ["SGS", 1369], ["may", 1373], ["be", 1377], ["more", 1380], ["common", 1385], ["than", 1392], ["previously", 1397], ["assumed", 1408], [".", 1415]]}
{"context": "Imatinib mesylate is a tyrosine kinase inhibitor with high affinity for the BCR-ABL fusion protein expressed by the hematopoietic cells in chronic myelogenous leukemia (CML). Some patients with chronic-phase or accelerated-phase CML either relapse after an initial response or are refractory to imatinib, prompting us to evaluate the efficacy of dose increase in such patients. Twelve chronic-phase patients initially receiving 400 mg/day and 4 patients with accelerated phase initially receiving either 400 mg/day (two patients) or 600 mg/day (two patients) had their dose increased (14 to 800 mg/day and 2 to 600 mg/day) because of progressive disease (usually clonal evolution) or inadequate cytogenetic response after at least 1 year of therapy. Six patients had major cytogenetic responses after dose increase (3 complete and 3 partial). Two others had minor cytogenetic responses. Two patients with clonal evolution transiently lost the additional clonal aberrations. Almost all of the responses occurred within 6 months, and were typically 3-6 months in duration. However, 3 patients have continuing major cytogenetic responses of >18 months duration. Dose increase was well tolerated, with thrombocytopenia, mild leukopenia, and exacerbation of prior edema being the most common adverse events. Although increasing the dose of imatinib can benefit a subgroup of patients with CML with either an inadequate cytogenetic response or disease progression, our results suggest the majority will not have a sustained meaningful response, and that other options, such as allogeneic stem cell transplant or investigational therapies, also need to be considered at the time of dose increase.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "52dc16109e66480083c5d9ca84eb049e", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[12, 14]], "char_spans": [[76, 82]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["is", 18], ["a", 21], ["tyrosine", 23], ["kinase", 32], ["inhibitor", 39], ["with", 49], ["high", 54], ["affinity", 59], ["for", 68], ["the", 72], ["BCR", 76], ["-", 79], ["ABL", 80], ["fusion", 84], ["protein", 91], ["expressed", 99], ["by", 109], ["the", 112], ["hematopoietic", 116], ["cells", 130], ["in", 136], ["chronic", 139], ["myelogenous", 147], ["leukemia", 159], ["(", 168], ["CML", 169], [")", 172], [".", 173], ["Some", 175], ["patients", 180], ["with", 189], ["chronic", 194], ["-", 201], ["phase", 202], ["or", 208], ["accelerated", 211], ["-", 222], ["phase", 223], ["CML", 229], ["either", 233], ["relapse", 240], ["after", 248], ["an", 254], ["initial", 257], ["response", 265], ["or", 274], ["are", 277], ["refractory", 281], ["to", 292], ["imatinib", 295], [",", 303], ["prompting", 305], ["us", 315], ["to", 318], ["evaluate", 321], ["the", 330], ["efficacy", 334], ["of", 343], ["dose", 346], ["increase", 351], ["in", 360], ["such", 363], ["patients", 368], [".", 376], ["Twelve", 378], ["chronic", 385], ["-", 392], ["phase", 393], ["patients", 399], ["initially", 408], ["receiving", 418], ["400", 428], ["mg", 432], ["/", 434], ["day", 435], ["and", 439], ["4", 443], ["patients", 445], ["with", 454], ["accelerated", 459], ["phase", 471], ["initially", 477], ["receiving", 487], ["either", 497], ["400", 504], ["mg", 508], ["/", 510], ["day", 511], ["(", 515], ["two", 516], ["patients", 520], [")", 528], ["or", 530], ["600", 533], ["mg", 537], ["/", 539], ["day", 540], ["(", 544], ["two", 545], ["patients", 549], [")", 557], ["had", 559], ["their", 563], ["dose", 569], ["increased", 574], ["(", 584], ["14", 585], ["to", 588], ["800", 591], ["mg", 595], ["/", 597], ["day", 598], ["and", 602], ["2", 606], ["to", 608], ["600", 611], ["mg", 615], ["/", 617], ["day", 618], [")", 621], ["because", 623], ["of", 631], ["progressive", 634], ["disease", 646], ["(", 654], ["usually", 655], ["clonal", 663], ["evolution", 670], [")", 679], ["or", 681], ["inadequate", 684], ["cytogenetic", 695], ["response", 707], ["after", 716], ["at", 722], ["least", 725], ["1", 731], ["year", 733], ["of", 738], ["therapy", 741], [".", 748], ["Six", 750], ["patients", 754], ["had", 763], ["major", 767], ["cytogenetic", 773], ["responses", 785], ["after", 795], ["dose", 801], ["increase", 806], ["(", 815], ["3", 816], ["complete", 818], ["and", 827], ["3", 831], ["partial", 833], [")", 840], [".", 841], ["Two", 843], ["others", 847], ["had", 854], ["minor", 858], ["cytogenetic", 864], ["responses", 876], [".", 885], ["Two", 887], ["patients", 891], ["with", 900], ["clonal", 905], ["evolution", 912], ["transiently", 922], ["lost", 934], ["the", 939], ["additional", 943], ["clonal", 954], ["aberrations", 961], [".", 972], ["Almost", 974], ["all", 981], ["of", 985], ["the", 988], ["responses", 992], ["occurred", 1002], ["within", 1011], ["6", 1018], ["months", 1020], [",", 1026], ["and", 1028], ["were", 1032], ["typically", 1037], ["3", 1047], ["-", 1048], ["6", 1049], ["months", 1051], ["in", 1058], ["duration", 1061], [".", 1069], ["However", 1071], [",", 1078], ["3", 1080], ["patients", 1082], ["have", 1091], ["continuing", 1096], ["major", 1107], ["cytogenetic", 1113], ["responses", 1125], ["of", 1135], [">", 1138], ["18", 1139], ["months", 1142], ["duration", 1149], [".", 1157], ["Dose", 1159], ["increase", 1164], ["was", 1173], ["well", 1177], ["tolerated", 1182], [",", 1191], ["with", 1193], ["thrombocytopenia", 1198], [",", 1214], ["mild", 1216], ["leukopenia", 1221], [",", 1231], ["and", 1233], ["exacerbation", 1237], ["of", 1250], ["prior", 1253], ["edema", 1259], ["being", 1265], ["the", 1271], ["most", 1275], ["common", 1280], ["adverse", 1287], ["events", 1295], [".", 1301], ["Although", 1303], ["increasing", 1312], ["the", 1323], ["dose", 1327], ["of", 1332], ["imatinib", 1335], ["can", 1344], ["benefit", 1348], ["a", 1356], ["subgroup", 1358], ["of", 1367], ["patients", 1370], ["with", 1379], ["CML", 1384], ["with", 1388], ["either", 1393], ["an", 1400], ["inadequate", 1403], ["cytogenetic", 1414], ["response", 1426], ["or", 1435], ["disease", 1438], ["progression", 1446], [",", 1457], ["our", 1459], ["results", 1463], ["suggest", 1471], ["the", 1479], ["majority", 1483], ["will", 1492], ["not", 1497], ["have", 1501], ["a", 1506], ["sustained", 1508], ["meaningful", 1518], ["response", 1529], [",", 1537], ["and", 1539], ["that", 1543], ["other", 1548], ["options", 1554], [",", 1561], ["such", 1563], ["as", 1568], ["allogeneic", 1571], ["stem", 1582], ["cell", 1587], ["transplant", 1592], ["or", 1603], ["investigational", 1606], ["therapies", 1622], [",", 1631], ["also", 1633], ["need", 1638], ["to", 1643], ["be", 1646], ["considered", 1649], ["at", 1660], ["the", 1663], ["time", 1667], ["of", 1672], ["dose", 1675], ["increase", 1680], [".", 1688]]}
{"context": "Diamond-Blackfan anemia (DBA) is a rare congenital pure red cell aplasia characterized by normochromic macrocytic anemia, reticulocytopenia, and normocellular bone marrow with a selective deficiency of erythroid precursors. Ribosomal protein S19 (RPS19), currently the only gene associated with DBA, is mutated in 25% of DBA patients, but its role in erythropoiesis is unknown. We attempted to elucidate the importance of RPS19 in translation in relation to the pathogenesis of DBA. We measured translation and proliferation rates in unstimulated and phytohemagglutinin (PHA)-stimulated lymphocytes isolated from DBA patients, as well as in K562 cells expressing several RPS19 mutants to directly test the effect of RPS19 mutations on translation. The effect of leucine on overall translation was also studied. We found that the level of translation was on average 48-73% of controls in both unstimulated and PHA-activated DBA lymphocytes irrespective of mutations in RPS19. The addition of leucine increased the translational level in RPS19-non-mutated DBA cells, but not in cells with an RPS19 mutation. In unstimulated DBA cells, proliferation was significantly impaired in both RPS19-mutated and non-mutated cells, but in both groups could be efficiently activated by PHA. Studies on K562 cells showed that RPS19 mutations affecting RPS19 conserved arginines R56Q and R62Q could significantly inhibit the rate of protein synthesis, indicating the importance of RPS19 in translation. Our results indicate that inefficient translation may be the main cause of DBA, and administration of leucine may be beneficial for at least some DBA patients.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "f06fc76bb7624c4ba8baf1c01fb0c0a8", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[48, 48], [192, 192], [83, 83], [5, 5], [100, 100], [276, 276], [263, 263], [56, 56], [158, 158], [178, 178]], "char_spans": [[295, 297], [1122, 1124], [478, 480], [25, 27], [613, 615], [1633, 1635], [1562, 1564], [321, 323], [923, 925], [1054, 1056]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["rare", 35], ["congenital", 40], ["pure", 51], ["red", 56], ["cell", 60], ["aplasia", 65], ["characterized", 73], ["by", 87], ["normochromic", 90], ["macrocytic", 103], ["anemia", 114], [",", 120], ["reticulocytopenia", 122], [",", 139], ["and", 141], ["normocellular", 145], ["bone", 159], ["marrow", 164], ["with", 171], ["a", 176], ["selective", 178], ["deficiency", 188], ["of", 199], ["erythroid", 202], ["precursors", 212], [".", 222], ["Ribosomal", 224], ["protein", 234], ["S19", 242], ["(", 246], ["RPS19", 247], [")", 252], [",", 253], ["currently", 255], ["the", 265], ["only", 269], ["gene", 274], ["associated", 279], ["with", 290], ["DBA", 295], [",", 298], ["is", 300], ["mutated", 303], ["in", 311], ["25", 314], ["%", 316], ["of", 318], ["DBA", 321], ["patients", 325], [",", 333], ["but", 335], ["its", 339], ["role", 343], ["in", 348], ["erythropoiesis", 351], ["is", 366], ["unknown", 369], [".", 376], ["We", 378], ["attempted", 381], ["to", 391], ["elucidate", 394], ["the", 404], ["importance", 408], ["of", 419], ["RPS19", 422], ["in", 428], ["translation", 431], ["in", 443], ["relation", 446], ["to", 455], ["the", 458], ["pathogenesis", 462], ["of", 475], ["DBA", 478], [".", 481], ["We", 483], ["measured", 486], ["translation", 495], ["and", 507], ["proliferation", 511], ["rates", 525], ["in", 531], ["unstimulated", 534], ["and", 547], ["phytohemagglutinin", 551], ["(", 570], ["PHA)-stimulated", 571], ["lymphocytes", 587], ["isolated", 599], ["from", 608], ["DBA", 613], ["patients", 617], [",", 625], ["as", 627], ["well", 630], ["as", 635], ["in", 638], ["K562", 641], ["cells", 646], ["expressing", 652], ["several", 663], ["RPS19", 671], ["mutants", 677], ["to", 685], ["directly", 688], ["test", 697], ["the", 702], ["effect", 706], ["of", 713], ["RPS19", 716], ["mutations", 722], ["on", 732], ["translation", 735], [".", 746], ["The", 748], ["effect", 752], ["of", 759], ["leucine", 762], ["on", 770], ["overall", 773], ["translation", 781], ["was", 793], ["also", 797], ["studied", 802], [".", 809], ["We", 811], ["found", 814], ["that", 820], ["the", 825], ["level", 829], ["of", 835], ["translation", 838], ["was", 850], ["on", 854], ["average", 857], ["48", 865], ["-", 867], ["73", 868], ["%", 870], ["of", 872], ["controls", 875], ["in", 884], ["both", 887], ["unstimulated", 892], ["and", 905], ["PHA", 909], ["-", 912], ["activated", 913], ["DBA", 923], ["lymphocytes", 927], ["irrespective", 939], ["of", 952], ["mutations", 955], ["in", 965], ["RPS19", 968], [".", 973], ["The", 975], ["addition", 979], ["of", 988], ["leucine", 991], ["increased", 999], ["the", 1009], ["translational", 1013], ["level", 1027], ["in", 1033], ["RPS19-non", 1036], ["-", 1045], ["mutated", 1046], ["DBA", 1054], ["cells", 1058], [",", 1063], ["but", 1065], ["not", 1069], ["in", 1073], ["cells", 1076], ["with", 1082], ["an", 1087], ["RPS19", 1090], ["mutation", 1096], [".", 1104], ["In", 1106], ["unstimulated", 1109], ["DBA", 1122], ["cells", 1126], [",", 1131], ["proliferation", 1133], ["was", 1147], ["significantly", 1151], ["impaired", 1165], ["in", 1174], ["both", 1177], ["RPS19-mutated", 1182], ["and", 1196], ["non", 1200], ["-", 1203], ["mutated", 1204], ["cells", 1212], [",", 1217], ["but", 1219], ["in", 1223], ["both", 1226], ["groups", 1231], ["could", 1238], ["be", 1244], ["efficiently", 1247], ["activated", 1259], ["by", 1269], ["PHA", 1272], [".", 1275], ["Studies", 1277], ["on", 1285], ["K562", 1288], ["cells", 1293], ["showed", 1299], ["that", 1306], ["RPS19", 1311], ["mutations", 1317], ["affecting", 1327], ["RPS19", 1337], ["conserved", 1343], ["arginines", 1353], ["R56Q", 1363], ["and", 1368], ["R62Q", 1372], ["could", 1377], ["significantly", 1383], ["inhibit", 1397], ["the", 1405], ["rate", 1409], ["of", 1414], ["protein", 1417], ["synthesis", 1425], [",", 1434], ["indicating", 1436], ["the", 1447], ["importance", 1451], ["of", 1462], ["RPS19", 1465], ["in", 1471], ["translation", 1474], [".", 1485], ["Our", 1487], ["results", 1491], ["indicate", 1499], ["that", 1508], ["inefficient", 1513], ["translation", 1525], ["may", 1537], ["be", 1541], ["the", 1544], ["main", 1548], ["cause", 1553], ["of", 1559], ["DBA", 1562], [",", 1565], ["and", 1567], ["administration", 1571], ["of", 1586], ["leucine", 1589], ["may", 1597], ["be", 1601], ["beneficial", 1604], ["for", 1615], ["at", 1619], ["least", 1622], ["some", 1628], ["DBA", 1633], ["patients", 1637], [".", 1645]]}
{"context": "This case report is about an elderly man who presented with a long-standing history of high-grade fever and weight loss. He initially had only hepatosplenomegaly, but then developed jaundice. He also had pancytopenia and raised liver enzymes. His septic screen was negative, but he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus. The liver biopsy showed sinusoidal phagocytosis and the subsequent bone marrow aspiration and biopsy showed significant hemophagocytosis, hence Hemophagocytic syndrome was diagnosed. The fever was refractory to antibiotic and anti-tuberculosis therapy, but it responded only partially to steroids. Full response was only noticed following anti-viral treatment in the form of intravenous Ganciclovir. The patient's general condition, liver enzymes, bilirubin, hematological parameters and even the weight returned back to their normal range 2 weeks after Ganciclovir therapy. Cessation of this drug resulted in relapse of his symptoms and oral antivirals did not help. Splenectomy, steroid pulse therapy and immunosuppressive treatment were only partially helpful. Reintroduction of Ganciclovir did help for a short period. We conclude that our patient had virus-associated hemophagocytic syndrome most likely related to Epstein-Barr virus infection, which was then confirmed by the splenic biopsy, and that Ganciclovir can be of great help in eradicating the virus and treating the disease, provided that it is given for a long enough period.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "27f01386fc37446ab4eaa091c48db4f9", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[62, 65], [212, 215]], "char_spans": [[336, 353], [1276, 1293]]}]}], "context_tokens": [["This", 0], ["case", 5], ["report", 10], ["is", 17], ["about", 20], ["an", 26], ["elderly", 29], ["man", 37], ["who", 41], ["presented", 45], ["with", 55], ["a", 60], ["long", 62], ["-", 66], ["standing", 67], ["history", 76], ["of", 84], ["high", 87], ["-", 91], ["grade", 92], ["fever", 98], ["and", 104], ["weight", 108], ["loss", 115], [".", 119], ["He", 121], ["initially", 124], ["had", 134], ["only", 138], ["hepatosplenomegaly", 143], [",", 161], ["but", 163], ["then", 167], ["developed", 172], ["jaundice", 182], [".", 190], ["He", 192], ["also", 195], ["had", 200], ["pancytopenia", 204], ["and", 217], ["raised", 221], ["liver", 228], ["enzymes", 234], [".", 241], ["His", 243], ["septic", 247], ["screen", 254], ["was", 261], ["negative", 265], [",", 273], ["but", 275], ["he", 279], ["had", 282], ["a", 286], ["positive", 288], ["Monospot", 297], ["test", 306], ["and", 311], ["immunoglobulin", 315], ["G", 330], ["for", 332], ["Epstein", 336], ["-", 343], ["Barr", 344], ["virus", 349], [".", 354], ["The", 356], ["liver", 360], ["biopsy", 366], ["showed", 373], ["sinusoidal", 380], ["phagocytosis", 391], ["and", 404], ["the", 408], ["subsequent", 412], ["bone", 423], ["marrow", 428], ["aspiration", 435], ["and", 446], ["biopsy", 450], ["showed", 457], ["significant", 464], ["hemophagocytosis", 476], [",", 492], ["hence", 494], ["Hemophagocytic", 500], ["syndrome", 515], ["was", 524], ["diagnosed", 528], [".", 537], ["The", 539], ["fever", 543], ["was", 549], ["refractory", 553], ["to", 564], ["antibiotic", 567], ["and", 578], ["anti", 582], ["-", 586], ["tuberculosis", 587], ["therapy", 600], [",", 607], ["but", 609], ["it", 613], ["responded", 616], ["only", 626], ["partially", 631], ["to", 641], ["steroids", 644], [".", 652], ["Full", 654], ["response", 659], ["was", 668], ["only", 672], ["noticed", 677], ["following", 685], ["anti", 695], ["-", 699], ["viral", 700], ["treatment", 706], ["in", 716], ["the", 719], ["form", 723], ["of", 728], ["intravenous", 731], ["Ganciclovir", 743], [".", 754], ["The", 756], ["patient", 760], ["'s", 767], ["general", 770], ["condition", 778], [",", 787], ["liver", 789], ["enzymes", 795], [",", 802], ["bilirubin", 804], [",", 813], ["hematological", 815], ["parameters", 829], ["and", 840], ["even", 844], ["the", 849], ["weight", 853], ["returned", 860], ["back", 869], ["to", 874], ["their", 877], ["normal", 883], ["range", 890], ["2", 896], ["weeks", 898], ["after", 904], ["Ganciclovir", 910], ["therapy", 922], [".", 929], ["Cessation", 931], ["of", 941], ["this", 944], ["drug", 949], ["resulted", 954], ["in", 963], ["relapse", 966], ["of", 974], ["his", 977], ["symptoms", 981], ["and", 990], ["oral", 994], ["antivirals", 999], ["did", 1010], ["not", 1014], ["help", 1018], [".", 1022], ["Splenectomy", 1024], [",", 1035], ["steroid", 1037], ["pulse", 1045], ["therapy", 1051], ["and", 1059], ["immunosuppressive", 1063], ["treatment", 1081], ["were", 1091], ["only", 1096], ["partially", 1101], ["helpful", 1111], [".", 1118], ["Reintroduction", 1120], ["of", 1135], ["Ganciclovir", 1138], ["did", 1150], ["help", 1154], ["for", 1159], ["a", 1163], ["short", 1165], ["period", 1171], [".", 1177], ["We", 1179], ["conclude", 1182], ["that", 1191], ["our", 1196], ["patient", 1200], ["had", 1208], ["virus", 1212], ["-", 1217], ["associated", 1218], ["hemophagocytic", 1229], ["syndrome", 1244], ["most", 1253], ["likely", 1258], ["related", 1265], ["to", 1273], ["Epstein", 1276], ["-", 1283], ["Barr", 1284], ["virus", 1289], ["infection", 1295], [",", 1304], ["which", 1306], ["was", 1312], ["then", 1316], ["confirmed", 1321], ["by", 1331], ["the", 1334], ["splenic", 1338], ["biopsy", 1346], [",", 1352], ["and", 1354], ["that", 1358], ["Ganciclovir", 1363], ["can", 1375], ["be", 1379], ["of", 1382], ["great", 1385], ["help", 1391], ["in", 1396], ["eradicating", 1399], ["the", 1411], ["virus", 1415], ["and", 1421], ["treating", 1425], ["the", 1434], ["disease", 1438], [",", 1445], ["provided", 1447], ["that", 1456], ["it", 1461], ["is", 1464], ["given", 1467], ["for", 1473], ["a", 1477], ["long", 1479], ["enough", 1484], ["period", 1491], [".", 1497]]}
{"context": "The excision of introns from nascent eukaryotic transcripts is catalyzed by the spliceosome, a highly complex and dynamic macromolecular machine composed of RNA and protein. Because of its complexity, biochemical analysis of the spliceosome has been previously limited to bulk assays in largely unfractionated cell extracts. We now report development of methodologies for studying the splicing of isolated single pre-mRNA molecules in real time. In this system, a fluorescently tagged pre-mRNA is tethered to a glass surface via its 3'-end. Splicing can be observed in Saccharomyces cerevisiae whole cell extract by monitoring loss of intron-specific fluorescence with a multi-wavelength total internal reflection fluorescence (TIRF) microscope. To prolong fluorophore lifetime, two enzyme-based O2 scavenging systems compatible with splicing were also developed. This work provides a powerful new approach for elucidating the mechanisms of spliceosome function and demonstrates the feasibility of utilizing TIRF microscopy for biochemical studies of single molecules in highly complex environments.", "qas": [{"question": "What is the function of the spliceosome complex?", "answers": ["The excision of introns from nascent eukaryotic transcripts is catalyzed by the spliceosome."], "qid": "59b8dc15064f45a0b670dacf91a6101a", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["function", 12], ["of", 21], ["the", 24], ["spliceosome", 28], ["complex", 40], ["?", 47]], "detected_answers": [{"text": "The excision of introns from nascent eukaryotic transcripts is catalyzed by the spliceosome.", "token_spans": [[1, 12]], "char_spans": [[4, 90]]}]}], "context_tokens": [["The", 0], ["excision", 4], ["of", 13], ["introns", 16], ["from", 24], ["nascent", 29], ["eukaryotic", 37], ["transcripts", 48], ["is", 60], ["catalyzed", 63], ["by", 73], ["the", 76], ["spliceosome", 80], [",", 91], ["a", 93], ["highly", 95], ["complex", 102], ["and", 110], ["dynamic", 114], ["macromolecular", 122], ["machine", 137], ["composed", 145], ["of", 154], ["RNA", 157], ["and", 161], ["protein", 165], [".", 172], ["Because", 174], ["of", 182], ["its", 185], ["complexity", 189], [",", 199], ["biochemical", 201], ["analysis", 213], ["of", 222], ["the", 225], ["spliceosome", 229], ["has", 241], ["been", 245], ["previously", 250], ["limited", 261], ["to", 269], ["bulk", 272], ["assays", 277], ["in", 284], ["largely", 287], ["unfractionated", 295], ["cell", 310], ["extracts", 315], [".", 323], ["We", 325], ["now", 328], ["report", 332], ["development", 339], ["of", 351], ["methodologies", 354], ["for", 368], ["studying", 372], ["the", 381], ["splicing", 385], ["of", 394], ["isolated", 397], ["single", 406], ["pre", 413], ["-", 416], ["mRNA", 417], ["molecules", 422], ["in", 432], ["real", 435], ["time", 440], [".", 444], ["In", 446], ["this", 449], ["system", 454], [",", 460], ["a", 462], ["fluorescently", 464], ["tagged", 478], ["pre", 485], ["-", 488], ["mRNA", 489], ["is", 494], ["tethered", 497], ["to", 506], ["a", 509], ["glass", 511], ["surface", 517], ["via", 525], ["its", 529], ["3'-end", 533], [".", 539], ["Splicing", 541], ["can", 550], ["be", 554], ["observed", 557], ["in", 566], ["Saccharomyces", 569], ["cerevisiae", 583], ["whole", 594], ["cell", 600], ["extract", 605], ["by", 613], ["monitoring", 616], ["loss", 627], ["of", 632], ["intron", 635], ["-", 641], ["specific", 642], ["fluorescence", 651], ["with", 664], ["a", 669], ["multi", 671], ["-", 676], ["wavelength", 677], ["total", 688], ["internal", 694], ["reflection", 703], ["fluorescence", 714], ["(", 727], ["TIRF", 728], [")", 732], ["microscope", 734], [".", 744], ["To", 746], ["prolong", 749], ["fluorophore", 757], ["lifetime", 769], [",", 777], ["two", 779], ["enzyme", 783], ["-", 789], ["based", 790], ["O2", 796], ["scavenging", 799], ["systems", 810], ["compatible", 818], ["with", 829], ["splicing", 834], ["were", 843], ["also", 848], ["developed", 853], [".", 862], ["This", 864], ["work", 869], ["provides", 874], ["a", 883], ["powerful", 885], ["new", 894], ["approach", 898], ["for", 907], ["elucidating", 911], ["the", 923], ["mechanisms", 927], ["of", 938], ["spliceosome", 941], ["function", 953], ["and", 962], ["demonstrates", 966], ["the", 979], ["feasibility", 983], ["of", 995], ["utilizing", 998], ["TIRF", 1008], ["microscopy", 1013], ["for", 1024], ["biochemical", 1028], ["studies", 1040], ["of", 1048], ["single", 1051], ["molecules", 1058], ["in", 1068], ["highly", 1071], ["complex", 1078], ["environments", 1086], [".", 1098]]}
{"context": "The generation of reactive oxygen species (ROS) is required for proper cell signaling, but must be tightly regulated to minimize deleterious oxidizing effects. Activation of the NADPH oxidases (Nox) triggers ROS production and, thus, regulatory mechanisms exist to properly control Nox activity. In this study, we report a novel mechanism in which Nox1 activity is regulated through the proteasomal degradation of Nox organizer 1 (NoxO1). We found that through the interaction between NoxO1 and growth receptor-bound protein 2 (Grb2), the Casitas B-lineage lymphoma (Cbl) E3 ligase was recruited, leading to decreased NoxO1 stability and a subsequent reduction in ROS generation upon epidermal growth factor (EGF) stimulation. Additionally, we show that EGF-mediated phosphorylation of NoxO1 induced its release from Grb2 and facilitated its association with Nox activator 1 (NoxA1) to stimulate ROS production. Consistently, overexpression of Grb2 resulted in decreased Nox1 activity, whereas knockdown of Grb2 led to increased Nox1 activity in response to EGF. CRISPR/Cas9-mediated NoxO1 knockout in human colon cancer cells abrogated anchorage-independent growth on soft agar and tumor-forming ability in athymic nude mice. Moreover, the expression and stability of NoxO1 were significantly increased in human colon cancer tissues compared with normal colon. Taken together, these results support a model whereby Nox1 activity and ROS generation are regulated by Grb2/Cbl-mediated proteolysis of NoxO1 in response to EGF, providing new insight into the processes by which excessive ROS production may promote oncogenic signaling to drive colorectal tumorigenesis.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "9017897d71c2434d90f474f17544eebd", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[172, 172], [247, 247], [182, 182], [62, 62]], "char_spans": [[971, 974], [1416, 1419], [1029, 1032], [348, 351]]}]}], "context_tokens": [["The", 0], ["generation", 4], ["of", 15], ["reactive", 18], ["oxygen", 27], ["species", 34], ["(", 42], ["ROS", 43], [")", 46], ["is", 48], ["required", 51], ["for", 60], ["proper", 64], ["cell", 71], ["signaling", 76], [",", 85], ["but", 87], ["must", 91], ["be", 96], ["tightly", 99], ["regulated", 107], ["to", 117], ["minimize", 120], ["deleterious", 129], ["oxidizing", 141], ["effects", 151], [".", 158], ["Activation", 160], ["of", 171], ["the", 174], ["NADPH", 178], ["oxidases", 184], ["(", 193], ["Nox", 194], [")", 197], ["triggers", 199], ["ROS", 208], ["production", 212], ["and", 223], [",", 226], ["thus", 228], [",", 232], ["regulatory", 234], ["mechanisms", 245], ["exist", 256], ["to", 262], ["properly", 265], ["control", 274], ["Nox", 282], ["activity", 286], [".", 294], ["In", 296], ["this", 299], ["study", 304], [",", 309], ["we", 311], ["report", 314], ["a", 321], ["novel", 323], ["mechanism", 329], ["in", 339], ["which", 342], ["Nox1", 348], ["activity", 353], ["is", 362], ["regulated", 365], ["through", 375], ["the", 383], ["proteasomal", 387], ["degradation", 399], ["of", 411], ["Nox", 414], ["organizer", 418], ["1", 428], ["(", 430], ["NoxO1", 431], [")", 436], [".", 437], ["We", 439], ["found", 442], ["that", 448], ["through", 453], ["the", 461], ["interaction", 465], ["between", 477], ["NoxO1", 485], ["and", 491], ["growth", 495], ["receptor", 502], ["-", 510], ["bound", 511], ["protein", 517], ["2", 525], ["(", 527], ["Grb2", 528], [")", 532], [",", 533], ["the", 535], ["Casitas", 539], ["B", 547], ["-", 548], ["lineage", 549], ["lymphoma", 557], ["(", 566], ["Cbl", 567], [")", 570], ["E3", 572], ["ligase", 575], ["was", 582], ["recruited", 586], [",", 595], ["leading", 597], ["to", 605], ["decreased", 608], ["NoxO1", 618], ["stability", 624], ["and", 634], ["a", 638], ["subsequent", 640], ["reduction", 651], ["in", 661], ["ROS", 664], ["generation", 668], ["upon", 679], ["epidermal", 684], ["growth", 694], ["factor", 701], ["(", 708], ["EGF", 709], [")", 712], ["stimulation", 714], [".", 725], ["Additionally", 727], [",", 739], ["we", 741], ["show", 744], ["that", 749], ["EGF", 754], ["-", 757], ["mediated", 758], ["phosphorylation", 767], ["of", 783], ["NoxO1", 786], ["induced", 792], ["its", 800], ["release", 804], ["from", 812], ["Grb2", 817], ["and", 822], ["facilitated", 826], ["its", 838], ["association", 842], ["with", 854], ["Nox", 859], ["activator", 863], ["1", 873], ["(", 875], ["NoxA1", 876], [")", 881], ["to", 883], ["stimulate", 886], ["ROS", 896], ["production", 900], [".", 910], ["Consistently", 912], [",", 924], ["overexpression", 926], ["of", 941], ["Grb2", 944], ["resulted", 949], ["in", 958], ["decreased", 961], ["Nox1", 971], ["activity", 976], [",", 984], ["whereas", 986], ["knockdown", 994], ["of", 1004], ["Grb2", 1007], ["led", 1012], ["to", 1016], ["increased", 1019], ["Nox1", 1029], ["activity", 1034], ["in", 1043], ["response", 1046], ["to", 1055], ["EGF", 1058], [".", 1061], ["CRISPR", 1063], ["/", 1069], ["Cas9-mediated", 1070], ["NoxO1", 1084], ["knockout", 1090], ["in", 1099], ["human", 1102], ["colon", 1108], ["cancer", 1114], ["cells", 1121], ["abrogated", 1127], ["anchorage", 1137], ["-", 1146], ["independent", 1147], ["growth", 1159], ["on", 1166], ["soft", 1169], ["agar", 1174], ["and", 1179], ["tumor", 1183], ["-", 1188], ["forming", 1189], ["ability", 1197], ["in", 1205], ["athymic", 1208], ["nude", 1216], ["mice", 1221], [".", 1225], ["Moreover", 1227], [",", 1235], ["the", 1237], ["expression", 1241], ["and", 1252], ["stability", 1256], ["of", 1266], ["NoxO1", 1269], ["were", 1275], ["significantly", 1280], ["increased", 1294], ["in", 1304], ["human", 1307], ["colon", 1313], ["cancer", 1319], ["tissues", 1326], ["compared", 1334], ["with", 1343], ["normal", 1348], ["colon", 1355], [".", 1360], ["Taken", 1362], ["together", 1368], [",", 1376], ["these", 1378], ["results", 1384], ["support", 1392], ["a", 1400], ["model", 1402], ["whereby", 1408], ["Nox1", 1416], ["activity", 1421], ["and", 1430], ["ROS", 1434], ["generation", 1438], ["are", 1449], ["regulated", 1453], ["by", 1463], ["Grb2/Cbl", 1466], ["-", 1474], ["mediated", 1475], ["proteolysis", 1484], ["of", 1496], ["NoxO1", 1499], ["in", 1505], ["response", 1508], ["to", 1517], ["EGF", 1520], [",", 1523], ["providing", 1525], ["new", 1535], ["insight", 1539], ["into", 1547], ["the", 1552], ["processes", 1556], ["by", 1566], ["which", 1569], ["excessive", 1575], ["ROS", 1585], ["production", 1589], ["may", 1600], ["promote", 1604], ["oncogenic", 1612], ["signaling", 1622], ["to", 1632], ["drive", 1635], ["colorectal", 1641], ["tumorigenesis", 1652], [".", 1665]]}
{"context": "Shprintzen-Goldberg syndrome is one of a group of disorders characterized by craniosynostosis and marfanoid habitus. Eleven cases were reported previously. We present 4 new patients and review one of the patients of the original report of Shprintzen and Goldberg [1982: J Craniofac Genet Dev Biol 2:65-74], 15 years later. The clinical and radiologic findings on our patients are compared with those of the previously reported patients and also with those of Furlong et al. [1987: Am J Med Genet 26:599-604] and Lacombe and Battin [1993: Clin Dysmorphol 2: 220-224], who share many of the characteristics of Shprintzen-Goldberg syndrome. Some of the clinical data are helpful in determining if the patients of Furlong et al. [1987: Am J Med Genet 26:599-604] and Lacombe and Battin [1993: Clin Dysmorphol 2: 220-224] have a separate syndrome or represent a variant of Shprintzen-Goldberg syndrome. However, radiologic investigations appear to be more specific, since an abnormality of the first and second cervical vertebrae, hydrocephalus, dilatation of the lateral ventricles, and a Chiari-I malformation of the brain were found only in the patients with Shprintzen-Goldberg syndrome. The apparently diagnostic findings of the 15 patients with this syndrome may be helpful in differentiating between Shprintzen-Goldberg syndrome and other syndromes with craniosynostosis and marfanoid habitus.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "3dfda990261e42298551bc5ea767d706", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[257, 257], [13, 13]], "char_spans": [[1356, 1371], [77, 92]]}]}], "context_tokens": [["Shprintzen", 0], ["-", 10], ["Goldberg", 11], ["syndrome", 20], ["is", 29], ["one", 32], ["of", 36], ["a", 39], ["group", 41], ["of", 47], ["disorders", 50], ["characterized", 60], ["by", 74], ["craniosynostosis", 77], ["and", 94], ["marfanoid", 98], ["habitus", 108], [".", 115], ["Eleven", 117], ["cases", 124], ["were", 130], ["reported", 135], ["previously", 144], [".", 154], ["We", 156], ["present", 159], ["4", 167], ["new", 169], ["patients", 173], ["and", 182], ["review", 186], ["one", 193], ["of", 197], ["the", 200], ["patients", 204], ["of", 213], ["the", 216], ["original", 220], ["report", 229], ["of", 236], ["Shprintzen", 239], ["and", 250], ["Goldberg", 254], ["[", 263], ["1982", 264], [":", 268], ["J", 270], ["Craniofac", 272], ["Genet", 282], ["Dev", 288], ["Biol", 292], ["2:65", 297], ["-", 301], ["74", 302], ["]", 304], [",", 305], ["15", 307], ["years", 310], ["later", 316], [".", 321], ["The", 323], ["clinical", 327], ["and", 336], ["radiologic", 340], ["findings", 351], ["on", 360], ["our", 363], ["patients", 367], ["are", 376], ["compared", 380], ["with", 389], ["those", 394], ["of", 400], ["the", 403], ["previously", 407], ["reported", 418], ["patients", 427], ["and", 436], ["also", 440], ["with", 445], ["those", 450], ["of", 456], ["Furlong", 459], ["et", 467], ["al", 470], [".", 472], ["[", 474], ["1987", 475], [":", 479], ["Am", 481], ["J", 484], ["Med", 486], ["Genet", 490], ["26:599", 496], ["-", 502], ["604", 503], ["]", 506], ["and", 508], ["Lacombe", 512], ["and", 520], ["Battin", 524], ["[", 531], ["1993", 532], [":", 536], ["Clin", 538], ["Dysmorphol", 543], ["2", 554], [":", 555], ["220", 557], ["-", 560], ["224", 561], ["]", 564], [",", 565], ["who", 567], ["share", 571], ["many", 577], ["of", 582], ["the", 585], ["characteristics", 589], ["of", 605], ["Shprintzen", 608], ["-", 618], ["Goldberg", 619], ["syndrome", 628], [".", 636], ["Some", 638], ["of", 643], ["the", 646], ["clinical", 650], ["data", 659], ["are", 664], ["helpful", 668], ["in", 676], ["determining", 679], ["if", 691], ["the", 694], ["patients", 698], ["of", 707], ["Furlong", 710], ["et", 718], ["al", 721], [".", 723], ["[", 725], ["1987", 726], [":", 730], ["Am", 732], ["J", 735], ["Med", 737], ["Genet", 741], ["26:599", 747], ["-", 753], ["604", 754], ["]", 757], ["and", 759], ["Lacombe", 763], ["and", 771], ["Battin", 775], ["[", 782], ["1993", 783], [":", 787], ["Clin", 789], ["Dysmorphol", 794], ["2", 805], [":", 806], ["220", 808], ["-", 811], ["224", 812], ["]", 815], ["have", 817], ["a", 822], ["separate", 824], ["syndrome", 833], ["or", 842], ["represent", 845], ["a", 855], ["variant", 857], ["of", 865], ["Shprintzen", 868], ["-", 878], ["Goldberg", 879], ["syndrome", 888], [".", 896], ["However", 898], [",", 905], ["radiologic", 907], ["investigations", 918], ["appear", 933], ["to", 940], ["be", 943], ["more", 946], ["specific", 951], [",", 959], ["since", 961], ["an", 967], ["abnormality", 970], ["of", 982], ["the", 985], ["first", 989], ["and", 995], ["second", 999], ["cervical", 1006], ["vertebrae", 1015], [",", 1024], ["hydrocephalus", 1026], [",", 1039], ["dilatation", 1041], ["of", 1052], ["the", 1055], ["lateral", 1059], ["ventricles", 1067], [",", 1077], ["and", 1079], ["a", 1083], ["Chiari", 1085], ["-", 1091], ["I", 1092], ["malformation", 1094], ["of", 1107], ["the", 1110], ["brain", 1114], ["were", 1120], ["found", 1125], ["only", 1131], ["in", 1136], ["the", 1139], ["patients", 1143], ["with", 1152], ["Shprintzen", 1157], ["-", 1167], ["Goldberg", 1168], ["syndrome", 1177], [".", 1185], ["The", 1187], ["apparently", 1191], ["diagnostic", 1202], ["findings", 1213], ["of", 1222], ["the", 1225], ["15", 1229], ["patients", 1232], ["with", 1241], ["this", 1246], ["syndrome", 1251], ["may", 1260], ["be", 1264], ["helpful", 1267], ["in", 1275], ["differentiating", 1278], ["between", 1294], ["Shprintzen", 1302], ["-", 1312], ["Goldberg", 1313], ["syndrome", 1322], ["and", 1331], ["other", 1335], ["syndromes", 1341], ["with", 1351], ["craniosynostosis", 1356], ["and", 1373], ["marfanoid", 1377], ["habitus", 1387], [".", 1394]]}
{"context": "In melanoma, transition to the vertical growth phase is the critical step in conversion to a deadly malignant disease. Here, we offer the first evidence that an antioxidant enzyme has a key role in this transition. We found that the antioxidant enzyme peroxiredoxin-2 (Prx2) inversely correlated with the metastatic capacity of human melanoma cells. Silencing Prx2 expression stimulated proliferation and migration, whereas ectopic expression of Prx2 produced the opposite effect. Mechanistic investigations indicated that Prx2 negatively regulated Src/ERK activation status, which in turn fortified adherens junctions function by increasing E-cadherin expression and phospho-Y654-dependent retention of \u03b2-catenin in the plasma membrane. In murine melanoma cells, Prx2 silencing enhanced lung metastasis in vivo. Interestingly, the natural compound gliotoxin, which is known to exert a Prx-like activity, inhibited proliferation and migration as well as lung metastasis of Prx2-deficient melanoma cells. Overall, our findings reveal that Prx2 is a key regulator of invasion and metastasis in melanoma, and also suggest a pharmacologic strategy to effectively decrease deadly malignant forms of this disease.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "4725ab4959074b2b82db8e9b8383de5d", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[44, 44], [30, 30]], "char_spans": [[233, 243], [161, 171]]}]}], "context_tokens": [["In", 0], ["melanoma", 3], [",", 11], ["transition", 13], ["to", 24], ["the", 27], ["vertical", 31], ["growth", 40], ["phase", 47], ["is", 53], ["the", 56], ["critical", 60], ["step", 69], ["in", 74], ["conversion", 77], ["to", 88], ["a", 91], ["deadly", 93], ["malignant", 100], ["disease", 110], [".", 117], ["Here", 119], [",", 123], ["we", 125], ["offer", 128], ["the", 134], ["first", 138], ["evidence", 144], ["that", 153], ["an", 158], ["antioxidant", 161], ["enzyme", 173], ["has", 180], ["a", 184], ["key", 186], ["role", 190], ["in", 195], ["this", 198], ["transition", 203], [".", 213], ["We", 215], ["found", 218], ["that", 224], ["the", 229], ["antioxidant", 233], ["enzyme", 245], ["peroxiredoxin-2", 252], ["(", 268], ["Prx2", 269], [")", 273], ["inversely", 275], ["correlated", 285], ["with", 296], ["the", 301], ["metastatic", 305], ["capacity", 316], ["of", 325], ["human", 328], ["melanoma", 334], ["cells", 343], [".", 348], ["Silencing", 350], ["Prx2", 360], ["expression", 365], ["stimulated", 376], ["proliferation", 387], ["and", 401], ["migration", 405], [",", 414], ["whereas", 416], ["ectopic", 424], ["expression", 432], ["of", 443], ["Prx2", 446], ["produced", 451], ["the", 460], ["opposite", 464], ["effect", 473], [".", 479], ["Mechanistic", 481], ["investigations", 493], ["indicated", 508], ["that", 518], ["Prx2", 523], ["negatively", 528], ["regulated", 539], ["Src", 549], ["/", 552], ["ERK", 553], ["activation", 557], ["status", 568], [",", 574], ["which", 576], ["in", 582], ["turn", 585], ["fortified", 590], ["adherens", 600], ["junctions", 609], ["function", 619], ["by", 628], ["increasing", 631], ["E", 642], ["-", 643], ["cadherin", 644], ["expression", 653], ["and", 664], ["phospho", 668], ["-", 675], ["Y654-dependent", 676], ["retention", 691], ["of", 701], ["\u03b2", 704], ["-", 705], ["catenin", 706], ["in", 714], ["the", 717], ["plasma", 721], ["membrane", 728], [".", 736], ["In", 738], ["murine", 741], ["melanoma", 748], ["cells", 757], [",", 762], ["Prx2", 764], ["silencing", 769], ["enhanced", 779], ["lung", 788], ["metastasis", 793], ["in", 804], ["vivo", 807], [".", 811], ["Interestingly", 813], [",", 826], ["the", 828], ["natural", 832], ["compound", 840], ["gliotoxin", 849], [",", 858], ["which", 860], ["is", 866], ["known", 869], ["to", 875], ["exert", 878], ["a", 884], ["Prx", 886], ["-", 889], ["like", 890], ["activity", 895], [",", 903], ["inhibited", 905], ["proliferation", 915], ["and", 929], ["migration", 933], ["as", 943], ["well", 946], ["as", 951], ["lung", 954], ["metastasis", 959], ["of", 970], ["Prx2-deficient", 973], ["melanoma", 988], ["cells", 997], [".", 1002], ["Overall", 1004], [",", 1011], ["our", 1013], ["findings", 1017], ["reveal", 1026], ["that", 1033], ["Prx2", 1038], ["is", 1043], ["a", 1046], ["key", 1048], ["regulator", 1052], ["of", 1062], ["invasion", 1065], ["and", 1074], ["metastasis", 1078], ["in", 1089], ["melanoma", 1092], [",", 1100], ["and", 1102], ["also", 1106], ["suggest", 1111], ["a", 1119], ["pharmacologic", 1121], ["strategy", 1135], ["to", 1144], ["effectively", 1147], ["decrease", 1159], ["deadly", 1168], ["malignant", 1175], ["forms", 1185], ["of", 1191], ["this", 1194], ["disease", 1199], [".", 1206]]}
{"context": "N6-methyladenosine (m6A) is a common modification of mRNA with potential roles in fine-tuning the RNA life cycle. Here, we identify a dense network of proteins interacting with METTL3, a component of the methyltransferase complex, and show that three of them (WTAP, METTL14, and KIAA1429) are required for methylation. Monitoring m6A levels upon WTAP depletion allowed the definition of accurate and near single-nucleotide resolution methylation maps and their classification into WTAP-dependent and -independent sites. WTAP-dependent sites are located at internal positions in transcripts, topologically static across a variety of systems we surveyed, and inversely correlated with mRNA stability, consistent with a role in establishing \"basal\" degradation rates. WTAP-independent sites form at the first transcribed base as part of the cap structure and are present at thousands of sites, forming a previously unappreciated layer of transcriptome complexity. Our data shed light on the proteomic and transcriptional underpinnings of this RNA modification.", "qas": [{"question": "Which properties of the mRNA does N6-methyladenosine (m6A) affect?", "answers": ["mRNA stability"], "qid": "c3596cdec1b2483b889a950b0ae18039", "question_tokens": [["Which", 0], ["properties", 6], ["of", 17], ["the", 20], ["mRNA", 24], ["does", 29], ["N6-methyladenosine", 34], ["(", 53], ["m6A", 54], [")", 57], ["affect", 59], ["?", 65]], "detected_answers": [{"text": "mRNA stability", "token_spans": [[117, 118]], "char_spans": [[683, 696]]}]}], "context_tokens": [["N6-methyladenosine", 0], ["(", 19], ["m6A", 20], [")", 23], ["is", 25], ["a", 28], ["common", 30], ["modification", 37], ["of", 50], ["mRNA", 53], ["with", 58], ["potential", 63], ["roles", 73], ["in", 79], ["fine", 82], ["-", 86], ["tuning", 87], ["the", 94], ["RNA", 98], ["life", 102], ["cycle", 107], [".", 112], ["Here", 114], [",", 118], ["we", 120], ["identify", 123], ["a", 132], ["dense", 134], ["network", 140], ["of", 148], ["proteins", 151], ["interacting", 160], ["with", 172], ["METTL3", 177], [",", 183], ["a", 185], ["component", 187], ["of", 197], ["the", 200], ["methyltransferase", 204], ["complex", 222], [",", 229], ["and", 231], ["show", 235], ["that", 240], ["three", 245], ["of", 251], ["them", 254], ["(", 259], ["WTAP", 260], [",", 264], ["METTL14", 266], [",", 273], ["and", 275], ["KIAA1429", 279], [")", 287], ["are", 289], ["required", 293], ["for", 302], ["methylation", 306], [".", 317], ["Monitoring", 319], ["m6A", 330], ["levels", 334], ["upon", 341], ["WTAP", 346], ["depletion", 351], ["allowed", 361], ["the", 369], ["definition", 373], ["of", 384], ["accurate", 387], ["and", 396], ["near", 400], ["single", 405], ["-", 411], ["nucleotide", 412], ["resolution", 423], ["methylation", 434], ["maps", 446], ["and", 451], ["their", 455], ["classification", 461], ["into", 476], ["WTAP", 481], ["-", 485], ["dependent", 486], ["and", 496], ["-independent", 500], ["sites", 513], [".", 518], ["WTAP", 520], ["-", 524], ["dependent", 525], ["sites", 535], ["are", 541], ["located", 545], ["at", 553], ["internal", 556], ["positions", 565], ["in", 575], ["transcripts", 578], [",", 589], ["topologically", 591], ["static", 605], ["across", 612], ["a", 619], ["variety", 621], ["of", 629], ["systems", 632], ["we", 640], ["surveyed", 643], [",", 651], ["and", 653], ["inversely", 657], ["correlated", 667], ["with", 678], ["mRNA", 683], ["stability", 688], [",", 697], ["consistent", 699], ["with", 710], ["a", 715], ["role", 717], ["in", 722], ["establishing", 725], ["\"", 738], ["basal", 739], ["\"", 744], ["degradation", 746], ["rates", 758], [".", 763], ["WTAP", 765], ["-", 769], ["independent", 770], ["sites", 782], ["form", 788], ["at", 793], ["the", 796], ["first", 800], ["transcribed", 806], ["base", 818], ["as", 823], ["part", 826], ["of", 831], ["the", 834], ["cap", 838], ["structure", 842], ["and", 852], ["are", 856], ["present", 860], ["at", 868], ["thousands", 871], ["of", 881], ["sites", 884], [",", 889], ["forming", 891], ["a", 899], ["previously", 901], ["unappreciated", 912], ["layer", 926], ["of", 932], ["transcriptome", 935], ["complexity", 949], [".", 959], ["Our", 961], ["data", 965], ["shed", 970], ["light", 975], ["on", 981], ["the", 984], ["proteomic", 988], ["and", 998], ["transcriptional", 1002], ["underpinnings", 1018], ["of", 1032], ["this", 1035], ["RNA", 1040], ["modification", 1044], [".", 1056]]}
{"context": "Mycobacterium bovis BCG is widely used as a vaccine against tuberculosis (TB), despite its variable protective efficacy. Relatively little is known about the immune response profiles following BCG vaccination in relation to protection against TB. Here we tested whether BCG vaccination results in immune responses to DosR (Rv3133c) regulon-encoded proteins. These so-called TB latency antigens are targeted by the immune system during persistent Mycobacterium tuberculosis infection and have been associated with immunity against latent M. tuberculosis infection. In silico analysis of the DosR regulon in BCG and M. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical. Transcriptional profiling of 14 different BCG strains, under hypoxia and nitric oxide exposure in vitro, revealed a functional DosR regulon similar to that observed in M. tuberculosis. Next, we assessed human immune responses to a series of immunodominant TB latency antigens and found that BCG vaccination fails to induce significant responses to latency antigens. Similar results were obtained with BCG-vaccinated BALB/c mice. In contrast, responses to latency antigens were observed in individuals with suspected exposure to TB (as indicated by positive gamma interferon responses to TB-specific antigens ESAT-6 and CFP-10) and in mice vaccinated with plasmid DNA encoding selected latency antigens. Since immune responses to TB latency antigens have been associated with control of latent M. tuberculosis infection, our findings support the development of vaccination strategies incorporating DosR regulon antigens to complement and improve the current BCG vaccine.", "qas": [{"question": "How many genes constitute the DosR regulon, controlled by the dormancy survival regulator (DosR) in Mycobacterium tuberculosis?", "answers": ["48 genes"], "qid": "f40c5ca38b964c3fbfd353444320a3b9", "question_tokens": [["How", 0], ["many", 4], ["genes", 9], ["constitute", 15], ["the", 26], ["DosR", 30], ["regulon", 35], [",", 42], ["controlled", 44], ["by", 55], ["the", 58], ["dormancy", 62], ["survival", 71], ["regulator", 80], ["(", 90], ["DosR", 91], [")", 95], ["in", 97], ["Mycobacterium", 100], ["tuberculosis", 114], ["?", 126]], "detected_answers": [{"text": "48 genes", "token_spans": [[116, 117]], "char_spans": [[695, 702]]}]}], "context_tokens": [["Mycobacterium", 0], ["bovis", 14], ["BCG", 20], ["is", 24], ["widely", 27], ["used", 34], ["as", 39], ["a", 42], ["vaccine", 44], ["against", 52], ["tuberculosis", 60], ["(", 73], ["TB", 74], [")", 76], [",", 77], ["despite", 79], ["its", 87], ["variable", 91], ["protective", 100], ["efficacy", 111], [".", 119], ["Relatively", 121], ["little", 132], ["is", 139], ["known", 142], ["about", 148], ["the", 154], ["immune", 158], ["response", 165], ["profiles", 174], ["following", 183], ["BCG", 193], ["vaccination", 197], ["in", 209], ["relation", 212], ["to", 221], ["protection", 224], ["against", 235], ["TB", 243], [".", 245], ["Here", 247], ["we", 252], ["tested", 255], ["whether", 262], ["BCG", 270], ["vaccination", 274], ["results", 286], ["in", 294], ["immune", 297], ["responses", 304], ["to", 314], ["DosR", 317], ["(", 322], ["Rv3133c", 323], [")", 330], ["regulon", 332], ["-", 339], ["encoded", 340], ["proteins", 348], [".", 356], ["These", 358], ["so", 364], ["-", 366], ["called", 367], ["TB", 374], ["latency", 377], ["antigens", 385], ["are", 394], ["targeted", 398], ["by", 407], ["the", 410], ["immune", 414], ["system", 421], ["during", 428], ["persistent", 435], ["Mycobacterium", 446], ["tuberculosis", 460], ["infection", 473], ["and", 483], ["have", 487], ["been", 492], ["associated", 497], ["with", 508], ["immunity", 513], ["against", 522], ["latent", 530], ["M.", 537], ["tuberculosis", 540], ["infection", 553], [".", 562], ["In", 564], ["silico", 567], ["analysis", 574], ["of", 583], ["the", 586], ["DosR", 590], ["regulon", 595], ["in", 603], ["BCG", 606], ["and", 610], ["M.", 614], ["tuberculosis", 617], ["showed", 630], ["at", 637], ["least", 640], ["97", 646], ["%", 648], ["amino", 650], ["acid", 656], ["sequence", 661], ["homology", 670], [",", 678], ["with", 680], ["41", 685], ["out", 688], ["of", 692], ["48", 695], ["genes", 698], ["being", 704], ["identical", 710], [".", 719], ["Transcriptional", 721], ["profiling", 737], ["of", 747], ["14", 750], ["different", 753], ["BCG", 763], ["strains", 767], [",", 774], ["under", 776], ["hypoxia", 782], ["and", 790], ["nitric", 794], ["oxide", 801], ["exposure", 807], ["in", 816], ["vitro", 819], [",", 824], ["revealed", 826], ["a", 835], ["functional", 837], ["DosR", 848], ["regulon", 853], ["similar", 861], ["to", 869], ["that", 872], ["observed", 877], ["in", 886], ["M.", 889], ["tuberculosis", 892], [".", 904], ["Next", 906], [",", 910], ["we", 912], ["assessed", 915], ["human", 924], ["immune", 930], ["responses", 937], ["to", 947], ["a", 950], ["series", 952], ["of", 959], ["immunodominant", 962], ["TB", 977], ["latency", 980], ["antigens", 988], ["and", 997], ["found", 1001], ["that", 1007], ["BCG", 1012], ["vaccination", 1016], ["fails", 1028], ["to", 1034], ["induce", 1037], ["significant", 1044], ["responses", 1056], ["to", 1066], ["latency", 1069], ["antigens", 1077], [".", 1085], ["Similar", 1087], ["results", 1095], ["were", 1103], ["obtained", 1108], ["with", 1117], ["BCG", 1122], ["-", 1125], ["vaccinated", 1126], ["BALB", 1137], ["/", 1141], ["c", 1142], ["mice", 1144], [".", 1148], ["In", 1150], ["contrast", 1153], [",", 1161], ["responses", 1163], ["to", 1173], ["latency", 1176], ["antigens", 1184], ["were", 1193], ["observed", 1198], ["in", 1207], ["individuals", 1210], ["with", 1222], ["suspected", 1227], ["exposure", 1237], ["to", 1246], ["TB", 1249], ["(", 1252], ["as", 1253], ["indicated", 1256], ["by", 1266], ["positive", 1269], ["gamma", 1278], ["interferon", 1284], ["responses", 1295], ["to", 1305], ["TB", 1308], ["-", 1310], ["specific", 1311], ["antigens", 1320], ["ESAT-6", 1329], ["and", 1336], ["CFP-10", 1340], [")", 1346], ["and", 1348], ["in", 1352], ["mice", 1355], ["vaccinated", 1360], ["with", 1371], ["plasmid", 1376], ["DNA", 1384], ["encoding", 1388], ["selected", 1397], ["latency", 1406], ["antigens", 1414], [".", 1422], ["Since", 1424], ["immune", 1430], ["responses", 1437], ["to", 1447], ["TB", 1450], ["latency", 1453], ["antigens", 1461], ["have", 1470], ["been", 1475], ["associated", 1480], ["with", 1491], ["control", 1496], ["of", 1504], ["latent", 1507], ["M.", 1514], ["tuberculosis", 1517], ["infection", 1530], [",", 1539], ["our", 1541], ["findings", 1545], ["support", 1554], ["the", 1562], ["development", 1566], ["of", 1578], ["vaccination", 1581], ["strategies", 1593], ["incorporating", 1604], ["DosR", 1618], ["regulon", 1623], ["antigens", 1631], ["to", 1640], ["complement", 1643], ["and", 1654], ["improve", 1658], ["the", 1666], ["current", 1670], ["BCG", 1678], ["vaccine", 1682], [".", 1689]]}
{"context": "Health care workers (HCW) are particularly at risk of acquiring tuberculosis (TB), even in countries with low TB incidence. Therefore, TB screening in HCW is a useful prevention strategy in countries with both low and high TB incidence. Tuberculin skin test (TST) is widely used although it suffers of low specificity; on the contrary, the in vitro enzyme immunoassay tests (IGRA) show superior specificity and sensitivity but are more expensive. The present study reports the results of a three-year TB surveillance among HCW in a large teaching hospital in Rome, using TST (by standard Mantoux technique) and IGRA (by QuantiFERON-TB) as first- and second-level screening tests, respectively. Out of 2290 HCW enrolled, 141 (6.1%) had a positive TST; among them, 99 (70.2%) underwent the IGRA and 16 tested positive (16.1%). The frequency of HCW tested positive for TB seems not far from other experiences in low incidence countries. Our results confirm the higher specificity of IGRA, but, due to its higher cost, TST can be considered a good first level screening test, whose positive results should be further confirmed by IGRA before the patients undergo X-ray diagnosis and/or chemotherapy.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "62a1183be31d4c208669a471c24c419c", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[12, 12]], "char_spans": [[64, 75]]}]}], "context_tokens": [["Health", 0], ["care", 7], ["workers", 12], ["(", 20], ["HCW", 21], [")", 24], ["are", 26], ["particularly", 30], ["at", 43], ["risk", 46], ["of", 51], ["acquiring", 54], ["tuberculosis", 64], ["(", 77], ["TB", 78], [")", 80], [",", 81], ["even", 83], ["in", 88], ["countries", 91], ["with", 101], ["low", 106], ["TB", 110], ["incidence", 113], [".", 122], ["Therefore", 124], [",", 133], ["TB", 135], ["screening", 138], ["in", 148], ["HCW", 151], ["is", 155], ["a", 158], ["useful", 160], ["prevention", 167], ["strategy", 178], ["in", 187], ["countries", 190], ["with", 200], ["both", 205], ["low", 210], ["and", 214], ["high", 218], ["TB", 223], ["incidence", 226], [".", 235], ["Tuberculin", 237], ["skin", 248], ["test", 253], ["(", 258], ["TST", 259], [")", 262], ["is", 264], ["widely", 267], ["used", 274], ["although", 279], ["it", 288], ["suffers", 291], ["of", 299], ["low", 302], ["specificity", 306], [";", 317], ["on", 319], ["the", 322], ["contrary", 326], [",", 334], ["the", 336], ["in", 340], ["vitro", 343], ["enzyme", 349], ["immunoassay", 356], ["tests", 368], ["(", 374], ["IGRA", 375], [")", 379], ["show", 381], ["superior", 386], ["specificity", 395], ["and", 407], ["sensitivity", 411], ["but", 423], ["are", 427], ["more", 431], ["expensive", 436], [".", 445], ["The", 447], ["present", 451], ["study", 459], ["reports", 465], ["the", 473], ["results", 477], ["of", 485], ["a", 488], ["three", 490], ["-", 495], ["year", 496], ["TB", 501], ["surveillance", 504], ["among", 517], ["HCW", 523], ["in", 527], ["a", 530], ["large", 532], ["teaching", 538], ["hospital", 547], ["in", 556], ["Rome", 559], [",", 563], ["using", 565], ["TST", 571], ["(", 575], ["by", 576], ["standard", 579], ["Mantoux", 588], ["technique", 596], [")", 605], ["and", 607], ["IGRA", 611], ["(", 616], ["by", 617], ["QuantiFERON", 620], ["-", 631], ["TB", 632], [")", 634], ["as", 636], ["first-", 639], ["and", 646], ["second", 650], ["-", 656], ["level", 657], ["screening", 663], ["tests", 673], [",", 678], ["respectively", 680], [".", 692], ["Out", 694], ["of", 698], ["2290", 701], ["HCW", 706], ["enrolled", 710], [",", 718], ["141", 720], ["(", 724], ["6.1", 725], ["%", 728], [")", 729], ["had", 731], ["a", 735], ["positive", 737], ["TST", 746], [";", 749], ["among", 751], ["them", 757], [",", 761], ["99", 763], ["(", 766], ["70.2", 767], ["%", 771], [")", 772], ["underwent", 774], ["the", 784], ["IGRA", 788], ["and", 793], ["16", 797], ["tested", 800], ["positive", 807], ["(", 816], ["16.1", 817], ["%", 821], [")", 822], [".", 823], ["The", 825], ["frequency", 829], ["of", 839], ["HCW", 842], ["tested", 846], ["positive", 853], ["for", 862], ["TB", 866], ["seems", 869], ["not", 875], ["far", 879], ["from", 883], ["other", 888], ["experiences", 894], ["in", 906], ["low", 909], ["incidence", 913], ["countries", 923], [".", 932], ["Our", 934], ["results", 938], ["confirm", 946], ["the", 954], ["higher", 958], ["specificity", 965], ["of", 977], ["IGRA", 980], [",", 984], ["but", 986], [",", 989], ["due", 991], ["to", 995], ["its", 998], ["higher", 1002], ["cost", 1009], [",", 1013], ["TST", 1015], ["can", 1019], ["be", 1023], ["considered", 1026], ["a", 1037], ["good", 1039], ["first", 1044], ["level", 1050], ["screening", 1056], ["test", 1066], [",", 1070], ["whose", 1072], ["positive", 1078], ["results", 1087], ["should", 1095], ["be", 1102], ["further", 1105], ["confirmed", 1113], ["by", 1123], ["IGRA", 1126], ["before", 1131], ["the", 1138], ["patients", 1142], ["undergo", 1151], ["X", 1159], ["-", 1160], ["ray", 1161], ["diagnosis", 1165], ["and/or", 1175], ["chemotherapy", 1182], [".", 1194]]}
